PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Naka, T; Narazaki, M; Hirata, M; Matsumoto, T; Minamoto, S; Aono, A; Nishimoto, N; Kajita, T; Taga, T; Yoshizaki, K; Akira, S; Kishimoto, T				Naka, T; Narazaki, M; Hirata, M; Matsumoto, T; Minamoto, S; Aono, A; Nishimoto, N; Kajita, T; Taga, T; Yoshizaki, K; Akira, S; Kishimoto, T			Structure and function of a new STAT-induced STAT inhibitor	NATURE			English	Article							TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; ACTIVATION; INTERLEUKIN-6; PATHWAYS; GP130; FAMILY; IL-3	The signalling pathway that comprises JAK kinases and STAT proteins (for signal transducer and activator of transcription) is important for relaying signals from various cytokines outside the cell to the inside(1-3). The feedback mechanism responsible for switching off the cytokine signal has not been elucidated. We now report the cloning and characterization of an inhibitor of STAT activation which we name SSI-1 (for STAT-induced STAT inhibitor-1). We found that SSI-1 messenger RNA was induced by the cytokines interleukins 4 and 6 (IL-4, IL-6), leukaemia-inhibitory factor (LIF), and granulocyte colony-stimulating factor (G-CSF). Stimulation by IL-6 or LIF of murine myeloid leukaemia cells (M1 cells) induced SSI-1 mRNA expression which was blocked by transfection of a dominant-negative mutant of Stat3, indicating that the SSI-1 gene is a target of Stat3 (refs 4-7). Forced overexpression of SSI-1 complementary DNA interfered with IL-6- and LIF-mediated apoptosis and macrophage differentiation of M1 cells, as well as IL-6 induced tyrosine-phosphorylation of a receptor glycoprotein component, gp130, and of Stat3. When SSI-1 is overexpressed in COS7 cells, it can associate with the kinases Jak2 and Tyk2, These findings indicate that SSI-1 is responsible for negative-feedback regulation of the JAK-STAT pathway induced by cytokine stimulation.	OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN; INT REAGENTS CORP,CTR RES & DEV,NISHI KU,KOBE 65122,JAPAN; TOKYO MED & DENT UNIV,MED RES INST,DEPT MOL CELL BIOL,CHIYODA KU,TOKYO 101,JAPAN; HYOGO MED UNIV,DEPT BIOCHEM,NISHINOMIYA,HYOGO 663,JAPAN; OSAKA UNIV,SCH HLTH & SPORTS SCI,SUITA,OSAKA 565,JAPAN	Osaka University; Tokyo Medical & Dental University (TMDU); Hyogo College of Medicine; University of Hyogo; Osaka University			Kishimoto, Tadamitsu/C-8470-2009; Akira, Shizuo/C-3134-2009	Naka, Tetsuji/0000-0002-1269-3997; narazaki, masashi/0000-0002-5613-4409				Adachi M, 1996, CELL, V85, P15; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HULI J, 1989, J IMMUNOL, V142, P800; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TIAN SS, 1994, BLOOD, V84, P1760; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	27	1098	1149	0	64	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					924	929		10.1038/43219	http://dx.doi.org/10.1038/43219			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202127	Bronze			2022-12-28	WOS:A1997XG41600057
J	Hensel, WA				Hensel, WA			Bea's legacy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1913	1914						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200617				2022-12-28	WOS:A1997XF08700001
J	Evens, RG				Evens, RG			Radiology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Evens, RG (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63130, USA.							Blum U, 1996, RADIOLOGY, V198, P25, DOI 10.1148/radiology.198.1.8539389; GUGHIELMI, 1995, ENDOVASCULAR NEUROLO, P179; Hovsepian DM, 1996, RADIOLOGY, V198, P14, DOI 10.1148/radiology.198.1.8539367; Massoud TF, 1996, AM J NEURORADIOL, V17, P549; Moore WS, 1996, J VASC SURG, V23, P543, DOI 10.1016/S0741-5214(96)80032-2; Pierot L, 1996, NEUROSURGERY, V38, P948, DOI 10.1097/00006123-199605000-00019; URPHY KD, 1996, RADIOLOGY, V198, P473; Urwin RW, 1996, NEUROIMAG CLIN N AM, V6, P957	8	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1897	1899						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185824				2022-12-28	WOS:A1997XD54400043
J	OBrien, WA; Hartigan, PM; Daar, ES; Simberkoff, MS; Hamilton, JD				OBrien, WA; Hartigan, PM; Daar, ES; Simberkoff, MS; Hamilton, JD			Changes in plasma HIV RNA levels and CD4(+) lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; ZIDOVUDINE; QUANTITATION; TUBERCULOSIS; REPLICATION; VACCINATION	Background: Markers are needed for assessing response to antiretroviral therapy over time. The CD4(+) lymphocyte count is one such surrogate, but it is relatively weak. Objective: To assess the association of changes in plasma human immunodeficiency virus (HIV) RNA level and CD4(+) lymphocyte count with progression to the acquired immunodeficiency syndrome (AIDS). Design: Analysis of data from a subset of patients in a multicenter, randomized, clinical trial. Setting: Six Veterans Affairs medical centers and one U.S. Army medical center. Patients: 270 symptomatic HIV-infected patients from the Veterans Affairs Cooperative Study on AIDS. Intervention: Patients were randomly assigned to receive zidovudine or placebo initially; a cross-over protocol was established for patients receiving placebo who had disease progression. Measurements: Reverse transcriptase polymerase chain reaction on cryopreserved plasma samples, previously obtained CD4(+) lymphocyte counts, and clinical events. Results: For each decrease of 0.5 log(10) copies/mL in plasma HIV RNA level, averaged over the 6 months after randomization, the relative risk (RR) for progression to AIDS was 0.67 (P < 0.001). In a subset of 70 treated patients with long-term follow-up, a return to baseline plasma HIV RNA levels within 6 months of randomization was associated with progression to AIDS (RR, 4.28; P = 0.004). Plasma HIV RNA levels or CD4(+) lymphocyte counts over time were more strongly associated with progression to AIDS than were baseline levels or counts. Conclusions: An adequate virologic response after initiation of antiretroviral therapy seems to require a decrease in plasma HIV RNA level of at least 0.5 log(10) copies/mL that is sustained for at least 6 months. The independent relation between plasma HIV RNA level and CD4(+) lymphocyte count over time and clinical outcome suggests that the measurement of plasma HIV RNA level, in addition to the CD4(+) lymphocyte count, has a role in guiding the management of antiretroviral therapy.	W LOS ANGELES VET AFFAIRS MED CTR, LOS ANGELES, CA 90073 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA; W HAVEN VET AFFAIRS MED CTR, West Haven, CT USA; CEDARS SINAI MED CTR, NEW YORK, NY USA; VET AFFAIRS MED CTR, NEW YORK, NY USA; NYU, SCH MED, NEW YORK, NY USA; DUKE UNIV, MED CTR, DIV INFECT DIS & INT HLTH, DURHAM, NC 27710 USA; VET AFFAIRS MED CTR, DURHAM, NC 27705 USA; RES CTR AIDS & HIV INFECT, DURHAM, NC USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Cedars Sinai Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); New York University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)								Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; [Anonymous], 1987, MMWR-MORBID MORTAL W, V36, p1S; Bartlett JA, 1996, ANN INTERN MED, V125, P161, DOI 10.7326/0003-4819-125-3-199608010-00001; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; Cox D. R., 1984, ANAL SURVIVAL DATA; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; ERON JJ, 1996, 3 C RETR OPP INF WAS; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HOLODNIY M, 1994, J ACQ IMMUN DEF SYND, V7, P363; JONES BE, 1994, AM J RESP CRIT CARE, V150, P1499, DOI 10.1164/ajrccm.150.6.7952606; KATENSTEI DA, 1996, NEW ENGL J MED, V335, P1091; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MOLE L, 1995, 2 NAT C HUM RETR REL, pA239; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBRIEN WA, 1995, BLOOD, V86, P1082; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PERNEGER TV, 1995, BMJ-BRIT MED J, V311, P1468, DOI 10.1136/bmj.311.7018.1468; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; Simberkoff MS, 1996, J ACQ IMMUN DEF SYND, V11, P142, DOI 10.1097/00042560-199602010-00005; Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903; STAPRANS SI, 1995, J EXP MED, V182, P1727, DOI 10.1084/jem.182.6.1727; URDEA MS, 1993, CLIN CHEM, V39, P725; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542	30	238	243	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1997	126	12					939	945		10.7326/0003-4819-126-12-199706150-00002	http://dx.doi.org/10.7326/0003-4819-126-12-199706150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE549	9182470				2022-12-28	WOS:A1997XE54900005
J	KlemanLeyer, K; Armbruster, DW; Daniels, CJ				KlemanLeyer, K; Armbruster, DW; Daniels, CJ			Properties of H-volcanii tRNA intron endonuclease reveal a relationship between the archaeal and eucaryal tRNA intron processing systems	CELL			English	Article							RNA-SPLICING ENDONUCLEASE; PRE-TRANSFER-RNA; ARCHAEBACTERIUM HALOFERAX-VOLCANII; SACCHAROMYCES-CEREVISIAE; HALOBACTERIUM-VOLCANII; SUBSTRATE RECOGNITION; STABLE RNA; MUTATIONS; EXCISION; TRANSCRIPTION	To better understand the relationship between archaeal and eucaryal tRNA introns and their processing systems, we have cloned the gene encoding the tRNA intron endonucleases from the archaeon H. volcanii. The gene encodes a 37 kDa protein that appears to be present as a homodimer under native conditions. Recombinant forms of this protein were expressed in E. coli and found to cleave precursor tRNAs lacking full mature tRNA structure, a property observed for the native endonuclease. Comparative sequence analysis revealed that similar proteins existed in other Archaea and that these proteins have significant similarity with two subunits of the yeast tRNA intron endonuclease. These results provide evidence that the archaeal and eucaryal tRNA intron processing systems are related and suggest a common origin for tRNA introns in these organisms.	OHIO STATE UNIV, DEPT MICROBIOL, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University					NIGMS NIH HHS [GM48665-04] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aagaard C, 1995, P NATL ACAD SCI USA, V92, P12285, DOI 10.1073/pnas.92.26.12285; AMIRI KA, 1994, J BACTERIOL, V176, P2124, DOI 10.1128/jb.176.7.2124-2127.1994; ARMBRUSTER DW, 1997, IN PRESS J BIOL CHEM; BALDI MI, 1983, CELL, V35, P109, DOI 10.1016/0092-8674(83)90213-1; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; BAUMANN P, 1995, TRENDS GENET, V11, P279, DOI 10.1016/S0168-9525(00)89075-7; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHARLEBOIS RL, 1991, J MOL BIOL, V222, P509, DOI 10.1016/0022-2836(91)90493-P; CHARLEBOIS RL, 1987, P NATL ACAD SCI USA, V84, P8530, DOI 10.1073/pnas.84.23.8530; DALGAARD JZ, 1993, P NATL ACAD SCI USA, V90, P5414, DOI 10.1073/pnas.90.12.5414; DALGAARD JZ, 1994, J BIOL CHEM, V269, P28885; GARRETT RA, 1994, SYST APPL MICROBIOL, V16, P680; HARRINGTON MG, 1990, METHOD ENZYMOL, V182, P488; HO CK, 1990, EMBO J, V9, P1245, DOI 10.1002/j.1460-2075.1990.tb08232.x; KAINE BP, 1983, P NATL ACAD SCI-BIOL, V80, P3309, DOI 10.1073/pnas.80.11.3309; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KJEMS J, 1988, CELL, V54, P693, DOI 10.1016/S0092-8674(88)80014-X; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P439, DOI 10.1073/pnas.88.2.439; KJEMS J, 1989, J BIOL CHEM, V264, P17834; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LYKKEANDERSEN J, 1994, J MOL BIOL, V243, P846, DOI 10.1006/jmbi.1994.1687; MATHISON L, 1989, MOL CELL BIOL, V9, P4220, DOI 10.1128/MCB.9.10.4220; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; NIEUWLANDT DT, 1990, J BACTERIOL, V172, P7104, DOI 10.1128/jb.172.12.7104-7110.1990; NIEUWLANDT DT, 1993, MOL MICROBIOL, V8, P93, DOI 10.1111/j.1365-2958.1993.tb01206.x; PEARSON D, 1985, MOL CELL BIOL, V5, P808, DOI 10.1128/MCB.5.4.808; POTTER S, 1995, SCIENCE, V268, P1056, DOI 10.1126/science.7538698; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SHAPERO MH, 1992, BIOCHEMISTRY-US, V31, P2359, DOI 10.1021/bi00123a022; THOMPSON LD, 1988, J BIOL CHEM, V263, P17951; THOMPSON LD, 1990, J BIOL CHEM, V265, P18104; THOMPSON LD, 1989, CAN J MICROBIOL, V35, P36, DOI 10.1139/m89-006; THOMPSON LD, 1990, THESIS OHIO STATE U; VANTOL H, 1989, EMBO J, V8, P293, DOI 10.1002/j.1460-2075.1989.tb03376.x; Weber U, 1996, NUCLEIC ACIDS RES, V24, P2212, DOI 10.1093/nar/24.12.2212; Westaway Shawn K., 1995, P79; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; WICH G, 1987, EMBO J, V6, P523, DOI 10.1002/j.1460-2075.1987.tb04784.x; WILLIS I, 1984, EMBO J, V3, P1573, DOI 10.1002/j.1460-2075.1984.tb02013.x; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004	41	84	90	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					839	847		10.1016/S0092-8674(00)80269-X	http://dx.doi.org/10.1016/S0092-8674(00)80269-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200602	Bronze			2022-12-28	WOS:A1997XE35700004
J	Heery, DM; Kalkhoven, E; Hoare, S; Parker, MG				Heery, DM; Kalkhoven, E; Hoare, S; Parker, MG			A signature motif in transcriptional co-activators mediates binding to nuclear receptor	NATURE			English	Article							STEROID-HORMONE RECEPTORS; ESTROGEN-RECEPTOR; PROTEIN; SUPERFAMILY; COACTIVATOR; SEQUENCE; PROMOTER	The binding of lipophilic hormones, retinoids and vitamins to members of the nuclear-receptor superfamily modifies the DNA-binding and transcriptional properties of these receptors, resulting in the activation or repression of target genes(1,2). Ligand binding induces conformational changes in nuclear receptors and promotes their association with a diverse group of nuclear proteins, including SRC1/p160 (refs 3-5), TIF-2/GRIP-1 (refs 6, 7) and CBP/p300 (refs 4, 5, 8, 9) which function as co-activators of transcription, and RIP-140 (ref. 10), TIF-1 (ref. II) and TRIP-1/SUG-1 (refs 12, 13) whose functions are unclear. Here we report that a short sequence motif LXXLL (where Lis leucine and X is any amino acid) present in RIP-140, SRC-1 and CBP is necessary and sufficient to mediate the binding of these proteins to liganded nuclear receptors. We show that the ability of SRC-1 to bind the oestrogen receptor and enhance its transcriptional activity is dependent upon the integrity of the LXXLL motifs and on key hydrophobic residues in a conserved helix (helix 12) of the oestrogen receptor that are required for its ligand-induced activation function(14). We propose that the LXXLL motif is a signature sequence that facilitates the interaction of different proteins with nuclear receptors, and is thus a defining feature of a new family of nuclear proteins.	IMPERIAL CANC RES FUND, MOL ENDOCRINOL LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK; University of London; Queen Mary University London				Heery, David/0000-0002-5035-2392				ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HEY S, 1996, P NATL ACAD SCI USA, V93, P5517; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LHorset F, 1996, MOL CELL BIOL, V16, P6029; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; ONATE SA, 1995, SCIENCE, V270, P1354; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	27	1691	1756	3	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	1997	387	6634					733	736		10.1038/42750	http://dx.doi.org/10.1038/42750			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192902				2022-12-28	WOS:A1997XD86900061
J	Ebrahim, S; Smith, GD				Ebrahim, S; Smith, GD			Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MIDDLE-AGED MEN; MULTIFACTORIAL PRIMARY PREVENTION; STANFORD 5-CITY PROJECT; CARDIOVASCULAR RISK; MYOCARDIAL-INFARCTION; HEALTH-EDUCATION; GENERAL-PRACTICE; BLOOD-PRESSURE; PRIMARY-CARE; COMMUNITY EDUCATION	Objective: To assess the effectiveness of multiple risk factor intervention in reducing cardiovascular risk factors, total mortality, and mortality from coronary heart disease among adults. Design: Systematic review and meta-analysis of randomised controlled trials in workforces and in primary care in which subjects were randomly allocated to more than one of six interventions (stopping smoking;, exercise, dietary advice, weight control, antihypertensive drugs, and cholesterol lowering drugs) and followed up for at least six months. Subjects: Adults aged 17-73 years. 903 000 person years of observation were included in nine trials with clinical event outcomes and 303 000 person years in five trials with risk factor outcomes alone. Main outcome measures: Changes in systolic and diastolic blood pressure, smoking rates, blood cholesterol concentrations, total mortality, and mortality from coronary heart disease. Results: Net decreases in systolic and diastolic blood pressure, smoking prevalence, and blood cholesterol were 4.2 mm Hg (SE 0.19 mm Hg), 2.7 mm Hg (0.09 mm Hg), 4.2% (0.3%), and 0.14 mmol/l (0.01 mmol/l) respectively. in the nine trials with clinical event end points the pooled odds ratios for total and coronary heart disease mortality were 0.97 (95%, confidence interval 0.92 to 1.02) and 0.96 (0.88 to 1.04) respectively. Statistical heterogeneity between the studies with respect to changes in mortality and risk factors was due to trials focusing on hypertensive participants and those using considerable amounts of drug treatment with only these trials showing significant reductions in mortality. Conclusions: The pooled effects of multiple risk factor intervention on mortality were insignificant and a small, but potentially important, benefit of treatment (about a 10% reduction in mortality) may have been missed. Changes in risk factors were modest, were related to the amount of pharmacological treatment used, and in some cases may have been overestimated because of regression to the mean, lack of intention to treat analyses, habituation to blood pressure measurement, and use of self reports of smoking. Interventions using personal or family counselling and education with or without pharmacological treatments seem to be more effective at reducing risk factors and therefore mortality in high risk hypertensive populations. The evidence suggests that such interventions implemented through standard health education methods have limited use In the general population. Wealth protection through fiscal and legislative measures may be more effective.	UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND	University of Bristol	Ebrahim, S (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PRIMARY CARE & POPULAT SCI, LONDON NW3 2PF, ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				BARON JA, 1990, BRIT J GEN PRACT, V40, P137; BENSHLOMO Y, 1994, AM J PUBLIC HEALTH, V84, P1235, DOI 10.2105/AJPH.84.8.1235; BLAKE RL, 1987, J FAM PRACTICE, V24, P369; BRUNNER E, IN PRESS AM J PUBLIC; BRUNO R, 1983, PREV MED, V12, P523, DOI 10.1016/0091-7435(83)90206-2; Canadian Public Health Association, 1986, OTT CHART HLTH PROM; CARLBERG A, 1992, FAM PRACT, V9, P304, DOI 10.1093/fampra/9.3.304; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOK DG, 1986, LANCET, V2, P1376; COULTER A, 1994, BRIT MED J, V308, P308; CROUCH M, 1986, PREV MED, V15, P282, DOI 10.1016/0091-7435(86)90047-2; CUPPLES ME, 1994, BRIT MED J, V309, P993, DOI 10.1136/bmj.309.6960.993; DOMARKENE SB, 1990, KARDIOLOGIYA, V30, P95; EDYE BV, 1989, MED J AUSTRALIA, V150, P574, DOI 10.5694/j.1326-5377.1989.tb136695.x; EGGER M, 1995, J HYPERTENS, V13, P813, DOI 10.1097/00004872-199507000-00014; FARQUHAR JW, 1977, LANCET, V1, P1192; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; FORTMANN SP, 1993, AM J EPIDEMIOL, V137, P82, DOI 10.1093/oxfordjournals.aje.a116605; FULLARD E, 1987, BRIT MED J, V294, P1080, DOI 10.1136/bmj.294.6579.1080; GEMSON DH, 1990, ARCH INTERN MED, V150, P985, DOI 10.1001/archinte.150.5.985; GLASGOW RE, 1995, AM J PUBLIC HEALTH, V85, P209, DOI 10.2105/AJPH.85.2.209; GOMEL M, 1993, AM J PUBLIC HEALTH, V83, P1231, DOI 10.2105/AJPH.83.9.1231; Hanlon P, 1995, BMJ-BRIT MED J, V311, P1609, DOI 10.1136/bmj.311.7020.1609; HJERMANN I, 1981, LANCET, V2, P1303; Holland W., 1977, INT J EPIDEMIOL, V6, P357; JARVIS M, 1984, PREV MED, V13, P501, DOI 10.1016/0091-7435(84)90018-5; JULA A, 1990, J INTERN MED, V227, P413, DOI 10.1111/j.1365-2796.1990.tb00180.x; KICKBUSH I, 1988, 2 INT C HLTH PROM AD; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KNUTSEN SF, 1991, PREV MED, V20, P197, DOI 10.1016/0091-7435(91)90020-5; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LINDHOLM LH, 1995, BRIT MED J, V310, P1105, DOI 10.1136/bmj.310.6987.1105; LOVIBOND SH, 1986, J BEHAV MED, V9, P415, DOI 10.1007/BF00845131; Luepker RV, 1996, AM J EPIDEMIOL, V144, P351, DOI 10.1093/oxfordjournals.aje.a008936; LUEPKER RV, 1994, AM J PUBLIC HEALTH, V84, P1383, DOI 10.2105/AJPH.84.9.1383; LYNN WR, 1995, AM J PUBLIC HEALTH, V85, P183; LYNN WR, 1995, AM J PUBLIC HEALTH, V85, P193; MARTINEZAMENOS A, 1990, J HUM HYPERTENS, V4, P362; MCCORMICK J, 1988, LANCET, V2, P839; Meimanaliev T. S., 1991, Cor et Vasa, V33, P451; MEIMANALIEV TS, 1993, TERAPEVT ARKH, V65, P28; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MORISKY DE, 1983, AM J PUBLIC HEALTH, V73, P153, DOI 10.2105/AJPH.73.2.153; MULLEN PD, 1992, PATIENT EDUC COUNS, V19, P143, DOI 10.1016/0738-3991(92)90194-N; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; NIKITIN YP, 1991, KLIN MED MOSCOW+, V69, P32; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; OSTWALD SK, 1989, J OCCUP ENVIRON MED, V31, P90; PATTERSON TL, 1988, J BEHAV MED, V11, P447, DOI 10.1007/BF00844838; PEARSON TA, 1993, DIS CONTROL PRIORITI, P577; PEDERSEN TR, 1994, LANCET, V344, P1383; PEDOE HT, 1982, EUR HEART J, V3, P184; PIERCE JP, 1984, PREV MED, V13, P185, DOI 10.1016/0091-7435(84)90050-1; PUSKA P, 1976, SCAND J SOC MED, V4, P57; PUSKA P, 1985, ANNU REV PUBL HEALTH, V6, P147, DOI 10.1146/annurev.pu.06.050185.001051; PUSKA P, 1981, COMMUNITY CONTROL CA, P1; *RES INF SYST, 1994, REF MAN BIBL SOL; ROBSON J, 1989, BMJ-BRIT MED J, V298, P433, DOI 10.1136/bmj.298.6671.433; ROSE G, 1992, STRATEGY PREVENTIVE, P29; ROWLAND L, 1994, J EPIDEMIOL COMMUN H, V48, P123, DOI 10.1136/jech.48.2.123; SCHOENBERGER JA, 1990, CLIN EXP HYPERTENS A, V12, P931, DOI 10.3109/10641969009073510; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH; SMITH GD, 1994, BMJ-BRIT MED J, V308, P72, DOI 10.1136/bmj.308.6921.72; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH KW, 1991, AM J PUBLIC HEALTH, V81, P466, DOI 10.2105/AJPH.81.4.466; *SPSS, 1987, STAT PACK SOC SCI SP; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; *STAT EP RES CORP, 1992, EGRET REF MAN; STEINBACH M, 1982, REV ROUM MED-MED INT, V20, P197; STOTT N, 1994, BRIT MED J, V308, P285, DOI 10.1136/bmj.308.6924.285; STOTT NCH, 1994, BMJ-BRIT MED J, V309, P971, DOI 10.1136/bmj.309.6960.971; STRANDBERG TE, 1991, JAMA-J AM MED ASSOC, V266, P1225, DOI 10.1001/jama.266.9.1225; SUSSER M, 1995, AM J PUBLIC HEALTH, V85, P156, DOI 10.2105/AJPH.85.2.156; Valkonen T, 1992, Int J Health Sci, V3, P157; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; VOLOZH OI, 1991, KARDIOLOGIYA, V31, P20; WANNAMETHEE SG, 1995, JAMA-J AM MED ASSOC, V274, P155; *WHO EUR COLL GROU, 1989, WHO EUR COLL TRIAL M; WILHELMSEN L, 1986, EUR HEART J, V7, P279, DOI 10.1093/oxfordjournals.eurheartj.a062065; WOOD DA, 1994, BRIT MED J, V308, P313, DOI 10.1136/bmj.308.6924.313; 1982, LANCET, V1, P1395; 1984, BRIT MED J, V289, P514; 1979, JAMA-J AM MED ASSOC, V242, P2362; 1982, LANCET, V2, P803	88	238	246	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	1997	314	7095					1666	1674		10.1136/bmj.314.7095.1666	http://dx.doi.org/10.1136/bmj.314.7095.1666			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD874	9193292	Green Published			2022-12-28	WOS:A1997XD87400028
J	Rudel, T; Bokoch, GM				Rudel, T; Bokoch, GM			Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2	SCIENCE			English	Article							FLOW CYTOMETRIC DETECTION; PHOSPHATIDYLSERINE EXPRESSION; POLY(ADP-RIBOSE) POLYMERASE; ANNEXIN-V; PROTEASE; DEATH; INTERLEUKIN-1-BETA	Apoptosis of Jurkat T cells induced the caspase-mediated proteolytic cleavage of p21-activated kinase 2 (PAK2). Cleavage occurred between the amino-terminal regulatory domain and the carboxyl-terminal catalytic domain, which generated a constitutively active PAK2 fragment. Stable Jurkat cell lines that expressed a dominant-negative PAK mutant were resistant to the Fas-induced formation of apoptotic bodies, but had an enhanced externalization of phosphatidlyserine at the cell surface. Thus, proteolytic activation of PAK2 represents a guanosine triphosphatase-independent mechanism of PAK regulation that allows PAK2 to regulate morphological changes that are seen in apoptotic cells.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [HL48008] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALHEMRI ES, 1996, CELL, V87, P171; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; DHARMAWARDHANE S, UNPUB; Ding JB, 1996, J BIOL CHEM, V271, P24869, DOI 10.1074/jbc.271.40.24869; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MAJNO G, 1995, AM J PATHOL, V246, P3; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; MARTIN SJ, 1995, J EXP MED, V182, P1; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; RUDEL T, UNPUB; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; YUAN BJ, 1995, CURR OPIN CELL BIOL, V7, P211	32	589	603	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 6	1997	276	5318					1571	1574		10.1126/science.276.5318.1571	http://dx.doi.org/10.1126/science.276.5318.1571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171063				2022-12-28	WOS:A1997XC70100046
J	Kaplan, LD; Straus, DJ; Testa, MA; VonRoenn, J; Dezube, BJ; Cooley, TP; Herndier, B; Northfelt, DW; Huang, J; Tulpule, A; Levine, AM				Kaplan, LD; Straus, DJ; Testa, MA; VonRoenn, J; Dezube, BJ; Cooley, TP; Herndier, B; Northfelt, DW; Huang, J; Tulpule, A; Levine, AM			Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLONY-STIMULATING FACTOR; HOMOSEXUAL MEN; SYNDROME AIDS; REGIMEN CHOP; TRIAL; EXPERIENCE; NEOPLASIA	Background Reduced doses of cytotoxic chemotherapy or standard-dose therapy plus a myeloid colony-stimulating factor decreases hematologic toxicity and its complications in patients with non-Hodgkin's lymphoma associated with infection with the human immunodeficiency virus (HIV). However, the effect of reducing the doses of cytotoxic chemotherapeutic agents on clinical outcome is not known. Methods We randomly assigned 198 HIV-seropositive patients with previously untreated, aggressive non-Hodgkin's lymphoma to receive standard-dose therapy with methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD) along with granulocyte-macrophage colony-stimulating factor (GM-CSF; n=94) or reduced-dose m-BACOD with GM-CSF administered only as indicated (n=98). Results A complete response was achieved in 39 of the 94 assessable patients assigned to low-dose therapy (41 percent) and in 42 of the 81 assessable patients assigned to standard-dose therapy (52 percent, P=0.56). There were no significant differences in overall or disease-free survival; median survival times were 35 weeks for patients receiving low-dose therapy and 31 weeks for those receiving standard-dose therapy (risk ratio for death in the standard-dose group, 1.17; 95 percent confidence interval, 0.84 to 1.63; P=0.25). Toxic effects of chemotherapy rated grade 3 or higher occurred in 66 of 94 patients assigned to standard-dose therapy (70 percent) and 50 of 98 patients assigned to low-dose treatment (51 percent, P=0.008). Hematologic toxicity accounted for the difference. Conclusions As compared with treatment with standard doses of cytotoxic chemotherapy (m-BACOD), reduced doses caused significantly fewer hematologic toxic effects yet had similar efficacy in patients with HIV-related lymphoma. Dose-modified chemotherapy should be considered for most HIV-infected patients with lymphoma. (C) 1997, Massachusetts Medical Society.	SAN FRANCISCO GEN HOSP, DEPT PATHOL, SAN FRANCISCO, CA 94110 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; CORNELL UNIV MED COLL, NEW YORK, NY USA; HARVARD UNIV, SCH PUBL HLTH, STAT & DATA ANAL CTR, BOSTON, MA 02115 USA; NORTHWESTERN UNIV, DEPT HEMATOL ONCOL, CHICAGO, IL 60611 USA; BETH ISRAEL DEACONESS MED CTR, BOSTON, MA USA; BOSTON MED CTR, DEPT MED, SECT HEMATOL, BOSTON, MA USA; BOSTON MED CTR, DEPT MED, SECT ONCOL, BOSTON, MA USA; BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA; UNIV SO CALIF, NORRIS CANC HOSP, SCH MED, LOS ANGELES, CA 90089 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; Cornell University; Harvard University; Harvard T.H. Chan School of Public Health; Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Boston Medical Center; Boston Medical Center; Boston University; University of Southern California	Kaplan, LD (corresponding author), SAN FRANCISCO GEN HOSP, AIDS PROGRAM,DEPT MED,DIV ONCOL,WARD 84, 995 POTRERO AVE, SAN FRANCISCO, CA 94110 USA.		Testa, Marianna/L-9768-2019	Cooley, Timothy/0000-0002-3373-1569	NCRR NIH HHS [GCRC-RR00533-28] Funding Source: Medline; NIAID NIH HHS [UO1-AI-27573, CFAR-P30 AI 27763] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763, R01AI027573] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; GILL PS, 1987, J CLIN ONCOL, V5, P1322, DOI 10.1200/JCO.1987.5.9.1322; GISSELBRECHT C, 1993, AM J MED, V95, P188, DOI 10.1016/0002-9343(93)90259-R; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; HARNLY ME, 1988, AM J EPIDEMIOL, V128, P261, DOI 10.1093/oxfordjournals.aje.a114966; KAPLAN L D, 1989, Journal of the American Medical Association, V261, P719, DOI 10.1001/jama.261.5.719; KAPLAN LD, 1995, BLOOD, V85, P1727, DOI 10.1182/blood.V85.7.1727.bloodjournal8571727; KAPLAN LD, 1991, J CLIN ONCOL, V9, P929, DOI 10.1200/JCO.1991.9.6.929; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; LEVINE AM, 1984, ANN INTERN MED, V100, P7, DOI 10.7326/0003-4819-100-1-7; LEVINE AM, 1991, CANCER, V68, P2466, DOI 10.1002/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO;2-G; LEVINE AM, 1991, JAMA-J AM MED ASSOC, V266, P84, DOI 10.1001/jama.266.1.84; LOWENTHAL DA, 1988, CANCER, V61, P2325, DOI 10.1002/1097-0142(19880601)61:11<2325::AID-CNCR2820611130>3.0.CO;2-0; SERRAINO D, 1992, BRIT J CANCER, V66, P912, DOI 10.1038/bjc.1992.384; TESTA MA, 1995, AIDS CLIN TRIALS, P213; Vaccher E, 1996, J CLIN ONCOL, V14, P2217, DOI 10.1200/JCO.1996.14.8.2217; WALSH C, 1993, J ACQ IMMUN DEF SYND, V6, P265; ZIEGLER JL, 1984, NEW ENGL J MED, V311, P565, DOI 10.1056/NEJM198408303110904	18	241	248	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1641	1648		10.1056/NEJM199706053362304	http://dx.doi.org/10.1056/NEJM199706053362304			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC086	9171066	Bronze			2022-12-28	WOS:A1997XC08600004
J	Rigel, DS				Rigel, DS			Epiluminescence microscopy in clinical diagnosis of pigmented skin lesions?	LANCET			English	Editorial Material											Rigel, DS (corresponding author), NYU, MED CTR, RONALD O PERELMAN DEPT DERMATOL, NEW YORK, NY 10016 USA.							BINDER M, 1995, ARCH DERMATOL, V131, P286, DOI 10.1001/archderm.131.3.286; FRIEDMAN RJ, 1985, CA-CANCER J CLIN, V35, P130, DOI 10.3322/canjclin.35.3.130; KENET RO, 1994, JOURNAL OF DERMATOLOGY, VOL 21, NO 11, NOVEMBER 1994, P881, DOI 10.1111/j.1346-8138.1994.tb03306.x; NACHBAR F, 1994, J AM ACAD DERMATOL, V30, P551, DOI 10.1016/S0190-9622(94)70061-3; SOBER AJ, 1993, SEMIN SURG ONCOL, V9, P198; STEINER A, 1987, ANTICANCER RES, V7, P433	6	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	1997	349	9065					1566	1567		10.1016/S0140-6736(05)61625-X	http://dx.doi.org/10.1016/S0140-6736(05)61625-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174555	hybrid			2022-12-28	WOS:A1997XB67300004
J	Berglund, JA; Chua, K; Abovich, N; Reed, R; Rosbash, M				Berglund, JA; Chua, K; Abovich, N; Reed, R; Rosbash, M			The splicing factor BBP interacts specifically with the pre-mRNA branchpoint sequence UACUAAC	CELL			English	Article							U2 SNRNP; PROTEIN; YEAST; COMPLEX; INTRON; MUTATIONS; SELECTION; BINDING; INVITRO; U1	The yeast splicing factor BBP (branchpoint bridging protein) interacts directly with pre-mRNA at or very near the highly conserved branchpoint sequence UACUAAC within the commitment complex. We also show that the recombinant protein recognizes the UACUAAC sequence. Therefore, BBP is also an acronym for branchpoint binding protein. The mammalian splicing factor SF1 is a BBP ortholog (mBBP) and an E complex component, and also has branchpoint sequence specificity. The relative conservation of this region in yeast and mammals correlates well with the RNA-binding differences between BBP and mBBP, suggesting that BBP contributes to branchpoint sequence definition in both systems.	BRANDEIS UNIV, HOWARD HUGHES MED INST, DEPT BIOL & BIOCHEM, WALTHAM, MA 02254 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Brandeis University; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			Berglund, Andrew/AAS-1065-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023549] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-23549] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Arning S, 1996, RNA, V2, P794; CHAMPIONARNAUD P, 1995, MOL CELL BIOL, V15, P5750; Chiara MD, 1996, MOL CELL BIOL, V16, P3317; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; England T E, 1980, Methods Enzymol, V65, P65; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283; JACQUIER A, 1986, P NATL ACAD SCI USA, V83, P5835, DOI 10.1073/pnas.83.16.5835; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAMER A, 1992, MOL CELL BIOL, V12, P4545; LU JR, 1995, J MOL BIOL, V247, P739, DOI 10.1016/S0022-2836(05)80152-4; MACMILLAN AM, 1994, GENE DEV, V8, P3008, DOI 10.1101/gad.8.24.3008; Moore M., 1993, RNA WORLD, P303; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; Query CC, 1996, EMBO J, V15, P1392, DOI 10.1002/j.1460-2075.1996.tb00481.x; SERAPHIN B, 1991, EMBO J, V10, P1209, DOI 10.1002/j.1460-2075.1991.tb08062.x; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	28	269	272	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	1997	89	5					781	787		10.1016/S0092-8674(00)80261-5	http://dx.doi.org/10.1016/S0092-8674(00)80261-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182766	Bronze			2022-12-28	WOS:A1997XB92500015
J	Millman, JS; Andrews, DW				Millman, JS; Andrews, DW			Switching the model: A concerted mechanism for GTPases in protein targeting	CELL			English	Review							SIGNAL RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM; RECEPTOR; GTP				Millman, JS (corresponding author), MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA.			Andrews, David/0000-0002-9266-7157; Millman, Jonathan/0000-0002-1766-2348				ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CZARNOTA GJ, 1994, J STRUCT BIOL, V113, P35, DOI 10.1006/jsbi.1994.1030; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; RAPIEJKO PJ, 1994, MOL BIOL CELL, V5, P887, DOI 10.1091/mbc.5.8.887; RAPIEJKO PJ, 1997, CELL, V89; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; YARMUS M, 1992, TRENDS BIOCHEM SCI, V17, P130; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650	14	30	30	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					673	676		10.1016/S0092-8674(00)80248-2	http://dx.doi.org/10.1016/S0092-8674(00)80248-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182753	Bronze			2022-12-28	WOS:A1997XB92500002
J	Smith, CM; Steitz, JA				Smith, CM; Steitz, JA			Sno storm in the nucleolus: New roles for myriad small RNPs	CELL			English	Review							PRE-RIBOSOMAL-RNA; YEAST				Smith, CM (corresponding author), YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,HOWARD HUGHES MED INST,POB 6666,NEW HAVEN,CT 06536, USA.							BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; BOUSQUETANTONEL.C, 1997, IN PRESS EMBO J; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; Ganot P, 1997, GENE DEV, V11, P941, DOI 10.1101/gad.11.7.941; GANOT P, 1997, CELL, V89; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; RIMOLDI OJ, 1993, MOL CELL BIOL, V13, P4382, DOI 10.1128/MCB.13.7.4382; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Tycowski KT, 1996, P NATL ACAD SCI USA, V93, P14480, DOI 10.1073/pnas.93.25.14480; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0	16	280	307	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					669	672		10.1016/S0092-8674(00)80247-0	http://dx.doi.org/10.1016/S0092-8674(00)80247-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182752	hybrid			2022-12-28	WOS:A1997XB92500001
J	Bussey, H; Storms, RK; Ahmed, A; Albermann, K; Allen, E; Ansorge, W; Araujo, R; Aparicio, A; Barrell, B; Badcock, K; Benes, V; Botstein, D; Bowman, S; Bruckner, M; Carpenter, J; Cherry, JM; Chung, E; Churcher, C; Coster, F; Davis, K; Davis, RW; Dietrich, FS; Delius, H; DiPaolo, T; Dubois, E; Dusterhoft, A; Duncan, M; Floeth, M; Fortin, N; Friesen, JD; Fritz, C; Goffeau, A; Hall, J; Hebling, U; Heumann, K; Hilbert, H; Hillier, L; HunickeSmith, S; Hyman, R; Johnston, M; Kalman, S; Kleine, K; Komp, C; Kurdi, O; Lashkari, D; Lew, H; Lin, A; Lin, D; Louis, EJ; Marathe, R; Messenguy, F; Mewes, HW; Mirtipati, S; Moestl, D; MullerAuer, S; Namath, A; Nentwich, U; Oefner, P; Pearson, D; Petel, FX; Pohl, TM; Purnelle, B; Rajandream, MA; Rechmann, S; Rieger, M; Riles, L; Roberts, D; Schafer, M; Scharfe, M; Scherens, B; Schramm, S; Schroder, M; Sdicu, AM; Tettelin, H; Urrestarazu, LA; Ushinsky, S; Vierendeels, F; Vissers, S; Voss, H; Walsh, SV; Wambutt, R; Wang, Y; Wedler, E; Wedler, H; Winnett, E; Zhong, WW; Zollner, A; Vo, DH; Hani, J				Bussey, H; Storms, RK; Ahmed, A; Albermann, K; Allen, E; Ansorge, W; Araujo, R; Aparicio, A; Barrell, B; Badcock, K; Benes, V; Botstein, D; Bowman, S; Bruckner, M; Carpenter, J; Cherry, JM; Chung, E; Churcher, C; Coster, F; Davis, K; Davis, RW; Dietrich, FS; Delius, H; DiPaolo, T; Dubois, E; Dusterhoft, A; Duncan, M; Floeth, M; Fortin, N; Friesen, JD; Fritz, C; Goffeau, A; Hall, J; Hebling, U; Heumann, K; Hilbert, H; Hillier, L; HunickeSmith, S; Hyman, R; Johnston, M; Kalman, S; Kleine, K; Komp, C; Kurdi, O; Lashkari, D; Lew, H; Lin, A; Lin, D; Louis, EJ; Marathe, R; Messenguy, F; Mewes, HW; Mirtipati, S; Moestl, D; MullerAuer, S; Namath, A; Nentwich, U; Oefner, P; Pearson, D; Petel, FX; Pohl, TM; Purnelle, B; Rajandream, MA; Rechmann, S; Rieger, M; Riles, L; Roberts, D; Schafer, M; Scharfe, M; Scherens, B; Schramm, S; Schroder, M; Sdicu, AM; Tettelin, H; Urrestarazu, LA; Ushinsky, S; Vierendeels, F; Vissers, S; Voss, H; Walsh, SV; Wambutt, R; Wang, Y; Wedler, E; Wedler, H; Winnett, E; Zhong, WW; Zollner, A; Vo, DH; Hani, J			The nucleotide sequence of Saccharomyces cerevisiae chromosome XVI	NATURE			English	Article							COMPLETE DNA-SEQUENCE; PHYSICAL MAPS; PROTEINS; SYNTHASE; HISTONE; CLONING; GENES	The nucleotide sequence of the 948,061 base pairs of chromosome XVI has been determined, completing the sequence of the yeast genome. Chromosome XVI was the last yeast chromosome identified(1), and some of the genes mapped early to it, such as GAL4, PEP4 and RAD1 (ref. 2) have played important roles in the development of yeast biology. The architecture of this final chromosome seems to be typical of the large yeast chromosomes, and shows large duplications with other yeast chromosomes. Chromosome XVI contains 487 potential protein-encoding genes, 17 tRNA genes and two small nuclear RNA genes; 27% of the genes have significant similarities to human gene products, and 48% are new and of unknown biological function. Systematic efforts to explore gene function have begun.	CONCORDIA UNIV,DEPT BIOL,MONTREAL,PQ H3G 1M8,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA; MAX PLANCK INST BIOCHEM,MARTINSRIEDER INST PROT SEQUENZEN,D-82152 MARTINSRIED,GERMANY; STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305; EUROPEAN MOL BIOL LAB,PROT DESIGN GRP,D-69117 HEIDELBERG,GERMANY; SANGER CTR,CAMBRIDGE CB10 1SA,ENGLAND; GENOTYPE GMBH,D-69259 WILHELMSFELD,GERMANY; UNIV CATHOLIQUE LOUVAIN,UNITE BIOCHIM PHYSIOL,B-1348 LOUVAIN,BELGIUM; DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY; CERIA COOVI,RES INST,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,MICROBIOL LAB,B-1050 BRUSSELS,BELGIUM; QIAGEN GMBH,D-40724 HILDEN,GERMANY; WASHINGTON UNIV,SCH MED,GENOME SEQUENCING CTR,ST LOUIS,MO 63110; JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9DU,ENGLAND; GESELL ANAL TECH & CONSULTING MBH,D-78467 CONSTANCE,GERMANY; GESELL MOL BIOL TECHNOL MBH,AGON,D-12489 BERLIN,GERMANY; VLAAMS INSTERUNIV INST BIOTHECHNOL,DEPT MICROBIOL,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,LAB ERFELIJKHEIDSLEER & MICROBIOL,BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,LAB PHYSIOL CELLULAIRE & GENET LEVURES,B-1050 BRUSSELS,BELGIUM	Concordia University - Canada; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Max Planck Society; Stanford University; European Molecular Biology Laboratory (EMBL); Wellcome Trust Sanger Institute; Universite Catholique Louvain; Helmholtz Association; German Cancer Research Center (DKFZ); Universite Libre de Bruxelles; Vrije Universiteit Brussel; QIAGEN GmbH; Washington University (WUSTL); University of Oxford; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Bussey, H (corresponding author), MCGILL UNIV,DEPT BIOL,1205 DR PENFIELD AVE,MONTREAL,PQ H3A 1B1,CANADA.		Ansorge, Wilhelm/AAN-8780-2020; Storms, Reginald/B-2405-2013; Johnston, Mark/K-3543-2019; Louis, Edward/B-7920-2008; Johnston, Mark/R-6156-2019; Wilson, Richard K./AAF-4139-2019; Mewes, Hans-Werner/A-8204-2019	Johnston, Mark/0000-0002-4932-7229; Louis, Edward/0000-0003-1157-3608; Wilson, Richard K./0000-0002-1992-1358; Mewes, Hans-Werner/0000-0002-9713-6398; Cherry, J. Michael/0000-0001-9163-5180; Benes, Vladimir/0000-0002-0352-2547	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bassett DE, 1996, NATURE, V379, P589, DOI 10.1038/379589a0; BROACH JR, 1981, MOL BIOL YEAST SACCH, P653; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; Galibert F, 1996, EMBO J, V15, P2031, DOI 10.1002/j.1460-2075.1996.tb00557.x; GOEBL MG, 1986, CELL, V46, P983, DOI 10.1016/0092-8674(86)90697-5; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1993, FEBS LETT, V325, P112, DOI 10.1016/0014-5793(93)81425-Y; GOFFEAU A, 1996, SCIENCE, V274, P563, DOI DOI 10.1126/SCIENCE.274.5287.546; GUELIN E, 1993, J BIOL CHEM, V268, P161; HAWTHORNE DC, 1968, GENETICS, V60, P735; HEUMANN K, UNPUB NATURE GENET; HEUMANN K, 1996, P 4 INT C INT SYST M; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; LOUIS EJ, 1995, GENETICS, V139, P125; LOUIS EJ, 1995, BIOCHEMICA, V3, P25; Lussier M, 1997, YEAST, V13, P267, DOI 10.1002/(SICI)1097-0061(19970315)13:3<267::AID-YEA72>3.0.CO;2-K; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; RILES L, 1993, GENETICS, V134, P81; ROEMER T, 1994, YEAST, V10, P1527, DOI 10.1002/yea.320101117; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; TANAKA S, 1992, NUCLEIC ACIDS RES, V21, P1149; Ushinsky SC, 1997, YEAST, V13, P151, DOI 10.1002/(SICI)1097-0061(199702)13:2<151::AID-YEA94>3.0.CO;2-5; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZLATANOVA J, 1994, FASEB J, V8, P1260, DOI 10.1096/fasebj.8.15.8001738	31	57	581	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632		S			103	105		10.1038/387s103	http://dx.doi.org/10.1038/387s103			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169875				2022-12-28	WOS:A1997XB54600015
J	Rothman, JE; Sollner, TH				Rothman, JE; Sollner, TH			Membrane trafficking - Throttles and dampers: Controlling the engine of membrane fusion	SCIENCE			English	Editorial Material							BINDING YPT1 PROTEIN; TRANSPORT VESICLES; ENDOPLASMIC-RETICULUM; GOLGI TRANSPORT; YEAST; SECRETION; SYNTAXIN; GTPASES; COMPLEX; SEC4				Rothman, JE (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.							AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0	24	91	94	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1212	1213		10.1126/science.276.5316.1212	http://dx.doi.org/10.1126/science.276.5316.1212			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9182331				2022-12-28	WOS:A1997XA49700029
J	Kastner, JH; Zuckerman, B; Weintraub, DA; Forveille, T				Kastner, JH; Zuckerman, B; Weintraub, DA; Forveille, T			X-ray and molecular emission from the nearest region of recent star formation	SCIENCE			English	Article							T-TAURI STARS; CIRCUMSTELLAR DISKS; DARK CLOUD; ROSAT; NEBULAE; GAS	The isolated, young, sunlike star TW Hya and four other young stars in its vicinity are strong x-ray sources. Their similar x-ray and optical properties indicate that the stars make up a physical association that is on the order of 20 million years old and that lies between about 40 and 60 parsecs (between about 130 and 200 light years) from Earth. TW Hya itself displays circumstellar CO, HCN, CN, and HCO+ emission. These molecules probably orbit the star in a solar-system-sized disk viewed more or less face-on, whereas the star is likely viewed pole-on. Being at least three times closer to Earth than any well-studied region of star formation, the TW Hya Association serves as a test-bed for the study of x-ray emission from young stars and the formation of planetary systems around sunlike stars.	UNIV CALIF LOS ANGELES,DEPT PHYS & ASTRON,LOS ANGELES,CA 90095; VANDERBILT UNIV,DEPT PHYS & ASTRON,NASHVILLE,TN 37235; OBSERV GRENOBLE,GRP ASTROPHYS,F-38041 GRENOBLE,FRANCE	University of California System; University of California Los Angeles; Vanderbilt University; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Kastner, JH (corresponding author), MIT,CTR SPACE RES,70 VASSAR ST,BLDG 37-667A,CAMBRIDGE,MA 02139, USA.							BACHILLER R, IN PRESS; BECKWITH SVW, 1990, ASTRON J, V99, P924, DOI 10.1086/115385; BECKWITH SVW, 1993, ASTROPHYS J, V402, P280, DOI 10.1086/172131; Briceno C, 1997, ASTRON J, V113, P740, DOI 10.1086/118293; CASANOVA S, 1995, ASTROPHYS J, V439, P752, DOI 10.1086/175214; COX P, 1992, ASTRON ASTROPHYS, V266, P420; DANTONA F, 1994, ASTROPHYS J SUPPL S, V90, P467, DOI 10.1086/191867; DELAREZA R, 1989, ASTROPHYS J, V343, pL61, DOI 10.1086/185511; FEIGELSON ED, 1993, ASTROPHYS J, V416, P623, DOI 10.1086/173264; Feigelson ED, 1996, ASTROPHYS J, V468, P306, DOI 10.1086/177691; FLEMING TA, 1995, ASTROPHYS J, V450, P401, DOI 10.1086/176150; GENZEL R, 1987, MILLIMETER SUBMILLIM, P223; GHEZ A, COMMUNICATION; GREGORIOHETEM J, 1992, ASTRON J, V103, P549, DOI 10.1086/116082; HALL DS, 1991, IAU C, V130, P353; KASTNER J, UNPUB; Lawson WA, 1996, MON NOT R ASTRON SOC, V280, P1071; MAGNANI L, 1995, ASTROPHYS J SUPPL S, V96, P1; NEUHAUSER R, 1995, ASTRON ASTROPHYS, V297, P391; OMODAKA T, 1992, ASTROPHYS J, V396, pL87, DOI 10.1086/186523; Patten BM, 1996, ASTROPHYS J SUPPL S, V106, P489, DOI 10.1086/192346; PYE JP, 1994, MON NOT R ASTRON SOC, V266, P798, DOI 10.1093/mnras/266.4.798; RANDICH S, 1995, ASTRON ASTROPHYS, V300, P134; Randich S, 1996, ASTRON ASTROPHYS, V305, P785; RUCINSKI SM, 1985, ASTRON J, V90, P2321, DOI 10.1086/113937; RUCINSKI SM, 1983, ASTRON ASTROPHYS, V121, P217; Soderblom DR, 1996, ASTROPHYS J, V460, P984, DOI 10.1086/177026; STAHLER SW, COMMUNICATION; Stauffer JR, 1997, ASTROPHYS J, V479, P776, DOI 10.1086/303930; STAUFFER JR, 1994, ASTROPHYS J SUPPL S, V91, P625, DOI 10.1086/191951; TORRES G, 1995, ASTROPHYS J, V452, P870, DOI 10.1086/176355; VOGES W, IN PRESS ASTRON ASTR; WEINTRAUB DA, 1989, ASTROPHYS J, V340, pL69, DOI 10.1086/185441; WICHMANN R, 1997, HIPP VEN 97 S VEN IT; Zboril M, 1997, MON NOT R ASTRON SOC, V284, P685, DOI 10.1093/mnras/284.3.685; ZUCKERMAN B, 1995, NATURE, V373, P494, DOI 10.1038/373494a0	37	339	339	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					67	71		10.1126/science.277.5322.67	http://dx.doi.org/10.1126/science.277.5322.67			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204898				2022-12-28	WOS:A1997XJ41800038
J	Auleley, GR; Ravaud, P; Giraudeau, B; Kerboull, L; Nizard, R; Massin, P; deLoubresse, CG; Vallee, C; Durieux, P				Auleley, GR; Ravaud, P; Giraudeau, B; Kerboull, L; Nizard, R; Massin, P; deLoubresse, CG; Vallee, C; Durieux, P			Implementation of the Ottawa ankle rules in France - A multicenter randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL DECISION RULES; X-RAY EXAMINATIONS; INVERSION INJURIES; RADIOGRAPHY; GUIDELINES; VALIDATION; PHYSICIANS; EMERGENCY; ACCIDENT; SPRAIN	Objectives.-To assess the impact of the implementation of the Ottawa ankle rules on radiography requests in French hospitals during a 5-month intervention period and the impact of using posters alone to sustain the effect of the rules during a 5-month postintervention period. Design.-Multicenter randomized controlled trial preceded and followed by observational studies of radiological practices. Setting.-The emergency departments of 5 Paris university teaching hospitals of the Assistance Publique-Hopitaux de Paris. Patients.-A total of 2218, 1911, and 851 patients-all aged 18 years and older-who were seen for acute ankle or midfoot injuries in emergency departments during preintervention, intervention, and postintervention periods, respectively. Intervention.-Implementation of the Ottawa ankle rules by emergency department physicians in the intervention hospitals (using meetings, posters, pocket cards, and data forms). During the postintervention period, posters alone were used to sustain the intervention effect. Main Outcome Measure.-Percentage of patients for whom radiography was requested. Results.-During the preintervention period, 98% and 98.5% of patients were referred for radiography in the intervention and control groups, respectively. During the intervention period, the mean proportions of patients referred for radiography by physicians was 78.9% in the intervention group and 99% in the control group (P=.03). Between preintervention and intervention periods, a relative reduction of 22.4% (95% confidence interval [CI], 19.8%-24.9%) in radiography requests was observed in the intervention group, while requests increased by 0.5% (95% CI, 0%-1.4%) in the control group. During the postintervention period, the proportion of radiography requests in the intervention hospitals was lower than the proportion observed in the preintervention period (83.1% vs 98%). Conclusions.-Implementation of the Ottawa ankle rules significantly reduced radiography requests in French hospitals. Using a minimal postintervention implementation strategy, the effect of this intervention decreased but persisted after it was discontinued.	ASSISTANCE PUBL HOP PARIS,SERV EVALUAT QUAL,DELEGAT EVALUAT MED,DIRECT PROSPECT & INFORMAT MED,F-75004 PARIS,FRANCE; HOP ST LOUIS,DEPT BIOSTAT & MED COMP,PARIS,FRANCE; HOP ST LOUIS,DEPT ORTHOPED,PARIS,FRANCE; COCHIN HOSP,DEPT ORTHOPED,PARIS,FRANCE; HOP XAVIER BICHAT,DEPT ORTHOPED,PARIS,FRANCE; HOP XAVIER BICHAT,EMERGENCY DEPT,PARIS,FRANCE; TENON HOSP,DEPT ORTHOPED,PARIS,FRANCE; RAYMOND POINCARE HOSP,DEPT MED IMAGING,GARCHES,FRANCE	Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP			Nizard, Remy/R-5845-2019; Massin, Philippe/AAX-4015-2020; ravaud, philippe/C-1694-2009; Giraudeau, Bruno/L-9003-2015	Giraudeau, Bruno/0000-0003-3031-8258; Ravaud, Philippe/0000-0001-8264-9206				BEAULIEU MD, 1986, CAN MED ASSOC J, V135, P1003; BRAND DA, 1982, NEW ENGL J MED, V306, P333, DOI 10.1056/NEJM198202113060604; BROOKS SC, 1981, BRIT MED J, V282, P607, DOI 10.1136/bmj.282.6264.607; COCKSHOTT WP, 1983, CAN MED ASSOC J, V129, P129; CORNFIELD J, 1978, AM J EPIDEMIOL, V108, P100, DOI 10.1093/oxfordjournals.aje.a112592; DELACEY G, 1979, BRIT MED J, V1, P1597, DOI 10.1136/bmj.1.6178.1597; DELACEY G, 1979, BRIT MED J, V1, P1595, DOI 10.1136/bmj.1.6178.1595; DIEHR P, 1988, MED DECIS MAKING, V8, P40, DOI 10.1177/0272989X8800800106; DIVINE GW, 1992, J GEN INTERN MED, V7, P623, DOI 10.1007/BF02599201; Donner A, 1996, J CLIN EPIDEMIOL, V49, P435, DOI 10.1016/0895-4356(95)00511-0; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; DUNLOP MG, 1986, BRIT MED J, V293, P603, DOI 10.1136/bmj.293.6547.603; DUNN OJ, 1974, APPLIED STATISTICS; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; FOWKES FGR, 1986, BRIT MED J, V292, P883, DOI 10.1136/bmj.292.6524.883; GLEADHILL DNS, 1987, BRIT MED J, V294, P943, DOI 10.1136/bmj.294.6577.943; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; KERR L, 1994, NEW ZEAL MED J, V107, P294; LUCCHESI GM, 1995, ANN EMERG MED, V26, P1, DOI 10.1016/S0196-0644(95)70229-6; MATTHEWS MG, 1986, BRIT MED J, V293, P957, DOI 10.1136/bmj.293.6552.957-a; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; MCNALLY E, 1995, BRIT MED J, V310, P640, DOI 10.1136/bmj.310.6980.640; PIGMAN EC, 1994, ANN EMERG MED, V24, P41, DOI 10.1016/S0196-0644(94)70160-1; SATTERTHWAITE FE, 1946, BIOMETRICS BULL, V2, P110, DOI 10.2307/3002019; SMITH GF, 1993, J FAM PRACTICE, V37, P345; Snedecor GW, 1980, STAT METHODS, V7th; Soumerai SB, 1994, PHARMACOEPIDEM DR S, P395; STIELL I, 1995, BRIT MED J, V311, P594, DOI 10.1136/bmj.311.7005.594; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; STOTHER IG, 1983, INJURY, V5, P213; SUJITKUMAR P, 1986, ARCH EMERG MED, V3, P101; SVENSON J, 1988, LANCET, V1, P244; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; VARGISH T, 1983, INJURY, V14, P507, DOI 10.1016/0020-1383(83)90053-0; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; WHITINGOKEEFE QE, 1984, MED CARE, V22, P1101, DOI 10.1097/00005650-198412000-00005	41	62	62	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1935	1939						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200633				2022-12-28	WOS:A1997XF08700037
J	Eissenberg, T; Bigelow, GE; Strain, EC; Walsh, SL; Brooner, RK; Stitzer, ML; Johnson, RE				Eissenberg, T; Bigelow, GE; Strain, EC; Walsh, SL; Brooner, RK; Stitzer, ML; Johnson, RE			Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence - A randomized clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADDICTION SEVERITY INDEX; METHADONE-MAINTENANCE TREATMENT; ABUSE; VALIDITY	Objective.-To compare the clinical efficacy of different doses of levomethadyl Design.-A randomized controlled, double-blind, parallel group, 17-week study. Setting.-Outpatient facilities at Johns Hopkins University Bayview Medical Center, Baltimore, Md. Patients.-Opioid-dependent volunteers (N=180) applying to a treatment-research clinic. Intervention.-Thrice-weekly (Monday/Wednesday/Friday) oral LAAM dose conditions of 25/25/35 mg, 50/50/70 mg, and 100/100/140 mg and nonmandatory counseling. Main Outcome Measures.-Retention in treatment, self-reported heroin use, and opioid-positive urine specimens. Results.-Retention was independent of subjects' sex and dose. Self-reported heroin use decreased in a dose-related manner. At final assessment, patients in the high-dose condition reported using heroin 2.5 of 30 days as compared with 4.1 or 6.3 days for patients in the medium-dose and low-dose conditions, respectively (high dose vs low dose, P<.05); urinalysis results were similarly dose related. Overall, 20 (34%) of 59 patients in the high-dose condition remained opioid-abstinent for 4 consecutive weeks, as compared with 8 (14%) of 59 in the medium-dose and 7 (11%) of 62 in the low-dose conditions (P<.01). Self-report and urinalysis data are consistent with a greater than 90% reduction in illicit opioid use by the high-dose group relative to pretreatment levels. Conclusion.-Opioid substitution treatment with LAAM substantially reduces illicit opioid use. The clinical efficacy of LAAM is positively related to dose.	JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BEHAV PHARMACOL RES UNIT, BALTIMORE, MD 21224 USA; VIRGINIA COMMONWEALTH UNIV, DEPT PSYCHOL, RICHMOND, VA 23284 USA; VIRGINIA COMMONWEALTH UNIV, CTR DRUG & ALCOHOL STUDIES, RICHMOND, VA 23284 USA	Johns Hopkins University; Virginia Commonwealth University; Virginia Commonwealth University			, Thomas/AAD-4757-2020	Walsh, Sharon/0000-0002-9722-5681; Eissenberg, Thomas/0000-0002-8277-5437	NATIONAL INSTITUTE ON DRUG ABUSE [K20DA000166, P50DA005273, K05DA000050] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BABST DV, 1971, BRIT J ADDICT, V66, P195; Ball J.C., 2012, EFFECTIVENESS METHAD; Bouffard R, 2003, CAN J PSYCHIAT, V48, P546, DOI 10.1177/070674370304800806; Brooner RK, 1997, ARCH GEN PSYCHIAT, V54, P71; CAPLEHORN JRM, 1993, ADDICTION, V88, P119, DOI 10.1111/j.1360-0443.1993.tb02769.x; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V37, P23; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; COOPER JR, 1995, JAMA-J AM MED ASSOC, V273, P1619, DOI 10.1001/jama.273.20.1619; DAUNNO T, 1992, JAMA-J AM MED ASSOC, V267, P253, DOI 10.1001/jama.267.2.253; DEROGATIS L, 1983, SCL 90 R MANUAL 2; DOLE VP, 1992, JAMA-J AM MED ASSOC, V267, P2234, DOI 10.1001/jama.267.16.2234; DOLE VP, 1965, JAMA-J AM MED ASSOC, V193, P80; Finney D. J., 1978, Statistical method in biological assay.; *FOOD DRUG ADM, 1985, COSTART; FRASER HF, 1952, J PHARMACOL EXP THER, V105, P458; FREEDMAN RR, 1981, DRUG ALCOHOL DEPEN, V8, P215, DOI 10.1016/0376-8716(81)90064-8; Fulco C.E., 1995, DEV MEDICATIONS TREA; Goldstein A., 1994, ADDICTION BIOL DRUG; HARGREAVES WA, 1979, J PSYCHEDEL DRUG, V11, P223, DOI 10.1080/02791072.1979.10472108; HARGREAVES WA, 1986, RES TREATMENT NARCOT, P19; HARTEL DM, 1995, AM J PUBLIC HEALTH, V85, P83, DOI 10.2105/AJPH.85.1.83; HSER YI, 1991, INT J ADDICT, V25, P1295, DOI 10.3109/10826089009068465; JAFFE JH, 1970, J AMER MED ASSOC, V211, P1834; JAFFE JH, 1972, J AMER MED ASSOC, V222, P437, DOI 10.1001/jama.222.4.437; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; KIRN TF, 1988, JAMA-J AM MED ASSOC, V260, P2970, DOI 10.1001/jama.260.20.2970; KOSTEN TR, 1986, AM J DRUG ALCOHOL AB, V12, P1, DOI 10.3109/00952998609083739; KOSTEN TR, 1983, J NERV MENT DIS, V171, P606, DOI 10.1097/00005053-198310000-00003; KREEK MJ, 1992, RES P ARNMD, V70, P205; *LAAM COLL STUD GR, IN PRESS J MAINTENAN; Ling W, 1996, ARCH GEN PSYCHIAT, V53, P401; LING W, 1978, ARCH GEN PSYCHIAT, V35, P345; LING W, 1976, ARCH GEN PSYCHIAT, V33, P709; Magura S, 1996, SUBST USE MISUSE, V31, P1131, DOI 10.3109/10826089609063969; MARTIN WR, 1973, ARCH GEN PSYCHIAT, V28, P286; MCGLOTHLIN WH, 1981, ARCH GEN PSYCHIAT, V38, P1055; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; MCLELLAN AT, 1983, ARCH GEN PSYCHIAT, V40, P620; *MED EC DAT, 1996, PHYS DESK REF; Meinert CL., 1986, CLIN TRIALS DESIGN C; *NAT I DRUG AB, 1985, GUID ADD SEV IND BAC; NOVICK DM, 1988, JAMA-J AM MED ASSOC, V259, P3299, DOI 10.1001/jama.259.22.3299; *OFF NAT DRUG CONT, 1996, NAT DRUG CONTR STRAT; Pocock SJ., 2013, CLIN TRIALS PRACTICA; Rettig RA., 1995, FEDERAL REGULATION M; ROUNSAVILLE BJ, 1982, ARCH GEN PSYCHIAT, V39, P161; SAVAGE C, 1976, COMPR PSYCHIAT, V17, P415, DOI 10.1016/0010-440X(76)90044-4; SENAY EC, 1977, JAMA-J AM MED ASSOC, V237, P138, DOI 10.1001/jama.237.2.138; Silverman K, 1996, ARCH GEN PSYCHIAT, V53, P409; Silverman K, 1996, DRUG ALCOHOL DEPEN, V41, P157, DOI 10.1016/0376-8716(96)01246-X; Spitzer RL, 1987, INSTRUCTION MANUAL S; STRAIN EC, 1993, ANN INTERN MED, V119, P23, DOI 10.7326/0003-4819-119-1-199307010-00004; STRAIN EC, IN PRESS J MAINTENAN; *SUBST AB MENT HLT, 1996, PREL EST DRUG AB WAR; TENNANT F S JR, 1986, Journal of Substance Abuse Treatment, V3, P195; *US GEN ACC OFF, 1990, METH MAINT SOM TREAT; WOODY GE, 1985, ARCH GEN PSYCHIAT, V42, P1081; ZAKS A, 1972, J AMER MED ASSOC, V220, P811, DOI 10.1001/jama.220.6.811	60	45	46	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1945	1951		10.1001/jama.277.24.1945	http://dx.doi.org/10.1001/jama.277.24.1945			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200635				2022-12-28	WOS:A1997XF08700039
J	Babcock, M; deSilva, D; Oaks, R; DavisKaplan, S; Jiralerspong, S; Montermini, L; Pandolfo, M; Kaplan, J				Babcock, M; deSilva, D; Oaks, R; DavisKaplan, S; Jiralerspong, S; Montermini, L; Pandolfo, M; Kaplan, J			Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; FRIEDREICHS ATAXIA	The gene responsible for Friedreich's ataxia, a disease characterized by neurodegeneration and cardiomyopathy, has recently been cloned and its product designated frataxin. A gene in Saccharomyces cerevisiae was characterized whose predicted protein product has high sequence similarity to the human frataxin protein. The yeast gene (yeast frataxin homolog, YFH1) encodes a mitochondrial protein involved in iron homeostasis and respiratory function. Human frataxin also was shown to be a mitochondrial protein. Characterizing the mechanism by which YFH1 regulates iron homeostasis in yeast may help to define the pathologic process leading to cell damage in Friedreich's ataxia.	UNIV UTAH, SCH MED, DEPT PATHOL, DIV CELL BIOL & IMMUNOL, SALT LAKE CITY, UT 84132 USA; CTR RECH LOUIS CHARLES SIMARD, MONTREAL, PQ H2L 4M1, CANADA; UNIV MONTREAL, DEPT MED, MONTREAL, PQ H2L 4M1, CANADA; MCGILL UNIV, DEPT NEUROL & NEUROSURG, MONTREAL, PQ H3A 2B4, CANADA	Utah System of Higher Education; University of Utah; Universite de Montreal; Universite de Montreal; McGill University			Pandolfo, Massimo/B-2853-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030534, P50DK049219, R01DK030534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034192] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30534, DK49219] Funding Source: Medline; NINDS NIH HHS [NS34192] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BARBEAU A, 1980, CAN J NEUROL SCI, V7, P455, DOI 10.1017/S0317167100023064; BENHAMIDA M, 1993, NEUROLOGY, V43, P2179, DOI 10.1212/WNL.43.11.2179; BLASS JP, 1976, NEW ENGL J MED, V295, P62, DOI 10.1056/NEJM197607082950202; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Carvajal JJ, 1996, NAT GENET, V14, P157, DOI 10.1038/ng1096-157; CHAMBERLAIN S, 1982, J NEUROL NEUROSUR PS, V45, P1136, DOI 10.1136/jnnp.45.12.1136; Cossee M, 1997, NAT GENET, V15, P337, DOI 10.1038/ng0497-337; DIJKSTRA UJ, 1983, ANN NEUROL, V13, P325, DOI 10.1002/ana.410130317; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Filla A, 1996, AM J HUM GENET, V59, P554; FINOCCHIARO G, 1988, NEUROLOGY, V38, P1292, DOI 10.1212/WNL.38.8.1292; GEOFFROY G, 1976, Canadian Journal of Neurological Sciences, V3, P279; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; HARDING AE, 1993, ADV NEUROL, V61, P1; HARDING AE, 1983, Q J MED, V52, P489; JIRALERSPONG S, IN PRESS NEUROBIOL D; Lamarche J., 1993, HDB CEREBELLAR DIS, P453; Montermini L, 1997, ANN NEUROL, V41, P675, DOI 10.1002/ana.410410518; MORGAN RO, 1979, CAN J NEUROL SCI, V6, P227, DOI 10.1017/S0317167100119699; NAKAI K, 1991, B I CHEM RES KYOTO U, V69, P269; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Schols L, 1996, EUR J NEUROL, V3, P55, DOI 10.1111/j.1468-1331.1996.tb00190.x; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STUMPF DA, 1982, NEUROLOGY, V32, P221, DOI 10.1212/WNL.32.3.221; THOMAS SM, 1989, BIOCHIM BIOPHYS ACTA, V1002, P189, DOI 10.1016/0005-2760(89)90286-5; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	30	757	776	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	1997	276	5319					1709	1712		10.1126/science.276.5319.1709	http://dx.doi.org/10.1126/science.276.5319.1709			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180083				2022-12-28	WOS:A1997XD94700046
J	Cwirla, SE; Balasubramanian, P; Duffin, DJ; Wagstrom, CR; Gates, CM; Singer, SC; Davis, AM; Tansik, RL; Mattheakis, LC; Boytos, CM; Schatz, PJ; Baccanari, DP; Wrighton, NC; Barrett, RW; Dower, WJ				Cwirla, SE; Balasubramanian, P; Duffin, DJ; Wagstrom, CR; Gates, CM; Singer, SC; Davis, AM; Tansik, RL; Mattheakis, LC; Boytos, CM; Schatz, PJ; Baccanari, DP; Wrighton, NC; Barrett, RW; Dower, WJ			Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine	SCIENCE			English	Article							FILAMENTOUS PHAGE; LIGANDS; MPL; SUPERFAMILY; INTERFACE; LIBRARIES; INSERTION; HORMONE; DOMAIN	Two families of small peptides that bind to the human thrombopoietin receptor and compete with the binding of the natural ligand thrombopoietin (TPO) were identified from recombinant peptide libraries, The sequences of these peptides were not found in the primary sequence of TPO, Screening libraries of variants of one of these families under affinity-selective conditions yielded a 14-amino acid peptide (Ile-Glu-Gly-Pro-Thr-Leu-Arg-Gln-Trp-Leu-Ala-Ala-Arg-Ala) with high affinity (dissociation constant approximate to 2 nanomolar) that stimulates the proliferation of a TPO-responsive Ba/F3 cell line with a median effective concentration (EC50) of 400 nanomolar, Dimerization of this peptide by a carboxyl-terminal linkage to a lysine branch produced a compound with an EC50 of 100 picomolar, which was equipotent to the 332-amino acid natural cytokine in cell-based assays, The peptide dimer also stimulated the in vitro proliferation and maturation of megakaryocytes from human bone marrow cells and promoted an increase in platelet count when administered to normal mice.	AFFYMAX RES INST,PALO ALTO,CA 94304; GLAXO WELLCOME INC,RES INST,RES TRIANGLE PK,NC 27709	GlaxoSmithKline								ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BARRETT RW, 1992, ANAL BIOCHEM, V204, P357, DOI 10.1016/0003-2697(92)90252-3; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOMSIFE R, 1991, ANTIMICROB AGENTS CH, V35, P322; DUFFIN DJ, UNPUB; Gates CM, 1996, J MOL BIOL, V255, P373, DOI 10.1006/jmbi.1996.0031; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; MARTENS CL, 1995, J BIOL CHEM, V270, P21129, DOI 10.1074/jbc.270.36.21129; Mattheakis LC, 1996, METHOD ENZYMOL, V267, P195; MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PETERS EA, 1994, J BACTERIOL, V176, P4296, DOI 10.1128/jb.176.14.4296-4305.1994; Schatz PJ, 1996, METHOD ENZYMOL, V267, P171; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WHITEHORN EA, 1995, BIO-TECHNOL, V13, P1215, DOI 10.1038/nbt1195-1215; Wrighton N. C., 1996, Blood, V88, p543A; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Yanofsky SD, 1996, P NATL ACAD SCI USA, V93, P7381, DOI 10.1073/pnas.93.14.7381; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	24	348	457	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1696	1699		10.1126/science.276.5319.1696	http://dx.doi.org/10.1126/science.276.5319.1696			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180079				2022-12-28	WOS:A1997XD94700042
J	Dent, OF; Sulway, MR; Broe, GA; Creasey, H; Kos, SC; Jorm, AF; Tennant, C; Fairley, MJ				Dent, OF; Sulway, MR; Broe, GA; Creasey, H; Kos, SC; Jorm, AF; Tennant, C; Fairley, MJ			Alcohol consumption and cognitive performance in a random sample of Australian soldiers who served in the Second World War	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SOCIAL DRINKERS; POPULATION	Objective: To examine the association between the average daily alcohol intake of older men in 1982 and cognitive performance and brain atrophy nine years later, Subjects: Random sample of 209 Australian men living in the community who were veterans of the second world war. Their mean age in 1982 was 64.3 years, Main outcome measures: 18 standard neuropsychological tests measuring a range of intellectual functions. Cortical, sylvian, and vermian atrophy on computed tomography. Results: Compared with Australian men of the same age in previous studies these men had sustained a high rate of alcohol consumption into old age, However, there was no significant correlation, linear or non-linear, between alcohol consumption in 1982 and results in any of die neuropsychological tests in 1991; neither was alcohol consumption associated with brain atrophy on computed tomography. Conclusion: No evidence was found that apparently persistent lifelong consumption of alcohol was related to the cognitive functioning of these men in old age.	CONCORD HOSP, CTR EDUC & RES AGEING, SYDNEY, NSW 2319, AUSTRALIA; CONCORD HOSP, DEPT RADIOL, SYDNEY, NSW 2139, AUSTRALIA; CONCORD HOSP, DEPT PSYCHIAT, SYDNEY, NSW 2139, AUSTRALIA; AUSTRALIAN NATL UNIV, NATL HLTH & MRC SOCIAL PSYCHIAT RES UNIT, CANBERRA, ACT 0200, AUSTRALIA; ROYAL N SHORE HOSP, SYDNEY ACAD PSYCHIAT UNIT, SYDNEY, NSW 2065, AUSTRALIA	Concord Repatriation General Hospital; Concord Repatriation General Hospital; Concord Repatriation General Hospital; Australian National University; Royal North Shore Hospital; University of Sydney	Dent, OF (corresponding author), AUSTRALIAN NATL UNIV, DEPT SOCIOL, CANBERRA, ACT 0200, AUSTRALIA.		Jorm, Anthony F/B-5555-2009	Jorm, Anthony F/0000-0002-1424-4116				Benton A.L., 1974, REVISED VISUAL RETEN; BOWDEN SC, 1987, ALCOHOL CLIN EXP RES, V11, P407, DOI 10.1111/j.1530-0277.1987.tb01332.x; Castles I, 1991, 1989 90 NATL HLTH SU; Cohen J., 1988, STAT POWER ANAL BEHA, DOI DOI 10.1016/B978-0-12-179060-8.50006-2; Dufour M C, 1992, Clin Geriatr Med, V8, P127; Edwards G, 1996, BRIT MED J, V312, P1, DOI 10.1136/bmj.312.7022.1; Goodglass H., 1983, BOSTON NAMING TEST; GOODWIN JS, 1987, AM J PUBLIC HEALTH, V77, P173, DOI 10.2105/AJPH.77.2.173; GOULSTON KJ, 1985, MED J AUSTRALIA, V143, P6, DOI 10.5694/j.1326-5377.1985.tb122757.x; HEBERT LE, 1993, AM J EPIDEMIOL, V137, P881, DOI 10.1093/oxfordjournals.aje.a116749; ILIFFE S, 1991, AGE AGEING, V20, P120, DOI 10.1093/ageing/20.2.120; JACKSON R, 1995, LANCET, V346, P716, DOI 10.1016/S0140-6736(95)91496-X; Lezak M.D., 2012, NEUROPSYCHOLOGICAL A; Nelson H.E., 1982, NATIONAL ADULT READI; PAGE RD, 1987, ALCOHOL CLIN EXP RES, V11, P376, DOI 10.1111/j.1530-0277.1987.tb01328.x; POLS RG, 1995, IS THERE SAFE LEVEL; Raven J.C., 1965, GUIDE USING COLOURED; Raven JC., 1984, MANUAL RAVENS PROGR; REID WGJ, 1989, INT J NEUROSCI, V48, P205, DOI 10.3109/00207458909002162; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1964, LEXAMEN CLINIQUE PSY; SCHERR PA, 1988, AM J EPIDEMIOL, V128, P1084; WAUGH M, 1989, BRIT J ADDICT, V84, P659; Wechsler D., 1945, WECHSLER MEMORY SCAL; Wechsler D., 2010, WAIS R MANUAL, VUK 4th Edn	25	45	45	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	1997	314	7095					1655	1657		10.1136/bmj.314.7095.1655	http://dx.doi.org/10.1136/bmj.314.7095.1655			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD874	9180067	Green Published			2022-12-28	WOS:A1997XD87400024
J	Ramirez, A; House, A				Ramirez, A; House, A			ABC of mental health - Common mental health problems in hospital	BRITISH MEDICAL JOURNAL			English	Article									LAMBETH HEALTHCARE NHS TRUST,LONDON,ENGLAND; GEN INFIRM,DEPT LIAISON PSYCHIAT,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary	Ramirez, A (corresponding author), UNITED MED & DENT SCH,ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND.			House, Allan/0000-0001-8721-8026				Creed F., 1992, MED SYMPTOMS NOT EXP; House A, 1995, PSYCHIAT ASPECTS PHY; *ROYAL COLL PHYS R, 1995, PSYCHOL CAR MED PLAN; Royal College of Psychiatrists, 1994, GEN HOSP MAN AD DEL	4	8	9	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 7	1997	314	7095					1679	1681		10.1136/bmj.314.7095.1679	http://dx.doi.org/10.1136/bmj.314.7095.1679			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD874	9193294	Green Published, Green Submitted			2022-12-28	WOS:A1997XD87400031
J	Wagner, S; Castel, M; Gainer, H; Yarom, Y				Wagner, S; Castel, M; Gainer, H; Yarom, Y			GABA in the mammalian suprachiasmatic nucleus and its role in diurnal rhythmicity	NATURE			English	Article							NEURONS; CLOCK; ACID; NEUROTRANSMISSION; HYPOTHALAMUS; MECHANISMS; RESPONSES; RECEPTORS; HAMSTER	Mammals manifest circadian behaviour timed by an endogenous clock in the hypothalamic suprachiasmatic nucleus (SCN)(1). Considerable progress has been made in identifying the molecular basis of the circadian clock(2,3), but the mechanisms by which it is translated into cyclic firing activity, high during the day and low at night, are still poorly understood. GABA (gamma-aminobutyric acid), a common inhibitory neurotransmitter in the central nervous system, is particularly densely distributed within the SCN, where it is located in the majority of neuronal somata(4,5) and synaptic terminals(6,7). Using an in vitro brain-slice technique, we have now studied the effect of bath-applied GABA on adult SCN neurons at various times of the day. We find that GABA acts as an inhibitory neurotransmitter at night, decreasing the firing frequency; but during the day GABA acts as an excitatory neurotransmitter, increasing the firing frequency. We show that this dual effect, which is mediated by GABA(A) receptors, may be attributed to an oscillation in intracellular chloride concentration. A likely explanation is that the amplitude of the oscillation in firing rate, displayed by individual neurons, is amplified by the dual effect of GABA in the SCN's GABAergic network.	HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT CELL & ANIM BIOL,IL-91904 JERUSALEM,ISRAEL; NINCDS,NEUROCHEM LAB,NIH,BETHESDA,MD 20892	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Wagner, S (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT NEUROBIOL,IL-91904 JERUSALEM,ISRAEL.			Wagner, Shlomo/0000-0002-7618-0752				ANDERSEN P, 1980, J PHYSIOL-LONDON, V305, P279, DOI 10.1113/jphysiol.1980.sp013363; Belenky M, 1996, NEUROSCIENCE, V70, P127, DOI 10.1016/0306-4522(95)00327-F; BOS NPA, 1993, BRAIN RES BULL, V31, P67, DOI 10.1016/0361-9230(93)90012-Z; BUIJS RM, 1994, J COMP NEUROL, V340, P381, DOI 10.1002/cne.903400308; BUIJS RM, 1995, J COMP NEUROL, V358, P343, DOI 10.1002/cne.903580304; CASTEL M, 1993, EUR J NEUROSCI, V5, P368, DOI 10.1111/j.1460-9568.1993.tb00504.x; CASTEL M, 1990, EUR J NEUROSCI, V3, P111; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; DECAVEL C, 1990, J COMP NEUROL, V302, P1019, DOI 10.1002/cne.903020423; Estibeiro JP, 1996, TRENDS NEUROSCI, V19, P257, DOI 10.1016/S0166-2236(96)30010-6; Gillette MU, 1991, SUPRACHIASMATIC NUCL, P125; Klein D.C., 1991, SUPRACHIASMATIC NUCL; LIOU SY, 1990, BRAIN RES BULL, V25, P93, DOI 10.1016/0361-9230(90)90257-Z; MASON R, 1991, BRAIN RES, V552, P53, DOI 10.1016/0006-8993(91)90659-J; MOORE RY, 1993, NEUROSCI LETT, V150, P112, DOI 10.1016/0304-3940(93)90120-A; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; OBRIETAN K, 1995, J NEUROSCI, V15, P5065; OKAMURA H, 1989, NEUROSCI LETT, V102, P131, DOI 10.1016/0304-3940(89)90067-0; PAGE TL, 1994, SCIENCE, V263, P1570, DOI 10.1126/science.8128243; PROSSER RA, 1989, J NEUROSCI, V9, P1073; RALPH MR, 1989, J NEUROSCI, V9, P2858; SMITH RD, 1990, BRAIN RES, V530, P275, DOI 10.1016/0006-8993(90)91295-R; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; Strecker G. J., 1994, Society for Neuroscience Abstracts, V20, P1439; STRECKER GJ, 1995, SEMIN NEUROSCI, V7, P43, DOI 10.1016/1044-5765(95)90016-0; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7	28	272	273	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					598	603		10.1038/42468	http://dx.doi.org/10.1038/42468			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177347				2022-12-28	WOS:A1997XC52200055
J	Lip, GYH				Lip, GYH			Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk?	LANCET			English	Editorial Material							SPONTANEOUS ECHO CONTRAST; EMBOLIC COMPLICATIONS				Lip, GYH (corresponding author), UNIV BIRMINGHAM,CITY HOSP,DEPT MED,HAEMOSTASIS THROMBOSIS & VASC BIOL UNIT,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							*ATR FIBR INV, 1994, ARCH INTERN MED, V154, P1449; BLACK IW, 1993, J AM COLL CARDIOL, V21, P451, DOI 10.1016/0735-1097(93)90688-W; FATKIN D, 1994, AM J CARDIOL, V73, P672, DOI 10.1016/0002-9149(94)90932-6; KANNEL WB, 1983, AM HEART J, V106, P389, DOI 10.1016/0002-8703(83)90208-9; LIP GYH, 1995, INT J CARDIOL, V51, P245, DOI 10.1016/0167-5273(95)02434-X; LIP GYH, 1995, LANCET, V346, P1313, DOI 10.1016/S0140-6736(95)92339-X; Lip GYH, 1996, AM HEART J, V131, P724, DOI 10.1016/S0002-8703(96)90278-1; Lip GYH, 1996, BRIT MED J, V312, P45, DOI 10.1136/bmj.312.7022.45; OBARSKI TP, 1990, AM HEART J, V120, P988, DOI 10.1016/0002-8703(90)90224-L; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622; PETERSEN P, 1989, ACTA NEUROL SCAND, V79, P482, DOI 10.1111/j.1600-0404.1989.tb03818.x; ROY D, 1986, AM HEART J, V112, P1039, DOI 10.1016/0002-8703(86)90318-2; Sohara H, 1997, J AM COLL CARDIOL, V29, P106, DOI 10.1016/S0735-1097(96)00427-5	13	25	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 31	1997	349	9065					1565	1566		10.1016/S0140-6736(05)61624-8	http://dx.doi.org/10.1016/S0140-6736(05)61624-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174554				2022-12-28	WOS:A1997XB67300003
J	McLellan, MF				McLellan, MF			Literature and medicine: Narratives of physical illness	LANCET			English	Editorial Material									UNIV TEXAS,MED BRANCH,INST MED HUMANITIES,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston	McLellan, MF (corresponding author), UNIV TEXAS,MED BRANCH,DEPT ANESTHESIOL,GALVESTON,TX 77555, USA.			McLellan, Faith/0000-0003-0744-1450				Bauby J.D., 1997, DIVING BELL BUTTERFL, V4th ed.; Brody H., 1987, STORIES SICKNESS; Broyard, 1992, INTOXICATED MY ILLNE; Butler Sandra, 1991, CANC 2 VOICES; Cousins N., 1979, ANATOMY ILLNESS; CROCE A, 1995, NEW YORKER      0102, P54; CROCE A, 1994, NEW YORKER      1226; DONNE J, 1959, DEVOTIONS UPON EMERG; FRANK AW, 1994, LIT MED, V13, P1, DOI 10.1353/lm.2011.0180; Frank AW., 2013, WOUNDED STORYTELLER; Grealy L., 1994, AUTOBIOGRAPHY FACE; GUNTHER J, 1953, DEATH BE NOT PROUD M; HAFNER K, 1996, NEWSWEEK        0527, P77; Hawkins Anne Hunsaker, 1999, RECONSTRUCTING ILLNE; Jones AH, 1997, LANCET, V349, P1243, DOI 10.1016/S0140-6736(97)03395-3; JONES AH, 1990, MED HUM REV, V4, P38; JONES AH, 1995, MED HUM REV, V9, P9; Kleinman A., 1988, ILLNESS NARRATIVES; LEAR MW, 1980, HEARTSOUNDS STORY LO; McLellan F, 1997, LIT MED, V16, P88, DOI 10.1353/lm.1997.0007; MURRAY P, 1997, MY EXPERIENCE BREAST; OATES JC, 1995, NY TIMES        0219, V1, P22; OBER WB, 1990, LIT MED, V9, P21, DOI 10.1353/lm.2011.0174; OCONNOR F, 1979, HABIT BEING LETT FLA, P163; PAGET MA, 1993, COMPLEX SORROW REFLE; Price Reynolds, 1994, WHOLE NEW LIFE ILLNE; SCHWARTZ AE, 1994, WASHINGTON POST 0923, pA27; Sontag Susan, 1978, ILLNESS AS METAPHOR; Woolf Virginia, 1948, MOMENT OTHER ESSAYS, P9; ZUGER A, 1993, MED HUM REV, V7, P38	30	12	12	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 31	1997	349	9065					1618	1620		10.1016/S0140-6736(97)04429-2	http://dx.doi.org/10.1016/S0140-6736(97)04429-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174572				2022-12-28	WOS:A1997XB67300044
J	Ramachandran, S; Giles, PD; Hartland, A				Ramachandran, S; Giles, PD; Hartland, A			Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment	BRITISH MEDICAL JOURNAL			English	Letter									UNIV HOSP,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham	Ramachandran, S (corresponding author), MANOR HOSP,WALSALL WS2 9PS,W MIDLANDS,ENGLAND.							DAVISON C, 1975, DRUG METAB DISPOS, V3, P520; MILLS RFN, 1973, XENOBIOTICA, V3, P58	2	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 31	1997	314	7094					1593	1593		10.1136/bmj.314.7094.1593a	http://dx.doi.org/10.1136/bmj.314.7094.1593a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9186171	Green Published			2022-12-28	WOS:A1997XC50000025
J	Rossjohn, J; Feil, SC; McKinstry, WJ; Tweten, RK; Parker, MW				Rossjohn, J; Feil, SC; McKinstry, WJ; Tweten, RK; Parker, MW			Structure of a cholesterol-binding, thiol-activated cytolysin and a model of its membrane form	CELL			English	Article							PERFRINGENS THETA-TOXIN; STREPTOLYSIN-O; PERFRINGOLYSIN-O; CLOSTRIDIUM-PERFRINGENS; ERYTHROCYTE-MEMBRANES; CRYSTAL-STRUCTURE; ELECTRON-MICROSCOPY; 2.5-A RESOLUTION; CELL-MEMBRANES; PROTEIN MODELS	The mechanisms by which proteins gain entry into membranes is a fundamental problem in biology. Here, we present the first crystal structure of a thiol-activated cytolysin, perfringolysin O, a member of a large family of toxins that kill eukaryotic cells by punching holes in their membranes. The molecule adopts an unusually elongated shape rich in beta sheet. We have used electron microscopy data to construct a detailed model of the membrane channel form of the toxin. The structures reveal a novel mechanism for membrane insertion. Surprisingly, the toxin receptor, cholesterol, appears to play multiple roles: targeting, promotion of oligomerization, triggering a membrane insertion competent form, and stabilizing the membrane pore.	ST VINCENTS INST MED RES,IAN POTTER FDN,PROT CRYSTALLOG LAB,FITZROY,VIC 3065,AUSTRALIA; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,OKLAHOMA CITY,OK 73190	St. Vincent's Institute of Medical Research; University of Oklahoma System; University of Oklahoma Health Sciences Center			Parker, Michael W/F-9069-2013; Rossjohn, Jamie/F-9032-2013; McKinstry, William J/D-2612-2013	Parker, Michael W/0000-0002-3101-1138; Rossjohn, Jamie/0000-0002-2020-7522; McKinstry, William J/0000-0001-9668-9364				Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; BERENDES R, 1993, SCIENCE, V262, P427, DOI 10.1126/science.7692599; BHAKDI S, 1988, PROG ALLERGY, V40, P1; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BOULNOIS GJ, 1990, BACTERIAL PROTEIN TO, P43; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; COWELL JL, 1978, BIOCHIM BIOPHYS ACTA, V507, P230, DOI 10.1016/0005-2736(78)90419-4; Darji A, 1996, INFECT IMMUN, V64, P2356, DOI 10.1128/IAI.64.6.2356-2358.1996; DEJONGH HHJ, 1994, BIOCHEMISTRY-US, V33, P14529, DOI 10.1021/bi00252a020; DelaCruz X, 1996, PROTEIN SCI, V5, P857; delosToyos JR, 1996, INFECT IMMUN, V64, P480, DOI 10.1128/IAI.64.2.480-484.1996; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; Feil SC, 1996, FEBS LETT, V397, P290, DOI 10.1016/S0014-5793(96)01200-8; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; HARRIS RW, 1991, J BIOL CHEM, V266, P6936; HILL J, 1994, INFECT IMMUN, V62, P757, DOI 10.1128/IAI.62.2.757-758.1994; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLM L, 1994, PROTEINS, V19, P256, DOI 10.1002/prot.340190309; IWAMOTO M, 1990, EUR J BIOCHEM, V194, P25, DOI 10.1111/j.1432-1033.1990.tb19422.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MICHEL E, 1990, MOL MICROBIOL, V4, P2167, DOI 10.1111/j.1365-2958.1990.tb00578.x; MITSUI K, 1979, BIOCHIM BIOPHYS ACTA, V558, P307, DOI 10.1016/0005-2736(79)90265-7; MITSUI K, 1979, BIOCHIM BIOPHYS ACTA, V554, P68, DOI 10.1016/0005-2736(79)90007-5; MORGAN PJ, 1994, J BIOL CHEM, V269, P25315; MORGAN PJ, 1995, FEBS LETT, V371, P77, DOI 10.1016/0014-5793(95)00887-F; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; NAMBUDRIPAD R, 1991, SCIENCE, V252, P1305, DOI 10.1126/science.1925543; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIEDERMEYER W, 1985, TOXICON, V23, P425, DOI 10.1016/0041-0101(85)90026-1; OHNOIWASHITA Y, 1992, BIOCHIM BIOPHYS ACTA, V1109, P81, DOI 10.1016/0005-2736(92)90190-W; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; OWEN RHG, 1994, FEMS MICROBIOL LETT, V121, P217, DOI 10.1016/0378-1097(94)90129-5; PALMER M, 1995, EUR J BIOCHEM, V231, P388, DOI 10.1111/j.1432-1033.1995.tb20711.x; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PARKER MW, 1996, PROTEIN TOXIN STRUCT; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; PINKNEY M, 1989, INFECT IMMUN, V57, P2553, DOI 10.1128/IAI.57.8.2553-2558.1989; ROTTEM S, 1982, J BACTERIOL, V152, P888; SAUNDERS FK, 1989, INFECT IMMUN, V57, P2547, DOI 10.1128/IAI.57.8.2547-2552.1989; SEKIYA K, 1993, J BACTERIOL, V175, P5953, DOI 10.1128/JB.175.18.5953-5961.1993; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P233, DOI 10.1038/nsb0396-233; TWETEN RK, 1991, J BIOL CHEM, V266, P12449; TWETEN RK, 1995, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 2ND EDITION, P207; TWETEN RK, 1988, INFECT IMMUN, V56, P3235, DOI 10.1128/IAI.56.12.3235-3240.1988; WALEV I, 1995, INFECT IMMUN, V63, P1188, DOI 10.1128/IAI.63.4.1188-1194.1995; 1994, ACTA CRYSTALLOGR D, V50, P750	58	376	394	2	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					685	692		10.1016/S0092-8674(00)80251-2	http://dx.doi.org/10.1016/S0092-8674(00)80251-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182756	Bronze			2022-12-28	WOS:A1997XB92500005
J	Prager, KM				Prager, KM			For everything a blessing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	1997	277	20					1589	1589		10.1001/jama.277.20.1589	http://dx.doi.org/10.1001/jama.277.20.1589			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA022	9168278				2022-12-28	WOS:A1997XA02200013
J	Irvine, D				Irvine, D			The performance of doctors .1. Professionalism and self regulation in a changing world	BRITISH MEDICAL JOURNAL			English	Article											Irvine, D (corresponding author), GEN MED COUNCIL,LONDON W1N 6JE,ENGLAND.							ALLEN I, 1997, COMMITTED CRITICAL E; Allsop J., 1996, REGULATING MED WORK; ARMSTRONG D, 1990, BRIT MED J, V301, P691, DOI 10.1136/bmj.301.6754.691; *BMA, 1995, COR VAL C; *BRIT MED ASS, 1995, COR VAL MED PROF 21; Freidson E., 1988, PROFESSION MED; *GEN MED COUNC, 1997, NEW DOCT REC GEN CLI; *GEN MED COUNC, 1995, DUT DOCT GOOD MED PR; *GEN MED COUNC, 1993, TOM DOCT REC UND MED; Kennedy I, 1983, UNMASKING MED; KLEIN R, 1990, BRIT MED J, V301, P700, DOI 10.1136/bmj.301.6754.700; LOCK S, 1989, BRIT MED J, V299, P137, DOI 10.1136/bmj.299.6692.137; MARINKER M, 1974, J R COLL GEN PRACT, V24, P83; Rosenthal Marilyn, 1997, PROBLEM DOCTORS CONS; ROSENTHAL MM, 1995, INCOMPETENT DOCTOR C; *SEL COMM PARL COM, 1997, REP HLTH SERV OMB 19; SMITH R, 1989, BRIT MED J, V298, P1241, DOI 10.1136/bmj.298.6682.1241; STACEY M, 1989, PUBLIC POLICY ADMIN, V4, P12; STACEY M, 1992, REGULATING BRIT MED; 1992, TIMES           0302, P15; 1975, CMND6018	21	98	102	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 24	1997	314	7093					1540	1542		10.1136/bmj.314.7093.1540	http://dx.doi.org/10.1136/bmj.314.7093.1540			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9183205	Green Published			2022-12-28	WOS:A1997XB48400034
J	Maurer, K; Volk, S; Gerbaldo, H				Maurer, K; Volk, S; Gerbaldo, H			Auguste D and Alzheimer's disease	LANCET			English	Article									UNIV FRANKFURT, DEPT PSYCHIAT & PSYCOTHERAPY 2, D-60528 FRANKFURT, GERMANY	Goethe University Frankfurt	Maurer, K (corresponding author), UNIV FRANKFURT, DEPT PSYCHIAT & PSYCOTHERAPY 1, HEINRICH HOFFMANN STR 10, D-60528 FRANKFURT, GERMANY.							Alzheimer A, 1906, NEUROLOGISCHES CENTR, V23, P1129; BEACH TG, 1987, J HIST MED ALL SCI, V42, P327, DOI 10.1093/jhmas/42.3.327; BERRIOS GE, 1990, INT J GERIATR PSYCH, V5, P355, DOI 10.1002/gps.930050603; BICK K, 1987, EARLY STORY ALZHEIME, P82; BONFIGLIO F, 1908, RIV SPERIMENTALE FRE, V34, P196; Fischer O, 1907, MON PSYCHIATR NEUROL, V22, P361; KRAEPELIN E, 1910, LEHRBUCH STUDIERENDE, P593; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; OBrien C, 1996, SCIENCE, V273, P28, DOI 10.1126/science.273.5271.28; Perusini G., 1909, HISTOLOGISCHE HISTOP, P297	10	213	222	1	39	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	1997	349	9064					1546	1549		10.1016/S0140-6736(96)10203-8	http://dx.doi.org/10.1016/S0140-6736(96)10203-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XA901	9167474				2022-12-28	WOS:A1997XA90100053
J	Yirrell, DI; Robertson, P; Goldberg, DJ; McMenamin, J; Cameron, S; Brown, AJL				Yirrell, DI; Robertson, P; Goldberg, DJ; McMenamin, J; Cameron, S; Brown, AJL			Molecular investigation into outbreak of HIV in a Scottish prison	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RISK BEHAVIORS; INFECTION; TRANSMISSION; PREVALENCE; EPIDEMIOLOGY; SEQUENCES; EDINBURGH; ENTRANTS	Objectives: To support already established epidemiological links between inmates of Glenochil prison positive for HIV infection by using molecular techniques and thus provide evidence of the extent of acquisition during a recent outbreak of the disease resulting from needle sharing. To identify possible sources of the outbreak, and to demonstrate the ability of the methodology to make further links beyond the original outbreak. Design: Viral sequences obtained from the blood of HIV positive prisoners previously identified by standard epidemiological methods were compared with each other and with sequences from other Scottish patients. Setting: Glenochil prison for men, central Scotland. Subjects: Adults inmates and their possible contacts. Results: Phylogenetic analysis of viral sequences in two different genomic regions showed that 13 of the 14 HIV positive prisoners had been infected from a common source. Previous research had shown that six of these had acquired their infection in Glenochil; molecular evidence suggests that more than double this number were infected while incarcerated. Virus from two long term HIV positive patients who were in the prison at the time of the outbreak but who were not identified in the original or subsequent surveys was sufficiently different to make it unlikely that they were the source, A viral sequence from heterosexual transmission from one inmate showed the ability of these techniques to follow the infection through different routes of infection. Conclusion: The number of prisoners infected with HIV during the 1993 outbreak within Glenochil prison was more than twice that previously shown. This shows the potential for the spread of bloodborne diseases within prisons bg injecting drugs.	RUCHILL HOSP, SCOTTISH CTR INFECT & ENVIRONM HLTH, GLASGOW G20 9BN, LANARK, SCOTLAND; RUCHILL HOSP, REG VIRUS LAB, GLASGOW G20 9NB, LANARK, SCOTLAND		Yirrell, DI (corresponding author), UNIV EDINBURGH, INST CELL ANIM & POPULAT BIOL, CTR HIV RES, W MAINS RD, EDINBURGH EH9 3JN, MIDLOTHIAN, SCOTLAND.		Brown, Andrew Leigh/ABF-8269-2020; Leigh Brown, Andrew/F-3802-2010	Brown, Andrew Leigh/0000-0002-5700-3128; Leigh Brown, Andrew/0000-0002-5700-3128				ALBERT J, 1993, NATURE, V361, P595, DOI 10.1038/361595b0; ALBERT J, 1994, J VIROL, V68, P5918, DOI 10.1128/JVI.68.9.5918-5924.1994; BIRD AG, 1993, BRIT MED J, V307, P228, DOI 10.1136/bmj.307.6898.228; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BROWN AJL, 1995, HIV PRACTICAL APPROA, V1, P161; CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; Clewley JP, 1996, LANCET, V347, P1487, DOI 10.1016/S0140-6736(96)91724-9; Connick E, 1996, AIDS RES HUM RETROV, V12, P1129, DOI 10.1089/aid.1996.12.1129; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; GAUGHWIN MD, 1991, AIDS, V5, P845, DOI 10.1097/00002030-199107000-00008; GOJOBORI T, 1990, P NATL ACAD SCI USA, V87, P10015, DOI 10.1073/pnas.87.24.10015; GORE SM, 1993, BRIT MED J, V307, P147, DOI 10.1136/bmj.307.6897.147; GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293; HILLIS DM, 1994, NATURE, V369, P24, DOI 10.1038/369024a0; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLMES EC, 1993, J INFECT DIS, V167, P1411, DOI 10.1093/infdis/167.6.1411; HOLMES EC, 1995, J INFECT DIS, V171, P45, DOI 10.1093/infdis/171.1.45; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; KISHINO H, 1989, J MOL EVOL, V4, P406; Leitner T, 1996, P NATL ACAD SCI USA, V93, P10864, DOI 10.1073/pnas.93.20.10864; MARTIN V, 1990, AIDS, V4, P1023, DOI 10.1097/00002030-199010000-00013; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; POWER KG, 1991, BMJ-BRIT MED J, V303, P783, DOI 10.1136/bmj.303.6805.783-b; SIMMONDS P, 1991, J VIROL, V65, P6266, DOI 10.1128/JVI.65.11.6266-6276.1991; SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289; VLAHOV D, 1991, JAMA-J AM MED ASSOC, V265, P1129, DOI 10.1001/jama.265.9.1129; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHANG LQ, 1991, AIDS, V5, P575	30	59	59	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1446	1450		10.1136/bmj.314.7092.1446	http://dx.doi.org/10.1136/bmj.314.7092.1446			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167560	Green Published, Green Submitted			2022-12-28	WOS:A1997XA20200021
J	Manuelidis, L; Fritch, W; Xi, YG				Manuelidis, L; Fritch, W; Xi, YG			Evolution of a strain of CJD that induces BSE-like plaques	SCIENCE			English	Article								Bovine spongiform encephalopathy (BSE) has become a public health issue because a recently evolved BSE agent has infected people, yielding an unusual form of Creutzfeld-Jakob disease (CJD). A new CJD agent that provokes similar amyloid plaques and cerebellar pathology was serially propagated. First-passage rats showed obvious clinical signs and activated microglia but had negligible PrP-res (the more protease-resistant form of host PrP) or cerebellar lesions. Microglia and astrocytes may participate in strain selection because the agent evolved, stabilized, and reproducibly provoked BSE-like disease in subsequent passages. Early vacuolar change involving activated microglia and astrocytes preceded significant PrP-res accumulation by more than 50 days. These studies reveal several inflammatory host reactions to an exogenous agent.			Manuelidis, L (corresponding author), YALE UNIV,SCH MED,SECT NEUROPATHOL,310 CEDAR ST,NEW HAVEN,CT 06510, USA.				NINDS NIH HHS [NS34569, NS12674] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034569, R01NS012674] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))			0	119	121	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					94	98		10.1126/science.277.5322.94	http://dx.doi.org/10.1126/science.277.5322.94			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204907				2022-12-28	WOS:A1997XJ41800047
J	Ogas, J; Cheng, JC; Sung, ZR; Somerville, C				Ogas, J; Cheng, JC; Sung, ZR; Somerville, C			Cellular differentiation regulated by gibberellin in the Arabidopsis thaliana pickle mutant	SCIENCE			English	Article							LYCOPERSICON-ESCULENTUM MILL; GENE FAMILY; GA1 LOCUS; WILD-TYPE; PLANT; GROWTH; TRANSFORMATION; ROOTS; SITES; ACID	The plant growth regulator gibberellin (GA) has a profound effect on shoot development and promotes developmental transitions such as flowering. Little is known about any analogous effect GA might have on root development. In a screen for mutants, Arabidopsis plants carrying a mutation designated pickle (pkl) were isolated in which the primary root meristem retained characteristics of embryonic tissue. Expression of this aberrant differentiation state was suppressed by GA. Root tissue from plants carrying the pkl mutation spontaneously regenerated new embryos and plants.	UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	Ogas, J (corresponding author), CARNEGIE INST WASHINGTON,DEPT PLANT BIOL,290 PANAMA ST,STANFORD,CA 94305, USA.		Somerville, Christopher R/A-4048-2009	Somerville, Christopher R/0000-0003-4647-0094; Ogas, Joe/0000-0002-1332-7729; Sung, Zinmay/0000-0003-0478-9144				BALUSKA F, 1993, PLANTA, V191, P149, DOI 10.1007/BF00199744; BARLOW PW, 1991, J EXP BOT, V42, P339, DOI 10.1093/jxb/42.3.339; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BRUNDRETT MC, 1991, BIOTECH HISTOCHEM, V66, P111, DOI 10.3109/10520299109110562; Chien JC, 1996, PLANT PHYSIOL, V111, P1321, DOI 10.1104/pp.111.4.1321; FAY JM, 1991, ECON BOT, V45, P16, DOI 10.1007/BF02860046; FINKELSTEIN RR, 1994, ARABIDOPSIS, P523; GUERCHE P, 1990, PLANT CELL, V2, P469, DOI 10.1105/tpc.2.5.469; IZUMI K, 1985, PLANT CELL PHYSIOL, V26, P821; KOORNNEEF M, 1985, PHYSIOL PLANTARUM, V65, P33, DOI 10.1111/j.1399-3054.1985.tb02355.x; KOORNNEEF M, 1983, GENET RES, V41, P57, DOI 10.1017/S0016672300021066; KREBBERS E, 1988, PLANT PHYSIOL, V87, P859, DOI 10.1104/pp.87.4.859; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; MARTON L, 1991, PLANT CELL REP, V10, P235, DOI 10.1007/BF00232565; MCCLINTON RS, IN PRESS PLANTA; METZ AM, 1992, GENE, V120, P313, DOI 10.1016/0378-1119(92)90112-3; MORRIS PC, 1994, ARABIDOPSIS, P173; NAKIELSKI J, 1995, PLANTA, V196, P30, DOI 10.1007/BF00193214; OHLROGGE JB, 1991, BIOCHIM BIOPHYS ACTA, V1082, P1, DOI 10.1016/0005-2760(91)90294-R; Okamuro JK, 1996, P NATL ACAD SCI USA, V93, P13831, DOI 10.1073/pnas.93.24.13831; PATTON DA, 1990, AM J BOT, V77, P653, DOI 10.2307/2444811; PENG JR, 1993, PLANT CELL, V5, P351, DOI 10.1105/tpc.5.3.351; Ross JHE, 1996, PLANT J, V9, P625, DOI 10.1046/j.1365-313X.1996.9050625.x; SUN TP, 1992, PLANT CELL, V4, P119, DOI 10.1105/tpc.4.2.119; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; TRAAS J, 1995, PLANT J, V7, P785, DOI 10.1046/j.1365-313X.1995.07050785.x; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VANROOIJEN GJH, 1992, PLANT MOL BIOL, V18, P1177, DOI 10.1007/BF00047721; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362	29	248	277	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					91	94		10.1126/science.277.5322.91	http://dx.doi.org/10.1126/science.277.5322.91			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204906				2022-12-28	WOS:A1997XJ41800046
J	Ji, GY; Beavis, R; Novick, RP				Ji, GY; Beavis, R; Novick, RP			Bacterial interference caused by autoinducing peptide variants	SCIENCE			English	Article							GENE REGULATOR AGR; DELTA-LYSIN GENE; STAPHYLOCOCCUS-AUREUS; HLD; RNA	The synthesis of virulence factors and other extracellular proteins by Staphylococcus aureus is globally controlled by the agr locus, which encodes a two-component signaling pathway whose activating ligand is an agr-encoded autoinducing peptide. The cognate peptides produced by some strains inhibit the expression of agr in other strains, and the amino acid sequences of peptide and receptor are markedly different between such strains, suggesting a hypervariability-generating mechanism. Cross-inhibition of gene expression represents a type of bacterial interference that could be correlated with the ability of one strain to exclude others from infection or colonization sites, or both.	NYU MED CTR, SKIRBALL INST BIOMOLEC MED, NEW YORK, NY 10016 USA	New York University				Novick, richard/0000-0003-4418-7893	NIAID NIH HHS [R01-AI30138] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030138] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARC MC, 1986, CAN J MICROBIOL, V32, P751, DOI 10.1139/m86-136; BEAVIS R, UNPUB; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HICKS J, 1979, NATURE, V282, P478, DOI 10.1038/282478a0; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HOLM SE, 1983, SCAND J INFECT DIS, P73; JANZON L, 1989, MOL GEN GENET, V219, P480, DOI 10.1007/BF00259623; JANZON L, 1990, EMBO J, V9, P1391, DOI 10.1002/j.1460-2075.1990.tb08254.x; JI G, UNPUB; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; KORNBLUM J, 1990, MOL BIOL STAPHYLOCOC, pCH28; LINA G, UNPUB; MORFELDT E, 1995, EMBO J, V14, P4569, DOI 10.1002/j.1460-2075.1995.tb00136.x; MURPHY GL, 1988, BIOESSAYS, V9, P7, DOI 10.1002/bies.950090103; NOBLE WC, 1980, BRIT J EXP PATHOL, V61, P339; NOVICK RP, 1995, MOL GEN GENET, V248, P446, DOI 10.1007/BF02191645; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; PEDRAZA A, UNPUB; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; SHINEFIE.HR, 1974, ANN NY ACAD SCI, V236, P444, DOI 10.1111/j.1749-6632.1974.tb41509.x; WILSKE B, 1992, RES MICROBIOL, V143, P583, DOI 10.1016/0923-2508(92)90116-6; WILSON KH, 1983, J INFECT DIS, V147, P733, DOI 10.1093/infdis/147.4.733; Wolz C, 1996, INFECT IMMUN, V64, P3142, DOI 10.1128/IAI.64.8.3142-3147.1996	23	578	606	4	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	1997	276	5321					2027	2030		10.1126/science.276.5321.2027	http://dx.doi.org/10.1126/science.276.5321.2027			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197262				2022-12-28	WOS:A1997XG74800060
J	Cooper, LT; Berry, GJ; Shabetai, R				Cooper, LT; Berry, GJ; Shabetai, R			Idiopathic giant-cell myocarditis - Natural history and treatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSPLANTED HEART; ULCERATIVE-COLITIS	Background Idiopathic giant-cell myocarditis is a rare and frequently fatal disorder. We used a multicenter data base to define the natural history of giant-cell myocarditis and the effect of treatment, Methods We identified 63 patients with idiopathic giant-cell myocarditis through journal announcements and direct mailings to cardiovascular centers worldwide. Results The patients consisted of 33 men and 30 women with an average age of 42.6 years; 88 percent were white, 5 percent were black, 5 percent were Southeast Asian or Indian, and 2 percent were Middle Eastern. Most presented with congestive heart failure (47 patients, or 75 percent), ventricular arrhythmia (9 patients, or 14 percent), or heart block (3 patients, or 5 percent), although in some cases the initial symptoms resembled those of acute myocardial infarction (4 patients). Nineteen percent had associated autoimmune disorders. The rate of survival was worse than among 111 patients with lymphocytic myocarditis in the Myocarditis Treatment Trial (P<0,001); among our patients, the rate of death or cardiac transplantation was 89 percent, and median survival was only 5.5 months from the onset of symptoms. The 22 patients treated with corticosteroids and cyclosporine, azathioprine, or both therapies survived for an average of 12.3 months, as compared with an average of 3.0 months for the 30 patients who received no immunosuppressive therapy (P=0.001). Of the 34 patients who underwent heart transplantation, 9 (26 percent) had a giant-cell infiltrate in the transplanted heart and 1 died of recurrent giant-cell myocarditis. Conclusions Giant-cell myocarditis is a disease of relatively young, predominantly healthy adults, Patients usually die of heart failure and ventricular arrhythmia unless cardiac transplantation is performed. Despite the possibility of fatal disease recurrence, transplantation is the treatment of choice for most patients. (C) 1997, Massachusetts Medical Society.	UNIV CALIF SAN DIEGO, MED CTR, DEPT MED, SAN DIEGO, CA 92103 USA; STANFORD UNIV HOSP, DEPT PATHOL, STANFORD, CA 94305 USA	University of California System; University of California San Diego; Stanford University				Berry, Gerald/0000-0002-6176-2629; Cooper, Leslie/0000-0003-1002-3313				ARIZA A, 1995, HUM PATHOL, V26, P121, DOI 10.1016/0046-8177(95)90124-8; BRIGANTI E, 1993, J HEART LUNG TRANSPL, V12, P880; BURKE JS, 1969, ARCH PATHOL, V88, P359; COOPER DKC, 1994, J HEART LUNG TRANSPL, V13, P555; Cooper LT, 1996, CIRCULATION, V93, P199; COOPER LT, 1995, AM J CARDIOL, V76, P640, DOI 10.1016/S0002-9149(99)80181-7; COOPER LT, 1995, J AM COLL CARDIOL, V26, P301, DOI 10.1016/0735-1097(95)90848-I; COOPER LT, 1995, AM HEART J, V130, P1312, DOI 10.1016/0002-8703(95)90168-X; COOPER LT, 1995, J HEART LUNG TRANSPL, V14, P394; DAVIDOFF R, 1991, CIRCULATION, V83, P953, DOI 10.1161/01.CIR.83.3.953; DAVIES MJ, 1975, BRIT HEART J, V37, P192; DESJARDINS V, 1992, CAN J CARDIOL, V8, P788; Glennon PE, 1996, HEART, V75, P531, DOI 10.1136/hrt.75.5.531; Glesby MJ, 1996, ANN INTERN MED, V124, P999, DOI 10.7326/0003-4819-124-11-199606010-00008; GOLDBERG GM, 1955, AM J CLIN PATHOL, V25, P510; GRANT SCD, 1993, J HEART LUNG TRANSPL, V12, P155; GRANT SCD, 1993, EUR HEART J, V14, P1437, DOI 10.1093/eurheartj/14.10.1437; GRIES W, 1992, J HEART LUNG TRANSPL, V11, P370; HANAWA H, 1994, CLIN EXP IMMUNOL, V96, P470; HUDSON REB, 1970, CARDIOVASC PATHOL, V3, P820; HYDE J, 1977, BIOMETRIKA, V64, P225, DOI 10.2307/2335688; KLEIN BR, 1989, NEUROLOGY, V39, P988, DOI 10.1212/WNL.39.7.988; KLOIN JE, 1985, AM J MED, V78, P355, DOI 10.1016/0002-9343(85)90450-4; KODAMA M, 1994, CIRC RES, V75, P278, DOI 10.1161/01.RES.75.2.278; KODAMA M, 1990, CLIN IMMUNOL IMMUNOP, V57, P250, DOI 10.1016/0090-1229(90)90039-S; KONG G, 1991, EUR HEART J, V12, P554, DOI 10.1093/oxfordjournals.eurheartj.a059938; LEIB ML, 1994, OPHTHALMOLOGY, V101, P950; MARTIN AB, 1994, CIRCULATION, V90, P330, DOI 10.1161/01.CIR.90.1.330; MASON JW, 1995, NEW ENGL J MED, V333, P269, DOI 10.1056/NEJM199508033330501; MCKEON J, 1986, AM HEART J, V111, P1208, DOI 10.1016/0002-8703(86)90031-1; REN H, 1993, MODERN PATHOL, V6, P402; ROBERTS WC, 1968, ARCH INTERN MED, V122, P141, DOI 10.1001/archinte.122.2.141; ROBERTS WC, 1966, AM J MED, V41, P453, DOI 10.1016/0002-9343(66)90091-X; SHARMA OP, 1993, CHEST, V103, P253, DOI 10.1378/chest.103.1.253; THEAKER JM, 1988, HUM PATHOL, V19, P974, DOI 10.1016/S0046-8177(88)80015-7; ZHANG SS, 1993, J AM COLL CARDIOL, V21, P1254, DOI 10.1016/0735-1097(93)90254-X	36	455	466	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	1997	336	26					1860	1866		10.1056/NEJM199706263362603	http://dx.doi.org/10.1056/NEJM199706263362603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF756	9197214				2022-12-28	WOS:A1997XF75600003
J	Hoffman, DA; Magee, JC; Colbert, CM; Johnston, D				Hoffman, DA; Magee, JC; Colbert, CM; Johnston, D			K+ channel regulation of signal propagation in dendrites of hippocampal pyramidal neurons	NATURE			English	Article							ACTION-POTENTIALS; CELL DENDRITES; IN-VITRO; CA1; CONDUCTANCE; MODULATION; AMPLIFICATION; INACTIVATION; INTEGRATION; ACTIVATION	Pyramidal neurons receive tens of thousands of synaptic inputs on their dendrites. The dendrites dynamically after the strengths of these synapses and coordinate them to produce an output in ways that are not well understood. surprisingly, there turns out to be a very high density of transient A-type potassium ion channels in dendrites of hippocampal CA1 pyramidal neurons. These channels prevent initiation of an action potential in the dendrites, limit the back-propagation of action potentials into the dendrites, and reduce excitatory synaptic events. The channels act to prevent large, rapid dendritic depolarizations, thereby regulating orthograde and retrograde propagation of dendritic potentials.	BAYLOR COLL MED,DEPT NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine			Hoffman, Dax A/E-5155-2011	Hoffman, Dax A/0000-0001-6999-2157				Alonso G, 1997, NEUROSCIENCE, V77, P617; ANDREASEN M, 1995, J PHYSIOL-LONDON, V483, P421, DOI 10.1113/jphysiol.1995.sp020595; CALLAWAY JC, 1995, J NEUROPHYSIOL, V74, P1395, DOI 10.1152/jn.1995.74.4.1395; CHEN QX, 1991, J NEUROSCI, V11, P337; Christie BR, 1996, LEARN MEMORY, V3, P160, DOI 10.1101/lm.3.2-3.160; Colbert CM, 1996, J NEUROSCI, V16, P6676; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; GAGE PW, 1992, TRENDS NEUROSCI, V15, P46, DOI 10.1016/0166-2236(92)90025-4; HALLIWELL JV, 1986, P NATL ACAD SCI USA, V83, P493, DOI 10.1073/pnas.83.2.493; Helmchen F, 1996, BIOPHYS J, V70, P1069, DOI 10.1016/S0006-3495(96)79653-4; Hines M, 1993, NEURAL SYSTEMS ANAL, P127; HOUNSGAARD J, 1988, J PHYSIOL-LONDON, V402, P731, DOI 10.1113/jphysiol.1988.sp017231; JAFFE DB, 1995, NATURE, V374, P1395; Johnston D, 1996, BIOPHYS J, V70, P1095, DOI 10.1016/S0006-3495(96)79674-1; Johnston D, 1996, ANNU REV NEUROSCI, V19, P165, DOI 10.1146/annurev.ne.19.030196.001121; KLEE R, 1995, J NEUROPHYSIOL, V74, P1982, DOI 10.1152/jn.1995.74.5.1982; Lipowsky R, 1996, J NEUROPHYSIOL, V76, P2181, DOI 10.1152/jn.1996.76.4.2181; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; Magee JC, 1996, J NEUROPHYSIOL, V76, P3460, DOI 10.1152/jn.1996.76.5.3460; MAGEE JC, 1995, SCIENCE, V268, P301, DOI 10.1126/science.7716525; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; Mainen ZF, 1995, NEURON, V15, P1427, DOI 10.1016/0896-6273(95)90020-9; MALETICSAVATIC M, 1995, J NEUROSCI, V15, P3840; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; NICOLL A, 1993, J PHYSIOL-LONDON, V468, P693, DOI 10.1113/jphysiol.1993.sp019795; Rapp M, 1996, P NATL ACAD SCI USA, V93, P11985, DOI 10.1073/pnas.93.21.11985; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SCHWINDT PC, 1995, J NEUROPHYSIOL, V74, P2220, DOI 10.1152/jn.1995.74.5.2220; SEGAL M, 1984, J NEUROSCI, V4, P604; SEGAL M, 1984, J NEUROPHYSIOL, V51, P1409, DOI 10.1152/jn.1984.51.6.1409; SERIDIO P, 1994, J NEUROPHYSIOL, V72, P1516; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; SOLC CK, 1987, SCIENCE, V236, P1094, DOI 10.1126/science.2437657; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; STORM JF, 1988, NATURE, V336, P379, DOI 10.1038/336379a0; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; TALUKDER G, 1995, J NEUROPHYSIOL, V73, P73, DOI 10.1152/jn.1995.73.1.73; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; TURNER RW, 1991, J NEUROSCI, V11, P2270; WU RL, 1992, J NEUROSCI, V12, P2235; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4	44	1044	1089	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					869	875		10.1038/43119	http://dx.doi.org/10.1038/43119			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202119	Bronze			2022-12-28	WOS:A1997XG41600041
J	Grodstein, F; Stampfer, MJ; Colditz, GA; Willett, WC; Manson, JE; Joffe, M; Rosner, B; Fuchs, C; Hankinson, SE; Hunter, DJ; Hennekens, CH; Speizer, FE				Grodstein, F; Stampfer, MJ; Colditz, GA; Willett, WC; Manson, JE; Joffe, M; Rosner, B; Fuchs, C; Hankinson, SE; Hunter, DJ; Hennekens, CH; Speizer, FE			Postmenopausal hormone therapy and mortality	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESTROGEN REPLACEMENT THERAPY; FOLLOW-UP; WOMEN; DISEASE; CANCER; RISK	Background Postmenopausal hormone therapy has both benefits and hazards, including decreased risks of osteoporosis and cardiovascular disease and an increased risk of breast cancer. Methods We examined the relation between the use of postmenopausal hormones and mortality among participants in the Nurses' Health Study, who were 30 to 55 years of age at base line in 1976. Data were collected by biennial questionnaires beginning in 1976 and continuing th rough 1992. We documented 3637 deaths from 1976 to 1994. Each participant who died was matched with 10 controls alive at the time of her death. For each death, we defined the subject's hormone status according to the last biennial questionnaire before her death or before the diagnosis of the fatal disease; this reduced bias caused by the discontinuation of hormone use between the time of diagnosis of a potentially fatal disease and death. Results After adjustment for confounding variables, current hormone users had a lower risk-of death (relative risk, 0.63; 95 percent confidence interval, 0.56 to 0.70) than subjects who had never taken hormones; however, the apparent benefit decreased with long-term use (relative risk, 0.80; 0.67 to 0.96, after 10 or more years) because of an increase in mortality from breast cancer among long-term hormone users. Current hormone users with coronary risk factors (69 percent of the women) had the largest reduction in mortality (relative risk, 0.51; 95 percent confidence interval, 0.45 to 0.57), with substantially less benefit for those at low risk (13 percent of the women; relative risk, 0.89; 95 percent confidence interval, 0.62 to 1.28). Conclusions On average, mortality among women who use postmenopausal hormones is lower than among nonusers; however, the survival benefit diminishes with longer duration of use and is lower for women at low risk for coronary disease. (C)1997, Massachusetts Medical Society.	BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Grodstein, F (corresponding author), BRIGHAM & WOMENS HOSP,CHANNING LAB,181 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COLDITZ GA, 1995, NEW ENGL J MED, V333, P1357; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; FOLSOM AR, 1995, AM J PUBLIC HEALTH, V85, P1128, DOI 10.2105/AJPH.85.8_Pt_1.1128; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, AM J EPIDEMIOL, V143, P979; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F., 1996, American Journal of Epidemiology, V143, pS63; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, NEW ENGL J MED, V335, P1406; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HOSMER DW, 1989, APPL LOGISTIC REGRES; *NAT CTR HLTH STAT, 1967, DHEW PUBL, V1693; PETITTI DB, 1987, OBSTET GYNECOL, V70, P289; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; VANDENBROUCKE JP, 1995, EPIDEMIOLOGY, V6, P207; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598	24	981	994	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 19	1997	336	25					1769	1775		10.1056/NEJM199706193362501	http://dx.doi.org/10.1056/NEJM199706193362501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE485	9187066	Bronze			2022-12-28	WOS:A1997XE48500001
J	Millis, JM; Thistlethwaite, JR				Millis, JM; Thistlethwaite, JR			Transplantation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Millis, JM (corresponding author), UNIV CHICAGO, CHICAGO, IL 60637 USA.		Millis, Michael/K-5346-2019; Griva, Konstadina/A-6549-2018; FUNG, John Julian/A-2679-2012	FUNG, John Julian/0000-0002-3038-0441				[Anonymous], 1996, Clin Transplant, V10, P131; Bartlett ST, 1996, ANN SURG, V224, P440, DOI 10.1097/00000658-199610000-00003; *FK506 KIDN TRANSP, 1996, 22 ANN M AM SOC TRAN; Johnson LB, 1996, SURGERY, V120, P580, DOI 10.1016/S0039-6060(96)80002-X; Kalayoglu M, 1996, J AM COLL SURGEONS, V182, P381; Keown P, 1996, TRANSPLANTATION, V61, P1029; Langnas AN, 1996, PEDIATRICS, V97, P443; Millis JM, 1996, TRANSPLANTATION, V61, P1365, DOI 10.1097/00007890-199605150-00014; Rogiers X, 1996, ANN SURG, V224, P331, DOI 10.1097/00000658-199609000-00009; Terasaki PI, 1996, TRANSPLANTATION, V62, P441, DOI 10.1097/00007890-199608270-00003; WATERWORTH PD, 1996, 16 INT C TRANSPL SOC; Woodle ES, 1996, TRANSPLANTATION, V62, P594, DOI 10.1097/00007890-199609150-00009	12	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1902	1904						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185827				2022-12-28	WOS:A1997XD54400046
J	Maki, M; Collin, P				Maki, M; Collin, P			Coeliac disease	LANCET			English	Article							GLUTEN-FREE DIET; ADULT CELIAC-DISEASE; ANTIGLIADIN ANTIBODIES; DERMATITIS-HERPETIFORMIS; CLINICAL-FEATURES; JEJUNAL BIOPSY; A-GLIADIN; SPRUE; SENSITIVITY; MALIGNANCY		TAMPERE UNIV HOSP, DEPT MED, FIN-33101 TAMPERE, FINLAND; UNIV TAMPERE, FIN-33101 TAMPERE, FINLAND	Tampere University; Tampere University Hospital	Maki, M (corresponding author), TAMPERE UNIV HOSP, DEPT PAEDIAT, POB 607, FIN-33101 TAMPERE, FINLAND.							AINE L, 1990, J ORAL PATHOL MED, V19, P241, DOI 10.1111/j.1600-0714.1990.tb00834.x; Aine L, 1996, ANN MED, V28, P9, DOI 10.3109/07853899608999067; ARRANZ E, 1993, GASTROENTEROLOGY, V104, P1263, DOI 10.1016/0016-5085(93)90333-8; ASCHER H, 1991, ARCH DIS CHILD, V66, P608, DOI 10.1136/adc.66.5.608; BRANDTZAEG P, 1989, GASTROENTEROLOGY, V97, P1562, DOI 10.1016/0016-5085(89)90406-X; CATASSI C, 1994, LANCET, V343, P200, DOI 10.1016/S0140-6736(94)90989-X; *COD STAN, 1981, JOINT FAO WHO FOOD S, P118; COLLIN P, 1994, GUT, V35, P1215, DOI 10.1136/gut.35.9.1215; Collin P, 1996, GUT, V38, P528, DOI 10.1136/gut.38.4.528; COLLIN P, 1991, NEUROLOGY, V41, P372, DOI 10.1212/WNL.41.3.372; COLLIN P, 1990, SCAND J GASTROENTERO, V25, P245, DOI 10.1080/00365521.1990.12067098; COLLIN P, 1993, SCAND J GASTROENTERO, V28, P595, DOI 10.3109/00365529309096094; COLLIN P, 1994, SCAND J GASTROENTERO, V29, P769, DOI 10.3109/00365529409092508; CORAZZA GR, 1993, J CLIN GASTROENTEROL, V16, P16, DOI 10.1097/00004836-199301000-00006; CORAZZA GR, 1995, GASTROENTEROLOGY, V109, P1333, DOI 10.1016/0016-5085(95)90597-9; CORAZZA GR, 1995, GASTROENTEROLOGY, V109, P122, DOI 10.1016/0016-5085(95)90276-7; DERITIS G, 1988, GASTROENTEROLOGY, V94, P41, DOI 10.1016/0016-5085(88)90607-5; Dicke W.K., 1950, THESIS UTRECHT; Ferguson A, 1996, J INTERN MED, V240, P315, DOI 10.1046/j.1365-2796.1996.41875000.x; FERGUSON A, 1993, GUT, V34, P150, DOI 10.1136/gut.34.2.150; FERREIRA M, 1992, GUT, V33, P1633, DOI 10.1136/gut.33.12.1633; Gee S., 1888, ST BARTHOLOMEWS HOSP, V24, P17; GOBBI G, 1992, LANCET, V340, P439; Greco L., 1992, COMMON FOOD INTOLERA, P25; GRODZINSKY E, 1992, ANN ALLERGY, V69, P66; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; HALLERT C, 1981, SCAND J GASTROENTERO, V16, P257, DOI 10.3109/00365528109181965; HANKEY GL, 1994, GUT, V35, P65, DOI 10.1136/gut.35.1.65; HOLM K, 1992, LANCET, V339, P1500, DOI 10.1016/0140-6736(92)91262-7; HOLMES GKT, 1976, GUT, V17, P612, DOI 10.1136/gut.17.8.612; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; HOWDLE PD, 1995, BAILLIERE CLIN GASTR, V9, pR9; JANATUINEN EK, 1995, NEW ENGL J MED, V333, P1033, DOI 10.1056/NEJM199510193331602; Johansen BH, 1996, CLIN IMMUNOL IMMUNOP, V79, P288, DOI 10.1006/clin.1996.0081; KAGNOFF MF, 1984, J EXP MED, V160, P1544, DOI 10.1084/jem.160.5.1544; KARPATI S, 1990, LANCET, V336, P1335, DOI 10.1016/0140-6736(90)92893-M; KASARDA DD, 1981, P NATL ACAD SCI USA, P4712; LADINSER B, 1994, GUT, V35, P776, DOI 10.1136/gut.35.6.776; LEONARD JN, 1983, BRIT MED J, V286, P16, DOI 10.1136/bmj.286.6358.16; LEONE NA, 1996, 7 INT S COEL DIS SEP, P69; Lewis HM, 1996, BRIT J DERMATOL, V135, P363; LOGAN RFA, 1986, GASTROENTEROLOGY, V90, P334, DOI 10.1016/0016-5085(86)90929-7; LOGAN RFA, 1983, BMJ-BRIT MED J, V286, P95, DOI 10.1136/bmj.286.6359.95; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; MACDONALD WC, 1965, NEW ENGL J MED, V272, P448, DOI 10.1056/NEJM196503042720903; Maiuri L, 1996, GASTROENTEROLOGY, V110, P1368, DOI 10.1053/gast.1996.v110.pm8613040; MAKI M, 1990, ARCH DIS CHILD, V65, P1137, DOI 10.1136/adc.65.10.1137; MAKI M, 1995, GUT, V36, P239, DOI 10.1136/gut.36.2.239; MAKI M, 1991, LANCET, V338, P724, DOI 10.1016/0140-6736(91)91445-Z; Maki M, 1996, LANCET, V348, P1046, DOI 10.1016/S0140-6736(05)64411-X; MAKI M, 1991, LANCET, V338, P1350, DOI 10.1016/0140-6736(91)92234-S; MAKI M, 1988, ACTA PAEDIATR SCAND, V77, P408, DOI 10.1111/j.1651-2227.1988.tb10668.x; MAKI M, 1995, BAILLIERE CLIN GASTR, V9, P231, DOI 10.1016/0950-3528(95)90030-6; MAKI M, 1990, ACTA PAEDIATR SCAND, V78, P739; MANTZARIS G, 1991, SCAND J GASTROENTERO, V26, P392, DOI 10.3109/00365529108996500; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; MARSH MN, 1994, AM J GASTROENTEROL, V89, P2105; MARSH MN, 1995, QJM-MON J ASSOC PHYS, V88, P9; MCFARLANE XA, 1995, GUT, V36, P710, DOI 10.1136/gut.36.5.710; MCMILLAN SA, 1991, BRIT MED J, V303, P1163, DOI 10.1136/bmj.303.6811.1163; McMillan SA, 1996, GUT, V39, P43, DOI 10.1136/gut.39.1.43; MOLTENI N, 1990, AM J GASTROENTEROL, V85, P51; PARE P, 1988, J CLIN GASTROENTEROL, V10, P395, DOI 10.1097/00004836-198808000-00010; Picarelli A, 1996, GASTROENTEROLOGY, V111, P608, DOI 10.1053/gast.1996.v111.pm8780564; REUNALA T, 1984, ARCH DIS CHILD, V59, P517, DOI 10.1136/adc.59.6.517; Reunala T., 1993, EUR J DERMATOL, V3, P519; SAVILAHT.E, 1971, ARCH DIS CHILD, V46, P665, DOI 10.1136/adc.46.249.665; SAVILAHTI E, 1983, LANCET, V1, P320; SHER KS, 1994, DIGEST DIS, V12, P186, DOI 10.1159/000171452; SOLLID LM, 1993, GASTROENTEROLOGY, V105, P910, DOI 10.1016/0016-5085(93)90912-V; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; Srinivasan U, 1996, BRIT MED J, V313, P1300, DOI 10.1136/bmj.313.7068.1300; STURGESS R, 1994, LANCET, V343, P758, DOI 10.1016/S0140-6736(94)91837-6; SWINSON CM, 1983, LANCET, V1, P111; SWINSON CM, 1980, BRIT MED J, V281, P1258, DOI 10.1136/bmj.281.6250.1258; TALLEY NJ, 1994, AM J GASTROENTEROL, V89, P843; TIGHE MR, 1995, BAILLIERE CLIN GASTR, V9, P211, DOI 10.1016/0950-3528(95)90029-2; TRONCONE R, 1991, J PEDIATR GASTR NUTR, V12, P150, DOI 10.1097/00005176-199102000-00002; Troncone R, 1996, PEDIATR CLIN N AM, V43, P355, DOI 10.1016/S0031-3955(05)70410-7; TRONCONE R, 1995, ACTA PAEDIATR, V84, P1252, DOI 10.1111/j.1651-2227.1995.tb13543.x; UNSWORTH DJ, 1994, GUT, V35, P61, DOI 10.1136/gut.35.1.61; Valdimarsson T, 1996, GUT, V38, P322, DOI 10.1136/gut.38.3.322; vandeWal Y, 1996, IMMUNOGENETICS, V44, P246, DOI 10.1007/s002510050120; VISAKORPI JK, 1994, ACTA PAEDIATR, V83, P10, DOI 10.1111/j.1651-2227.1994.tb13221.x; VOLTA U, 1995, DIGEST DIS SCI, V40, P1902, DOI 10.1007/BF02208653; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909; Zhong F, 1996, NAT GENET, V14, P329, DOI 10.1038/ng1196-329	87	464	481	0	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	1997	349	9067					1755	1759		10.1016/S0140-6736(96)70237-4	http://dx.doi.org/10.1016/S0140-6736(96)70237-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193393				2022-12-28	WOS:A1997XE06500042
J	Sabri, O; Erkwoh, R; Schreckenberger, M; Owega, A; Sass, H; Buell, U				Sabri, O; Erkwoh, R; Schreckenberger, M; Owega, A; Sass, H; Buell, U			Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics	LANCET			English	Article							EMISSION COMPUTED-TOMOGRAPHY; NEUROLEPTIC-NAIVE PATIENTS; BLOOD-FLOW; GLUCOSE-METABOLISM; SPECT; HYPOFRONTALITY; QUANTIFICATION; PATTERNS	Background Studies of schizophrenia by single photon emission computed tomography (SPECT) and positron emission tomography (PET) have shown both regional cerebral hyperperfusion and hypoperfusion. The aim of this study was to examine the inter-relations between regional cerebral blood flow (rCBF), psychopathology, and effects of neuroleptic therapy. Methods 24 never-treated patients with acute schizophrenia were examined with hexamethyl-propyleneamine-oxime brain SPECT and assessed psychopathologically according to the positive and negative syndrome scale; they were studied again after neuroleptic treatment and psychopathological remission. rCBF values that deviated from those of 20 controls by more than 2 SD were regarded as abnormal. Findings Both hyperperfused and hypoperfused patterns were found among schizophrenia patients during acute illness. The seven positive symptoms on the symptom scale showed different correlations with rCBF, formal thought disorders and grandiosity correlated positively (and strongly) with bifrontal and bitemporal rCBF; delusions, hallucinations, and distrust correlated negatively (and strongly) with cingulate, left thalamic, left frontal, and left temporal rCBF. Stereotyped ideas as a negative symptom correlated negatively (and strongly) with left frontal, cingulate, left temporal, and left parietal rCBF, After neuroleptic treatment (and reduction of positive symptoms), only negative symptoms correlated exclusively with bifrontal, bitemporal, cingulate, basal ganglia, and thalamic hypoperfusion, Interpretation Different positive symptoms are accompanied by different rCBF values-some related to hyperperfusion, others to hypoperfusion. This finding may help to explain observed inconsistencies of perfusion patterns in drug-naive schizophrenics.	RHEIN WESTFAL TH AACHEN,DEPT PSYCHIAT,D-52057 AACHEN,GERMANY	RWTH Aachen University	Sabri, O (corresponding author), RHEIN WESTFAL TH AACHEN,DEPT NUCL MED,PAUWELSSTR 30,D-52057 AACHEN,GERMANY.			Sabri, Osama/0000-0002-6425-3504				American Psychiatric Association, 1987, DSM 3 R DIAGN STAT M; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; BRODIE JD, 1984, ANN NEUROL, V15, P166; CATAFAU AM, 1994, J NUCL MED, V35, P935; CHANG LT, 1978, IEEE T NUCL SCI, V25, P638, DOI 10.1109/TNS.1978.4329385; COSTA DC, 1986, NUCL MED COMMUN, V7, P647; EBMEIER KP, 1993, BIOL PSYCHIAT, V33, P487, DOI 10.1016/0006-3223(93)90002-U; FLURY B, 1983, ANGEW MULTIVARIATE S, P135; HOLM S, 1979, SCAND J STAT, V6, P65; KAISER HJ, 1994, NUKLEARMED, V33, P123; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; KOJIMA A, 1989, J NUCL MED, V30, P508; Kretschmann H. J., 1991, KLINISCHE NEUROANATO; LEWIS SW, 1992, PSYCHOL MED, V22, P27, DOI 10.1017/S0033291700032694; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; Mellers JDC, 1996, ACTA PSYCHIAT SCAND, V93, P92, DOI 10.1111/j.1600-0447.1996.tb09808.x; PAULMAN RG, 1990, BIOL PSYCHIAT, V27, P377, DOI 10.1016/0006-3223(90)90549-H; SABRI O, 1995, NUKLEARMED-NUCL MED, V34, P50; SHEPPARD G, 1983, LANCET, V2, P1448, DOI 10.1016/S0140-6736(83)90798-5; SYED GMS, 1992, NUCL MED COMMUN, V13, P811, DOI 10.1097/00006231-199211000-00007; SYED GMS, 1992, NUCL MED COMMUN, V13, P879, DOI 10.1097/00006231-199212000-00005; SZECHTMAN H, 1988, ARCH GEN PSYCHIAT, V45, P523; TALAIRACIN J, 1967, ATLAS ANATOMIE STERE; VOLKOW ND, 1986, J NEUROL NEUROSUR PS, V49, P1199, DOI 10.1136/jnnp.49.10.1199; WIESEL FA, 1987, ACTA PSYCHIAT SCAND, V76, P628, DOI 10.1111/j.1600-0447.1987.tb02933.x; WOLKIN A, 1985, AM J PSYCHIAT, V142, P564; WOLKIN A, 1992, ARCH GEN PSYCHIAT, V49, P959	27	146	150	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1735	1739		10.1016/S0140-6736(96)08380-8	http://dx.doi.org/10.1016/S0140-6736(96)08380-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XE065	9193384				2022-12-28	WOS:A1997XE06500011
J	Fox, CA; EhrenhoferMurray, AE; Loo, S; Rine, J				Fox, CA; EhrenhoferMurray, AE; Loo, S; Rine, J			The origin recognition complex, SIR1, and the S phase requirement for silencing	SCIENCE			English	Article							MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; SHUTTLE VECTORS; GENE-EXPRESSION; YEAST SILENCER; REPRESSION; PROTEINS	Silencing of transcription in Saccharomyces cerevisiae has several links to DNA replication, including a role for the origin recognition complex (ORC), the DNA replication initiator, in both processes. In addition, the establishment of silencing at the HML and HMR loci requires cells to pass through the S phase of the cell cycle. Passage through S phase was required for silencing of HMR even under conditions in which ORC itself was no longer required. The requirement for ORC in silencing of HMR could be bypassed by tethering the Sir1 protein to the HMR-E silencer. However, ORC had a Sir1-independent role in transcriptional silencing at telomeres. Thus, the role of ORC in silencing was separable from its role in initiation, and the role of S phase in silencing was independent of replication initiation at the silencers.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031105, R01GM031105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; AXELROD A, 1991, MOL CELL BIOL, V11, P1080, DOI 10.1128/MCB.11.2.1080; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; CHEREST H, 1987, MOL GEN GENET, V210, P307, DOI 10.1007/BF00325699; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX C, UNPUB; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RIVIER D, UNPUB; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SIKORSKI RS, 1989, GENETICS, V122, P19; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; ZHU JG, 1992, MOL CELL BIOL, V12, P4733, DOI 10.1128/MCB.12.10.4733	42	137	138	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	1997	276	5318					1547	1551		10.1126/science.276.5318.1547	http://dx.doi.org/10.1126/science.276.5318.1547			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171055				2022-12-28	WOS:A1997XC70100038
J	Das, A; Gilbert, CD				Das, A; Gilbert, CD			Distortions of visuotopic map match orientation singularities in primary visual cortex	NATURE			English	Article							MONKEY STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; INTRINSIC SIGNALS; DYNAMIC CHANGES; FIELD SIZE; ORGANIZATION	The map of orientation columns in primary visual cortex (V1) is known to show strong local distortions, with a generally smooth progression of orientation preference across extended regions of cortex, interrupted by sharp jumps (fractures) and point singularities(1-4). The map of visual space on V1, in contrast, has been assumed to be locally smooth and isotropic. We find, on the contrary, that the map of visual space on cat V1 shows strong and systematic local distortions in register with inhomogeneities in the orientation map, with the rate of receptive field movement across cortex being largely proportional to the local rate of change of orientation. This suggests possible systematic local variations in the functional connectivity of short-range lateral connections that underlie local cortical processing.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University								[Anonymous], 1941, AM J OPHTHALMOL, DOI [10.1016/S0002-9394(41)91363-6, DOI 10.1016/S0002-9394(41)91363-6]; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; DANIEL PM, 1961, J PHYSIOL-LONDON, V159, P203, DOI 10.1113/jphysiol.1961.sp006803; DAS A, 1995, J NEUROPHYSIOL, V74, P779, DOI 10.1152/jn.1995.74.2.779; DURBIN R, 1990, NATURE, V343, P644, DOI 10.1038/343644a0; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HUBEL DH, 1974, J COMP NEUROL, V158, P295, DOI 10.1002/cne.901580305; HUBEL DH, 1974, J COMP NEUROL, V158, P267, DOI 10.1002/cne.901580304; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; PETTET MW, 1992, P NATL ACAD SCI USA, V89, P8366, DOI 10.1073/pnas.89.17.8366; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630	13	99	99	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					594	598		10.1038/42461	http://dx.doi.org/10.1038/42461			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177346				2022-12-28	WOS:A1997XC52200054
J	Jenkins, CNH; Dai, PX; Ngoc, DH; VanKinh, H; Hoang, TT; Bales, S; Stewart, S; McPhee, SJ				Jenkins, CNH; Dai, PX; Ngoc, DH; VanKinh, H; Hoang, TT; Bales, S; Stewart, S; McPhee, SJ			Tobacco use in Vietnam - Prevalence, predictors, and the role of the transnational tobacco corporations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	5th Conference of the Asian-Pacific-Association-for-the-Control-of-Tobacco	NOV 23, 1995	CHIANG MAI, THAILAND	Asian Pacif Assoc Control Tobacco			DEVELOPING-COUNTRIES	Objective.-To describe tobacco use in Vietnam and the impact of transnational tobacco corporations there. Design.-In cities, a multistage cluster design; in communes, a systematic sample design, using face-to-face interviews in all sites. Setting.-Hanoi, Ho Chi Minh City, and 2 rural communes in Vietnam. Participants.-Random samples totaling 2004 men and women aged 18 years or older. Main Outcome Measures.-Prevalence and correlates of tobacco smoking, amount and duration of smoking, age at initiation, quitting behavior, knowledge of health hazards of and attitudes toward smoking, and cigarette brand smoked, preferred, and recognized as most widely advertised. Results.-Smoking prevalence among men (n=970) was 72.8% and 4.3% among women (n=1031). Male smokers had smoked a mean of 15.5 years; the median age at initiation was 19.5 years. Among male smokers, 16% smoked non-Vietnamese cigarettes. More than twice as many (38%), however, said that they would prefer to smoke a non-Vietnamese brand if they could afford the cost. Among those who recalled any cigarette advertising (38%), 71% recalled a non-Vietnamese brand as the most commonly advertised. Male smokers who were significantly more likely to smoke non-Vietnamese brands lived in the south, were engaged in blue collar or business/service occupations, earned higher incomes, and lived in urban areas. Conclusions.-Vietnam has the highest reported male smoking prevalence rate in the world, Unless forceful steps are taken to reduce smoking among men and prevent the uptake of smoking by youth and women, Vietnam will face a tremendous health and economic burden in the near future, Implementation of a comprehensive national tobacco control campaign together with international regulation will be the keys to the eradication of the tobacco epidemic in Vietnam and throughout the developing world.	INST SOCIOL, NATL CTR HUMAN & SOCIAL SCI, HANOI, VIETNAM; HO CHI MINH CITY DEPT HLTH, HLTH INFORMAT & EDUC CTR, HO CHI MINH CITY, VIETNAM; HANOI TRADE COLL, HANOI, VIETNAM; UNIV CALIF BERKELEY, DEPT ECON, BERKELEY, CA 94720 USA; NO CALIF CANC CTR, UNION CITY, CA USA; UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA 94143 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco	Jenkins, CNH (corresponding author), UNIV CALIF SAN FRANCISCO, DIV GEN INTERNAL MED, VIETNAMESE COMMUNITY HLTH PROMOT PROJECT, SAN FRANCISCO, CA 94104 USA.			Stewart, Susan/0000-0002-1593-440X				[Anonymous], 1996, GLOBAL BURDEN DIS CO; BANNISTER J, 1993, VIETNAM POPULATION D; BARRY M, 1991, NEW ENGL J MED, V324, P917, DOI 10.1056/NEJM199103283241311; Centers for Disease Control and Prevention (CDC), 1996, MMWR-MORBID MORTAL W, V45, P588; Chaloupka Frank J., 1996, 5543 NAT BUR EC RES; CHEN TTL, 1990, AM J PUBLIC HEALTH, V80, P659, DOI 10.2105/AJPH.80.6.659; COLLINS G, 1997, NY TIMES        0130, pD2; COLLINS G, 1997, NY TIMES        0129, pD4; CRAIG D, 1996, ASIAN STUD REV, V20, P53; DO NH, 1995, VIETNAM TOBACCO EPID, P89; Fforde, 1996, PLAN MARKET EC TRANS; FLINT A, 1996, BOSTON GLOBE    0609, pB30; Frankel Glenn, 1996, WASH POST; GONG YL, 1995, JAMA-J AM MED ASSOC, V274, P1232, DOI 10.1001/jama.274.15.1232; MACKAY JL, 1994, TUBERCLE LUNG DIS, V75, P8, DOI 10.1016/0962-8479(94)90097-3; *MIN LIGHT IND, 1992, TINH HINH SAN XUAT T; Nellen MEAH, 1995, TOBACCO AND HEALTH, P323; PARKERPOPE T, 1996, WALL STREET J   1009, pB1; Peto R, 1994, MORTALITY SMOKING DE; REUTERS, 1994, CIGARETTE FIRM FINAN; Shah BV, 1997, SOFTWARE STAT ANAL C; *US DEP HHS, 1989, DHHS PUBL; *USDA, 1996, USDA PUBL; Wald NJ, 1996, BRIT MED BULL, V52, P3, DOI 10.1093/oxfordjournals.bmb.a011530; *WHO PROGR TOB HLT, 1996, TOBACCO ALERT    JUL, P11; World Health Organization, 1996, WORLD NO TOBACO 0531, P7; 1994, STAT YB 1994; 1994, PHILIPPINE STAR 1128	28	61	63	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1726	1731		10.1001/jama.277.21.1726	http://dx.doi.org/10.1001/jama.277.21.1726			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XB088	9169903				2022-12-28	WOS:A1997XB08800037
J	Bashaw, GJ; Baker, BS				Bashaw, GJ; Baker, BS			The regulation of the Drosophila msl-2 gene reveals a function for Sex-lethal in translational control	CELL			English	Article							DOSAGE COMPENSATION; TRANSFORMER GENE; X-CHROMOSOMES; RNA-BINDING; IN-VIVO; MELANOGASTER; PROTEIN; EXPRESSION; DIFFERENTIATION; LOCALIZATION	In Drosophila, dosage compensation occurs by increasing the transcription of the single male X chromosome. Four trans-acting factors encoded by the male-specific lethal genes are required for this process. Dosage compensation is restricted to males by the splicing regulator Sex-lethal, which functions to prevent the production of the MSL-2 protein in females by an unknown mechanism. In this report, we provide evidence that Sex-lethal acts synergistically through sequences in both the 5' and 3' untranslated regions of MSL-2 to mediate repression. We also provide evidence that the repression of MSL-2 is directly regulated by Sex-lethal at the level of translation.			Bashaw, GJ (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.							BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; Bone JR, 1996, GENETICS, V144, P705; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Franke A, 1996, DEVELOPMENT, V122, P2751; GORMAN M, 1995, DEVELOPMENT, V121, P463; GORMAN M, 1993, CELL, V72, P39, DOI 10.1016/0092-8674(93)90048-U; HILFIKER A, 1994, EMBO J, V13, P3542, DOI 10.1002/j.1460-2075.1994.tb06661.x; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; JONES FE, 1995, J VIROL, V69, P4863, DOI 10.1128/JVI.69.8.4863-4871.1995; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; Marin I, 1996, NATURE, V383, P160, DOI 10.1038/383160a0; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Smibert CA, 1996, GENE DEV, V10, P2600, DOI 10.1101/gad.10.20.2600; Sokal R. R, 1981, BIOMETRY; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	38	166	170	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					789	798		10.1016/S0092-8674(00)80262-7	http://dx.doi.org/10.1016/S0092-8674(00)80262-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182767	Bronze			2022-12-28	WOS:A1997XB92500016
J	Bracken, MB; Shepard, MJ; Holford, TR; LeoSummers, L; Aldrich, EF; Fazl, M; Fehlings, M; Herr, DL; Hitchon, PW; Marshall, LF; Nockels, RP; Pascale, V; Perot, PL; Piepmeier, J; Sonntag, VKH; Wagner, F; Wilberger, JE; Winn, HR; Young, W				Bracken, MB; Shepard, MJ; Holford, TR; LeoSummers, L; Aldrich, EF; Fazl, M; Fehlings, M; Herr, DL; Hitchon, PW; Marshall, LF; Nockels, RP; Pascale, V; Perot, PL; Piepmeier, J; Sonntag, VKH; Wagner, F; Wilberger, JE; Winn, HR; Young, W			Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury - Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SODIUM SUCCINATE; NEUROLOGICAL FUNCTION; NALOXONE; ISCHEMIA; METABOLISM	Objective.-To compare the efficacy of methylprednisolone administered for 24 hours with methyprednisolone administered for 48 hours or tirilazad mesylate administered for 48 hours in patients with acute spinal cord injury. Design.-Double-blind, randomized clinical trial. Setting.-Sixteen acute spinal cord injury centers in North America. Patients.-A total of 499 patients with acute spinal cord injury diagnosed in National Acute Spinal Cord Injury Study (NASCIS) centers within 8 hours of injury. Intervention.-All patients received an intravenous bolus of methylprednisolone (30 mg/kg) before randomization. Patients in the 24-hour regimen group (n=166) received a methylprednisolone infusion of 5.4 mg/kg per hour for 24 hours, those in the 48-hour regimen group (n=167) received a methylprednisolone infusion of 5.4 mg/kg per hour for 48 hours, and those in the tirilazad group (n=166) received a 2.5 mg/kg bolus infusion of tirilazad mesylate every 6 hours for 48 hours. Main Outcome Measures.-Motor function change between initial presentation and at 6 weeks and 6 months after injury, and change in Functional independence Measure (FIM) assessed at 6 weeks and 6 months. Results.-Compared with patients treated with methylprednisolone for 24 hours, those treated with methylprednisolone for 48 hours showed improved motor recovery at 6 weeks (P=.09) and 6 months (P=.07) after injury. The effect of the 48-hour methylprednisolone regimen was significant at 6 weeks (P=.04) and 6 months (P=.01) among patients whose therapy was initiated 3 to 8 hours after injury. Patients who received the 48-hour regimen and who started treatment at 3 to 8 hours were more likely to improve 1 full neurologic grade (P=.03) at 6 months, to show more improvement in 6-month FIM (P=.08), and to have more severe sepsis and severe pneumonia than patients in the 24-hour methylprednisolone group and the tirilazad group, but other complications and mortality (P=.97) were similar, Patients treated with tirilazad for 48 hours showed motor recovery rates equivalent to patients who received methylprednisolone for 24 hours. Conclusions.-Patients with acute spinal cord injury who receive methylprednisolone within 3 hours of injury should be maintained on the treatment regimen for 24 hours. When methylprednisolone is initiated 3 to 8 hours after injury, patients should be maintained on steroid therapy for 48 hours.			Bracken, MB (corresponding author), YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, 60 COLL ST, POB 208034, NEW HAVEN, CT 06520 USA.		Herr, Daniel/X-4215-2019	Hitchon, Patrick/0000-0002-8175-9136; Fehlings, Michael/0000-0002-5722-6364; Herr, Daniel/0000-0001-8533-9000	NINDS NIH HHS [NS-15078] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015078] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		*AM SPIN INJ ASS, 1992, STAND NEUR FUNCT CLA; ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; ANDERSON DK, 1994, BRAIN RES, V637, P119, DOI 10.1016/0006-8993(94)91224-6; Anderson DK, 1991, J NEUROTRAUM, V8, P187, DOI 10.1089/neu.1991.8.187; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; BRACKEN MB, 1981, AM J EPIDEMIOL, V113, P615, DOI 10.1093/oxfordjournals.aje.a113140; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BRACKEN MB, 1985, CENTRAL NERVOUS SYST; BRAUGHLER JM, 1983, J NEUROSURG, V59, P256, DOI 10.3171/jns.1983.59.2.0256; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; Chiles BW, 1996, NEW ENGL J MED, V334, P514, DOI 10.1056/NEJM199602223340807; Collins W F, 1986, Cent Nerv Syst Trauma, V3, P317; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1995, J NEUROTRAUM, V12, P245, DOI 10.1089/neu.1995.12.245; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1984, J NEUROSURG, V61, P124, DOI 10.3171/jns.1984.61.1.0124; HALL ED, 1993, MOL CELLULAR APPROAC, P91; Hamilton B. B., 1987, REHABILITATION OUTCO, P137; HOLFORD TR, 1992, STAT MED, V11, P1171, DOI 10.1002/sim.4780110904; HOLTZ A, 1992, NEUROL RES, V14, P44; HSU C Y, 1990, Journal of Neurotrauma, V7, P115, DOI 10.1089/neu.1990.7.115; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; OTANI K, 1994, SEKITSUI SEKIZUI J, V7, P633; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; Sano K, 1980, Neurol Res, V2, P253; SAS-Institute-Inc, 1988, SAS STAT US GUID; XU J, 1992, J NEUROTRAUM, V9, P245, DOI 10.1089/neu.1992.9.245	36	976	1057	2	50	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	1997	277	20					1597	1604		10.1001/jama.277.20.1597	http://dx.doi.org/10.1001/jama.277.20.1597			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA022	9168289				2022-12-28	WOS:A1997XA02200029
J	Speight, EL; MacSween, RM; Stevens, A				Speight, EL; MacSween, RM; Stevens, A			Lesson of the week - Persistent itching due to etherified starch plasma expander	BRITISH MEDICAL JOURNAL			English	Review							PRURITUS; THERAPY; SKIN		UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT HISTOPATHOL,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	Speight, EL (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT DERMATOL,NOTTINGHAM NG7 2UH,ENGLAND.							ALBEGGER K, 1992, WIEN MED WOCHENSCHR, V142, P1; CARMICHAEL AJ, 1992, LANCET, V339, P932, DOI 10.1016/0140-6736(92)90971-5; CARMICHAEL AJ, 1992, LANCET, V339, P815, DOI 10.1016/0140-6736(92)91950-D; Cox NH, 1996, BRIT J DERMATOL, V134, P353; GALL H, 1993, HAUTARZT, V44, P713; JURECKA W, 1993, ARCH DERMATOL RES, V285, P13, DOI 10.1007/BF00370817; LACY JH, 1992, DRUGS, V44, P720, DOI 10.2165/00003495-199244050-00004; PARKER NE, 1982, BRIT MED J, V284, P385, DOI 10.1136/bmj.284.6313.385-a; SZEIMIES RM, 1994, BRIT J DERMATOL, V131, P380, DOI 10.1111/j.1365-2133.1994.tb08529.x	9	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1466	1467		10.1136/bmj.314.7092.1466	http://dx.doi.org/10.1136/bmj.314.7092.1466			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167566	Green Published			2022-12-28	WOS:A1997XA20200028
J	Erickson, HP				Erickson, HP			Protein biophysics - Stretching single protein molecules: Titin is a weird spring	SCIENCE			English	Editorial Material							ELASTICITY				Erickson, HP (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710, USA.							ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; Gautel M, 1996, FEBS LETT, V385, P11, DOI 10.1016/0014-5793(96)00338-9; Granzier H, 1996, BIOPHYS J, V70, P430, DOI 10.1016/S0006-3495(96)79586-3; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; SOTERIOU A, 1993, P ROY SOC B-BIOL SCI, V254, P83, DOI 10.1098/rspb.1993.0130; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0	9	90	91	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 16	1997	276	5315					1090	1092		10.1126/science.276.5315.1090	http://dx.doi.org/10.1126/science.276.5315.1090			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9173540				2022-12-28	WOS:A1997WZ22500035
J	Maisonpierre, PC; Suri, C; Jones, PF; Bartunkova, S; Wiegand, S; Radziejewski, C; Compton, D; McClain, J; Aldrich, TH; Papadopoulos, N; Daly, TJ; Davis, S; Sato, TN; Yancopoulos, GD				Maisonpierre, PC; Suri, C; Jones, PF; Bartunkova, S; Wiegand, S; Radziejewski, C; Compton, D; McClain, J; Aldrich, TH; Papadopoulos, N; Daly, TJ; Davis, S; Sato, TN; Yancopoulos, GD			Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; ENDOTHELIAL GROWTH-FACTOR; MOLECULAR-CLONING; EXPRESSION; PROTEIN; GENES; TEK; VASCULOGENESIS; INHIBITION; PATTERNS	Angiogenesis is thought to depend on a precise balance of positive and negative regulation. Angiopoietin-1 (Ang1) is an angiogenic factor that signals through the endothelial cell-specific Tie2 receptor tyrosine kinase. Like Vascular endothelial growth factor, Ang1 is essential for normal vascular development in the mouse. An Ang1 relative, termed angiopoietin-2 (Ang2), was identified by homology screening and shown to be a naturally occurring antagonist for Ang1 and Tie2. Transgenic overexpression of Ang2 disrupts blood vessel formation in the mouse embryo. in adult mice and humans, Ang2 is expressed only at sites of vascular remodeling. Natural antagonists for vertebrate receptor tyrosine kinases are atypical; thus, the discovery of a negative regulator acting on Tie2 emphasizes the need for exquisite regulation of this angiogenic receptor system.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; BETH ISRAEL DEACONESS MED CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Regeneron; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School								AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Davis S.M, UNPUB; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FINDLAY JK, 1986, J ENDOCRINOL, V111, P357, DOI 10.1677/joe.0.1110357; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; MAISONPIERRE P, UNPUB; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHALABY F, 1996, NATURE, V380, P435; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; ZIEGLER SF, 1993, ONCOGENE, V8, P663	37	2725	2985	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					55	60		10.1126/science.277.5322.55	http://dx.doi.org/10.1126/science.277.5322.55			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204896				2022-12-28	WOS:A1997XJ41800036
J	Montague, CT; Farooqi, IS; Whitehead, JP; Soos, MA; Rau, H; Wareham, NJ; Sewter, CP; Digby, JE; Mohammed, SN; Hurst, JA; Cheetham, CH; Earley, AR; Barnett, AH; Prins, JB; ORahilly, S				Montague, CT; Farooqi, IS; Whitehead, JP; Soos, MA; Rau, H; Wareham, NJ; Sewter, CP; Digby, JE; Mohammed, SN; Hurst, JA; Cheetham, CH; Earley, AR; Barnett, AH; Prins, JB; ORahilly, S			Congenital leptin deficiency is associated with severe early-onset obesity in humans	NATURE			English	Article							MESSENGER-RNA; GENE-PRODUCT; OB RNA; MICE; PROTEIN	The extreme obesity of the obese (ob/ob) mouse is attributable to mutations in the gene encoding leptin(1), an adipocyte-specific secreted protein which has profound effects on appetite and energy expenditure. We know of no equivalent evidence regarding leptin's role in the control of fat mass in humans. We have examined two severely obese children who are members of the same highly consanguineous pedigree. Their serum leptin levels were very low despite their markedly elevated fat mass and, in both, a homozygous frame-shift mutation involving the deletion of a single guanine nucleotide in codon 133 of the gene for leptin was found. The severe obesity found in these congenitally leptin-deficient subjects provides the first genetic evidence that leptin is an important regulator of energy balance in humans.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QR,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT COMMUNITY MED,CAMBRIDGE CB2 2QR,ENGLAND; GUYS HOSP,S THAMES REG GENET CTR E,LONDON SE1 9RT,ENGLAND; CHURCHILL HOSP,OXFORD REG GENET SERV,OXFORD OX3 7LJ,ENGLAND; WYCOMBE GEN HOSP,HIGH WYCOMBE B9 5SS,BUCKS,ENGLAND; UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND; BIRMINGHAM HEARTLANDS HOSP,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Guy's & St Thomas' NHS Foundation Trust; University of Oxford; University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham			Farooqi, Ismaa Sadaf/AAZ-3046-2020; Prins, Johannes/I-3610-2019; Whitehead, Jonathan/F-5022-2014; O'Rahilly, Stephen/ABF-6509-2020; Prins, Johannes B/M-5884-2013	Prins, Johannes/0000-0001-9497-927X; O'Rahilly, Stephen/0000-0003-2199-4449; Prins, Johannes B/0000-0001-9497-927X; Montague, Carl/0000-0001-5411-9291; Farooqi, Sadaf/0000-0001-7609-3504; Whitehead, Jonathan/0000-0003-3978-3148	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Bouchard C, 1996, DIABETOLOGIA, V39, P1532, DOI 10.1007/s001250050610; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; COLEMAN DL, 1979, SCIENCE, V203, P663, DOI 10.1126/science.760211; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; FOMON SJ, 1982, AM J CLIN NUTR, V35, P1169, DOI 10.1093/ajcn/35.5.1169; GARROW JS, 1985, INT J OBESITY, V9, P147; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; KRAWCZAK M, 1992, HUM GENET, V90, P41; Maffei M, 1996, DIABETES, V45, P679, DOI 10.2337/diabetes.45.5.679; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Ravussin E, 1997, NAT MED, V3, P238, DOI 10.1038/nm0297-238; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; YORK DA, 1978, COMP BIOCH PHYSL, V590, P59; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	21	2157	2227	5	147	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					903	908		10.1038/43185	http://dx.doi.org/10.1038/43185			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202122	Bronze			2022-12-28	WOS:A1997XG41600052
J	Starr, R; Willson, TA; Viney, EM; Murray, LJL; Rayner, JR; Jenkins, BJ; Gonda, TJ; Alexander, WS; Metcalf, D; Nicola, NA; Hilton, DJ				Starr, R; Willson, TA; Viney, EM; Murray, LJL; Rayner, JR; Jenkins, BJ; Gonda, TJ; Alexander, WS; Metcalf, D; Nicola, NA; Hilton, DJ			A family of cytokine-inducible inhibitors of signalling	NATURE			English	Article							TYROSINE PHOSPHORYLATION; ACTIVATION; RECEPTORS; CLONING; CHAIN	Cytokines are secreted proteins that regulate important cellular responses such as proliferation and differentiation(1). Key events in cytokine signal transduction are well defined: cytokines induce receptor aggregation, leading to activation of members of the JAK family of cytoplasmic tyrosine kinases. In turn, members af the STAT family of transcription factors are phosphorylated, dimerize and increase the transcription of genes with STAT recognition sites in their promoters(1-4). Less is known of how cytokine signal transduction is switched off. We have cloned a complementary DNA encoding a protein SOCS-1, containing an SH2-domain, by its ability to inhibit the macrophage differentiation of M1 cells in response to interleukin-6. Expression of SOCS-1 inhibited both interleukin-6-induced receptor phosphorylation and STAT activation. We have also cloned two-relatives of SOCS-1, named SOCS-2 and SOCS-3, which together with the previously described CIS (ref. 5) form a new family of proteins. Transcription of all four SOCS genes is increased rapidly in response to interleukin-6, in vitro and in vivo, suggesting they may act in a classic negative feedback loop to regulate cytokine signal transduction.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3052, AUSTRALIA; COOPERAT RES CTR CELLULAR GROWTH FACTORS, PARKVILLE, VIC 3052, AUSTRALIA; INST MED & VET SCI, HANSON CTR CANC RES, ADELAIDE, SA 5000, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Institute Medical & Veterinary Science Australia			jenkins, brendan/J-7854-2012; Nicola, Nicos/D-2989-2011; jenkins, brendan/A-2401-2009; Hilton, Douglas J/C-7250-2013; Gonda, Thomas J/A-3620-2012	Nicola, Nicos/0000-0003-1054-7889; Hilton, Douglas J/0000-0002-7698-2392; Jenkins, Brendan/0000-0002-7552-4656				ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FENG J, IN PRESS MOL CELL BI; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Howard M, 1994, GUIDEBOOK CYTOKINES; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1994, BLOOD CELLS, V20, P65; LOTEM J, 1989, LEUKEMIA, V3, P804; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1995, LEUKEMIA, V9, P1556; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nicola NA, 1996, GROWTH FACTORS, V13, P141, DOI 10.3109/08977199609034574; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; QUELLE EW, 1996, MOL CELL BIOL, V16, P1622; Rasko JEJ, 1995, LEUKEMIA, V9, P2058; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; Schluter G, 1996, MOL REPROD DEV, V43, P1, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;1::AID-MRD1&gt;3.0.CO;2-W; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	27	1735	1848	0	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	1997	387	6636					917	921		10.1038/43206	http://dx.doi.org/10.1038/43206			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202125	Bronze			2022-12-28	WOS:A1997XG41600055
J	OBrien, CP; McLellan, AT				OBrien, CP; McLellan, AT			Addiction medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL DEPENDENCE; LIVER-TRANSPLANTATION; NALTREXONE; DISEASE				OBrien, CP (corresponding author), UNIV PENN, PHILADELPHIA, PA 19104 USA.							Allen JP, 1997, J STUD ALCOHOL, V58, P7; BENJAMIN D, 1993, BRAIN RES, V621, P137, DOI 10.1016/0006-8993(93)90309-B; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; Gianoulakis C, 1996, ARCH GEN PSYCHIAT, V53, P250; GISH RG, 1993, AM J GASTROENTEROL, V88, P1337; King AC, 1997, PSYCHOPHARMACOLOGY, V129, P15, DOI 10.1007/s002130050156; LITTLETON J, 1995, ADDICTION, V90, P1179, DOI 10.1046/j.1360-0443.1995.90911793.x; MASON BJ, 1994, ALCOHOL CLIN EXP RES, V18, P1162, DOI 10.1111/j.1530-0277.1994.tb00098.x; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; Shelton W, 1997, ALCOHOL CLIN EXP RES, V21, P93, DOI 10.1111/j.1530-0277.1997.tb03734.x; VANTHIEL DH, 1995, ALCOHOL CLIN EXP RES, V19, P1151; VOLPICELLI JR, 1990, ALCOHOL, V7, P133, DOI 10.1016/0741-8329(90)90074-M; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; VOLPICELLI JR, 1990, OPIOIDS, BULIMIA, AND ALCOHOL ABUSE & ALCOHOLISM, P195	15	6	6	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1840	1841						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD544	9185790				2022-12-28	WOS:A1997XD54400009
J	Weibert, RT; Le, DT; Kayser, SR; Rapaport, SI				Weibert, RT; Le, DT; Kayser, SR; Rapaport, SI			Correction of excessive anticoagulation with low-dose oral vitamin K-1	ANNALS OF INTERNAL MEDICINE			English	Article							THERAPY; COMPLICATIONS; WARFARIN	Background: Despite earlier acceptance of oral Vitamin K-1 (phytonadione) for the treatment of excessive anticoagulation, some recent guidelines do not recommend its use. Objective: To reevaluate the efficacy of oral vitamin K-1 in correcting excessive anticoagulation. Design: Case series. Setting: Anticoagulation clinics at two university medical centers. Patients: 81 outpatients who had an international normalized ratio (INR) greater than 5.0 but did not have significant bleeding. Interventions: Withholding 1 or 2 doses of warfarin, administering 2.5 mg of oral vitamin K-1, measuring the INR after 24 to 48 hours, and adjusting the warfarin dose. Measurements: INRs were obtained from a portable capillary fingerstick monitor or from an automated photo-optical coagulometer. Results: In 68 of 71 patients (96%), oral vitamin K-1 lowered the INR from between 5.0 and 10.0 to less than 5.0 without inducing resistance to further anticoagulation. Conclusions: Withholding 1 or 2 doses of warfarin and administering 2.5 mg of oral vitamin K-1 is a reliable, safe, and inexpensive way to rapidly correct excessive anticoagulation (INR > 5.0) in patients who do not have serious bleeding episodes and have an INR of less than 10.0.	UNIV CALIF SAN FRANCISCO, SCH PHARM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Francisco; University of California System; University of California San Diego	Weibert, RT (corresponding author), UNIV CALIF SAN DIEGO, MED CTR, 200 W ARBOR DR, SAN DIEGO, CA 92103 USA.				PHS HHS [H27234] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSEN P, 1975, ACTA MED SCAND, V198, P269; Azar AJ, 1996, J AM COLL CARDIOL, V27, P1349, DOI 10.1016/0735-1097(96)00020-4; BECKER RC, 1995, ARCH INTERN MED, V155, P149, DOI 10.1001/archinte.155.2.149; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; COSGRIFF SW, 1956, ANN INTERN MED, V45, P14, DOI 10.7326/0003-4819-45-1-14; GLOVER JJ, 1995, CHEST, V108, P987, DOI 10.1378/chest.108.4.987; Hirsh J, 1996, CIRCULATION, V93, P2212, DOI 10.1161/01.CIR.93.12.2212; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; LAUNBJERG J, 1991, J INTERN MED, V229, P351, DOI 10.1111/j.1365-2796.1991.tb00358.x; LEVINE MN, 1995, CHEST, V108, pS276, DOI 10.1378/chest.108.4_Supplement.276S; PARK BK, 1984, BRIT J CLIN PHARMACO, V18, P655, DOI 10.1111/j.1365-2125.1984.tb02526.x; PENGO V, 1993, BLOOD COAGUL FIBRIN, V4, P739, DOI 10.1097/00001721-199304050-00010; SCHIRGER A, 1959, P STAFF M MAYO CLIN, V34, P453; SHETTY HG, 1995, THROMB HAEMOSTASIS, V67, P13; Van der Meer J, 1968, Thromb Diath Haemorrh Suppl, V29, P1; vanderMeer FJM, 1996, THROMB HAEMOSTASIS, V76, P12	16	85	86	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1997	126	12					959	962		10.7326/0003-4819-126-12-199706150-00005	http://dx.doi.org/10.7326/0003-4819-126-12-199706150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE549	9182473				2022-12-28	WOS:A1997XE54900008
J	MaymoGatell, X; Chien, YT; Gossett, JM; Zinder, SH				MaymoGatell, X; Chien, YT; Gossett, JM; Zinder, SH			Isolation of a bacterium that reductively dechlorinates tetrachloroethene to ethene	SCIENCE			English	Article							ENRICHMENT CULTURE; TRICHLOROETHYLENE; METHANOGENESIS; ABSENCE	Tetrachloroethene is a prominent groundwater pollutant that can be reductively dechlorinated by mixed anaerobic microbial populations to the nontoxic product ethene. Strain 195, a coccoid bacterium that dechlorinates tetrachloroethene to ethene, was isolated and characterized. Growth of strain 195 with H-2 and tetrachloroethene as the electron donor and acceptor pair required extracts from mixed microbial cultures. Growth of strain I 195 was resistant to ampicillin and vancomycin; its cell wall did not react with a peptidoglycan-specific lectin and its ultrastructure resembled S-layers of Archaea. Analysis of the 16S ribosomal DNA sequence of strain 195 indicated that it is a eubacterium without close affiliation to any known groups.	CORNELL UNIV, MICROBIOL SECT, ITHACA, NY 14853 USA; CORNELL UNIV, SCH CIVIL & ENVIRONM ENGN, ITHACA, NY 14853 USA	Cornell University; Cornell University								ABELSON PH, 1990, SCIENCE, V250, P73; Bozzola JJ., 1992, ELECT MICROSCOPY PRI, P16; COLLINS MD, 1994, INT J SYST BACTERIOL, V44, P812, DOI 10.1099/00207713-44-4-812; DEBRUIN WP, 1992, APPL ENVIRON MICROB, V58, P1996, DOI 10.1128/AEM.58.6.1996-2000.1992; DISTEFANO TD, 1992, APPL ENVIRON MICROB, V58, P3622, DOI 10.1128/AEM.58.11.3622-3629.1992; DISTEFANO TD, 1991, APPL ENVIRON MICROB, V57, P2287, DOI 10.1128/AEM.57.8.2287-2292.1991; ENSLEY BD, 1991, ANNU REV MICROBIOL, V45, P283; Felsenstein J., 1993, PHYLOGENETIC INFEREN; Fennell DE, 1995, BIOREMED SER, V3, P9; FREEDMAN DL, 1989, APPL ENVIRON MICROB, V55, P2144, DOI 10.1128/AEM.55.9.2144-2151.1989; GANTZER CJ, 1991, ENVIRON SCI TECHNOL, V25, P715, DOI 10.1021/es00016a017; Gerritse J, 1996, ARCH MICROBIOL, V165, P132, DOI 10.1007/s002030050308; GOODWIN DC, 1993, BIOTECHNIQUES, V15, P438; HINCHEE RE, 1995, BIOREMEDIATION CHLOR; HOLLIGER C, 1993, APPL ENVIRON MICROB, V59, P2991, DOI 10.1128/AEM.59.9.2991-2997.1993; Johnson John L., 1994, P683; KANDLER O, 1994, SYST APPL MICROBIOL, V16, P501; Krumholz LR, 1996, APPL ENVIRON MICROB, V62, P4108, DOI 10.1128/AEM.62.11.4108-4113.1996; MAIDAK BL, 1994, NUCLEIC ACIDS RES, V22, P3485, DOI 10.1093/nar/22.17.3485; MAYMOGATELL X, 1995, APPL ENVIRON MICROB, V61, P3928; MAYMOGATELL X, UNPUB; MOHN WW, 1992, MICROBIOL REV, V56, P482, DOI 10.1128/MMBR.56.3.482-507.1992; SCHOLZMURAMATSU H, 1995, ARCH MICROBIOL, V163, P48, DOI 10.1007/BF00262203; Sharma PK, 1996, APPL ENVIRON MICROB, V62, P761, DOI 10.1128/AEM.62.3.761-765.1996; SIZEMORE RK, 1990, APPL ENVIRON MICROB, V56, P2245, DOI 10.1128/AEM.56.7.2245-2247.1990; Sprott G. Dennis, 1994, P72; TANDOI V, 1994, ENVIRON SCI TECHNOL, V28, P973, DOI 10.1021/es00054a033; WESTRICK JJ, 1984, J AM WATER WORKS ASS, V76, P52	28	811	853	4	256	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 6	1997	276	5318					1568	1571		10.1126/science.276.5318.1568	http://dx.doi.org/10.1126/science.276.5318.1568			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171062				2022-12-28	WOS:A1997XC70100045
J	Carette, S; Leclaire, R; Marcoux, S; Morin, F; Blaise, GA; StPierre, A; Truchon, R; Parent, F; Levesque, J; Bergeron, V; Montminy, P; Blanchette, C				Carette, S; Leclaire, R; Marcoux, S; Morin, F; Blaise, GA; StPierre, A; Truchon, R; Parent, F; Levesque, J; Bergeron, V; Montminy, P; Blanchette, C			Epidural corticosteroid injections for sciatica due to herniated nucleus pulposus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-BACK-PAIN; SICKNESS IMPACT PROFILE; HEALTH-STATUS MEASURE; STEROID INJECTIONS; MANAGEMENT	Background Although epidural corticosteroid injections are commonly used for sciatica, their efficacy has not been established. Methods In a randomized, double-blind trial, we administered up to three epidural injections of methylprednisolone acetate (80 mg in 8 ml of isotonic saline) or isotonic saline (1 ml) to 158 patients with sciatica due to a herniated nucleus pulposus. All patients had Oswestry disability scores higher than 20 (on a scale of 1 to 100, with scores of 20 or less indicating minimal disability, and higher scores greater disability). Results At three weeks, the Oswestry score had improved by a mean of -8.0 in the methylprednisolone group and -5.5 in the placebo group (95 percent confidence interval for the difference, -7.1 to 2.2). Differences in improvements between the groups were not significant, except for improvements in the finger-to-floor distance (P=0.006) and sensory deficits (P=0.03), which were greater in the methylprednisolone group. After six weeks, the only significant difference was the improvement in leg pain, which was greater in the methylprednisolone group (P=0.03). After three months, there were no significant differences between the groups. The Oswestry score had improved by a mean of -17.3 in the methylprednisolone group and -15.4 in the placebo group (95 percent confidence interval for the difference, -9.3 to 5.4). At 12 months, the cumulative probability of back surgery was 25.8 percent in the methylprednisolone group and 24.8 percent in the placebo group (P=0.90). Conclusions Although epidural injections of methylprednisolone may afford short-term improvement in leg pain and sensory deficits in patients with sciatica due to a herniated nucleus pulposus, this treatment offers no significant functional benefit, nor does it reduce the need for surgery. (C) 1997, Massachusetts Medical Society.	UNIV LAVAL, DEPT MED, QUEBEC CITY, PQ G1K 7P4, CANADA; UNIV LAVAL, DEPT SOCIAL & PREVENT MED, QUEBEC CITY, PQ G1K 7P4, CANADA; UNIV LAVAL, DEPT ANESTHESIOL, QUEBEC CITY, PQ G1K 7P4, CANADA; UNIV LAVAL, DEPT RADIOL, QUEBEC CITY, PQ G1K 7P4, CANADA; UNIV LAVAL, DEPT ORTHOPED SURG, QUEBEC CITY, PQ G1K 7P4, CANADA; UNIV MONTREAL, DEPT MED, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, DEPT ANESTHESIOL, MONTREAL, PQ H3C 3J7, CANADA	Laval University; Laval University; Laval University; Laval University; Laval University; Universite de Montreal; Universite de Montreal								ABRAM SE, 1989, ARCH NEUROL-CHICAGO, V46, P719, DOI 10.1001/archneur.1989.00520430013005; BARRY P J, 1962, Ann Phys Med, V6, P267; Beliveau P, 1971, Rheumatol Phys Med, V11, P40, DOI 10.1093/rheumatology/11.1.40; BENZON HT, 1986, PAIN, V24, P277, DOI 10.1016/0304-3959(86)90115-6; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERGNER M, 1976, INT J HEALTH SERV, V6, P393, DOI 10.2190/RHE0-GGH4-410W-LA17; BOGDUK N, 1985, MED J AUSTRALIA, V143, P402, DOI 10.5694/j.1326-5377.1985.tb123102.x; BREIVIK H, 1976, ADV PAIN RES THER, V1, P927; BUSH K, 1992, SPINE, V17, P1205, DOI 10.1097/00007632-199210000-00013; BUSH K, 1991, SPINE, V16, P572, DOI 10.1097/00007632-199105000-00015; Cohen J., 1988, STAT POWER ANAL BEHA, DOI DOI 10.1016/B978-0-12-179060-8.50006-2; CUCKLER JM, 1985, J BONE JOINT SURG AM, V67A, P63, DOI 10.2106/00004623-198567010-00009; DELANEY TJ, 1980, ANESTH ANALG, V59, P610; DILKE TFW, 1973, BRIT MED J, V2, P635, DOI 10.1136/bmj.2.5867.635; Fairbank J C, 1980, Physiotherapy, V66, P271; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; KEPES ER, 1985, PAIN, V22, P33, DOI 10.1016/0304-3959(85)90146-0; KLEINBAUM DG, 1978, APPLIED REGRESSION A; KLENERMAN L, 1984, BRIT J RHEUMATOL, V23, P35; Koes BW, 1995, PAIN, V63, P279, DOI 10.1016/0304-3959(95)00124-7; LAWLESS JF, 1982, STATISTICAL MODELS M; LEHMANN EL, 1975, NONPARAMETRICS; LIEVRE J A, 1957, Bull Mem Soc Med Hop Paris, V73, P1110; LIEVRE JA, 1953, B MEM SOC MED HOP P, V20, P310; MATHEWS JA, 1987, BRIT J RHEUMATOL, V26, P416; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; RIDLEY MG, 1988, BRIT J RHEUMATOL, V27, P295; ROCCO AG, 1989, PAIN, V36, P297, DOI 10.1016/0304-3959(89)90088-2; SERRAO JM, 1992, PAIN, V48, P5, DOI 10.1016/0304-3959(92)90125-U; SNEDECOR GW, 1967, STATIST METHODS; SNOEK W, 1977, ACTA ORTHOP SCAND, V48, P635, DOI 10.3109/17453677708994810; YATES DW, 1978, RHEUMATOL REHABIL, V17, P181, DOI 10.1093/rheumatology/17.3.181	33	357	369	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1634	1640		10.1056/NEJM199706053362303	http://dx.doi.org/10.1056/NEJM199706053362303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC086	9171065				2022-12-28	WOS:A1997XC08600003
J	Walz, T; Hirai, T; Murata, K; Heymann, JB; Mitsuoka, K; Fujiyoshi, Y; Smith, BL; Agre, P; Engel, A				Walz, T; Hirai, T; Murata, K; Heymann, JB; Mitsuoka, K; Fujiyoshi, Y; Smith, BL; Agre, P; Engel, A			The three-dimensional structure of aquaporin-1	NATURE			English	Article							ELECTRON CRYSTALLOGRAPHY; WATER CHANNELS; CHIP; RESOLUTION; PROJECTION; PROTEIN; MODEL	The entry and exit of water from cells is a fundamental process of life. Recognition of the high water permeability of red blood cells led to the proposal that specialized water pores exist in the plasma membrane(1). Expression in Xenopus oocytes and functional studies of an erythrocyte integral membrane protein of relative molecular mass 28,000, identified it as the mercury-sensitive water channel, aquaporin-1 (AQP1)(2). Many related proteins, all belonging to the major intrinsic protein (MIP) family, are found throughout nature(3). AQP1 is a homotetramer containing four independent aqueous channels(4-6). When reconstituted into lipid bilayers, the protein forms two-dimensional lattices with a unit cell containing two tetramers in opposite orientation(7-10). Here we present the three-dimensional structure of AQP1 determined at 6 Angstrom resolution by cryo-electron microscopy. Each AQP1 monomer has six tilted, bilayer-spanning alpha-helices which form a right-handed bundle surrounding a central density. These results, together with functional studies, provide a model that identifies the aqueous pore in the AQP1 molecule and indicates the organization of the tetrameric complex in the membrane.	UNIV BASEL, BIOZENTRUM, ME MULLER INST MICROSCOP STRUCT BIOL, CH-4056 BASEL, SWITZERLAND; MATSUSHITA ELECT IND CO LTD, INT INST ADV RES, SEIKA 61902, JAPAN; KYOTO UNIV, FAC SCI, DEPT BIOPHYS, KYOTO 60601, JAPAN; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA	University of Basel; Panasonic; Kyoto University; Johns Hopkins University; Johns Hopkins University			Heymann, Bernard/H-8265-2019; Fujiyoshi, Yoshinori/E-5989-2012; Heymann, Bernard/F-6825-2011; Hirai, Teruhisa/G-2105-2015	Heymann, Bernard/0000-0002-8872-5326; Fujiyoshi, Yoshinori/0000-0002-8070-1493; Hirai, Teruhisa/0000-0002-2114-8149; Walz, Thomas/0000-0003-2606-2835				CABIAUX V, IN PRESS BIOPHYSICAL; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; FUJIYOSHI Y, 1991, ULTRAMICROSCOPY, V38, P241, DOI 10.1016/0304-3991(91)90159-4; Henn C, 1996, J STRUCT BIOL, V116, P86, DOI 10.1006/jsbi.1996.0015; JAP BK, 1995, J MOL BIOL, V251, P413, DOI 10.1006/jmbi.1995.0444; JUNG JS, 1994, J BIOL CHEM, V269, P14648; MITRA AK, 1995, NAT STRUCT BIOL, V2, P726, DOI 10.1038/nsb0995-726; MITSUOKA K, IN PRESS ULTRAMICROS; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; SIDEL VW, 1957, J GEN PHYSIOL, V41, P243, DOI 10.1085/jgp.41.2.243; SMITH BL, 1991, J BIOL CHEM, V266, P6407; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; Walther D, 1996, J MOL BIOL, V255, P536, DOI 10.1006/jmbi.1996.0044; WALZ T, 1994, J BIOL CHEM, V269, P1583; WALZ T, 1994, EMBO J, V13, P2985, DOI 10.1002/j.1460-2075.1994.tb06597.x; WALZ T, 1995, NAT STRUCT BIOL, V2, P730, DOI 10.1038/nsb0995-730; Walz T, 1996, J MOL BIOL, V264, P907, DOI 10.1006/jmbi.1996.0686	20	327	351	3	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	1997	387	6633					624	627		10.1038/42512	http://dx.doi.org/10.1038/42512			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177353				2022-12-28	WOS:A1997XC52200061
J	Hendin, H; Rutenfrans, C; Zylicz, Z				Hendin, H; Rutenfrans, C; Zylicz, Z			Physician-assisted suicide and euthanasia in the Netherlands - Lessons from the Dutch	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DEATH		NEW YORK MED COLL,DEPT PSYCHIAT,NEW YORK,NY; DEPT JUSTICE,THE HAGUE,NETHERLANDS; HOSP ROSENHUYVEL,ROZENDAAL,NETHERLANDS	New York Medical College	Hendin, H (corresponding author), AMER FDN SUICIDE PREVENT,120 WALL ST,NEW YORK,NY 10005, USA.							ANGELL M, 1996, NEW ENGL J MED, V335, P1675; Bokhove J., 1996, BALANS REKENONDERWIJ; *BRIT MED ASS WORK, 1988, EUTHANASIA, P49; Callahan Daniel, 1996, Univ Richmond Law Rev, V30, P1; DORREPAAL KL, 1989, CANCER, V63, P593, DOI 10.1002/1097-0142(19890201)63:3<593::AID-CNCR2820630332>3.0.CO;2-5; *GEN BOARD ROYAL D, 1994, EUTHANASIA NETHERLAN; GOMEZ G, 1991, REGULATING DEATH EUT; GUNNING KF, 1991, LANCET, V338, P1010, DOI 10.1016/0140-6736(91)91867-T; Hendin H, 1997, NEW ENGL J MED, V336, P1385; HENDIN H, 1995, HASTINGS CENT REP, V25, P19, DOI 10.2307/3562109; Hendin H, 1996, Duquesne Law Rev, V35, P427; HENDIN H, 1996, SEDUCED DEATH DOCTOR; Keown J., 1995, EUTHANASIA EXAMINED; TENHAVE H, 1985, GENEESKUNDE TUSSEN D; Twycross R., 1995, EUTHANASIA EXAMINED; van der Maas P. J., 1992, EUTHANASIA OTHER MED; Van der Mass PJ, 1996, NEW ENGL J MED, V335, P1609; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; WALTON J, 1994, J ROY COLL PHYS LOND, V28, P235; Zylic Zbigniew, 1993, AM J HOSPICE PAL JUL, V30; ZYLICZ Z, 1991, LANCET, V338, P1150, DOI 10.1016/0140-6736(91)92010-Y	21	51	51	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1720	1722		10.1001/jama.277.21.1720	http://dx.doi.org/10.1001/jama.277.21.1720			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169901				2022-12-28	WOS:A1997XB08800035
J	Bates, C; Read, RC; Morice, AH				Bates, C; Read, RC; Morice, AH			A malicious mould	LANCET			English	Article									UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,SCH MED,DEPT MED MICROBIOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,SCH MED,DEPT INFECT DIS,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,SCH MED,DEPT MED & PHARMACOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield; University of Sheffield; University of Sheffield				Read, Robert/0000-0002-4297-6728				PITT JI, 1985, FUNGI FOOD SPOILAGE, P214; RIPPON SW, 1988, MED MYCOLOGY PATHOGE, P728; WANG ZG, 1992, CHINESE J PREV MED, V26, P8	3	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 31	1997	349	9065					1598	1598		10.1016/S0140-6736(97)03231-5	http://dx.doi.org/10.1016/S0140-6736(97)03231-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174563				2022-12-28	WOS:A1997XB67300012
J	Taylor, CJ; Threlfall, D				Taylor, CJ; Threlfall, D			Postural drainage techniques and gastrooesophageal reflux in cystic fibrosis	LANCET			English	Editorial Material							GASTROESOPHAGEAL REFLUX; INFANTS		UNIV SHEFFIELD, SHEFIELD CHILDRENS HOSP, DEPT PHYSIOTHERAPY, SHEFFIELD S10 2TH, S YORKSHIRE, ENGLAND	Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Sheffield	Taylor, CJ (corresponding author), UNIV SHEFFIELD, SHEFIELD CHILDRENS HOSP, DEPT PAEDIAT, SHEFFIELD S10 2TH, S YORKSHIRE, ENGLAND.							Button BM, 1997, ARCH DIS CHILD, V76, P148, DOI 10.1136/adc.76.2.148; CUCCHIARA S, 1991, ARCH DIS CHILD, V66, P617, DOI 10.1136/adc.66.5.617; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; MALFROOT A, 1991, ARCH DIS CHILD, V66, P1339, DOI 10.1136/adc.66.11.1339; MCVEAGH P, 1987, AM J DIS CHILD, V141, P917, DOI 10.1001/archpedi.1987.04460080103039; VANDENPLAS Y, 1991, PEDIATRICS, V88, P834; VANVANDENPLAS Y, 1987, J PEDIATR GASTR NUTR, V6, P220, DOI 10.1097/00005176-198703000-00010	7	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	1997	349	9065					1567	1568		10.1016/S0140-6736(05)61626-1	http://dx.doi.org/10.1016/S0140-6736(05)61626-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174556				2022-12-28	WOS:A1997XB67300005
J	Glover, JR; Kowal, AS; Schirmer, EC; Patino, MM; Liu, JJ; Lindquist, S				Glover, JR; Kowal, AS; Schirmer, EC; Patino, MM; Liu, JJ; Lindquist, S			Self-seeded fibers formed by Sup35, the protein determinant of [PSI+], a heritable prion-like factor of S-cerevisiae	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; ALZHEIMERS-DISEASE; AMYLOID FORMATION; GENE; SCRAPIE; TERMINATION; PROPAGATION; TRANSLATION; EXPRESSION; VECTORS	The [PSI+] factor of S. cerevisiae represents a new form of inheritance: cytosolic transmission of an altered phenotype is apparently based upon inheritance of an altered protein structure rather than an altered nucleic acid. The molecular basis of its propagation is unknown. We report that purified Sup35 and subdomains that induce [PSI+] elements in vivo form highly ordered fibers in vitro. Fibers bind Congo red and are rich in beta sheet, characteristics of amyloids found in certain human diseases, including the prion diseases. Some fibers have distinct structures and these, once initiated, are self-perpetuating. Preformed fibers greatly accelerate fiber formation by unpolymerized protein. These data support a ''protein-only'' seeded polymerization model for the inheritance of [PSI+].	UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MOL GENET & CELL BIOL, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago				Schirmer, Eric/0000-0003-2635-1338	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025874, R37GM025874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25874] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKASURA S, 1970, ADV BIOPHYS, V1, P99; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Derkatch IL, 1996, GENETICS, V144, P1375; DIDICHENKO SA, 1991, EUR J BIOCHEM, V198, P705, DOI 10.1111/j.1432-1033.1991.tb16070.x; DOEL SM, 1994, GENETICS, V137, P659; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Horwich AL, 1997, CELL, V89, P499, DOI 10.1016/S0092-8674(00)80232-9; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; KUSHNIROV VV, 1990, YEAST, V6, P461, DOI 10.1002/yea.320060603; LANSBURY PT, 1995, CHEM BIOL, V2, P1, DOI 10.1016/1074-5521(95)90074-8; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; NESIONEY CL, 1996, BIOORGAN MED CHEM, V4, P739; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, MOL CELL BIOL, V17, P2798, DOI 10.1128/MCB.17.5.2798; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SHERMAN F, 1986, MANUAL METHODS YEAST; SIKORSKI RS, 1989, GENETICS, V122, P19; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; SPIESS E, 1987, ELECT MICROSCOPY MOL, P147; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; STANSFIELD I, 1994, CURR GENET, V25, P385, DOI 10.1007/BF00351776; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	42	535	545	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	1997	89	5					811	819		10.1016/S0092-8674(00)80264-0	http://dx.doi.org/10.1016/S0092-8674(00)80264-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182769	Bronze			2022-12-28	WOS:A1997XB92500018
J	Carraway, KL; Weber, JL; Unger, MJ; Ledesma, J; Yu, N; Gassmann, M; Lai, C				Carraway, KL; Weber, JL; Unger, MJ; Ledesma, J; Yu, N; Gassmann, M; Lai, C			Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases	NATURE			English	Article							NEU DIFFERENTIATION FACTOR; CARDIAC DEVELOPMENT; NERVOUS-SYSTEM; RECEPTOR; HEREGULIN; EXPRESSION; FAMILY; ERBB2; ARIA; HER4/P180(ERBB4)	The neuregulins (NRGs) are a family of multipotent epidermal-growth-factor-like (EGF-like) factors that arise from splice variants of a single gene. They influence the growth, differentiation, survival and fate of several cell types. We have now discovered a set of new neuregulin-like growth factors, which we call neuregulin-2 (NRG-2): these are encoded by their own gene and exhibit a distinct expression pattern in adult brain and developing heart. Like NRG-1, the EGF-like domain of the new ligands binds to both the ErbB3- and ErbB4-receptor tyrosine kinases. However, NRG-2 stimulates different ErbB-receptor tyrosine-phosphorylation profiles from NRG-1. Our results indicate that NRG-1 and NRG-2 mediate distinct biological processes by acting at different sites in tissues and eliciting different biochemical responses in cells.	Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA; SALK INST BIOL STUDIES, MOL NEUROBIOL LAB, LA JOLLA, CA 92037 USA	Scripps Research Institute; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Salk Institute				Gassmann, Martin/0000-0001-6201-3032				ALIMANDI M, 1995, ONCOGENE, V10, P1813; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; Carraway KL, 1996, BIOESSAYS, V18, P263, DOI 10.1002/bies.950180403; CHEN MS, 1994, J COMP NEUROL, V349, P389, DOI 10.1002/cne.903490306; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; STERN DF, 1994, BIOCHIM BIOPHYS ACTA, V1198, P165; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	336	377	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632					512	516		10.1038/387512a0	http://dx.doi.org/10.1038/387512a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168115				2022-12-28	WOS:A1997XB47900051
J	Davies, T				Davies, T			ABC of mental health - Mental health assessment	BRITISH MEDICAL JOURNAL			English	Review											Davies, T (corresponding author), UNITED MED & DENT SCH,ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND.							*DEP HLTH, 1994, HLTH NAT KEY AR HDB; Hinds K, 1995, 1 OPCS SURV PSYCH MO; KENDRICK T, 1996, PREVENTION MENTAL IL; KOPELMAN MD, 1994, BRIT J HOSP MED, V52, P93	4	3	3	4	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 24	1997	314	7093					1536	1539		10.1136/bmj.314.7093.1536	http://dx.doi.org/10.1136/bmj.314.7093.1536			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XB484	9183204	Green Published			2022-12-28	WOS:A1997XB48400032
J	Hesketh, T; Zhu, WX				Hesketh, T; Zhu, WX			Health in China - From Mao to market reform	BRITISH MEDICAL JOURNAL			English	Article								After the Liberation by Mao Ze Dong's Communist army in 1949, China experienced massive social and economic change. The dramatic reductions in mortality and morbidity of the next two decades were brought about through improvements in socioeconomic conditions, an emphasis on prevention, and almost universal access to basic health care. The economic mismanagement of the Great Leap Forward brought about a temporary reversal in these positive trends. During the Cultural Revolution there was a sustained attack on the privileged position of the medical profession. Most city doctors were sent to work in the countryside, where they trained over a million barefoot doctors. Deng Xiao Ping's radical economic reforms of the late 1970s replaced the socialist system with a market economy. Although average incomes have increased, the Sap between rich and poor has widened.	HLTH UNLIMITED,LONDON SE1 9NT,ENGLAND		Hesketh, T (corresponding author), CTR INT CHILD HLTH,LONDON WC1N 1EH,ENGLAND.			Hesketh, Therese/0000-0002-7564-9221				SCHELL O, 1985, GET RICH GLORIOUS CH; Sidel Victor W., 1982, HLTH CHINA; TAYLOR CE, 1991, OXFORD TXB PUBLIC HL; 1997, FAR E EC REV    0116, P68	4	64	65	0	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 24	1997	314	7093					1543	1545		10.1136/bmj.314.7093.1543	http://dx.doi.org/10.1136/bmj.314.7093.1543			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9183206	Green Published			2022-12-28	WOS:A1997XB48400035
J	vanderHorst, CM; Saag, MS; Cloud, GA; Hamill, RJ; Graybill, JR; Sobel, JD; Johnson, PC; Tuazon, CU; Kerkering, T; Moskovitz, BL; Powderly, WG; Dismukes, WE; Riser, L; Thomas, C; Lacke, C; White, AC; Patterson, S; Davis, D; Flanigan, C; Harden, T; Phillips, D; Ullom, I; Vasquez, J; McMullen, S; Flowers, D; Bosha, M; Britton, M; Fisher, JF; Newman, C; Willis, B; Henderson, H; Johnson, E; Dungo, L; Pierce, M; Morgan, M; Stern, J; Petrosky, N; Bamberger, D; Farnan, R; Feinberg, J; Apuzzo, L; Royal, W; Thompson, S; Barrett, K; Kauffman, C; Gutsch, H; McKinsey, D; Lee, B; Hyslop, N; Greenspan, D; Strata, R; Fessel, WJ; VanRaalte, G; Pankey, G; Schneider, D; Briggs, ND; Pierce, D; Lee, S; Vangness, I; Longmire, B; Stansell, J; Jacobson, M; Gray, D; Coleman, R; Voorhees, J; Klebert, M; Royal, M; Mildvan, D; Friedland, G; Cooney, E; Walesky, M; Leedom, JM; Larsen, R; Diamond, D; Wheat, LJ; Nixon, H; Craft, J; Neidig, JL; Fass, RJ; Russell, J; MacGregor, RR; Kappes, R; Tselis, A; Skahan, KJ; Jackson, B; Daniel, P; PaulsonWhite, C; Hewitt, R; Cohn, S; Lewis, M; Greisberger, C; Heller, H; Sugar, A; Karchmer, AW; Fitch, H; Flam, R; Joseph, M; ElSadr, W; Soeiro, R; Stein, D; Zingman, B; Pollard, R; Hausrath, S; Waterman, K; Squires, K; Ponticello, L; Grieco, M; Hafner, R; Dixon, D				vanderHorst, CM; Saag, MS; Cloud, GA; Hamill, RJ; Graybill, JR; Sobel, JD; Johnson, PC; Tuazon, CU; Kerkering, T; Moskovitz, BL; Powderly, WG; Dismukes, WE; Riser, L; Thomas, C; Lacke, C; White, AC; Patterson, S; Davis, D; Flanigan, C; Harden, T; Phillips, D; Ullom, I; Vasquez, J; McMullen, S; Flowers, D; Bosha, M; Britton, M; Fisher, JF; Newman, C; Willis, B; Henderson, H; Johnson, E; Dungo, L; Pierce, M; Morgan, M; Stern, J; Petrosky, N; Bamberger, D; Farnan, R; Feinberg, J; Apuzzo, L; Royal, W; Thompson, S; Barrett, K; Kauffman, C; Gutsch, H; McKinsey, D; Lee, B; Hyslop, N; Greenspan, D; Strata, R; Fessel, WJ; VanRaalte, G; Pankey, G; Schneider, D; Briggs, ND; Pierce, D; Lee, S; Vangness, I; Longmire, B; Stansell, J; Jacobson, M; Gray, D; Coleman, R; Voorhees, J; Klebert, M; Royal, M; Mildvan, D; Friedland, G; Cooney, E; Walesky, M; Leedom, JM; Larsen, R; Diamond, D; Wheat, LJ; Nixon, H; Craft, J; Neidig, JL; Fass, RJ; Russell, J; MacGregor, RR; Kappes, R; Tselis, A; Skahan, KJ; Jackson, B; Daniel, P; PaulsonWhite, C; Hewitt, R; Cohn, S; Lewis, M; Greisberger, C; Heller, H; Sugar, A; Karchmer, AW; Fitch, H; Flam, R; Joseph, M; ElSadr, W; Soeiro, R; Stein, D; Zingman, B; Pollard, R; Hausrath, S; Waterman, K; Squires, K; Ponticello, L; Grieco, M; Hafner, R; Dixon, D			Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	SEP 17-22, 1995	SAN FRANCISCO, CA	Amer Soc Microbiol			B PLUS FLUCYTOSINE; AMPHOTERICIN-B; AIDS; FLUCONAZOLE; 5-FLUOROCYTOSINE; THERAPY	Background Treatment with low-dose amphotericin B (0.4 mg per kilogram of body weight per day) or oral azole therapy in patients with the acquired immunodeficiency syndrome (AIDS) and cryptococcal meningitis has been associated with high mortality and low rates of cerebrospinal fluid sterilization. Methods In a double-blind multicenter trial we randomly assigned patients with a first episode of AIDS-associated cryptococcal meningitis to treatment with higher-dose amphotericin B (0.7 mg per kilogram per day) with or without flucytosine (100 mg per kilogram per day) for two weeks (step one), followed by eight weeks of treatment with itraconazole (400 mg per day) or fluconazole (400 mg per day) (step two). Treatment was considered successful if cerebrospinal fluid cultures were negative at 2 and 10 weeks or if the patient was clinically stable at 2 weeks and asymptomatic at 10 weeks. Results At two weeks, the cerebrospinal fluid cultures were negative in 60 percent of the 202 patients receiving amphotericin B plus flucytosine and in 51 percent of the 179 receiving amphotericin B alone (P=0.06). Elevated intracranial pressure was associated with death in 13 of 14 patients during step one. The clinical outcome did not differ significantly between the two groups. Seventy-two percent of the 151 fluconazole recipients and 60 percent of the 155 itraconazole recipients had negative cultures at 10 weeks (95 percent confidence interval for the difference in percentages, -100 to 21). The proportion of patients who had clinical responses was similar with fluconazole (68 percent) and itraconazole (70 per cent). Overall mortality was 5.5 percent in the first two weeks and 3.9 percent in the next eight weeks, with no significant difference between the groups. In a multivariate analysis, the addition of flucytosine during the initial two weeks and treatment with fluconazole for the next eight weeks were independently associated with cerebrospinal fluid sterilization. Conclusions For the initial treatment of AIDS-associated cryptococcal meningitis, the use of higher-dose amphotericin B plus flucytosine is associated with an increased rate of cerebrospinal fluid sterilization and decreased mortality at two weeks, as compared with regimens used in previous studies. Although consolidation therapy with fluconazole is associated with a higher rate of cerebrospinal fluid sterilization, itraconazole may be a suitable alternative for patients unable to take fluconazole. (C) 1997, Massachusetts Medical Society.	UNIV ALABAMA,SCH MED,DEPT MED,DIV INFECT DIS,BIRMINGHAM,AL; UNIV ALABAMA,SCH MED,CTR COMPREHENS CANC,BIOSTAT UNIT,BIRMINGHAM,AL; VET AFFAIRS MED CTR,INFECT DIS SECT,HOUSTON,TX 77030; BAYLOR COLL MED,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX; WAYNE STATE UNIV,DIV INFECT DIS,DETROIT,MI; UNIV TEXAS,HOUSTON MED CTR,DEPT MED,HOUSTON,TX; GEORGE WASHINGTON UNIV,DEPT MED,WASHINGTON,DC; VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,DIV INFECT DIS,RICHMOND,VA; JANSSEN RES FDN,TITUSVILLE,NJ; WASHINGTON UNIV,SCH MED,DIV INFECT DIS,ST LOUIS,MO 63130; DETROIT MED CTR,DETROIT,MI; GEORGE WASHINGTON UNIV,MED CTR,WASHINGTON,DC 20052; UNIV MISSISSIPPI,MED CTR,UNIVERSITY,MS 38677; ST MICHAELS HOSP,NEWARK,NJ 07102; VANDERBILT UNIV,NASHVILLE,TN 37203; PENN HOSP,PHILADELPHIA,PA 19107; UNIV MISSOURI,KANSAS CITY,MO 64110; JOHNS HOPKINS UNIV,BALTIMORE,MD 21218; EMORY UNIV,ATLANTA,GA 30322; UNIV MICHIGAN,ANN ARBOR,MI 48109; INFECT DIS ASSOCIATES KANSAS CITY,KANSAS CITY,MO; TULANE UNIV,NEW ORLEANS,LA 70118; PERMANENTE MED GRP INC,SACRAMENTO,CA; ALTON OCHSNER MED FDN & OCHSNER CLIN,NEW ORLEANS,LA 70121; FRONTIER SCI & TECHNOL RES FDN INC,CTR DATA,AMHERST,NY 14226; SOCIAL & SCI SYST,OPERAT OFF,BETHESDA,MD 20814; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; BETH ISRAEL MED CTR,NEW YORK,NY 10003; YALE UNIV,NEW HAVEN,CT 06520; UNIV SO CALIF,LOS ANGELES,CA 90089; INDIANA UNIV,BLOOMINGTON,IN 47405; OHIO STATE UNIV,COLUMBUS,OH 43210; UNIV PENN,PHILADELPHIA,PA 19104; UNIV CINCINNATI,CINCINNATI,OH 45221; UNIV ROCHESTER,ROCHESTER,NY 14627; HARVARD UNIV,CAMBRIDGE,MA 02138; HARLEM HOSP MED CTR,NEW YORK,NY 10037; UNIV MASSACHUSETTS,AMHERST,MA 01003; ALBERT EINSTEIN COLL MED,NEW YORK,NY; UNIV TEXAS,GALVESTON,TX; CORNELL UNIV,ITHACA,NY 14853; ST LUKES ROOSEVELT HOSP,NEW YORK,NY	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio; Wayne State University; University of Texas System; George Washington University; Virginia Commonwealth University; Johnson & Johnson; Johnson & Johnson USA; Washington University (WUSTL); Detroit Medical Center; George Washington University; University of Mississippi; University of Mississippi Medical Center; Vanderbilt University; University of Pennsylvania; Pennsylvania Medicine; University of Missouri System; University of Missouri Kansas City; Johns Hopkins University; Emory University; University of Michigan System; University of Michigan; Tulane University; Permanente Medical Groups; Ochsner Health System; Frontier Science Foundation; Social & Scientific Systems; University of California System; University of California San Francisco; Harvard University; Beth Israel Deaconess Medical Center; Yale University; University of Southern California; Indiana University System; Indiana University Bloomington; University System of Ohio; Ohio State University; University of Pennsylvania; University System of Ohio; University of Cincinnati; University of Rochester; Harvard University; University of Massachusetts System; University of Massachusetts Amherst; Yeshiva University; University of Texas System; University of Texas Medical Branch Galveston; Cornell University; Mount Sinai St. Luke's; Mount Sinai West	vanderHorst, CM (corresponding author), UNIV N CAROLINA,DEPT MED,DIV INFECT DIS,CB 7030,CHAPEL HILL,NC 27599, USA.		Bamberger, David/GYV-3403-2022	Powderly, William/0000-0001-7808-3086	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI065296, N01AI015082] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-15082, N01-AI-65296] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENNETT JE, 1979, NEW ENGL J MED, V301, P126, DOI 10.1056/NEJM197907193010303; BLACKWELDER WC, 1982, CONTROL CLIN TRIALS, V3, P345, DOI 10.1016/0197-2456(82)90024-1; BLOCK ER, 1973, P SOC EXP BIOL MED, V142, P476, DOI 10.3181/00379727-142-37049; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; Cochran W.G., 1967, STAT METHODS; DEGANS J, 1992, AIDS, V6, P185, DOI 10.1097/00002030-199202000-00007; DELALLA F, 1995, CLIN INFECT DIS, V20, P263, DOI 10.1093/clinids/20.2.263; DENNING DW, 1991, AM J MED, V91, P267, DOI 10.1016/0002-9343(91)90126-I; DISMUKES WE, 1987, NEW ENGL J MED, V317, P334, DOI 10.1056/NEJM198708063170602; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HOSMER DW, 1989, APPL LOGISTIC REGRES; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LARSEN RA, 1990, ANN INTERN MED, V113, P183, DOI 10.7326/0003-4819-113-3-183; LARSEN RA, 1994, CLIN INFECT DIS, V19, P741, DOI 10.1093/clinids/19.4.741; MEDOFF G, 1971, P SOC EXP BIOL MED, V138, P571, DOI 10.3181/00379727-138-35943; MOSKOVITZ BL, 1993, P 1 NAT C HUM RETR R; POWDERLY WG, 1993, CLIN INFECT DIS, V17, P837, DOI 10.1093/clinids/17.5.837; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; SAAG MS, 1995, 35 INT C ANT AG CHEM	19	521	541	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	1997	337	1					15	21		10.1056/NEJM199707033370103	http://dx.doi.org/10.1056/NEJM199707033370103			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH186	9203426	Bronze			2022-12-28	WOS:A1997XH18600003
J	DeCherney, AH; Koos, B				DeCherney, AH; Koos, B			Obstetrics and gynecology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CALCIUM SUPPLEMENTATION; TRANSMISSION; PREECLAMPSIA; ZIDOVUDINE				DeCherney, AH (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024, USA.		DeCherney, Alan H/AAS-2944-2020					BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; Bucher HC, 1996, JAMA-J AM MED ASSOC, V275, P1113, DOI 10.1001/jama.275.14.1113; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; Flake AW, 1996, NEW ENGL J MED, V335, P1806, DOI 10.1056/NEJM199612123352404; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; RICHARDSON BE, 1995, AM J EPIDEMIOL, V141, P667, DOI 10.1093/oxfordjournals.aje.a117483; SANCHEZRAMOS L, 1995, OBSTET GYNECOL, V85, P915, DOI 10.1016/0029-7844(95)00052-S; SANCHEZRAMOS L, 1994, OBSTET GYNECOL, V84, P349; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Touraine J L, 1996, J Hematother, V5, P195, DOI 10.1089/scd.1.1996.5.195	11	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1878	1879						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185813				2022-12-28	WOS:A1997XD54400032
J	Silverstein, MJ				Silverstein, MJ			Recent advances - Diagnosis and treatment of early breast cancer	BRITISH MEDICAL JOURNAL			English	Review							COMPARING RADICAL-MASTECTOMY; LYMPH-NODE DISSECTION; TERM FOLLOW-UP; SENTINEL LYMPHADENECTOMY; NATURAL-HISTORY; CARCINOMA; WOMEN; TRIAL; RADIOTHERAPY; LUMPECTOMY				Silverstein, MJ (corresponding author), BREAST CTR,14624 SHERMAN WAY,SUITE 600,VAN NUYS,CA 91405, USA.							Albertini JJ, 1996, JAMA-J AM MED ASSOC, V276, P1818, DOI 10.1001/jama.276.22.1818; Alex J C, 1996, Surg Oncol Clin N Am, V5, P33; Barth A, 1997, CANCER-AM CANCER SOC, V79, P1918, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1918::AID-CNCR12>3.0.CO;2-Y; Beahrs OH, 1993, HDB STAGING CANC, P161; BOSTICK P, 1997, P AM SOC CLIN ONCOL, V16, pA153; CADY B, 1994, CANCER, V73, P505, DOI 10.1002/1097-0142(19940201)73:3<505::AID-CNCR2820730302>3.0.CO;2-B; Diel IJ, 1996, JNCI-J NATL CANCER I, V88, P1652, DOI 10.1093/jnci/88.22.1652; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; Fisher ER, 1996, CANCER-AM CANCER SOC, V78, P1403, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1403::AID-CNCR6>3.0.CO;2-L; GALLAGER HS, 1971, CANCER, V28, P1505, DOI 10.1002/1097-0142(197112)28:6<1505::AID-CNCR2820280624>3.0.CO;2-W; GAMAGAMI P, 1996, ATLAS MAMMOGRAPHY, P179; GARDNER B, 1993, ANN SURG, V218, P270, DOI 10.1097/00000658-199309000-00006; GIULIANO AE, 1995, ANN SURG, V222, P394, DOI 10.1097/00000658-199509000-00016; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; HARRIS JR, 1985, BREAST CANCER RES TR, V5, P17, DOI 10.1007/BF01807645; HART IR, 1980, CANCER RES, V40, P2281; HELLMAN S, 1994, J CLIN ONCOL, V12, P2229, DOI 10.1200/JCO.1994.12.10.2229; KOPANS DB, 1994, CANCER, V74, P1196, DOI 10.1002/1097-0142(19940815)74:4<1196::AID-CNCR2820740403>3.0.CO;2-Y; KRAG DN, 1993, SURG ONCOL, V2, P335, DOI 10.1016/0960-7404(93)90064-6; Noguchi S, 1996, AM J PATHOL, V148, P649; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; ROSEN PP, 1993, J CLIN ONCOL, V11, P2090, DOI 10.1200/JCO.1993.11.11.2090; SCHNITT SJ, 1996, CANCER, V77, P10941; Silverstein M J, 1997, Surg Oncol Clin N Am, V6, P301; SILVERSTEIN MJ, 1995, J AM COLL SURGEONS, V180, P700; SILVERSTEIN MJ, 1994, CANCER-AM CANCER SOC, V73, P664, DOI 10.1002/1097-0142(19940201)73:3<664::AID-CNCR2820730326>3.0.CO;2-S; SILVERSTEIN MJ, 1997, DUCTA CARCINOMA IN S; SINGH R, 1995, TECH PROT CHEM, V6, P259, DOI 10.1016/S1080-8914(06)80033-5; SMART CR, 1995, CANCER, V75, P1619, DOI 10.1002/1097-0142(19950401)75:7<1619::AID-CNCR2820750711>3.0.CO;2-T; SWAIN S, 1997, DUCTAL CARCINOMA IN, P595; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; TABAR L, 1995, CANCER, V75, P2507, DOI 10.1002/1097-0142(19950515)75:10<2507::AID-CNCR2820751017>3.0.CO;2-H; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102	36	17	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1736	1739		10.1136/bmj.314.7096.1736	http://dx.doi.org/10.1136/bmj.314.7096.1736			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9202505	Green Published			2022-12-28	WOS:A1997XE90900028
J	Farr, GW; Scharl, EC; Schumacher, RJ; Sondek, S; Horwich, AL				Farr, GW; Scharl, EC; Schumacher, RJ; Sondek, S; Horwich, AL			Chaperonin-mediated folding in the eukaryotic cytosol proceeds through rounds of release of native and nonnative forms	CELL			English	Article							CYTOPLASMIC CHAPERONIN; BETA-ACTIN; G-PROTEIN; IN-VIVO; BINDING; ALPHA; TUBULIN; COMPLEX; TCP-1; EXTRACTS	The eukaryotic cytosolic chaperonin, CCT, plays an essential role in mediating ATP-dependent folding of actin and tubulin. There is debate about whether it mediates folding through a single round of association followed by release of native forms, or through cycles of binding and full release in which only a fraction of released molecules reaches native form in any cycle. We examine the fate of newly synthesized substrate proteins bound to CCT in reticulocyte lysate or intact Xenopus oocytes. When a chaperonin ''trap,'' able to bind but not release substrate protein, is introduced, production of the native state is strongly inhibited, associated with transfer to trap. While predominantly nonnative forms of actin, tubulin, and a newly identified substrate, G(alpha)-transducin, are released from CCT, a small fraction reaches native form with each round of release, inaccessible to trap. This overall mechanism resembles that of the bacterial chaperonin, GroEL.	YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University								Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; Fenton WA, 1997, PROTEIN SCI, V6, P743; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO Y, 1994, J CELL BIOL, V125, P980; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEVILLIERS N, 1984, BIOCHIMIE, V66, P531, DOI 10.1016/0300-9084(84)90147-0; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; MARCO S, 1994, BIOPHYS J, V67, P364, DOI 10.1016/S0006-3495(94)80489-8; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MAZZONI MR, 1989, BIOCHEMISTRY-US, V28, P9873, DOI 10.1021/bi00451a047; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Melki R, 1996, BIOCHEMISTRY-US, V35, P10422, DOI 10.1021/bi960788r; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; ROSENBLATT J, 1995, MOL BIOL CELL, V6, P227, DOI 10.1091/mbc.6.2.227; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; STERNLICHT H, 1979, J BIOL CHEM, V254, P540; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YAFFE MB, 1988, J BIOL CHEM, V263, P16023; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	38	147	148	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					927	937		10.1016/S0092-8674(00)80278-0	http://dx.doi.org/10.1016/S0092-8674(00)80278-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200611	hybrid			2022-12-28	WOS:A1997XE35700013
J	Tanaka, K; Watase, K; Manabe, T; Yamada, K; Watanabe, M; Takahashi, K; Iwama, H; Nishikawa, T; Ichihara, N; Hori, S; Takimoto, M; Wada, K				Tanaka, K; Watase, K; Manabe, T; Yamada, K; Watanabe, M; Takahashi, K; Iwama, H; Nishikawa, T; Ichihara, N; Hori, S; Takimoto, M; Wada, K			Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1	SCIENCE			English	Article							AMINO-ACID TRANSPORTER; RAT-BRAIN; MOUSE-BRAIN; EXPRESSION; CLONING; RECEPTORS; KINETICS; DISEASE; DEATH	Extracellular levels of the excitatory neurotransmitter glutamate in the nervous system are maintained by transporters that actively remove glutamate from the extracellular space. Homozygous mice deficient in GLT-1, a widely distributed astrocytic glutamate transporter, show lethal spontaneous seizures and increased susceptibility to acute cortical injury. These effects can be attributed to elevated levels of residual glutamate in the brains of these mice.	UNIV TOKYO,FAC MED,DEPT NEUROPHYSIOL,TOKYO 113,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT ANAT,SAPPORO,HOKKAIDO 060,JAPAN; NATL INST NEUROSCI,DEPT ANIM MODELS HUMAN DIS,KODAIRA,TOKYO 187,JAPAN; TAISHO PHARMACEUT CO LTD,MED RES LABS,LAB 1,OMIYA,SAITAMA 330,JAPAN; CIBA GEIGY JAPAN,INT RES LABS,TAKARAZUKA,HYOGO 665,JAPAN	University of Tokyo; Hokkaido University; National Center for Neurology & Psychiatry - Japan; Taisho Pharmaceutical Holdings Co Ltd	Tanaka, K (corresponding author), NATL INST NEUROSCI,DEPT DEGENERAT NEUROL DIS,KODAIRA,TOKYO 187,JAPAN.		Watanabe, Masahiko/S-3614-2019; WATANABE, Masahiko/A-4055-2012	Watanabe, Masahiko/0000-0001-5037-7138; WATANABE, Masahiko/0000-0001-5037-7138				CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; ISAACSON JS, 1993, J NEUROPHYSIOL, V70, P2187, DOI 10.1152/jn.1993.70.5.2187; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KIRSCHNER MA, 1994, GENOMICS, V24, P218, DOI 10.1006/geno.1994.1609; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MUKAINAKA Y, 1995, BBA-GEN SUBJECTS, V1244, P233, DOI 10.1016/0304-4165(95)00062-G; OURY TD, 1993, J BIOL CHEM, V268, P15394; PALMER AM, 1986, NEUROSCI LETT, V66, P199, DOI 10.1016/0304-3940(86)90190-4; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601; ROBINSON MB, 1991, BRAIN RES, V544, P196, DOI 10.1016/0006-8993(91)90054-Y; ROGAWSKI MA, 1989, J PHARMACOL EXP THER, V249, P708; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Shibata T, 1996, NEUROREPORT, V7, P705, DOI 10.1097/00001756-199602290-00006; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; Tanaka K., 1995, Society for Neuroscience Abstracts, V21, P1862; TANAKA K, 1993, NEUROSCI RES, V16, P149, DOI 10.1016/0168-0102(93)90082-2; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Yamada K, 1996, NEUROREPORT, V7, P2013, DOI 10.1097/00001756-199608120-00032	27	1380	1413	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1699	1702		10.1126/science.276.5319.1699	http://dx.doi.org/10.1126/science.276.5319.1699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180080				2022-12-28	WOS:A1997XD94700043
J	Toker, A; Cantley, LC				Toker, A; Cantley, LC			Signalling through the lipid products of phosphoinositide-3-OH kinase	NATURE			English	Article							PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; ACTIVATION; 3-KINASE	When a stimulatory agonist molecule binds at the exterior of the cell membrane, a second messenger transduces the signal to the interior of the cell. Second messengers can be derived from phospholipids in the membrane by the action of the enzymes phospholipase C or phosphoinositide-3-OH kinase (PI(3)K). PI(3)K is a key player in many cellular responses, including the movement of organelle membranes, shape alteration through rearrangement of cytoskeletal actin, transformation and chemotaxis. But how PI(3)K mediates these responses is only now becoming clear.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; BETH ISRAEL DEACONESS MED CTR, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Toker, A (corresponding author), BOSTON BIOMED RES INST, 20 STANIFORD ST, BOSTON, MA 02114 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [R01 GM041890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHANG HW, IN PRESS SCIENCE; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Lu PJ, 1997, J BIOL CHEM, V272, P466; Lu PJ, 1996, BIOCHEMISTRY-US, V35, P14027, DOI 10.1021/bi961878z; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAMEH LE, IN PRESS J BIOL CHEM; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Sossin WS, 1996, J NEUROCHEM, V67, P220; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	47	1174	1205	2	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	1997	387	6634					673	676		10.1038/42648	http://dx.doi.org/10.1038/42648			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192891				2022-12-28	WOS:A1997XD86900044
J	Morgan, G				Morgan, G			What, if any, is the effect of malnutrition on immunological competence?	LANCET			English	Editorial Material											Morgan, G (corresponding author), KUWAIT UNIV,FAC MED,POB 24923,KUWAIT 13110,KUWAIT.								0	47	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1693	1695		10.1016/S0140-6736(96)12038-9	http://dx.doi.org/10.1016/S0140-6736(96)12038-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186397				2022-12-28	WOS:A1997XD10000045
J	Rodan, GA; Harada, S				Rodan, GA; Harada, S			The missing bone	CELL			English	Review							CLEIDOCRANIAL DYSPLASIA; TRANSCRIPTION FACTOR; OSTEOCALCIN GENE; FAMILY; EXPRESSION; PROMOTER; CELLS; MICE				Rodan, GA (corresponding author), MERCK RES LABS,DEPT BONE BIOL & OSTEOPOROSIS RES,W POINT,PA 19486, USA.							DUCY P, 1995, MOL CELL BIOL, V15, P1858; DUCY P, 1997, CELL, V89; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; JENSEN BL, 1990, AM J MED GENET, V35, P69, DOI 10.1002/ajmg.1320350113; KOMORI T, 1997, CELL, V89; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; MUNDLOS S, 1997, CELL, V89; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OTTO F, 1997, CELL, V89; Rawls A, 1997, CELL, V89, P5, DOI 10.1016/S0092-8674(00)80175-0; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SELBY PB, 1978, MUTAT RES, V51, P199, DOI 10.1016/S0027-5107(78)80019-0; SILLENCE DO, 1987, AM J MED GENET, V27, P75, DOI 10.1002/ajmg.1320270109; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444	21	110	123	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					677	680		10.1016/S0092-8674(00)80249-4	http://dx.doi.org/10.1016/S0092-8674(00)80249-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182754	Bronze			2022-12-28	WOS:A1997XB92500003
J	Grossman, DC; Neckerman, HJ; Koepsell, TD; Liu, PY; Asher, KN; Beland, K; Frey, K; Rivara, FP				Grossman, DC; Neckerman, HJ; Koepsell, TD; Liu, PY; Asher, KN; Beland, K; Frey, K; Rivara, FP			Effectiveness of a violence prevention curriculum among children in elementary school - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Ambulatory-Pediatric-Association	MAY, 1995	WASHINGTON, DC	Ambulatory Pediat Assoc			LONGITUDINAL DATA-ANALYSIS; ANTISOCIAL-BEHAVIOR; DELINQUENT-BEHAVIOR; AGGRESSION; STABILITY; CLUSTER; SKILLS; TIME	Objective.-To determine if a commonly used violence prevention curriculum, Second Step: A Violence Prevention Curriculum, leads to a reduction in aggressive behavior and an increase in prosocial behavior among elementary school students. Design.-Randomized controlled trial. Setting.-Urban and suburban elementary schools in the state of Washington. Participants.-Six matched pairs of schools with 790 second-grade and third-grade students. The students were 53% male and 79% white. Intervention.-The curriculum uses 30 specific lessons to teach social skills related to anger management, impulse control, and empathy. Main Outcome Measures.-Aggressive and prosocial behavior changes were measured 2 weeks and 6 months after participation in the curriculum by parent and teacher reports (Achenbach Child Behavior Checklist and Teacher Report Form, the School Social Behavior Scale, and the Parent-Child Rating Scale) and by observation of a random subsample of 588 students in the classroom and playground/cafeteria settings. Results.-After adjusting for sex, age, socioeconomic status, race, academic performance, household size, and class size, change scores did not differ significantly between the intervention and control schools for any of the parent-reported or teacher-reported behavior scales. However, the behavior observations did reveal an overall decrease 2 weeks after the curriculum in physical aggression (P=.03) and an increase in neutral/prosocial behavior (P=.04) in the intervention group compared with the control group. Most effects persisted 6 months later. Conclusions.-The Second Step violence prevention curriculum appears to lead to a moderate observed decrease in physically aggressive behavior and an increase in neutral and prosocial behavior in school.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT EDUC PSYCHOL,SEATTLE,WA 98104; COMM CHILDREN,SEATTLE,WA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Grossman, DC (corresponding author), UNIV WASHINGTON,HARBORVIEW INJURY PREVENT & RES CTR,325 9TH AVE,BOX 359960,SEATTLE,WA 98104, USA.				PHS HHS [R49/CCR002570] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Achenbach T.M., 1991, MANUAL TEACHERS REPO; ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; BAKEMAN R, 1983, OBSERVING INTERACTIO; Cairns R, 1979, ANAL SOCIAL INTERACT, P209; Denham S. A., 1987, J APPLIED DEV PSYCHO, V8, P391, DOI DOI 10.1016/0193-3973(87)90029-3; Dolan L.J., 1993, J APPL DEV PSYCHOL, V14, P317, DOI [DOI 10.1016/0193-3973(93)90013-L, 10.1016/0193-3973(93)90013-l]; DONNER A, 1987, STAT MED, V6, P43, DOI 10.1002/sim.4780060106; DONNER A, 1987, AM J EPIDEMIOL, V126, P972, DOI 10.1093/oxfordjournals.aje.a114735; FARRINGTON DP, 1991, DEVELOPMENT AND TREATMENT OF CHILDHOOD AGGRESSION, P5; GOTTFREDSON DC, 1986, CRIMINOLOGY, V24, P705, DOI 10.1111/j.1745-9125.1986.tb01508.x; GREEN SB, 1995, AM J EPIDEMIOL, V142, P576; GREENBERG M, 1994, CLASSROOM ATMOSPHERE; Greenberg M.T., 1993, PROMOTING SOCIAL EMO; HAWKINS JD, 1991, J AM ACAD CHILD PSY, V30, P208, DOI 10.1097/00004583-199103000-00008; HIGHTOWER AD, 1986, SCHOOL PSYCHOL REV, V15, P393; HIGHTOWER AD, 1990, PARENT CHILD RATING; Hollingshead A.B., 1975, 4 FACTOR INDEX SOCIA; HUESMANN LR, 1984, DEV PSYCHOL, V20, P1120, DOI 10.1037/0012-1649.20.6.1120; KAZDIN AE, 1992, J CONSULT CLIN PSYCH, V60, P733, DOI 10.1037/0022-006X.60.5.733; KOEPSELL TD, 1992, ANNU REV PUBL HEALTH, V13, P31, DOI 10.1146/annurev.pu.13.050192.000335; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LOCHMAN JE, 1992, J CONSULT CLIN PSYCH, V60, P426, DOI 10.1037/0022-006X.60.3.426; LOEBER R, 1994, J CONSULT CLIN PSYCH, V62, P887, DOI 10.1037/0022-006X.62.5.887; MCCORD J, 1991, CRIMINOLOGY, V29, P397, DOI 10.1111/j.1745-9125.1991.tb01072.x; Mercy J A, 1988, Violence Vict, V3, P285; MERRELL KW, 1993, SCHOOL PSYCHOL REV, V22, P115; MOFFITT TE, 1993, PSYCHOL REV, V100, P674, DOI 10.1037/0033-295X.100.4.674; NECKERMAN HJ, 1994, SOCIAL INTERACTION O; OLWEUS D, 1979, PSYCHOL BULL, V86, P852, DOI 10.1037/0033-2909.86.4.852; PELLEGRINI DS, 1985, J CHILD PSYCHOL PSYC, V26, P17, DOI 10.1111/j.1469-7610.1985.tb01626.x; PEPLER DJ, 1995, COERCION PUNISHMENT, P213; REID JB, HDB ANTISOCIAL BEHAV; RIVARA FP, 1995, ARCH PEDIAT ADOL MED, V149, P421, DOI 10.1001/archpedi.1995.02170160075011; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P519; SAUDARGAS RA, 1986, SCHOOL PSYCHOL REV, V15, P36; Tremblay R. E., 1995, BUILDING SAFER SOC S; TREMBLAY RE, 1992, J CONSULT CLIN PSYCH, V60, P64, DOI 10.1037/0022-006X.60.1.64; TREMBLAY RE, 1992, PREVENTING ANTISOCIA; TREMBLAY RE, 1995, BUILDING SAFER SOC S, V19, P151; WEBSTER DW, 1993, HEALTH AFFAIR, V12, P126, DOI 10.1377/hlthaff.12.4.126; Weissberg R.P., 1993, APPLIED PREVENTIVE P, DOI [10.1016/S0962-1849(05)80088-5, DOI 10.1016/S0962-1849(05)80088-5]; WILSONBREWER R, 1991, VIOLENCE PREVENTION; YOSHIKAWA H, 1994, PSYCHOL BULL, V115, P28, DOI 10.1037/0033-2909.115.1.28; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	44	293	298	1	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	1997	277	20					1605	1611		10.1001/jama.277.20.1605	http://dx.doi.org/10.1001/jama.277.20.1605			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XA022	9168290				2022-12-28	WOS:A1997XA02200030
J	Nielsen, BB; Liljestrand, J; Hedegaard, M; Thilsted, SH; Joseph, A				Nielsen, BB; Liljestrand, J; Hedegaard, M; Thilsted, SH; Joseph, A			Reproductive pattern, perinatal mortality, and sex preference in rural Tamil Nadu, South India: Community based, cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD MORTALITY; CHINA; MARRIAGE; BIRTH; BANGLADESH; FERTILITY; FEMALE; AGE; BEHAVIOR; CHILDREN	Objectives: To study reproductive pattern and perinatal mortality in rural Tamil Nadu, South India. Design: Community based, cross sectional questionnaire study of 30 randomly selected areas served by health subcentres. Setting: Rural parts of Salem District, Tamil Nadu, South India, Subjects: 1321 women and their offspring delivered in the 6 months before the interview. Main outcome measures: Number of pregnancies, pregnancy outcome, spacing of pregnancies, sex of offspring, perinatal and neonatal mortality rates. Results: 41% of the women (535) were primiparous; 7 women (0.5%) were grand multiparous (> 6 births). The women had a mean age of 22 years and a mean of 2.3 pregnancies and 1.8 live children. The sex ratio at birth of the index children was 107 boys per 100 girls. The stillbirth rate was 13.5/1000 births, the neonatal mortality rate was 35.3/1000, and the perinatal mortality rate was 42.0/1000. Girls had an excess neonatal mortality (rate ratio 3.42; 95% confidence interval 1.68 to 6.98; this was most pronounced among girls born to multiparous women with no living sons (rate ratio 15.48 (2.04 to 117.73) v 1.87 (0.63 to 5.58) in multiparous women with at least one son alive). Conclusions:In this rural part of Tamil Nadu, women had a controlled reproductive pattern. The excess neonatal mortality among girls constitutes about one third of the perinatal mortality rate. It seems to be linked to a preference for sons and should therefore be addressed through a holistic societal approach rather than through specific healthcare measures.	BALTIC INT SCH HLTH, S-37185 KARLSKRONA, SWEDEN; ROYAL VET & AGR UNIV, RES DEPT HUMAN NUTR, DK-1958 FREDERIKSBERG C, DENMARK; CHRISTIAN MED COLL & HOSP, DEPT COMMUNITY HLTH, VELLORE 632002, TAMIL NADU, INDIA	University of Copenhagen; Christian Medical College & Hospital (CMCH) Vellore	Nielsen, BB (corresponding author), AARHUS UNIV HOSP, PERINATAL EPIDEMIOL RES UNIT, DEPT OBSTET & GYNAECOL, DK-8200 AARHUS N, DENMARK.			Thilsted, Shakuntala/0000-0002-4041-1651				BLOOM DE, 1986, DEMOGRAPHY, V23, P509, DOI 10.2307/2061348; CALDWELL JC, 1983, POP STUD-J DEMOG, V37, P343, DOI 10.2307/2174503; CHEN LC, 1981, POPUL DEV REV, V7, P55, DOI 10.2307/1972764; CHOE MK, 1995, SOC BIOL, V42, P50; COALE AJ, 1994, DEMOGRAPHY, V31, P459, DOI 10.2307/2061752; DAS N, 1987, DEMOGRAPHY, V24, P517, DOI 10.2307/2061389; DASGUPTA M, 1987, POPUL DEV REV, V13, P77; DESILVA WI, 1990, J BIOSOC SCI, V22, P395, DOI 10.1017/S0021932000018812; DYSON T, 1983, POPUL DEV REV, V9, P35, DOI 10.2307/1972894; ELBADRY MA, 1969, J AM STAT ASSOC, V64, P1234, DOI 10.2307/2286064; GEORGE S, 1992, ECON POLIT WEEKLY, V27, P1153; Harper A, 1996, WHO, V12, P1; JOHANSSON S, 1991, POPUL DEV REV, V17, P35, DOI 10.2307/1972351; Kishor Sunita., 1994, UNDERSTANDING REPROD, P65; KOENIG MA, 1986, SOC SCI MED, V22, P15, DOI 10.1016/0277-9536(86)90303-5; Krishnaswamy S., 1988, Women in Indian society. A reader., P186; MUHURI PK, 1991, POPUL DEV REV, V17, P415, DOI 10.2307/1971948; NATH DC, 1994, J BIOSOC SCI, V26, P377, DOI 10.1017/S0021932000021453; PRESTON SH, 1984, POPUL DEV REV, V10, P481, DOI 10.2307/1973516; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P171; SIMMONS GB, 1982, DEMOGRAPHY, V19, P371, DOI 10.2307/2060977; SIVARAM M, 1995, J BIOSOC SCI, V27, P325, DOI 10.1017/S0021932000022847; *UNICEF, 1996, STAT WORLDS CHILDR, P10; Waldron I, 1987, World Health Stat Q, V40, P194; WALDRON I, 1982, FUNDAMENTAL CONNECTI, P69; WEN XY, 1993, J BIOSOC SCI, V25, P509, DOI 10.1017/S002193200002188X; XU BH, 1994, SCAND J SOC MED, V22, P242, DOI 10.1177/140349489402200402; YANG QH, 1990, J BIOSOC SCI, V22, P143, DOI 10.1017/S0021932000018496	28	40	41	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	1997	314	7093					1521	1524		10.1136/bmj.314.7093.1521	http://dx.doi.org/10.1136/bmj.314.7093.1521			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XB484	9169399	Green Published			2022-12-28	WOS:A1997XB48400025
J	Dominguez, AE				Dominguez, AE			The chief complaint	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					4	4						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207319				2022-12-28	WOS:A1997XG38700003
J	Kouchoukos, NT; Dougenis, D				Kouchoukos, NT; Dougenis, D			Surgery of the thoracic aorta	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE-RENAL-FAILURE; PENETRATING ATHEROSCLEROTIC ULCERS; HYPOTHERMIC CIRCULATORY ARREST; ASCENDING AORTA; GRAFT REPLACEMENT; NATURAL-HISTORY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; THORACOABDOMINAL AORTA; CARDIAC OPERATIONS; ROOT REPLACEMENT		WASHINGTON UNIV, SCH MED, DIV CARDIOTHORAC SURG, ST LOUIS, MO 63110 USA; BJC HLTH SYST, CTR HEART, MISSOURI BAPTIST MED CTR, ST LOUIS, MO USA	Washington University (WUSTL)			Dougenis, Dimitrios/AAG-3803-2020					ADACHI H, 1991, CIRCULATION, V84, P14; AMARENCO P, 1994, NEW ENGL J MED, V331, P1474, DOI 10.1056/NEJM199412013312202; Amarenco P, 1996, NEW ENGL J MED, V334, P1216; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; ANAGNOSTOPOULOS CE, 1972, AM J CARDIOL, V30, P263, DOI 10.1016/0002-9149(72)90070-7; ANDO M, 1994, ANN THORAC SURG, V57, P669, DOI 10.1016/0003-4975(94)90565-7; AOYAGI S, 1994, ANN THORAC SURG, V58, P1469, DOI 10.1016/0003-4975(94)91937-2; BARZILAI B, 1989, CIRCULATION, V80, P275; BERENS ES, 1992, J VASC SURG, V15, P313, DOI 10.1016/0741-5214(92)90253-5; BICKERSTAFF LK, 1982, SURGERY, V92, P1103; BLAUTH CI, 1992, J THORAC CARDIOV SUR, V103, P1104; BORST HG, 1994, J THORAC CARDIOV SUR, V107, P126; BROWN SL, 1985, J VASC SURG, V2, P393, DOI 10.1067/mva.1985.avs0020393; BRYAN AJ, 1995, ANN THORAC SURG, V59, P773, DOI 10.1016/0003-4975(94)00818-3; BUSUTTIL RW, 1982, J SURG RES, V32, P214, DOI 10.1016/0022-4804(82)90093-2; CABROL C, 1986, J THORAC CARDIOV SUR, V91, P17; CAIN HD, 1979, CHEST, V76, P130, DOI 10.1378/chest.76.2.130; CANNON DJ, 1982, ANN THORAC SURG, V34, P10, DOI 10.1016/S0003-4975(10)60845-4; CARLSON DE, 1983, ANN THORAC SURG, V35, P58, DOI 10.1016/S0003-4975(10)61432-4; CARLSSON J, 1964, Acta Chir Scand, V127, P466; CHEN JTT, 1990, J THORAC IMAG, V5, P1, DOI 10.1097/00005382-199010000-00004; COCHRAN RP, 1995, J THORAC CARDIOV SUR, V109, P1049, DOI 10.1016/S0022-5223(95)70187-7; Cohn LH, 1996, ANN THORAC SURG, V62, P463, DOI 10.1016/0003-4975(96)00280-9; COOKE JP, 1988, MAYO CLIN PROC, V63, P718, DOI 10.1016/S0025-6196(12)65534-7; COOLEY DA, 1956, JAMA-J AM MED ASSOC, V162, P1158, DOI 10.1001/jama.1956.72970290003013a; COSELLI JS, 1996, HAIMOVICIS VASCULAR, P759; COSTELLO P, 1992, AM J ROENTGENOL, V158, P1127, DOI 10.2214/ajr.158.5.1566679; CRAWFORD ES, 1992, J THORAC CARDIOV SUR, V104, P46; CRAWFORD ES, 1986, J VASC SURG, V3, P578, DOI 10.1067/mva.1986.avs0030578; CRAWFORD ES, 1986, J VASC SURG, V3, P389, DOI 10.1067/mva.1986.avs0030389; CRESWELL LL, 1995, ANN THORAC SURG, V59, P585, DOI 10.1016/0003-4975(94)00880-9; Daily P O, 1970, Ann Thorac Surg, V10, P237; DAPUNT OE, 1994, J THORAC CARDIOV SUR, V107, P1323, DOI 10.1016/S0022-5223(94)70054-0; DAVID TE, 1995, EUR J CARDIO-THORAC, V9, P175, DOI 10.1016/S1010-7940(05)80141-1; DAVID TE, 1994, J CARDIAC SURG, V9, P182, DOI 10.1111/j.1540-8191.1994.tb00922.x; DAVID TE, 1992, J THORAC CARDIOV SUR, V103, P617; DavilaRoman VG, 1996, J AM COLL CARDIOL, V28, P942, DOI 10.1016/S0735-1097(96)00263-X; DAVILAROMAN VG, 1994, STROKE, V25, P2010, DOI 10.1161/01.STR.25.10.2010; DEBAKEY ME, 1957, SURG GYNECOL OBSTET, V105, P657; DEBAKEY ME, 1982, SURGERY, V92, P1118; DEBAKEY ME, 1953, JAMA-J AM MED ASSOC, V152, P673, DOI 10.1001/jama.1953.03690080017005; EARNEST F, 1979, MAYO CLIN PROC, V54, P43; ERBEL R, 1989, LANCET, V1, P457; ERBEL R, 1987, THORAC CARDIOV SURG, V35, P126, DOI 10.1055/s-2007-1020273; ERGIN MA, 1994, J CARDIAC SURG, V9, P525, DOI 10.1111/j.1540-8191.1994.tb00886.x; ERGIN MA, 1994, J THORAC CARDIOV SUR, V107, P788; ERNST CB, 1993, NEW ENGL J MED, V328, P1167; FINKBOHNER R, 1995, CIRCULATION, V91, P728, DOI 10.1161/01.CIR.91.3.728; FINKELMEIER BA, 1982, J THORAC CARDIOV SUR, V84, P257; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; Francke U, 1993, Semin Thorac Cardiovasc Surg, V5, P3; GILLUM RF, 1995, J CLIN EPIDEMIOL, V48, P1289, DOI 10.1016/0895-4356(95)00045-3; GLOWER DD, 1991, ANN SURG, V214, P31; GORE I, 1952, AMA ARCH PATHOL, V53, P142; GOTT VL, 1986, NEW ENGL J MED, V314, P1070, DOI 10.1056/NEJM198604243141702; GOTT VL, 1995, J THORAC CARDIOV SUR, V109, P536, DOI 10.1016/S0022-5223(95)70286-5; Griepp R B, 1991, Semin Thorac Cardiovasc Surg, V3, P258; GROSS RE, 1949, SURG GYNECOL OBSTET, V88, P689; HARRIS JA, 1994, J VASC SURG, V19, P90, DOI 10.1016/S0741-5214(94)70124-5; HARTNELL GG, 1994, RADIOLOGY, V191, P697, DOI 10.1148/radiology.191.3.8184049; HAVERICH A, 1985, CIRCULATION, V72, P22; HEINEMANN M, 1991, CIRCULATION, V84, P25; HINES GL, 1994, J CARDIOVASC SURG, V35, P243; HIROSE Y, 1995, ANGIOLOGY, V46, P413, DOI 10.1177/000331979504600508; HIROSE Y, 1992, RADIOLOGY, V185, P249, DOI 10.1148/radiology.185.1.1523317; HIRST AE, 1958, MEDICINE, V37, P217, DOI 10.1097/00005792-195809000-00003; HOLLIER LH, 1992, AM J SURG, V164, P210, DOI 10.1016/S0002-9610(05)81072-4; HUSSAIN S, 1989, J VASC SURG, V9, P710, DOI 10.1067/mva.1989.vs0090710; JIN XY, 1995, ANN THORAC SURG, V60, pS395, DOI 10.1016/0003-4975(95)00202-V; JOHNSTON KW, 1991, J VASC SURG, V13, P452, DOI 10.1067/mva.1991.26737; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; KATZ ES, 1992, J AM COLL CARDIOL, V20, P70, DOI 10.1016/0735-1097(92)90139-E; Khatibzadeh M, 1996, J AM COLL CARDIOL, V27, P664, DOI 10.1016/0735-1097(95)00526-9; Kirklin J W, 1993, Semin Thorac Cardiovasc Surg, V5, P27; Kouchoukos N T, 1986, J Card Surg, V1, P333, DOI 10.1111/j.1540-8191.1986.tb00721.x; Kouchoukos N T, 1991, Semin Thorac Cardiovasc Surg, V3, P323; Kouchoukos N T, 1993, Semin Thorac Cardiovasc Surg, V5, P47; KOUCHOUKOS NT, 1991, ANN SURG, V214, P308, DOI 10.1097/00000658-199109000-00013; KOUCHOUKOS NT, 1990, J THORAC CARDIOV SUR, V99, P659; KOUCHOUKOS NT, 1995, ANN THORAC SURG, V60, P67; KOUCHOUKOS NT, 1994, J CARDIAC SURG, V9, P490, DOI 10.1111/j.1540-8191.1994.tb00881.x; KOUCHOUKOS NT, 1994, ANN THORAC SURG, V57, P243, DOI 10.1016/0003-4975(94)90417-0; KOUCHOUKOS NT, 1986, J THORAC CARDIOV SUR, V92, P691; LAM CR, 1951, ANN SURG, V134, P743, DOI 10.1097/00000658-195113440-00019; LAWRIE GM, 1993, ANN SURG, V217, P711, DOI 10.1097/00000658-199306000-00013; LEWIS CTP, 1992, ANN THORAC SURG, V53, P38, DOI 10.1016/0003-4975(92)90755-S; LINDSAY J, 1988, AM J CARDIOL, V61, P182, DOI 10.1016/0002-9149(88)91327-6; LINDSAY J, 1967, CIRCULATION, V35, P880, DOI 10.1161/01.CIR.35.5.880; LINK KM, 1993, SEMIN ULTRASOUND CT, V14, P91, DOI 10.1016/S0887-2171(05)80045-9; LUI RC, 1992, ANN THORAC SURG, V53, P886, DOI 10.1016/0003-4975(92)91460-Q; LYTLE BW, 1990, J THORAC CARDIOV SUR, V99, P651; MANIGLIA R, 1952, AMA ARCH PATHOL, V54, P298; MARSALESE DL, 1989, J AM COLL CARDIOL, V14, P422, DOI 10.1016/0735-1097(89)90197-6; MASUDA Y, 1992, CHEST, V102, P461, DOI 10.1378/chest.102.2.461; MCCOLLUM CH, 1979, J TRAUMA, V19, P248, DOI 10.1097/00005373-197904000-00006; MILLER DC, 1987, J VASC SURG, V5, P518, DOI 10.1067/mva.1987.avs0050518; MILLIKEN EC, 1990, J MATER RES, V5, P53, DOI 10.1557/JMR.1990.0053; Mitchell RS, 1996, J THORAC CARDIOV SUR, V111, P1054, DOI 10.1016/S0022-5223(96)70382-3; MOORE EH, 1984, AM J ROENTGENOL, V143, P1195, DOI 10.2214/ajr.143.6.1195; MOVSOWITZ HD, 1994, AM HEART J, V128, P1210, DOI 10.1016/0002-8703(94)90753-6; Muehrcke DD, 1996, ANN THORAC SURG, V61, P1516, DOI 10.1016/0003-4975(95)01105-6; MUNA WF, 1977, J THORAC CARDIOV SUR, V74, P65; NICHOLSON WJ, 1978, AM J CARDIOL, V41, P103, DOI 10.1016/0002-9149(78)90139-X; NICOD P, 1989, J AM COLL CARDIOL, V13, P811, DOI 10.1016/0735-1097(89)90221-0; Nienaber C A, 1994, Int J Card Imaging, V10, P1, DOI 10.1007/BF01151576; NIENABER CA, 1995, CIRCULATION, V92, P1465, DOI 10.1161/01.CIR.92.6.1465; NIENABER CA, 1992, CIRCULATION, V85, P434, DOI 10.1161/01.CIR.85.2.434; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; OLSON LJ, 1984, MAYO CLIN PROC, V59, P835, DOI 10.1016/S0025-6196(12)65618-3; PEDOWITZ P, 1957, AM J OBSTET GYNECOL, V73, P720, DOI 10.1016/0002-9378(57)90380-0; PERKO MJ, 1995, ANN THORAC SURG, V59, P1204, DOI 10.1016/0003-4975(95)00132-5; PETASNICK JP, 1991, RADIOLOGY, V180, P297, DOI 10.1148/radiology.180.2.2068287; PRESSLER V, 1980, J THORAC CARDIOV SUR, V79, P489; RIZZO RJ, 1989, J VASC SURG, V10, P365; ROBBINS RC, 1993, CIRCULATION, V88, P1; RUBIN BG, 1992, SURGERY, V112, P607; SAFI HJ, 1993, ANN THORAC SURG, V56, P270, DOI 10.1016/0003-4975(93)91158-J; SARSAM MAI, 1993, J THORAC CARDIOV SUR, V105, P435; Savunen T, 1996, EUR J CARDIO-THORAC, V10, P428, DOI 10.1016/S1010-7940(96)80110-2; SCHEININ SA, 1994, ANN THORAC SURG, V58, P19, DOI 10.1016/0003-4975(94)91065-0; SCHEPENS MA, 1994, ANN SURG, V219, P400, DOI 10.1097/00000658-199404000-00011; Schor JS, 1996, ANN THORAC SURG, V61, P1339, DOI 10.1016/0003-4975(96)00105-1; Stanson A W, 1986, Ann Vasc Surg, V1, P15, DOI 10.1016/S0890-5096(06)60697-3; Svensjo S, 1996, BRIT J SURG, V83, P68, DOI 10.1002/bjs.1800830122; SVENSSON LG, 1989, J VASC SURG, V10, P230, DOI 10.1067/mva.1989.13947; SVENSSON LG, 1989, CIRCULATION, V80, P233; SVENSSON LG, 1993, J THORAC CARDIOV SUR, V106, P19, DOI 10.1016/S0022-5223(19)33737-7; SVENSSON LG, 1992, ANN THORAC SURG, V54, P427, DOI 10.1016/0003-4975(92)90432-4; SVENSSON LG, 1992, CURR PROB SURG, V29, P915; SVENSSON LG, 1992, CURR PROB SURG, V29, P819; SVENSSON LG, 1992, J VASC SURG, V16, P378, DOI 10.1016/0741-5214(92)90371-E; SVENSSON LG, 1993, J VASC SURG, V17, P357, DOI 10.1016/0741-5214(93)90421-H; SWAN H, 1950, AMA ARCH SURG, V61, P732, DOI 10.1001/archsurg.1950.01250020738013; SWANSON SJ, 1995, ANN THORAC SURG, V60, P457, DOI 10.1016/0003-4975(95)00166-I; TAKASU J, 1994, ATHEROSCLEROSIS, V110, P175, DOI 10.1016/0021-9150(94)90202-X; TUNICK PA, 1994, J AM COLL CARDIOL, V23, P1085, DOI 10.1016/0735-1097(94)90595-9; VERDANT A, 1995, J VASC SURG, V21, P385, DOI 10.1016/S0741-5214(95)70280-6; VONSEGESSER LK, 1994, J THORAC CARDIOV SUR, V108, P755; WALLS JT, 1993, J THORAC CARDIOV SUR, V106, P283; WAREING TH, 1992, J THORAC CARDIOV SUR, V103, P453; WAREING TH, 1993, ANN THORAC SURG, V55, P1400, DOI 10.1016/0003-4975(93)91079-3; YAMADA T, 1988, RADIOLOGY, V168, P347, DOI 10.1148/radiology.168.2.3393653; YUCEL EK, 1990, RADIOLOGY, V177, P779, DOI 10.1148/radiology.177.3.2243989; YUN KL, 1991, J THORAC CARDIOV SUR, V102, P355	144	319	333	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	1997	336	26					1876	1888		10.1056/NEJM199706263362606	http://dx.doi.org/10.1056/NEJM199706263362606			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF756	9197217				2022-12-28	WOS:A1997XF75600006
J	Vitek, CR; Redd, SC; Redd, SB; Hadler, SC				Vitek, CR; Redd, SC; Redd, SB; Hadler, SC			Trends in importation of measles to the United States, 1986-1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPORTING EFFICIENCY	Objectives.-To describe patterns among imported measles cases to the United States. Design.-Descriptive analysis of national case-based surveillance data on measles cases. Setting.-United States in the period 1986 through 1994. Patients.-All reported confirmed cases of measles. Main Outcome Measures.-Demographic variables, immunization history, country of exposure, and reporting state. Results.-The number of reported imported cases of measles to the United States has dropped from an average of 99 cases annually in 1986 through 1988 and 190 cases in 1989 through 1991 to 61 cases in 1992 through 1994. Since 1990, the number of imported cases originating in Latin America declined by 98%, despite continued increase in the number of travelers to this region; cases from other regions remained relatively constant. This decrease paralleled the rapid decrease in measles incidence in the Western Hemisphere associated with national measles elimination programs. Most imported cases occurred among children, although 22% of cases occurred among young adults. Rates of measles cases per 1 million travelers are higher among non-US citizens than among US citizens. Conclusions.-The sharp decline in importations into the United States from Latin America since 1991 provides evidence of the success of measles control efforts undertaken there. The decrease in imported cases has been associated with a decline in total measles cases in the United States. Sustained elimination of measles in the United States will require improved measles control in other countries in addition to a high level of population immunity.			Vitek, CR (corresponding author), CTR DIS CONTROL & PREVENT,NATL IMMUNIZAT PROGRAM,EPIDEMIOL & SURVEILLANCE DIV,MAILSTOP E-61,ATLANTA,GA 30333, USA.							[Anonymous], 1990, MMWR Recomm Rep, V39, P1; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P57; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P925; *CDCP, 1978, MMWR-MORBID MORTAL W, V27, P391; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P486; CONRAD JL, 1971, AM J PUBLIC HEALTH N, V61, P2304, DOI 10.2105/AJPH.61.11.2304; DAVIS SF, 1993, AM J PUBLIC HEALTH, V83, P1011, DOI 10.2105/AJPH.83.7.1011; deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224; EWERT DP, 1994, AM J PUBLIC HEALTH, V84, P868, DOI 10.2105/AJPH.84.5.868-a; HERSH BS, 1992, JAMA-J AM MED ASSOC, V267, P1936, DOI 10.1001/jama.267.14.1936; *OFF RES US TRAV T, 1994, ABSTR INT TRAV US 19; Rota JS, 1996, J INFECT DIS, V173, P32, DOI 10.1093/infdis/173.1.32; *US IMM NAT SERV, 1996, STAT YB IMM NAT SERV; World Health Organization, 1995, WHO PUBL; 1989, MMWR MORB MORTAL S9, V38, P1; 1996, WKLY EPIDEMIOL REC, V71, P305	16	23	23	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1952	1956						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XF087	9200636				2022-12-28	WOS:A1997XF08700040
J	Goldfarb, DS				Goldfarb, DS			Nuclear transport - Whose finger is on the switch?	SCIENCE			English	Editorial Material							IMPORT				Goldfarb, DS (corresponding author), UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627, USA.							Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; Clarkson WD, 1996, J MOL BIOL, V263, P517, DOI 10.1006/jmbi.1996.0594; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; GOLDFARB DS, 1994, CURR BIOL, V4, P57, DOI 10.1016/S0960-9822(00)00013-0; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Her LS, 1997, SCIENCE, V276, P1845, DOI 10.1126/science.276.5320.1845; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; Moroianu J, 1997, CRIT REV EUKAR GENE, V7, P61, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.40; Nakielny S, 1996, EXP CELL RES, V229, P261, DOI 10.1006/excr.1996.0369; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; Percipalle P, 1997, J MOL BIOL, V266, P722, DOI 10.1006/jmbi.1996.0801; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REN MD, 1995, MOL CELL BIOL, V15, P2117; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451; Zolotukhin AS, 1997, J BIOL CHEM, V272, P11356, DOI 10.1074/jbc.272.17.11356	28	24	24	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1814	1816		10.1126/science.276.5320.1814	http://dx.doi.org/10.1126/science.276.5320.1814			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206840				2022-12-28	WOS:A1997XF10300032
J	Orenstein, JM; Fox, C; Wahl, SM				Orenstein, JM; Fox, C; Wahl, SM			Macrophages as a source of HIV during opportunistic infections	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUBERCULOSIS; COINFECTION; TYPE-1; AIDS	The source of increasing viremia that characterizes the latter stages of human immunodeficiency virus (HIV) disease has remained a paradox because it occurs at a time when lymphoid tissue is quantitatively and qualitatively impaired, and the patients' CD4 T lymphocytes are steadily declining. Here, macrophages, both infected and uninfected with common opportunistic pathogens of HIV disease such as Mycobacterium avium complex and Pneumocystis carinii, were identified as highly productive sources of HIV in coinfected lymph nodes. These observations indicate that tissue macrophages are not only infected with HIV, but that common pathogens of HIV disease can dramatically increase their production of virus. Thus, prevention or successful treatment of opportunistic coinfections, or both, potentially benefits the patient twofold by limiting the pathology caused by opportunistic infection and by controlling induction of HIV replication.	MOL HISTOL INC,GAITHERSBURG,MD 20879; NIDR,ORAL INFECT & IMMUN BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Orenstein, JM (corresponding author), GEORGE WASHINGTON UNIV,DEPT PATHOL,WASHINGTON,DC 20037, USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012585] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12585] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; CHIN DP, 1994, J INFECT DIS, V170, P578, DOI 10.1093/infdis/170.3.578; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAYDON EJ, 1991, AIDS, V5, P113, DOI 10.1097/00002030-199101000-00022; COOPER ER, 1997, 4 C RETR OPP INF WAS, P185; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DENIS M, 1994, CLIN EXP IMMUNOL, V97, P76; Donovan RM, 1996, J INFECT DIS, V174, P401, DOI 10.1093/infdis/174.2.401; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; Feinberg MB, 1996, LANCET, V348, P239, DOI 10.1016/S0140-6736(96)06231-9; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GHASSEMI M, 1995, J INFECT DIS, V171, P68, DOI 10.1093/infdis/171.1.68; Goletti D, 1996, J IMMUNOL, V157, P1271; HENG MCY, 1994, LANCET, V343, P255, DOI 10.1016/S0140-6736(94)91110-X; LAZZAROTTO T, 1994, J INFECTION, V28, P287, DOI 10.1016/S0163-4453(94)91843-0; Magro CM, 1996, HUM PATHOL, V27, P1066, DOI 10.1016/S0046-8177(96)90285-3; PANTALEO G, 1994, IMMUNOL REV, V140, P104; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; TOOSSI Z, 1993, J EXP MED, V177, P1511, DOI 10.1084/jem.177.5.1511; WAHL SM, IN PRESS J LEUKOCYTE; WAHL SM, 1996, IMMUNOLOGY HIV INFEC, P303; WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542; Whalen C, 1997, AIDS, V11, P455, DOI 10.1097/00002030-199704000-00008; ZHANG YH, 1995, J CLIN INVEST, V95, P2324, DOI 10.1172/JCI117924	30	445	449	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1857	1861		10.1126/science.276.5320.1857	http://dx.doi.org/10.1126/science.276.5320.1857			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188531				2022-12-28	WOS:A1997XF10300048
J	Bowman, MA; Nicklin, DE				Bowman, MA; Nicklin, DE			Family medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Bowman, MA (corresponding author), UNIV PENN,SCH MED,PHILADELPHIA,PA 19104, USA.		bowman, marjorie a/F-7235-2013	bowman, marjorie a/0000-0002-1945-9212				Bergus GR, 1996, ARCH FAM MED, V5, P523, DOI 10.1001/archfami.5.9.523; Butler JC, 1996, J INFECT DIS, V174, P986, DOI 10.1093/infdis/174.5.986; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Jonas BS, 1997, ARCH FAM MED, V6, P43, DOI 10.1001/archfami.6.1.43; Kreiger Nancy, 1996, American Journal of Public Health, V86, P1370; Merlo J, 1996, BRIT MED J, V313, P457; OKEEFE JH, 1996, MAYO CLIN P, V91, P957; Salamone LM, 1996, ARCH INTERN MED, V156, P1293, DOI 10.1001/archinte.156.12.1293; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Volk RJ, 1997, ARCH FAM MED, V6, P72, DOI 10.1001/archfami.6.1.72	12	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1857	1858						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185800				2022-12-28	WOS:A1997XD54400019
J	Andreasen, NC; OLeary, DS; Flaum, M; Nopoulos, P; Watkins, GL; Ponto, LLB; Hichwa, RD				Andreasen, NC; OLeary, DS; Flaum, M; Nopoulos, P; Watkins, GL; Ponto, LLB; Hichwa, RD			Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic-naive patients	LANCET			English	Article							DORSOLATERAL PREFRONTAL CORTEX; POSITRON EMISSION TOMOGRAPHY; CEREBRAL BLOOD-FLOW; GLUCOSE-METABOLISM; PHYSIOLOGIC DYSFUNCTION; ABNORMALITIES; DISORDERS; MEMORY	Background There have been reports that patients with schizophrenia have decreased metabolic activity in prefrontal cortex. However, findings have been confounded by medication effects, chronic illness, and difficulties of measurement. We aimed to address these problems by examination of cerebral blood flow with positron emission tomography (PET). Methods We studied 17 neuroleptic-native patients at the early stages of illness by means of image analysis and statistical methods that can detect abnormalities at the gyral level. Findings An initial omnibus test with a randomisation analysis indicated that patients differed from normal controls at the 0.06 level. In the follow-up analysis, three separate prefrontal regions had decreased perfusion (lateral, orbital, medial), as well as regions in inferior temporal and parietal cortex that are known to be anatomically connected. Regions with increased perfusion were also identified (eg, thalamus, cerebellum, retrosplenial cingulate), which suggests an imbalance in distributed cortical and subcortical circuits. Interpretation These distributed dysfunctional circuits may form the neural basis of schizophrenia through cognitive impairment of the brain, which prevents it from processing input efficiently and producing output effectively, thereby leading to symptoms such as hallucinations, delusions, and loss of volition.	UNIV IOWA,COLL MED,PET IMAGING CTR,IOWA CITY,IA 52242; UNIV IOWA HOSP & CLIN,IOWA CITY,IA 52242	University of Iowa; University of Iowa	Andreasen, NC (corresponding author), UNIV IOWA,COLL MED,MENTAL HLTH CLIN RES CTR,IOWA CITY,IA 52242, USA.			Ponto, Laura/0000-0003-1197-6714; O'Leary, Daniel/0000-0003-1959-6521; Nopoulos, Peggy/0000-0001-8810-1903				ANDREASEN N, 1986, ARCH GEN PSYCHIAT, V43, P136; ANDREASEN NC, 1995, AM J PSYCHIAT, V152, P1576; Andreasen NC, 1996, P NATL ACAD SCI USA, V93, P9985, DOI 10.1073/pnas.93.18.9985; ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; Andreasen NC, 1996, J COMPUT ASSIST TOMO, V20, P98, DOI 10.1097/00004728-199601000-00018; ANDREASEN NC, 1994, JAMA-J AM MED ASSOC, V272, P1763, DOI 10.1001/jama.272.22.1763; ANDREASEN NC, 1995, P NATL ACAD SCI USA, V92, P5111, DOI 10.1073/pnas.92.11.5111; Arndt S, 1996, J CEREBR BLOOD F MET, V16, P1271, DOI 10.1097/00004647-199611000-00023; BENES FM, 1995, NEUROSCIENTIST, V1, P104; BERMAN KF, 1986, ARCH GEN PSYCHIAT, V43, P126; BERMAN KF, 1988, ARCH GEN PSYCHIAT, V45, P616; BILDER RM, 1992, PSYCHOPHARMACOL BULL, V28, P353; BUCHSBAUM MS, 1990, BRIT J PSYCHIAT, V156, P216, DOI 10.1192/bjp.156.2.216; BUCHSBAUM MS, 1982, ARCH GEN PSYCHIAT, V39, P251; CLEGHORN JM, 1989, PSYCHIAT RES, V28, P119, DOI 10.1016/0165-1781(89)90040-1; EARLY TS, 1987, P NATL ACAD SCI USA, V84, P561, DOI 10.1073/pnas.84.2.561; FRITH C. D., 1992, COGNITIVE NEUROPSYCH; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; GUR RC, 1995, LANCET, V345, P1383, DOI 10.1016/S0140-6736(95)92591-0; GUR RE, 1995, ARCH GEN PSYCHIAT, V52, P657; GUR RE, 1985, ARCH GEN PSYCHIAT, V42, P329; INGVAR DH, 1974, ACTA PSYCHIAT SCAND, V50, P425, DOI 10.1111/j.1600-0447.1974.tb09707.x; LIDDLE PF, 1992, BRIT J PSYCHIAT, V160, P179, DOI 10.1192/bjp.160.2.179; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; SILBERSWEIG DA, 1995, NATURE, V378, P176, DOI 10.1038/378176a0; SZECHTMAN H, 1988, ARCH GEN PSYCHIAT, V45, P523; VOLKOW ND, 1987, AM J PSYCHIAT, V144, P151; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WIESEL FA, 1987, ACTA PSYCHIAT SCAND, V76, P642, DOI 10.1111/j.1600-0447.1987.tb02934.x	30	489	500	1	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1730	1734		10.1016/S0140-6736(96)08258-X	http://dx.doi.org/10.1016/S0140-6736(96)08258-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XE065	9193383				2022-12-28	WOS:A1997XE06500010
J	Fletcher, TJ; Tunnicliffe, WS; Hammond, K; Roberts, K; Ayres, JG				Fletcher, TJ; Tunnicliffe, WS; Hammond, K; Roberts, K; Ayres, JG			Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease	BRITISH MEDICAL JOURNAL			English	Article									BIRMINGHAM HEARTLANDS HOSP,CHEST RES INST,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND	Heart of England NHS Foundation Trust; University of Birmingham								BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; FEDSON DS, 1995, ROY SOC MED INT CONG, P49; HUANG KL, 1987, JAMA-J AM MED ASSOC, V257, P2047, DOI 10.1001/jama.257.15.2047; MACFARLANE J, 1995, ROY SOC MED INT CONG, P9; SALISBURY DM, 1992, IMMUNISATION INFECT	5	22	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 7	1997	314	7095					1663	1665		10.1136/bmj.314.7095.1663	http://dx.doi.org/10.1136/bmj.314.7095.1663			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD874	9193290	Green Published			2022-12-28	WOS:A1997XD87400026
J	Fulcher, KY; White, PD				Fulcher, KY; White, PD			Randomised controlled trial of graded exercise in patients with the chronic fatigue syndrome	BRITISH MEDICAL JOURNAL			English	Article							FATIGUABILITY; FIBROMYALGIA; PERFORMANCE; ACTIVATION; STRENGTH; PROGRAM; HEALTH	Objective: To test the efficacy of a graded aerobic exercise programme in the Design: Randomised controlled trial with control treatment crossover after the first follow up examination. Setting: Chronic fatigue clinic in a general hospital department of psychiatry. Subjects: 66 patients with the chronic fatigue syndrome who had neither a psychiatric disorder nor appreciable sleep disturbance. Interventions: Random allocation to 12 weeks of either graded aerobic exercise or flexibility exercises and relaxation therapy Patients who completed the flexibility programme were invited to cross over to the exercise programme afterwards. Main outcome measure: The self rated clinical global impression change score, ''very much better'' or ''much better'' being considered as clinically important. Results: Four patients receiving exercise and three receiving flexibility treatment dropped out before completion. 16 of 29 patients rated themselves as better after completing exercise treatment compared with eight of 30 patients who completed flexibility treatment Analysis by intention to treat gave similar results (17/33 v 9/33 patients better). Fatigue, functional capacity, and fitness were significantly better after exercise than after flexibility treatment 12 of 22 patients who crossed over to exercise after flexibility treatment rated themselves as better after completing exercise treatment. 32 of 47 patients rated themselves as better three months after completing supervised exercise treatment 35 of 47 patients rated themselves as better one year after completing supervised exercise treatment. Conclusion: These findings support the use of appropriately prescribed graded aerobic exercise in the management of patients with the chronic fatigue syndrome.	ST BARTHOLOMEWS & ROYAL LONDON MED SCH, DEPT MED PSYCHOL, LONDON EC1A 7BE, ENGLAND; ST BARTHOLOMEWS & ROYAL LONDON MED SCH, NATL SPORTS MED INST, LONDON EC1M 6BQ, ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London				White, Peter/0000-0002-8193-5355				[Anonymous], 1991, GUID EX TEST PRESCR; BLOMQVIST CG, 1983, ANNU REV PHYSIOL, V45, P169, DOI 10.1146/annurev.ph.45.030183.001125; BOMBARDIER CH, 1995, ARCH INTERN MED, V155, P2105, DOI 10.1001/archinte.155.19.2105; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; BUCHWALD D, 1994, ARCH INTERN MED, V154, P2049, DOI 10.1001/archinte.154.18.2049; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Deale A, 1997, AM J PSYCHIAT, V154, P408; Feldman R M, 1987, Birth Defects Orig Artic Ser, V23, P335; Fleiss JL, 1981, STAT METHODS RATES P; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; GIBSON H, 1993, J NEUROL NEUROSUR PS, V56, P993, DOI 10.1136/jnnp.56.9.993; Guy W., 1976, ECDEU ASSESSMENT MAN, P218; Jones NL., 1988, CLIN EXERCISE TESTIN, V3rd edn; LLOYD AR, 1991, BRAIN, V114, P85; MCCAIN GA, 1988, ARTHRITIS RHEUM, V31, P1135, DOI 10.1002/art.1780310908; McCully KK, 1996, SPORTS MED, V21, P35, DOI 10.2165/00007256-199621010-00004; MORGAN WP, 1994, MED SCI SPORT EXER, V26, P1071, DOI 10.1249/00005768-199409000-00001; MYLES WS, 1985, MED SCI SPORT EXER, V17, P580; Newham D, 1979, Physiotherapy, V65, P52; RILEY MS, 1990, BRIT MED J, V301, P953, DOI 10.1136/bmj.301.6758.953; RUTHERFORD OM, 1986, J NEUROL NEUROSUR PS, V49, P1288, DOI 10.1136/jnnp.49.11.1288; RUTHERFORD OM, 1991, J NEUROL NEUROSUR PS, V54, P961, DOI 10.1136/jnnp.54.11.961; Saltin B., 1968, CIRCULATION, V38, P1, DOI 10.1161/01.CIR.38.1.1; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; Spitzer RL, 1990, STRUCTURED CLIN INTE; STOKES MJ, 1988, BRIT MED J, V297, P1014, DOI 10.1136/bmj.297.6655.1014; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEYERER S, 1994, SPORTS MED, V17, P108, DOI 10.2165/00007256-199417020-00003; WHITE PD, 1995, PSYCHOL MED, V25, P917, DOI 10.1017/S0033291700037405; ZIGMOND A, 1983, ACTA PSYCHIAT SCAND, V87, P361	32	258	262	0	51	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 7	1997	314	7095					1647	1652		10.1136/bmj.314.7095.1647	http://dx.doi.org/10.1136/bmj.314.7095.1647			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD874	9180065	Green Published			2022-12-28	WOS:A1997XD87400022
J	Gottesman, II				Gottesman, II			Human genetics - Twins: En route to QTLs for cognition	SCIENCE			English	Editorial Material							BEHAVIOR				Gottesman, II (corresponding author), UNIV VIRGINIA,DEPT PSYCHOL,GILMER HALL,CHARLOTTESVILLE,VA 22903, USA.		G, I/D-8042-2011					Bouchard TJ, 1993, TWINS TOOL BEHAV GEN; CARDON LR, 1994, SCIENCE, V266, P276, DOI 10.1126/science.7939663; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; Daniels J, 1996, J BIOSOC SCI, V28, P491; FESKENS EJM, 1994, BRIT MED J, V309, P1202, DOI 10.1136/bmj.309.6963.1202; Gottesman I. I., 1972, SCHIZOPHRENIA GENETI; Hall JG, 1996, CURR OPIN GENET DEV, V6, P343, DOI 10.1016/S0959-437X(96)80012-8; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P905; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LOEHLIN JC, 1989, AM PSYCHOL, V44, P1285, DOI 10.1037/0003-066X.44.10.1285; McClearn GE, 1997, SCIENCE, V276, P1560, DOI 10.1126/science.276.5318.1560; McGue M, 1993, NATURE NURTURE PSYCH, P59, DOI DOI 10.1037/10131-003; Merriman C, 1924, PSYCHOL MONOGR, V33, P1; NEALE MC, 1992, METHODOLOGY GENETICS; PLOMIN R, 1994, SCIENCE, V264, P1733, DOI 10.1126/science.8209254; PLOMIN R, 1997, INTELLIGENCE, V24, P41; PLOMIN R, 1997, BEHAVIORAL GENETICS; REISS AL, 1995, NAT GENET, V11, P331, DOI 10.1038/ng1195-331; Risch N, 1997, SCIENCE, V275, P1329; Roses A., 1996, APOLIPOPROTEIN E ALZ; Scott WK, 1997, SCIENCE, V275, P1327, DOI 10.1126/science.275.5304.1327; Shakespeare William, TEMPEST; Siemens H., 1924, ZWILLINGSPATHOLOGIE; Silva AJ, 1997, NAT GENET, V15, P281, DOI 10.1038/ng0397-281; SING CF, 1994, CLIN GENET, V46, P6; SING CF, 1996, VARIATION HUMAN GENO, V197, P211; Stokstad E, 1997, SCIENCE, V275, P1882, DOI 10.1126/science.275.5308.1882; Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397-194; TAKAHASHI JS, 1994, SCIENCE, V264, P1724, DOI 10.1126/science.8209253; TURKHEIMER E, 1995, HUM DEV, V38, P142, DOI 10.1159/000278307; VOGEL F, 1997, HUMAN GENETICS, pCH6; Zerba KE, 1996, GENETICS, V143, P463	32	40	39	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 6	1997	276	5318					1522	1523		10.1126/science.276.5318.1522	http://dx.doi.org/10.1126/science.276.5318.1522			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XC701	9190689				2022-12-28	WOS:A1997XC70100029
J	Reich, Z; Boniface, JJ; Lyons, DS; Borochov, N; Wachtel, EJ; Davis, MM				Reich, Z; Boniface, JJ; Lyons, DS; Borochov, N; Wachtel, EJ; Davis, MM			Ligand-specific oligomerization of T-cell receptor molecules	NATURE			English	Article							LIPID-LINKED FORM; ANTIGEN RECEPTOR; MHC; EXPRESSION; COMPLEXES	T cells initiate many immune responses through the interaction of their T-cell antigen receptors (TCR) with antigenic peptides bound to major histocompatibility complex (MHC) molecules, This interaction sends a biochemical signal into the T cell by a mechanism that is not clearly understood. We have used quasielastic light scattering (QELS) to show that, in the presence of MHC molecules bound to a full agonist peptide, TCR/peptide-MHC complexes oligomerize in solution to form supramolecular structures at concentrations near the dissociation constant of the binding reaction. The size of the oligomers is concentration dependent and is calculated to contain two to six ternary complexes for the concentrations tested here. This effect is specific as neither molecule forms oligomers by itself, nor were oligomers observed unless the correct peptide was bound to the MHC. These results provide direct evidence for models of T-cell signalling based on the specific assembly of multiple TCR/peptide-MHC complexes(1-4) in which the degree of assembly determines the extent and qualitative nature of the transduced signal(5). They may also explain how T cells maintain sensitivity to antigens present in only low abundance on the antigen-presenting cell.	STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; CTR TECHNOL EDUC HOLON,HOLON,ISRAEL; WEIZMANN INST SCI,CHEM SERV UNIT,IL-76100 REHOVOT,ISRAEL	Stanford University; Weizmann Institute of Science	Reich, Z (corresponding author), STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305, USA.			Davis, Mark/0000-0001-6868-657X				Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; DAVIS MM, 1995, NATURE, V375, P104, DOI 10.1038/375104a0; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GERMAIN RN, 1993, CURR BIOL, V3, P586, DOI 10.1016/0960-9822(93)90004-8; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; HELDIN CH, 1995, CELL, V80, P200; KIRKWOOD JG, 1954, J POLYM SCI, V12, P1, DOI 10.1002/pol.1954.120120102; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SYMER DE, 1992, J EXP MED, V176, P1421, DOI 10.1084/jem.176.5.1421; TAKAHAMA Y, 1994, NATURE, V371, P67, DOI 10.1038/371067a0; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219	24	204	209	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					617	620		10.1038/42500	http://dx.doi.org/10.1038/42500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177351				2022-12-28	WOS:A1997XC52200059
J	Miller, RS; Dunn, MR; Whitcomb, ME				Miller, RS; Dunn, MR; Whitcomb, ME			Initial employment status of resident physicians completing training in 1995	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To assess the degree and type of difficulty encountered by resident physicians attempting to enter the workforce in 1995. Design.-Employment information derived from a 1-page descriptive survey completed by residency program directors from January 1, 1996, to June 15, 1996, is described and compared with the results of a similar survey completed 1 year earlier. Setting.-Directors of 4568 residency programs in 31 specialties and subspecialties accredited by the Accreditation Council for Graduate Medical Education. Main Outcome Measure.-The number of 1995 program graduates, their current professional status, and program directors' characterization of the experience of graduates who entered clinical practice, including the number who experienced major difficulties securing an acceptable practice position, Program directors reported actual and anticipated decreases in the number of residency positions and the likely availability of future professional opportunities. Results.-The 3819 program directors (83.6%) who completed the survey reported that 20 065 resident physicians completed a residency program during 1995. Of those seeking employment (n = 13 215), most entered clinical practice (80.1%) or took an academic position (15.6%); 2.2% were unemployed or had taken a position in a specialty or subspecialty different from the one in which they were last trained. A portion (6.3%) of graduates who entered clinical practice in their specialty or subspecialty experienced difficulty finding a suitable position;the percentage was lowest among graduates of general surgery, psychiatry, and primary care specialties. Conclusions.-Survey results regarding the 1995 graduates are consistent with those obtained regarding the 1994 graduates and suggest that the market for physician services in some disciplines continues to be restrictive. We found that graduates of the specialties of anesthesiology and plastic surgery, whom we reported had the greatest difficulty finding acceptable positions in 1994, had less difficulty in 1995, suggesting a possible improvement in the market, less competition, a change in the respondents' perception of ''acceptable,'' or a change in the resident physicians' willingness to pursue different opportunities. The general consistency of our results and their congruence with other published data suggest that this method is useful to identify and monitor trends in the physician market.	ASSOC AMER MED COLL,DIV MED EDUC,WASHINGTON,DC	Association of American Medical Colleges	Miller, RS (corresponding author), AMER MED ASSOC,DIV GRAD MED EDUC,DEPT RES & DATA ANAL,515 N STATE ST,CHICAGO,IL 60610, USA.							*I MED, 1996, NAT PHYS WORKF OPT B; Miller RS, 1996, JAMA-J AM MED ASSOC, V275, P708, DOI 10.1001/jama.275.9.708; Pew Health Professions Commission, 1995, CRIT CHALL REV HLTH; Seifer SD, 1996, JAMA-J AM MED ASSOC, V276, P695, DOI 10.1001/jama.276.9.695; Simon CJ, 1996, HEALTH AFFAIR, V15, P124, DOI 10.1377/hlthaff.15.3.124	5	59	59	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1699	1704		10.1001/jama.277.21.1699	http://dx.doi.org/10.1001/jama.277.21.1699			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169897				2022-12-28	WOS:A1997XB08800031
J	Rapiejko, PJ; Gilmore, R				Rapiejko, PJ; Gilmore, R			Empty site forms of the SRP54 and SR alpha GTPases mediate targeting of ribosome nascent chain complexes to the endoplasmic reticulum	CELL			English	Article							SIGNAL-RECOGNITION PARTICLE; METHIONINE-RICH DOMAIN; GTP-BINDING; PROTEIN TRANSLOCATION; SEQUENCE RECOGNITION; RECEPTOR; MEMBRANE; SUBUNIT; HYDROLYSIS; POLYPEPTIDE	The SRP54 and SR alpha subunits of the signal recognition particle (SRP) and the SRP receptor (SR) undergo a tightly coupled GTPase cycle that mediates the signal sequence-dependent attachment of ribosomes to the Sec61 complex. Here, we show that SRP54 and SR alpha are in the empty site conformation prior to contact between the SRP-ribosome complex and the membrane-bound SR. Cooperative binding of GTP to SRP54 and SR alpha stabilizes the SRP-SR complex and initiates signal sequence transfer from SRP54 to Sec61 alpha. The GTP-bound conformations of SR alpha and SRP54 perform distinct roles, with SR alpha performing a predominant role in complex stabilization. Hydrolysis by both SRP54 and SR alpha is a prerequisite for dissociation of the SRP-SR complex.	UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester				Rapiejko, Piotr/0000-0003-3868-0294	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035687] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35687] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTHOFF SM, 1994, MOL CELL BIOL, V14, P7839, DOI 10.1128/MCB.14.12.7839; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; CONNOLLY T, 1993, J CELL BIOL, V123, P799, DOI 10.1083/jcb.123.4.799; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; GILMORE R, 1983, CELL, V35, P677, DOI 10.1016/0092-8674(83)90100-9; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HWANG YW, 1987, J BIOL CHEM, V262, P13081; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; RAPIEJKO PJ, 1994, MOL BIOL CELL, V5, P887, DOI 10.1091/mbc.5.8.887; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Yanachkov I, 1997, MOL PHARMACOL, V51, P47, DOI 10.1124/mol.51.1.47; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	39	108	109	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	1997	89	5					703	713		10.1016/S0092-8674(00)80253-6	http://dx.doi.org/10.1016/S0092-8674(00)80253-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182758	Bronze			2022-12-28	WOS:A1997XB92500007
J	Pui, CH; Boyett, JM; Hughes, WT; Rivera, GK; Hancock, ML; Sandlund, JT; Synold, T; Relling, MV; Ribeiro, RC; Crist, WM; Evans, WE				Pui, CH; Boyett, JM; Hughes, WT; Rivera, GK; Hancock, ML; Sandlund, JT; Synold, T; Relling, MV; Ribeiro, RC; Crist, WM; Evans, WE			Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; PNEUMOCYSTIS-CARINII PNEUMONITIS; ACUTE MYELOGENOUS LEUKEMIA; HIGH-DOSE CHEMOTHERAPY; PHASE-III TRIAL; FACTOR G-CSF; CONGENITAL NEUTROPENIA; INTENSIVE INDUCTION; THERAPY	Background Recombinant human granulocyte colony-stimulating factor (G-CSF, or filgrastim) hastens the recovery from neutropenia after intensive chemotherapy, but its role in the management of childhood leukemia is unclear. Methods We randomly assigned 164 patients with acute lymphoblastic leukemia (age range, 2 months to 17 years) to receive placebo or G-CSF (10 mu g per kilogram of body weight per day subcutaneously), beginning one day after the completion of remission-induction therapy and continuing until the neutrophil count was greater than or equal to 1000 per cubic millimeter for two days. The clinical and laboratory effects of this therapy were documented for 21 days. The area under the plasma G-CSF concentration-time curve was measured on days 1 and 7 in both groups. Results Responses to the growth factor could be assessed in 148 patients (73 in the G-CSF group and 75 in the placebo group). G-CSF treatment did not significantly lower the rate of hospitalization for febrile neutropenia (58 percent in the G-CSF group vs. 68 percent in the placebo group; relative risk, 0.85; 95 percent confidence interval, 0.59 to 1.16), increase the likelihood of event-free survival at three years (83 percent in both groups), or decrease the number of severe infections (five in the G-CSF group vs. six in the placebo group). Patients treated with G-CSF had shorter median hospital stays (6 days vs. 10 days, P=0.011) and fewer documented infections (12 vs. 27, P=0.009). The median total costs of supportive care were similar in the G-CSF and placebo groups ($8,768 and $8,616, respectively). Among patients who did not have febrile neutropenia during the first week of G-CSF or placebo injections, higher systemic exposure to the growth factor on day 7 was significantly related to a lower probability of subsequent hospitalization (P=0.049). Conclusions G-CSF treatment had some clinical benefit in children who received induction chemotherapy for acute lymphoblastic leukemia, but it did not reduce the rate of hospitalization for febrile neutropenia, prolong survival, or reduce the cost of supportive care. (C)1997, Massachusetts Medical Society.	UNIV TENNESSEE, COLL MED, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, COLL PHARM, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Pui, CH (corresponding author), ST JUDE CHILDRENS RES HOSP, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.		Evans, William E./C-2069-2012; Relling, Mary/N-5032-2018; Pui, Ching-Hon/N-8076-2018	Evans, William E./0000-0002-9333-5322; Pui, Ching-Hon/0000-0003-0303-5658; Synold, Timothy/0000-0002-4075-2544				[Anonymous], 1994, J CLIN ONCOL, V12, P2471; BEKSAC M, 1992, BLOOD, V80, P2946; BONILLA MA, 1994, BRIT J HAEMATOL, V88, P723, DOI 10.1111/j.1365-2141.1994.tb05110.x; CLEVERLEY WHO, 1996, 1996 97 ALMANAC HOSP; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; DARGENIO DZ, 1992, ADAPT 2 MATH SOFTWAR; DIBENEDETTO SP, 1995, EUR J HAEMATOL, V55, P93; DOMBRET H, 1995, NEW ENGL J MED, V332, P1678, DOI 10.1056/NEJM199506223322504; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; DREGER P, 1994, BRIT J HAEMATOL, V87, P609, DOI 10.1111/j.1365-2141.1994.tb08321.x; ESTEY E, 1994, J CLIN ONCOL, V12, P671, DOI 10.1200/JCO.1994.12.4.671; FURMAN WL, 1991, J CLIN ONCOL, V9, P1022, DOI 10.1200/JCO.1991.9.6.1022; GISSELBRECHT C, 1994, LANCET, V343, P696, DOI 10.1016/S0140-6736(94)91579-2; GISSELBRECHT C, 1994, LANCET, V343, P804; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; HUGHES WT, 1992, CLIN INFECT DIS, V15, pS206, DOI 10.1093/clind/15.Supplement_1.S206; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1987, NEW ENGL J MED, V316, P1627, DOI 10.1056/NEJM198706253162604; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; HUGHES WT, 1990, J INFECT DIS, V161, P1316; HUGHES WT, 1996, HOSP EPIDEMIOLOGY IN, P618; IMASHUKU S, 1995, BRIT J HAEMATOL, V89, P188, DOI 10.1111/j.1365-2141.1995.tb08928.x; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KANTARJIAN HM, 1993, CANCER-AM CANCER SOC, V72, P2950, DOI 10.1002/1097-0142(19931115)72:10<2950::AID-CNCR2820721015>3.0.CO;2-B; KITA K, 1993, LEUKEMIA, V7, P1184; KLUMPP TR, 1995, J CLIN ONCOL, V13, P1323, DOI 10.1200/JCO.1995.13.6.1323; KUBOTA M, 1995, PEDIATR HEMAT ONCOL, V12, P393, DOI 10.3109/08880019509029590; LARSON RA, 1994, P AN M AM SOC CLIN, V13, P305; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99; LINDEMANN A, 1989, BLOOD, V74, P2644; Locatelli F, 1996, BONE MARROW TRANSPL, V17, P31; MADERO L, 1995, BONE MARROW TRANSPL, V15, P349; MAYORDOMO JI, 1995, J NATL CANCER I, V87, P803, DOI 10.1093/jnci/87.11.803; MIKSITS K, 1993, BONE MARROW TRANSPL, V11, P375; MIRRO J, 1993, LEUKEMIA, V7, P1026; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; OHNO R, 1993, INT J HEMATOL, V58, P73; OHNO R, 1994, BLOOD, V83, P2086; OHNO R, 1990, NEW ENGL J MED, V323, P871, DOI 10.1056/NEJM199009273231304; OTTMANN OG, 1995, BLOOD, V86, P444, DOI 10.1182/blood.V86.2.444.bloodjournal862444; PETTENGELL R, 1992, BLOOD, V80, P1430; Pui CH, 1995, LEUKEMIA, V9, P1990; PUI CH, 1995, LEUKEMIA, V9, P1680; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; PUI CH, 1994, HAEMATOL BLOOD TRANS, V36, P307; Reisbach G, 1996, BRIT J HAEMATOL, V92, P907, DOI 10.1046/j.1365-2141.1996.434972.x; RIIKONEN P, 1995, STEM CELLS, V13, P289, DOI 10.1002/stem.5530130310; Saarinen UM, 1996, MED PEDIATR ONCOL, V26, P380, DOI 10.1002/(SICI)1096-911X(199606)26:6<380::AID-MPO2>3.0.CO;2-D; SANTANA VM, 1990, MED PEDIATR ONCOL, V18, P395; SCHERRER R, 1993, ANN HEMATOL, V66, P283, DOI 10.1007/BF01695970; SCHRIBER JR, 1994, BLOOD, V84, P1680; SHENEP JL, 1988, NEW ENGL J MED, V319, P1053, DOI 10.1056/NEJM198810203191604; STAHEL RA, 1994, J CLIN ONCOL, V12, P1931, DOI 10.1200/JCO.1994.12.9.1931; STUTE N, 1992, BLOOD, V79, P2849; SYNOLD TW, 1994, J CLIN INVEST, V94, P1996, DOI 10.1172/JCI117552; VEY N, 1994, BONE MARROW TRANSPL, V14, P779; WATARI K, 1989, BLOOD, V73, P117; Welte K, 1996, BLOOD, V87, P3143, DOI 10.1182/blood.V87.8.3143.bloodjournal8783143; 1996, J CLIN ONCOL, V14, P1957	59	115	118	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	1997	336	25					1781	1787		10.1056/NEJM199706193362503	http://dx.doi.org/10.1056/NEJM199706193362503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE485	9187068				2022-12-28	WOS:A1997XE48500003
J	Schwappach, J; Swiontkowski, MF				Schwappach, J; Swiontkowski, MF			Orthopedics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Schwappach, J (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,325 9TH AVE,SEATTLE,WA 98104, USA.			Swiontkowski, Marc/0000-0001-7036-1782				Brighton CT, 1996, J BONE JOINT SURG AM, V78A, P1337, DOI 10.2106/00004623-199609000-00007; Engelberg R, 1996, J ORTHOPAED RES, V14, P182, DOI 10.1002/jor.1100140204; Hefley WF, 1996, J BONE JOINT SURG AM, V78A, P581, DOI 10.2106/00004623-199604000-00012; Hertel R, 1996, J ORTHOP TRAUMA, V10, P223, DOI 10.1097/00005131-199605000-00001; Hunziker EB, 1996, J BONE JOINT SURG AM, V78A, P721, DOI 10.2106/00004623-199605000-00012; Jupiter JB, 1996, J BONE JOINT SURG AM, V78A, P1817, DOI 10.2106/00004623-199612000-00004; Leclerc JR, 1996, ANN INTERN MED, V124, P619, DOI 10.7326/0003-4819-124-7-199604010-00001; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Lieberman JR, 1996, J BONE JOINT SURG AM, V78A, P835, DOI 10.2106/00004623-199606000-00005; Matta JM, 1996, J BONE JOINT SURG AM, V78A, P1632, DOI 10.2106/00004623-199611000-00002; Mermelstein LE, 1996, J ORTHOP TRAUMA, V10, P15, DOI 10.1097/00005131-199601000-00003; Mulroy WF, 1996, J BONE JOINT SURG AM, V78A, P325, DOI 10.2106/00004623-199603000-00002; Rubin C, 1996, J BONE JOINT SURG AM, V78A, P1523, DOI 10.2106/00004623-199610000-00010; Werntz JR, 1996, J ORTHOP RES, V14, P85, DOI 10.1002/jor.1100140115	14	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1883	1884						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185816				2022-12-28	WOS:A1997XD54400035
J	Mellors, JW; Munoz, A; Giorgi, JV; Margolick, JB; Tassoni, CJ; Gupta, P; Kingsley, LA; Todd, JA; Saah, AJ; Detels, R; Phair, JP; Rinaldo, CR				Mellors, JW; Munoz, A; Giorgi, JV; Margolick, JB; Tassoni, CJ; Gupta, P; Kingsley, LA; Todd, JA; Saah, AJ; Detels, R; Phair, JP; Rinaldo, CR			Plasma viral load and CD4(+) lymphocytes as prognostic markers of HIV-1 infection	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MULTICENTER AIDS COHORT; NATURAL-HISTORY; RNA; QUANTITATION	Background: The rate of disease progression among persons infected with human immunodeficiency virus type 1 (HIV-1) varies widely, and the relative prognostic value of markers of disease activity has not been defined. Objective: To compare clinical, serologic, cellular, and virologic markers for their ability to predict progression to the acquired immunodeficiency syndrome (AIDS) and death during a 10-year period. Design: Prospective, multicenter cohort study. Setting: Four university-based clinical centers participating in the Multicenter AIDS Cohort Study. Patients: 1604 men infected with HIV-1. Measurements: The markers compared were oral candidiasis (thrush) or fever; serum neopterin levels; serum beta(2)-microglobulin levels; number and percentage of CD3(+), CD4(+), and CD8(+) lymphocytes; and plasma viral load, which was measured as the concentration of HIV-1 RNA found using a sensitive branched-DNA signal-amplification assay. Results: Plasma viral load was the single best predictor of progression to AIDS and death, followed (in order of predictive strength) by CD4(+) lymphocyte count and serum neopterin levels, serum beta(2)-microglobulin levels, and thrush or fever. Plasma viral load discriminated risk at all levels of CD4(+) lymphocyte counts and predicted their subsequent rate of decline. Five risk categories were defined by plasma HIV-l RNA concentrations: 500 copies/mL or less, 501 to 3000 copies/mL, 3001 to 10 000 copies/mL, 10 001 to 30 000 copies/mL, and more than 30 000 copies/mL. Highly significant (P < 0.001) differences in the percentages of participants who progressed to AIDS within 6 years were seen in the five risk categories: 5.4%, 16.6%, 31.7%, 55.2%, and 80.0%, respectively. Highly significant (P < 0.001) differences in the percentages of participants who died of AIDS within 6 years were also seen in the five risk categories: 0.9%, 6.3%, 18.1%, 34.9%, and 69.5%, respectively. A regression tree incorporating both HIV-1 RNA measurements and CD4(+) lymphocyte counts provided better discrimination of outcome than did either marker alone; use of both variables defined categories of risk for AIDS within 6 yea rs that ranged from less than 2% to 98%. Conclusions: Plasma viral load strongly predicts the rate of decrease in CD4(+) lymphocyte count and progression to AIDS and death, but the prognosis of HIV-infected persons is more accurately defined by combined measurement of plasma HIV-1 RNA and CD4(+) lymphocytes.	JOHNS HOPKINS SCH PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, CTR HLTH SCI, LOS ANGELES, CA 90095 USA; CHIRON CORP, EMERYVILLE, CA 94608 USA; NORTHWESTERN UNIV, SCH MED, COMPREHENS AIDS CTR, CHICAGO, IL 60611 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Novartis; Northwestern University	Mellors, JW (corresponding author), UNIV PITTSBURGH, GRAD SCH PUBL HLTH, 603 PARRAN HALL, 130 DESOTO ST, PITTSBURGH, PA 15261 USA.			Kingsley, Lawrence/0000-0002-7000-8556	NCRR NIH HHS [5-MO1-RR-00722] Funding Source: Medline; NIAID NIH HHS [U01-AI-35042, UO1-AI-35043] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035043, U01AI035042] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CIAMPI A, 1988, J CLIN EPIDEMIOL, V41, P737, DOI 10.1016/0895-4356(88)90160-6; DIGGLE PJ, 1994, ANAL LONGITUDINAL DA, P79; Efron B, 1993, INTRO BOOTSTRAP, V13, P170; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLODNIY M, 1995, J CLIN MICROBIOL, V33, P1562, DOI 10.1128/JCM.33.6.1562-1566.1995; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P10; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KIEVITS T, 1991, J VIROL METHODS, V35, P273, DOI 10.1016/0166-0934(91)90069-C; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; Munoz A, 1996, STAT MED, V15, P2459, DOI 10.1002/(SICI)1097-0258(19961130)15:22<2459::AID-SIM464>3.0.CO;2-Q; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Pezzotti P, 1996, BRIT MED J, V313, P583; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; TODD J, 1995, J ACQ IMMUN DEF SYND, V10, pS35; TSOUKAS CM, 1994, CLIN MICROBIOL REV, V7, P14, DOI 10.1128/CMR.7.1.14-28.1994; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; [No title captured]	26	1551	1611	1	64	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1997	126	12					946	954		10.7326/0003-4819-126-12-199706150-00003	http://dx.doi.org/10.7326/0003-4819-126-12-199706150-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE549	9182471				2022-12-28	WOS:A1997XE54900006
J	Bapat, VN; Tendolkar, AG				Bapat, VN; Tendolkar, AG			Turning a blind eye	LANCET			English	Article									SETH GS MED COLL,DEPT CARDIOVASC & THORAC SURG,BOMBAY,MAHARASHTRA,INDIA; KING EDWARD VII MEM HOSP,BOMBAY,MAHARASHTRA,INDIA	Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital; Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital								COTTRELL ED, 1995, VASCULAR SURG, P1622; KANSKI JJ, 1994, CLIN OPHTHALMOLOGY S, P285; LUPIHERRERA E, 1977, AM HEART J, V93, P94, DOI 10.1016/S0002-8703(77)80178-6; Takayasu M, 1908, ACTA SOCIETATIS OPHT, V12, P554	4	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1740	1740		10.1016/S0140-6736(97)04207-4	http://dx.doi.org/10.1016/S0140-6736(97)04207-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193385				2022-12-28	WOS:A1997XE06500012
J	Stoltzfus, RJ				Stoltzfus, RJ			Rethinking anaemia surveillance	LANCET			English	Editorial Material							IRON-DEFICIENCY; INFANT				Stoltzfus, RJ (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, CTR HUMAN NUTR, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.							Christian P, 1996, FASEB J, V10, P1417; COOK JD, 1986, BLOOD, V68, P803; Dreyfuss ML, 1996, FASEB J, V10, P4219; DREYFUSS ML, IN PRESS J NEPAL MED; FAO, 1992, WORLD FOOD SUPPL PRE, P1; *FAO WHO, 1992, 6 FAO WHO; FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; GILLESPIE S, 1991, CONTROLLING IRON DEF, P1; HAAS JD, 1989, AM J CLIN NUTR, V50, P703, DOI 10.1093/ajcn/50.3.703; MASON JB, 1984, NUTR SURVEILLANCE, P1; SCHOLL TO, 1992, AM J CLIN NUTR, V55, P985, DOI 10.1093/ajcn/55.5.985; SHAPIRO S, 1980, AM J OBSTET GYNECOL, V136, P363, DOI 10.1016/0002-9378(80)90863-7; STOLTZFUS RJ, 1993, J NUTR, V123, P666, DOI 10.1093/jn/123.4.666; Stoltzfus RJ, 1997, AM J CLIN NUTR, V65, P153, DOI 10.1093/ajcn/65.1.153; Tyler RD, 1996, COMP HAEMATOL INT, V6, P1, DOI 10.1007/BF00368096; *UNICEF, 1995, STAT WORLDS CHILDR, P1; United Nations Administrative Committee on Coordination-Sub-Committee on Nutrition, 1992, 2 REP WORLD NUTR SIT, V1; VONSCHENCK H, 1986, CLIN CHEM, V32, P526; World Bank, 2013, WOR DEV REP, P1, DOI 10.1596/978-0-8213-9575-2; Yip Ray, 1996, P31; Zhou LM, 1997, FASEB J, V11, P3770	22	59	60	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	1997	349	9067					1764	1766		10.1016/S0140-6736(96)12355-2	http://dx.doi.org/10.1016/S0140-6736(96)12355-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193395	hybrid			2022-12-28	WOS:A1997XE06500044
J	Anderson, K; Moore, MJ				Anderson, K; Moore, MJ			Bimolecular exon ligation by the human spliceosome	SCIENCE			English	Article							PRE-MESSENGER-RNA; MAMMALIAN INTRONS; SPLICING INVITRO; SITE SELECTION; SEQUENCE; PRECURSORS; TRANS; ENHANCER; PROTEINS; LENGTH	Intron excision is an essential step in eukaryotic gene expression, but the molecular mechanisms by which the spliceosome accurately identifies splice sites in nuclear precursors to messenger RNAs (pre-mRNAs) are not well understood. A bimolecular assay for the second step of splicing has now revealed that exon ligation by the human spliceosome does not require covalent attachment of a 3' splice site to the branch site. Furthermore, accurate definition of the 3' splice site in this system is independent of either a covalently attached polypyrimidine tract or specific 3' exon sequences. Rather, in this system 3' splice site selection apparently occurs with a 5' --> 3' directionality.	BRANDEIS UNIV, DEPT BIOCHEM, WM KECK INST CELLULAR VISUALIZAT, WALTHAM, MA 02254 USA	Brandeis University					NIGMS NIH HHS [GM53007] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON K, UNPUB; BRUZIK JP, 1992, NATURE, V360, P692, DOI 10.1038/360692a0; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FU XD, 1995, RNA, V1, P663; FURDON PJ, 1988, MOL CELL BIOL, V8, P860, DOI 10.1128/MCB.8.2.860; GHETTI A, 1995, P NATL ACAD SCI USA, V92, P11461, DOI 10.1073/pnas.92.25.11461; GOZANI O, 1994, EMBO J, V13, P3356, DOI 10.1002/j.1460-2075.1994.tb06638.x; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; KONFORTI BB, 1995, RNA, V1, P815; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kramer A., 1995, PREMRNA PROCESSING, P35; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MASCHHOFF KL, 1993, NUCLEIC ACIDS RES, V21, P5456, DOI 10.1093/nar/21.23.5456; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NILSEN TW, 1992, INFECT AGENT DIS, V1, P212; NILSEN TW, 1995, MOL BIOCHEM PARASIT, V73, P1, DOI 10.1016/0166-6851(94)00107-X; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; NOBLE JCS, 1989, MOL CELL BIOL, V9, P2007, DOI 10.1128/MCB.9.5.2007; PADGETT RA, 1984, SCIENCE, V225, P898, DOI 10.1126/science.6206566; PARENT A, 1987, J BIOL CHEM, V262, P11284; Pasman Z, 1996, NUCLEIC ACIDS RES, V24, P1638, DOI 10.1093/nar/24.9.1638; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; ROSCIGNO RF, 1993, J BIOL CHEM, V268, P11222; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; TURNBULLROSS AD, 1988, NUCLEIC ACIDS RES, V16, P395, DOI 10.1093/nar/16.2.395; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; Umen JG, 1995, RNA, V1, P869; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6	43	68	69	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	1997	276	5319					1712	1716		10.1126/science.276.5319.1712	http://dx.doi.org/10.1126/science.276.5319.1712			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180084				2022-12-28	WOS:A1997XD94700047
J	Horne, JH; Meyer, T				Horne, JH; Meyer, T			Elementary calcium-release units induced by inositol trisphosphate	SCIENCE			English	Article							1,4,5-TRISPHOSPHATE; MUSCLE	The extent to which inositol 1,4,5-trisphosphate (InsP(3))-induced calcium signals are localized is a critical parameter for understanding the mechanism of effector activation, The spatial characteristics of InsP(3)-mediated calcium signals were determined by targeting a dextran-based calcium indicator to intracellular membranes through the in situ addition of a geranylgeranyl lipid group. Elementary calcium-release events observed with this indicator typically lasted less than 33 milliseconds, had diameters less than 2 micrometers, and were uncoupled from each other by the calcium buffer EGTA. Cellwide calcium transients are likely to result from synchronized triggering of such local release events, suggesting that calcium-dependent effector proteins could be selectively activated by localization near sites of local calcium release.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University				Meyer, Tobias/0000-0003-4339-3804	NHLBI NIH HHS [P01-HL-47053] Funding Source: Medline; NIGMS NIH HHS [GM-51457, R01-GM-48113] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048113] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HIROSE K, 1994, NATURE, V372, P791; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; HORNE JH, UNPUB; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Oancea E, 1996, J BIOL CHEM, V271, P17253, DOI 10.1074/jbc.271.29.17253; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; TERUEL M, UNPUB; THOM P, 1993, CELL, V74, P661; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WALKER JW, 1989, BIOCHEMISTRY-US, V28, P3272, DOI 10.1021/bi00434a023; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	21	85	86	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	1997	276	5319					1690	1693		10.1126/science.276.5319.1690	http://dx.doi.org/10.1126/science.276.5319.1690			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180077				2022-12-28	WOS:A1997XD94700040
J	Shalaby, F; Ho, J; Stanford, WL; Fischer, KD; Schuh, AC; Schwartz, L; Bernstein, A; Rossant, J				Shalaby, F; Ho, J; Stanford, WL; Fischer, KD; Schuh, AC; Schwartz, L; Bernstein, A; Rossant, J			A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis	CELL			English	Article							RECEPTOR TYROSINE KINASE; ENDOTHELIAL GROWTH-FACTOR; YOLK-SAC; MOUSE EMBRYO; STEM-CELLS; PARAAORTIC SPLANCHNOPLEURA; VASCULAR ENDOTHELIUM; INVITRO DEVELOPMENT; ES CELLS; C-KIT	Mouse embryos lacking the receptor tyrosine kinase, Flk1, die without mature endothelial and hematopoietic cells. To investigate the role of Flk1 during vasculogenesis and hematopoiesis, we examined the developmental potential of Flk1(-/-) embryonic stem cells in chimeras. We show that Flk1 is required cell autonomously for endothelial development. Furthermore, Flk1(-/-) cells do not contribute to primitive hematopoiesis in chimeric yolk sacs or definitive hematopoiesis in adult chimeras and chimeric fetal livers. We also demonstrate that cells lacking Flk1 are unable to reach the correct location to form blood islands, suggesting that Flk1 is involved in the movement of cells from the posterior primitive streak to the yolk sac and, possibly, to the intraembryonic sites of early hematopoiesis.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON, CANADA; UNIV TORONTO, DEPT MED, DEPT MED BIOPHYS, TORONTO, ON, CANADA; UNIV TORONTO, DEPT OBSTET & GYNECOL, TORONTO, ON, CANADA; TORONTO HOSP, DIV HEMATOL ONCOL, TORONTO, ON M5G 2C4, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Ho, Jackie/AAP-1531-2021	Ho, Jackie/0000-0001-7115-1381; Stanford, William/0000-0002-5813-8016				Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212; Bautch VL, 1996, DEV DYNAM, V205, P1; BERGER CN, 1995, DEV BIOL, V170, P651, DOI 10.1006/dbio.1995.1244; BRUNKOW ME, 1995, GENOMICS, V25, P421, DOI 10.1016/0888-7543(95)80042-K; CUMANO A, 1993, P NATL ACAD SCI USA, V90, P6429, DOI 10.1073/pnas.90.14.6429; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIETERLENLIEVRE F, 1981, DEV BIOL, V88, P180, DOI 10.1016/0012-1606(81)90228-1; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GARCIAPORRERO JA, 1995, ANAT EMBRYOL, V192, P427; GODIN I, 1995, P NATL ACAD SCI USA, V92, P773, DOI 10.1073/pnas.92.3.773; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; Hashiyama M, 1996, BLOOD, V87, P93; HUANG H, 1993, P NATL ACAD SCI USA, V90, P10110, DOI 10.1073/pnas.90.21.10110; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; LIU CP, 1991, DEVELOPMENT, V113, P1315; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Murray PDF, 1932, P R SOC LOND B-CONTA, V111, P497, DOI 10.1098/rspb.1932.0070; Nagy A., 1993, Gene targeting: a practical approach., P147; OGAWA M, 1993, DEVELOPMENT, V117, P1089; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Partanen J, 1996, DEVELOPMENT, V122, P3013; PERAH G, 1977, J CELL PHYSIOL, V91, P193, DOI 10.1002/jcp.1040910205; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; REITH AD, 1991, GENOME ANAL, V3, P105; RISAU W, 1991, PHARMACOL THERAPEUT, V51, P371, DOI 10.1016/0163-7258(91)90066-U; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sabin FR, 1920, CONTRIB EMBRYOL, V9, P215; Sanchez MJ, 1996, IMMUNITY, V5, P513, DOI 10.1016/S1074-7613(00)80267-8; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SONODA T, 1983, DEV BIOL, V97, P89, DOI 10.1016/0012-1606(83)90066-0; SPRITZ RA, 1994, GENOMICS, V22, P431, DOI 10.1006/geno.1994.1405; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; SYMANN M, 1978, EXP HEMATOL, V6, P749; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WILES MV, 1991, DEVELOPMENT, V111, P259; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; Wurst W., 1993, Gene targeting: a practical approach., P33; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	61	696	731	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					981	990		10.1016/S0092-8674(00)80283-4	http://dx.doi.org/10.1016/S0092-8674(00)80283-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200616	Bronze			2022-12-28	WOS:A1997XE35700018
J	Trotta, CR; Miao, F; Arn, EA; Stevens, SW; Ho, CK; Rauhut, R; Abelson, JN				Trotta, CR; Miao, F; Arn, EA; Stevens, SW; Ho, CK; Rauhut, R; Abelson, JN			The yeast tRNA splicing endonuclease: A tetrameric enzyme with two active site subunits homologous to the archaeal tRNA endonucleases	CELL			English	Article							ARCHAEBACTERIUM DESULFUROCOCCUS-MOBILIS; PROTEIN-PROTEIN INTERACTIONS; RIBOSOMAL-RNA GENE; SACCHAROMYCES-CEREVISIAE; HALOBACTERIUM-VOLCANII; SUBSTRATE RECOGNITION; INTRON ENDONUCLEASE; LIGASE; BACTERIA; SEQUENCE	The splicing of tRNA precursors is essential for the production of mature tRNA in organisms from all major phyla. In yeast, the tRNA splicing endonuclease is responsible for identification and cleavage of the splice sites in pre-tRNA. We have cloned the genes encoding all four protein subunits of endonuclease. Each gene is essential. Two subunits, Sen2p and Sen34p, contain a homologous domain of approximately 130 amino acids, This domain is found in the gene encoding the archaeal tRNA splicing endonuclease of H. volcanii and in other Archaea. Our results demonstrate that the eucaryal tRNA splicing endonuclease contains two functionally independent active sites for cleavage of the 5' and 3' splice sites, encoded by SEN2 and SEN34, respectively. The presence of endonuclease in Eucarya and Archaea suggests an ancient origin for the tRNA splicing reaction.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Ho, KIong/GPP-6051-2022					ABELSON J, 1991, HARVEY LECT, V85, P1; Arn EA, 1996, J BIOL CHEM, V271, P31145, DOI 10.1074/jbc.271.49.31145; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BELFORD HG, 1993, J BIOL CHEM, V268, P2444; BINISZKIEWICZ D, 1994, EMBO J, V13, P4629, DOI 10.1002/j.1460-2075.1994.tb06785.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGGRAF S, 1993, P NATL ACAD SCI USA, V90, P2547, DOI 10.1073/pnas.90.6.2547; CECH TR, 1993, RNA WORLD, P239; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GREER CL, 1983, CELL, V33, P899, DOI 10.1016/0092-8674(83)90032-6; Guthrie C., 1991, METHODS ENZYMOLOGY G; Hannon G, 1995, METHOD MOL CELL BIOL, V5, P289; Harlow E., 1988, ANTIBODIES LAB MANUA; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HO CK, 1990, EMBO J, V9, P1245, DOI 10.1002/j.1460-2075.1990.tb08232.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KJEMS J, 1989, CAN J MICROBIOL, V35, P210, DOI 10.1139/m89-033; KJEMS J, 1985, NATURE, V318, P675, DOI 10.1038/318675a0; LEE MC, 1985, J BIOL CHEM, V260, P3108; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MCCRAITH SM, 1991, J BIOL CHEM, V266, P11986; MIAO F, 1993, J BIOL CHEM, V268, P672; Moore M., 1993, RNA WORLD, P303; OGDEN RC, 1984, NUCLEIC ACIDS RES, V12, P9367, DOI 10.1093/nar/12.24.9367; PALMER JR, 1994, J BACTERIOL, V176, P3820, DOI 10.1128/JB.176.12.3820-3823.1994; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sherman F., 1986, METHODS YEAST GENETI; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; THOMPSON LD, 1988, J BIOL CHEM, V263, P17951; THOMPSON LD, 1990, J BIOL CHEM, V265, P18104; THOMPSON LD, 1989, CAN J MICROBIOL, V35, P36, DOI 10.1139/m89-006; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WESTAWAY SK, 1993, J BIOL CHEM, V268, P2435; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; WINEY M, 1988, GENETICS, V118, P609; WINEY M, 1989, YEAST, V5, P405; YANAGISAWA S, 1993, J BIOL CHEM, V268, P16028	46	172	184	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					849	858		10.1016/S0092-8674(00)80270-6	http://dx.doi.org/10.1016/S0092-8674(00)80270-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200603	Bronze			2022-12-28	WOS:A1997XE35700005
J	Cowan, DN; DeFraites, RF; Gray, GC; Goldenbaum, MB; Wishik, SM				Cowan, DN; DeFraites, RF; Gray, GC; Goldenbaum, MB; Wishik, SM			The risk of birth defects among children of Persian Gulf War veterans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGENITAL-MALFORMATIONS	Background There has been suspicion that service in the Persian Gulf War affected the health of veterans adversely, and there have been claims of an increased rate of birth defects among the children of those veterans. Methods We evaluated the routinely collected data on all live births at 135 military hospitals in 1991, 1992, and 1993. The data base included up to eight diagnoses from the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) for each birth hospitalization, plus information on the demographic characteristics and service history of the parents. The records of over 75,000 newborns were evaluated for any birth defect (ICD-9-CM codes 740 to 759, plus neoplasms and hereditary diseases) and for birth defects defined as severe on the basis of the specific diagnoses and the criteria of the Centers for Disease Control and Prevention. Results During the study period, 33,998 infants were born to Gulf War veterans and 41,463 to nondeployed veterans at military hospitals. The overall risk of any birth defect was 7.45 percent, and the risk of severe birth defects was 1.85 percent. These rates are similar to those reported in civilian populations. In the multivariate analysis, there was no significant association for either men or women between service in the Gulf War and the risk of any birth defect or of severe birth defects in their children. Conclusions This analysis found no evidence of an increase in the risk of birth defects among the children of Gulf War veterans. (C) 1997, Massachusetts Medical Society.	WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,WASHINGTON,DC 20307; USN,HLTH RES CTR,SAN DIEGO,CA 92152; US DEPT DEF,DEPLOYMENT SURVEILLANCE TEAM,WASHINGTON,DC; UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC); United States Department of Defense; University of California System; University of California San Diego	Cowan, DN (corresponding author), SRA TECHNOL INC,8110 GATEHOUSE RD,SUITE 600W,FALLS CHURCH,VA 22042, USA.		Gray, Gregory C./ABF-1298-2020	Gray, Gregory/0000-0002-4628-5908				BRIGGS J, 1995, LIFE MAGAZINE    NOV, P46; BROADNAX GB, 1992, MEMORANDUM ABORTION; CALLE EE, 1991, AM J EPIDEMIOL, V134, P69, DOI 10.1093/oxfordjournals.aje.a115994; DEAN AG, 1990, EPIINFO VERSION 5 WO; EDMONDS LD, 1981, INT J EPIDEMIOL, V10, P247, DOI 10.1093/ije/10.3.247; EGGERT RW, 1994, DEPT AIR FORCE PUBLI; *GAO FIN REP, 1994, PUBL GAO; GRAY GC, 1996, NEW ENGL J MED, V335, P505; Institute of Medicine, 1995, HLTH CONS SERV PERS; JEROME R, 1995, PEOPLE          1030, P32; KULLER LH, 1995, AM J PUBLIC HEALTH, V85, P1198, DOI 10.2105/AJPH.85.9.1198; *NAT CTR ENV HLTH, 1993, METR ATL CONG DEF PR; Penman AD, 1996, MIL MED, V161, P1; *PERS ADV COMM GUL, 1996, WORK PLAN RES PERS G; *PRES ADV COMM GUL, 1996, INT REP; SEVER L, 1993, TERATOLOGY, V48, P547, DOI 10.1002/tera.1420480603; TIPPIT S, 1994, LADIES HOME J    JUN, P100	17	90	92	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1650	1656		10.1056/NEJM199706053362306	http://dx.doi.org/10.1056/NEJM199706053362306			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC086	9171068				2022-12-28	WOS:A1997XC08600006
J	Mathers, PH; Grinberg, A; Mahon, KA; Jamrich, M				Mathers, PH; Grinberg, A; Mahon, KA; Jamrich, M			The Rx homeobox gene is essential for vertebrate eye development	NATURE			English	Article							XENOPUS-LAEVIS; NERVOUS-SYSTEM; EYELESS GENE; EXPRESSION; DROSOPHILA; ANIRIDIA; RETINA; MOUSE; HEAD	Development of the vertebrate eye requires a series of steps including specification of the anterior neural plate, evagination of the optic vesicles from the ventral forebrain, and the cellular differentiation of the lens and retina. Homeobox-containing genes, especially the transcription regulator Pax6, play a critical role in vertebrate and invertebrate eye formation. Mutations in Pax6 function result in eye malformations known as Aniridia in humans and Small eye syndrome in mice(1-3). The Drosophila homologue of Pax6, eyeless, is also necessary for correct invertebrate eye development, and its misexpression leads to formation of ectopic eyes in Drosophila(4,5). Here we show that a conserved vertebrate homeobox gene, Rx, is essential for normal eye development, and that its misexpression has profound effects on eye morphology. Xenopus embryos injected with synthetic Rx RNA develop ectopic retinal tissue and display hyperproliferation in the neuroretina. Mouse embryos carrying a null allele of this gene do not form optic cups and so do not develop eyes. The Rx gene family plays an important role in the establishment and/or proliferation of retinal progenitor cells.	US FDA,DEV BIOL LAB,ROCKVILLE,MD 20852; NICHHD,LAB MAMMALIAN GENES & DEV,BETHESDA,MD 20892; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Baylor College of Medicine								BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CONLON RA, 1992, DEVELOPMENT, V116, P357; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOGAN BLM, 1986, J EMBRYOL EXP MORPH, V97, P95; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HUANG S, 1993, J NEUROSCI, V13, P3193; JAMRICH M, 1989, DEVELOPMENT, V105, P779; MATHERS PH, 1995, DEV BIOL, V171, P641, DOI 10.1006/dbio.1995.1311; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; SAKAGUCHI DA, 1990, NEUR ABSTR, V16; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; STIEMKE MM, 1995, DIFFERENTIATION, V58, P189, DOI 10.1046/j.1432-0436.1995.5830189.x; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WETTS R, 1989, DEV BIOL, V136, P154; YOUNOSSIHARTENSTEIN A, 1993, ROUX ARCH DEV BIOL, V203, P60, DOI 10.1007/BF00539891	25	553	567	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					603	607		10.1038/42475	http://dx.doi.org/10.1038/42475			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177348				2022-12-28	WOS:A1997XC52200056
J	Salisbury, C				Salisbury, C			Postal survey of patient's satisfaction with a general practice out of hours cooperative	BRITISH MEDICAL JOURNAL			English	Article							CARE	Objective: To assess patients' satisfaction with out of hours care by a general practice cooperative compared with that by a deputising service. Design: Postal questionnaire survey. Setting: A general practice cooperative in London and a deputising service operating in an overlapping area. Subjects: Weighted samples of patients receiving telephone advice, a home visit, or attending a primary care centre after contacting either service in an eight week period. Main outcome measures: Patients' overall satisfaction and scores for specific aspects of satisfaction. Satisfaction with telephone advice or attendance at centre compared with home visit. Relation between satisfaction and patient's age, sex, ethnic group, car ownership, preference for consulting own doctor, and expectation of a visit. Results: The over-all response rate was 67% (1555/2312). There was little difference in overall satisfaction between patients contacting the cooperative or the deputising service, but patients contacting the latter were less satisfied with the explanation and advice received and the wait for a visit. There were significant differences between patients in different age and ethnic groups, with white patients and those aged over 60 years being more satisfied. Lower scores for overall satisfaction were reported by patients who received telephone advice, those who would have preferred to see their own doctor or who originally wanted a home visit, and those who waited longer for their consultation. Overall levels of patients' satisfaction seemed to be lower than previously reported. Conclusions: There were larger differences in satisfaction between different groups of patients than between different models of organisation for out of hours care. A shift to a service based predominantly on telephone advice may lead to increased patient dissatisfaction.			Salisbury, C (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT PRIMARY HLTH CARE & GEN PRACTICE,PRAED ST,LONDON W2 1PG,ENGLAND.		Salisbury, Chris/C-6724-2008	Salisbury, Chris/0000-0002-4378-3960				BAKER R, 1995, BRIT MED J, V310, P533, DOI 10.1136/bmj.310.6978.533c; Bamford C, 1992, Qual Health Care, V1, P153, DOI 10.1136/qshc.1.3.153; Blaxter M, 1995, CONSUMERS RES NHS CO; BOLLAM MJ, 1988, BRIT MED J, V296, P829, DOI 10.1136/bmj.296.6625.829; CRAGG DK, 1994, BRIT MED J, V309, P1627, DOI 10.1136/bmj.309.6969.1627; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; FITZPATRICK R, 1991, BMJ-BRIT MED J, V302, P1129, DOI 10.1136/bmj.302.6785.1129; FITZPATRICK R, 1991, BRIT MED J, V302, P887, DOI 10.1136/bmj.302.6781.887; MARSH GN, 1987, J ROY COLL GEN PRACT, V37, P301; MCKINLEY R, 1996, BRIT MED J, V314, P193; OLESEN F, 1994, BRIT MED J, V309, P1624, DOI 10.1136/bmj.309.6969.1624; RASHID A, 1992, BRIT J GEN PRACT, V42, P197; REYNOLDS M, 1995, PULSE, V55, P48; Salisbury C, 1997, BRIT MED J, V314, P182, DOI 10.1136/bmj.314.7075.182	14	65	65	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 31	1997	314	7094					1594	1598		10.1136/bmj.314.7094.1594	http://dx.doi.org/10.1136/bmj.314.7094.1594			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9186172	Green Published			2022-12-28	WOS:A1997XC50000026
J	Sandercock, P; Collins, R; Counsell, C; Farrell, B; Peto, R; Slattery, J; Warlow, C; Anderson, S; Bowie, A; Boyle, J; Brownlie, A; Charlton, D; Cranswick, G; Day, L; Dennis, M; Dorman, P; Fraser, H; Kaye, M; Lindley, R; Liu, M; MacDonald, C; McCrindle, I; Middleton, G; Perry, D; Scoltock, V; Smith, B; Taylor, H; Waddell, F; Wardlaw, J; Crowther, J; Heineman, J; Knight, S; Radley, A; Ripley, R; Richards, S; Wilberforce, S; Chen, ZM; vanGijn, J; Harrison, M; Wilhelmsen, L				Sandercock, P; Collins, R; Counsell, C; Farrell, B; Peto, R; Slattery, J; Warlow, C; Anderson, S; Bowie, A; Boyle, J; Brownlie, A; Charlton, D; Cranswick, G; Day, L; Dennis, M; Dorman, P; Fraser, H; Kaye, M; Lindley, R; Liu, M; MacDonald, C; McCrindle, I; Middleton, G; Perry, D; Scoltock, V; Smith, B; Taylor, H; Waddell, F; Wardlaw, J; Crowther, J; Heineman, J; Knight, S; Radley, A; Ripley, R; Richards, S; Wilberforce, S; Chen, ZM; vanGijn, J; Harrison, M; Wilhelmsen, L			The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke	LANCET			English	Article							ACUTE ISCHEMIC STROKE; COMMUNITY; PROJECT; INFARCTION	Background Only a few small trials have compared antithrombotic therapy (antiplatelet or anticoagulant agents) versus control in acute ischaemic stroke, and none has been large enough to provide reliable evidence on safety or efficacy. Methods The International Stroke Trial (IST) was a large, randomised, open trial of up to 14 days of antithrombotic therapy started as soon as possible after stroke onset. The aim was to provide reliable evidence on the safety and efficacy of aspirin and of subcutaneous heparin. Half the patients were allocated unfractionated heparin (5000 or 12 500 IU bd [twice daily]) and half were allocated ''avoid heparin''; and, in a factorial design, half were allocated aspirin 300 mg daily and half ''avoid aspirin'', The primary outcomes were death within 14 days and death or dependency at 6 months. 19 435 patients with suspected acute ischaemic stroke entering 467 hospitals in 36 countries were randomised within 48 hours of symptom onset. Results Among heparin-allocated patients, there were non-significantly fewer deaths within 14 days (876 [9.0%] heparin vs 905 [9.3%] no heparin), corresponding to 3 (SD 4) fewer deaths per 1000 patients. At 6 months the percentage dead or dependent was identical in both groups (62.9%). Patients allocated to heparin had significantly fewer recurrent ischaemic strokes within 14 days (2.9% vs 3.8%) but this was offset by a similar-sized increase in haemorrhagic strokes (1.2% vs 0.4%), so the difference in death or non-fatal recurrent stroke (11.7% vs 12.0%) was not significant. Heparin was associated with a significant excess of 9 (SD 1) transfused or fatal extracranial bleeds per 1000. Compared with 5000 IU bd heparin, 12500 IU bd heparin was associated with significantly more transfused or fatal extracranial bleeds, more haemorrhagic strokes, and more deaths or non-fatal strokes within 14 days (12.6% vs 10.8%). Among aspirin-allocated patients there were non-significantly fewer deaths within 14 days (872 [9.0%] vs 909 [9.4%]), corresponding to 4 (SD 4) fewer deaths per 1000 patients. At 6 months there was a non-significant trend towards a smaller percentage of the aspirin group being dead or dependent (62.2% vs 63.5%, 2p=0.07), a difference of 13 (SD 7) per 1000; after adjustment for baseline prognosis the benefit from aspirin was significant (14 [SD 6] per 1000, 2p=0.03). Aspirinal-located patients had significantly fewer recurrent ischaemic strokes within 14 days (2.8% vs 3.9%) with no significant excess of haemorrhagic strokes (0.9% vs 0.8%), so the reduction in death or non-fatal recurrent stroke with aspirin (11.3% vs 12.4%) was significant. Aspirin was associated with a significant excess of 5 (SD 1) transfused or fatal extracranial bleeds per 1000; in the absence of heparin the excess was 2 (SD 1) and was not significant. There was no interaction between aspirin and heparin in the main outcomes. Interpretation Neither heparin regimen offered any clinical advantage at 6 months. The results suggest that if heparin is given in routine clinical practice, the dose should not exceed 5000 IU subcutaneously twice daily. For aspirin, the IST suggests a small but worthwhile improvement at 6 months. Taking the IST together with the comparably large Chinese Acute Stroke Trial, aspirin produces a small but real reduction of about 10 deaths or recurrent strokes per 1000 during the first few weeks. Both trials suggest that aspirin should be started as soon as possible after the onset of ischaemic stroke; previous trials have already shown that continuation of tow-dose aspirin gives protection in the longer term.			Sandercock, P (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Lindley, Richard/B-8148-2013; Wardlaw, Joanna M/Y-3456-2019; sandercock, peter/GQI-3167-2022; Zampolini, Mauro/B-7749-2009; Chen, Christopher/E-7023-2013; van Gijn, Jan/A-9444-2008; Hernandez, María/GYU-3543-2022	Lindley, Richard/0000-0002-0104-5679; Wardlaw, Joanna M/0000-0002-9812-6642; sandercock, peter/0000-0001-8484-0135; Chen, Christopher/0000-0002-1047-9225; 				ADAMS HP, 1994, STROKE, V25, P1901, DOI 10.1161/01.STR.25.9.1901; Adams JHp, 1994, STROKE, V25, P545; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AMARENCO P, 1995, STROKE SYNDROMES, P344; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1994, BMJ, V308, P235; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P824, DOI 10.1136/jnnp.53.10.824; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BURN J, 1994, STROKE, V25, P333, DOI 10.1161/01.STR.25.2.333; CHEN ZM, 1995, CEREBROVASC DIS, V5, P228; *CHIN AC STROK TRI, IN PRESS LANCET; Collins R, 1997, NEW ENGL J MED, V336, P847, DOI 10.1056/NEJM199703203361207; Collins R, 1996, BMJ-BRIT MED J, V313, P652; COUNSELL C, 1997, STROKE MODULE COCHRA; COUNSELL C, 1996, COCHRANE DATABASE SY; Davenport RJ, 1996, STROKE, V27, P415, DOI 10.1161/01.STR.27.3.415; Dennis M, 1997, CEREBROVASC DIS, V7, P22, DOI 10.1159/000108159; Dennis M, 1997, CEREBROVASC DIS, V7, P19, DOI 10.1159/000108158; Hankey G, 1996, J NEUROL NEUROSUR PS, V60, P371; HUNT D, 1992, LANCET, V339, P753; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; Kitchen S, 1996, THROMB HAEMOSTASIS, V75, P734; KOUDSTAAL PJ, 1993, STROKE, V24, P219, DOI 10.1161/01.STR.24.2.219; LINDLEY R, 1993, THESIS U NEWCASTLE T, P98; Lindley RI, 1995, J ROY COLL PHYS LOND, V29, P479; MARSH EE, 1989, NEUROLOGY, V39, P1631, DOI 10.1212/WNL.39.12.1631; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; SANDERCOCK P, 1992, BRIT MED J, V305, P1460, DOI 10.1136/bmj.305.6867.1460; Sandercock P, 1997, CEREBROVASC DIS, V7, P10, DOI 10.1159/000108231; SANDERCOCK PAG, 1993, J NEUROL NEUROSUR PS, V56, P17, DOI 10.1136/jnnp.56.1.17; SLATTERY J, 1996, CEREBROVASC DIS, V6, P8; TAVAZZI L, 1989, LANCET, V2, P182; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; VANKOOTEN F, 1994, STROKE, V25, P278, DOI 10.1161/01.STR.25.2.278; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124	35	1401	1443	1	45	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	1997	349	9065					1569	1581						13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174558				2022-12-28	WOS:A1997XB67300007
J	Aguinaldo, AMA; Turbeville, JM; Linford, LS; Rivera, MC; Garey, JR; Raff, RA; Lake, JA				Aguinaldo, AMA; Turbeville, JM; Linford, LS; Rivera, MC; Garey, JR; Raff, RA; Lake, JA			Evidence for a clade of nematodes, arthropods and other moulting animals	NATURE			English	Article							EVOLUTIONARY TREES; PHYLOGENETIC ANALYSIS; DNA; SEQUENCES; METAZOA; ORIGIN	The arthropods constitute the most diverse animal group, but, despite their rich fossil record and a century of study, their phylogenetic relationships remain unclear(1). Taxa previously proposed to be sister groups to the arthropods include Annelida, Onychophora, Tardigrada and others, but hypotheses of phylogenetic relationships have been conflicting(2,3). For example, onychophorans, like arthropods, moult periodically, have an arthropod arrangement of haemocoel(1,4), and have been related to arthropods in morphological and mitochondrial DNA sequence analyses(4,5). Like annelids, they possess segmental nephridia and muscles that are a combination of smooth and obliquely striated fibres(6). Our phylogenetic analysis of 18S ribosomal DNA sequences indicates a close relationship between arthropods, nematodes and all other moulting phyla. The results suggest that ecdysis (moulting) arose once and support the idea of a new clade, Ecdysozoa, containing moulting animals: arthropods, tardigrades, onychophorans, nematodes, nematomorphs, kinorhynchs and priapulids. No support is found for a clade of segmented animals, the Articulata, uniting annelids with arthropods. The hypothesis that nematodes are related to arthropods has important implications for developmental genetic studies using as model systems the nematode Caenorhabditis elegans and the arthropod Drosophila melanogaster, which are generally held to be phylogenetically distant from each other.	UNIV CALIF LOS ANGELES, INST MOL BIOL, LOS ANGELES, CA 90095 USA; UNIV ARKANSAS, DEPT BIOL SCI, FAYETTEVILLE, AR 72701 USA; UNIV S FLORIDA, DEPT BIOL, TAMPA, FL 33620 USA; DUQUESNE UNIV, DEPT SCI BIOL, PITTSBURGH, PA 15282 USA; INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA; INDIANA UNIV, INDIANA MOL BIOL INST, BLOOMINGTON, IN 47405 USA	University of California System; University of California Los Angeles; University of Arkansas System; University of Arkansas Fayetteville; State University System of Florida; University of South Florida; Duquesne University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington			Rivera, Maria/GYU-2150-2022; Garey, James/J-1062-2017	Garey, James/0000-0001-8205-5563				Balavoine G, 1997, CR ACAD SCI III-VIE, V320, P83, DOI 10.1016/S0764-4469(99)80090-0; BALLARD JWO, 1992, SCIENCE, V258, P1345, DOI 10.1126/science.1455227; BOORE JL, 1995, NATURE, V376, P163, DOI 10.1038/376163a0; Boudreaux H. B., 1979, ARTHROPOD PHYLOGENY; Brusca R.C., 1990, INVERTEBRATES; DEQUEIROZ K, 1990, SYST ZOOL, V39, P307, DOI 10.2307/2992353; EERNISSE DJ, 1992, SYST BIOL, V41, P305, DOI 10.1093/sysbio/41.3.305; Felsenstein J, 1996, MOL BIOL EVOL, V13, P93, DOI 10.1093/oxfordjournals.molbev.a025575; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; Garey JR, 1996, INVERTEBR BIOL, V115, P79, DOI 10.2307/3226943; Gee H., 1996, BACKBONE VIEWS ORIGI; GOLDMAN N, 1993, J MOL EVOL, V37, P650; HALANYCH KM, 1995, SCIENCE, V267, P1641, DOI 10.1126/science.7886451; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; LAKE JA, 1991, MOL BIOL EVOL, V8, P378; LAKE JA, 1995, P NATL ACAD SCI USA, V92, P9662, DOI 10.1073/pnas.92.21.9662; LAKE JA, 1994, P NATL ACAD SCI USA, V91, P1455, DOI 10.1073/pnas.91.4.1455; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; Nielsen C., 1995, ANIMAL EVOLUTION INT; PATTERSON C, 1989, INT CONGR SER, V824, P471; RAFF RA, 1994, ANNU REV ECOL SYST, V25, P351, DOI 10.1146/annurev.es.25.110194.002031; Ruppert EE, 1991, MICROSCOPIC ANATOMY, V4, P1; STEWART CB, 1993, NATURE, V361, P603, DOI 10.1038/361603a0; VALENTINE JW, 1989, P NATL ACAD SCI USA, V86, P2272, DOI 10.1073/pnas.86.7.2272; Wallace RL, 1996, INVERTEBR BIOL, V115, P104, DOI 10.2307/3227041; WEYGOLDT P, 1986, Z ZOOL SYST EVOL, V24, P19; WINNEPENNINCKX B, 1995, MOL BIOL EVOL, V12, P1132; WRIGHT KA, 1991, MICROSCOPIC ANATOMY, V4, P111	30	1251	1289	2	174	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632					489	493		10.1038/387489a0	http://dx.doi.org/10.1038/387489a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168109				2022-12-28	WOS:A1997XB47900045
J	Cherry, JM; Ball, C; Weng, S; Juvik, G; Schmidt, R; Adler, C; Dunn, B; Dwight, S; Riles, L; Mortimer, RK; Botstein, D				Cherry, JM; Ball, C; Weng, S; Juvik, G; Schmidt, R; Adler, C; Dunn, B; Dwight, S; Riles, L; Mortimer, RK; Botstein, D			Genetic and physical maps of Saccharomyces cerevisiae	NATURE			English	Article								Genetic and physical maps for the 16 chromosomes of Saccharomyces cerevisiae are presented. The genetic map is the result of 40 years of genetic analysis. The physical map was produced from the results of an international systematic sequencing effort. The data for the maps are accessible electronically from the Saccharomyces Genome Database (SGD: http://genome-www.stanford. edu/Saccharomyces/).	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	University of California System; University of California Berkeley; Washington University (WUSTL)	Cherry, JM (corresponding author), STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305, USA.			Dunn, Barbara/0000-0002-7041-0035; Cherry, J. Michael/0000-0001-9163-5180	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P41HG001315] Funding Source: NIH RePORTER; NHGRI NIH HHS [P41 HG001315, P41 HG001315-06] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		HAWTHORNE DC, 1960, GENETICS, V45, P1085; HAWTHORNE DC, 1968, GENETICS, V60, P735; KING JS, 1991, GENETICS, V129, P597; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; MORTIMER RK, 1973, GENETICS, V74, P33; MORTIMER RK, 1985, MICROBIOL REV, V49, P181, DOI 10.1128/MMBR.49.3.181-213.1985; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; MORTIMER RK, 1980, MICROBIOL REV, V44, P519, DOI 10.1128/MMBR.44.4.519-571.1980; MORTIMER RK, 1966, GENETICS, V53, P165; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; MORTIMER RK, 1984, MICROBIOL SCI, V1, P145; Mortimer RK, 1982, MOL BIOL YEAST SACCH, P639; RILES L, 1993, GENETICS, V134, P81	13	325	334	4	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632		S			67	73		10.1038/387s067	http://dx.doi.org/10.1038/387s067			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169866				2022-12-28	WOS:A1997XB54600006
J	Laurila, A; Bloigu, A; Nayha, S; Hassi, J; Leinonen, M; Saikku, P				Laurila, A; Bloigu, A; Nayha, S; Hassi, J; Leinonen, M; Saikku, P			Chlamydia pneumoniae antibodies and serum lipids in Finnish men: Cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									REG INST OCCUPAT HLTH,FIN-90220 OULU,FINLAND		Laurila, A (corresponding author), NATL PUBL HLTH INST,POB 310,FIN-90101 OULU,FINLAND.							GALLIN JI, 1969, NEW ENGL J MED, V281, P1081, DOI 10.1056/NEJM196911132812001; NAYHA S, 1993, SOCIAL INS I PUBLICA; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; Ward ME, 1995, APMIS, V103, P769, DOI 10.1111/j.1699-0463.1995.tb01436.x	4	41	42	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1456	1457		10.1136/bmj.314.7092.1456	http://dx.doi.org/10.1136/bmj.314.7092.1456			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167563	Green Published			2022-12-28	WOS:A1997XA20200024
J	Bach, DS				Bach, DS			Rheumatic mitral stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Bach, DS (corresponding author), UNIV MICHIGAN,ANN ARBOR,MI 48109, USA.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	1997	337	1					31	31		10.1056/NEJM199707033370106	http://dx.doi.org/10.1056/NEJM199707033370106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH186	9203429				2022-12-28	WOS:A1997XH18600006
J	Edwards, DA; Hanes, J; Caponetti, G; Hrkach, J; BenJebria, A; Eskew, ML; Mintzes, J; Deaver, D; Lotan, N; Langer, R				Edwards, DA; Hanes, J; Caponetti, G; Hrkach, J; BenJebria, A; Eskew, ML; Mintzes, J; Deaver, D; Lotan, N; Langer, R			Large porous particles for pulmonary drug delivery	SCIENCE			English	Article							LEUPROLIDE ACETATE; SIZE; PHAGOCYTOSIS; AEROSOL; BIOAVAILABILITY; INTRATRACHEAL; MICROSPHERES; DEPOSITION; PROTEINS; PEPTIDE	A new type of inhalation aerosol, characterized by particles of small mass density and large size, permitted the highly efficient delivery of inhaled therapeutics into the systemic circulation. Particles with mass densities less than 0.4 gram per cubic centimeter and mean diameters exceeding 5 micrometers were inspired deep into the lungs and escaped the lungs' natural clearance mechanisms until the inhaled particles delivered their therapeutic payload. Inhalation of large porous insulin particles resulted in elevated systemic levels of insulin and suppressed systemic glucose levels for 96 hours, whereas small nonporous insulin particles had this effect for only 4 hours. High systemic bioavailability of testosterone was also achieved by inhalation delivery of porous particles with a mean diameter (20 micrometers) approximately 10 times that of conventional inhaled therapeutic particles.	MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; UNIV PARMA,DEPT PHARM,I-43100 PARMA,ITALY; PENN STATE UNIV,FENSKE LAB,UNIVERSITY PK,PA 16802; PENN STATE UNIV,DEPT ANIM SCI,UNIVERSITY PK,PA 16802; TECHNION ISRAEL INST TECHNOL,DEPT BIOMED ENGN,IL-32000 HAIFA,ISRAEL	Massachusetts Institute of Technology (MIT); University of Parma; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Technion Israel Institute of Technology	Edwards, DA (corresponding author), PENN STATE UNIV,DEPT CHEM ENGN,204 FENSKE LAB,UNIVERSITY PK,PA 16802, USA.				NICHD NIH HHS [HD29125] Funding Source: Medline; NIGMS NIH HHS [GM26698] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026698] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADJEI A, 1990, PHARMACEUT RES, V7, P565, DOI 10.1023/A:1015853824722; ADJEI A, 1994, INT J PHARM, V107, P57, DOI 10.1016/0378-5173(94)90302-6; BRAIN JD, 1985, RETICULOENDOTHELIAL, P315; COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384; COLTHORPE P, 1992, PHARMACEUT RES, V9, P764, DOI 10.1023/A:1015851521551; EDWARDS DA, 1995, J AEROSOL SCI, V26, P293, DOI 10.1016/0021-8502(94)00101-4; Einarsson O, 1995, ANN NY ACAD SCI, V762, P89; French DL, 1996, J AEROSOL SCI, V27, P769, DOI 10.1016/0021-8502(96)00021-3; Ganderton, 1992, GENERATION RESPIRABL; Gennaro, 2003, REMINGTON SCI PRACTI; GONDA I, 1992, TOPICS IN PHARMACEUTICAL SCIENCES 1991, P95; GONDA I, 1990, CRIT REV THER DRUG, V6, P4273; HEYDER J, 1986, J AEROSOL SCI, V17, P811, DOI 10.1016/0021-8502(86)90035-2; HRKACH JS, 1995, MACROMOLECULES, V28, P4736, DOI 10.1021/ma00117a055; Jeyanthi R, 1996, J CONTROL RELEASE, V38, P235, DOI 10.1016/0168-3659(95)00125-5; KAWAGUCHI H, 1986, BIOMATERIALS, V7, P61, DOI 10.1016/0142-9612(86)90091-8; KOMADA F, 1994, J PHARM SCI, V83, P863, DOI 10.1002/jps.2600830621; KRENIS LJ, 1961, P SOC EXP BIOL MED, V107, P748; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LECORRE P, 1994, INT J PHARM, V107, P41, DOI 10.1016/0378-5173(94)90300-X; Li WI, 1996, J AEROSOL SCI, V27, P1269, DOI 10.1016/0021-8502(96)00046-8; LIU FY, 1993, PHARMACEUT RES, V10, P228, DOI 10.1023/A:1018934810512; NIVEN RW, 1995, CRIT REV THER DRUG, V12, P151, DOI 10.1615/CritRevTherDrugCarrierSyst.v12.i2-3.20; PATTON JS, 1992, ADV DRUG DELIVER REV, V8, P179, DOI 10.1016/0169-409X(92)90002-8; PAVIA D, 1984, AEROSOLS LUNG CLIN E, P200; RUDT S, 1992, J CONTROL RELEASE, V22, P263, DOI 10.1016/0168-3659(92)90101-V; Sacchetti M., 1996, INHALATION AEROSOLS, P337; SMITH SJ, 1996, INHALATION AEROSOLS, P233; TOM JW, 1991, J AEROSOL SCI, V22, P555, DOI 10.1016/0021-8502(91)90013-8; VIDGREN MT, 1987, INT J PHARM, V35, P139, DOI 10.1016/0378-5173(87)90082-2; WARHEIT DB, 1993, MICROSC RES TECHNIQ, V26, P412, DOI 10.1002/jemt.1070260509	31	934	1023	8	232	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1868	1871		10.1126/science.276.5320.1868	http://dx.doi.org/10.1126/science.276.5320.1868			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188534				2022-12-28	WOS:A1997XF10300051
J	Vidal, RA; Bahr, D; Baragiola, RA; Peters, M				Vidal, RA; Bahr, D; Baragiola, RA; Peters, M			Oxygen on Ganymede: Laboratory studies	SCIENCE			English	Article							AMORPHOUS WATER ICE; GALILEAN SATELLITES; ASTROPHYSICAL IMPLICATIONS; ION-BOMBARDMENT; SUBLIMATION; ATMOSPHERE; EUROPA; PHOTODESORPTION; CALLISTO; EJECTION	To test proposals for the origin of oxygen absorption bands in the visible reflectance spectrum of Ganymede, the reflectance of condensed films of pure oxygen (O-2) and O-2-water mixtures and the evolution of O-2 from the films as a function of temperature were determined, Absorption band shapes and positions for oxygen at 26 kelvin were similar to those reported for Ganymede, whereas those for the mixtures were slightly shifted. The band intensity dropped by more than two orders of magnitude when the ice mixture was warmed to 100 keivin, although about 20 percent of the O-2 remained trapped in the ice, which suggested that at these temperatures O-2 molecules dissolve in the ice rather than aggregate in clusters or bubbles. The experiments suggest that the absorption bands in Ganymede's spectrum were not produced in the relatively warm surface of the satellite but in a much colder source. Solid O-2 may exist in a cold subsurface layer or in an atmospheric haze.	UNIV VIRGINIA,LAB ATOM & SURFACE PHYS,CHARLOTTESVILLE,VA 22901; TEIKYO UNIV,SCH MED,PHYS LAB,HACHIOJI,TOKYO 192,JAPAN	University of Virginia; Teikyo University				Vidal, Ricardo/0000-0001-7082-9787				BARNUN A, 1987, PHYS REV B, V35, P2427, DOI 10.1103/PhysRevB.35.2427; BARNUN A, 1985, SURF SCI, V150, P143, DOI 10.1016/0039-6028(85)90215-8; BLAKE D, 1991, SCIENCE, V254, P548, DOI 10.1126/science.11538372; BROADFOOT AL, 1979, SCIENCE, V204, P979, DOI 10.1126/science.204.4396.979; BURATTI BJ, 1991, ICARUS, V92, P312, DOI 10.1016/0019-1035(91)90054-W; CALVIN W, UNPUB; Calvin WM, 1996, GEOPHYS RES LETT, V23, P673, DOI 10.1029/96GL00450; CARLSON RW, 1973, SCIENCE, V182, P53, DOI 10.1126/science.182.4107.53; CLARK RN, 1980, ICARUS, V44, P388, DOI 10.1016/0019-1035(80)90033-0; DEPATER I, 1984, ICARUS, V57, P93, DOI 10.1016/0019-1035(84)90011-3; DIANOVKLOKOV VI, 1962, OPT SPECTROSC, V13, P109; DOWELL LG, 1960, NATURE, V188, P1144, DOI 10.1038/1881144a0; GREENBLATT GD, 1990, J GEOPHYS RES-ATMOS, V95, P18577, DOI 10.1029/JD095iD11p18577; Grun E, 1996, NATURE, V381, P395, DOI 10.1038/381395a0; Gurnett DA, 1996, NATURE, V384, P535, DOI 10.1038/384535a0; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; HANSEN OL, 1973, ICARUS, V18, P237, DOI 10.1016/0019-1035(73)90208-X; JENNISKENS P, 1994, SCIENCE, V265, P753, DOI 10.1126/science.11539186; JOHNSON RE, 1997, ASTROPHYS J LETT, V480, P1; Kivelson MG, 1996, NATURE, V384, P537, DOI 10.1038/384537a0; LANDAU A, 1962, SPECTROCHIM ACTA, V18, P1; MATSON DL, 1989, ICARUS, V77, P67, DOI 10.1016/0019-1035(89)90007-9; MATSON DL, 1983, J GEOPHYS RES-SPACE, V88, P4771, DOI 10.1029/JA088iA06p04771; MAYER E, 1986, NATURE, V319, P298, DOI 10.1038/319298a0; Mishchenko MI, 1996, J QUANT SPECTROSC RA, V56, P673, DOI 10.1016/S0022-4073(96)00117-3; MORENO MA, 1991, ICARUS, V93, P63, DOI 10.1016/0019-1035(91)90164-O; MORRISON D, 1973, ICARUS, V18, P224, DOI 10.1016/0019-1035(73)90207-8; Noll KS, 1996, SCIENCE, V273, P341, DOI 10.1126/science.273.5273.341; Orton GS, 1996, SCIENCE, V274, P389, DOI 10.1126/science.274.5286.389; REIMANN CT, 1984, SURF SCI, V147, P227, DOI 10.1016/0039-6028(84)90177-8; SACK NJ, 1993, PHYS REV B, V48, P9973, DOI 10.1103/PhysRevB.48.9973; SACK NJ, 1991, J GEOPHYS RES-PLANET, V96, P17535, DOI 10.1029/91JE01681; SHI M, 1995, NUCL INSTRUM METH B, V96, P524, DOI 10.1016/0168-583X(95)00249-9; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; Urquhart ML, 1996, J GEOPHYS RES-PLANET, V101, P21169, DOI 10.1029/96JE02239; WESTLEY MS, 1995, PLANET SPACE SCI, V43, P1311, DOI 10.1016/0032-0633(95)00088-M; WESTLEY MS, 1995, NATURE, V373, P405, DOI 10.1038/373405a0; WONG MC, 1995, ICARUS, V115, P109, DOI 10.1006/icar.1995.1082; YUNG YL, 1977, ICARUS, V30, P97, DOI 10.1016/0019-1035(77)90124-5; [No title captured]; [No title captured]	41	55	55	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1839	1842		10.1126/science.276.5320.1839	http://dx.doi.org/10.1126/science.276.5320.1839			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188525				2022-12-28	WOS:A1997XF10300042
J	Reed, JC				Reed, JC			Double identity for proteins of the Bcl-2 family	NATURE			English	Article							CELL-DEATH; ENDOPLASMIC-RETICULUM; APOPTOSIS; ONCOPROTEIN	Bcl-2 is an oncogenic protein that acts by inhibiting programmed cell death. The mechanisms used by this and related anti-apoptotic proteins to protect cells from cytotoxic stimuli are now emerging, with the discovery that Bcl-2 can function both as an ion channel and as an adaptor or docking protein.			Reed, JC (corresponding author), BURNHAM INST,PROGRAM APOPTOSIS & CELL DEATH RES,10901 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							BAFFY G, 1993, J BIOL CHEM, V268, P6511; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Diaz JL, 1997, J BIOL CHEM, V272, P11350; HACKER G, 1995, CURR BIOL, V5, P622, DOI 10.1016/S0960-9822(95)00126-6; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HUANG DCS, IN PRESS EMBO J; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Middleton G, 1996, DEVELOPMENT, V122, P695; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MONTAL M, 1996, CURR OPIN STRUC BIOL, V6, P49; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; PIETENPOL JA, 1994, CANCER RES, V54, P3714; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SPECTOR MS, 1997, NATURE, V275, P1122; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	40	1333	1404	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 19	1997	387	6635					773	776		10.1038/42867	http://dx.doi.org/10.1038/42867			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF144	9194558				2022-12-28	WOS:A1997XF14400040
J	Foege, WH				Foege, WH			Public health and preventive medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Foege, WH (corresponding author), EMORY UNIV, ROLLINS SCH PUBL HLTH, ATLANTA, GA 30322 USA.							Foege WH, 1996, AM J EPIDEMIOL, V144, pS11, DOI 10.1093/aje/144.Supplement_8.S11; FRIEDE A, 1997, CDC PREVENTION GUIDE; Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; *TASK FORC CHILD S, 1996, 17 MERCK CO INC TASK; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; *WHO, 1995, N96 WHO DIV DIARRH A; 1997, AM J PREV MED    MAR	8	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1894	1895						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185822				2022-12-28	WOS:A1997XD54400041
J	Shuchman, M; Wilkes, MS				Shuchman, M; Wilkes, MS			Medical scientists and health news reporting: A case of miscommunication	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PUBLICATION BIAS; INGELFINGER RULE; PRESS; AUTHORSHIP; ATTITUDES; SCIENCE; CANCER	The public is poorly served by the coverage of medical science in the general press. Scientists and physicians blame the press, claiming that journalists are careless in their reporting, subject to competitive pressures, and ignorant of the scientific process. Journalists accuse the medical community of limiting access to information and erecting barriers to the public dissemination of medical research. In many areas of health news reporting, the underlying problem is an interactive dynamic that involves scientists and journalists. Both parties share the responsibility for accurate communication to the public. This report suggests ways to improve health news reporting, focusing on four problem areas: sensationalism, biases and conflicts of interest, lack of follow-up, and stories that are not covered.	SUNY BUFFALO, DEPT PSYCHIAT, ERIE CTY MED CTR, BUFFALO, NY 14215 USA; UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90095 USA; NATL PUBL RADIO, WEEKEND EDIT, WASHINGTON, DC USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of California System; University of California Los Angeles								Altman L.A., 1995, NY TIMES        0110, pB6; Altman L. K. (, 1994, NY TIMES, pA1; Altman LK, 1996, LANCET, V347, P1382, DOI 10.1016/S0140-6736(96)91016-8; ALTMAN LK, 1994, NY TIMES        0512, pA12; ANGELL M, 1993, ANN INTERN MED, V118, P646, DOI 10.7326/0003-4819-118-8-199304150-00015; ANGELL M, 1994, NEW ENGL J MED, V331, P189, DOI 10.1056/NEJM199407213310309; ANGELL M, 1991, NEW ENGL J MED, V325, P1371, DOI 10.1056/NEJM199111073251910; ANGELL M, 1996, SCI TRAIL CLASH MED, P154; [Anonymous], 1987, WALL STR J, P1; ANTON T, 1995, NEW SCI JOURNALISTS, P313; BARNETT HJM, 1995, ANN INTERN MED, V123, P723, DOI 10.7326/0003-4819-123-9-199511010-00012; BOGDANICH W, 1991, GREAT WHITE LIT AM H; BOGDANICH W, 1988, PULITZER PRIZES 1988, P499; BRENNAN TA, 1994, NEW ENGL J MED, V331, P673, DOI 10.1056/NEJM199409083311012; Brown D, 1996, ANN INTERN MED, V124, P255, DOI 10.7326/0003-4819-124-2-199601150-00010; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; Cohn V, 1989, NEWS NUMBERS GUIDE R; COWLEY G, 1995, NEWSWEEK        0807, P46; CREWDSON J, 1994, CHICAGO TRIBUNE 0313, P1; Deyo RA, 1997, NEW ENGL J MED, V336, P1176, DOI 10.1056/NEJM199704173361611; DICKERSIN K, 1993, ANN NY ACAD SCI, V703, P135, DOI 10.1111/j.1749-6632.1993.tb26343.x; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; Dong BJ, 1997, JAMA-J AM MED ASSOC, V277, P1205, DOI 10.1001/jama.277.15.1205; Eckert CH, 1997, JAMA-J AM MED ASSOC, V277, P1200, DOI 10.1001/jama.277.15.1200; EISNER JR, 1995, PHILADELPHIA IN 0319, pD7; ENTWISTLE V, 1995, BRIT MED J, V310, P920, DOI 10.1136/bmj.310.6984.920; Fallows J. M., 1996, BREAKING NEWS MEDIA; GREEN MS, 1994, JAMA-J AM MED ASSOC, V271, P1904, DOI 10.1001/jama.1994.03510480028013; HORTON R, 1995, LANCET, V346, P586, DOI 10.1016/S0140-6736(95)91429-3; HOUN F, 1995, AM J PUBLIC HEALTH, V85, P1082, DOI 10.2105/AJPH.85.8_Pt_1.1082; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1608, DOI 10.1056/NEJM199406023302211; KING RT, 1996, WALL STREET J   0425, P1; Kinsella James, 1989, COVERING PLAGUE AIDS; KLAIDMAN S, 1991, HLTH HEADLINES STORI; KOREN G, 1991, JAMA-J AM MED ASSOC, V266, P1824, DOI 10.1001/jama.266.13.1824; KOSHLAND DE, 1991, SCIENCE, V254, P629, DOI 10.1126/science.1948037; Kurtz H, 1991, WASH POST, pA10; Lamberg L, 1996, JAMA-J AM MED ASSOC, V276, P1011, DOI 10.1001/jama.276.13.1011; Lu B, 1996, NEW ENGL J MED, V335, P135; MACMAHON B, 1981, NEW ENGL J MED, V304, P630, DOI 10.1056/NEJM198103123041102; MCCLENEGHAN JS, 1994, SOC SCI J, V31, P467, DOI 10.1016/0362-3319(94)90036-1; MITTLER BS, 1995, FORBES MEDIACRITIC, V36, P72; Nelkin D., 1987, SELLING SCI PRESS CO; PARMLEY WW, 1995, J AM COLL CARDIOL, V26, P836, DOI 10.1016/0735-1097(95)93247-A; PERLMAN D, 1992, NEW ENGL J MED, V326, P957; PHILLIPS DP, 1991, NEW ENGL J MED, V325, P1180, DOI 10.1056/NEJM199110173251620; Pini P, 1995, LANCET, V346, P1681, DOI 10.1016/S0140-6736(95)92845-6; Pisetsky DS, 1996, ANN INTERN MED, V124, P345, DOI 10.7326/0003-4819-124-3-199602010-00013; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Reiter R. J., 1995, MELATONIN YOUR BODYS; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238; RENNIE D, 1994, JAMA-J AM MED ASSOC, V271, P469, DOI 10.1001/jama.271.6.469; Rosenberg SA, 1996, NEW ENGL J MED, V334, P392, DOI 10.1056/NEJM199602083340610; SCHUCHMAN M, 1995, NY TIMES        0707, V7, pA17; Senard JM, 1996, LANCET, V347, P987, DOI 10.1016/S0140-6736(96)90141-5; SQUIRES S, 1995, WASHINGTON POST 0608, pA1; Stryer DB, 1996, JAMA-J AM MED ASSOC, V275, P517, DOI 10.1001/jama.275.7.517; Sulmasy DP, 1996, J GEN INTERN MED, V11, P62, DOI 10.1007/BF02603494; VANTRIGT AM, 1994, SOC SCI MED, V38, P637, DOI 10.1016/0277-9536(94)90261-5; Wallack Lawrence., 1993, MEDIA ADVOCACY PUBLI; WILKES MS, 1995, J GEN INTERN MED, V10, P443, DOI 10.1007/BF02599916; WILKES MS, 1992, JAMA-J AM MED ASSOC, V268, P999, DOI 10.1001/jama.268.8.999; WILLS KJ, 1987, PULITZER PRIZES, V1, P468; WILTSE DW, 1992, B AM SOC NEWSPAPER E, V744, P28; Winsten J A, 1985, Health Aff (Millwood), V4, P5, DOI 10.1377/hlthaff.4.1.5; 1969, NEW ENGL J MED, V281, P676	66	88	90	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1997	126	12					976	982		10.7326/0003-4819-126-12-199706150-00008	http://dx.doi.org/10.7326/0003-4819-126-12-199706150-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE549	9182476				2022-12-28	WOS:A1997XE54900011
J	Hartl, DL				Hartl, DL			Microbiology - Mariner sails into Leishmania	SCIENCE			English	Editorial Material							TRANSPOSABLE ELEMENT MARINER; DROSOPHILA; TRANSPOSITION; INSECTS				Hartl, DL (corresponding author), HARVARD UNIV, DEPT ORGANISM & EVOLUTIONARY BIOL, CAMBRIDGE, MA 02138 USA.							AUGEGOUILLOU C, 1995, FEBS LETT, V368, P541, DOI 10.1016/0014-5793(95)00735-R; Capy P, 1996, J MOL EVOL, V42, P359, DOI 10.1007/BF02337546; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; FADOOL J, COMMUNICATION; GARCIAFERNANDEZ J, 1995, MOL BIOL EVOL, V12, P421; GARZA D, 1991, GENETICS, V128, P303; Gueiros FJ, 1997, SCIENCE, V276, P1716, DOI 10.1126/science.276.5319.1716; Hartl DL, 1997, TRENDS GENET, V13, P197, DOI 10.1016/S0168-9525(97)01087-1; JACOBSON JW, 1986, P NATL ACAD SCI USA, V83, P8684, DOI 10.1073/pnas.83.22.8684; Lohe AR, 1997, P NATL ACAD SCI USA, V94, P1293, DOI 10.1073/pnas.94.4.1293; Lohe AR, 1996, GENETICS, V143, P365; MARUYAMA K, 1991, J MOL EVOL, V33, P514, DOI 10.1007/BF02102804; MORGAN GT, 1995, J MOL BIOL, V254, P1, DOI 10.1006/jmbi.1995.0593; Reiter LT, 1996, NAT GENET, V12, P288, DOI 10.1038/ng0396-288; Robertson H.M., 1993, Insect Molecular Biology, V2, P125, DOI 10.1111/j.1365-2583.1993.tb00132.x; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; Robertson HM, 1996, NAT GENET, V12, P360, DOI 10.1038/ng0496-360	17	6	9	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	1997	276	5319					1659	1660		10.1126/science.276.5319.1659	http://dx.doi.org/10.1126/science.276.5319.1659			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9206830				2022-12-28	WOS:A1997XD94700029
J	Taddei, F; Radman, M; MaynardSmith, J; Toupance, B; Gouyon, PH; Godelle, B				Taddei, F; Radman, M; MaynardSmith, J; Toupance, B; Gouyon, PH; Godelle, B			Role of mutator alleles in adaptive evolution	NATURE			English	Article							ESCHERICHIA-COLI; POPULATIONS; STRAINS; COMPETITION; ADAPTATION; SELECTION	Because most newly arising mutations are neutral or deleterious, it has been argued(1-3) that the mutation rate has evolved to be as low as possible, limited only by the cost of error-avoidance and error-correction mechanisms, But up to one per cent of natural bacterial isolates are 'mutator' clones that have high mutation rates(4-6). We consider here whether high mutation rates might play an important role in adaptive evolution, Models of large, asexual, clonal populations adapting to a new environment show that strong mutator genes (such as those that increase mutation rates by 1,000-fold) can accelerate adaptation, even if the mutator gene remains at a very low frequency (for example, 10(-5)), Less potent mutators (10 to 100-fold increase) can become fixed in a fraction of finite populations, The parameters of the model have been set to values typical for Escherichia coli cultures, which behave in a manner similar to the model in long-term adaptation experiments(7).	UNIV SUSSEX,SCH BIOL SCI,MICROBIAL GENET GRP,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND; UNIV PARIS 11,CNRS,LAB EVOLUT & SYSTEMAT,F-91405 ORSAY,FRANCE; INST NATL AGRON PARIS GRIGNON,F-75005 PARIS,FRANCE; ECOLE NATL GENIE RURAL EAUX & FORETS,F-75732 PARIS,FRANCE	University of Sussex; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; AgroParisTech; UDICE-French Research Universities; Universite Paris Saclay	Taddei, F (corresponding author), UNIV PARIS 07,INST JACQUES MONOD,CNRS,LAB MUTAGENESE,2 PL JUSSIEU,F-75251 PARIS,FRANCE.		Gouyon, Pierre-Henri/A-9603-2013; Radman, Miroslav/HDM-5955-2022	Radman, Miroslav/0000-0003-0216-3148; TOUPANCE, Bruno/0000-0002-8244-1824; Radman, Miroslav/0000-0002-7034-4365				CHAO L, 1983, NATURE, V303, P633, DOI 10.1038/303633a0; CHAO L, 1983, EVOLUTION, V37, P125, DOI 10.1111/j.1558-5646.1983.tb05521.x; DAVID JL, 1993, HEREDITY, V71, P642, DOI 10.1038/hdy.1993.189; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; GROSS MD, 1981, MUTAT RES, V91, P107, DOI 10.1016/0165-7992(81)90081-6; Haraguchi Y, 1996, J THEOR BIOL, V183, P121, DOI 10.1006/jtbi.1996.9999; HARTL DL, 1984, ANNU REV GENET, V18, P31, DOI 10.1146/annurev.ge.18.120184.000335; ISHII K, 1989, GENETICS, V121, P163; JYSSUM K., 1960, ACTA PATHOL ET MICROBIOL SCAND, V48, P113; KIMURA M, 1967, GENET RES, V9, P23, DOI 10.1017/S0016672300010284; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; LEIGH EG, 1973, GENETICS, V73, P1; LEIGH EG, 1970, AM NAT, V104, P301, DOI 10.1086/282663; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; LIBERMAN U, 1986, THEOR POPUL BIOL, V30, P125, DOI 10.1016/0040-5809(86)90028-6; Magnasco MO, 1996, PHYS LETT A, V221, P287, DOI 10.1016/0375-9601(96)00599-3; Mao EF, 1997, J BACTERIOL, V179, P417, DOI 10.1128/jb.179.2.417-422.1997; Matic I, 1996, TRENDS MICROBIOL, V4, P69, DOI 10.1016/0966-842X(96)81514-9; MAYNARDSMITH J, 1993, P NATIONAL ACADEMY S, V90, P4384; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; NINIO J, 1991, GENETICS, V129, P957; PECK JR, 1994, GENETICS, V137, P597; Sniegowski PD, 1997, NATURE, V387, P703, DOI 10.1038/42701; TADDEI F, IN PRESS ENV STRESS; Tomlinson IPM, 1996, P NATL ACAD SCI USA, V93, P14800, DOI 10.1073/pnas.93.25.14800; TROBNER W, 1984, MOL GEN GENET, V198, P175, DOI 10.1007/BF00328719; TROBNER W, 1981, Z ALLG MIKROBIOL, V21, P347, DOI 10.1002/jobm.3630210412; TROBNER W, 1985, NATURWISSENSCHAFTEN, V72, P377, DOI 10.1007/BF00410603; Van Valen L., 1973, EVOL THEORY REV, V1, P1, DOI DOI 10.1038/344864A0	30	536	546	0	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					700	702		10.1038/42696	http://dx.doi.org/10.1038/42696			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192893	Bronze			2022-12-28	WOS:A1997XD86900052
J	Krumholz, HM; Murillo, JE; Chen, J; Vaccarino, V; Radford, MJ; Ellerbeck, EF; Wang, Y				Krumholz, HM; Murillo, JE; Chen, J; Vaccarino, V; Radford, MJ; Ellerbeck, EF; Wang, Y			Thrombolytic therapy for eligible elderly patients with acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WORCESTER-HEART-ATTACK; AGE; MORTALITY	Objective.-To determine the correlates of thrombolytic therapy use in a population-based sample of elderly patients hospitalized with acute myocardial infarction who were eligible for the therapy on presentation. Design.-Retrospective cohort study using data from medical charts and administrative files. Setting.-All acute care, nongovernmental hospitals in Connecticut. Patients.-A cohort of 3093 patients aged 65 years and older with a discharge diagnosis of acute myocardial infarction covered by Medicare from May 1992 to May 1993. Results.-Among the 753 patients with ST-segment elevation of 1 mm or more in at least 2 contiguous leads, left bundle branch block not known to be old, and no absolute contraindications to thrombolytic therapy who were not referred for direct angioplasty or bypass surgery, 419 patients (56%) did not receive thrombolytic therapy. The strongest predictors of not receiving thrombolytic therapy included advanced age, absence of chest pain, presentation more than 6 hours after the onset of symptoms, left bundle branch block, total ST-segment elevation of 6 mm or less, presence of Q waves, ST-segment elevation in only 2 leads, and altered mental status. Physicians documented why they did not administer thrombolytic therapy in 19% of the charts, Delay in presentation and increased age were the most common reasons cited, Among the subset of 261 patients who presented with chest pain and within 6 hours of symptoms, 197 (75%) received thrombolytic therapy. Conclusions.-Many eligible and ideal patients for thrombolytic therapy are not treated. Physicians are less likely to use thrombolytic therapy in eligible patients with characteristics associated with an increased risk of bleeding, lower-risk infarction, less certain diagnosis, less certain efficacy, or altered mental status, These findings suggest that the lack of treatment represents a clinical judgment rather than an inadvertent omission. in some cases, such as the lower use of thrombolytic therapy with older age, these judgments are not consistent with the published literature and may represent opportunities to improve care.	YALE UNIV, SCH MED, DEPT MED, SECT CARDIOVASC MED, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, SECT CHRON DIS EPIDEMIOL, NEW HAVEN, CT 06520 USA; YALE NEW HAVEN MED CTR, CTR OUTCOMES RES & EVALUAT, NEW HAVEN, CT 06504 USA; CONNECTICUT PEER REVIEW ORG, MIDDLETOWN, CT USA; UNIV CONNECTICUT, SCH MED, DEPT MED, DIV CARDIOL, FARMINGTON, CT USA; HLTH CARE FINANCING ADM, KANSAS CITY, MO USA	Yale University; Yale University; Yale University; University of Connecticut			Ellerbeck, Edward/I-8438-2014; , Harlan/AAI-2875-2020	Ellerbeck, Edward/0000-0002-7774-2729; Radford, Martha/0000-0001-7503-9557				APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Arnold AER, 1995, EUR HEART J, V16, P1502, DOI 10.1093/oxfordjournals.eurheartj.a060770; BAYER AJ, 1986, J AM GERIATR SOC, V34, P263, DOI 10.1111/j.1532-5415.1986.tb04221.x; COX DA, 1994, AM J CARDIOL, V73, P729, DOI 10.1016/0002-9149(94)90872-9; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FURBERG CD, 1992, AM J CARDIOL, V69, P1329, DOI 10.1016/0002-9149(92)91231-R; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; *GRP IT STUD STREP, 1986, LANCET, V1, P397; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; Gurwitz Jerry H., 1994, Archives of Internal Medicine, V154, P2202, DOI 10.1001/archinte.154.19.2202; Gurwitz JH, 1996, ANN INTERN MED, V124, P283, DOI 10.7326/0003-4819-124-3-199602010-00001; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOSMER DW, 1989, APPL LOGISTIC REGRES; *ISIS I COLL GROUP, 1988, LANCET, V2, P849; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; LANDWEHR JM, 1984, J AM STAT ASSOC, V79, P61, DOI 10.2307/2288334; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Sgarbossa EB, 1996, NEW ENGL J MED, V334, P481, DOI 10.1056/NEJM199602223340801; *US DEP HHS, 1988, INT CLASS DIS 9 REV; Vorchheimer David A., 1996, Journal of the American College of Cardiology, V27, p389A; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7	23	144	147	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1683	1688		10.1001/jama.277.21.1683	http://dx.doi.org/10.1001/jama.277.21.1683			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169894				2022-12-28	WOS:A1997XB08800028
J	Komori, T; Yagi, H; Nomura, S; Yamaguchi, A; Sasaki, K; Deguchi, K; Shimizu, Y; Bronson, RT; Gao, YH; Inada, M; Sato, M; Okamoto, R; Kitamura, Y; Yoshiki, S; Kishimoto, T				Komori, T; Yagi, H; Nomura, S; Yamaguchi, A; Sasaki, K; Deguchi, K; Shimizu, Y; Bronson, RT; Gao, YH; Inada, M; Sato, M; Okamoto, R; Kitamura, Y; Yoshiki, S; Kishimoto, T			Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts	CELL			English	Article							COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; IN-SITU HYBRIDIZATION; TRANSCRIPTION FACTOR; ALKALINE-PHOSPHATASE; INSITU HYBRIDIZATION; MESSENGER-RNA; RUNT DOMAIN; DEVELOPMENTAL EXPRESSION; SPARC OSTEONECTIN	A transcription factor, Cbfa1, which belongs to the rent-domain gene family, is expressed restrictively in fetal development. To elucidate the function of Cbfa1, we generated mice with a mutated Cbfa1 locus. Mice with a homozygous mutation in Cbfa1 died just after birth without breathing. Examination of their skeletal systems showed a complete lack of ossification. Although immature osteoblasts, which expressed alkaline phophatase weakly but not Osteopontin and Osteocalcin, and a few immature osteoclasts appeared at the perichondrial region, neither vascular nor mesenchymal cell invasion was observed in the cartilage. Therefore, our data suggest that both intramembranous and endochondral ossification were completely blocked, owing to the maturational arrest of osteoblasts in the mutant mice, and demonstrate that Cbfa1 plays an essential role in osteogenesis.	OSAKA UNIV,SCH MED,DEPT PATHOL,SUITA,OSAKA 565,JAPAN; SHOWA UNIV,SCH DENS,DEPT ORAL PATHOL,SHINAGAWA KU,TOKYO 142,JAPAN; TUFTS UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02111; TUFTS UNIV,SCH VET MED,BOSTON,MA 02111; OSAKA CITY UNIV,SCH MED,DEPT ANAT 1,ABENO KU,OSAKA 545,JAPAN	Osaka University; Showa University; Tufts University; Tufts University; Osaka Metropolitan University	Komori, T (corresponding author), OSAKA UNIV,SCH MED,DEPT MED 3,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.		Kishimoto, Tadamitsu/C-8470-2009	Yagi, Hideshi/0000-0002-8506-8965				Aubin Jane E., 1993, P1; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; BRONCKERS ALJJ, 1987, BONE MINER, V2, P361; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; CHEN J, 1991, HISTOCHEM J, V23, P281, DOI 10.1007/BF01045047; COPRAY JCVM, 1989, J ANAT, V162, P43; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Frank R, 1995, ONCOGENE, V11, P2667; FRANZEN A, 1989, MATRIX, V9, P261, DOI 10.1016/S0934-8832(89)80001-0; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; HALE JE, 1988, J BIOL CHEM, V263, P5820; HALLBERG B, 1992, NUCLEIC ACIDS RES, V20, P6495, DOI 10.1093/nar/20.24.6495; HIRAKAWA K, 1994, J BONE MINER RES, V9, P1551; HIROTA S, 1994, CELL TISSUE RES, V277, P27, DOI 10.1007/BF00303077; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; IBARAKI K, 1992, J BONE MINER RES, V7, P743; IKEDA T, 1992, J HISTOCHEM CYTOCHEM, V40, P1079, DOI 10.1177/40.8.1619274; JARVIS JL, 1974, AM J ROENTGENOL, V121, P5, DOI 10.2214/ajr.121.1.5; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; KODAMA H, 1991, J EXP MED, V173, P1291, DOI 10.1084/jem.173.5.1291; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322; MARK MP, 1988, DIFFERENTIATION, V37, P123, DOI 10.1111/j.1432-0436.1988.tb00804.x; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1996, ANN NY ACAD SCI, V785, P301, DOI 10.1111/j.1749-6632.1996.tb56290.x; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; NODA M, 1987, J BONE MINER RES, V2, P161; NOMURA S, 1993, ACTA HISTOCHEM CYTOC, V26, P303, DOI 10.1267/ahc.26.303; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RODAN GA, 1988, CIBA F SYMP, V136, P78; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; SOMERMAN MJ, 1987, J BONE MINER RES, V2, P259; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WARGNIER A, 1995, P NATL ACAD SCI USA, V92, P6930, DOI 10.1073/pnas.92.15.6930; WEINREB M, 1990, J BONE MINER RES, V5, P831; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	65	3440	3594	5	159	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					755	764		10.1016/S0092-8674(00)80258-5	http://dx.doi.org/10.1016/S0092-8674(00)80258-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182763	Bronze			2022-12-28	WOS:A1997XB92500012
J	Dietrich, FS; Mulligan, J; Hennessy, K; Yelton, MA; Allen, E; Araujo, R; Aviles, E; Berno, A; Brennan, T; Carpenter, J; Chen, E; Cherry, JM; Chung, E; Duncan, M; Guzman, E; Hartzell, G; HunickeSmith, S; Hyman, RW; Kayser, A; Komp, C; Lashkari, D; Lew, H; Lin, D; Mosedale, D; Nakahara, K; Namath, A; Norgren, R; Oefner, P; Oh, C; Petel, FX; Roberts, D; Sehl, P; Schramm, S; Shogren, T; Smith, V; Taylor, P; Wei, Y; Botstein, D; Davis, RW				Dietrich, FS; Mulligan, J; Hennessy, K; Yelton, MA; Allen, E; Araujo, R; Aviles, E; Berno, A; Brennan, T; Carpenter, J; Chen, E; Cherry, JM; Chung, E; Duncan, M; Guzman, E; Hartzell, G; HunickeSmith, S; Hyman, RW; Kayser, A; Komp, C; Lashkari, D; Lew, H; Lin, D; Mosedale, D; Nakahara, K; Namath, A; Norgren, R; Oefner, P; Oh, C; Petel, FX; Roberts, D; Sehl, P; Schramm, S; Shogren, T; Smith, V; Taylor, P; Wei, Y; Botstein, D; Davis, RW			The nucleotide sequence of Saccharomyces cerevisiae chromosome V	NATURE			English	Article							PHYSICAL MAPS; GENE; YEAST	Here we report the sequence of 569,202 base pairs of Saccharomyces cerevisiae chromosome V. Analysis of the sequence revealed a centromere, two telomeres and 271 open reading frames (ORFs) plus 13 tRNAs and four small nuclear RNAs. There are two Ty1 transposable elements, each of which contains an ORF (included in the count of 271). Of the ORFs, 78 (29%) are new, 81 (30%) have potential homologues in the public databases, and 112 (41%) are previously characterized yeast genes.	STANFORD DNA SEQUENCING & TECHNOL CTR,PALO ALTO,CA 94304; STANFORD UNIV,SCH MED,DEPT BIOCHEM,PALO ALTO,CA 94305; STANFORD UNIV,SCH MED,DEPT GENET,PALO ALTO,CA 94305	Stanford University; Stanford University; Stanford University			Tuluc, Petronel/C-2527-2011; Oh, Chulmin/ABB-6024-2021	Cherry, J. Michael/0000-0001-9163-5180	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000205] Funding Source: NIH RePORTER; NHGRI NIH HHS [P01 HG000205, P01 HG000205-11] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; FLEER R, 1987, MOL CELL BIOL, V7, P1180, DOI 10.1128/MCB.7.3.1180; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GLEESON TJ, 1991, COMPUT APPL BIOSCI, V7, P398; LASHKARI DA, 1995, P NATL ACAD SCI USA, V92, P7912, DOI 10.1073/pnas.92.17.7912; LOUIS EJ, 1994, GENETICS, V136, P789; LOUIS EJ, 1992, GENETICS, V131, P559; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; Oefner PJ, 1996, NUCLEIC ACIDS RES, V24, P3879, DOI 10.1093/nar/24.20.3879; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RILES L, 1993, GENETICS, V134, P81; SMITH TF, 1985, NUCLEIC ACIDS RES, V13, P645, DOI 10.1093/nar/13.2.645; STILES JI, 1981, J MOL BIOL, V148, P331, DOI 10.1016/0022-2836(81)90179-0; WEBER E, 1990, MOL MICROBIOL, V4, P585, DOI 10.1111/j.1365-2958.1990.tb00627.x	16	37	368	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632		S			78	81		10.1038/387s078	http://dx.doi.org/10.1038/387s078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169868				2022-12-28	WOS:A1997XB54600008
J	Nalbantoglu, J; TiradoSantiago, G; Lahsaini, A; Poirier, J; Goncalves, O; Verge, A; Momoli, F; Welner, SA; Massicotte, G; Julien, JP; Shapiro, ML				Nalbantoglu, J; TiradoSantiago, G; Lahsaini, A; Poirier, J; Goncalves, O; Verge, A; Momoli, F; Welner, SA; Massicotte, G; Julien, JP; Shapiro, ML			Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein	NATURE			English	Article							BETA-PROTEIN; TRANSGENIC MICE; WATER-MAZE; DISEASE; NEURONS; DERIVATIVES; HIPPOCAMPUS; CHANNELS; PEPTIDE; CELLS	Proteolytic processing of amyloid precursor protein (APP) through an endosomal/lysosomal pathway generates carboxyterminal polypeptides that contain an intact beta-amyloid domain(1-3). Cleavage by as-yet unidentified proteases releases the beta-amyloid peptide in soluble form(4-6). In Alzheimer's disease, aggregated beta-amyloid is deposited in extracellular neuritic plaques. Although most of the molecular mechanisms involving beta-amyloid and APP in the aetiology of Alzheimer's disease are still unclear, changes in APP metabolism maybe important in the pathogenesis of the disease, Here we show that transgenic mice expressing the amyloidogenic carboxy-terminal 104 amino acids of APP develop, with ageing, extracellular beta-amyloid immunoreactivity, increased gliosis and microglial reactivity, as well as cell loss in the CA1 region of the hippocampus. Adult transgenic mice demonstrate spatial-learning deficits in the Morris water maze and in maintenance of long-term potentiation (LTP). Our results indicate that alterations in the processing of APP may have considerable physiological effects on synaptic plasticity.	MCGILL UNIV,DEPT PSYCHOL,MONTREAL,PQ H3A 2B4,CANADA; MCGILL UNIV,DEPT PSYCHIAT,MONTREAL,PQ H3A 2B4,CANADA; MCGILL UNIV,MCGILL CTR STUDIES AGING,MONTREAL,PQ H3A 2B4,CANADA; MONTREAL NEUROL HOSP & INST,MONTREAL,PQ H3A 2B4,CANADA; UNIV QUEBEC,TROIS RIVIERES,PQ G9A 5H7,CANADA; MONTREAL GEN HOSP,CTR NEUROSCI,MONTREAL,PQ H3G 1A4,CANADA	McGill University; McGill University; McGill University; McGill University; University of Quebec; University of Quebec Trois Rivieres; McGill University	Nalbantoglu, J (corresponding author), MCGILL UNIV,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA.							ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; ElKhoury J, 1996, NATURE, V382, P716; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HYMAN BT, 1992, PROG CLIN BIOL RES, V379, P123; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SKELTON RW, 1992, HIPPOCAMPUS, V2, P73, DOI 10.1002/hipo.450020110; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	30	295	311	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					500	505		10.1038/387500a0	http://dx.doi.org/10.1038/387500a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168112				2022-12-28	WOS:A1997XB47900048
J	McQuay, H; Moore, A; Justins, D				McQuay, H; Moore, A; Justins, D			Fortnightly review: Treating acute pain in hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MANAGEMENT; ANALGESIA		ST THOMAS HOSP, DEPT ANAESTHESIA, LONDON SE1 7EH, ENGLAND; CHURCHILL HOSP, PAIN RELIEF UNIT, OXFORD OX3 7LJ, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of Oxford								ATTARD AR, 1992, BRIT MED J, V305, P554, DOI 10.1136/bmj.305.6853.554; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BRIDENBAUGH PO, 1988, NEURAL BLOCKADE CLIN, P695; BRUSTER S, 1994, BRIT MED J, V309, P1542, DOI 10.1136/bmj.309.6968.1542; *BURF NURS DEV UN, 1984, NURS TIMES, V18, P94; Carroll D, 1997, BRIT J OBSTET GYNAEC, V104, P169, DOI 10.1111/j.1471-0528.1997.tb11039.x; Carroll D, 1996, BRIT J ANAESTH, V77, P798, DOI 10.1093/bja/77.6.798; Clinical Standards Advisory Group on Back Pain, 1994, BACK PAIN; GOULD TH, 1992, BRIT MED J, V305, P1187, DOI 10.1136/bmj.305.6863.1187; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; Jadad AR, 1996, PAIN, V66, P239, DOI 10.1016/0304-3959(96)03033-3; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; JUSTINS DM, 1991, BRIT MED BULL, V47, P561, DOI 10.1093/oxfordjournals.bmb.a072493; KANE RE, 1981, ANESTH ANALG, V60, P150; Koes BW, 1995, PAIN, V63, P279, DOI 10.1016/0304-3959(95)00124-7; MCGRATH PJ, 1993, PIAN MANAGEMENT NURS, P100; MCQUAY HJ, 1988, PAIN, V33, P291, DOI 10.1016/0304-3959(88)90287-4; MCQUAY HJ, 1995, ANN MED, V27, P249, DOI 10.3109/07853899509031967; MCQUAY HJ, 1994, TXB PAIN, P1025; Moore A, 1996, PAIN, V66, P229, DOI 10.1016/0304-3959(96)03032-1; MOORE A, IN PRESS PAIN; Moore RA, 1997, PAIN, V69, P287, DOI 10.1016/S0304-3959(96)03291-5; NAGLE C, 1990, CURR ANAESTH CRIT CA, V1, P247; PORTER J, 1980, NEW ENGL J MED, V302, P123; RAWAL N, 1994, PAIN, V57, P117, DOI 10.1016/0304-3959(94)90115-5; READY LB, 1988, ANESTHESIOLOGY, V68, P100, DOI 10.1097/00000542-198801000-00016; SZETO HH, 1977, ANN INTERN MED, V86, P738, DOI 10.7326/0003-4819-86-6-738; vanderHeijden GJMG, 1996, BRIT J GEN PRACT, V46, P309; WATTS RW, 1995, ANAESTH INTENS CARE, V23, P564, DOI 10.1177/0310057X9502300506; *WORK PART PAIN SU, 1990, REP	31	82	84	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	1997	314	7093					1531	1535		10.1136/bmj.314.7093.1531	http://dx.doi.org/10.1136/bmj.314.7093.1531			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9183203	Green Published			2022-12-28	WOS:A1997XB48400030
J	Moghaddam, A; Rosenzweig, M; LeeParritz, D; Annis, B; Johnson, RP; Wang, F				Moghaddam, A; Rosenzweig, M; LeeParritz, D; Annis, B; Johnson, RP; Wang, F			An animal model for acute and persistent Epstein-Barr virus infection	SCIENCE			English	Article							HERPESVIRUS PAPIO; MALIGNANT-LYMPHOMA; REPLICATION; ACTIVATION; EXPRESSION; SEQUENCE; ORIGIN; CELLS; DNA	Epstein-Barr virus (EBV) is a human lymphocryptovirus that causes infectious mononucleosis, persists asymptomatically for life in nearly all adults, and is associated with the development of B cell lymphomas and nasopharyngeal carcinomas. A highly similar rhesus lymphocryptovirus naturally endemic in rhesus monkeys was used to orally inject naive animals from a pathogen-free colony. This animal model reproduced key aspects of human EBV injection, including oral transmission, atypical lymphocytosis, lymphadenopathy, activation of CD23(+) peripheral blood B cells, sustained serologic responses to lytic and latent EBV antigens, latent infection in the peripheral blood, and virus persistence in oropharyngeal secretions. This system may be useful for studying the pathogenesis, prevention, and treatment of EBV infection and associated oncogenesis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,NEW ENGLAND REG PRIMATE RES CTR,SCH MED,DIV IMMUNOL,SOUTHBOROUGH,MA 01172; HARVARD UNIV,NEW ENGLAND REG PRIMATE RES CTR,SCH MED,DIV PRIMATE RESOURCES,SOUTHBOROUGH,MA 01172; HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,AIDS RES CTR,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,CHARLESTOWN,MA 02129	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital					NCI NIH HHS [CA65319, CA68051] Funding Source: Medline; NCRR NIH HHS [P51RR00168] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068051, R01CA065319] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABLASHI DV, 1979, COMP IMMUNOL MICROB, V2, P229, DOI 10.1016/0147-9571(79)90011-0; Alfieri C, 1996, BLOOD, V87, P812, DOI 10.1182/blood.V87.2.812.bloodjournal872812; DANIEL MD, 1988, INT J CANCER, V41, P601, DOI 10.1002/ijc.2910410421; DUNKEL VC, 1972, J NATL CANCER I, V49, P435; FEICHTINGER H, 1992, J EXP MED, V176, P281, DOI 10.1084/jem.176.1.281; Frank A, 1976, Adv Cancer Res, V23, P171, DOI 10.1016/S0065-230X(08)60546-1; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; FRANKEN M, 1995, J VIROL, V69, P8011, DOI 10.1128/JVI.69.12.8011-8019.1995; FURUKAWA S, 1992, J INFECT DIS, V166, P691, DOI 10.1093/infdis/166.3.691; GERBER P, 1977, INT J CANCER, V20, P448, DOI 10.1002/ijc.2910200318; GERBER P, 1969, P SOC EXP BIOL MED, V130, P14, DOI 10.3181/00379727-130-33478; GRATAMA JW, 1989, TRANSPLANT P, V21, P307; HELLER M, 1981, J VIROL, V37, P698, DOI 10.1128/JVI.37.2.698-709.1981; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HESTON L, 1982, NATURE, V295, P160, DOI 10.1038/295160a0; KALTER SS, 1972, NATURE, V238, P353, DOI 10.1038/238353a0; Kieff E, 1996, VIROLOGY, P2343; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; LEVINE MD, 1980, PEDIATRICS, V66, P341; LEVY JA, 1971, NATURE, V233, P559, DOI 10.1038/233559a0; LING PD, 1995, J VIROL, V69, P1944, DOI 10.1128/JVI.69.3.1944-1950.1995; LOEB DD, 1990, J VIROL, V64, P2876, DOI 10.1128/JVI.64.6.2876-2883.1990; MOGHADDAM A, UNPUB; MOSIER DE, 1990, CURR TOP MICROBIOL, V166, P317; RANGAN SRS, 1986, INT J CANCER, V38, P425, DOI 10.1002/ijc.2910380319; Rickinson AB, 1996, VIROLOGY, P2397; RYON JJ, 1993, J VIROL, V67, P4006, DOI 10.1128/JVI.67.7.4006-4016.1993; SHOPE T, 1973, P NATL ACAD SCI USA, V70, P2487, DOI 10.1073/pnas.70.9.2487; THORLEYLAWSON DA, 1985, J IMMUNOL, V134, P3007; YAO QY, 1985, INT J CANCER, V35, P35, DOI 10.1002/ijc.2910350107; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	31	142	147	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2030	2033		10.1126/science.276.5321.2030	http://dx.doi.org/10.1126/science.276.5321.2030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197263				2022-12-28	WOS:A1997XG74800061
J	Caskey, CT				Caskey, CT			Medical genetics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Caskey, CT (corresponding author), MERCK RES LABS,W POINT,PA 19486, USA.							Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Lapham EV, 1996, SCIENCE, V274, P621, DOI 10.1126/science.274.5287.621; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; *SCAND SIMV SURV S, 1994, LANCET, V344, P1383; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Timchenko LT, 1996, FASEB J, V10, P1589, DOI 10.1096/fasebj.10.14.9002550; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	18	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1869	1870						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185807				2022-12-28	WOS:A1997XD54400026
J	Reinhardt, UE				Reinhardt, UE			Economies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Reinhardt, UE (corresponding author), PRINCETON UNIV,PRINCETON,NJ 08544, USA.							ADELSON A, 1997, NY TIMES        0405, P35; Azevedo D, 1997, Med Econ, V74, P194	2	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1850	1851						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD544	9185796				2022-12-28	WOS:A1997XD54400015
J	Yoshida, T; Terada, M				Yoshida, T; Terada, M			Oncology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Yoshida, T (corresponding author), NATL CANC CTR,RES INST,TOKYO 104,JAPAN.							Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHEN QX, 1996, NAT MED, V2, P1033; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAHNE M, 1996, SCIENCE, V274, P1368; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Schutte M, 1996, CANCER RES, V56, P2527; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8	18	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1880	1881						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185814				2022-12-28	WOS:A1997XD54400033
J	Hughes, MD; Johnson, VA; Hirsch, MS; Bremer, JW; Elbeik, T; Erice, A; Kuritzkes, DR; Scott, WA; Spector, SA; Basgoz, N; Fischl, MA; DAquila, RT				Hughes, MD; Johnson, VA; Hirsch, MS; Bremer, JW; Elbeik, T; Erice, A; Kuritzkes, DR; Scott, WA; Spector, SA; Basgoz, N; Fischl, MA; DAquila, RT			Monitoring plasma HIV-1 RNA levels in addition to CD4(+) lymphocyte count improves assessment of antiretroviral therapeutic response	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; TYPE-1 RNA; INFECTION; ASSAY; AIDS; QUANTIFICATION; QUANTITATION; PROGRESSION; PCR	Background: CD4(+) lymphocyte counts and plasma HIV-1 RNA levels predict progression of HIV-related disease, but the relative importance of these and other virological factors in defining response to antiretroviral therapy is not yet clear. Objective: To determine the short-term variability of plasma HIV-1 RNA level during stable therapy; the relative importance of pretreatment values and early changes in CD4(+) count, HIV-1 RNA levels, and infectious HIV-1 titers in mononuclear cells of peripheral blood and pretreatment syncytium-inducing phenotype of an HIV-1 isolate for prediction of disease progression and decline in CD4(+) counts during therapy. Design: Data were collected prospectively in a randomized, clinical trial comparing two combination regimens (ACTG [AIDS Clinical Trials Group] Protocol 241) and pooled across treatments. Setting: 8 AIDS Clinical Trials Units. Patients: 198 adults with HIV-1 infection and no more than 350 CD4(+) lymphocytes/mm(3) who had received at least 6 months of nucleoside therapy. Interventions: All patients received zidovudine and didanosine; 100 received nevirapine and 98 received placebo. Measurements: CD4(+) lymphocyte counts, plasma HIV-1 RNA levels, and infectious HIV-1 titers in cells were measured before and 8 and 48 weeks after study treatment. Assay for the syncytium-inducing viral phenotype was done at baseline. Progression was defined as occurrence of opportunistic infection, malignancy, or death during the 48 weeks after treatment began. Results: The difference between two measurements of HIV-1 RNA levels at baseline was within +/-0.39 log(10) copies/mL (2.5-fold) for 90% of 167 patients receiving stable therapy. In a multivariate model, risk for disease progression was reduced by 56% (95% CI, 8% to 79% [P = 0.028]) for every 10-fold lower HIV-1 RNA level at baseline, by 52% (CI, 6% increase to 79% reduction [P = 0.071]) for every 10-fold reduction in HIV-1 RNA level at 8 weeks after treatment initiation, and by 67% (CI, 42% to 81% [P < 0.001]) for every 2-fold higher CD4(+) count at baseline. These risk factors and syncytium-inducing viral phenotype at baseline, but not infectious HIV-1 titers in circulating cells, were associated with change in CD4(+) counts over 48 weeks. Conclusions: For an individual patient, a change in plasma HIV-1 RNA level of 2.5-fold or more probably indicates a true biological change. Monitoring HIV-I RNA levels and CD4(+) lymphocytes before a change in antiretroviral treatment and monitoring HIV-1 RNA levers shortly thereafter improves prediction of disease progression and decline in CD4(+) counts for 1 year compared with monitoring CD4(+) counts or HIV-1 RNA levels alone. Additional monitoring of infectious HIV-1 titers in mononuclear cells of peripheral blood is not useful.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH PUBL HLTH, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH MED, CAMBRIDGE, MA 02138 USA; VET AFFAIRS MED CTR, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH MED, BIRMINGHAM, AL 35294 USA; RUSH MED COLL, CHICAGO, IL 60612 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; UNIV MINNESOTA, SCH MED, CTR HLTH, MINNEAPOLIS, MN 55455 USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80262 USA; UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOL BIOL, MIAMI, FL 33101 USA; UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA; VET AFFAIRS MED CTR, DENVER, CO USA	Harvard University; Harvard T.H. Chan School of Public Health; Massachusetts General Hospital; Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Alabama System; University of Alabama Birmingham; Rush University; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Miami; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Hughes, MD (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, MED STAT UNIT, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.			Elbeik, Tarek/0000-0001-5983-0867	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029193, U01AI027675, U01AI027661] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27675, AI-29193, AI-27661] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMITAGE P, 1994, STAT METHODS MED RES, P219; CALVELLI T, 1993, CYTOMETRY, V14, P702, DOI 10.1002/cyto.990140703; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CLAYTON D, 1993, STAT MODELS EPIDEMIO, P229; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; COX DR, 1972, J R STAT SOC B, V34, P187; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; DRAPER NR, 1981, APPLIED REGRESSION A, P70; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; GELMAN R, 1993, CLIN IMMUNOL IMMUNOP, V66, P150, DOI 10.1006/clin.1993.1019; GUPTA P, 1993, VIROLOGY, V196, P586, DOI 10.1006/viro.1993.1514; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; HOLODNIY M, 1991, J INFECT DIS, V163, P862, DOI 10.1093/infdis/163.4.862; HOOPER CJ, 1995, 35 INT C ANT AG CHEM, P1152; JAPOUR AJ, 1994, J CLIN MICROBIOL, V32, P2291, DOI 10.1128/JCM.32.9.2291-2294.1994; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; Levy JA, 1996, SCIENCE, V271, P670, DOI 10.1126/science.271.5249.670; LIN HJ, 1994, J INFECT DIS, V170, P553, DOI 10.1093/infdis/170.3.553; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Phillips AN, 1996, AIDS, V10, P859, DOI 10.1097/00002030-199607000-00009; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; WATHEN LK, 1996, 3 C RETR OPP INFECT; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Welles SL, 1996, J INFECT DIS, V174, P696, DOI 10.1093/infdis/174.4.696; 1987, MMWR MORB MORTAL S1, V36, pS1	37	230	240	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1997	126	12					929	938		10.7326/0003-4819-126-12-199706150-00001	http://dx.doi.org/10.7326/0003-4819-126-12-199706150-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE549	9182469				2022-12-28	WOS:A1997XE54900004
J	Bonini, C; Ferrari, G; Verzeletti, S; Servida, P; Zappone, E; Ruggieri, L; Ponzoni, M; Rossini, S; Mavilio, F; Traversari, C; Bordignon, C				Bonini, C; Ferrari, G; Verzeletti, S; Servida, P; Zappone, E; Ruggieri, L; Ponzoni, M; Rossini, S; Mavilio, F; Traversari, C; Bordignon, C			HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia	SCIENCE			English	Article							BONE-MARROW TRANSPLANTATION; CHRONIC MYELOGENOUS LEUKEMIA; PERIPHERAL-BLOOD LYMPHOCYTES; CHRONIC MYELOID-LEUKEMIA; HOST DISEASE; LEUKOCYTE TRANSFUSIONS; CELL DEPLETION; THERAPY; RELAPSE; IMMUNOTHERAPY	In allogeneic bone marrow transplantation (allo-BMT), donor lymphocytes play a central therapeutic role in both graft-versus-leukemia (GvL) and immune reconstitution. However, their use is limited by the risk of severe graft-versus-host disease (GVHD). Eight patients who relapsed or developed Epstein-Barr virus-induced lymphoma after T cell-depleted BMT were then treated with donor lymphocytes transduced with the herpes simplex virus thymidine kinase (HSV-TK) suicide gene. The transduced lymphocytes survived for up to 12 months, resulting in antitumor activity in five patients. Three patients developed GVHD, which could be effectively controlled by ganciclovir-induced elimination of the transduced cells. These data show that genetic manipulation of donor lymphocytes may increase the efficacy and safety of allo-BMT and expand its application to a larger number of patients.	IST SCI SAN RAFFAELE,TELETHON INST GENE THERAPY,I-20132 MILAN,ITALY; MOLMED SPA,I-20132 MILAN,ITALY; IST SCI SAN RAFFAELE,DEPT PATHOL,I-20132 MILAN,ITALY	Fondazione Telethon; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			Ferrari, Giuliana/AAB-5546-2019; bonini, chiara/I-9202-2012	Ferrari, Giuliana/0000-0003-0790-3133; BONINI, Maria Chiara/0000-0002-0772-1674	Telethon [TGT95000, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; BORDIGNON C, 1995, HUM GENE THER, V6, P813, DOI 10.1089/hum.1995.6.6-813; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; CHENG YC, 1983, P NATL ACAD SCI-BIOL, V80, P2767, DOI 10.1073/pnas.80.9.2767; CULVER KW, 1994, HUM GENE THER, V5, P343, DOI 10.1089/hum.1994.5.3-343; CULVER KW, 1991, HUM GENE THER, V2, P107, DOI 10.1089/hum.1991.2.2-107; DROBYSKI WR, 1993, BLOOD, V82, P2310; FABER LM, 1995, BLOOD, V86, P2821; FERRARI G, 1991, SCIENCE, V251, P1363, DOI 10.1126/science.1848369; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GIRALT SA, 1994, BLOOD, V84, P3603, DOI 10.1182/blood.V84.11.3603.bloodjournal84113603; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; HOROWITZ MM, 1990, BLOOD, V75, P555; KERNAN NA, 1989, BLOOD, V74, P2227; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; KOLB HJ, COMMUNICATION; MACKINNON S, 1995, BLOOD, V86, P1261, DOI 10.1182/blood.V86.4.1261.bloodjournal8641261; MARSHALL E, 1995, SCIENCE, V270, P1751, DOI 10.1126/science.270.5243.1751; MAVILIO F, 1994, BLOOD, V83, P1988; MOOLTEN FL, 1990, HUM GENE THER, V1, P125, DOI 10.1089/hum.1990.1.2-125; MOOLTEN FL, 1994, CANCER GENE THER, V1, P279; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; OREILLY R, 1993, CURR OPIN HEMATOL, V1, P221; Organization W.H, 1979, WHO HDB REP RES CANC; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; PORTER DL, 1994, NEW ENGL J MED, V330, P100, DOI 10.1056/NEJM199401133300204; RIDDELL SR, 1992, SCIENCE, V257, P238; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; Slavin S, 1996, BLOOD, V87, P2195, DOI 10.1182/blood.V87.6.2195.bloodjournal8762195; SZER J, 1993, BONE MARROW TRANSPL, V11, P109; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TIBERGHIEN P, 1994, BLOOD, V84, P1333; TRAVERSARI C, UNPUB; Tricot G, 1996, BLOOD, V87, P1196, DOI 10.1182/blood.V87.3.1196.bloodjournal8731196; VANRHEE F, 1994, BLOOD, V83, P3377; VERZELETTI S, UNPUB; VOGELSANG GB, 1994, BLOOD, V84, P2061, DOI 10.1182/blood.V84.7.2061.bloodjournal8472061; WALDMANN H, 1994, CURR OPIN IMMUNOL, V6, P777, DOI 10.1016/0952-7915(94)90084-1; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603	41	960	1032	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1719	1724		10.1126/science.276.5319.1719	http://dx.doi.org/10.1126/science.276.5319.1719			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180086				2022-12-28	WOS:A1997XD94700049
J	Smith, LEH; Kopchick, JJ; Chen, W; Knapp, J; Kinose, F; Daley, D; Foley, E; Smith, RG; Schaeffer, JM				Smith, LEH; Kopchick, JJ; Chen, W; Knapp, J; Kinose, F; Daley, D; Foley, E; Smith, RG; Schaeffer, JM			Essential role of growth hormone in ischemia-induced retinal neovascularization	SCIENCE			English	Article							TRANSGENIC MICE; DIABETIC-RETINOPATHY; IGF-I; SOMATOSTATIN ANALOG; MOUSE; BINDING; PHOTOCOAGULATION; OCTREOTIDE; EXPRESSION; INHIBITION	Retinal neovascularization is the major cause of untreatable blindness, The role of growth hormone (GH) in ischemia-associated retinal neovascularization was studied in transgenic mice expressing a GH antagonist gene and in normal mice given an inhibitor of GH secretion (MK678), Retinal neovascularization was inhibited in these mice in inverse proportion to serum levels of GH and a downstream effector, insulin-like growth factor-I (IGF-I), Inhibition was reversed with exogenous IGF-I administration, GH inhibition did not diminish hypoxia-stimulated retinal vascular endothelial growth factor (VEGF) or VEGF receptor expression, These data suggest that systemic inhibition of GH or IGF-I, or both, may have therapeutic potential in preventing some forms of retinopathy.	CHILDRENS HOSP, BOSTON, MA 02115 USA; OHIO UNIV, EDISON BIOTECHNOL INST, ATHENS, OH 45701 USA; MERCK RES LABS, RAHWAY, NJ 07065 USA	Harvard University; Boston Children's Hospital; University System of Ohio; Ohio University; Merck & Company	Smith, LEH (corresponding author), HARVARD UNIV, SCH MED, DEPT OPHTHALMOL, BOSTON, MA 02115 USA.		CLIHON, Residencia Medica/K-4896-2013	CLIHON, Residencia Medica/0000-0001-6734-2513	NEI NIH HHS [EY08670] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008670] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; AMIEL SA, 1984, DIABETES, V33, P1175, DOI 10.2337/diabetes.33.12.1175; [Anonymous], 1979, Arch Ophthalmol, V97, P654; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; Burren CP, 1996, INVEST OPHTH VIS SCI, V37, P1459; BURRIN JM, 1989, METABOLISM, V38, P5896; CHEN WY, 1991, J BIOL CHEM, V266, P2252; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHEN WY, 1990, P NATL ACAD SCI USA, V87, P5061, DOI 10.1073/pnas.87.13.5061; CHEN WY, 1991, ENDOCRINOLOGY, V129, P1402, DOI 10.1210/endo-129-3-1402; DAMATO R, 1993, MICROVASC RES, V46, P135, DOI 10.1006/mvre.1993.1042; DILLS DG, 1990, DIABETES, V39, P191, DOI 10.2337/diabetes.39.2.191; DILLS DG, 1991, DIABETES, V40, P1725, DOI 10.2337/diabetes.40.12.1725; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; Ferrara N, 1996, EUR J CANCER, V32A, P2413, DOI 10.1016/S0959-8049(96)00387-5; FLIER JS, 1989, ENDOCRINOLOGY, V2, P1389; GRANT M, 1986, DIABETES, V35, P416, DOI 10.2337/diabetes.35.4.416; GRANT MB, 1993, REGUL PEPTIDES, V48, P267, DOI 10.1016/0167-0115(93)90356-D; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; JILIAL I, 1985, ENDOCRINOLOGY, V117, P1222; KIRKEGAARD C, 1990, ACTA ENDOCRINOL-COP, V122, P766, DOI 10.1530/acta.0.1220766; KLEIN HA, 1970, NIH DHEW PUBLICATION; KNAPP JR, 1994, J ANIM SCI, V72, P2812, DOI 10.2527/1994.72112812x; LARON Z, 1980, EUR J PEDIATR, V134, P79, DOI 10.1007/BF00442408; MALLET B, 1992, DIABETES METAB, V18, P438; MCCOMBE M, 1991, Eye (London), V5, P569; MCNAMARA JA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1714, DOI 10.1001/archopht.1992.01080240054029; MERIMEE TJ, 1970, J CLIN INVEST, V49, P1096, DOI 10.1172/JCI106325; MERIMEE TJ, 1983, NEW ENGL J MED, V309, P527, DOI 10.1056/NEJM198309013090904; MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877; MORIARTY P, 1994, BRIT J OPHTHALMOL, V78, P638, DOI 10.1136/bjo.78.8.638; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; POULSEN JE, 1953, DIABETES, V2, P7, DOI 10.2337/diab.2.1.7; RAYNOR K, 1993, MOL PHARMACOL, V43, P838; Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851; SHUMACK SL, 1990, CLIN INVEST MED, V5, P287; SMITH LA, UNPUB; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; WRIGHT AD, 1969, BRIT MED J, V2, P343; ZIMMERGALLER IE, 1995, INT OPHTHALMOL CLIN, V35, P37, DOI 10.1097/00004397-199503540-00005; 1990, ARCH OPHTHALMOL-CHIC, V108, P1408	42	320	335	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	1997	276	5319					1706	1709		10.1126/science.276.5319.1706	http://dx.doi.org/10.1126/science.276.5319.1706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180082				2022-12-28	WOS:A1997XD94700045
J	Englund, JA; Baker, CJ; Raskino, C; McKinney, RE; Petrie, B; Fowler, MG; Pearson, D; Gershon, A; McSherry, GD; Abrams, EJ; Schliozberg, J; Sullivan, JL				Englund, JA; Baker, CJ; Raskino, C; McKinney, RE; Petrie, B; Fowler, MG; Pearson, D; Gershon, A; McSherry, GD; Abrams, EJ; Schliozberg, J; Sullivan, JL			Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CLINICAL-TRIALS; GROWTH	Background Zidovudine has been the drug of choice for the initial treatment of symptomatic children infected with the human immunodeficiency virus (HIV). This trial was designed to assess the efficacy and safety of treatment with zidovudine alone as compared with either didanosine alone or combination therapy with zidovudine plus didanosine. Methods In this multicenter, double-blind study, symptomatic HIV-infected children 3 months through 18 years of age were stratified according to age (<30 months or greater than or equal to 30 months) and randomly assigned to receive zidovudine, didanosine, or zidovudine plus didanosine. The primary end point was length of time to death or to progression of HIV disease. Results Of the 831 children who could be evaluated, 92 percent had never received antiretroviral therapy and 90 percent had acquired HIV perinatally. An interim analysis (median follow-up, 23 months) showed a significantly higher risk of HIV-disease progression or death in patients receiving zidovudine alone than in those receiving combination therapy (relative risk, 0.61; 95 percent confidence interval, 0.42 to 0.88; P=0.007). The study arm with zidovudine alone was stopped and unblinded; the other two treatment arms were continued. At the end of the study, didanosine alone had an efficacy similar to that of zidovudine plus didanosine (median follow-up, 32 months) (relative risk of disease progression or death, 0.98; 95 percent confidence interval, 0.70 to 1.37; P=0.91). A significantly lower risk of anemia or neutropenia was seen in patients receiving didanosine alone (P=0.036). Conclusions In symptomatic HIV-infected children, treatment with either didanosine alone or zidovudine plus didanosine was more effective than treatment with zidovudine alone. The efficacy of didanosine alone was similar to that of the combination therapy and was associated with less hematologic toxicity. (C) 1997, Massachusetts Medical Society.	BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; DUKE UNIV, SCH MED, DEPT PEDIAT, DURHAM, NC USA; FRONTIER SCI & TECHNOL RES FDN INC, AMHERST, NY USA; NIAID, BETHESDA, MD 20892 USA; UNIV TEXAS, HLTH SCI CTR, DEPT PSYCHIAT & BEHAV SCI, HOUSTON, TX 77225 USA; COLUMBIA UNIV, DEPT PEDIAT, NEW YORK, NY 10027 USA; CHILDRENS HOSP NEW JERSEY, DEPT PEDIAT, NEWARK, NJ USA; HARLEM HOSP MED CTR, DEPT PEDIAT, NEW YORK, NY USA; ALBERT EINSTEIN COLL MED, DEPT PEDIAT, NEW YORK, NY USA; UNIV MASSACHUSETTS, DEPT PEDIAT, AMHERST, MA 01003 USA	Baylor College of Medicine; Harvard University; Harvard T.H. Chan School of Public Health; Duke University; Frontier Science Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; Columbia University; Yeshiva University; University of Massachusetts System; University of Massachusetts Amherst	Englund, JA (corresponding author), BAYLOR COLL MED, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77030 USA.		Koranyi, Katalin/E-3421-2011	moye, john/0000-0001-9976-8586				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Altman D.G., 1991, PRACTICAL STAT MED R; BALIS FM, 1989, ANN INTERN MED, V110, P279, DOI 10.7326/0003-4819-110-4-279; Brady MT, 1996, J INFECT DIS, V173, P1097, DOI 10.1093/infdis/173.5.1097; BUTLER KM, 1991, NEW ENGL J MED, V324, P137, DOI 10.1056/NEJM199101173240301; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; Englund JA, 1996, PEDIATR INFECT DIS J, V15, P1025, DOI 10.1097/00006454-199611000-00018; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; KALBTLEISCH JD, 1980, STAT ANAL FAILURE TI; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; MCKINNEY RE, 1994, J PEDIATR-US, V125, P728, DOI 10.1016/S0022-3476(94)70065-6; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; MUELLER BU, 1994, PEDIATRICS, V94, P724; MUELLER BU, 1997, 4 C RETR OPP INF WAS; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OGINO MT, 1993, J PEDIATR-US, V123, P1, DOI 10.1016/S0022-3476(05)81529-X; ROCHE AF, 1980, AM J CLIN NUTR, V33, P2041, DOI 10.1093/ajcn/33.9.2041; 1995, MMWR-MORBID MORTAL W, V44, P81	21	114	119	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	1997	336	24					1704	1712		10.1056/NEJM199706123362403	http://dx.doi.org/10.1056/NEJM199706123362403			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD543	9182213				2022-12-28	WOS:A1997XD54300003
J	Navab, F; Sabol, J				Navab, F; Sabol, J			Trichobezoars	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Navab, F (corresponding author), BAYSTATE MED CTR,SPRINGFIELD,MA 01199, USA.								0	7	7	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	1997	336	24					1721	1721		10.1056/NEJM199706123362405	http://dx.doi.org/10.1056/NEJM199706123362405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD543	9180089				2022-12-28	WOS:A1997XD54300005
J	Topol, EJ; Califf, RM; Lincoff, AM; Tcheng, JE; Cabot, CF; Weisman, HF; Kereiakes, D; Lausten, D; Runyon, JP; Howard, W; Kelly, T; Muncy, D; Timmis, G; Safian, M; Davey, D; Kleiman, NS; Rose, D; Basinger, L; Rouse, C; Kramer, J; Wilson, R; Talley, JD; Boyles, M; Navetta, FI; LeBueuf, R; Kraft, P; Dvorak, L; Smigla, RM; Ferguson, J; Harlan, M; Browne, K; Telatnik, M; Blankenship, J; Demko, L; Ivanhoe, RJ; Jackson, C; Shadoff, N; Goebel, S; Taylor, M; Cleary, E; Gacioch, G; Chiodo, V; Bates, E; Quain, L; Snyder, H; Bass, TA; Rohman, C; Gradman, A; Boltey, L; Tannenbaum, M; Stengl, D; Gordon, P; Wright, N; Cummins, F; Nonnweiler, J; Aversano, T; Peltzer, L; Bear, P; Craig, MB; Hattel, L; Tooke, G; Anderson, HV; Weigelt, L; Hettleman, B; Kennedy, S; Teirstein, PS; Claire, D; Sarembock, I; Sayre, S; Davidson, CJ; Schaechter, A; Aguirre, F; Stonner, T; Azrin, M; Bodett, J; Barry, MB; Worley, S; Frey, LA; Spriggs, DJ; Wahl, SA; Weston, MW; Yedinak, K; George, B; Smith, D; Gilliland, C; Smith, D; Ricci, DR; Fox, R; Hartman, C; Lunow, S; Farah, T; Petruolo, S; Sander, G; Stevens, A; Delise, K; Reen, B; Whisnant, D; Henderson, L; Heuser, R; Swiderski, K; Kaluzniak, M; Larkin, T; Jackson, BJ; Popma, J; Prunka, N; Sanz, M; Mayer, D; Mackey, K; Burton, J; Hogg, N; Brown, R; Stevens, K; French, W; Wang, S; Adelman, AG; Foulger, V; Weber, S; Gottlieb, R; Lavoie, J; King, S; Frerichs, F; Hollywood, L; Ducas, J; Schick, U; Hochman, JS; Slater, J; Tormey, D; ONeill, BJ; Foshay, K; Fitzgerald, N; Cheung, PK; Bedard, D; Knudtson, ML; Galbraith, D; Watt, H; Samaha, J; Hamilton, B; Klein, LW; Hebson, L; Almond, D; White, J; Rosenberg, MJ; Teully, S; Unks, M; Rodgers, K; Faxon, D; Gore, J; Kelsey, S; Lee, K; Sane, D; Walters, L; Booth, J; Cannata, R; Castle, V; Cohen, H; DeLuca, S; Kutner, M; Knuth, T; McCollough, T; McPherson, J; Melton, J; Miller, D; Pulliam, M; Sapp, S; Sigmon, KN; Montague, E; Alexander, K; Augostini, R; Bajzer, C; Bart, B; Belli, G; Carlson, J; Challapalli, R; Crenshaw, B; Dawson, I; Dickey, A; Echols, A; Erickson, B; Fontana, MB; Ghaffari, S; Gordon, C; Granger, C; Grano, G; Grimm, R; Johnson, T; Juran, N; Kingsley, A; Kruse, K; Lauer, M; Mahaffey, K; Malone, K; Mark, D; Marwick, T; Migrino, R; Miller, J; Newby, K; Pace, C; Peterson, E; Rabbani, R; Ragan, J; Rimmerman, C; Rodkey, S; Savor, V; Shaw, WF; Sila, C; Silver, M; Tan, W; Tobiasz, D; Vandervoort, P; Wang, CW; Ward, C; Waters, J; Wiehle, D; Winchell, M; Underwood, D; Clemons, P; Heupler, S; Powers, J; Rubin, D; Sgarbossa, E; Steinhubl, S; Moliterno, D; Debowey, D; Balazs, E; Crowe, T; Ivanc, T; Ols, L; Poliszczuk, R; Vilsack, H; Witherspoon, B; DavidsonRay, L; Anderson, KM; Giel, KM; Musco, MH; Stoner, GL				Topol, EJ; Califf, RM; Lincoff, AM; Tcheng, JE; Cabot, CF; Weisman, HF; Kereiakes, D; Lausten, D; Runyon, JP; Howard, W; Kelly, T; Muncy, D; Timmis, G; Safian, M; Davey, D; Kleiman, NS; Rose, D; Basinger, L; Rouse, C; Kramer, J; Wilson, R; Talley, JD; Boyles, M; Navetta, FI; LeBueuf, R; Kraft, P; Dvorak, L; Smigla, RM; Ferguson, J; Harlan, M; Browne, K; Telatnik, M; Blankenship, J; Demko, L; Ivanhoe, RJ; Jackson, C; Shadoff, N; Goebel, S; Taylor, M; Cleary, E; Gacioch, G; Chiodo, V; Bates, E; Quain, L; Snyder, H; Bass, TA; Rohman, C; Gradman, A; Boltey, L; Tannenbaum, M; Stengl, D; Gordon, P; Wright, N; Cummins, F; Nonnweiler, J; Aversano, T; Peltzer, L; Bear, P; Craig, MB; Hattel, L; Tooke, G; Anderson, HV; Weigelt, L; Hettleman, B; Kennedy, S; Teirstein, PS; Claire, D; Sarembock, I; Sayre, S; Davidson, CJ; Schaechter, A; Aguirre, F; Stonner, T; Azrin, M; Bodett, J; Barry, MB; Worley, S; Frey, LA; Spriggs, DJ; Wahl, SA; Weston, MW; Yedinak, K; George, B; Smith, D; Gilliland, C; Smith, D; Ricci, DR; Fox, R; Hartman, C; Lunow, S; Farah, T; Petruolo, S; Sander, G; Stevens, A; Delise, K; Reen, B; Whisnant, D; Henderson, L; Heuser, R; Swiderski, K; Kaluzniak, M; Larkin, T; Jackson, BJ; Popma, J; Prunka, N; Sanz, M; Mayer, D; Mackey, K; Burton, J; Hogg, N; Brown, R; Stevens, K; French, W; Wang, S; Adelman, AG; Foulger, V; Weber, S; Gottlieb, R; Lavoie, J; King, S; Frerichs, F; Hollywood, L; Ducas, J; Schick, U; Hochman, JS; Slater, J; Tormey, D; ONeill, BJ; Foshay, K; Fitzgerald, N; Cheung, PK; Bedard, D; Knudtson, ML; Galbraith, D; Watt, H; Samaha, J; Hamilton, B; Klein, LW; Hebson, L; Almond, D; White, J; Rosenberg, MJ; Teully, S; Unks, M; Rodgers, K; Faxon, D; Gore, J; Kelsey, S; Lee, K; Sane, D; Walters, L; Booth, J; Cannata, R; Castle, V; Cohen, H; DeLuca, S; Kutner, M; Knuth, T; McCollough, T; McPherson, J; Melton, J; Miller, D; Pulliam, M; Sapp, S; Sigmon, KN; Montague, E; Alexander, K; Augostini, R; Bajzer, C; Bart, B; Belli, G; Carlson, J; Challapalli, R; Crenshaw, B; Dawson, I; Dickey, A; Echols, A; Erickson, B; Fontana, MB; Ghaffari, S; Gordon, C; Granger, C; Grano, G; Grimm, R; Johnson, T; Juran, N; Kingsley, A; Kruse, K; Lauer, M; Mahaffey, K; Malone, K; Mark, D; Marwick, T; Migrino, R; Miller, J; Newby, K; Pace, C; Peterson, E; Rabbani, R; Ragan, J; Rimmerman, C; Rodkey, S; Savor, V; Shaw, WF; Sila, C; Silver, M; Tan, W; Tobiasz, D; Vandervoort, P; Wang, CW; Ward, C; Waters, J; Wiehle, D; Winchell, M; Underwood, D; Clemons, P; Heupler, S; Powers, J; Rubin, D; Sgarbossa, E; Steinhubl, S; Moliterno, D; Debowey, D; Balazs, E; Crowe, T; Ivanc, T; Ols, L; Poliszczuk, R; Vilsack, H; Witherspoon, B; DavidsonRay, L; Anderson, KM; Giel, KM; Musco, MH; Stoner, GL			Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERIPHERAL VASCULAR COMPLICATIONS; ACTIVATED CLOTTING TIMES; INTERVENTIONAL PROCEDURES; MYOCARDIAL-INFARCTION; ANGIOPLASTY; THERAPY; TRIAL; ANTIBODY; INTEGRIN; COMPLEX	Background Blockade of the platelet glycoprotein IIb/IIIa receptor with abciximab (a monoclonal-antibody Fab fragment directed against the receptor) has been shown to diminish ischemic complications among patients undergoing high-risk coronary angioplasty or atherectomy but increases bleeding complications. The widespread applicability of this treatment is unknown, particularly in view of the observed risk of hemorrhage. Methods In a prospective, double-blind trial, we randomly assigned patients undergoing urgent or elective percutaneous coronary revascularization at 69 centers to receive abciximab with standard-dose, weight-adjusted heparin (initial bolus of 100 U per kilogram of body weight); abciximab with low-dose, weight-adjusted heparin (initial bolus of 70 U per kilogram); or placebo with standard-dose, weight-adjusted heparin. The primary efficacy end point was death from any cause, myocardial infarction, or urgent revascularization within 30 days of randomization. Results The trial was terminated at the first interim analysis, with 2792 of the planned 4800 patients enrolled. At 30 days, the composite event rate was 11.7 percent in the group assigned to placebo with standard-dose heparin; 5.2 percent in the group assigned to abciximab with low-dose heparin (hazard ratio, 0.43; 95 percent confidence interval, 0.30 to 0.60; P<0.001); and 5.4 percent in the group as signed to abciximab with standard-dose heparin (hazard ratio, 0.45; 95 percent confidence interval, 0.32 to 0.63; P<0.001). There were no significant differences among the groups in the risk of major bleeding, although minor bleeding was more frequent among patients receiving abciximab with standard-dose heparin. Conclusions Inhibition of the platelet glycoprotein IIb/IIIa receptor with abciximab, together with low-dose, weight-adjusted heparin, markedly reduces the risk of acute ischemic complications in patients undergoing percutaneous coronary revascularization. (C) 1997, Massachusetts Medical Society.	CLEVELAND CLIN FDN, DEPT CARDIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation			Marwick, Thomas H/C-7261-2013; Blankenship, James/AAX-4084-2020	Marwick, Thomas H/0000-0001-9065-0899; Blankenship, James/0000-0003-4966-533X; Miller, Dave/0000-0003-2947-152X				Abdelmeguid AE, 1996, CIRCULATION, V94, P1528, DOI 10.1161/01.CIR.94.7.1528; AGUIRRE FV, 1995, CIRCULATION, V91, P2882, DOI 10.1161/01.CIR.91.12.2882; BOWERS J, 1994, CLIN CARDIOL, V17, P357, DOI 10.1002/clc.4960170704; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; DOUGHERTY KG, 1992, CATHETER CARDIO DIAG, V26, P260, DOI 10.1002/ccd.1810260404; FAITHFULL NS, 1992, ADV EXP MED BIOL, V317, P55; FRIEDMAN HZ, 1994, J AM COLL CARDIOL, V24, P1214, DOI 10.1016/0735-1097(94)90101-5; HARRINGTON RA, 1995, J AM COLL CARDIOL, V25, P1693, DOI 10.1016/0735-1097(95)00091-H; JOHNSON LW, 1994, CATHETER CARDIO DIAG, V31, P165, DOI 10.1002/ccd.1810310302; Kong TQ, 1997, JAMA-J AM MED ASSOC, V277, P461, DOI 10.1001/jama.277.6.461; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; LANDEFELD CS, 1987, AM J MED, V82, P703, DOI 10.1016/0002-9343(87)90004-0; Lincoff AM, 1997, AM J CARDIOL, V79, P286, DOI 10.1016/S0002-9149(96)00749-7; Mark DB, 1996, CIRCULATION, V94, P629, DOI 10.1161/01.CIR.94.4.629; MCGARRY TF, 1992, AM HEART J, V123, P1445, DOI 10.1016/0002-8703(92)90793-U; MULLER DWM, 1992, AM J CARDIOL, V69, P63, DOI 10.1016/0002-9149(92)90677-Q; Narins CR, 1996, CIRCULATION, V93, P667, DOI 10.1161/01.CIR.93.4.667; OWEIDA SW, 1990, J VASC SURG, V12, P310, DOI 10.1067/mva.1990.22293; PHILLIPS DR, 1988, BLOOD, V71, P831; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; REEDWOOD SR, 1996, J AM COLL CARDIOL  S, V27, pA167; Tardiff Barbara E., 1996, Journal of the American College of Cardiology, V27, p83A; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8	23	1568	1588	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	1997	336	24					1689	1696						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD543	9182212				2022-12-28	WOS:A1997XD54300001
J	Gao, GF; Tormo, J; Gerth, UC; Wyer, JR; McMichael, AJ; Stuart, DI; Bell, JI; Jones, EY; Jakobsen, BK				Gao, GF; Tormo, J; Gerth, UC; Wyer, JR; McMichael, AJ; Stuart, DI; Bell, JI; Jones, EY; Jakobsen, BK			Crystal structure of the complex between human CD8 alpha alpha and HLA-A2	NATURE			English	Article							PEPTIDE-MHC COMPLEXES; CLASS-I MOLECULES; ALPHA-3 DOMAIN; CD8; BINDING; ANTIGEN; CHAIN; RESOLUTION; PROGRAM	The dimeric cell-surface glycoprotein CD8 is crucial to the positive selection of cytotoxic T cells in the thymus(1). The homodimer CD8 alpha alpha or the heterodimer alpha beta stabilizes the interaction of the T-cell antigen receptor(TCR) with major histocompatibility complex (MHC) class I/peptide by binding to the class I molecule(2). Here we report the crystal structure at 2.7 Angstrom resolution of a complex between CD8 alpha alpha and the human MHC molecule HLA-A2, which is associated with peptide. CD8 alpha alpha binds one HLA-A2/ peptide molecule, interfacing with the alpha 2 and alpha 3 domains of HLA-A2 and also contacting beta(2)-microglobulin. A flexible loop of the alpha 3 domain (residues 223-229) is damped between the complementarity-determining region (CDR)-like loops of the two CD8 subunits in the classic manner of an antibody-antigen interaction, precluding the binding of a second MHC molecule. The position of the alpha 3 domain is different from that in uncomplexed HLA-A2 (refs 3, 4), being most similar to that in the TCR/Tax/HLA-A2 complex(5), but no conformational change extends to the MHC/peptide surface presented for TCR recognition. Although these shifts in alpha 3 may provide a synergistic modulation of affinity, the binding of CD8 to MHC is clearly consistent with an avidity-based contribution from CD8 to TCR-peptide-MHC interactions.	JOHN RADCLIFFE HOSP,INST MOL MED,NUFFIELD DEPT CLIN MED,MOL IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND; LAB MOL BIOPHYS,OXFORD OX1 3QU,ENGLAND; OXFORD CTR MOL SCI,OXFORD OX1 3QT,ENGLAND	University of Oxford; University of Oxford; University of Oxford			Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016; Gao, George Fu/ABD-5229-2021	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210				BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GIBLIN PA, 1994, P NATL ACAD SCI USA, V91, P1716, DOI 10.1073/pnas.91.5.1716; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIRSZBAUM L, 1989, J IMMUNOL, V142, P3931; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REIC SW, 1996, FEBS LETT, V383, P119; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; SUN JR, 1995, J EXP MED, V182, P1275, DOI 10.1084/jem.182.5.1275; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; ZAMOYSKA R, 1994, IMMUNITY, V1, P243, DOI 10.1016/1074-7613(94)90075-2	28	379	413	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					630	634		10.1038/42523	http://dx.doi.org/10.1038/42523			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177355				2022-12-28	WOS:A1997XC52200063
J	Peters, A; Doring, A; Wichmann, HE; Koenig, W				Peters, A; Doring, A; Wichmann, HE; Koenig, W			Increased plasma viscosity during an air pollution episode: A link to mortality?	LANCET			English	Article							CARDIOVASCULAR RISK FACTOR; FIBRINOGEN; DISEASE; ADMISSIONS; PEOPLE; CITIES; EVENT; DEATH	Background Air pollution episodes have been consistently associated with increased mortality, and most strikingly with mortality due to cardiovascular disease. One hypothesis to explain this association is that inflammation of the peripheral airways caused by pollution might increase blood coagulability. We have tested this hypothesis in a cross-sectional study by comparing measurements of plasma viscosity during a severe episode of air pollution during 1985 with those made on less polluted days. Methods Plasma viscosity was measured as part of the MONICA Augsburg survey during the winter of 1984-85 in 3256 randomly selected men and women aged 25-64 years. Daily mean concentrations of air pollutants and meteorological variables were measured in Augsburg as part of the automated Bavarian air-quality network. We compared measurements of plasma viscosity made in 324 people who attended for screening during the pollution episode and in 2932 people screened during the remainder of the survey period. Findings In January, 1985, high concentrations of sulphur dioxide (mean 200 mu g/m(3)) and total suspended particles (mean 98 mu g/m(3)) were recorded during a 13-day period in Augsburg. In men, the odds ratio for plasma viscosity above the 95th percentile of the distribution (1.38 mPa s) was 3.6 (95% CI 1.6-8.1) comparing measurements during the air pollution episode with non-episode measurements after adjustment for cardiovascular risk factors and meteorological variables. The corresponding odds ratio for women (95th percentile of plasma viscosity 1.37 mPa s) was 2.3 (1.0-5.3). High concentrations of carbon monoxide were also associated with increased plasma viscosity in women. Interpretation During the 1985 air pollution episode, an increased risk of extreme values of plasma viscosity was observed in both men and women. Altered blood rheology due to inflammatory processes in the lung that induce an acute-phase reaction might therefore be part of the pathological mechanisms linking air pollution to mortality.	UNIV ULM, MED CTR, DEPT INTERNAL MED CARDIOL 2, ULM, GERMANY	Ulm University	Peters, A (corresponding author), GSF, NATL RES CTR ENVIRONM & HLTH, INST EPIDEMIOL, POSTFACH 1129, D-85758 OBERSCHLEISSHEIM, GERMANY.		Wichmann, Heinz Erich/AAA-5695-2022; Peters, Annette/A-6117-2011	Peters, Annette/0000-0001-6645-0985				AYRES J, 1989, ENVIRON HEALTH PERSP, V79, P83, DOI 10.2307/3430533; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; BATES DV, 1992, ENVIRON RES, V59, P336, DOI 10.1016/S0013-9351(05)80040-4; Benderly M, 1996, ARTERIOSCL THROM VAS, V16, P351, DOI 10.1161/01.ATV.16.3.351; BURNETT RT, 1995, AM J EPIDEMIOL, V142, P15, DOI 10.1093/oxfordjournals.aje.a117540; DASSEN W, 1986, JAPCA J AIR WASTE MA, V36, P1223, DOI 10.1080/00022470.1986.10466168; DELEEUW FAAM, 1989, ENVIRON HEALTH PERSP, V79, P53, DOI 10.2307/3430529; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; Godleski JJ, 1996, AM J RESP CRIT CARE, V153, pA15; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; Jousilahti P, 1996, LANCET, V348, P567, DOI 10.1016/S0140-6736(96)02374-4; KEIL U, 1988, ACTA MED SCAND, P119; KOENIG W, 1992, CIRCULATION, V86, P1045, DOI 10.1161/01.CIR.86.3.1045; KOENIG W, 1994, LANCET, V344, P711, DOI 10.1016/S0140-6736(94)92207-1; LEWIS SM, 1982, CLIN LAB HAEMATOL, V4, P83; LIP GYH, 1995, QJM-INT J MED, V88, P155; MORRIS RD, 1995, AM J PUBLIC HEALTH, V85, P1361, DOI 10.2105/AJPH.85.10.1361; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669, DOI 10.1164/ajrccm/151.3_Pt_1.669; SCHWARTZ J, 1995, AM J EPIDEMIOL, V142, P23, DOI 10.1093/oxfordjournals.aje.a117541; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; WICHMANN HE, 1989, ENVIRON HEALTH PERSP, V79, P89, DOI 10.2307/3430534; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; World Health Organization, 1990, MONICA MAN; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836	29	529	556	1	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	1997	349	9065					1582	1587		10.1016/S0140-6736(97)01211-7	http://dx.doi.org/10.1016/S0140-6736(97)01211-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174559				2022-12-28	WOS:A1997XB67300008
J	Schuckit, MA				Schuckit, MA			Science, medicine, and the future - Substance use disorders	BRITISH MEDICAL JOURNAL			English	Review							ALCOHOL DEPENDENCE; COCAINE; NALTREXONE		UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92161	University of California System; University of California San Diego	Schuckit, MA (corresponding author), VET AFFAIRS MED CTR,DEPT PSYCHIAT,RES CTR,SAN DIEGO,CA 92161, USA.				PHS HHS [05526, 08401, 08403] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM PSYCH ASS, 1995, AM J PSYCHIAT S, V52, P1; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BEGLEITER H, IN PRESS SCIENCE; BELKNAP JK, IN PRESS BEHAV GENET; BUCK KJ, IN PRESS J NEUROSCI; Cadas H, 1996, J NEUROSCI, V16, P3934; CAINE SB, 1995, BEHAV PHARMACOL, V6, P333; CARRERA MRA, 1995, NATURE, V378, P727, DOI 10.1038/378727a0; CARROLL KM, 1994, ARCH GEN PSYCHIAT, V51, P177; Crabbe JC, 1996, J PHARMACOL EXP THER, V277, P624; Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; diTomaso E, 1996, NATURE, V382, P677, DOI 10.1038/382677a0; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Gordis E, 1996, ARCH GEN PSYCHIAT, V53, P199; Grant BF, 1996, ALCOHOL CLIN EXP RES, V20, P1481, DOI 10.1111/j.1530-0277.1996.tb01152.x; KOOB M, 1996, PATHWAYS ADDICTION, P56; Leshner AI, 1996, NEW ENGL J MED, V335, P128, DOI 10.1056/NEJM199607113350211; MARKEL PD, IN PRESS GENOME RES; Mason BJ, 1996, ALCOHOL CLIN EXP RES, V20, pA10, DOI 10.1111/j.1530-0277.1996.tb01184.x; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Mendelson JH, 1996, NEW ENGL J MED, V334, P965, DOI 10.1056/NEJM199604113341507; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; *PROJ MATCH RES GR, 1997, J STUD ALCOHOL, V58, P7; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SCHUCKIT M, 1995, DRUG ALCOHOL ABUSE C; SCHUCKIT M, IN PRESS AM J PSYCHI; Schuckit MA, 1996, ARCH GEN PSYCHIAT, V53, P202; SCHUCKIT MA, 1995, ADDICTION, V90, P1335, DOI 10.1046/j.1360-0443.1995.901013355.x; Schuckit MA, 1996, J CONSULT CLIN PSYCH, V64, P669; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; Whitworth AB, 1996, LANCET, V347, P1438, DOI 10.1016/S0140-6736(96)91682-7	36	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 31	1997	314	7094					1605	1608		10.1136/bmj.314.7094.1605	http://dx.doi.org/10.1136/bmj.314.7094.1605			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XC500	9186175	Green Published			2022-12-28	WOS:A1997XC50000030
J	Bowman, S; Churcher, C; Badcock, K; Brown, D; Chillingworth, T; Connor, R; Dedman, K; Devlin, K; Gentles, S; Hamlin, N; Hunt, S; Jagels, K; Lye, G; Moule, S; Odell, C; Pearson, D; Rajandream, M; Rice, P; Skelton, J; Walsh, S; Whitehead, S; Barrell, B				Bowman, S; Churcher, C; Badcock, K; Brown, D; Chillingworth, T; Connor, R; Dedman, K; Devlin, K; Gentles, S; Hamlin, N; Hunt, S; Jagels, K; Lye, G; Moule, S; Odell, C; Pearson, D; Rajandream, M; Rice, P; Skelton, J; Walsh, S; Whitehead, S; Barrell, B			The nucleotide sequence of Saccharomyces cerevisiae chromosome XIII	NATURE			English	Article							COMPLETE DNA-SEQUENCE; YEAST; GENE; HOMOLOG; INTERACTS; RECQ; SGS1	Systematic sequencing of the genome of Saccharomyces cerevisiae has revealed thousands of new predicted genes and allowed analysis of long-range features of chromosomal organization. Generally, genes and predicted genes seem to be distributed evenly throughout the genome, having no overall preference for DNA strand. Apart from the smaller chromosomes, which can have substantially lower gene density in their telomeric: regions(1-3), there is a consistent average of one open reading frame (ORF) approximately every two kilobases. However, one of the most surprising findings for a eukaryote with approximately 6,000 genes was the amount of apparent redundancy in its genome. This redundancy occurs both between individual ORFs and over more extensive chromosome regions, which have been duplicated preserving gene order and orientation(4-6). Here we report the entire nucleotide sequence of chromosome XIII, the sixth-largest S. cerevisiae chromosome, and demonstrate that its features and organization are consistent with those observed for other S. cerevisiae chromosomes. Analysis revealed 459 ORFs, 284 have not been identified previously. Both intra- and interchromosomal duplications of regions of this chromosome have occurred.	SANGER CTR,CAMBRIDGE CB10 1SA,ENGLAND	Wellcome Trust Sanger Institute				Hunt, Sarah/0000-0002-8350-1235	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P21, DOI 10.1093/nar/24.1.21; BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; CALDER KM, 1990, NUCLEIC ACIDS RES, V18, P1632, DOI 10.1093/nar/18.6.1632; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FITZGERALDHAYES M, 1987, YEAST, V3, P187, DOI 10.1002/yea.320030306; Galibert F, 1996, EMBO J, V15, P2031, DOI 10.1002/j.1460-2075.1996.tb00557.x; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KEARSEY SE, 1993, DNA SEQUENCE, V4, P69, DOI 10.3109/10425179309015625; LOUIS EJ, 1994, GENETICS, V136, P789; LOUIS EJ, 1995, BIOCHEMICA, V3, P25; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; SMITH V, 1993, METHOD ENZYMOL, V218, P173; STRAND M, 1995, P NATL ACAD SCI USA, V92, P10418, DOI 10.1073/pnas.92.22.10418; Termier M, 1996, YEAST, V12, P369, DOI 10.1002/(SICI)1097-0061(19960330)12:4<369::AID-YEA922>3.0.CO;2-#; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; [No title captured]	27	38	560	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632		S			90	93		10.1038/387s090	http://dx.doi.org/10.1038/387s090			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169872				2022-12-28	WOS:A1997XB54600012
J	Lusser, A; Brosch, G; Loidl, A; Haas, H; Loidl, P				Lusser, A; Brosch, G; Loidl, A; Haas, H; Loidl, P			Identification of maize histone deacetylase HD2 as an acidic nucleolar phosphoprotein	SCIENCE			English	Article							ACETYLATION	The steady state of histone acetylation is established and maintained by multiple histone acetyltransferases and deacetylases, and this steady state affects chromatin structure and function. The identification of a maize complementary DNA encoding the chromatin-bound deacetylase HD2 is reported. This protein was not homologous to the yeast RPD3 transcriptional regulator. It was expressed throughout embryo germination in correlation with the proliferative activity of cells. Antibodies against recombinant HD2-p39 immunoprecipitated the native enzyme complex, which was composed of phosphorylated p39 subunits. Immunofluorescence microscopy and sequence homologies suggested nucleolar localization. HD2 is an acidic nucleolar phosphoprotein that might regulate ribosomal chromatin structure and function.	UNIV INNSBRUCK, SCH MED, DEPT MICROBIOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck				Lusser, Alexandra/0000-0002-2226-9081				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BROSCH G, 1992, J BIOL CHEM, V267, P20561; BROSCH G, 1995, PLANT CELL, V7, P1941, DOI 10.1105/tpc.7.11.1941; Brosch G, 1996, BIOCHEMISTRY-US, V35, P15907, DOI 10.1021/bi961294x; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; DarkinRattray SJ, 1996, P NATL ACAD SCI USA, V93, P13143, DOI 10.1073/pnas.93.23.13143; DeRubertis F, 1996, NATURE, V384, P589; GEORGIEVA EI, 1994, PLANTA, V192, P118, DOI 10.1007/BF00198701; GRABHER A, 1994, BIOCHEMISTRY-US, V33, P14887, DOI 10.1021/bi00253a028; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Lechner T, 1996, BBA-PROTEIN STRUCT M, V1296, P181, DOI 10.1016/0167-4838(96)00069-6; LECHNER T, UNPUB; LOIDL P, 1994, CHROMOSOMA, V103, P441; LUSSER A, UNPUB; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Trendelenburg MF, 1996, HISTOCHEM CELL BIOL, V106, P167; TURNER BM, 1991, J CELL SCI, V99, P13; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845	23	193	216	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					88	91		10.1126/science.277.5322.88	http://dx.doi.org/10.1126/science.277.5322.88			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204905				2022-12-28	WOS:A1997XJ41800045
J	Rettig, MB; Ma, HJ; Vescio, RA; Pold, M; Schiller, G; Belson, D; Savage, A; Nishikubo, C; Wu, C; Fraser, J; Said, JW; Berenson, JR				Rettig, MB; Ma, HJ; Vescio, RA; Pold, M; Schiller, G; Belson, D; Savage, A; Nishikubo, C; Wu, C; Fraser, J; Said, JW; Berenson, JR			Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients	SCIENCE			English	Article							MONOCLONAL GAMMOPATHY; DNA-SEQUENCES; UNDETERMINED SIGNIFICANCE; INTERLEUKIN-6; CYTOKINES; RECEPTOR	Kaposi's sarcoma-associated herpesvirus (KSHV) was found in the bone marrow dendritic cells of multiple myeloma patients but not in malignant plasma cells or bone marrow dendritic cells from normal individuals or patients with other malignancies. In addition the virus was detected in the bone marrow dendritic cells from two out of eight patients with monoclonal gammopathy of undetermined significance (MGUS), a precursor to myeloma. Viral interleukin-6, the human homolog of which is a growth factor for myeloma, was found to be transcribed in the myeloma bone marrow dendritic cells. KSHV may be required for transformation from MGUS to myeloma and perpetuate the growth of malignant plasma cells.	UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL & ONCOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rettig, MB (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR,DIV HEMATOL ONCOL,11301 WILSHIRE BLVD,111-H,LOS ANGELES,CA 90073, USA.		Fraser, John K/I-7309-2013					ANDERSON KC, 1989, BLOOD, V73, P1915; BERAL V, 1991, CANCER SURV, V10, P5; BLADE J, 1992, BRIT J HAEMATOL, V81, P391, DOI 10.1111/j.1365-2141.1992.tb08245.x; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; BOSHOFF C, 1995, LANCET, V345, P1043; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Corbellino M, 1996, CLIN INFECT DIS, V22, P1120, DOI 10.1093/clinids/22.6.1120; Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GARTNER S, 1980, P NATL ACAD SCI-BIOL, V77, P4756, DOI 10.1073/pnas.77.8.4756; Gessain A, 1996, BLOOD, V87, P414; HIRANO T, 1991, INT J CELL CLONING, V9, P166, DOI 10.1002/stem.5530090303; HO J, 1994, APPL IMMUNOHISTOCHEM, V2, P282; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; KING AG, 1988, J IMMUNOL, V141, P2016; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KITTLER ELW, 1992, BLOOD, V79, P3168; KYLE RA, 1978, AM J MED, V64, P814, DOI 10.1016/0002-9343(78)90522-3; KYLE RA, 1993, MAYO CLIN PROC, V68, P26, DOI 10.1016/S0025-6196(12)60015-9; LICHTENSTEIN A, 1989, BLOOD, V74, P1266; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; LINDSTROM FD, 1978, CLIN IMMUNOL IMMUNOP, V10, P168, DOI 10.1016/0090-1229(78)90024-7; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MOSEIGLOS G, 1996, AM J PATHOL, V148, P593; Paladini G, 1989, Recenti Prog Med, V80, P123; PASTORE C, 1995, BRIT J HAEMATOL, V91, P918, DOI 10.1111/j.1365-2141.1995.tb05410.x; PETERMAN TA, 1993, AIDS, V7, P605, DOI 10.1097/00002030-199305000-00001; Pinkus GS, 1997, AM J PATHOL, V150, P543; Said JW, 1996, BLOOD, V87, P4937, DOI 10.1182/blood.V87.12.4937.bloodjournal87124937; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; UCHIYAMA H, 1993, BLOOD, V82, P3712; VESCIO RA, 1995, CANC TREATMENT, P1094; Weiss RA, 1996, NAT MED, V2, P277, DOI 10.1038/nm0396-277; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641; ZHOU LJ, 1995, J IMMUNOL, V154, P3821	40	402	424	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1851	1854		10.1126/science.276.5320.1851	http://dx.doi.org/10.1126/science.276.5320.1851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188529				2022-12-28	WOS:A1997XF10300046
J	Schwartz, SH; Tan, BC; Gage, DA; Zeevaart, JAD; McCarty, DR				Schwartz, SH; Tan, BC; Gage, DA; Zeevaart, JAD; McCarty, DR			Specific oxidative cleavage of carotenoids by VP14 of maize	SCIENCE			English	Article							ABSCISIC-ACID; RETINOIC ACID; BEAN-LEAVES; BIOSYNTHESIS; METABOLISM; EXPRESSION; CLONING	The plant growth regulator abscisic acid (ABA) is formed by the oxidative cleavage of an epoxy-carotenoid. The synthesis of other apocarotenoids, such as vitamin A in animals, may occur by a similar mechanism. In ABA biosynthesis, oxidative cleavage is the first committed reaction and is believed to be the key regulatory step. A new ABA-deficient mutant of maize has been identified and the corresponding gene, Vp14, has been cloned. The recombinant VP14 protein catalyzes the cleavage of 9-cis-epoxy-carotenoids to form C-25 apo-aldehydes and xanthoxin, a precursor of ABA in higher plants.	MICHIGAN STATE UNIV, DEPT ENERGY, PLANT RES LAB, E LANSING, MI 48824 USA; UNIV FLORIDA, GRAD PROGRAM PLANT MOL & CELLULAR BIOL, GAINESVILLE, FL 32611 USA; MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University; State University System of Florida; University of Florida; Michigan State University				Schwartz, Steve/0000-0002-5982-8553				BIBIKOV SI, 1993, P NATL ACAD SCI USA, V90, P9446, DOI 10.1073/pnas.90.20.9446; BULOCK JD, 1983, BIOSYNTHESIS ISOPREN, P437; CREELMAN RA, 1984, PLANT PHYSIOL, V75, P166, DOI 10.1104/pp.75.1.166; Douce R., 1979, Advances in Botanical Research, V7, P1, DOI 10.1016/S0065-2296(08)60087-7; FOSTER KW, 1984, NATURE, V311, P756, DOI 10.1038/311756a0; GASKIN P, 1992, GC MS GIBBERELLINS R, pS885; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GOODMAN DS, 1966, J BIOL CHEM, V241, P1929; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; JUTTNER F, 1985, ARCH MICROBIOL, V141, P337, DOI 10.1007/BF00428846; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P926, DOI 10.1271/bbb.57.926; Kaneko T, 1996, DNA Res, V3, P109; LI Y, 1990, PLANT PHYSIOL, V92, P551, DOI 10.1104/pp.92.3.551; OLSON JA, 1993, AM J CLIN NUTR, V57, P833, DOI 10.1093/ajcn/57.6.833; PARRY AD, 1991, PHYTOCHEMISTRY, V30, P815, DOI 10.1016/0031-9422(91)85258-2; PARRY AD, 1993, METHODS PLANT BIOCH, V9, P381; ROCK CD, 1991, P NATL ACAD SCI USA, V88, P7496, DOI 10.1073/pnas.88.17.7496; SINDHU RK, 1987, PLANT PHYSIOL, V85, P916, DOI 10.1104/pp.85.4.916; Tan B. S. W., UNPUB; TAYLOR HF, 1967, NATURE, V215, P1513, DOI 10.1038/2151513a0; Taylor IB., 1991, ABSCISIC ACID PHYSL, P23; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WANG XD, 1992, ARCH BIOCHEM BIOPHYS, V293, P298, DOI 10.1016/0003-9861(92)90399-H; ZECHMEISTER L, 1962, CIS T ISOMERIC CAROT, P85; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.arplant.39.1.439	25	674	738	5	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	1997	276	5320					1872	1874		10.1126/science.276.5320.1872	http://dx.doi.org/10.1126/science.276.5320.1872			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188535				2022-12-28	WOS:A1997XF10300052
J	Panush, RS; Arend, WP				Panush, RS; Arend, WP			Rheumatology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARTHRITIS		UNIV COLORADO,HLTH SCI CTR,DENVER,CO	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Panush, RS (corresponding author), ST BARNABAS HOSP,LIVINGSTON,NJ 07039, USA.							Albani S, 1996, IMMUNOL TODAY, V17, P466, DOI 10.1016/0167-5699(96)20029-G; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; Bresnihan B., 1996, Arthritis and Rheumatism, V39, pS73; Epstein WV, 1996, ARTHRITIS RHEUM, V39, P1773, DOI 10.1002/art.1780391102; FOX DA, IN PRESS PERSPECT BI; Kavanaugh A. F., 1996, Arthritis and Rheumatism, V39, pS123; Kotzin BL, 1996, CELL, V85, P303, DOI 10.1016/S0092-8674(00)81108-3; Moreland LW, 1997, ARTHRITIS RHEUM, V40, P397, DOI 10.1002/art.1780400302; Mottonen T, 1996, ARTHRITIS RHEUM, V39, P996, DOI 10.1002/art.1780390617; Muller-Ladner U, 1996, Curr Opin Rheumatol, V8, P210; PANUSH RS, 1995, J RHEUMATOL, V22, P2197; STRAND V, 1996, P EARLY DECISIONS DM, V4, P1; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; WEYAND CM, 1995, J CLIN INVEST, V95, P2120, DOI 10.1172/JCI117900; Wilske KR, 1996, J RHEUMATOL, V23, P1	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1899	1900						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185825				2022-12-28	WOS:A1997XD54400044
J	Hesketh, T; Zhu, WX				Hesketh, T; Zhu, WX			Health in China - The one child family policy: The good, the bad, and the ugly	BRITISH MEDICAL JOURNAL			English	Article								Rapid population growth in China during the 1950s and '60s led to the ''late, long, few'' policy of the 1970s and a dramatic reduction in the total fertility rate. However, population growth remained too high for the economic targets of Deng Xiao Ping's reforms, so the one child family policy was introduced in 1979 and has remained in force ever since. The strategy is different in urban and rural areas, and implementation varies from place to place depending on local conditions. The policy has been beneficial in terms of curbing population growth, aiding economic growth, and improving the health and welfare of women and children. On the negative side there are concerns about demographic and sex imbalance and the psychological effects for a generation of only children in the cities. The atrocities often associated with the policy, such as female infanticide, occur rarely now China may relax the policy in the near future, probably allowing two children for everyone.	HLTH UNLIMITED,LONDON SE1 9NT,ENGLAND		Hesketh, T (corresponding author), CTR INT CHILD HLTH,LONDON WC1 N1EH,ENGLAND.			Hesketh, Therese/0000-0002-7564-9221				GREEN L, 1988, J PUBLIC HLTH POLICY, V6, P27383; GREENHALGH S, 1987, SCIENCE, V235, P1167, DOI 10.1126/science.3823877; HULL TH, 1990, POPUL DEV REV, V16, P62; McMichael AJ, 1995, BRIT MED J, V311, P1651, DOI 10.1136/bmj.311.7021.1651; *UNICEF, 1989, CHILDR WOM CHIN UN S; WEN XY, 1993, J BIOSOC SCI, V25, P509, DOI 10.1017/S002193200002188X; World Bank, 1992, CHIN LONG TERM ISS O; YAO XW, 1994, BASIC DATA CHINAS PO; YOUNG ME, 1990, HEALTH POLICY, V14, P87, DOI 10.1016/0168-8510(90)90369-O; ZHU B, 1996, CHINA DAILY     0215; ZHU W, 1991, CHINA POPULATION TOD, V1, P2; 1996, CHINA DAILY     1017	12	86	87	2	93	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 7	1997	314	7095					1685	1687		10.1136/bmj.314.7095.1685	http://dx.doi.org/10.1136/bmj.314.7095.1685			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD874	9193296	Green Published			2022-12-28	WOS:A1997XD87400034
J	PundaPolic, V; Bradaric, N; Grgic, D				PundaPolic, V; Bradaric, N; Grgic, D			A 9-year-old with fever and severe muscle pains	LANCET			English	Article									UNIV HOSP SPLIT,DEPT INFECT DIS,SPLIT,CROATIA	University of Split	PundaPolic, V (corresponding author), MED SCH & UNIV HOSP SPLIT,DEPT CLIN MICROBIOL,SPINCICEVA 1,SPLIT 21000,CROATIA.		Grgic, Dora/ABE-2194-2021					BAILY GG, 1994, J INFECTION, V29, P241, DOI 10.1016/S0163-4453(94)91059-6; Bryceson A. D. M., 1996, Manson's tropical diseases., P1213; Marty P, 1995, T ROY SOC TROP MED H, V89, P690, DOI 10.1016/0035-9203(95)90447-6; TANDAN R, 1994, HARRISONS PRINCIPLES, P2379; *WHO, 1990, TECH REP SER WHO, V793	5	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1666	1666		10.1016/S0140-6736(97)03316-3	http://dx.doi.org/10.1016/S0140-6736(97)03316-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186386				2022-12-28	WOS:A1997XD10000012
J	Snow, RW; Omumbo, JA; Lowe, B; Molyneux, CS; Obiero, JO; Palmer, A; Weber, MW; Pinder, M; Nahlen, B; Obonyo, C; Newbold, C; Gupta, S; Marsh, K				Snow, RW; Omumbo, JA; Lowe, B; Molyneux, CS; Obiero, JO; Palmer, A; Weber, MW; Pinder, M; Nahlen, B; Obonyo, C; Newbold, C; Gupta, S; Marsh, K			Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa	LANCET			English	Article							INDICATORS; MORTALITY	Background Malaria remains a major cause of mortality and morbidity in Africa; Many approaches to malaria control involve reducing the chances of infection but little is known of the relations between parasite exposure and the development of effective clinical immunity so the longterm effect of suck approaches to control on the pattern and frequency of malaria cannot be predicted. Methods We have prospectively recorded paediatric admissions with severe malaria over three to five years from five discrete communities in The Gambia and Kenya, Demographic analysis of the communities exposed to disease risk allowed the estimation of age-specific rates for severe malaria. Within each community the exposure to Plasmodium falciparum infection was determined through repeated parasitological and serological surveys among children and infants,We used acute respiratory-tract infections (ARI) as a comparison. Findings 3556 malaria admissions were recorded for the five sites. Marked differences were observed in age, clinical spectrum and rates of severe malaria between the five sites, Paradoxically, the risks of severe disease in childhood were lowest among populations with the highest transmission intensities, and the highest disease risks were observed among populations exposed to low-to-moderate intensities of transmission. For severe malaria, for example, admission rates (per 1000 per year) for children up to their 10th birthday were estimated as 3.9, 25.8, 25.9, 16.7 and 18.0 in the five communities; the forces of infection estimated for those communities (new infections per infant per month) were 0.001, 0.034, 0.050, 0.093, and 0.176, respectively. Similar trends were noted for cerebral malaria and for severe malaria anaemia but not for ARI. Mean age of disease decreased with increasing transmission intensity. Interpretation We propose that a critical determinant of life-time disease risk is the ability to develop clinical immunity early in life during a period when other protective mechanisms may operate. In highly endemic areas measures which reduce parasite transmission,and thus immunity, may lead to a change in both the clinical spectrum of severe disease and the overall burden of severe malaria morbidity.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,MOL PARASITOL GRP,INST MOL MED,OXFORD OX3 9DU,ENGLAND; KENYA GOVT MED RES CTR,CLIN RES CTR,COASTAL UNIT,KILIFI,KENYA; ROYAL VICTORIA HOSP,DEPT PAEDIAT,BANJUL,GAMBIA; MRC,FAJARA,GAMBIA; CTR DIS CONTROL,KENYA MED RES INST,COLLABORAT PROGRAMME,VECTOR BIOL & CONTROL RES CTR,KISUMU,KENYA; CTR DIS CONTROL & PREVENT,DIV PARASIT DIS,ATLANTA,GA; UNIV OXFORD,WELLCOME CTR EPIDEMIOL INFECT DIS,DEPT ZOOL,OXFORD OX1 2JD,ENGLAND	University of Oxford; Kenya Medical Research Institute; University of London; London School of Hygiene & Tropical Medicine; Kenya Medical Research Institute; Centers for Disease Control & Prevention - USA; University of Oxford	Snow, RW (corresponding author), KENYA GOVT MED RES CTR,WELLCOME TRUST COLLABORAT PROGRAMME,POB 43640,NAIROBI,KENYA.		Snow, Robert William/AFR-1436-2022; Nahlen, Bernard/AAH-2051-2021; Molyneux, Catherine/HGB-8464-2022; Obonyo, Charles/AAX-5992-2020	Snow, Robert William/0000-0003-3725-6088; Molyneux, Catherine/0000-0001-9522-416X; Obonyo, Charles/0000-0003-0741-8533; Newbold, Chris/0000-0002-9274-3789; Omumbo, Judy/0000-0002-9475-9346	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; Arriaga E.E., 1994, POPULATION ANAL MICR; Brabin B., 1990, Tropical Diseases Bulletin, V87, pR1; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; English M, 1996, AM J TROP MED HYG, V55, P521, DOI 10.4269/ajtmh.1996.55.521; EWBANK DC, 1981, AGE MISREPORTING AGE, P1; GARNHAM PCC, 1949, ANN TROP MED PARASIT, V43, P47, DOI 10.1080/00034983.1949.11685394; GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7; LACRITZ EM, 1992, LANCET, V340, P524; LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553, DOI 10.1080/00034983.1990.11812510; Macdonald G., 1950, Tropical Diseases Bulletin, V47, P915; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; MCGREGOR IA, 1970, CLIN EXP IMMUNOL, V7, P51; MESELAAR D, 1959, TROP GEOG MED, V11, P157; MOLYNEUX ME, 1989, Q J MED, V71, P441; MULLHOLLAND EK, 1997, LANCET, V349, P1191; Nevill CG, 1996, TROP MED INT HEALTH, V1, P139; Snow RW, 1996, AM J TROP MED HYG, V55, P144, DOI 10.4269/ajtmh.1996.55.2.TM0550020144; SNOW RW, 1994, INT J EPIDEMIOL, V23, P1013, DOI 10.1093/ije/23.5.1013; SNOW RW, 1995, PARASITOL TODAY, V11, P188, DOI 10.1016/0169-4758(95)80156-1; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; SNOW RW, 1994, EVALUATION IMPACT HL, P297; TODD JE, 1994, ANN TROP PAEDIATR, V14, P31, DOI 10.1080/02724936.1994.11747689; Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201; WARRELL DA, 1990, T R SOC TROP MED S2, V84; *WHO, 1950, TECH REP SER WHO, V38, P1; Wilson D. B., 1950, Tropical Diseases Bulletin, V47, P677	29	493	497	0	58	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1650	1654		10.1016/S0140-6736(97)02038-2	http://dx.doi.org/10.1016/S0140-6736(97)02038-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186382				2022-12-28	WOS:A1997XD10000008
J	Ducy, P; Zhang, R; Geoffroy, V; Ridall, AL; Karsenty, G				Ducy, P; Zhang, R; Geoffroy, V; Ridall, AL; Karsenty, G			Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation	CELL			English	Article							OSTEOCALCIN GENE; C-FOS; RUNT; EXPRESSION; FAMILY; DROSOPHILA; DYSPLASIA; PROMOTER; CELLS; BONE	The osteoblast is the bone-forming cell. The molecular basis of osteoblast-specific gene expression and differentiation is unknown. We previously identified an osteoblast-specific cis-acting element, termed OSE2, in the Osteocalcin promoter. We have now cloned the cDNA encoding Osf2/Cbfa1, the protein that binds to OSE2. Osf2/Cbfa1 expression is initiated in the mesenchymal condensations of the developing skeleton, is strictly restricted to cells of the osteoblast lineage thereafter, and is regulated by BMP7 and vitamin D-3. Osf2/Cbfa1 binds to and regulates the expression of multiple genes expressed in osteoblasts. Finally, forced expression of Osf2/Cbfa1 in nonosteoblastic cells induces the expression of the principal osteoblast-specific genes. this study identifies Osf2/Cbfa1 as an osteoblast-specific transcription factor and as a regulator of osteoblast differentiation.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030; UNIV TEXAS,DENT BRANCH,DEPT BASIC SCI,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System			Geoffroy, Valerie/P-1521-2014	Geoffroy, Valerie/0000-0003-3920-7482	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011290] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-11290] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aubin Jane E., 1996, P51; BAE SC, 1993, ONCOGENE, V8, P809; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; Cohn MJ, 1996, TRENDS GENET, V12, P253, DOI 10.1016/0168-9525(96)10030-5; DUCY P, 1995, MOL CELL BIOL, V15, P1858; FURUKAWA K, 1990, CELL GROWTH DIFFER, V1, P135; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; GERGEN JP, 1985, DEV BIOL, V109, P321, DOI 10.1016/0012-1606(85)90459-2; GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Horton William A., 1993, P73; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P389; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Sambrook J., 2002, MOL CLONING LAB MANU; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SILLENCE DO, 1987, AM J MED GENET, V27, P75, DOI 10.1002/ajmg.1320270109; SIMEONE A, 1995, DEV DYNAM, V203, P61, DOI 10.1002/aja.1002030107; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WIJMENGA C, 1995, GENOMICS, V26, P611, DOI 10.1016/0888-7543(95)80185-O; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110	36	3387	3617	17	192	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					747	754		10.1016/S0092-8674(00)80257-3	http://dx.doi.org/10.1016/S0092-8674(00)80257-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182762	Bronze			2022-12-28	WOS:A1997XB92500011
J	Jacq, C; AltMorbe, J; Andre, B; Arnold, W; Bahr, A; Ballesta, JPG; Bargues, M; Baron, L; Becker, A; Biteau, N; Blocker, H; Blugeon, C; Boskovic, J; Brandt, P; Bruckner, M; Buitrago, MJ; Coster, F; Delaveau, T; delRey, F; Dujon, B; Eide, LG; GarciaCantalejo, JM; Goffeau, A; GomezPeris, A; Granotier, C; Hanemann, V; Hankeln, T; Hoheisel, JD; Jager, W; Jimenez, A; Jonniaux, JL; Kramer, C; Kuster, H; Laamanen, P; Legros, Y; Louis, E; MollerRieker, S; Monnet, A; Moro, M; MullerAuer, S; Nussbaumer, B; Paricio, N; Paulin, L; Perea, J; PerezAlonso, M; PerezOrtin, JE; Pohl, TM; Prydz, H; Purnelle, B; Rasmussen, SW; Remacha, M; Revuelta, JL; Rieger, M; Salom, D; Saluz, HP; Saiz, JE; Saren, AM; Schafer, M; Scharfe, M; Schmidt, ER; Schneider, C; Scholler, P; Schwarz, S; SolerMira, A; Urrestarazu, LA; Verhasselt, P; Vissers, S; Voet, M; Volckaert, G; Wagner, G; Wambutt, R; Wedler, E; Wedler, H; Wolfl, S; Harris, DE; Bowman, S; Brown, D; Churcher, CM; Connor, R; Dedman, K; Gentles, S; Hamlin, N; Hunt, S; Jones, L; McDonald, S; Murphy, L; Niblett, D; Odell, C; Oliver, K; Rajandream, MA; Richards, C; Shore, L; Walsh, SV; Barrell, BG; Dietrich, FS; Mulligan, J; Allen, E; Araujo, R; Aviles, E; Berno, O; Carpenter, J; Chen, E; Cherry, JM; Chung, E; Duncan, M; HunickeSmith, S; Hyman, R; Komp, C; Lashkari, D; Lew, H; Lin, D; Mosedale, D; Nakahara, K; Namath, A; Oefner, P; Oh, C; Petel, FX; Roberts, D; Schramm, S; Schroeder, M; Shogren, T; Shroff, N; Winant, A; Yelton, M; Botstein, D; Davis, RW; Johnston, M; Hillier, L; Riles, L; Albermann, K; Hani, J; Heumann, K; Kleine, K; Mewes, HW; Zollner, A; Zaccaria, P				Jacq, C; AltMorbe, J; Andre, B; Arnold, W; Bahr, A; Ballesta, JPG; Bargues, M; Baron, L; Becker, A; Biteau, N; Blocker, H; Blugeon, C; Boskovic, J; Brandt, P; Bruckner, M; Buitrago, MJ; Coster, F; Delaveau, T; delRey, F; Dujon, B; Eide, LG; GarciaCantalejo, JM; Goffeau, A; GomezPeris, A; Granotier, C; Hanemann, V; Hankeln, T; Hoheisel, JD; Jager, W; Jimenez, A; Jonniaux, JL; Kramer, C; Kuster, H; Laamanen, P; Legros, Y; Louis, E; MollerRieker, S; Monnet, A; Moro, M; MullerAuer, S; Nussbaumer, B; Paricio, N; Paulin, L; Perea, J; PerezAlonso, M; PerezOrtin, JE; Pohl, TM; Prydz, H; Purnelle, B; Rasmussen, SW; Remacha, M; Revuelta, JL; Rieger, M; Salom, D; Saluz, HP; Saiz, JE; Saren, AM; Schafer, M; Scharfe, M; Schmidt, ER; Schneider, C; Scholler, P; Schwarz, S; SolerMira, A; Urrestarazu, LA; Verhasselt, P; Vissers, S; Voet, M; Volckaert, G; Wagner, G; Wambutt, R; Wedler, E; Wedler, H; Wolfl, S; Harris, DE; Bowman, S; Brown, D; Churcher, CM; Connor, R; Dedman, K; Gentles, S; Hamlin, N; Hunt, S; Jones, L; McDonald, S; Murphy, L; Niblett, D; Odell, C; Oliver, K; Rajandream, MA; Richards, C; Shore, L; Walsh, SV; Barrell, BG; Dietrich, FS; Mulligan, J; Allen, E; Araujo, R; Aviles, E; Berno, O; Carpenter, J; Chen, E; Cherry, JM; Chung, E; Duncan, M; HunickeSmith, S; Hyman, R; Komp, C; Lashkari, D; Lew, H; Lin, D; Mosedale, D; Nakahara, K; Namath, A; Oefner, P; Oh, C; Petel, FX; Roberts, D; Schramm, S; Schroeder, M; Shogren, T; Shroff, N; Winant, A; Yelton, M; Botstein, D; Davis, RW; Johnston, M; Hillier, L; Riles, L; Albermann, K; Hani, J; Heumann, K; Kleine, K; Mewes, HW; Zollner, A; Zaccaria, P			The nucleotide sequence of Saccharomyces cerevisiae chromosome IV	NATURE			English	Article							COMPLETE DNA-SEQUENCE; YEAST; RESOLUTION; ELEMENTS; XI	The complete DNA sequence of the yeast Saccharomyces cerevisiae chromosome IV has been determined. Apart from chromosome XII, which contains the 1-2 Mb rDNA cluster, chromosome IV is the longest S. cerevisiae chromosome. It was split into three parts, which were sequenced by a consortium from the European Community, the Sanger Centre, and groups from St Louis and Stanford in the United States. The sequence of 1,531,974 base pairs contains 796 predicted or known genes, 318 (39.9%) of which have been previously identified. Of the 478 new genes, 225 (28.3%) are homologous to previously identified genes and 253 (32%) have unknown functions or correspond to spurious open reading frames (ORFs). On average there is one gene approximately every two kilobases. Superimposed on alternating regional variations in G+C composition, there is a large central domain with a lower G+C content that contains all the yeast transposon (Ty) elements and most of the tRNA genes. Chromosome IV shares with chromosomes II, V, XII, XIII and XV some long clustered duplications which partly explain its origin.	LAB DNA ANALYT, D-79100 FREIBURG, GERMANY; LAB PHYSIOL CELLULAIRE & GENET LEVURES, B-1050 BRUSSELS, BELGIUM; UNIV BIELEFELD, FAK BIOL, LEHRSTUHL GENET, D-33501 BIELEFELD, GERMANY; UNIV MAINZ, INST GENET MOL, D-55099 MAINZ, GERMANY; CSIC, CTR BIOL MOL, E-28049 MADRID, SPAIN; UNIV AUTONOMA MADRID, E-28049 MADRID 28049, SPAIN; UNIV VALENCIA, DEPT GENET, E-46100 BURJASSOT, SPAIN; PHARM BIOTECH, F-91898 ORSAY, FRANCE; GB GENOME ANAL, D-38124 BRAUNSCHWEIG, GERMANY; GENOTYPE GMBH, D-69259 WILHELMSFELD, GERMANY; UNIV SALAMANCA, DEPT MICROBIOL & GENET, E-37007 SALAMANCA, SPAIN; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; INST PASTEUR, DEPT BIOTECHNOL, UNITE GENET MOL LEVURES, F-75724 PARIS 15, FRANCE; CTR BIOTECHNOL, N-0371 OSLO, NORWAY; UNIV VALENCIA, FAC BIOL, DEPT BIOQUIM & BIOL MOL, E-46100 BURJASSOT, SPAIN; HANS KNOLL INST, D-07745 JENA, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69210 HEIDELBERG, GERMANY; UNIV HELSINKI, INST BIOTECHNOL, DNA SYNTH & SEQUENCING LAB, FIN-00014 HELSINKI, FINLAND; JOHN RADCLIFFE HOSP, INST MOL MED, DEPT YEAST GENET, OXFORD OX3 9DU, ENGLAND; LNCIB, AREA SCI PK, I-34012 TRIESTE, ITALY; GATC GMBH, D-78467 CONSTANCE, GERMANY; CARLSBERG LAB, DK-2500 COPENHAGEN, DENMARK; AGON GMBH, D-12489 BERLIN, GERMANY; KATHOLIEKE UNIV LEUVEN, LAB GENE TECHNOL, B-3001 LOUVAIN, BELGIUM; SANGER CTR, CAMBRIDGE CB10 1SA, ENGLAND; STANFORD UNIV, BECKMAN CTR, DEPT BIOCHEM, STANFORD, CA 94305 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, GENOME SEQUENCING CTR, ST LOUIS, MO 63110 USA; MAX PLANCK INST BIOCHEM, MARTINSRIEDER INST PROT SEQUENZEN, D-82152 MARTINSRIED, GERMANY	University of Bielefeld; Johannes Gutenberg University of Mainz; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; University of Valencia; University of Salamanca; Universite Catholique Louvain; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Valencia; Hans Knoll Institute (HKI); Helmholtz Association; German Cancer Research Center (DKFZ); University of Helsinki; University of Oxford; KU Leuven; Wellcome Trust Sanger Institute; Stanford University; Washington University (WUSTL); Max Planck Society	Jacq, C (corresponding author), ECOLE NORMALE SUPER, CNRS, URA 1302, GENET MOL LAB, 46 RUE ULM, F-75230 PARIS 05, FRANCE.		Louis, Edward/B-7920-2008; Dujon, Bernard A/F-4971-2010; Pérez-Ortín, José E./K-8582-2014; Paricio, Nuria/K-2184-2014; del Rey, Francisco/L-7132-2014; boskovic, jasminka/L-5117-2018; Pérez-Alonso, Manuel/M-3333-2014; Revuelta, Jose Luis/ABG-1502-2020; André, Bruno/D-1725-2010; Küster, Helge/A-4487-2013; Wilson, Richard K./AAF-4139-2019; Oh, Chulmin/ABB-6024-2021; Gómez, Ana/K-6998-2014; Revuelta, Jose L/C-2324-2012; Remacha, Miguel/G-1250-2016	Louis, Edward/0000-0003-1157-3608; Pérez-Ortín, José E./0000-0002-1992-513X; Paricio, Nuria/0000-0001-7193-2532; del Rey, Francisco/0000-0002-6517-7400; boskovic, jasminka/0000-0001-6135-0686; Pérez-Alonso, Manuel/0000-0002-3266-0340; Revuelta, Jose Luis/0000-0001-7838-5308; Küster, Helge/0000-0002-9197-9802; Wilson, Richard K./0000-0002-1992-1358; Gómez, Ana/0000-0003-4714-8064; Revuelta, Jose L/0000-0001-7838-5308; Murphy, Lee/0000-0001-6467-7449; Garcia-Cantalejo, Jesus/0000-0001-6465-1273; Buitrago, Maria Jose/0000-0003-1878-6067; Salom, David/0000-0002-3208-1509; Hunt, Sarah/0000-0002-8350-1235; Cherry, J. Michael/0000-0001-9163-5180; Biteau, Nicolas/0000-0003-1301-0665				BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Casari G, 1996, TRENDS GENET, V12, P244, DOI 10.1016/0168-9525(96)30057-7; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; Galibert F, 1996, EMBO J, V15, P2031, DOI 10.1002/j.1460-2075.1996.tb00557.x; HEUMANN K, UNPUB NATURE GENET; II H, 1993, CELL, V73, P1007; JINKSROBERTSON S, 1985, P NATL ACAD SCI USA, V82, P3350, DOI 10.1073/pnas.82.10.3350; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KALOGEROPOULOS A, 1995, YEAST, V11, P555, DOI 10.1002/yea.320110605; KUPIEC M, 1988, MOL CELL BIOL, V8, P2942, DOI 10.1128/MCB.8.7.2942; LALO D, 1993, CR ACAD SCI III-VIE, V316, P367; LOCHMULLER H, 1989, CURR GENET, V16, P247, DOI 10.1007/BF00422110; LOUIS EJ, 1995, GENETICS, V139, P125; MELNICK L, 1993, J MOL BIOL, V233, P372, DOI 10.1006/jmbi.1993.1518; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; NAVARRE C, 1994, J BIOL CHEM, V269, P21262; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; Olson M., 1991, MOL CELLULAR BIOL YE, P1; PRYDE FE, 1995, YEAST, V11, P371, DOI 10.1002/yea.320110410; RILES L, 1993, GENETICS, V134, P81; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; Termier M, 1996, YEAST, V12, P369, DOI 10.1002/(SICI)1097-0061(19960330)12:4<369::AID-YEA922>3.0.CO;2-#; THIERRY A, 1995, YEAST, V11, P121, DOI 10.1002/yea.320110204; VOYTAS DF, 1993, TRENDS GENET, V9, P421, DOI 10.1016/0168-9525(93)90105-Q	29	80	938	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632		S			75	78		10.1038/387s075	http://dx.doi.org/10.1038/387s075			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169867				2022-12-28	WOS:A1997XB54600007
J	Tettelin, H; Carbone, MLA; Albermann, K; Albers, M; Arroyo, J; Backes, U; Barreiros, T; Bertani, I; Bjourson, AJ; Bruckner, M; Bruschi, CV; Carignani, G; Castagnoli, L; Cerdan, E; Clemente, ML; Coblenz, A; Coglievina, M; Coissac, E; Defoor, E; DelBino, S; Delius, H; Delneri, D; deWergifosse, P; Dujon, B; Durand, P; Entian, KD; Eraso, P; Escribano, V; Fabiani, L; Fartmann, B; Feroli, F; Feuermann, M; Frontali, L; GarciaGonzalez, M; GarciaSaez, MI; Goffeau, A; Guerreiro, P; Hani, J; Hansen, M; Hebling, U; Hernandez, K; Heumann, K; Hilger, F; Hofmann, B; Indge, KJ; James, CM; Klima, R; Kotter, P; Kramer, B; Kramer, W; Lauquin, G; Leuther, H; Louis, EJ; Maillier, E; Marconi, A; Martegani, E; Mazon, MJ; Mazzoni, C; McReynolds, ADK; Melchioretto, P; Mewes, HW; Minenkova, O; MullerAuer, S; Nawrocki, A; Netter, P; Neu, R; Nombela, C; Oliver, SG; Panzeri, L; Paoluzi, S; Plevani, P; Portetelle, D; Portillo, F; Potier, S; Purnelle, B; Rieger, M; Riles, L; Rinaldi, T; Robben, J; RodriguesPousada, C; RodriguezBelmonte, E; RodriguezTorres, AM; Rose, M; Ruzzi, M; Saliola, M; SanchezPerez, M; Schafer, B; Schafer, M; Scharfe, M; Schmidhelni, T; Schreer, A; Skala, J; Souciet, JL; Steensma, HY; Talla, E; Thierry, A; Vandenbol, M; vanderAart, QJM; VanDyck, L; Vanoni, M; Verhasselt, P; Voet, M; Volckaert, G; Wambutt, R; Watson, MD; Weber, N; Wedler, E; Wedler, H; Wipfli, P; Wolf, K; Wright, LF; Zaccaria, P; Zimmermann, M; Zollner, A; Kleine, K				Tettelin, H; Carbone, MLA; Albermann, K; Albers, M; Arroyo, J; Backes, U; Barreiros, T; Bertani, I; Bjourson, AJ; Bruckner, M; Bruschi, CV; Carignani, G; Castagnoli, L; Cerdan, E; Clemente, ML; Coblenz, A; Coglievina, M; Coissac, E; Defoor, E; DelBino, S; Delius, H; Delneri, D; deWergifosse, P; Dujon, B; Durand, P; Entian, KD; Eraso, P; Escribano, V; Fabiani, L; Fartmann, B; Feroli, F; Feuermann, M; Frontali, L; GarciaGonzalez, M; GarciaSaez, MI; Goffeau, A; Guerreiro, P; Hani, J; Hansen, M; Hebling, U; Hernandez, K; Heumann, K; Hilger, F; Hofmann, B; Indge, KJ; James, CM; Klima, R; Kotter, P; Kramer, B; Kramer, W; Lauquin, G; Leuther, H; Louis, EJ; Maillier, E; Marconi, A; Martegani, E; Mazon, MJ; Mazzoni, C; McReynolds, ADK; Melchioretto, P; Mewes, HW; Minenkova, O; MullerAuer, S; Nawrocki, A; Netter, P; Neu, R; Nombela, C; Oliver, SG; Panzeri, L; Paoluzi, S; Plevani, P; Portetelle, D; Portillo, F; Potier, S; Purnelle, B; Rieger, M; Riles, L; Rinaldi, T; Robben, J; RodriguesPousada, C; RodriguezBelmonte, E; RodriguezTorres, AM; Rose, M; Ruzzi, M; Saliola, M; SanchezPerez, M; Schafer, B; Schafer, M; Scharfe, M; Schmidhelni, T; Schreer, A; Skala, J; Souciet, JL; Steensma, HY; Talla, E; Thierry, A; Vandenbol, M; vanderAart, QJM; VanDyck, L; Vanoni, M; Verhasselt, P; Voet, M; Volckaert, G; Wambutt, R; Watson, MD; Weber, N; Wedler, E; Wedler, H; Wipfli, P; Wolf, K; Wright, LF; Zaccaria, P; Zimmermann, M; Zollner, A; Kleine, K			The nucleotide sequence of Saccharomyces cerevisiae chromosome VII	NATURE			English	Article							OPEN READING FRAMES; MEMBRANE-SPANNING PROTEINS; COMPLETE DNA-SEQUENCE; RIGHT ARM; KB SEGMENT; ATE1 LOCI; FRAGMENT; REVEALS; GENES; XI	The complete nucleotide sequence of Saccharomyces cerevisiae chromosome VII has 572 predicted open reading frames (ORFs), of which 341 are new. No correlation was found between G+C content and gene density along the chromosome, and their variations are random. Of the ORFs, 17% show high similarity to human proteins. Almost half of the ORFs could be classified in functional categories, and there is a slight increase in the number of transcription (7.0 %) and translation (5.2 %) factors when compared with the complete S. cerevisiae genome. Accurate verification procedures demonstrate that there are less than two errors per 10,000 base pairs in the published sequence.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; UNIV MILAN, DIPARTIMENTO GENET & BIOL MICROORGANISMI, I-20133 MILAN, ITALY; MAX PLANCK INST BIOCHEM, MARTINSRIEDER INST PROT SEQUENZEN, D-82152 MARTINSRIED, GERMANY; RHEIN WESTFAL TH AACHEN, INST BIOL 4, D-52056 AACHEN, GERMANY; UNIV COMPLUTENSE MADRID, FAC FARM, DEPT MICROBIOL 2, E-28040 MADRID, SPAIN; UNIV COMPLUTENSE MADRID, FAC FARM, UCM, CTR SECUENCIAC DNA, E-28040 MADRID, SPAIN; GULBENKIAN INST SCI, GENET MOL LAB, P-2781 OEIRAS, PORTUGAL; INT CTR GENET ENGN & BIOTECHNOL, MICROBIOL GRP, I-34012 TRIESTE, ITALY; QUEENS UNIV BELFAST, BIOTECHNOL CTR ANIM & PLANT HLTH, BELFAST BT9 5PX, ANTRIM, NORTH IRELAND; GENOTYPE GMBH, D-69259 WILHELMSFELD, GERMANY; UNIV PADUA, DIPARTIMENTO CHIM BIOL, I-35121 PADUA, ITALY; UNIV ROMA TOR VERGATA, DIPARTIMENTO BIOL, I-00133 ROME, ITALY; UNIV LA CORUNA, FAC CIENCIAS, DEPT BIOL CELULAR & MOL, LA CORUNA, SPAIN; UNIV PARIS 06, CTR GENET MOL, CNRS, LAB ASSOCIE, F-91198 GIF SUR YVETTE, FRANCE; KATHOLIEKE UNIV LEUVEN, LAB GENE TECHNOL, B-3001 LOUVAIN, BELGIUM; DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT APPL VIROL, D-69120 HEIDELBERG, GERMANY; FAC UNIV SCI AGRON GEMBLOUX, UNITE MICROBIOL, B-5030 GEMBLOUX, BELGIUM; UNIV FRANKFURT, INST MIKROBIOL, D-60439 FRANKFURT, GERMANY; UNIV AUTONOMA MADRID, FAC MED, CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN; UNIV AUTONOMA MADRID, FAC MED, DEPT BIOQUIM, E-28029 MADRID, SPAIN; UNIV ROMA LA SAPIENZA, DIPARTIMENTO BIOL CELLULARE & SVILUPPO, I-00185 ROME, ITALY; UNIV GOTTINGEN, INST MOL GENET, D-37077 GOTTINGEN, GERMANY; UNIV STRASBOURG 1, CNRS, INST BOT, LAB MICROBIOL & GENET, URA 1481, F-67083 STRASBOURG, FRANCE; MICROSYNTH GMBH, CH-9436 BALGACH, SWITZERLAND; UNIV MANCHESTER, INST SCI & TECHNOL, DEPT BIOCHEM & APPL MOL BIOL, MANCHESTER M60 1QD, LANCS, ENGLAND; CNRS, INST BIOCHIM CELLULAIRE, F-33077 BORDEAUX, FRANCE; JOHN RADCLIFFE HOSP, INST MOL MED, OXFORD OX3 9DU, ENGLAND; UNIV MILAN, DIPARTIMENTO FISIOL & BIOCHIM GEN, I-20133 MILAN, ITALY; UNIV WROCLAW, INST MICROBIOL, PL-51148 WROCLAW, POLAND; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, GENOME SEQUENCING CTR, ST LOUIS, MO 63110 USA; UNIV TUSCIA, DIPARTIMENTO AGROBIOL & AGROCHIM, I-01100 VITERBO, ITALY; AGON GMBH, D-12489 BERLIN, GERMANY; LEIDEN UNIV, INST MOL PLANT SCI, NL-2333 AL LEIDEN, NETHERLANDS; DELFT UNIV TECHNOL, DEPT MICROBIOL & ENZYMOL, NL-2628 BC DELFT, NETHERLANDS; UNIV DURHAM, DEPT BIOL SCI, DURHAM DH1 3LE, ENGLAND; INST PASTEUR, DEPT BIOTECHNOL,CNRS,URA 1149, UNITE GENET MOL LEVURES, F-75724 PARIS 15, FRANCE; UNIV PARIS 06, INST PASTEUR, DEPT BIOTECHNOL, UPR 927, F-75724 PARIS 15, FRANCE	Universite Catholique Louvain; University of Milan; Max Planck Society; RWTH Aachen University; Complutense University of Madrid; Complutense University of Madrid; International Center for Genetic Engineering & Biotechnology (ICGEB); Queens University Belfast; University of Padua; University of Rome Tor Vergata; Universidade da Coruna; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; KU Leuven; Helmholtz Association; German Cancer Research Center (DKFZ); University of Liege; Goethe University Frankfurt; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Sapienza University Rome; University of Gottingen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Manchester; Centre National de la Recherche Scientifique (CNRS); University of Oxford; University of Milan; University of Wroclaw; Washington University (WUSTL); Washington University (WUSTL); Tuscia University; Leiden University; Leiden University - Excl LUMC; Delft University of Technology; Durham University; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite			Rinaldi, Teresa/AAC-9710-2020; Rodríguez-Belmonte, Esther/E-1675-2012; Mazzoni, Cristina/U-2658-2018; Coissac, Éric/AAE-8735-2019; Mazmela, Pilar Eraso/E-9248-2016; RUZZI, Maurizio/AAC-2603-2020; Dujon, Bernard A/F-4971-2010; Rodríguez-Belmonte, Esther/AAL-5653-2020; Dujon, Bernard/AAL-8410-2021; Entian, Karl-Dieter/D-3080-2011; Louis, Edward/B-7920-2008; Ruzzi, Maurizio/N-1312-2015; Nombela Cano, César/H-2565-2015; Arroyo, Javier/E-9308-2016; Calpena, María Jesús Mazón/E-9168-2016; Mewes, Hans-Werner/A-8204-2019; CERDAN, MARIA ESPERANZA/D-5644-2013	Rinaldi, Teresa/0000-0001-6291-245X; Rodríguez-Belmonte, Esther/0000-0001-8243-1303; Mazzoni, Cristina/0000-0002-1504-6189; Coissac, Éric/0000-0001-7507-6729; Mazmela, Pilar Eraso/0000-0002-6928-3219; Dujon, Bernard/0000-0003-4661-3534; Louis, Edward/0000-0003-1157-3608; Ruzzi, Maurizio/0000-0003-4616-1507; Nombela Cano, César/0000-0003-0757-4034; Arroyo, Javier/0000-0002-1971-1721; Calpena, María Jesús Mazón/0000-0003-4151-4051; PLEVANI, PAOLO/0000-0003-1869-2626; Delneri, Daniela/0000-0001-8070-411X; Rodrigues-Pousada, Claudina/0000-0002-5075-3639; Mewes, Hans-Werner/0000-0002-9713-6398; Feuermann, Marc/0000-0002-4187-2863; Guerreiro, Paulo/0000-0002-0070-7757; Castagnoli, Luisa/0000-0001-5283-8671; Martegani, Enzo/0000-0001-9196-4224; CERDAN, MARIA ESPERANZA/0000-0001-8540-1417; TALLA, Emmanuel/0000-0002-7775-8296; Del Bino, Sandra/0000-0002-8488-1890; John, Anthony/0000-0002-1105-7147; Portillo Perez, Francisco/0000-0003-4922-346X				ARROYO J, 1995, YEAST, V11, P587, DOI 10.1002/yea.320110609; BERTANI I, 1995, YEAST, V11, P1187, DOI 10.1002/yea.320111209; CAPIEAUX E, 1991, YEAST, V7, P275, DOI 10.1002/yea.320070309; CHEN WN, 1991, YEAST, V7, P287, DOI 10.1002/yea.320070311; COGLIEVINA M, 1995, YEAST, V11, P767, DOI 10.1002/yea.320110808; Coissac E, 1996, YEAST, V12, P1555; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; Escribano V, 1996, YEAST, V12, P887; GOFFEAU A, 1993, YEAST, V9, P691, DOI 10.1002/yea.320090703; Guerreiro P, 1996, YEAST, V12, P273, DOI 10.1002/(SICI)1097-0061(19960315)12:3<273::AID-YEA898>3.0.CO;2-1; GUERREIRO P, 1995, YEAST, V11, P1087, DOI 10.1002/yea.320111110; Hansen M, 1996, YEAST, V12, P1273, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1273::AID-YEA21>3.0.CO;2-J; JAMES CM, 1995, YEAST, V11, P1413, DOI 10.1002/yea.320111409; Klima R, 1996, YEAST, V12, P1033; LOUIS EJ, 1995, GENETICS, V139, P125; MILOSAVLJEVIC A, 1993, CABIOS, V9, P409; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OLSON MV, 1991, MOL CELLULAR BIOL YE, V1, P1; RodriguezBelmonte E, 1996, YEAST, V12, P145, DOI 10.1002/(SICI)1097-0061(199602)12:2<145::AID-YEA888>3.0.CO;2-E; RYMOND BC, 1993, P NATL ACAD SCI USA, V90, P848, DOI 10.1073/pnas.90.3.848; SKALA J, 1995, YEAST, V11, P1421, DOI 10.1002/yea.320111410; TETTELIN H, 1995, METHODS MOL GENETICS; THIERRY A, 1995, YEAST, V11, P121, DOI 10.1002/yea.320110204; Tizon B, 1996, YEAST, V12, P1047, DOI 10.1002/(SICI)1097-0061(199609)12:10B<1047::AID-YEA991>3.3.CO;2-E; Vandenbol M, 1995, YEAST, V11, P1519, DOI 10.1002/yea.320111507; vanderAart QJM, 1996, YEAST, V12, P385; WOOLFORD JL, 1991, MOL CELLULAR BIOL YE, V1, P597	30	45	655	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632		S			81	84		10.1038/387s081	http://dx.doi.org/10.1038/387s081			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169869				2022-12-28	WOS:A1997XB54600009
J	Nichols, AW				Nichols, AW			Arizona overwhelmingly adopts health care initiative	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nichols, AW (corresponding author), UNIV ARIZONA,COLL MED,HLTH SCI CTR,DEPT FAMILY & COMMUNITY MED,RURAL HLTH OFF,2501 ELM ST,TUCSON,AZ 85715, USA.							BUTLER D, 1978, REFERENDUMS COMP STU; Cronin Thomas, 1989, DIRECT DEMOCRACY POL, P50; Suksi Markku, 1993, BRINGING PEOPLE COMP; WILCOX D, 1972, GOVT ALL PEOPLE INIT; 1996, NY TIMES        1107, pA19	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	1997	277	20					1645	1648		10.1001/jama.277.20.1645	http://dx.doi.org/10.1001/jama.277.20.1645			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA022	9168298				2022-12-28	WOS:A1997XA02200039
J	Karpatkin, S				Karpatkin, S			Autoimmune (idiopathic) thrombocytopenic purpura	LANCET			English	Article							ANTI-PLATELET ANTIBODY; INTRAVENOUS GAMMA-GLOBULIN; GLYCOPROTEIN-IIIA; MATERNAL THROMBOCYTOPENIA; ANTIPLATELET ANTIBODY; IMMUNOGLOBULIN-G; BOUND IGG; AUTOANTIBODIES; KINETICS; THERAPY				Karpatkin, S (corresponding author), NYU, SCH MED, DEPT MED, 550 1ST AVE, NEW YORK, NY 10003 USA.							ALMOFADA S, 1991, AM J PERINAT, V11, P423; ANDERSEN JC, 1994, NEW ENGL J MED, V330, P1560, DOI 10.1056/NEJM199406023302203; ASTER RH, 1964, J CLIN INVEST, V43, P856, DOI 10.1172/JCI104971; ASTER RH, 1969, BRIT J HAEMATOL, V16, P61, DOI 10.1111/j.1365-2141.1969.tb00379.x; BALLEM PJ, 1987, J CLIN INVEST, V80, P33, DOI 10.1172/JCI113060; BEARDSLEY DS, 1984, J CLIN INVEST, V74, P1701, DOI 10.1172/JCI111587; BENNER R, 1975, CELL IMMUNOL, V19, P167, DOI 10.1016/0008-8749(75)90201-4; BEST WR, 1962, MED CLIN N AM, V46, P19, DOI 10.1016/S0025-7125(16)33746-4; BLANCHETTE V, 1994, LANCET, V344, P703, DOI 10.1016/S0140-6736(94)92205-5; BORKOWSKY W, 1984, BLOOD, V63, P83; BRANEHOG I, 1975, BLOOD, V45, P551; Burrows R F, 1993, Obstet Gynecol Surv, V48, P781, DOI 10.1097/00006254-199312000-00003; BURROWS RF, 1993, NEW ENGL J MED, V329, P1463, DOI 10.1056/NEJM199311113292005; BUSSEL JB, 1983, BLOOD, V62, P480; CARPENTER AF, 1958, JAMA-J AM MED ASSOC, V166, P1805; Chang M, 1996, BLOOD, V88, P3354, DOI 10.1182/blood.V88.9.3354.bloodjournal8893354; CINES DB, 1979, NEW ENGL J MED, V300, P106, DOI 10.1056/NEJM197901183000302; DIFINO SM, 1980, AM J MED, V69, P430, DOI 10.1016/0002-9343(80)90016-9; DIXON R, 1975, NEW ENGL J MED, V292, P230, DOI 10.1056/NEJM197501302920503; DOAN CA, 1960, ANN INTERN MED, V53, P861, DOI 10.7326/0003-4819-53-5-861; EPSTEIN RD, 1950, AM J MED, V9, P44, DOI 10.1016/0002-9343(50)90007-6; FIRKIN BG, 1969, BLOOD-J HEMATOL, V33, P240, DOI 10.1182/blood.V33.2.240.240; FLUG F, 1994, BRIT J HAEMATOL, V86, P1, DOI 10.1111/j.1365-2141.1994.tb03244.x; FUJISAWA K, 1993, BLOOD, V81, P1284; FUJISAWA K, 1991, BLOOD, V77, P2207; FUJISAWA K, 1993, BLOOD, V81, P2872; GARG SK, 1971, NEW ENGL J MED, V284, P11, DOI 10.1056/NEJM197101072840103; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; GEORGE JN, 1988, BLOOD, V72, P362; GREENDYK.RM, 1965, J CLIN INVEST, V44, P746, DOI 10.1172/JCI105187; GROSSI A, 1983, SCAND J HAEMATOL, V31, P206; HANDAGAMA PJ, 1987, P NATL ACAD SCI USA, V84, P861, DOI 10.1073/pnas.84.3.861; HARKER LA, 1970, BRIT J HAEMATOL, V19, P95, DOI 10.1111/j.1365-2141.1970.tb01605.x; HARRINGTON WJ, 1951, J LAB CLIN MED, V38, P1; HART D, 1986, AM J OBSTET GYNECOL, V154, P878, DOI 10.1016/0002-9378(86)90475-8; HILGARTNER MW, 1970, ACTA PAEDIATR SCAND, V59, P409, DOI 10.1111/j.1651-2227.1970.tb15536.x; HIRSCH EO, 1951, ARCH INTERN MED, V88, P701, DOI 10.1001/archinte.1951.03810120002001; HYMES K, 1979, J LAB CLIN MED, V94, P639; HYMES K, 1981, ANN INTERN MED, V94, P27, DOI 10.7326/0003-4819-94-1-27; HYMES KB, 1990, BRIT J HAEMATOL, V74, P330, DOI 10.1111/j.1365-2141.1990.tb02591.x; IMBACH P, 1981, LANCET, V1, P1228; JACOB HS, 1963, J CLIN INVEST, V42, P1476, DOI 10.1172/JCI104832; JACOBSON BM, 1952, NEW ENGL J MED, V246, P247, DOI 10.1056/NEJM195202142460702; KARPATKI.S, 1969, BLOOD-J HEMATOL, V33, P795, DOI 10.1182/blood.V33.6.795.795; KARPATKIN S, 1971, AM J MED, V51, P1, DOI 10.1016/0002-9343(71)90317-2; KARPATKIN S, 1985, SEMIN HEMATOL, V22, P260; KARPATKIN S, 1992, BLOOD, V80, P3164; KARPATKIN S, 1972, BRIT J HAEMATOL, V23, P167, DOI 10.1111/j.1365-2141.1972.tb03470.x; KARPATKIN S, 1972, AM J MED, V52, P776, DOI 10.1016/0002-9343(72)90084-8; KARPATKIN S, 1978, BLOOD, V51, P307; KEKOMAKI R, 1991, J CLIN INVEST, V88, P847, DOI 10.1172/JCI115386; KERNOFF LM, 1980, BLOOD, V55, P730; KURATA Y, 1994, THROMB HAEMOSTASIS, V71, P184; LOBUGLIO AF, 1983, NEW ENGL J MED, V309, P459, DOI 10.1056/NEJM198308253090804; LURHUMA AZ, 1977, CLIN EXP IMMUNOL, V28, P49; MASON D, 1984, BRIT J HAEMATOL, V56, P529; MCMILLAN R, 1974, NEW ENGL J MED, V290, P249, DOI 10.1056/NEJM197401312900505; MCMILLAN R, 1978, JAMA-J AM MED ASSOC, V239, P2460, DOI 10.1001/jama.239.23.2460; MCMILLAN R, 1981, NEW ENGL J MED, V304, P1135, DOI 10.1056/NEJM198105073041904; MCMILLAN R, 1972, NEW ENGL J MED, V286, P681, DOI 10.1056/NEJM197203302861302; MCMILLAN R, 1976, J IMMUNOL, V116, P1592; NAJEAN Y, 1967, BRIT J HAEMATOL, V13, P409, DOI 10.1111/j.1365-2141.1967.tb08755.x; RABINOWITZ Y, 1960, ANN INTERN MED, V52, P1, DOI 10.7326/0003-4819-52-1-1; REINER AP, 1995, BLOOD, V86, P415; RIES CA, 1974, ANN INTERN MED, V80, P702, DOI 10.7326/0003-4819-80-6-702; ROWLEY DA, 1950, J IMMUNOL, V65, P515; RUIZ P, 1991, J CLIN INVEST, V88, P149, DOI 10.1172/JCI115271; SALAMA A, 1984, BLUT, V49, P29, DOI 10.1007/BF00320381; SCHMIDT KG, 1985, SCAND J HAEMATOL, V34, P47; SCHREIBER AD, 1975, J CLIN INVEST, V56, P1189, DOI 10.1172/JCI108196; SCOTT JR, 1983, AM J OBSTET GYNECOL, V145, P932, DOI 10.1016/0002-9378(83)90843-8; SEMPLE JW, 1995, BLOOD, V4, P327; Shulman N R, 1965, Trans Assoc Am Physicians, V78, P374; STASI R, 1994, BLOOD, V84, P4203, DOI 10.1182/blood.V84.12.4203.bloodjournal84124203; STOLL D, 1985, BLOOD, V65, P584; SZATKOWSKI NS, 1986, BLOOD, V67, P310; TOMIYAMA Y, 1989, BRIT J HAEMATOL, V71, P77, DOI 10.1111/j.1365-2141.1989.tb06278.x; VANLEEUWEN EF, 1982, BLOOD, V59, P23; VARON D, 1983, P NATL ACAD SCI-BIOL, V80, P6992, DOI 10.1073/pnas.80.22.6992; VERP M, 1975, J LAB CLIN MED, V85, P478; WHITAKER AN, 1969, MED J AUSTRALIA, V1, P1213, DOI 10.5694/j.1326-5377.1969.tb62293.x; WOODS VL, 1984, BLOOD, V64, P156	82	145	152	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	1997	349	9064					1531	1536		10.1016/S0140-6736(96)12118-8	http://dx.doi.org/10.1016/S0140-6736(96)12118-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167472	hybrid			2022-12-28	WOS:A1997XA90100043
J	Mahal, LK; Yarema, KJ; Bertozzi, CR				Mahal, LK; Yarema, KJ; Bertozzi, CR			Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis	SCIENCE			English	Article							N-ACETYLNEURAMINIC ACID; SIALIC-ACID; MONOCLONAL-ANTIBODIES; RICIN; MODULATION; PROTEINS; ALDOLASE; ANALOGS; VIRUS	Cell surface oligosaccharides can be engineered to display unusual functional groups for the selective chemical remodeling of cell surfaces. An unnatural derivative of N-acetylmannosamine, which has a ketone group, was converted to the corresponding sialic acid and incorporated into cell surface oligosaccharides metabolically, resulting in the cell surface display of ketone groups. The ketone group on the cell surface can then be covalently ligated under physiological conditions with molecules carrying a complementary reactive functional group such as the hydrazide. Cell surface reactions of this kind should prove useful in the introduction of new recognition epitopes, such as peptides, oligosaccharides, or small organic molecules, onto cell surfaces and in the subsequent modulation of cell-cell or cell-small molecule binding events. The versatility of this technology was demonstrated by an example of selective drug delivery. Cells were decorated with biotin through selective conjugation to ketone groups, and selectively killed in the presence of a ricin A chain-avidin conjugate.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,CTR ADV MAT,DIV SCI MAT,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Mahal, LK (corresponding author), UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720, USA.		Yarema, Kevin/A-3329-2010; Mahal, Lara/GRY-7287-2022	Mahal, Lara/0000-0003-4791-8524				AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; CANNE LE, 1995, J AM CHEM SOC, V117, P2998, DOI 10.1021/ja00116a005; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; FITZ W, 1994, J ORG CHEM, V59, P8279, DOI 10.1021/jo00105a057; KAYSER H, 1992, J BIOL CHEM, V267, P16934; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; KOSA RE, 1993, BIOCHEM BIOPH RES CO, V190, P914, DOI 10.1006/bbrc.1993.1136; LIN CH, 1992, J AM CHEM SOC, V114, P10138, DOI 10.1021/ja00052a008; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029; PILLER V, 1990, J BIOL CHEM, V265, P9264; Potvin B, 1995, J BIOL CHEM, V270, P30415, DOI 10.1074/jbc.270.51.30415; RAMAKRISHNAN S, 1984, CANCER RES, V44, P201; RIDEOUT D, 1994, CANCER INVEST, V12, P189, DOI 10.3109/07357909409024874; RIDEOUT D, 1990, BIOPOLYMERS, V29, P247, DOI 10.1002/bip.360290129; ROSE K, 1994, J AM CHEM SOC, V116, P30, DOI 10.1021/ja00080a004; SELL S, 1990, HUM PATHOL, V21, P1003, DOI 10.1016/0046-8177(90)90250-9; SHAMES S L, 1991, Glycobiology, V1, P187, DOI 10.1093/glycob/1.2.187; SHAO J, 1995, J AM CHEM SOC, V117, P3893, DOI 10.1021/ja00119a001; SPARKS MA, 1993, TETRAHEDRON, V49, P1, DOI 10.1016/S0040-4020(01)80502-0; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; WAERREN L, 1994, BOUND CARBOHYDRATES; WRIGHT HT, 1987, ARCH BIOCHEM BIOPHYS, V256, P280, DOI 10.1016/0003-9861(87)90447-4	25	578	673	13	182	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 16	1997	276	5315					1125	1128		10.1126/science.276.5315.1125	http://dx.doi.org/10.1126/science.276.5315.1125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9173543	Green Submitted			2022-12-28	WOS:A1997WZ22500048
J	Krongrad, A; Lai, H; Lai, SH				Krongrad, A; Lai, H; Lai, SH			Survival after radical prostatectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; MORTALITY; OUTCOMES	Context.-The generalizability of currently available estimates of survival after radical prostatectomy is theoretically limited. Objective.-To obtain generalizable estimates of survival after radical prostatectomy. Design.-A population-based retrospective cohort study. Setting.-Nine regions of the United States. Patients.-Patients who were diagnosed with prostate cancer between 1983 and 1987 and underwent radical prostatectomy and lymph node dissection. Main Outcome Measures-Proportional hazards models incorporating geographical region, age, race, pathological stage, lymph node involvement, and tumor grade to identify independent correlates of disease-specific and overall survival and life table analyses to estimate 10-year survival distributions. Results.-A total of 3626 patients with a mean age of 65 years were included in the study; 92.6% were white, 54.2% had moderate-grade cancer, 60.4% had no extension beyond the prostate, and 91.2% had no lymph node involvement. Using San Francisco-Oakland, Calif, as a reference region, no other region was significantly associated with a risk of disease-specific or overall mortality. Older age and black race were independently associated with worse overall but not disease-specific survival. Higher grade, extension beyond the prostate, and lymph node involvement were independently associated with worse disease-specific and overall survival. Estimates of 10-year disease-specific survival ranged from 75% to 97% for patients with well-differentiated and moderately differentiated cancers and from 60% to 86% for patients with poorly differentiated cancers. Conclusions.-Neither disease-specific nor overall survival varied by region, suggesting geographically uniform assessments of risk in patient selection for radical prostatectomy. Across regions, overall survival varied by patient and prostate cancer characteristic while disease-specific survival varied substantially by prostate cancer but not patient characteristics. The present analyses provide the most generalizable current estimates of survival after radical prostatectomy.	UNIV MIAMI,SCH MED,DEPT UROL,MIAMI,FL; UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL; UNIV MIAMI,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,MIAMI,FL; UNIV MIAMI,SYLVESTER COMPREHENS CANC CTR,MIAMI,FL 33152	University of Miami; University of Miami; University of Miami; University of Miami	Krongrad, A (corresponding author), VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN,1201 NW 16TH ST,MIAMI,FL 33125, USA.							BENNETT CL, 1991, CANCER, V67, P2633, DOI 10.1002/1097-0142(19910515)67:10<2633::AID-CNCR2820671039>3.0.CO;2-9; COX DR, 1972, J R STAT SOC B, V34, P187; Fryback DG, 1996, JAMA-J AM MED ASSOC, V276, P1723; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; Gilliland FD, 1996, UROLOGY, V48, P67, DOI 10.1016/S0090-4295(96)00083-0; Helgesen F, 1996, JNCI-J NATL CANCER I, V88, P1216, DOI 10.1093/jnci/88.17.1216; HSING AW, 1994, CANCER EPIDEM BIOMAR, V3, P527; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; Krongrad A, 1996, J UROLOGY, V156, P1084, DOI 10.1016/S0022-5347(01)65710-0; Krongrad A, 1996, Urol Oncol, V2, P35, DOI 10.1016/1078-1439(96)00038-5; KRONGRAD A, IN PRESS J UROL; KRONGRAD A, IN PRESS MANAGE CLIN; LERNER SE, 1995, J UROLOGY, V154, P1447, DOI 10.1016/S0022-5347(01)66888-5; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; Riley G, 1985, Health Care Financ Rev, V7, P37; Schellhammer P, 1997, UROLOGY, V49, P27, DOI 10.1016/S0090-4295(99)80321-5; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933	18	38	38	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					44	46						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207337				2022-12-28	WOS:A1997XG38700035
J	Kohler, RH; Cao, J; Zipfel, WR; Webb, WW; Hanson, MR				Kohler, RH; Cao, J; Zipfel, WR; Webb, WW; Hanson, MR			Exchange of protein molecules through connections between higher plant plastids	SCIENCE			English	Article							CHLOROPLASTS; MICROSCOPY	Individual plastids of vascular plants have generally been considered to be discrete autonomous entities that do not directly communicate with each other. However, in transgenic plants in which the plastid stroma was labeled with green fluorescent protein (GFP), thin tubular projections emanated from individual plastids and sometimes connected to other plastids. Flow of GFP between interconnected plastids could be observed when a single plastid or an interconnecting plastid tubule was photobleached and the loss of green fluorescence by both plastids was seen. These tubules allow the exchange of molecules within an interplastid communication system, which may facilitate the coordination of plastid activities.	CORNELL UNIV,GENET & DEV SECT,ITHACA,NY 14853; CORNELL UNIV,SCH APPL & ENGN PHYS,ITHACA,NY 14853	Cornell University; Cornell University			Hanson, Maureen R/D-3879-2009; Webb, Watt W./B-5905-2011; Zipfel, Warren/B-4059-2016	Hanson, Maureen R/0000-0001-8141-3058; kohler, rainer/0000-0001-6269-6590; Zipfel, Warren/0000-0003-2640-329X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004224] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04224] Funding Source: Medline; PHS HHS [R07719] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], [No title captured]; CERUTTI H, 1992, P NATL ACAD SCI USA, V89, P8068, DOI 10.1073/pnas.89.17.8068; CLINE R, 1996, ANN REV CELL DEV BIO, V12, P1; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; EHARA T, 1990, EXP CELL RES, V190, P104, DOI 10.1016/0014-4827(90)90150-9; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; HASELOFF J, 1995, TRENDS GENET, V11, P328, DOI 10.1016/0168-9525(95)90186-8; HONGLADAROM T, 1965, ORGANELLES LIVING PL; HOOD EE, 1986, J BACTERIOL, V168, P1291, DOI 10.1128/jb.168.3.1291-1301.1986; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HUANG JT, 1990, PLANT CELL, V2, P1249, DOI 10.1105/tpc.2.12.1249; Kirk J., 1978, PLASTIDS THEIR CHEM, V2nd ed.; KOHLER R, UNPUB; Kohler RH, 1997, PLANT J, V11, P613, DOI 10.1046/j.1365-313X.1997.11030613.x; MENZEL D, 1994, PROTOPLASMA, V179, P166, DOI 10.1007/BF01403955; OSAFUNE T, 1993, J ELECT MICROSC, V42, P201; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; SPENCER D, 1962, AUST J BIOL SCI, V15, P599, DOI 10.1071/BI9620599; TOBIAS M, 1996, PLANT J, V10, P523; VESK MARET, 1965, AUSTRALIAN J BOT, V13, P161; WELER TE, 1962, AM J BOT, V49, P807; WILDMAN SG, 1962, SCIENCE, V138, P434, DOI 10.1126/science.138.3538.434; Wildman SG, 1967, BIOCHEM CHLOROP, V2, P295; WILLIAMS RM, 1994, FASEB J, V8, P804, DOI 10.1096/fasebj.8.11.8070629; ZHAO JM, 1995, J BIOL CHEM, V270, P6081, DOI 10.1074/jbc.270.11.6081	25	476	502	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2039	2042		10.1126/science.276.5321.2039	http://dx.doi.org/10.1126/science.276.5321.2039			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197266				2022-12-28	WOS:A1997XG74800064
J	Barkai, N; Leibler, S				Barkai, N; Leibler, S			Robustness in simple biochemical networks	NATURE			English	Article							BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; METHYLATION; ADAPTATION; MODEL; MECHANISM; PROTEINS	Cells use complex networks of interacting molecular components to transfer and process information, These ''computational devices of living cells''(1) are responsible for many important cellular processes, including cell-cycle regulation and signal transduction. Here we address the issue of the sensitivity of the networks to variations in their biochemical parameters, We propose a mechanism for robust adaptation in simple signal transduction networks. We show that this mechanism applies in particular to bacterial chemotaxis(2-7). This is demonstrated within a quantitative model which explains, in a unified way, many aspects of chemotaxis, including proper responses to chemical gradients(8-12). The adaptation property(10,13-16) is a consequence of the network's connectivity and does not require the 'fine-tuning' of parameters. We argue that the key properties of biochemical networks should be robust in order to ensure their proper functioning.	PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Princeton University; Princeton University								ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; ADLER J, 1975, ANNU REV BIOCHEM, V44, P341, DOI 10.1146/annurev.bi.44.070175.002013; ASAKURA S, 1984, J MOL BIOL, V176, P349, DOI 10.1016/0022-2836(84)90494-7; BERG HC, 1975, P NATL ACAD SCI USA, V72, P3235, DOI 10.1073/pnas.72.8.3235; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; BLOCK SM, 1982, CELL, V31, P215, DOI 10.1016/0092-8674(82)90421-4; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; HAURI DC, 1995, BIOPHYS J, V68, P708, DOI 10.1016/S0006-3495(95)80232-8; HAZELBAUER GL, 1993, CELL, V73, P15, DOI 10.1016/0092-8674(93)90156-K; KHAN S, 1995, P NATL ACAD SCI USA, V92, P9757, DOI 10.1073/pnas.92.21.9757; KLEENE SJ, 1979, P NATL ACAD SCI USA, V76, P6309, DOI 10.1073/pnas.76.12.6309; KOSHLAND DE, 1977, SCIENCE, V196, P1055, DOI 10.1126/science.870969; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; SEGEL LA, 1986, J THEOR BIOL, V120, P151, DOI 10.1016/S0022-5193(86)80171-0; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103	21	1070	1095	1	120	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					913	917		10.1038/43199	http://dx.doi.org/10.1038/43199			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202124				2022-12-28	WOS:A1997XG41600054
J	Her, LS; Lund, E; Dahlberg, JE				Her, LS; Lund, E; Dahlberg, JE			Inhibition of Ran guanosine triphosphatase-dependent nuclear transport by the matrix protein of vesicular stomatitis virus	SCIENCE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; BINDING-PROTEIN; ACTIVATING PROTEIN; CAP TRIMETHYLATION; EXPORT PATHWAY; RNA TRANSPORT; U-SNRNA; IMPORT; RAN/TC4; TRANSCRIPTION	Transport of macromolecules into and out of nuclei, essential steps in gene expression, are potential points of control. The matrix protein (M protein) of vesicular stomatitis virus (VSV) was shown to block transport of RNAs and proteins between the nucleus and cytoplasm of Xenopus laevis oocytes. The pattern of inhibition indicated that M protein interfered with transport that is dependent on the ras-like nuclear guanosine triphosphatase (GTPase) Ran-TC4 and its associated factors. This inhibition of nuclear transport by M protein explains several observations about the effects of VSV infection on host cell gene expression and suggests that RNA export is closely coupled to protein import.	UNIV WISCONSIN, DEPT BIOMOL CHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030220, R37GM030220] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30220] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; AZUMA Y, 1995, P NATL ACAD SCI USA, V92, P5159, DOI 10.1073/pnas.92.11.5159; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BLACK BL, 1994, J VIROL, V68, P555, DOI 10.1128/JVI.68.1.555-560.1994; BLACK BL, 1992, J VIROL, V66, P4058, DOI 10.1128/JVI.66.7.4058-4064.1992; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CRONE DE, 1989, J VIROL, V63, P4172, DOI 10.1128/JVI.63.10.4172-4180.1989; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; Dahlberg JE, 1997, SEMIN CELL DEV BIOL, V8, P65, DOI 10.1006/scdb.1996.0123; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; FELDHERR C, 1995, MOL CELL BIOL, V15, P7043; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FORRESTER W, 1992, GENE DEV, V6, P1914, DOI 10.1101/gad.6.10.1914; FRESCO LD, 1987, MOL CELL BIOL, V7, P1148, DOI 10.1128/MCB.7.3.1148; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P4421, DOI 10.1073/pnas.93.9.4421; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GOLDFARB DS, 1994, CURR BIOL, V4, P57, DOI 10.1016/S0960-9822(00)00013-0; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Grimm C, 1997, EMBO J, V16, P793, DOI 10.1093/emboj/16.4.793; GRIMM C, UNPUB; Hadjilov AA, 1985, NUCL RIBOSOME BIOGEN; HER LS, UNPUB; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; LEFRANCOIS L, 1982, VIROLOGY, V121, P157, DOI 10.1016/0042-6822(82)90125-8; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; LUND E, 1989, EMBO J, V8, P287, DOI 10.1002/j.1460-2075.1989.tb03375.x; LUND E, UNPUB; Lyles DS, 1996, VIROLOGY, V225, P172, DOI 10.1006/viro.1996.0585; Marshallsay C, 1996, NUCLEIC ACIDS RES, V24, P1829, DOI 10.1093/nar/24.10.1829; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAEL WM, 1995, CELL, V83, P415; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; Pante N, 1996, SCIENCE, V273, P1729, DOI 10.1126/science.273.5282.1729; Pante N, 1995, INT REV CYTOL, V162B, P225; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; Pasquinelli AE, 1995, RNA, V1, P957; PINOLROMA S, 1993, TRENDS CELL BIOL, V315, P730; POLLARD VW, 1996, TRENDS CELL BIOL, V86, P985; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; QUI Y, 1994, J VIROL, V68, P2425; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Saavedra C, 1996, GENE DEV, V10, P1608, DOI 10.1101/gad.10.13.1608; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Stutz F, 1996, MOL CELL BIOL, V16, P7144; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; THOMAS D, 1985, J VIROL, V54, P598, DOI 10.1128/JVI.54.2.598-607.1985; TOROK I, 1995, J CELL BIOL, V129, P1473, DOI 10.1083/jcb.129.6.1473; VARVEL V, UNPUB; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; WAGNER RR, 1984, COMPR VIROL, V19, P223; WECK PK, 1979, J VIROL, V30, P410, DOI 10.1128/JVI.30.1.410-413.1979; WU FS, 1980, BIOCHEMISTRY-US, V19, P804, DOI 10.1021/bi00545a029; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	81	153	157	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 20	1997	276	5320					1845	1848		10.1126/science.276.5320.1845	http://dx.doi.org/10.1126/science.276.5320.1845			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188527				2022-12-28	WOS:A1997XF10300044
J	deBono, D				deBono, D			Diastolic ventricular interaction: Starling (and Bernheim) revisited	LANCET			English	Editorial Material											deBono, D (corresponding author), UNIV LEICESTER,DEPT MED & THERAPEUT,DIV CARDIOL,LEICESTER LE3 9QP,LEICS,ENGLAND.							BRADLEY R, 1978, STUDIES HEART FAILUR; DEBERNHEIM E, 1910, REV MED, V30, P785; WHITE P, 1945, HEART DIS; WOOD P, 1968, DIS HEART CIRCULATIO, P294	4	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1712	1712		10.1016/S0140-6736(05)62950-9	http://dx.doi.org/10.1016/S0140-6736(05)62950-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193377				2022-12-28	WOS:A1997XE06500004
J	Lacey, CJN; Merrick, DW; Bensley, DC; Fairley, I				Lacey, CJN; Merrick, DW; Bensley, DC; Fairley, I			Analysis of the sociodemographic of gonorrhoea in Leeds, 1989-93	BRITISH MEDICAL JOURNAL			English	Article							TRANSMISSION; INTERVENTION; PREVENTION	Objective: To investigate the epidemiology of gonorrhoea in an urban area in the United Kingdom. Design: Analysis of all cases of gonorrhoea with regard to age, sex, ethnic group, and socioeconomic group with 1991 census data: as a denominator. Setting: Leeds, a comparatively large urban area (population around 700 000) in the United Kingdom. Subjects: All residents of Leeds with culture proved cases of gonorrhoea during 1989-93. Main outcome measure: Relative risk of gonorrhoea Results: Sex, age, race, and socioeconomic group and area of residence were all independently predictive of risk of infection. Young black men aged 20-29 were at highest risk, with incidences of 3-4% per year. Black subjects were 10 times more likely than white subjects to acquire-infection, and subjects from the most deprived socioeconomic areas were more than four times more likely than those from the most affluent areas to acquire infection. Conclusions: Different ethnic and socioeconomic groups vary in their risk of infection with gonorrhoea within an urban area Targeted interventions and screening to reduce the incidence of sexually transmitted disease are now priorities.	GEN INFIRM,DEPT GENITOURINARY MED,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; NO & YORKSHIRE REG HLTH AUTHOR,REG PUBL HLTH ANAL UNIT,HARROGATE HG1 5AH,N YORKSHIRE,ENGLAND	Leeds General Infirmary								BENSLEY DC, 1994, CENSUS BASED VIEW PO; Blair I, 1994, Commun Dis Rep CDR Rev, V4, pR25; Breslow NE, 1980, IARC SCI PUBL, V32; BRESLOW NE, 1987, IARC SCI PUBL, V82; BROWN B, 1994, DESIGN CONSTRUCTION; Department of Health, 1992, HLTH NAT STRAT HLTH; FURSTENBERG FF, 1987, MILBANK Q, V65, P381, DOI 10.2307/3349996; JEMMOTT JB, 1992, AM J PUBLIC HEALTH, V82, P372, DOI 10.2105/AJPH.82.3.372; Johnson AM, 1994, SEXUAL ATTITUDES LIF; KELLY JA, 1994, AM J PUBLIC HEALTH, V84, P1918, DOI 10.2105/AJPH.84.12.1918; MAY RM, 1981, NATURE, V291, P376, DOI 10.1038/291376a0; MIETTINEN OS, 1970, BIOMETRICS, V26, P75, DOI 10.2307/2529046; POTTERAT JJ, 1985, SEX TRANSM DIS, V12, P25, DOI 10.1097/00007435-198501000-00006; RALEIGH VS, 1994, BRIT MED J, V309, P287, DOI 10.1136/bmj.309.6950.287; RICE RJ, 1991, AM J PUBLIC HEALTH, V81, P1252, DOI 10.2105/AJPH.81.10.1252; ROTHENBERG RB, 1983, AM J EPIDEMIOL, V117, P688, DOI 10.1093/oxfordjournals.aje.a113602; Wallace R, 1997, BRIT MED J, V314, P1341, DOI 10.1136/bmj.314.7090.1341; Webster Linda A., 1993, Morbidity and Mortality Weekly Report, V42, P1; YORKE JA, 1978, SEX TRANSM DIS, V5, P51, DOI 10.1097/00007435-197804000-00003; [No title captured]; 1995, COMMUN DIS REP CDR W, V5, P62; 1996, COMMUN DIS REP CDR W, V6, P110	22	85	85	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1715	1718		10.1136/bmj.314.7096.1715	http://dx.doi.org/10.1136/bmj.314.7096.1715			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9185496	Green Published			2022-12-28	WOS:A1997XE90900018
J	Sniegowski, PD; Gerrish, PJ; Lenski, RE				Sniegowski, PD; Gerrish, PJ; Lenski, RE			Evolution of high mutation rates in experimental populations of E-coli	NATURE			English	Article							TERM EXPERIMENTAL EVOLUTION; ESCHERICHIA-COLI; GENE-PRODUCT; IDENTIFICATION; ADAPTATION; ENVIRONMENT; COMPETITION; SELECTION; CLONING; MUTS	Most mutations are likely to be deleterious, and so the spontaneous mutation rate is generally held at a very low value(1). Nonetheless, evolutionary theory predicts that high mutation rates can evolve under certain circumstances(2-4). Empirical observations have previously been limited to short-term studies of the fates of mutator strains deliberately introduced into laboratory populations of Escherichia coli(5-7), an to the effects of intense selective events on mutator frequencies in E. coli(8). Here we report the rise of spontaneously originated mutators in populations of E. coli undergoing long-term adaptation to a new environment; Our results corroborate computer simulations of mutator evolution in adapting clonal populations(4), and may help to explain observations that associate high mutation rates with emerging pathogens' and with certain cancers(10).	MICHIGAN STATE UNIV,CTR MICROBIAL ECOL,E LANSING,MI 48824	Michigan State University	Sniegowski, PD (corresponding author), UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104, USA.		Gerrish, Philip/AAE-7346-2019	Lenski, Richard/0000-0002-1064-8375; Gerrish, Philip/0000-0001-6393-0553				BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; Carlton BC, 1981, MANUAL METHODS GENER, P222; CHAO L, 1983, EVOLUTION, V37, P125, DOI 10.1111/j.1558-5646.1983.tb05521.x; COX EC, 1974, GENETICS, V77, P169; DRAKE JW, 1991, ANNU REV GENET, V25, P125, DOI 10.1146/annurev.ge.25.120191.001013; Elena SF, 1996, SCIENCE, V272, P1802, DOI 10.1126/science.272.5269.1802; HORIUCHI T, 1981, P NATL ACAD SCI-BIOL, V78, P3770, DOI 10.1073/pnas.78.6.3770; ISHII K, 1989, GENETICS, V121, P163; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; LEDERBERG S, 1966, J BACTERIOL, V91, P1029, DOI 10.1128/JB.91.3.1029-1036.1966; LEIGH EG, 1970, AM NAT, V104, P301, DOI 10.1086/282663; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; Luria SE, 1943, GENETICS, V28, P491; MA WT, 1992, J APPL PROBAB, V29, P255, DOI 10.2307/3214564; Mao EF, 1997, J BACTERIOL, V179, P417, DOI 10.1128/jb.179.2.417-422.1997; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1995, PHILOS T ROY SOC B, V347, P89, DOI 10.1098/rstb.1995.0014; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PANG PP, 1985, J BACTERIOL, V163, P1007, DOI 10.1128/JB.163.3.1007-1015.1985; SAMBROOK E, 1989, MOL CLONING LAB MANU; SCHAAPER RM, 1992, J BACTERIOL, V174, P1974, DOI 10.1128/jb.174.6.1974-1982.1992; STEWART FM, 1994, GENETICS, V137, P1139; Taddei F, 1997, NATURE, V387, P700, DOI 10.1038/42696; TAUCHERSCHOLZ G, 1983, EUR J BIOCHEM, V137, P573, DOI 10.1111/j.1432-1033.1983.tb07864.x; Travisano M, 1996, GENETICS, V143, P15; TROBNER W, 1984, MOL GEN GENET, V198, P175, DOI 10.1007/BF00328719; VASI F, 1994, AM NAT, V144, P432, DOI 10.1086/285685	30	641	652	4	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					703	705		10.1038/42701	http://dx.doi.org/10.1038/42701			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192894	Bronze			2022-12-28	WOS:A1997XD86900053
J	SuarezAlmazor, ME; Belseck, E; Russell, AS; Mackel, JV				SuarezAlmazor, ME; Belseck, E; Russell, AS; Mackel, JV			Use of lumbar radiographs for the early diagnosis of low back pain - Proposed guidelines would increase utilization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY; SPINE EXAMINATION; PRIMARY CARE	Objective.-The Agency for Health Care Policy and Research (AHCPR) has recently published guidelines for the management of patients with acute low back pain, which include recommendations for the use of lumbar radiographs, based on the identification of ''red flags'' for fractures, tumors, or infections. The purpose of this study was to evaluate the potential impact of these guidelines in patients with new episodes of low back pain seen in primary care settings. Design.-Retrospective cohort study. Setting.-Four family clinics (18 physicians) in Edmonton, Alberta. Patients.-The records of all patients seen in 1992 and 1993 with a new episode of low back pain were reviewed: 963 patients had a history of back pain of less than 3 months. Outcome Measures.-Lumbar radiograph utilization at the initial low back pain visit. Charts were also reviewed to determine subsequent occurrence of spinal tumors, infection, or fractures that could be related to low back pain. Results.-One hundred twenty-seven (13%) of the 963 patients with acute low back pain had lumbar radiographs during their first visit, 68 (54%) with oblique views. If the AHCPR guidelines had been applied to this population, 426 (44%) of the patients would have undergone radiography, increasing current utilization by 238%. Eight of the 963 patients had a diagnosis of fracture or bone tumor during follow-up. The sensitivity of the guidelines to potentially detect these diseases was higher than the physicians' utilization patterns, but their specificity and positive predictive values were low. Conclusions.-The implementation of the AHCPR guidelines for the initial use of radiographs in patients with low back pain may increase utilization and economic costs. A more restricted and cost-efficient set of guidelines should be proposed.	UNIV ALBERTA,DEPT MED,EDMONTON,AB,CANADA; UNIV ALBERTA,DEPT FAMILY MED,EDMONTON,AB,CANADA	University of Alberta; University of Alberta	SuarezAlmazor, ME (corresponding author), UNIV ALBERTA,HERITAGE MED RES CTR 214,HEALTHCARE QUAL & OUTCOMES RES CTR,DEPT PUBL HLTH SCI,EDMONTON,AB T6G 2S2,CANADA.							ABENHAIM L, 1987, J OCCUP ENVIRON MED, V29, P670; [Anonymous], 1994, AHCPR PUBL, V94-0592; Barton J E, 1976, J Fam Pract, V3, P363; BIERINGSORENSEN F, 1983, SCAND J REHABIL MED, V15, P89; BIERINGSORENSEN F, 1985, SPINE, V10, P445, DOI 10.1097/00007632-198506000-00008; BIGOS S, 1994, AAHCPR PUBL; BREKKAN A, 1983, CLIN RADIOL, V34, P321, DOI 10.1016/S0009-9260(83)80349-3; CYPRESS BK, 1983, AM J PUBLIC HEALTH, V73, P389, DOI 10.2105/AJPH.73.4.389; DEYO RA, 1986, J GEN INTERN MED, V1, P328, DOI 10.1007/BF02596214; DEYO RA, 1986, J GEN INTERN MED, V1, P20, DOI 10.1007/BF02596320; Edelstyn G A, 1967, Clin Radiol, V18, P158, DOI 10.1016/S0009-9260(67)80010-2; FRAZIER LM, 1986, ARCH INTERN MED, V149, P47; FRYMOYER JW, 1980, SPINE, V5, P419, DOI 10.1097/00007632-198009000-00005; HALL FM, 1976, RADIOLOGY, V120, P443, DOI 10.1148/120.2.443; HALPIN SFS, 1991, BRIT MED J, V303, P813, DOI 10.1136/bmj.303.6806.813; LIANG M, 1982, ARCH INTERN MED, V142, P1108, DOI 10.1001/archinte.142.6.1108; MAGORA A, 1980, SCAND J REHABIL MED, V12, P47; NACHEMSON A L, 1976, Spine, V1, P59, DOI 10.1097/00007632-197603000-00009; RHEA JT, 1980, RADIOLOGY, V134, P45, DOI 10.1148/radiology.134.1.7350633; SACKETT DS, 1985, CLIN EPIDEMIOLOGY BA, P148; SARASTE H, 1984, INT ORTHOP, V8, P163, DOI 10.1007/BF00269912; SCAVONE JG, 1981, AM J ROENTGENOL, V136, P715, DOI 10.2214/ajr.136.4.715; SCHROTH WS, 1992, J GEN INTERN MED, V7, P486, DOI 10.1007/BF02599449; SIMMONS ED, 1995, SPINE, V20, P1839, DOI 10.1097/00007632-199508150-00017; SKOVRON ML, 1992, BAILLIERE CLIN RHEUM, V6, P559, DOI 10.1016/S0950-3579(05)80127-X; Spitzer WO, 1987, SPINE, V12, P1, DOI DOI 10.1097/00007632-198701000-00001; *US DEP HHS, 1988, INT CLASS DIS 9 REV; WHALEN JP, 1982, DIS MON, V28, P73; *WHO, 1983, RAT APPR RAD INV, P31; *WHO, 1983, WHO TECHN REP SER, V689; WITT I, 1984, SPINE, V9, P298, DOI 10.1097/00007632-198404000-00014	31	75	75	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	1997	277	22					1782	1786		10.1001/jama.277.22.1782	http://dx.doi.org/10.1001/jama.277.22.1782			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC499	9178791				2022-12-28	WOS:A1997XC49900031
J	Irvine, D				Irvine, D			The performance of doctors .2. Maintaining good practice, protecting patients from poor performance	BRITISH MEDICAL JOURNAL			English	Article											Irvine, D (corresponding author), GEN MED COUNCIL,LONDON W1N 6JE,ENGLAND.							CALMAN K, 1994, BRIT MED J, V309, P1140, DOI 10.1136/bmj.309.6962.1140; *CHIEF MED OFF ENG, 1996, MAINT MED EXC; *DEP HLTH, 1995, MAINT MED EXC REV GU; Freidson Eliot, 1990, Jurimetrics, V30, P431; *GEN MED COUNC, 1997, NEW PERF PROC CONS D; *GEN MED COUNC, 1995, DUT DOCT GOOD MED PR; Irvine D, 1997, BRIT MED J, V314, P1540, DOI 10.1136/bmj.314.7093.1540; IRVINE D, 1996, PRACTICE QUALITY; IRVINE D, 1990, MANAGING QUALITY GEN; ROSENTHAL MM, 1995, INCOMPETENT DOCTOR C; Smith R, 1997, BRIT MED J, V314, P841	11	54	55	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 31	1997	314	7094					1613	1615		10.1136/bmj.314.7094.1613	http://dx.doi.org/10.1136/bmj.314.7094.1613			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9186177	Green Published			2022-12-28	WOS:A1997XC50000033
J	Swerdlow, AJ; Higgins, CD; Pike, MC				Swerdlow, AJ; Higgins, CD; Pike, MC			Risk of testicular cancer in cohort of boys with cryptorchidism	BRITISH MEDICAL JOURNAL			English	Article							INGUINAL-HERNIA; TESTIS; BIOPSY; AGE	Objective: To determine the risk of testicular cancer in relation to undescended testis and its treatment based on recorded details of the maldescent, treatment, and biopsy from case notes. Design: Cohort study. Setting: Hospital for Sick Children, Great Ormond Street, London. Subjects: 1075 boys with cryptorchidism treated by orchidopexy or hormones at the hospital during 1951-64. Main outcome measures: Relative risk of testicular cancer in the cohort compared with men in the general population. Results: 12 testicular cancers occurred in 11 of the patients during follow up to mid-1990 (relative risk of cancer in males with cryptorchidism = 7.5 (95% confidence interval 3.9 to 12.8)). The relative risk fell significantly beyond 15 years after orchidopexy but did not decrease with younger age at orchidopexy. Risk was significantly raised in testes that had had biopsy samples removed during orchidopexy (relative risk = 66.7 (23.9 to 143.3) compared with a testis in a man in the general population) and was significantly greater in these testes than in undescended testes that had not had biopsy samples taken at orchidopexy (6.7 (2.7 to 13.5)). No reasons for biopsy or distinguishing clinical aspects of the testes that had had biopsy samples taken and later developed malignancies were evident in the case notes. No histological abnormalities were evident at initial biopsy except in one testis that had features of dysgenesis. Conclusions: Biopsy seems to be a stronger risk factor for testicular cancer than any factor previously identified. The trauma of open biopsy may contribute substantially to risk of malignancy or the testes may have been selected for biopsy on the basis of clinical factors predictive of malignancy but not mentioned in the case notes.	UNIV SO CALIF,SCH MED,DEPT PREVENT MED,NORRIS COTTON CANC CTR,LOS ANGELES,CA 90033	Norris Cotton Cancer Center; University of Southern California	Swerdlow, AJ (corresponding author), LONDON SCH HYG & TROP MED,EPIDEMIOL MONITORING UNIT,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.			Swerdlow, Anthony/0000-0001-5550-4159	NCI NIH HHS [CA14089] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014089] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENSON RC, 1991, MAYO CLIN PROC, V66, P372, DOI 10.1016/S0025-6196(12)60660-0; CHILVERS C, 1986, J PEDIATR SURG, V21, P691, DOI 10.1016/S0022-3468(86)80389-X; CHILVERS C, 1992, EUROPEAN UROLOGY UPD, V1, P74; Farrington GH, 1971, CONGENITAL DEFORMITI; FORMAN D, 1994, BRIT MED J, V308, P1393, DOI 10.1136/bmj.308.6941.1393; GASSNER FX, 1955, FERTIL STERIL, V6, P290; GIWERCMAN A, 1987, J UROLOGY, V138, P1214, DOI 10.1016/S0022-5347(17)43553-1; GORDON DL, 1965, FERTIL STERIL, V16, P522; HAWKINS MM, 1992, BRIT J CANCER, V66, P408, DOI 10.1038/bjc.1992.279; HENDERSON BE, 1983, UROLOGICAL CANC, P237; HJORT T, 1974, CLIN EXP IMMUNOL, V18, P201; JOHNSON DE, 1968, SURGERY, V63, P919; MENGEL W, 1974, J PEDIATR SURG, V9, P445, DOI 10.1016/S0022-3468(74)80003-5; PARKINSON MC, 1994, BRIT J UROL, V73, P431, DOI 10.1111/j.1464-410X.1994.tb07610.x; PIKE MC, 1986, LANCET, V1, P1246; PINCZOWSKI D, 1991, J UROLOGY, V146, P1291, DOI 10.1016/S0022-5347(17)38071-0; PLOEN L, 1984, DEV RECENTS ENDOCRIN, V123, P97; POTTERN LM, 1985, J NATL CANCER I, V74, P377; Prener A, 1996, EPIDEMIOLOGY, V7, P14, DOI 10.1097/00001648-199601000-00004; PRESTON DL, 1993, EPICURE; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; ROWLEY MJ, 1969, J UROLOGY, V101, P347, DOI 10.1016/S0022-5347(17)62341-3; Schwedes U, 1974, Andrologia, V6, P71; SPITZ MR, 1986, CANCER, V58, P1785, DOI 10.1002/1097-0142(19861015)58:8<1785::AID-CNCR2820580836>3.0.CO;2-2; STAMPFLI M, 1991, EUR J PEDIATR SURG, V1, P36, DOI 10.1055/s-2008-1042456; STRADER CH, 1988, AM J EPIDEMIOL, V127, P1013, DOI 10.1093/oxfordjournals.aje.a114877; SWERDLOW AJ, 1988, BRIT J UROL, V61, P518, DOI 10.1111/j.1464-410X.1988.tb05094.x; SWERDLOW AJ, 1988, BRIT J IND MED, V45, P225; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P97, DOI 10.1038/bjc.1987.20; VERP MS, 1987, CANCER GENET CYTOGEN, V25, P191, DOI 10.1016/0165-4608(87)90180-4	30	145	148	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 24	1997	314	7093					1507	1511		10.1136/bmj.314.7093.1507	http://dx.doi.org/10.1136/bmj.314.7093.1507			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9169396	Green Published			2022-12-28	WOS:A1997XB48400020
J	Ktistaki, E; Talianidis, I				Ktistaki, E; Talianidis, I			Modulation of hepatic gene expression by hepatocyte nuclear factor 1	SCIENCE			English	Article							ENRICHED TRANSCRIPTION FACTOR; HORMONE RECEPTOR SUPERFAMILY; DNA-BINDING; FACTOR-IV; LIVER; HNF-4; APOCIII; DOMAIN; LF-B1	Hepatocyte nuclear factors 1 and 4 (HNF-1 and HNF-4) are river-enriched transcription factors that function in the regulation of several liver-specific genes. HNF-1 activates genes containing promoters with HNF-1 binding sites. However, this factor negatively regulates its own expression and that of other HNF-4-dependent genes that lack HNF-1 binding sites in their promoter region. This repression is exerted by a direct interaction of HNF-1 with AF2, the main activation domain of HNF-4. The dual functions of gene activation and repression suggest that HNF-1 is a global regulator of the transcriptional network involved in the maintenance of hepatocyte-specific phenotype.	FDN RES & TECHNOL HELLAS,INST MOL BIOL & BIOTECHNOL,IRAKLION 71110,GREECE	Foundation for Research & Technology - Hellas (FORTH)			Talianidis, Iannis/F-7556-2016	Talianidis, Iannis/0000-0002-1209-3609				BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; KRITIS AA, 1993, NUCLEIC ACIDS RES, V21, P5882, DOI 10.1093/nar/21.25.5882; Kritis AA, 1996, GENE, V173, P275, DOI 10.1016/0378-1119(96)00183-7; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; Ktistaki E, 1997, MOL CELL BIOL, V17, P2790, DOI 10.1128/MCB.17.5.2790; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; KTISTAKI E, UNPUB; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; PIAGGIO G, 1994, NUCLEIC ACIDS RES, V22, P4284, DOI 10.1093/nar/22.20.4284; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, pCH11; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TRONCHE F, 1994, LIVER GENE EXPRESSIO, pCH9; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276	25	114	115	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 4	1997	277	5322					109	112		10.1126/science.277.5322.109	http://dx.doi.org/10.1126/science.277.5322.109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204893				2022-12-28	WOS:A1997XJ41800051
J	Carabello, BA; Crawford, FA				Carabello, BA; Crawford, FA			Valvular heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AORTIC-VALVE REPLACEMENT; LEFT-VENTRICULAR FUNCTION; CORONARY-ARTERY DISEASE; CHRONIC MITRAL REGURGITATION; LONG-TERM SURVIVAL; ASYMPTOMATIC PATIENTS; EJECTION PERFORMANCE; SYMPTOMATIC PATIENTS; NATURAL-HISTORY; WALL STRESS		MED UNIV S CAROLINA,GAZES CARDIAC RES INST,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT SURG,DIV CARDIOTHORAC SURG,CHARLESTON,SC 29425; RALPH H JOHNSON DEPT VET AFFAIRS,CHARLESTON,SC 29425	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Carabello, BA (corresponding author), MED UNIV S CAROLINA,DIV CARDIOL,DEPT MED,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.							AKINS CW, 1994, ANN THORAC SURG, V58, P668, DOI 10.1016/0003-4975(94)90725-0; ALEXOPOULOS D, 1993, ANGIOLOGY, V44, P707, DOI 10.1177/000331979304400906; ALJUBAIR K, 1992, J THORAC CARDIOV SUR, V104, P487; ASSEY ME, IN PRESS DIAGNOSTIC; AURIGEMMA GP, 1992, CIRCULATION, V86, P538; BERMAN AD, 1996, CARDIAC CATHETERIZAT, P659; BONOW RO, 1991, CIRCULATION, V84, P1625, DOI 10.1161/01.CIR.84.4.1625; BROGAN WC, 1993, J AM COLL CARDIOL, V21, P1657, DOI 10.1016/0735-1097(93)90383-C; CANNON JD, 1992, J AM COLL CARDIOL, V20, P1517, DOI 10.1016/0735-1097(92)90445-S; Carabello B A, 1993, J Heart Valve Dis, V2, P250; CARABELLO B A, 1991, Cardiology Clinics, V9, P229; CARABELLO BA, 1980, CIRCULATION, V62, P42, DOI 10.1161/01.CIR.62.1.42; CARABELLO BA, 1988, MOD CONC CARDIOV DIS, V57, P53; CARABELLO BA, 1981, CIRCULATION, V64, P1212, DOI 10.1161/01.CIR.64.6.1212; CARABELLO BA, 1987, J AM COLL CARDIOL, V10, P991, DOI 10.1016/S0735-1097(87)80335-2; Carabello BA, 1995, CURRENT DIAGNOSIS TR, P87; CARABELLO BA, 1994, ACC CURR J REV, V3, P25; CARRIE PJ, 1985, CIRCULATION, V71, P1162; CARROLL JD, 1992, CIRCULATION, V86, P1099, DOI 10.1161/01.CIR.86.4.1099; CLYNE CA, 1991, AM J CARDIOL, V68, P1469, DOI 10.1016/0002-9149(91)90281-O; COHN LH, 1990, J AM COLL CARDIOL, V16, P1575, DOI 10.1016/0735-1097(90)90303-7; CONNOLLY MW, 1986, J THORAC CARDIOV SUR, V91, P379; COSGROVE DM, 1991, J THORAC CARDIOV SUR, V102, P571; Cosgrove DM, 1996, ANN THORAC SURG, V62, P596, DOI 10.1016/0003-4975(96)00418-3; CRAWFORD MH, 1990, CIRCULATION, V81, P1173, DOI 10.1161/01.CIR.81.4.1173; CULLIFORD AT, 1991, AM J CARDIOL, V67, P1256, DOI 10.1016/0002-9149(91)90937-G; DAVID TE, 1984, J THORAC CARDIOV SUR, V88, P718; DAVID TE, 1994, J CARDIAC SURG, V9, P182, DOI 10.1111/j.1540-8191.1994.tb00922.x; DEFILIPPI CR, 1995, AM J CARDIOL, V75, P191, DOI 10.1016/S0002-9149(00)80078-8; DOUGLAS PS, 1995, BRIT HEART J, V73, P548; DURAN CMG, 1993, J CARDIAC SURG, V8, P443, DOI 10.1111/j.1540-8191.1993.tb00392.x; ELAYDA MA, 1993, CIRCULATION, V88, P11; ENRIQUEZSARANO M, 1995, CIRCULATION, V91, P1022, DOI 10.1161/01.CIR.91.4.1022; ENRIQUEZSARANO M, 1994, CIRCULATION, V90, P830, DOI 10.1161/01.CIR.90.2.830; FRASER CD, 1994, ANN THORAC SURG, V58, P386, DOI 10.1016/0003-4975(94)92212-8; GAASCH W H, 1987, Primary Cardiology, V13, P104; GASH AK, 1984, J AM COLL CARDIOL, V3, P703, DOI 10.1016/S0735-1097(84)80246-6; GOLDMAN ME, 1987, J AM COLL CARDIOL, V10, P568, DOI 10.1016/S0735-1097(87)80199-7; GORLIN R, 1951, AM HEART J, V41, P1, DOI 10.1016/0002-8703(51)90002-6; HANSEN DE, 1989, J THORAC CARDIOV SUR, V97, P521; HATLE L, 1978, BRIT HEART J, V40, P131; HENRY WL, 1980, CIRCULATION, V61, P471, DOI 10.1161/01.CIR.61.3.471; HESS OM, 1984, CIRCULATION, V69, P855, DOI 10.1161/01.CIR.69.5.855; HOCHREITER C, 1986, CIRCULATION, V73, P900, DOI 10.1161/01.CIR.73.5.900; Hoff SJ, 1996, ANN THORAC SURG, V61, P1689, DOI 10.1016/0003-4975(96)00165-8; Horskotte D, 1993, J Heart Valve Dis, V2, P150; HUBER D, 1981, CIRCULATION, V64, P126, DOI 10.1161/01.CIR.64.1.126; Kawaguchi AT, 1996, J AM COLL CARDIOL, V28, P985, DOI 10.1016/S0735-1097(96)00275-6; KELLY TA, 1988, AM J CARDIOL, V61, P123, DOI 10.1016/0002-9149(88)91317-3; KETTUNEN R, 1992, AM J CARDIOL, V69, P1442, DOI 10.1016/0002-9149(92)90898-9; Kobayashi J, 1996, J THORAC CARDIOV SUR, V112, P1216, DOI 10.1016/S0022-5223(96)70134-4; KRATZ JM, 1993, ANN THORAC SURG, V56, P462, DOI 10.1016/0003-4975(93)90880-Q; KUPARI M, 1992, AM J CARDIOL, V70, P635, DOI 10.1016/0002-9149(92)90204-C; LEVINSON JR, 1989, CIRCULATION, V80, P49; LIEBERMAN EB, 1995, J AM COLL CARDIOL, V26, P1522, DOI 10.1016/0735-1097(95)00363-0; LINDBLOM D, 1990, J AM COLL CARDIOL, V15, P566, DOI 10.1016/0735-1097(90)90627-2; LINDERHOLM H, 1985, ACTA MED SCAND, V218, P181; LUND O, 1990, CIRCULATION, V82, P124, DOI 10.1161/01.CIR.82.1.124; LUND O, 1990, J THORAC CARDIOV SUR, V100, P327; LYTLE BW, 1988, J THORAC CARDIOV SUR, V95, P402; LYTLE BW, 1989, J THORAC CARDIOV SUR, V97, P675; MANN T, 1975, NEW ENGL J MED, V293, P108, DOI 10.1056/NEJM197507172930302; MARCUS ML, 1982, NEW ENGL J MED, V307, P1362, DOI 10.1056/NEJM198211253072202; MARTIN RP, 1979, AM J CARDIOL, V43, P560, DOI 10.1016/0002-9149(79)90014-6; MORRIS JJ, 1994, CIRCULATION, V90, P183; Odell JA, 1996, ANN THORAC SURG, V62, P1424, DOI 10.1016/0003-4975(96)00635-2; OKEEFE JH, 1987, MAYO CLIN PROC, V62, P986, DOI 10.1016/S0025-6196(12)65068-X; OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844; OTTO CM, 1994, CIRCULATION, V89, P642, DOI 10.1161/01.CIR.89.2.642; OTTO CM, 1989, J AM COLL CARDIOL, V13, P545, DOI 10.1016/0735-1097(89)90590-1; OTTO CM, 1992, J AM COLL CARDIOL, V20, P1160, DOI 10.1016/0735-1097(92)90373-U; PASSIK CS, 1987, MAYO CLIN PROC, V62, P119, DOI 10.1016/S0025-6196(12)61880-1; PELLIKKA PA, 1990, J AM COLL CARDIOL, V15, P1012, DOI 10.1016/0735-1097(90)90234-G; PETERSEN P, 1988, EUR HEART J, V9, P291, DOI 10.1093/oxfordjournals.eurheartj.a062499; REYES VP, 1994, NEW ENGL J MED, V331, P961, DOI 10.1056/NEJM199410133311501; RICHARDS AM, 1984, LANCET, V2, P1113; Ross J Jr, 1968, Circulation, V38, P61; ROZICH JD, 1992, CIRCULATION, V86, P1718, DOI 10.1161/01.CIR.86.6.1718; RUSHMER RF, 1956, AM J PHYSIOL, V184, P188, DOI 10.1152/ajplegacy.1955.184.1.188; Sandoval N, 1996, AM J CARDIOL, V77, P591, DOI 10.1016/S0002-9149(97)89312-5; SARELI P, 1986, AM J CARDIOL, V57, P413, DOI 10.1016/0002-9149(86)90763-0; SCHLANT RC, 1990, J AM COLL CARDIOL, V16, P1061, DOI 10.1016/0735-1097(90)90532-T; SCHON HR, 1994, J HYPERTENS, V12, pS95; SCHWARTZ LS, 1969, AM J CARDIOL, V23, P647, DOI 10.1016/0002-9149(69)90025-3; SCHWARZ F, 1982, CIRCULATION, V66, P1105, DOI 10.1161/01.CIR.66.5.1105; SCOGNAMIGLIO R, 1994, NEW ENGL J MED, V331, P689, DOI 10.1056/NEJM199409153311101; SMITH N, 1978, CIRCULATION, V58, P255, DOI 10.1161/01.CIR.58.2.255; STRAUER BE, 1979, AM J CARDIOL, V44, P999, DOI 10.1016/0002-9149(79)90235-2; SUTTON MS, 1987, CIRCULATION, V76, P77, DOI 10.1161/01.CIR.76.1.77; TANIGUCHI K, 1990, CIRCULATION, V82, P798, DOI 10.1161/01.CIR.82.3.798; WALLER B, 1994, CLIN CARDIOL, V17, P85, DOI 10.1002/clc.4960170208; WARD C, 1975, BRIT HEART J, V37, P74; WILKINS GT, 1988, BRIT HEART J, V60, P299; WISENBAUGH T, 1994, CIRCULATION, V89, P191, DOI 10.1161/01.CIR.89.1.191; WISENBAUGH T, 1988, CIRCULATION, V77, P515, DOI 10.1161/01.CIR.77.3.515; Wisenbaugh T, 1994, J Heart Valve Dis, V3, P197; WISENBAUGH T, 1984, J AM COLL CARDIOL, V3, P916, DOI 10.1016/S0735-1097(84)80349-6; ZILE M R, 1991, Cardiology Clinics, V9, P239; ZILE MR, 1984, J AM COLL CARDIOL, V3, P235, DOI 10.1016/S0735-1097(84)80006-6	99	192	202	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	1997	337	1					32	41		10.1056/NEJM199707033370107	http://dx.doi.org/10.1056/NEJM199707033370107			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH186	9203430				2022-12-28	WOS:A1997XH18600007
J	Harris, KM; Rosenbloom, M				Harris, KM; Rosenbloom, M			Aortic intramural hematoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									MEM REG HEART CTR,HOLLYWOOD,FL 33021		Harris, KM (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.								0	7	7	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 26	1997	336	26					1875	1875		10.1056/NEJM199706263362605	http://dx.doi.org/10.1056/NEJM199706263362605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF756	9197216				2022-12-28	WOS:A1997XF75600005
J	Martensen, RL; Jones, DS				Martensen, RL; Jones, DS			When US medicine became imperial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									HARVARD UNIV,CAMBRIDGE,MA 02138	Harvard University	Martensen, RL (corresponding author), UNIV KANSAS,SCH MED,DEPT HIST & PHILOSOPHY MED,3901 RAINBOW BLVD,KANSAS CITY,KS 66160, USA.							BANISTER JM, 1906, J ASS MILIT SURG US, V18, P148; BANISTER JM, 1906, J ASS MILIT SURG US, V18, P258; DEKRUIF P, 1954, MICROBE HUNTERS, P286; Farmer P, 1997, SOC SCI MED, V44, P347, DOI 10.1016/S0277-9536(96)00143-8; LEIGH JG, 1905, LANCET, V71, P1597; LEIGH JG, 1905, LANCET, V71, P1726; LEIGH JG, 1905, LANCET, V71, P1530; LUGOVINA J, 1903, J ASS MILIT SURG US, V18, P150; MAXWELL GT, 1896, SANITARIAN, V36, P97; MENZIES R, 1993, TUBERCLE LUNG DIS, V74, P32, DOI 10.1016/0962-8479(93)90066-7; Reed CAL, 1905, JAMA-J AM MED ASSOC, VXLIV, P812	11	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1917	1917						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200618				2022-12-28	WOS:A1997XF08700002
J	Bone, RC				Bone, RC			Critical care medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOSOCOMIAL SINUSITIS; PNEUMONIA; MORTALITY; UNIT				Bone, RC (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.							AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; BERT F, 1995, J INFECTION, V31, P5, DOI 10.1016/S0163-4453(95)91147-2; BERT F, 1995, AM J RESP CRIT CARE, V152, P1424, DOI 10.1164/ajrccm.152.4.7551404; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P565, DOI 10.1001/jama.276.7.565; BUENOCAVANILLAS A, 1994, CRIT CARE MED, V22, P55, DOI 10.1097/00003246-199401000-00013; Chatila W, 1996, CHEST, V109, P1577, DOI 10.1378/chest.109.6.1577; Hund EF, 1996, CRIT CARE MED, V24, P1328, DOI 10.1097/00003246-199608000-00010; KIRTON OC, 1995, CHEST, V108, P1021, DOI 10.1378/chest.108.4.1021; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; Latronico N, 1996, LANCET, V347, P1579, DOI 10.1016/S0140-6736(96)91074-0; Linden PK, 1996, CLIN INFECT DIS, V22, P663, DOI 10.1093/clinids/22.4.663; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; SILVERMAN HJ, 1995, ARCH INTERN MED, V155, P502, DOI 10.1001/archinte.155.5.502; Stein PD, 1996, CHEST, V109, P78, DOI 10.1378/chest.109.1.78	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1847	1848						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185794				2022-12-28	WOS:A1997XD54400013
J	Joynt, RJ; Kurlan, RM				Joynt, RJ; Kurlan, RM			Neurology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Joynt, RJ (corresponding author), UNIV ROCHESTER, 601 ELMWOOD AVE, ROCHESTER, NY 14627 USA.							Antel JP, 1996, NAT MED, V2, P1074, DOI 10.1038/nm1096-1074; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; Kittner SJ, 1996, NEW ENGL J MED, V335, P768, DOI 10.1056/NEJM199609123351102; Kretzschmar HA, 1996, ARCH NEUROL-CHICAGO, V53, P913, DOI 10.1001/archneur.1996.00550090125018; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; *MULT AC STROK TRI, 1996, NEW ENGL J MED, V53, P1306; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Riggs JE, 1996, ARCH NEUROL-CHICAGO, V53, P1306, DOI 10.1001/archneur.1996.00550120118026; SANDON DA, 1996, ARCH NEUROL-CHICAGO, V53, P125; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Vandenbark AA, 1996, NAT MED, V2, P1109, DOI 10.1038/nm1096-1109; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	16	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1873	1874						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185810				2022-12-28	WOS:A1997XD54400029
J	Sakamoto, J; Yasue, M				Sakamoto, J; Yasue, M			Do Japanese statistics on gastric carcinoma need to be revised?	LANCET			English	Editorial Material							CANCER				Sakamoto, J (corresponding author), AICHI PREFECTURAL HOSP,DEPT SURG,18 KURIYADO,OKAZAKI,AICHI 444,JAPAN.							HIOKI K, 1990, BRIT J SURG, V77, P1330, DOI 10.1002/bjs.1800771205; NAKAJIMA T, 1994, JPN J CANC CHEMOTHER, V21, P1813; SANO T, 1992, BRIT J SURG, V79, P241, DOI 10.1002/bjs.1800790319; Sasako M, 1997, GASTRIC CANCER -BOOK, P223; SUELING HM, 1992, GUT, V33, P1318, DOI 10.1136/gut.33.10.1318; SUELING HM, 1993, BMJ-BRIT MED J, V307, P591, DOI 10.1136/bmj.307.6904.591	6	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1711	1712		10.1016/S0140-6736(05)62949-2	http://dx.doi.org/10.1016/S0140-6736(05)62949-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193376				2022-12-28	WOS:A1997XE06500003
J	Vega, LR; Solomon, F				Vega, LR; Solomon, F			Microtubule function in morphological differentiation: Growth zones and growth cones	CELL			English	Review							ERM FAMILY MEMBERS; CELL-CYCLE; MORPHOGENESIS; CYTOSKELETON; LOCALIZATION; COMPONENT		MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	Vega, LR (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.		Vega, Leticia/AAF-4981-2021; Vega, Leticia/G-1984-2017	Vega, Leticia/0000-0001-7605-1048; 				BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; Chant J, 1991, CURR OPIN GENET DEV, V1, P342, DOI 10.1016/S0959-437X(05)80298-9; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; LAFONT F, 1994, NATURE, V372, P801; NURSE P, 1994, MOL BIOL CELL, V5, P613, DOI 10.1091/mbc.5.6.613; READ EB, 1992, MOL BIOL CELL, V3, P429, DOI 10.1091/mbc.3.4.429; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; VERDE F, 1995, J CELL BIOL, V131, P1529, DOI 10.1083/jcb.131.6.1529; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Yaffe MP, 1996, P NATL ACAD SCI USA, V93, P11664, DOI 10.1073/pnas.93.21.11664	14	33	33	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					825	828		10.1016/S0092-8674(00)80266-4	http://dx.doi.org/10.1016/S0092-8674(00)80266-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200600	Bronze			2022-12-28	WOS:A1997XE35700002
J	Forrest, CB; Simpson, L; Clancy, C				Forrest, CB; Simpson, L; Clancy, C			Child health services research - Challenges and opportunities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY DISCHARGE; UNITED-STATES; CHRONIC ILLNESS; SEXUAL ABUSE; CARE; PHYSICIAN; CONTINUITY; INSURANCE; PATTERNS; DISEASE	The characteristics of childhood as a unique developmental stage of life, the continuity of child health with adult health, and a distinctive child health care system justify a separate focus of health services research on children. Child health services research (CHSR) currently lacks the tools necessary to monitor the impact of health system change on children's health and health care and to compare the effectiveness of alternative treatment modalities. There is an urgent need to build the research capacity of this field of inquiry. Ignoring or minimizing attention to CHSR is both shortsighted and ultimately costly for families and the entire nation. We present arguments for why children merit a separate focus in health services research, identify factors that have led to the failure of appropriate development of CHSR, and offer a set of strategies for how to build the research capacity of the field.	US DEPT HHS,AGCY HLTH CARE POLICY & RES,ROCKVILLE,MD 20852	Agency for Healthcare Research & Quality	Forrest, CB (corresponding author), JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,624 N BROADWAY,ROOM 689,BALTIMORE,MD 21205, USA.		Forrest, Christopher/CAF-1379-2022	Forrest, Christopher/0000-0003-1252-068X	AHRQ HHS [R13 HS09320] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Amler RW, 1987, AM J PREV MED, V3, P181; BEITCHMAN JH, 1992, CHILD ABUSE NEGLECT, V16, P101, DOI 10.1016/0145-2134(92)90011-F; BLAND CJ, 1992, ACAD MED, V67, P385, DOI 10.1097/00001888-199206000-00010; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; Breslau N, 1996, AM J PUBLIC HEALTH, V86, P214, DOI 10.2105/AJPH.86.2.214; BRITTON JR, 1994, PEDIATRICS, V94, P291; CARPENTER ES, 1980, MED CARE, V18, P1208, DOI 10.1097/00005650-198012000-00006; CATZ C, 1995, PEDIATRICS, V96, P743; CHARLES S, 1995, PEDIATRICS, V96, P746; CORNELIUS L, 1991, AG HLTH CAR POL RES; Cunningham P J, 1994, Future Child, V4, P24, DOI 10.2307/1602433; Donaldson M, 1996, PRIMARY CARE AM HLTH; Durch J, 1993, EMERGENCY MED SERVIC; FIELD MJ, 1995, HLTH SERVICES RES WO; FORREST CB, 1996, CHILD HLTH SERVICES; FOX HB, 1993, AM J DIS CHILD, V147, P546, DOI 10.1001/archpedi.1993.02160290052025; FREUND DA, 1995, ANNU REV PUBL HEALTH, V16, P473; GABEL J, 1994, HEALTH AFFAIR, V13, P327, DOI 10.1377/hlthaff.13.1.327; GAUS CR, 1995, INQUIRY-J HEALTH CAR, V32, P130; Geltman PL, 1996, ARCH PEDIAT ADOL MED, V150, P384, DOI 10.1001/archpedi.1996.02170290050008; General Accounting Office, 1994, GEN ACC OFF PUBL; HARRINGTON R, 1990, ARCH GEN PSYCHIAT, V47, P465; HOMER CJ, 1995, AMBULATORY CHILD HLT, V1, P33; HORBAR JD, 1995, FUTURE CHILD, V5, P139, DOI 10.2307/1602512; HOUK VN, 1989, PUBLIC HEALTH REP, V104, P226; JAMESON EJ, 1993, STANFORD LAW POL FAL, P152; KAPLAN SH, 1995, AHSR FHSR ANN M ABST, V12, P3; KERTESZ L, 1995, MOD HEALTHCARE, V25, P19; KLEIN RG, 1991, J AM ACAD CHILD PSY, V30, P383, DOI 10.1097/00004583-199105000-00005; KLERMAN L, 1990, CHILDREN CHANGING HL; Kletke PR, 1996, JAMA-J AM MED ASSOC, V276, P555, DOI 10.1001/jama.276.7.555; KOCHANEK KD, 1995, MONTHLY VITAL STAT S, V43; KOGAN MD, 1995, JAMA-J AM MED ASSOC, V274, P1429, DOI 10.1001/jama.274.18.1429; LEWIS CC, 1989, MED CARE, V27, pS54, DOI 10.1097/00005650-198903001-00005; LOHR KN, 1989, MED CARE, V27, P1; Manzano J, 1994, Schweiz Arch Neurol Psychiatr (1985), V145, P13; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MILLER TR, 1995, ARCH PEDIAT ADOL MED, V149, P369, DOI 10.1001/archpedi.1995.02170160023003; *MM DOW, 1994, MM DOW MAN CAR DIG; MONHEIT AC, 1992, FUTURE CHILD, V2, P154; *NAT ASS COMM HLTH, 1993, ACC COMM HLTH CAR NA; *NAT COMM QUAL ASS, 1995, REP CAR PROJ; NEFF JM, 1995, JAMA-J AM MED ASSOC, V274, P1866, DOI 10.1001/jama.274.23.1866; NEWACHECK PW, 1995, HEALTH AFFAIR, V14, P244, DOI 10.1377/hlthaff.14.1.244; NEWACHECK PW, 1992, AM J PUBLIC HEALTH, V82, P364, DOI 10.2105/AJPH.82.3.364; *NIH, 1997, NIH GUID; *OFF SMOK HLTH, 1989, DHHS PUBL; PALFREY JS, 1980, PEDIATRICS, V65, P567; PALFREY JS, 1995, COMMUNITY CHILD HLTH; PALLARITO K, 1995, MOD HEALTHCARE, V25, P12; PARKER S, 1988, PEDIATR CLIN N AM, V35, P1227; PERRIN JM, 1994, PEDIATR ANN, V23, P676, DOI 10.3928/0090-4481-19941201-08; PERRIN JM, 1985, ISSUES CARE CHILDREN; *PHS, 1994, PREV TOB US YOUNG PE; *PHS, 1990, DHHS PUBL; POWER C, 1990, J EPIDEMIOL COMMUN H, V44, P69, DOI 10.1136/jech.44.1.69; ROBINS L, 1983, HDB HLTH HLTH CARE H; RUCHROSS HS, 1994, PEDIATRICS, V94, P508; SCHLESINGER M, 1990, CHILDREN CHANGING HL; SCHOR EL, 1986, PEDIATRICS, V77, P834; SCHWARTZ JE, 1995, AM J PUBLIC HEALTH, V85, P1237, DOI 10.2105/AJPH.85.9.1237; Sherman Arloc., 1994, WASTING AM FUTURE; SHORT PF, 1995, JAMA-J AM MED ASSOC, V274, P1302; STARFIELD B, 1993, PEDIATRICS, V91, P430; STARFIELD B, 1989, B NEW YORK ACAD MED, V65, P299; STARFIELD B, 1990, CHILDREN CHANGING HL; Stiehm ER, 1996, ARCH PEDIAT ADOL MED, V150, P971, DOI 10.1001/archpedi.1996.02170340085016; SWEETING H, 1994, SOC SCI MED, V40, P77; *US C, 1988, OFF TECHN ASS PUBL; *US CENS BUR, 1993, CURR POP REP SER; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; USSHER JM, 1995, BRIT J CLIN PSYCHOL, V34, P177, DOI 10.1111/j.2044-8260.1995.tb01453.x; WALLERSTEIN JS, 1991, J AM ACAD CHILD PSY, V30, P349, DOI 10.1097/00004583-199105000-00001; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENGER BL, 1996, DISABILITIES CHILDRE; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; Wilson M, 1996, PEDIATRICS, V97, P733; WOLFF S, 1991, BRIT J PSYCHIAT, V159, P620, DOI 10.1192/bjp.159.5.620; Wolff S, 1991, BRIT J PSYCHIAT, V159, P634, DOI DOI 10.1192/BJP.159.5.620; YOUNG PC, 1994, PEDIATRICS, V94, P284	80	148	148	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	1997	277	22					1787	1793		10.1001/jama.277.22.1787	http://dx.doi.org/10.1001/jama.277.22.1787			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC499	9178792				2022-12-28	WOS:A1997XC49900032
J	Katsouyanni, K; Touloumi, G; Spix, C; Schwartz, J; Balducci, F; Medina, S; Rossi, G; Wojtyniak, B; Sunyer, J; Bacharova, L; Schouten, JP; Ponka, A; Anderson, HR				Katsouyanni, K; Touloumi, G; Spix, C; Schwartz, J; Balducci, F; Medina, S; Rossi, G; Wojtyniak, B; Sunyer, J; Bacharova, L; Schouten, JP; Ponka, A; Anderson, HR			Short term effects of ambient sulphur dioxide and particulate matter on mortality in 12 European cities: Results from time series data from the APHEA project	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AIR-POLLUTION; META-ANALYSIS; HEALTH; ATHENS	Objectives: To carry out a prospective combined quantitative analysis of the associations between all cause mortality and ambient particulate matter and sulphur dioxide. . Design: Analysis of time series data on daily number of deaths from all causes and concentrations of sulphur dioxide and particulate matter (measured as black smoke or particles smaller than 10 mu m in diameter (PM10)) and potential confounders. Setting: 12 European cities in the APHEA project (Air Pollution and Health: a European Approach). Main outcome measure: Relative risk of death. Results: In western European cities it was found that an increase of 50 mu g/m(3) in sulphur dioxide or black smoke was associated with a 3% (95% confidence interval 2% to 4%) increase in daily mortality and the corresponding figure for PM10 was 2% (1% to 3%). In central eastern European cities the increases in mortality associated with a 50 mu/m(3) change in sulphur dioxide was 0.8% (-0.1% to 2.4%) and in black smoke 0.6% (0.2% to 1.1%). Cumulative effects of prolonged (two to four days) exposure to air pollutants resulted to estimates comparable with the one day effects. The effects of both pollutants were stronger during the summer and were mutually independent Conclusions: The internal consistency of the results in western European cities with wide differences in climate and environmental conditions suggest that these associations may be causal. The long term health impact of these effects is uncertain, but today's relatively low levels of sulphur dioxide and particles still have detectable short term effects on health and further reductions in air pollution are advisable.	GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT GMBH, INST EPIDEMIOL, MUNICH, GERMANY; HARVARD UNIV, SCH PUBL HLTH, ENVIRONM EPIDEMIOL PROGRAM, BOSTON, MA 02115 USA; UNIV GRENOBLE, FAC MED, DEPT PUBL HLTH, F-38706 LA TRONCHE, FRANCE; OBSERV REG SANTE PARIS, ORS ILE FRANCE, F-75732 PARIS 15, FRANCE; CNR, IFC, NATL RES COUNCIL, INST CLIN PHYSIOL, I-56100 PISA, ITALY; NATL INST HYG, PL-00791 WARSAW, POLAND; INST MUNICIPAL INVEST MED, E-08003 BARCELONA, SPAIN; NATL CTR HLTH PROMOT, BRATISLAVA 82007, SLOVAKIA; UNIV GRONINGEN, UNIV HOSP GRONINGEN, DEPT EPIDEMIOL & STAT, NL-9713 GRONINGEN, NETHERLANDS; HELSINKI CITY CTR ENVIRONM, ENVIRONM HLTH UNIT, HELSINKI 00530, FINLAND; UNIV LONDON ST GEORGES HOSP, SCH MED, DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Harvard T.H. Chan School of Public Health; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); National Institute of Hygiene (NIH); University of Groningen; St Georges University London	Katsouyanni, K (corresponding author), UNIV ATHENS, SCH MED, DEPT HYG & EPIDEMIOL, GR-11527 ATHENS, GREECE.		Rossi, Giuseppe/G-7838-2012; Sunyer, Jordi/G-6909-2014; Katsouyanni, Klea/D-4856-2014	Sunyer, Jordi/0000-0002-2602-4110; Katsouyanni, Klea/0000-0002-0132-9575; Wojtyniak, Bogdan/0000-0002-2135-8226				Anderson HR, 1996, BMJ-BRIT MED J, V312, P665; Ballester F, 1996, J EPIDEMIOL COMMUN H, V50, P527, DOI 10.1136/jech.50.5.527; DERRIENNIC F, 1989, INT J EPIDEMIOL, V18, P186, DOI 10.1093/ije/18.1.186; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; HATZAKIS A, 1986, INT J EPIDEMIOL, V15, P73, DOI 10.1093/ije/15.1.73; Katsouyanni K, 1996, J EPIDEMIOL COMMUN H, V50, pS12, DOI 10.1136/jech.50.Suppl_1.S12; KATSOUYANNI K, 1995, EUR RESPIR J, V8, P1030; KINNEY PL, 1995, INHAL TOXICOL, V7, P59, DOI 10.3109/08958379509014271; PONKA A, 1991, ARCH ENVIRON HEALTH, V46, P262, DOI 10.1080/00039896.1991.9934386; Samet JM, 1995, PARTICULATE AIR POLL; Schwartz J, 1996, J EPIDEMIOL COMMUN H, V50, pS3, DOI 10.1136/jech.50.Suppl_1.S3; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; SUH HH, 1992, ENVIRON SCI TECHNOL, V26, P2507, DOI 10.1021/es00036a026; SUNYER J, 1993, AM J EPIDEMIOL, V137, P701, DOI 10.1093/oxfordjournals.aje.a116730; TOULOUMI G, 1994, INT J EPIDEMIOL, V23, P957, DOI 10.1093/ije/23.5.957; TOULOUMI G, 1996, IN PRESS AM J EPIDEM; UTELL MJ, 1993, AM REV RESPIR DIS, V147, P1334, DOI 10.1164/ajrccm/147.6_Pt_1.1334; Verhoeff AP, 1996, EPIDEMIOLOGY, V7, P225, DOI 10.1097/00001648-199605000-00002; WARE JH, 1981, ENVIRON HEALTH PERSP, V41, P255, DOI 10.2307/3429322; WICHMANN HE, 1989, ENVIRON HEALTH PERSP, V79, P89, DOI 10.2307/3430534; Wietlisbach V, 1996, SOZ PRAVENTIV MED, V41, P107, DOI 10.1007/BF01323089; World Health Organization Regional Office for Europe, 1987, WHO REG PUBL EUR SER, V23; 1996, J EPIDEMIOL COMMUN S, V50, pS19	24	667	684	2	113	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	1997	314	7095					1658	1663		10.1136/bmj.314.7095.1658	http://dx.doi.org/10.1136/bmj.314.7095.1658			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD874	9180068	Green Published			2022-12-28	WOS:A1997XD87400025
J	Sharp, D				Sharp, D			Late but warranted pardons	LANCET			English	Editorial Material																		BABINGTON A, 1993, SAKE EXAMPLE CAPITAL; MORRIS CA, 1901, LANCET, V2, P1560; RICHARDSON F, 1993, SAKE EXAMPLE, P214	3	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1640	1640		10.1016/S0140-6736(05)62632-3	http://dx.doi.org/10.1016/S0140-6736(05)62632-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186380				2022-12-28	WOS:A1997XD10000006
J	Poland, GA; Borrud, A; Jacobson, RM; McDermott, K; Wollan, PC; Brakke, D; Charboneau, JW				Poland, GA; Borrud, A; Jacobson, RM; McDermott, K; Wollan, PC; Brakke, D; Charboneau, JW			Determination of deltoid fat pad thickness - Implications for needle length in adult immunization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	29th Annual Meeting of the Infectious-Disease-Society-of-America	MAY   16, 1995	LOS ANGELES, CA	Infect Dis Soc Amer			HEPATITIS-B VACCINE; HEALTH-CARE PERSONNEL; INJECTION-SITE; INTRAMUSCULAR INJECTION; ANTIBODY-RESPONSE; EFFICACY; ULTRASOUND; DIPHTHERIA; IMMUNITY; TETANUS	Objective.-To measure deltoid fat pad thickness and determine the optimal needle length for deltoid intramuscular immunization in healthy adults. Design, Setting, and Participants.-Prospective study of 220 healthy health care workers (126 women, 94 men) at the Mayo Medical Center, Rochester, Minn. Main Outcome Measures.-Deltoid fat pad thickness determined by high-resolution ultrasound scanning, weight, height, and mid-deltoid arm circumference. Results.-We found a highly significant difference between women and men in deltoid fat pad thickness, with women having a thicker deltoid fat pad (11.7 vs 8.3 mm; P<.001), Women had a greater deltoid skin-fold thickness than men (34.7 vs 17.2 mm, P<.001) and an equal body mass index, According to the ultrasound findings, a standard 16-mm (5/8-in) needle would not have reached 5 mm into muscle in 17% (16/94) of men and 48.4% (61/126) of women in this study. Conclusions.-Among healthy adults of the age range we studied, the following needle lengths appear to be appropriate for true deltoid intramuscular immunization: For men across the weight ranges we studied (59-118 kg), use of a 25-mm (1-in) needle would result in at least 5 mm of muscle penetration in all subjects. For women who weighed less than 60 kg, a 16-mm (5/8-in) needle would be sufficient to achieve muscle penetration of 5 mm. For women between 60 and 90 kg, a 25-mm (1-in) needle would be sufficient, and women greater than 90 kg would require a 38-mm (1.5-in) needle to ensure intramuscular administration.	MAYO CLIN & MAYO FDN,SECT BIOSTT HLTH SCI EVALUAT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT DIAGNOST RADIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	Poland, GA (corresponding author), MAYO CLIN & MAYO FDN,MAYO VACCINE RES GRP,CLIN PHARMACOL UNIT,200 1ST ST SW,601B GUGGENHEIM BLDG,ROCHESTER,MN 55905, USA.			Jacobson, Robert/0000-0002-6355-8752				*ACP TASK FORC AD, 1994, GUID AD IMM, P1; *AM AC PED, 1994, REP COMM INF DIS; BORKAN GA, 1982, AM J PHYS ANTHROPOL, V58, P307, DOI 10.1002/ajpa.1330580309; COCKSHOTT WP, 1982, NEW ENGL J MED, V307, P356, DOI 10.1056/NEJM198208053070607; DIENSTAG JL, 1984, ANN INTERN MED, V101, P34, DOI 10.7326/0003-4819-101-1-34; FRANCIS DP, 1982, ANN INTERN MED, V97, P362, DOI 10.7326/0003-4819-97-3-362; FRIED AM, 1986, INVEST RADIOL, V21, P71, DOI 10.1097/00004424-198601000-00012; FRISANCHO AR, 1974, AM J CLIN NUTR, V27, P1052, DOI 10.1093/ajcn/27.8.1052; GREENBLATT DJ, 1976, NEW ENGL J MED, V295, P542; GREENBLATT DJ, 1978, JAMA-J AM MED ASSOC, V240, P542, DOI 10.1001/jama.240.6.542; Haramati N, 1994, Arch Fam Med, V3, P146, DOI 10.1001/archfami.3.2.146; HATTORI K, 1991, HUM BIOL, V63, P53; HAYES PA, 1988, MED SCI SPORT EXER, V20, P303, DOI 10.1249/00005768-198806000-00015; HECKMATT JZ, 1988, J CLIN ULTRASOUND, V16, P171, DOI 10.1002/jcu.1870160305; HICK JF, 1989, PEDIATRICS, V84, P136; HOROWITZ MM, 1988, ANN INTERN MED, V108, P185, DOI 10.7326/0003-4819-108-2-185; IPP MM, 1989, PEDIATRICS, V83, P679; KOHRT WM, 1992, MED SCI SPORT EXER, V24, P832; LEMON SM, 1986, J GEN INTERN MED, V11, P199; LINDSAY KL, 1985, HEPATOLOGY, V5, P1088, DOI 10.1002/hep.1840050605; LO Y-S, 1992, Kaohsiung Journal of Medical Sciences, V8, P75; MCLEAN AA, 1985, MMWR-MORBID MORTAL W, V34, P105; MICHAELS L, 1970, CAN MED ASSOC J, V102, P626; *NAT ADV COMM IMM, 1989, CAN IMM GUID; PASKO MT, 1990, AM J PUBLIC HEALTH, V80, P590, DOI 10.2105/AJPH.80.5.590; PEAD PJ, 1985, LANCET, V1, P1152; RAMIREZ ME, 1993, INT J OBESITY, V17, P63; SENDEN TF, 1990, VACCINE, V8, P612, DOI 10.1016/0264-410X(90)90037-M; SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6; SJOSTROM L, 1988, FAT DISTRIBUTION GRO, P43; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; UKENA T, 1985, NEW ENGL J MED, V313, P579; WAHL M, 1987, SCAND J INFECT DIS, V19, P617, DOI 10.3109/00365548709117195; WEBER DJ, 1985, JAMA-J AM MED ASSOC, V254, P3187, DOI 10.1001/jama.254.22.3187; WEISS LW, 1987, EUR J APPL PHYSIOL O, V56, P217, DOI 10.1007/BF00640647; WEITS T, 1986, INT J OBESITY, V10, P161; 1994, MMWR-MORBID MORTAL W, V43, P1	37	118	135	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1709	1711		10.1001/jama.277.21.1709	http://dx.doi.org/10.1001/jama.277.21.1709			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169899				2022-12-28	WOS:A1997XB08800033
J	Bousser, MG				Bousser, MG			Aspirin or heparin immediately after a stroke?	LANCET			English	Editorial Material							ACUTE ISCHEMIC STROKE				Bousser, MG (corresponding author), HOP ST ANTOINE,DEPT NEUROL,F-75571 PARIS 12,FRANCE.							ADAMS HP, 1994, CIRCULATION, V90, P1588, DOI 10.1161/01.CIR.90.3.1588; CAPLAN LR, 1991, JAMA-J AM MED ASSOC, V266, P2413, DOI 10.1001/jama.266.17.2413; *EAFT STUD GROUP, 1993, LANCET, V342, P1255; Fisher M, 1997, STROKE, V28, P866, DOI 10.1161/01.STR.28.4.866; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; MARCHAL G, 1993, LANCET, V341, P2; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V333, P1581; 1997, BRIT MED J, V31, P1151	8	41	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 31	1997	349	9065					1564	1565		10.1016/S0140-6736(97)22022-2	http://dx.doi.org/10.1016/S0140-6736(97)22022-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174553				2022-12-28	WOS:A1997XB67300002
J	Salisbury, C				Salisbury, C			Evaluation of a general practice out of hours cooperative: A questionnaire survey of general practitioners	BRITISH MEDICAL JOURNAL			English	Article											Salisbury, C (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT PRIMARY HLTH CARE & GEN PRACTICE,PRAED ST,LONDON W2 1PG,ENGLAND.		Salisbury, Chris/C-6724-2008	Salisbury, Chris/0000-0002-4378-3960				Salisbury C, 1997, BRIT MED J, V314, P182, DOI 10.1136/bmj.314.7075.182; Salisbury C, 1997, BRIT MED J, V314, P1594, DOI 10.1136/bmj.314.7094.1594; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545	3	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 31	1997	314	7094					1598	1599		10.1136/bmj.314.7094.1598	http://dx.doi.org/10.1136/bmj.314.7094.1598			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9186173	Green Published			2022-12-28	WOS:A1997XC50000027
J	Summerfield, DA				Summerfield, DA			Legacy of war: Beyond ''trauma'' to the social fabric	LANCET			English	Editorial Material											Summerfield, DA (corresponding author), MED FDN CARE VICTIMS TORTURE,LONDON NW5 3EJ,ENGLAND.							Ager A., 1993, MENTAL HLTH ISSUES R; AGGER J, 1995, THEORY PRACTICE PSYC; Boyden J., 1996, VULNERABILITY RESILI; BRACKEN PJ, 1995, SOC SCI MED, V40, P1073, DOI 10.1016/0277-9536(94)00181-R; Kawachi I, 1997, BMJ-BRIT MED J, V314, P1037, DOI 10.1136/bmj.314.7086.1037; RAPHAEL B, 1995, BRIT MED J, V310, P1479, DOI 10.1136/bmj.310.6993.1479; SUMMERFIELD D, 1996, 14 OV DEV I REL REH; UNICEF, 1996, STAT WORLDS CHILDR; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; World Health Organization, 1995, BRIDG GAPS	10	21	21	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 31	1997	349	9065					1568	1568		10.1016/S0140-6736(05)61627-3	http://dx.doi.org/10.1016/S0140-6736(05)61627-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XB673	9174557				2022-12-28	WOS:A1997XB67300006
J	Macknight, R; Bancroft, I; Page, T; Lister, C; Schmidt, R; Love, K; Westphal, L; Murphy, G; Sherson, S; Cobbett, C; Dean, C				Macknight, R; Bancroft, I; Page, T; Lister, C; Schmidt, R; Love, K; Westphal, L; Murphy, G; Sherson, S; Cobbett, C; Dean, C			FCA, a gene controlling flowering time in Arabidopsis, encodes a protein containing RNA-binding domains	CELL			English	Article							POLYMORPHISM LINKAGE MAP; WW DOMAIN; THALIANA; EXPRESSION; TRANSFORMATION; VERNALIZATION; DYSTROPHIN; DROSOPHILA; SELECTION; MUTANTS	A strong promoter of the transition to flowering in Arabidopsis is encoded by FCA. FCA has been cloned and shown to encode a protein containing two RNA-binding domains and a WW protein interaction domain. This suggests that FCA functions in the posttranscriptional regulation of transcripts involved in the flowering process. The FCA transcript is alternatively spliced with only one form encoding the entire FCA protein. Plants carrying the FCA gene fused to the strong constitutive 35S promoter flowered earlier, and the ratio and abundance of the different FCA transcripts were altered. Thus, FCA appears to be a component of a posttranscriptional cascade involved in the control of flowering time.	JOHN INNES CTR PLANT SCI RES,DEPT MOL GENET,NORWICH NR4 7UH,NORFOLK,ENGLAND; UNIV MELBOURNE,DEPT GENET,MELBOURNE,VIC 3052,AUSTRALIA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Melbourne			Bancroft, Ian/AAH-3831-2020	Macknight, Richard/0000-0003-1146-9042; Bancroft, Ian/0000-0001-7707-1171; Schmidt, Renate/0000-0002-8037-3581; Macknight, Richard/0000-0002-3300-7124				Amasino RM, 1996, CURR OPIN GENET DEV, V6, P480, DOI 10.1016/S0959-437X(96)80071-2; ANDRE B, 1994, BIOCHEM BIOPH RES CO, V205, P1201, DOI 10.1006/bbrc.1994.2793; Aukerman MJ, 1996, SEMIN CELL DEV BIOL, V7, P427, DOI 10.1006/scdb.1996.0053; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Brown JWS, 1996, PLANT J, V10, P771, DOI 10.1046/j.1365-313X.1996.10050771.x; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURN JE, 1993, GENETICA, V90, P145; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CLARKE JH, 1994, MOL GEN GENET, V242, P81, DOI 10.1007/BF00277351; DEAN C, 1992, PLANT J, V2, P69, DOI 10.1111/j.1365-313X.1992.00069.x; DEAN C, 1985, EMBO J, V4, P3055, DOI 10.1002/j.1460-2075.1985.tb04045.x; DOLEZAL O, 1991, PLANT PHYSIOL, V96, P1255, DOI 10.1104/pp.96.4.1255; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Furner IJ, 1996, DEVELOPMENT, V122, P1041; Gao FB, 1996, J CELL SCI, V109, P579; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Hicks KA, 1996, SEMIN CELL DEV BIOL, V7, P409, DOI 10.1006/scdb.1996.0051; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koushika SP, 1996, CURR BIOL, V6, P1634, DOI 10.1016/S0960-9822(02)70787-2; LEE I, 1993, MOL GEN GENET, V237, P171, DOI 10.1007/BF00282798; LEE I, 1994, PLANT CELL, V6, P75, DOI 10.1105/tpc.6.1.75; LUEHRSEN KR, 1994, GENE DEV, V8, P1117, DOI 10.1101/gad.8.9.1117; MARTINEZZAPATER JM, 1990, PLANT PHYSIOL, V92, P770, DOI 10.1104/pp.92.3.770; MARTINEZZAPATER JM, 1995, PLANT J, V7, P543, DOI 10.1046/j.1365-313X.1995.7040543.x; Mattox W, 1996, GENETICS, V143, P303; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; Schmidt R, 1996, PLANT J, V9, P755, DOI 10.1046/j.1365-313X.1996.9050755.x; Schmidt R, 1995, METHOD MOL CELL BIOL, V5, P309; Simpson GG, 1996, PLANT MOL BIOL, V32, P1, DOI 10.1007/BF00039375; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536	45	394	431	4	51	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					737	745		10.1016/S0092-8674(00)80256-1	http://dx.doi.org/10.1016/S0092-8674(00)80256-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182761	Bronze			2022-12-28	WOS:A1997XB92500010
J	Campbell, MJ; Cogman, GR; Holgate, ST; Johnston, SL				Campbell, MJ; Cogman, GR; Holgate, ST; Johnston, SL			Age specific trends in asthma mortality in England and Wales, 1983-95: Results of an observational study	BRITISH MEDICAL JOURNAL			English	Article							DEATHS	Objective: To determine trends in asthma mortality by age group in England and Wales during 1983-95. Design: Observational study. Setting: England and Wales. Subjects: All deaths classified as having an underlying cause of asthma registered from 1 January 1983 to 31 December 1995. Main outcome measure: Time trends for age specific asthma deaths. Results: Deaths in the age group 5-14 pears showed an irregular downward trend during 1983-95; deaths in the age groups 15-44, 45-64, and 65-74 years peaked before 1989 and then showed a downward trend; and deaths in the age group 75-84 years peaked between 1988 and 1993 aad subsequently dropped. Trends were: age group 5-14 years, 6% (95% confidence interval 3% to 9%); 15-44 years, 6% (5% to 7%); 45-64 years, 5% (4% to 6%); 65-74 years, 2% (1% to 3%). Deaths in the 75-84 and 85 and over categories plateaued. Conclusions: There are downward tr ends in asthma mortality in Britain, which may be due to increased use of prophylactic treatment.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT MED,SOUTHAMPTON SP16 6YD,HANTS,ENGLAND	University of Southampton	Campbell, MJ (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT MED STAT & COMP,SOUTHAMPTON SP16 6YD,HANTS,ENGLAND.		Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200				BALDWIN DR, 1990, THORAX, V45, P130, DOI 10.1136/thx.45.2.130; *BTA RES COMM, 1984, THORAX, V39, P505; BURNEY PGJ, 1986, LANCET, V2, P323; CADET B, 1994, REV EPIDEMIOL SANTE, V42, P103; GARRETT J, 1995, THORAX, V50, P303, DOI 10.1136/thx.50.3.303; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596, DOI 10.1136/bmj.308.6944.1596; KHOT A, 1984, BRIT MED J, V289, P557, DOI 10.1136/bmj.289.6444.557; KHOT A, 1984, BRIT MED J, V289, P233, DOI 10.1136/bmj.289.6439.233; MACKAY TW, 1992, SCOT MED J, V37, P5, DOI 10.1177/003693309203700102; PHELAN PD, 1994, BRIT MED J, V308, P1584, DOI 10.1136/bmj.308.6944.1584; *STATC, 1997, STAT STAT SOFTW REL	11	133	134	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1439	1441		10.1136/bmj.314.7092.1439	http://dx.doi.org/10.1136/bmj.314.7092.1439			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167558	Green Published			2022-12-28	WOS:A1997XA20200019
J	Neal, RD; Maskrey, N; Williams, M				Neal, RD; Maskrey, N; Williams, M			How to do it - Run a preparation course for postgraduate examinations	BRITISH MEDICAL JOURNAL			English	Article							MRCGP	This paper provides a practical guided to running preparation courses for postgraduate examinations and is based on the authors' experiences. It is intended to be useful to organisers of proposed or existing courses as well as to potential users of courses - people in every specialty preparing for a postgraduate examination. The paper covers the practical aspects of staging and financing in course and recruiting tutors and attracting candidates, in addition to covering the structure, educational content, and evaluation of the course.	N YORKSHIRE HLTH AUTHOR,YORK YO1 1PE,N YORKSHIRE,ENGLAND; UNIV LEEDS,CTR RES PRIMARY CARE,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND; BEECH TREE SURG,SELBY YO8 9AJ,N YORKSHIRE,ENGLAND	University of Leeds								GODLEE F, 1991, BRIT MED J, V303, P235, DOI 10.1136/bmj.303.6796.235; JAQUES D, 1991, LEARNING GROUPS; MASKREY N, 1994, MRCGP WORKBOOK; WAKEFORD R, 1995, BRIT MED J, V311, P931	4	3	3	2	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1468	1472		10.1136/bmj.314.7092.1468	http://dx.doi.org/10.1136/bmj.314.7092.1468			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167567	Green Published			2022-12-28	WOS:A1997XA20200029
J	Deresiewicz, RL; Thaler, SJ; Hsu, LG; Zamani, AA				Deresiewicz, RL; Thaler, SJ; Hsu, LG; Zamani, AA			Clinical and neuroradiographic manifestations of Eastern equine encephalitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HERPES-SIMPLEX ENCEPHALITIS; CREUTZFELDT-JAKOB-DISEASE; MUMPS ENCEPHALITIS; MRI; CT; ABNORMALITIES; BRAIN	Background Eastern equine encephalitis occurs principally along the east and Gulf coasts of the United States. Recognition of the neuroradiographic manifestations of eastern equine encephalitis could hasten the diagnosis of the illness and speed the response to index cases. Methods We reviewed all cases of eastern equine encephalitis reported in the United States between 1988 and 1994. The records of 36 patients were studied, along with 57 computed tomographic (CT) scans and 23 magnetic resonance imaging (MRI) scans from 33 patients. Results The mortality rate was 36 percent, and 35 percent of the survivors were moderately or severely disabled. Neuroradiographic abnormalities were common and best visualized by MRI. Among the patients for whom MRI scans were available, the results were abnormal for all eight comatose patients as well as for all three noncomatose patients who subsequently became comatose. The CT results were abnormal in 21 of 32 patients with readable scans. The abnormal findings included focal lesions in the basal ganglia (found in 71 percent of patients on MRI and in 56 percent on CT), thalami (found in 71 percent on MRI and in 25 percent on CT), and brain stem (found in 43 percent on MRI and in 9 percent on CT). Cortical lesions, meningeal enhancement, and periventricular white-matter changes were less common. The presence of large radiographic lesions did not predict a poor outcome, but either high cerebrospinal fluid white-cell counts or severe hyponatremia did. Conclusions Eastern equine encephalitis produces focal radiographic signs. The characteristic early involvement of the basal ganglia and thalami distinguishes this illness from herpes simplex encephalitis. MRI is a sensitive technique to identify the characteristic early adiographic manifestations of this viral encephalitis. (C) 1997, Massachusetts Medical Society.	BRIGHAM & WOMENS HOSP,DIV INFECT DIS,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Deresiewicz, RL (corresponding author), BRIGHAM & WOMENS HOSP,CHANNING LAB,DEPT MED,181 LONGWOOD AVE,BOSTON,MA 02115, USA.							AICARDI J, 1985, DEV MED CHILD NEUROL, V27, P249; *CAS REC MASS GEN, 1984, NEW ENGL J MED, V311, P1559; DAVENPORT DS, 1982, ARCH NEUROL-CHICAGO, V39, P322, DOI 10.1001/archneur.1982.00510170064029; DEMAEREL P, 1992, NEURORADIOLOGY, V34, P490, DOI 10.1007/BF00598957; DENT J H, 1955, Bull Tulane Univ Med Fac, V14, P85; DIROCCO A, 1993, NEURORADIOLOGY, V35, P584, DOI 10.1007/BF00588398; Farber S, 1940, J AMER MED ASSOC, V114, P1725; FEEMSTER RF, 1957, NEW ENGL J MED, V257, P701, DOI 10.1056/NEJM195710102571504; Feemster RF, 1938, AM J PUBLIC HEALTH N, V28, P1403, DOI 10.2105/AJPH.28.12.1403; FERNANDEZ RJ, 1982, NEUROLOGY, V32, pA178; Fothergill LD, 1938, NEW ENGL J MED, V219, P411, DOI 10.1056/NEJM193809222191201; FUJII Y, 1992, PEDIATR NEUROL, V8, P133, DOI 10.1016/0887-8994(92)90035-W; GASECKI AP, 1991, EUR NEUROL, V31, P372, DOI 10.1159/000116696; GERTZ HJ, 1988, NEUROLOGY, V38, P1481, DOI 10.1212/WNL.38.9.1481; GOLDFIEL.M, 1968, AM J EPIDEMIOL, V87, P1; GRIFFITH JF, 1983, MED CLIN N AM, V67, P991, DOI 10.1016/S0025-7125(16)31163-4; HAUSER GEORGE H., 1948, NEW ORLEANS MED AND SURG JOUR, V100, P551; Hindmarsh T, 1986, Acta Radiol Suppl, V369, P192; ISSELBACHER KJ, 1994, HARRIONS PRINCIPLES; JORDAN RA, 1965, AM J TROP MED HYG, V14, P470, DOI 10.4269/ajtmh.1965.14.470; KIM JH, 1985, AM J CLIN PATHOL, V84, P223, DOI 10.1093/ajcp/84.2.223; LAVOIE SR, 1993, SOUTHERN MED J, V86, P812, DOI 10.1097/00007611-199307000-00019; LEHEUP BP, 1987, REV NEUROL, V143, P301; LETSON GW, 1993, AM J TROP MED HYG, V49, P677, DOI 10.4269/ajtmh.1993.49.677; MCGOWAN JE, 1973, AM J EPIDEMIOL, V97, P199, DOI 10.1093/oxfordjournals.aje.a121500; MONATH TP, 1979, B WORLD HEALTH ORGAN, V57, P513; MORSE RP, 1992, PEDIATR NEUROL, V8, P473, DOI 10.1016/0887-8994(92)90013-O; OCHI J, 1986, COMPUT RADIOL, V10, P137, DOI 10.1016/0730-4862(86)90058-2; PETERS ACB, 1979, NEUROLOGY, V29, P676, DOI 10.1212/WNL.29.5.676; PILIERO PJ, 1994, CLIN INFECT DIS, V18, P985, DOI 10.1093/clinids/18.6.985; PROTHEROE SM, 1991, ARCH DIS CHILD, V66, P702, DOI 10.1136/adc.66.6.702; PRZELOMSKI MM, 1988, NEUROLOGY, V38, P736, DOI 10.1212/WNL.38.5.736; SHOJI H, 1989, J NEUROL, V236, P255, DOI 10.1007/BF00314452; TARR RW, 1987, PEDIATR RADIOL, V17, P59, DOI 10.1007/BF02386597; Tsai T F, 1991, Infect Dis Clin North Am, V5, P73; 1990, MMWR MORB MORTAL WKL, V39; 1995, MMWR-MORBID MORTAL W, V44, P641	37	213	219	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 26	1997	336	26					1867	1874		10.1056/NEJM199706263362604	http://dx.doi.org/10.1056/NEJM199706263362604			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF756	9197215	Bronze			2022-12-28	WOS:A1997XF75600004
J	Saini, S				Saini, S			Imaging of the hepatobiliary tract	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HELICAL SPIRAL CT; HEPATIC METASTASES; SONOGRAPHIC DIAGNOSIS; MALIGNANT-TUMORS; LIVER; GALLBLADDER; DISEASES; EFFICACY		HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	Saini, S (corresponding author), MASSACHUSETTS GEN HOSP,DEPT RADIOL,32 FRUIT ST,BOSTON,MA 02114, USA.							BAKER ME, 1995, RADIOLOGY, V197, P329, DOI 10.1148/radiology.197.2.7480672; BARON RL, 1987, RADIOLOGY, V162, P419, DOI 10.1148/radiology.162.2.3797655; Baron RL, 1996, RADIOLOGY, V199, P505, DOI 10.1148/radiology.199.2.8668803; BARON RL, 1991, RADIOL CLIN N AM, V29, P1235; BARON RL, 1994, AM J ROENTGENOL, V163, P323, DOI 10.2214/ajr.163.2.8037023; BLUEMKE DA, 1995, RADIOL CLIN N AM, V33, P863; BRINK JA, 1994, RADIOLOGY, V190, P69, DOI 10.1148/radiology.190.1.8259431; Chan YL, 1996, RADIOLOGY, V200, P85, DOI 10.1148/radiology.200.1.8657949; CLARKE MP, 1989, SURGERY, V106, P849; COOPERBERG PL, 1987, RADIOLOGY, V163, P605, DOI 10.1148/radiology.163.3.3554340; CRONAN JJ, 1988, RADIOLOGY, V166, P135, DOI 10.1148/radiology.166.1.3275965; DODD GD, 1992, AM J ROENTGENOL, V159, P727, DOI 10.2214/ajr.159.4.1326883; DODD GD, 1996, RADIOLOGY LIVER BILI, P65; FEDERLE MP, 1996, RADIOLOGY LIVER BILI, P85; FREENY P C, 1988, Radiology, V168, P319; GAMORI JM, 1991, RADIOLOGY, V179, P367; GOLDBERG MA, 1993, RADIOGRAPHICS, V13, P1047, DOI 10.1148/radiographics.13.5.8210589; GOLDMAN IS, 1985, AM J ROENTGENOL, V144, P541, DOI 10.2214/ajr.144.3.541; GULLIVER DJ, 1992, AM J ROENTGENOL, V159, P503, DOI 10.2214/ajr.159.3.1323924; JONES EC, 1992, AM J ROENTGENOL, V158, P535, DOI 10.2214/ajr.158.3.1738990; KAN ZX, 1993, RADIOLOGY, V187, P621, DOI 10.1148/radiology.187.3.8497606; KANE R, 1995, RADIOLOGY, V195, P117, DOI 10.1148/radiology.195.1.7892450; KARHUNEN PJ, 1986, J CLIN PATHOL, V39, P183, DOI 10.1136/jcp.39.2.183; KIM EE, 1993, RADIOL CLIN N AM, V31, P923; Kuszyk BS, 1996, AM J ROENTGENOL, V166, P91, DOI 10.2214/ajr.166.1.8571914; LAING FC, 1984, AM J ROENTGENOL, V143, P949, DOI 10.2214/ajr.143.5.949; LEE MJ, 1991, AM J ROENTGENOL, V156, P317, DOI 10.2214/ajr.156.2.1898806; MCFARLAND EG, 1994, RADIOLOGY, V193, P43, DOI 10.1148/radiology.193.1.8090920; MILLER WJ, 1994, RADIOLOGY, V193, P645, DOI 10.1148/radiology.193.3.7972802; MITCHELL DG, 1992, RADIOLOGY, V185, P1; MITCHELL DG, 1995, SEMIN ULTRASOUND CT, V16, P49, DOI 10.1016/0887-2171(95)90014-4; NELSON RC, 1989, RADIOLOGY, V172, P27, DOI 10.1148/radiology.172.1.2662254; NGHIEM HV, 1996, RADIOLOGY LIVER BILI, P71; PARVEY HR, 1994, AM J ROENTGENOL, V162, P77, DOI 10.2214/ajr.162.1.8273695; POWIS RL, 1994, RADIOGRAPHICS, V14, P415, DOI 10.1148/radiographics.14.2.8190964; RALLS PW, 1981, AM J ROENTGENOL, V137, P65, DOI 10.2214/ajr.137.1.65; REGAN LS, 1989, ARCH INTERN MED, V149, P1741, DOI 10.1001/archinte.149.8.1741; Reinhold C, 1996, AM J ROENTGENOL, V166, P1285, DOI 10.2214/ajr.166.6.8633434; RUBIN GD, 1995, RADIOL CLIN N AM, V33, P51; RUMMENY EJ, 1992, RADIOLOGY, V182, P879, DOI 10.1148/radiology.182.3.1535912; SCHUHMANNGIAMPI.G, 1990, CONTRAST MEDIA MRI, P313; SIEGELMAN ES, 1991, RADIOLOGY, V179, P361, DOI 10.1148/radiology.179.2.2014275; SIMEONE JF, 1989, AM J ROENTGENOL, V152, P289, DOI 10.2214/ajr.152.2.289; WELTMAN DI, 1994, RADIOL CLIN N AM, V32, P933; WILSON SR, 1996, RADIOLOGY LIVER BILI, P17; WINTER TC, 1996, RADIOLOGY LIVER BILI, P33; ZEMAN RK, 1993, AM J ROENTGENOL, V160, P719, DOI 10.2214/ajr.160.4.8456652; ZWIEBEL WJ, 1995, SEMIN ULTRASOUND CT, V16, P34, DOI 10.1016/0887-2171(95)90013-6	48	75	83	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 26	1997	336	26					1889	1894		10.1056/NEJM199706263362607	http://dx.doi.org/10.1056/NEJM199706263362607			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF756	9197218				2022-12-28	WOS:A1997XF75600007
J	Riis, P				Riis, P			Ethics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE				Riis, P (corresponding author), MINIST SCI,CENT SCI ETH COMM DENMARK,HELLERUP,DENMARK.							[Anonymous], 1997, JAMA, V277, P927; Chan KW, 1996, J PEDIATR-US, V128, P644, DOI 10.1016/S0022-3476(96)80129-6; Council of Europe, 1996, CONV PROT HUM RIGHTS; DICKENS BM, 1996, CAN MED ASSOC J, V154, P885; Eastwood Susan, 1996, Sci Eng Ethics, V2, P89, DOI 10.1007/BF02639320; FUCHS VR, 1996, 1 INT C PRIOR HLTH C; HOJGAARD L, 1996, UGESKRIFT LAEGER, V158, P4777; McKee M, 1996, BRIT MED J, V312, P691; Mehlman MJ, 1996, AM J HUM GENET, V58, P393; NIGHTINGALE SL, 1996, JAMA-J AM MED ASSOC, V276, P1632; NILSTUN T, 1995, SCAND J SOC MED, V23, P81, DOI 10.1177/140349489502300201; RIIS P, ANN REPORT 1966 DANI; Stone DH, 1996, J PUBLIC HEALTH MED, V18, P3, DOI 10.1093/oxfordjournals.pubmed.a024458; WACHTER RM, 1995, SOUTHERN MED J, V88, P25, DOI 10.1097/00007611-199501000-00003; WEALE A, 1995, BRIT MED BULL, V51, P831, DOI 10.1093/oxfordjournals.bmb.a072998	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1855	1856						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185799				2022-12-28	WOS:A1997XD54400018
J	Ma, H				Ma, H			The on and off of floral regulatory genes	CELL			English	Review							FLOWER DEVELOPMENT; ARABIDOPSIS; APETALA1; IDENTITY; PLANTS				Ma, H (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.		Ma, Hong/W-5251-2018	Ma, Hong/0000-0001-8717-4422				Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; MA H, 1994, GENE DEV, V8, P745, DOI 10.1101/gad.8.7.745; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; Martinez-Zapater JM, 1994, ARABIDOPSIS, P403; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; Mizukami Y, 1997, PLANT CELL, V9, P393, DOI 10.1105/tpc.9.3.393; OKAMURO JK, 1993, PLANT CELL, V5, P1183, DOI 10.1105/tpc.5.10.1183; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	19	9	12	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					821	824		10.1016/S0092-8674(00)80265-2	http://dx.doi.org/10.1016/S0092-8674(00)80265-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200599	Bronze			2022-12-28	WOS:A1997XE35700001
J	Jankun, J; Selman, SH; Swiercz, R; SkrzypczakJankun, E				Jankun, J; Selman, SH; Swiercz, R; SkrzypczakJankun, E			Why drinking green tea could prevent cancer	NATURE			English	Letter									MED COLL OHIO, DEPT PHYSIOL & MOL MED, TOLEDO, OH 43699 USA; UNIV TOLEDO, DEPT CHEM, TOLEDO, OH 43606 USA	University System of Ohio; University of Toledo	Jankun, J (corresponding author), MED COLL OHIO, DEPT UROL, TOLEDO, OH 43699 USA.			Jankun, Jerzy/0000-0003-2354-4046				ACHBAROU A, 1994, CANCER RES, V54, P2372; FUJIKI H, 1992, PREV MED, V21, P503, DOI 10.1016/0091-7435(92)90057-O; HARVEY SR, 1988, CLIN EXP METASTAS, V6, P431, DOI 10.1007/BF01784375; Jankun J, 1997, CANCER RES, V57, P559; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; STONER GD, 1995, J CELL BIOCHEM, P169; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038	7	611	670	1	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	1997	387	6633					561	561		10.1038/42381	http://dx.doi.org/10.1038/42381			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177339				2022-12-28	WOS:A1997XC52200033
J	Molloy, AM; Daly, S; Mills, JL; Kirke, PN; Whitehead, AS; Ramsbottom, D; Conley, MR; Weir, DG; Scott, JM				Molloy, AM; Daly, S; Mills, JL; Kirke, PN; Whitehead, AS; Ramsbottom, D; Conley, MR; Weir, DG; Scott, JM			Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: Implications for folate intake recommendations	LANCET			English	Article							CORONARY-ARTERY DISEASE; NEURAL-TUBE DEFECTS; METHYLENETETRAHYDROFOLATE REDUCTASE; RISK FACTOR; VASCULAR-DISEASE; DEFICIENCY	Background The dietary reference values for folate, as for other nutrients, are targeted to the general and supposedly normal population, not people with special needs, such as those with genetic or metabolic abnormalities or diseases. However, 5-15% of general populations are homozygous for a thermolabile variant of 5,10-methylenetetrahydrofolate reductase (C677T) which causes mild hyperhomocysteinaemia and is positively associated with the development of vascular disease and the risk of neural-tube defects. If tissue-folate status is compromised in large sectors of the population by this or other genetic variants, the present dietary reference Values may need to be changed. Methods We identified the C677T genotype and measured red-cell folate concentrations in two groups of healthy women (pregnant, 242, not pregnant, 318). We then analysed the effect of genotype on red-cell folates, which are a reliable marker for tissue folate stores. Findings In the pregnant group there were 20 TT homozygotes, 114 wild-type CC homozygotes, and 108 CT heterozygotes. In the non-pregnant group, the numbers were 41, 148, and 129. In both pregnant and non-pregnant groups, red-cell folate was significantly lower among TT homozygous than CC homozygous women (mean 252 [95% CI 202-317] vs 347 [321-372] mu g/L, p=0.002 for pregnant women; 284 [250-327] vs 347 [342-372] mu g/L, p=0.01 for non-pregnant women). Plasma folate was also significantly lower in TT homozygous than in CC homozygous women in the pregnant group (p=0.009) but not in the non-pregnant group. Interpretation These results suggest that a substantial minority of people in general populatgions may have increased folate needs. Future studies may show the presence of other common genetic variants that interact with particular nutrients and place doubts on the validity of assuming ''normality'' for nutrient requirements in any general population.	UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN 2,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT CLIN MED,DUBLIN 2,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND; UNIV DUBLIN TRINITY COLL,INST BIOTECHNOL,DUBLIN 2,IRELAND; COOMBE WOMENS HOSP,DUBLIN,IRELAND; HLTH RES BOARD,DUBLIN,IRELAND; NICHHD,BETHESDA,MD 20892	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Health Research Board - Ireland; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Molloy, Anne/0000-0002-1688-9049; Mills, James/0000-0003-4496-332X				BAUMGARTNER ER, 1985, PEDIATR RES, V19, P1288, DOI 10.1203/00006450-198512000-00017; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Chanarin I, 1990, MEGALOBLASTIC ANAEMI; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; deFranchis R, 1995, LANCET, V346, P1703, DOI 10.1016/S0140-6736(95)92865-0; ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Jacques PF, 1996, CIRCULATION, V93, P7, DOI 10.1161/01.CIR.93.1.7; KANG SS, 1988, AM J HUM GENET, V43, P414; KANG SS, 1991, AM J HUM GENET, V48, P536; KANG SS, 1993, CIRCULATION, V88, P1463, DOI 10.1161/01.CIR.88.4.1463; KIRKE PN, 1993, Q J MED, V86, P703; Kirke PN, 1996, LANCET, V348, P1037, DOI 10.1016/S0140-6736(05)64971-9; Kluijtmans LAJ, 1996, AM J HUM GENET, V58, P35; OBROIN S, 1992, J CLIN PATHOL, V45, P344, DOI 10.1136/jcp.45.4.344; ROSENBLATT DS, 1979, J CLIN INVEST, V63, P1019, DOI 10.1172/JCI109370; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; VANDERPUT NMJ, 1995, LANCET, V346, P1070, DOI 10.1016/S0140-6736(95)91743-8; VISY JM, 1991, NEUROLOGY, V41, P1313, DOI 10.1212/WNL.41.8.1313; WHITEHEAD AS, 1995, QJM-MON J ASSOC PHYS, V88, P763	20	267	270	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 31	1997	349	9065					1591	1593		10.1016/S0140-6736(96)12049-3	http://dx.doi.org/10.1016/S0140-6736(96)12049-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174561				2022-12-28	WOS:A1997XB67300010
J	Munera, Y; Hugues, FC; LeJeunne, C; Pays, JF				Munera, Y; Hugues, FC; LeJeunne, C; Pays, JF			Interaction of thyroxine sodium with antimalarial drugs	BRITISH MEDICAL JOURNAL			English	Letter							CHLOROQUINE				Munera, Y (corresponding author), HOP LAENNEC,42 RUE SEVRES,F-75340 PARIS 7,FRANCE.							BEGAUD B, 1985, THERAPIE, V40, P111; CROES K, 1993, PHARM WORLD SCI, V15, P83, DOI 10.1007/BF01874088; FINIELZ P, 1993, NEPHRON, V65, P333, DOI 10.1159/000187506; ROLLOF J, 1993, ANN PHARMACOTHER, V27, P1058, DOI 10.1177/106002809302700909; SEIDEMAN P, 1994, ARTHRITIS RHEUM, V37, P830, DOI 10.1002/art.1780370609	5	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 31	1997	314	7094					1593	1593		10.1136/bmj.314.7094.1593	http://dx.doi.org/10.1136/bmj.314.7094.1593			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9186170	Green Published			2022-12-28	WOS:A1997XC50000024
J	Bier, E				Bier, E			Anti-neural-inhibition: A conserved mechanism for neural induction	CELL			English	Review							DORSAL-VENTRAL AXIS; DROSOPHILA EMBRYO; SHORT GASTRULATION; GENE; CHORDIN		UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	Bier, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; DAlessio M, 1996, MECH DEVELOP, V58, P217, DOI 10.1016/S0925-4773(96)00583-7; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PICOLLA S, 1996, CELL, V86, P589; RAY RP, 1991, DEVELOPMENT, V113, P35; Rusch J, 1996, CURR OPIN GENET DEV, V6, P416, DOI 10.1016/S0959-437X(96)80062-1; Schmidt J, 1995, DEVELOPMENT, V121, P4319; Schmidt JE, 1996, DEVELOPMENT, V122, P1711; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; Yu K, 1996, DEVELOPMENT, V122, P4033; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	20	55	56	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					681	684		10.1016/S0092-8674(00)80250-0	http://dx.doi.org/10.1016/S0092-8674(00)80250-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182755	Bronze			2022-12-28	WOS:A1997XB92500004
J	Unutzer, J; Patrick, DL; Simon, G; Grembowski, D; Walker, E; Rutter, C; Katon, W				Unutzer, J; Patrick, DL; Simon, G; Grembowski, D; Walker, E; Rutter, C; Katon, W			Depressive symptoms and the cost of health services in HMO patients aged 65 years and older - A 4-year prospective study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	8th Annual Meeting of the American-Association-for-Geriatric-Psychiatry	FEB 14-17, 1996	TUCSON, AZ	Amer Assoc Geriatr Psychiat			PRIMARY-CARE PATIENTS; MEDICAL UTILIZATION; COMMUNITY SAMPLE; CES-D; POPULATION; DISABILITY; PSYCHOPATHOLOGY; OUTPATIENTS; PREVALENCE; DIAGNOSES	Objective.-To examine whether depressive symptoms in older adults contribute to increased cost of general medical services. Design.-A 4-year prospective cohort study. Setting.-Four primary care clinics of a large staff-model health maintenance organization (HMO) in Seattle, Wash. Patients.-A total of 5012 Medicare enrollees older than 65 years were invited to participate in the study; 2558 subjects (51%) were successfully enrolled. Nonparticipants were somewhat older and had a higher level of chronic medical illness. Main Outcome Measures.-Depressive symptoms as measured by the Center for Epidemiological Studies Depression scale, which was administered as part of a mail survey at baseline, at 2 years, and at 4 years; and total cost of medical services from the perspective of the HMO. Data were obtained from the cost accounting system of the HMO. Results.-In this cohort of older adults, depressive symptoms were common, persistent, and associated with a significant increase in the cost of general medical services. This increase was seen for every component of health care costs and was not accounted for by an increase in specialty mental health care. The increase in health care costs remained significant after adjusting for differences in age, sex, and chronic medical illness. Conclusions.-Depressive symptoms in older adults are associated with a significant increase in the cost of medical services, even after adjusting for the severity of chronic medical illness.	UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, SEATTLE, WA 98101 USA	University of Washington; University of Washington Seattle; Group Health Cooperative	Unutzer, J (corresponding author), UNIV WASHINGTON, DEPT PSYCHIAT & BEHAV SCI, BOX 356560, SEATTLE, WA 98195 USA.		Unutzer, Jurgen/N-4048-2018; Patrick, Donald/Y-2460-2019; , David Grembowski/AGI-7345-2022; Rutter, Carolyn/AAZ-3677-2021	Patrick, Donald/0000-0003-0756-0492; , David Grembowski/0000-0003-4209-0019; 				*AG HLTH CAR POL R, 1993, US DEP HLTH HUM SERV; Alexopoulos G S, 1992, Clin Geriatr Med, V8, P363; Alexopoulos GS, 1996, AM J PSYCHIAT, V153, P877; ALEXOPOULOS GS, 1995, AM J GERIAT PSYCHIAT, V3, P280, DOI 10.1097/00019442-199503040-00002; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BALDWIN B, 1991, INT J GERIATR PSYCH, V6, P395, DOI 10.1002/gps.930060610; Banazak DA, 1996, J GEN INTERN MED, V11, P163, DOI 10.1007/BF02600269; BARRETT JE, 1988, ARCH GEN PSYCHIAT, V45, P1100; Blazer D, 1996, AM J PSYCHIAT, V153, P857; BLAZER D, 1987, GERONTOLOGIST, V27, P281, DOI 10.1093/geront/27.3.281; BLAZER D, 1993, DEPRESSION LATE LIFE; BLAZER DG, 1978, MULTIDIMENSIONAL FUN; BORSON S, 1986, J AM GERIATR SOC, V34, P341, DOI 10.1111/j.1532-5415.1986.tb04316.x; Broadhead WE, 1990, JAMA-J AM MED ASSOC, V264, P2525; BRUCE ML, 1994, AM J PUBLIC HEALTH, V84, P1796, DOI 10.2105/AJPH.84.11.1796; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P833, DOI 10.1111/j.1532-5415.1994.tb06554.x; CRAIG TJ, 1983, AM J PSYCHIAT, V140, P598; DURHAM ML, 1991, GERONTOLOGIST, V31, P603, DOI 10.1093/geront/31.5.603; FOELKER GA, 1992, J AM GERIATR SOC, V40, P259, DOI 10.1111/j.1532-5415.1992.tb02079.x; FORELL Y, 1994, AM J PSYCHIAT, V151, P1600; FRASURESMITH N, 1994, JAMA-J AM MED ASSOC, V271, P1082; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; FRIES BE, 1993, MED CARE, V31, P898, DOI 10.1097/00005650-199310000-00004; Gallo JJ, 1994, J GERONTOL, V49, P251; GANGULI M, 1995, AM J GERIAT PSYCHIAT, V3, P144, DOI 10.1097/00019442-199500320-00006; GOLDSTROM ID, 1987, J GERONTOL, V42, P147, DOI 10.1093/geronj/42.2.147; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; GREMBOWSKI D, 1993, J HEALTH SOC BEHAV, V34, P89, DOI 10.2307/2137237; GURLAND BJ, 1988, INT J GERIATR PSYCH, V3, P163, DOI 10.1002/gps.930030304; HAYS RD, 1995, ARCH GEN PSYCHIAT, V52, P11; HORWATH E, 1992, ARCH GEN PSYCHIAT, V49, P817; Husaini BA, 1980, J COMMUNITY PSYCHOL, V8, P20, DOI DOI 10.1002/1520-6629(198001; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; JUDD LL, 1994, J CLIN PSYCHIAT, V55, P18; Katon W, 1996, GEN HOSP PSYCHIAT, V18, P215, DOI 10.1016/0163-8343(96)00065-5; KATON W, 1990, GEN HOSP PSYCHIAT, V12, P355, DOI 10.1016/0163-8343(90)90002-T; KATZ IR, 1995, AM J GERIAT PSYCHIAT, V3, P161, DOI 10.1097/00019442-199500320-00007; KATZ IR, 1995, ANN M AM PSYCH ASS O; Kennedy G J, 1990, J Community Health, V15, P93, DOI 10.1007/BF01321314; KENNEDY GJ, 1991, AM J PSYCHIAT, V148, P174; KESSLER LG, 1987, AM J PUBLIC HEALTH, V77, P18, DOI 10.2105/AJPH.77.1.18; KOUZIS A, 1995, SOC PSYCH PSYCH EPID, V30, P165, DOI 10.1007/BF00790655; LEVENSON JL, 1990, AM J PSYCHIAT, V147, P1498; MANNING WG, 1992, MED CARE, V30, P541, DOI 10.1097/00005650-199206000-00007; MCFARLAND BH, 1985, MED CARE, V23, P1221, DOI 10.1097/00005650-198511000-00001; MECHANIC D, 1982, MED CARE, V20, P361, DOI 10.1097/00005650-198204000-00002; MIRANDA J, 1991, HEALTH PSYCHOL, V10, P46, DOI 10.1037/0278-6133.10.1.46; MUMFORD E, 1984, AM J PSYCHIAT, V141, P1145; MURPHY E, 1983, BRIT J PSYCHIAT, V142, P111, DOI 10.1192/bjp.142.2.111; MYERS JK, 1980, AM J PSYCHIAT, V137, P1081; NEWMANN JP, 1989, PSYCHOL AGING, V4, P150, DOI 10.1037/0882-7974.4.2.150; OLFSON M, 1992, SOC PSYCH PSYCH EPID, V27, P161, DOI 10.1007/BF00789000; PAVEZA GJ, 1996, MENTAL HLTH SERVICES; Penninx BWJH, 1996, J PSYCHOSOM RES, V40, P521, DOI 10.1016/0022-3999(95)00620-6; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RICE DP, 1983, MILBANK FUND Q, V61, P362, DOI 10.2307/3349863; Rost K, 1994, Arch Fam Med, V3, P333, DOI 10.1001/archfami.3.4.333; ROYALL RM, 1986, INT STAT REV, V54, P221, DOI 10.2307/1403146; SHAPIRO S, 1984, ARCH GEN PSYCHIAT, V41, P971; SHERMAN J, 1992, MED MENTAL HLTH BENE; SIMON G, 1995, AM J PSYCHIAT, V152, P352; Simon G E, 1992, Psychiatr Med, V10, P49; SIMON GE, 1995, ARCH GEN PSYCHIAT, V52, P850; Sturm Roland, 1995, JAMA (Journal of the American Medical Association), V273, P51, DOI 10.1001/jama.273.1.51; *US BUR LAB STAT, 1995, MONTHL LAB REV CPI D; VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G; WAXMAN HM, 1986, PUBLIC HEALTH REP, V101, P294; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; WELLS KB, 1992, ARCH GEN PSYCHIAT, V49, P788; WETZLER S, 1989, MEASURING MENTAL ILL, P71; WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526; ZICH JM, 1990, INT J PSYCHIAT MED, V20, P259, DOI 10.2190/LYKR-7VHP-YJEM-MKM2; ZONDERMAN AB, 1991, ANN M AM PSYCH ASS A	73	537	541	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	1997	277	20					1618	1623		10.1001/jama.277.20.1618	http://dx.doi.org/10.1001/jama.277.20.1618			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XA022	9168292				2022-12-28	WOS:A1997XA02200032
J	Beecham, L				Beecham, L			Learning to break bad news	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 24	1997	314	7093					1502	1502						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9183193				2022-12-28	WOS:A1997XB48400008
J	Stamler, JS; Jia, L; Eu, JP; McMahon, TJ; Demchenko, IT; Bonaventura, J; Gernert, K; Piantadosi, CA				Stamler, JS; Jia, L; Eu, JP; McMahon, TJ; Demchenko, IT; Bonaventura, J; Gernert, K; Piantadosi, CA			Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient	SCIENCE			English	Article							NITRIC-OXIDE; ARTERIOLES; INHIBITION; CLEARANCE	The binding of oxygen to heme irons in hemoglobin promotes the binding of nitric oxide (NO) to cysteine beta 93, forming S-nitrosohemoglobin. Deoxygenation is accompanied by an allosteric transition in S-nitrosohemoglobin [from the R (oxygenated) to the T (deoxygenated) structure] that releases the NO group, S-nitrosohemoglobin contracts blood vessels and decreases cerebral perfusion in the R structure and relaxes vessels to improve blood flow in the T structure. By thus sensing the physiological oxygen gradient in tissues, hemoglobin exploits conformation-associated changes in the position of cysteine beta 93 SNO to bring local blood flow into line with oxygen requirements.	DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOVASC MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,NICHOLAS SCH ENVIRONM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University; Duke University; Duke University	Stamler, JS (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV RESP MED,ROOM 321 MSRB,BOX 2612,DURHAM,NC 27710, USA.		McMahon, Tim/K-3986-2012; Demchenko, Ivan/AAN-8346-2020; Alekseeva, Olga/B-4180-2012	McMahon, Tim/0000-0002-3404-3223; Demchenko, Ivan/0000-0003-1246-135X; Alekseeva, Olga/0000-0001-5688-347X; Stamler, Jonathan/0000-0002-6866-1572; JIA, LEE/0000-0001-6839-5545	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052529] Funding Source: NIH RePORTER; NHLBI NIH HHS [HR59130, HL 52529] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BRAUNWALD E, 1988, HEART DISEASE TXB CA; BUERK DG, 1993, MICROVASC RES, V45, P134, DOI 10.1006/mvre.1993.1013; Casadevall M, 1996, GASTROENTEROLOGY, V110, P1156, DOI 10.1053/gast.1996.v110.pm8613005; DEWHIRST MW, 1994, CANCER RES, V54, P3333; DULING BR, 1970, CIRC RES, V27, P669, DOI 10.1161/01.RES.27.5.669; FILHO IPT, 1996, MICROVASC RES, V51, P202; GUYTON AC, 1981, TXB MED PHYSL, P208; GUYTON AC, 1981, TXB MED PHYSL, P504; HAMPL V, 1993, J APPL PHYSIOL, V75, P1748, DOI 10.1152/jappl.1993.75.4.1748; HEISS WD, 1981, STROKE, V12, P161, DOI 10.1161/01.STR.12.2.161; Intaglietta M, 1996, CARDIOVASC RES, V32, P632; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kasper SM, 1996, ANESTH ANALG, V83, P921; KERGER H, 1995, AM J PHYSIOL-HEART C, V268, pH802, DOI 10.1152/ajpheart.1995.268.2.H802; KING CE, 1994, J APPL PHYSIOL, V76, P1166, DOI 10.1152/jappl.1994.76.3.1166; Mitchell D, 1996, AM J PHYSIOL-HEART C, V270, pH1696, DOI 10.1152/ajpheart.1996.270.5.H1696; OAE S, 1983, ORG PREP PROCED INT, V15, P165, DOI 10.1080/00304948309355444; PARK KH, 1992, CIRC RES, V71, P992, DOI 10.1161/01.RES.71.4.992; PERSSON MG, 1990, BRIT J PHARMACOL, V100, P463, DOI 10.1111/j.1476-5381.1990.tb15829.x; PERUTZ MF, 1987, MOL BASIS BLOOD DISE, P127; Piantadosi CA, 1997, FREE RADICAL BIO MED, V22, P725, DOI 10.1016/S0891-5849(96)00423-6; POPEL AS, 1989, AM J PHYSIOL, V256, pH921, DOI 10.1152/ajpheart.1989.256.3.H921; POPEL AS, 1989, AM J PHYSIOL, V256, pH247; POPEL AS, 1991, AM J PHYSIOL, V261, P669; STAMLER J, UNPUB; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 1996, NATURE, V380, P108; STRYER L, 1981, BIOCHEMISTRY-US, P43; Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506; YOUNG W, 1980, STROKE, V11, P552, DOI 10.1161/01.STR.11.5.552	31	883	908	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2034	2037		10.1126/science.276.5321.2034	http://dx.doi.org/10.1126/science.276.5321.2034			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197264				2022-12-28	WOS:A1997XG74800062
J	Alexander, M				Alexander, M			A 36-year-old woman recuperating from a stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTSTROKE DEPRESSION; MOTOR RECOVERY; HEMIPARETIC PATIENTS; REHABILITATION; INFARCTION; THERAPY; PREDICTOR; APHASIA; TRIAL		HARVARD UNIV,DEPT NEUROL,BOSTON,MA 02115; BETH ISRAEL HOSP,BOSTON,MA 02215; YOUVILLE HOSP,CAMBRIDGE,MA	Harvard University; Harvard University; Beth Israel Deaconess Medical Center								Alexander MP, 1996, BRAIN LANG, V55, P213, DOI 10.1006/brln.1996.0102; *AM HEART ASS, 1991, HEART STROK FACTS; ANNETT M, 1985, LEFT RIGHT BRAIN RIG; ANNETT M, 1996, NEUROPSYCHOLOGIA, V4, P1215; ASTROM M, 1993, STROKE, V24, P976, DOI 10.1161/01.STR.24.7.976; BAHR M, 1994, TRENDS NEUROSCI, V17, P473, DOI 10.1016/0166-2236(94)90136-8; BARER DH, 1989, AGE AGEING, V18, P183, DOI 10.1093/ageing/18.3.183; BAYER AJ, 1987, LANCET, V1, P405; BOLLAWILSON K, 1989, AM J PSYCHIAT, V146, P627; BOYESON MG, 1994, ARCH NEUROL-CHICAGO, V51, P405, DOI 10.1001/archneur.1994.00540160107014; BRANCH C, 1964, J NEUROSURG, V21, P399, DOI 10.3171/jns.1964.21.5.0399; BROCKLEHURST JC, 1985, J AM GERIATR SOC, V33, P540, DOI 10.1111/j.1532-5415.1985.tb04618.x; Brott T, 1996, ARCH NEUROL-CHICAGO, V53, P1305, DOI 10.1001/archneur.1996.00550120117025; DAM M, 1993, STROKE, V24, P1186, DOI 10.1161/01.STR.24.8.1186; Dam M, 1996, STROKE, V27, P1211, DOI 10.1161/01.STR.27.7.1211; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; DOBKIN BH, 1991, ANN NEUROL, V30, P278; DOWNHILL JE, 1994, J NERV MENT DIS, V182, P425, DOI 10.1097/00005053-199408000-00001; DUNCAN PW, 1992, STROKE, V23, P1084, DOI 10.1161/01.STR.23.8.1084; ElAd B, 1996, NEUROLOGY, V47, P657, DOI 10.1212/WNL.47.3.657; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; GOLDBERGER ME, 1988, FUNCTIONAL RECOVERY, P361; GRANGER CV, 1989, ARCH PHYS MED REHAB, V70, P100; GRAY CS, 1990, AGE AGEING, V19, P179, DOI 10.1093/ageing/19.3.179; GRESHAM GE, 1995, AHCPR PUBLICATION; HAFFEY WJ, 1995, ARCH PHYS MED REHAB, V76, pSC2, DOI 10.1016/S0003--999(3()95)81395--0; HEISS WD, 1993, ARCH NEUROL-CHICAGO, V50, P958, DOI 10.1001/archneur.1993.00540090059011; HERRMANN M, 1995, STROKE, V26, P850, DOI 10.1161/01.STR.26.5.850; HESSE S, 1994, J NEUROL NEUROSUR PS, V57, P1321, DOI 10.1136/jnnp.57.11.1321; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; HIER DB, 1983, NEUROLOGY, V33, P345, DOI 10.1212/WNL.33.3.345; JOHANSSON K, 1993, NEUROLOGY, V43, P2189, DOI 10.1212/WNL.43.11.2189; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; KALIA KK, 1993, ARCH NEUROL-CHICAGO, V50, P1293, DOI 10.1001/archneur.1993.00540120010005; KALRA L, 1994, STROKE, V25, P821, DOI 10.1161/01.STR.25.4.821; KEITH RA, 1995, ARCH PHYS MED REHAB, V76, P495, DOI 10.1016/S0003-9993(95)80501-X; Kinsella G, 1985, Int Rehabil Med, V7, P102; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; LAZARUS LW, 1992, J CLIN PSYCHIAT, V53, P447; LEIJON G, 1989, PAIN, V36, P27, DOI 10.1016/0304-3959(89)90108-5; LIPSEY JR, 1984, LANCET, V1, P297; LUDWIN SK, 1988, FUNCTIONAL RECOVERY, P215; Mauthe RW, 1996, ARCH PHYS MED REHAB, V77, P10, DOI 10.1016/S0003-9993(96)90212-9; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V333, P1581; NORRIS JW, 1986, BMJ-BRIT MED J, V292, P21, DOI 10.1136/bmj.292.6512.21; NUGENT JA, 1994, ARCH PHYS MED REHAB, V75, P399, DOI 10.1016/0003-9993(94)90162-7; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; Parker V M, 1986, Int Rehabil Med, V8, P69; Patrono C, 1996, STROKE, V27, P756, DOI 10.1161/01.STR.27.4.756; PEDERSEN PM, 1995, ANN NEUROL, V68, P659; *QUAL STAND SUBC A, 1996, NEUROLOGY, V47, P835; REDDING MJ, 1988, STROKE, V19, P1354; Riggs JE, 1996, ARCH NEUROL-CHICAGO, V53, P1306, DOI 10.1001/archneur.1996.00550120118026; ROBINSON RG, 1987, STROKE, V18, P837, DOI 10.1161/01.STR.18.5.837; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SAEKI S, 1995, STROKE, V26, P399, DOI 10.1161/01.STR.26.3.399; SINYOR D, 1986, BRAIN, V109, P537, DOI 10.1093/brain/109.3.537; STINEMAN MG, 1994, MED CARE, V32, P366, DOI 10.1097/00005650-199404000-00005; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Ween JE, 1996, NEUROLOGY, V47, P388, DOI 10.1212/WNL.47.2.388; WEILLER C, 1995, ANN NEUROL, V37, P723, DOI 10.1002/ana.410370605; WEILLER C, 1993, ANN NEUROL, V33, P181; WEIN AJ, 1990, J AM GERIATR SOC, V33, P317; World Health Organization, 1980, INT CLASS IMP DIS HA; ZIHL J, 1985, BRAIN, V108, P335, DOI 10.1093/brain/108.2.335	67	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1970	1976						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XF087	9200639				2022-12-28	WOS:A1997XF08700043
J	Peskin, GW; Organ, CH				Peskin, GW; Organ, CH			General surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER				Peskin, GW (corresponding author), UNIV CALIF DAVIS,OAKLAND,CA, USA.							Balch CM, 1996, ANN SURG, V224, P255, DOI 10.1097/00000658-199609000-00002; Batista RJV, 1996, J CARDIAC SURG, V11, P96, DOI 10.1111/j.1540-8191.1996.tb00019.x; Bosshardt TL, 1996, ARCH SURG-CHICAGO, V131, P846; BRANTIGAN OC, 1961, CHEST, V39, P485; Cady B, 1996, ARCH SURG-CHICAGO, V131, P301; COOPER JD, 1995, J THORAC CARDIOV SUR, V109, P106, DOI 10.1016/S0022-5223(95)70426-4; DENT DM, 1988, BRIT J SURG, V75, P110, DOI 10.1002/bjs.1800750206; GIULIANO AE, 1995, ANN SURG, V222, P394, DOI 10.1097/00000658-199509000-00016; LITTLE AG, 1995, ANN SURG, V222, P365, DOI 10.1097/00000658-199509000-00013; Mastrangelo MJ, 1996, SEMIN ONCOL, V23, P4; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; Pachter HL, 1996, J TRAUMA, V40, P31, DOI 10.1097/00005373-199601000-00007; ROBERTSON CS, 1994, ANN SURG, V220, P176, DOI 10.1097/00000658-199408000-00009; Wanebo H, 1996, J AM COLL SURGEONS, V183, P616	14	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1862	1863						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185803				2022-12-28	WOS:A1997XD54400022
J	Emanuel, EJ				Emanuel, EJ			Care for dying patients	LANCET			English	Editorial Material									HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	Emanuel, EJ (corresponding author), DANA FARBER CANC INST,CTR OUTCOMES & POLICY RES,BOSTON,MA 02115, USA.							COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; EMANUEL L, 1995, JAMA-J AM MED ASSOC, V274, P501, DOI 10.1001/jama.274.6.501; LEE DKP, 1994, JAMA-J AM MED ASSOC, V271, P1358, DOI 10.1001/jama.271.17.1358; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; *SUPPORT PRINC INV, 1995, JAMA-J AM MED ASSOC, V274, P1591; Tulsky JA, 1996, ARCH INTERN MED, V156, P1285, DOI 10.1001/archinte.156.12.1285	6	15	16	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1714	1714		10.1016/S0140-6736(05)62952-2	http://dx.doi.org/10.1016/S0140-6736(05)62952-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193379				2022-12-28	WOS:A1997XE06500006
J	Krauzlis, RJ; Basso, MA; Wurtz, RH				Krauzlis, RJ; Basso, MA; Wurtz, RH			Shared motor error for multiple eye movements	SCIENCE			English	Article							SUPERIOR COLLICULUS; FIXATION; LESIONS; SYSTEM; MONKEY; AREA	Most natural actions are accomplished with a seamless combination of individual movements, Such coordination poses a problem: How does the motor system orchestrate multiple movements to produce a single goal-directed action? The results from current experiments suggest one possible solution. Oculomotor neurons in the superior colliculus of a primate responded to mismatches between eye and target positions, even when the animal made two different types of eye movements. This neuronal activity therefore does not appear to convey a command for a specific type of eye movement but instead encodes an error signal that could be used by multiple movements, The use of shared inputs is one possible strategy for ensuring that different movements share a common goal.	NEI,SENSORIMOTOR RES LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)				Richard, Krauzlis/0000-0002-1826-0447				Freedman Edward G., 1994, Society for Neuroscience Abstracts, V20, P142; Krauzlis RJ, 1996, VISION RES, V36, P1973, DOI 10.1016/0042-6989(95)00307-X; Krauzlis RJ, 1996, J NEUROPHYSIOL, V76, P2822, DOI 10.1152/jn.1996.76.5.2822; Leigh R.J., 1991, NEUROLOGY EYE MOVEME, V2nd; MUNOZ DP, 1992, J NEUROPHYSIOL, V67, P1000, DOI 10.1152/jn.1992.67.4.1000; MUNOZ DP, 1993, J NEUROPHYSIOL, V70, P559, DOI 10.1152/jn.1993.70.2.559; MUNOZ DP, 1991, J NEUROPHYSIOL, V66, P1624, DOI 10.1152/jn.1991.66.5.1624; NEWSOME WT, 1985, J NEUROSCI, V5, P825; SCHILLER PH, 1994, VISUAL NEUROSCI, V11, P229, DOI 10.1017/S0952523800001590; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SPARKS DL, 1990, ANNU REV NEUROSCI, V13, P309, DOI 10.1146/annurev.ne.13.030190.001521; VANESSEN DC, 1994, NEURON, V13, P1, DOI 10.1016/0896-6273(94)90455-3; WERNER W, 1993, EUR J NEUROSCI, V5, P335, DOI 10.1111/j.1460-9568.1993.tb00501.x; Zeki S., 1993, VISION BRAIN	14	142	143	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1693	1695		10.1126/science.276.5319.1693	http://dx.doi.org/10.1126/science.276.5319.1693			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180078				2022-12-28	WOS:A1997XD94700041
J	Marcotrigiano, J; Gingras, AC; Sonenberg, N; Burley, SK				Marcotrigiano, J; Gingras, AC; Sonenberg, N; Burley, SK			Cocrystal structure of the messenger RNA 5' cap-binding protein (eIF4E) bound to 7-methyl-GDP	CELL			English	Article							TRANSLATION INITIATION-FACTOR; IMPORTANT AROMATIC-COMPOUNDS; SITE-DIRECTED MUTAGENESIS; FACTOR EIF-4E; INDOLE-DERIVATIVES; EUKARYOTIC TRANSLATION; STACKING INTERACTION; CRYSTAL-STRUCTURE; SEQUENCE; RECOGNITION	The X-ray structure of the eukaryotic translation initiation factor 4E (elF4E), bound to 7-methyl-GDP, has been determined at 2.2 Angstrom resolution. elF4E recognizes 5' 7-methyl-G(5')ppp(5')N mRNA caps during the rate-limiting initiation step of translation. The protein resembles a cupped hand and consists of a curved, 8-stranded antiparallel beta sheet, backed by three long alpha helices. 7-methyl-GDP binds in a narrow cap-binding slot on the molecule's concave surface, where 7-methyl-guanine recognition is mediated by base sandwiching between two conserved tryptophans, plus formation of three hydrogen bonds and a van der Waals contact between its N7-methyl group and a third conserved tryptophan. The convex dorsal surface of the molecule displays a phylogenetically conserved hydrophobic/acidic portion, which may interact with other translation initiation factors and regulatory proteins.	ROCKEFELLER UNIV,MOL BIOPHYS LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; McGill University; McGill University			Marcotrigiano, Joseph/K-6697-2016; Gingras, Anne-Claude/E-9982-2010; Gingras, Anne-Claude/ABA-8341-2020	Marcotrigiano, Joseph/0000-0003-0346-3353; Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437; Burley, Stephen K./0000-0002-2487-9713	NIGMS NIH HHS [GM07982] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS BL, 1978, J BIOL CHEM, V253, P2589; ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; ALTMANN M, 1988, J BIOL CHEM, V263, P17229; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, X PLOR V 3 1 MANUAL; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; Cohen SL, 1996, STRUCTURE, V4, P1013, DOI 10.1016/S0969-2126(96)00108-6; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; DARZYNKIEWICZ E, 1985, BIOCHEMISTRY-US, V24, P1701, DOI 10.1021/bi00328a020; DARZYNKIEWICZ E, 1989, BIOCHEMISTRY-US, V28, P4771, DOI 10.1021/bi00437a038; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; FRIEDLAND DE, 1996, PROTEIN SCI, V6, P125; FURUICHI Y, 1979, J BIOL CHEM, V254, P6732; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HERNANDEZ G, 1995, BBA-GENE STRUCT EXPR, V1261, P427, DOI 10.1016/0167-4781(95)00039-J; Hodel AE, 1996, CELL, V85, P247, DOI 10.1016/S0092-8674(00)81101-0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ISHIDA T, 1991, J CHEM SOC PERK T 1, P1847, DOI 10.1039/p19910001847; ISHIDA T, 1983, BIOCHEMISTRY-US, V22, P3571, DOI 10.1021/bi00284a006; ISHIDA T, 1988, J AM CHEM SOC, V110, P2286, DOI 10.1021/ja00215a046; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; Jones RM, 1996, MOL CELL BIOL, V16, P4754; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MANTEUFFEL SR, 1996, P NATL ACAD SCI USA, V93, P4076; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; Merrick WC., 1996, TRANSLATION CONTROL, P31; METZ AM, 1992, NUCLEIC ACIDS RES, V20, P4096, DOI 10.1093/nar/20.15.4096; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Miyagi Y, 1995, LAB INVEST, V73, P890; Morino S, 1996, EUR J BIOCHEM, V239, P597, DOI 10.1111/j.1432-1033.1996.0597u.x; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PATIKOGLOU G, 1997, ANNU REV BIOPH BIOM, V26, P287; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Ptushkina M, 1996, J BIOL CHEM, V271, P32818, DOI 10.1074/jbc.271.51.32818; RHOADS RE, 1983, BIOCHEMISTRY-US, V22, P6084, DOI 10.1021/bi00295a007; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; RYCHLIK W, 1992, NUCLEIC ACIDS RES, V20, P6415, DOI 10.1093/nar/20.23.6415; SACHS A, 1993, J BIOL CHEM, V268, P22955; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SONENBERG N, 1978, P NATL ACAD SCI USA, V75, P4843, DOI 10.1073/pnas.75.10.4843; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; UEDA H, 1991, FEBS LETT, V280, P207, DOI 10.1016/0014-5793(91)80294-D; UEDA H, 1991, J BIOCHEM-TOKYO, V109, P882, DOI 10.1093/oxfordjournals.jbchem.a123475; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; Vasilescu S, 1996, J BIOL CHEM, V271, P7030, DOI 10.1074/jbc.271.12.7030; WAKIYAMA M, 1995, FEBS LETT, V360, P191, DOI 10.1016/0014-5793(95)00081-J; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831	64	553	561	1	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					951	961		10.1016/S0092-8674(00)80280-9	http://dx.doi.org/10.1016/S0092-8674(00)80280-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200613	Bronze			2022-12-28	WOS:A1997XE35700015
J	Flatau, G; Lemichez, E; Gauthier, M; Chardin, P; Paris, S; Fiorentini, C; Boquet, P				Flatau, G; Lemichez, E; Gauthier, M; Chardin, P; Paris, S; Fiorentini, C; Boquet, P			Toxin-induced activation of the G protein p21 Rho by deamidation of glutamine	NATURE			English	Article							CYTOTOXIC NECROTIZING FACTOR; ACTIN STRESS FIBERS; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; FOCAL ADHESIONS; FACTOR-I; GTP; CELLS; RAC; PURIFICATION	Pathogenic Escherichia coli are responsible for a variety of diseases, including diarrhoea, haemolytic uraemic syndrome, kidney infection, septicaemia, pneumonia and meningitis. Toxins called cytotoxic necrotizing factors (CNFs) are among the virulence factors produced by uropathogenic (CNF1)(1) or enteropathogenic (CNF2)(2) E. coli strains that cause diseases in humans and animals, respectively. CNFs induce an increase in the content of actin stress fibres and focal contacts in cultured cells(3,4). Effects of CNFs on the actin cytoskeleton correlated with a decrease in the electrophoretic mobility of the GTP-binding protein Rho(4,5) and indirect evidence indicates that CNF1 might constitutively activate Rho(6). Here we show that CNF1 catalyses the deamidation of a glutamine residue at position 63 of Rho, turning it into glutamic acid, which inhibits both intrinsic GTP hydrolysis and that stimulated by its GTPase-activating protein (GAP). Thus, this deamidation of glutamine 63 by CNF1 leads to the constitutive activation of Rho, and induces the reorganization of actin stress fibres. To our knowledge, CNF1 is the first example of a bacterial toxin acting by deamidation of a specific target protein.	FAC MED,INSERM,U452,F-06107 NICE 2,FRANCE; CNRS,INST PHARMACOL MOL & CELLULAIRE,ROUTE LUCIOLES,SOPHIA ANTIPOLIS,F-06560 VALBONNE,FRANCE; IST SUPER SANITA,DEPT ULTRASTRUCT,I-00161 ROME,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Istituto Superiore di Sanita (ISS)			FIORENTINI, CARLA/AAG-8005-2019; Lemichez, Emmanuel/G-3559-2013; Fiorentini, Carla/Q-2088-2015	FIORENTINI, CARLA/0000-0003-1707-6282; Lemichez, Emmanuel/0000-0001-9080-7761; Fiorentini, Carla/0000-0003-1707-6282				Adam T, 1996, EMBO J, V15, P3315, DOI 10.1002/j.1460-2075.1996.tb00696.x; CAPRIOLI A, 1983, INFECT IMMUN, V39, P1300, DOI 10.1128/IAI.39.3.1300-1306.1983; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DERYCKE J, 1990, J CLIN MICROBIOL, V28, P694, DOI 10.1128/JCM.28.4.694-699.1990; FALBO V, 1993, INFECT IMMUN, V61, P4909, DOI 10.1128/IAI.61.11.4909-4914.1993; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; FIORENTINI C, 1988, TOXICON, V26, P1047, DOI 10.1016/0041-0101(88)90203-6; FIORENTINI C, 1995, INFECT IMMUN, V63, P3936, DOI 10.1128/IAI.63.10.3936-3944.1995; FIORENTINI C, 1994, ZBL BAKT S, V24, P404; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HORIGUCHI Y, 1995, J CELL SCI, V108, P3243; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; RIDLEY AJ, 1995, METHOD ENZYMOL, V256, P313; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; WALKER KE, 1994, INFECT IMMUN, V62, P3817, DOI 10.1128/IAI.62.9.3817-3828.1994; Watarai M, 1997, J EXP MED, V185, P281, DOI 10.1084/jem.185.2.281; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	27	406	411	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					729	733		10.1038/42743	http://dx.doi.org/10.1038/42743			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192901	Bronze			2022-12-28	WOS:A1997XD86900060
J	Grun, R; Thorne, A				Grun, R; Thorne, A			Dating the Ngandong humans	SCIENCE			English	Article											Grun, R (corresponding author), AUSTRALIAN NATL UNIV,RES SCH PACIFIC & ASIAN STUDIES,CANBERRA,ACT 0200,AUSTRALIA.		Grun, Rainer/A-1437-2012; Klein, Richard G/B-5910-2009	Grun, Rainer/0000-0003-1366-3674; 				Barstra G., 1988, J HUM EVOL, V17, P325; GRUN R, 1988, NUCL TRACKS RAD MEAS, V14, P237; IKEYA M, 1996, NEW APPL ELECT SPIN; Swisher CC, 1996, SCIENCE, V274, P1870, DOI 10.1126/science.274.5294.1870; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; Thorne A. G., 1980, INDONESIA AUSTR PERS; THORNE AG, 1992, SCI AM, V266, P76, DOI 10.1038/scientificamerican0492-76; Weidenreich Franz, 1946, APES GIANTS MAN	8	39	40	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 6	1997	276	5318					1575	1575		10.1126/science.276.5318.1575	http://dx.doi.org/10.1126/science.276.5318.1575			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9190691				2022-12-28	WOS:A1997XC70100048
J	MarslenWilson, WD; Tyler, LK				MarslenWilson, WD; Tyler, LK			Dissociating types of mental computation	NATURE			English	Article							MORPHOLOGY; LANGUAGE; APHASICS; DYSLEXIA; WORDS	A fundamental issue in the study of cognition and the brain is the nature of mental computation. How far does this depend on internally represented systems of rules, expressed as strings of symbols with a syntax, as opposed to more distributed neural systems, operating subsymbolically and without syntax? The mental representation of the regular and irregular past tense of the English verb has become a crucial test case for this debate. Single-mechanism approaches argue that current multilayer connectionist networks can account for the learning and representation both of regular and of irregular forms(1,2). Dual-mechanism approaches, although accepting connectionist accounts for the irregular forms, argue that a symbolic, rule-based system is required to explain the properties of the regular past tense and, by extension, the properties of language and cognition in general(3-5). We show here that the regular and irregular past tense are supported by different neural systems, which can become dissociated by damage to the brain(6,7). This is evidence for functional and neurological distinctions in the types of mental computation that support these different aspects of linguistic and cognitive performance.			MarslenWilson, WD (corresponding author), UNIV LONDON BIRKBECK COLL,CTR SPEECH & LANGUAGE,MALET ST,LONDON WC1E 7HY,ENGLAND.			Marslen-Wilson, William/0000-0003-0690-6308; Tyler, Lorraine/0000-0002-9943-118X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Black M., 1991, J NEUROLINGUIST, V6, P79; FUNNELL E, 1987, Q J EXP PSYCHOL-A, V39, P497, DOI 10.1080/14640748708401801; GOODGLASS H, 1982, ASSESSMENT APHASIA R; Kay J., 1992, PSYCHOLINGUISTIC ASS; LINEBARGER MC, 1983, COGNITION, V13, P361, DOI 10.1016/0010-0277(83)90015-X; OSTRIN RK, 1995, COGNITIVE NEUROPSYCH, V12, P345, DOI 10.1080/02643299508252002; PATTERSON KE, 1977, Q J EXP PSYCHOL, V29, P307, DOI 10.1080/14640747708400606; PINKER S, 1988, COGNITION, V28, P73, DOI 10.1016/0010-0277(88)90032-7; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; PLUNKETT K, 1993, COGNITION, V48, P21, DOI 10.1016/0010-0277(93)90057-3; PRASADA S, 1993, LANG COGNITIVE PROC, V8, P1, DOI 10.1080/01690969308406948; Rumelhart D.E., 1986, PARALLEL DISTRIBUTED, P216; SHALLICE T, 1988, NEUROPYSHCOLOGY MENT; TEUBER HL, 1955, ANNU REV PSYCHOL, V9, P267; TYLER LK, 1995, BRAIN LANG, V48, P131, DOI 10.1006/brln.1995.1007; TYLER LK, 1994, NEUROPSYCHOLOGIA, V32, P1001, DOI 10.1016/0028-3932(94)90049-3; TYLER LK, 1992, SPOKEN LANGUAGE COMP	17	168	172	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					592	594		10.1038/42456	http://dx.doi.org/10.1038/42456			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XC522	9177345				2022-12-28	WOS:A1997XC52200053
J	Simons, K; Ikonen, E				Simons, K; Ikonen, E			Functional rafts in cell membranes	NATURE			English	Article							GPI-ANCHORED PROTEINS; POLARIZED EPITHELIAL-CELLS; PLASMA-MEMBRANE; PHOSPHATIDYLCHOLINE BILAYERS; INTRACELLULAR-TRANSPORT; DETERGENT INSOLUBILITY; ALKALINE-PHOSPHATASE; BINDING PROTEIN; CHOLESTEROL; CAVEOLAE		NATL PUBL HLTH INST, DEPT BIOCHEM, SF-00300 HELSINKI, FINLAND	Finland National Institute for Health & Welfare	Simons, K (corresponding author), EUROPEAN MOL BIOL LAB, CELL BIOL PROGRAMME, MEYERHOFSTR 1, D-69117 HEIDELBERG, GERMANY.			Simons, Kai/0000-0002-9231-9996				Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BOGGS JM, 1987, BIOCHIM BIOPHYS ACTA, V906, P353, DOI 10.1016/0304-4157(87)90017-7; BOGGS JM, 1994, BBA-BIOMEMBRANES, V1189, P233, DOI 10.1016/0005-2736(94)90070-1; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; CHONG PLG, 1994, P NATL ACAD SCI USA, V91, P10069, DOI 10.1073/pnas.91.21.10069; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; FRA AM, 1994, J BIOL CHEM, V269, P30745; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hannan LA, 1996, J CELL BIOL, V133, P1265, DOI 10.1083/jcb.133.6.1265; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Kusumi A, 1996, CURR OPIN CELL BIOL, V8, P566, DOI 10.1016/S0955-0674(96)80036-6; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MORROW MR, 1995, BIOPHYS J, V68, P179, DOI 10.1016/S0006-3495(95)80173-6; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NEURINGER LJ, 1979, BIOCHIM BIOPHYS ACTA, V558, P325, DOI 10.1016/0005-2736(79)90268-2; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; PARPAL S, 1995, J CELL BIOL, V131, P125, DOI 10.1083/jcb.131.1.125; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; ROCK P, 1990, BIOCHEMISTRY-US, V29, P8484, DOI 10.1021/bi00488a040; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SILVIUS JR, 1992, BIOCHEMISTRY-US, V31, P3398, DOI 10.1021/bi00128a014; SIMONS K, 1992, COLD SPRING HARB SYM, V57, P611, DOI 10.1101/SQB.1992.057.01.067; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Smaby JM, 1996, BIOCHEMISTRY-US, V35, P5696, DOI 10.1021/bi953057k; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SPIEGEL S, 1984, J CELL BIOL, V99, P1575, DOI 10.1083/jcb.99.5.1575; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	67	7736	7921	16	1103	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	1997	387	6633					569	572		10.1038/42408	http://dx.doi.org/10.1038/42408			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177342				2022-12-28	WOS:A1997XC52200045
J	Baskaran, R; Wood, LD; Whitaker, LL; Canman, CE; Morgan, SE; Xu, Y; Barlow, C; Baltimore, D; WynshawBoris, A; Kastan, MB; Wang, JYJ				Baskaran, R; Wood, LD; Whitaker, LL; Canman, CE; Morgan, SE; Xu, Y; Barlow, C; Baltimore, D; WynshawBoris, A; Kastan, MB; Wang, JYJ			Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation	NATURE			English	Article							CYCLE CHECKPOINT PATHWAY; DNA-DAMAGING AGENTS; CELL-CYCLE; P53; INDUCTION; DOMAIN; GENE; UV	Ataxia telangiectasia (AT) is a rare human autosomal recessive disorder with pleiotropic phenotypes, including neuronal degeneration, immune dysfunction, premature ageing and increased cancer risk. The gene mutated in AT, ATM, encodes a putative lipid or protein kinase(1,2). Most of the human AT patient phenotypes are recapitulated in Atm-deficient mice(3,4). Cells derived from Atm(-/-) mice, like those from AT patients, exhibit abnormal response to ionizing radiation(3,5,6). One of the known responses to ionizing radiation is the activation of a nuclear tyrosine kinase encoded by the c-abl proto-oncogene(7,8). Ionizing radiation does not activate c-Abl in cells from AT patients or in thymocytes or fibroblasts from the Arm-deficient mice. Ectopic expression of a functional ATM kinase domain corrects this defect, as it phosphorylates the c-Abl tyrosine kinase in vitro at Ser 465, leading to the activation of c-Abl. A mutant c-Abl with Ser 465 changed to Ala 465 is not activated by ionizing radiation or ATM kinase in vivo. These findings identify the c-Abl tyrosine kinase as a downstream target of phosphorylation and activation by the ATM kinase in the cellular response to ionizing radiation.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21205; MIT,DEPT BIOL,CAMBRIDGE 02139,ENGLAND; NIH,NCHGR,LAB GENET DIS RES,BETHESDA,MD 20892	University of California System; University of California San Diego; University of California System; University of California San Diego; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Wood, Laura/ABF-1531-2020	, Christine/0000-0001-8892-7430; Xu, Yang/0000-0001-5574-921X	NCI NIH HHS [R01 CA043054, R37 CA043054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1996, MOL CELL BIOL, V16, P3361; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CANMAN CE, 1994, CANCER RES, V54, P5054; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRIEDBERG EC, 1995, DNA REPAIR; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LEONARDO AD, 1994, GENE DEV, V8, P2540; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Siede W, 1996, J BACTERIOL, V178, P5841, DOI 10.1128/jb.178.19.5841-5843.1996; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	25	456	467	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					516	519		10.1038/387516a0	http://dx.doi.org/10.1038/387516a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168116				2022-12-28	WOS:A1997XB47900052
J	Gage, DA; Rhodes, D; Nolte, KD; Hicks, WA; Leustek, T; Cooper, AJL; Hanson, AD				Gage, DA; Rhodes, D; Nolte, KD; Hicks, WA; Leustek, T; Cooper, AJL; Hanson, AD			A new route for synthesis of dimethylsulphoniopropionate in marine algae	NATURE			English	Article							AMINO-ACID-METABOLISM; L-METHIONINE; BIOSYNTHESIS; DIMETHYLSULFONIOPROPIONATE; INTERMEDIATE; PHYTOPLANKTON; ESTERS; DMSP	The 3-dimethylsulphoniopropionate (DMSP) produced by marine algae is the main biogenic precursor of atmospheric dimethylsulphide (DMS)(1-3). This biogenic DMS, formed by bacterial and algal degradation of DMSP4,5, contributes about 1.5 x 10(13) g of sulphur to the atmosphere annually(3), and plays a major part in the global sulphur cycle, in cloud formation and potentially in climate regulation(1,3). Although DMSP biosynthesis has been partially elucidated in a higher plant(6,7), nothing is known about how alg-ae make DMSP except that the whole molecule is derived from methionine(8-12). Here we use in vivo isotope labelling to demonstrate that DMSP synthesis in the green macroalga Enteromorpha intestinalis proceeds by a route entirely distinct from that in higher plants. From methionine, the steps are transamination, reduction and S-methylation to give the novel sulphonium compound 4-dimethylsulphonio-2-hydroxybutyrate (DMSHB), which is oxidatively decarboxylated to DMSP. The key intermediate DMSHB was also identified in three diverse phytoplankton species, indicating that the same pathway operates in other algal classes that are important sources of DMS. The fact that a transamination initiates this pathway could help explain how algal DMSP (and thereby DMS) production is enhanced by nitrogen deficiency(12).	UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; PURDUE UNIV,DEPT HORT,W LAFAYETTE,IN 47907; RUTGERS STATE UNIV,CTR AGR MOL BIOL,NEW BRUNSWICK,NJ 08903; CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021	State University System of Florida; University of Florida; Michigan State University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Rutgers State University New Brunswick; Cornell University			Rhodes, David/L-4602-2019; Cooper, Arthur J.L./H-5171-2016					Blunden G., 1986, Progress phycol. Res., V4, P39; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; CHILLEMI R, 1990, J NAT PROD, V53, P87, DOI 10.1021/np50067a011; Christen P, 1985, TRANSAMINASES; DIBNER JJ, 1984, J NUTR, V114, P1716, DOI 10.1093/jn/114.9.1716; Gage DA, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P29; GOODAY GW, 1970, J MAR BIOL ASSOC UK, V50, P199, DOI 10.1017/S0025315400000710; GREENE RC, 1962, J BIOL CHEM, V237, P2251; GROENE T, 1995, J MARINE SYST, V6, P191, DOI 10.1016/0924-7963(94)00023-5; GUILLARD RR, 1962, CAN J MICROBIOL, V8, P229, DOI 10.1139/m62-029; HANSON AD, 1994, PLANT PHYSIOL, V105, P103, DOI 10.1104/pp.105.1.103; HUANG ZH, 1993, J CHROMATOGR, V635, P271, DOI 10.1016/0021-9673(93)80370-N; JAMES F, 1995, PLANT PHYSIOL, V108, P1439, DOI 10.1104/pp.108.4.1439; JAMES F, 1995, J BIOL CHEM, V270, P22344, DOI 10.1074/jbc.270.38.22344; Keller MD, 1989, ACS SYM SER, P167, DOI 10.1021/bk-1989-0393.ch011; Kirst GO, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P121; LAVINE TF, 1954, J BIOL CHEM, V207, P107; LEDYARD KM, 1994, MAR ECOL PROG SER, V110, P95, DOI 10.3354/meps110095; LIVESEY G, 1984, TRENDS BIOCHEM SCI, V9, P27, DOI 10.1016/0968-0004(84)90044-6; Malin G, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P177; MAYER RR, 1990, PLANT PHYSIOL, V94, P796, DOI 10.1104/pp.94.2.796; MIFLIN BJ, 1977, ANNU REV PLANT PHYS, V28, P299, DOI 10.1146/annurev.pp.28.060177.001503; MIZAYAKI HH, 1987, PLANT PHYSIOL, V84, P277; POKORNY M, 1970, PHYTOCHEMISTRY, V9, P2175, DOI 10.1016/S0031-9422(00)85382-0; SCISLOWSKI PWD, 1987, BIOCHEM J, V247, P35, DOI 10.1042/bj2470035; STEFELS J, 1993, MAR ECOL PROG SER, V97, P11, DOI 10.3354/meps097011; Uchida A, 1996, BIOLOGICAL AND ENVIRONMENTAL CHEMISTRY OF DMSP AND RELATED SULFONIUM COMPOUNDS, P97; WALSH CT, 1979, ENZYMATIC REACTION M; WALTERS DS, 1990, PLANT PHYSIOL, V93, P1544, DOI 10.1104/pp.93.4.1544; ZAPPIA V, 1969, J BIOL CHEM, V244, P4499	30	139	153	4	62	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					891	894		10.1038/43160	http://dx.doi.org/10.1038/43160			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202120	Bronze			2022-12-28	WOS:A1997XG41600048
J	Cohen, S; Doyle, WJ; Skoner, DP; Rabin, BS; Gwaltney, JM				Cohen, S; Doyle, WJ; Skoner, DP; Rabin, BS; Gwaltney, JM			Social ties and susceptibility to the common cold	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; HYPOTHESIS; MORTALITY; INFECTION; NETWORKS; SUPPORT; HEALTH; STRESS	Objective.-To examine the hypothesis that diverse ties to friends, family, work, and community are associated with increased host resistance to infection. Design.-After reporting the extent of participation in 12 types of social ties (eg, spouse, parent, friend, workmate, member of social group), subjects were given nasal drops containing 1 of 2 rhinoviruses and monitored for the development of a common cold. Setting.-Quarantine. Participants.-A total of 276 healthy volunteers, aged 18 to 55 years, neither seropositive for human immunodeficiency virus nor pregnant. Outcome Measures.-Colds (illness in the presence of a verified infection), mucus production, mucociliary clearance function, and amount of viral replication. Results.-In response to both viruses, those with more types of social ties were less susceptible to common colds, produced less mucus, were more effective in ciliary clearance of their nasal passages, and shed less virus. These relationships were unaltered by statistical controls for prechallenge virus-specific antibody, virus type, age, sex, season, body mass index, education, and race. Susceptibility to colds decreased in a dose-response manner with increased diversity of the social network. There was an adjusted relative risk of 4.2 comparing persons with fewest (1 to 3) to those with most (6 or more) types of social ties. Although smoking, poor sleep quality, alcohol abstinence, low dietary intake of vitamin C, elevated catecholamine levels, and being introverted were all associated with greater susceptibility to colds, they could only partially account for the relation between social network diversity and incidence of colds. Conclusions.-More diverse social networks were associated with greater resistance to upper respiratory illness.	CHILDRENS HOSP PITTSBURGH,DEPT OTOLARYNGOL,PITTSBURGH,PA 15213; CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA; UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Virginia	Cohen, S (corresponding author), CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213, USA.			Cohen, Sheldon/0000-0003-2248-4600	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050429] Funding Source: NIH RePORTER; NCRR NIH HHS [NCRR/GCRC 5M01 RR00056] Funding Source: Medline; NIMH NIH HHS [MH50429, MH00721] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ader R, 1991, PSYCHONEUROIMMUNOLOG; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; [Anonymous], 1975, APPL MULTIPLE REGRES, DOI 10.4324/9780203774441.; [Anonymous], 1994, HDB HUMAN STRESS IMM; Baum A.A.G.N., 1995, MEASURING STRESS GUI, P175; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; Berkman LF, 1983, HLTH WAYS LIVING ALA; BLOCK G, 1992, J AM DIET ASSOC, V92, P686; Block G, 1990, Epidemiology, V1, P58, DOI 10.1097/00001648-199001000-00013; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310; COHEN S, 1993, AM J PUBLIC HEALTH, V83, P1277, DOI 10.2105/AJPH.83.9.1277; COHEN S, 1988, HEALTH PSYCHOL, V7, P269, DOI 10.1037/0278-6133.7.3.269; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; COHEN S, 1991, LIFE SPAN DEV PSYCHO; Doyle W. J., 1988, AM J RHINOL, V2, P149, DOI DOI 10.2500/105065888781692961; FARR BM, 1990, J INFECT DIS, V162, P1173, DOI 10.1093/infdis/162.5.1173; FLETCHER MA, 1987, DIAGN CLIN IMMUNOL, V5, P68; Goldberg LR., 1992, PSYCHOL ASSESSMENT, V4, P26, DOI [10.1037/1040-3590.4.1.26, DOI 10.1037/1040-3590.4.1.26]; Gwaltney J.M., 1989, DIAGNOSTIC PROCEDURE, P579; GWALTNEY JM, 1984, VIRAL INFECT HUMANS; HOSMER DW, 1989, APPL LOGISTIC REGRES; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; KIECOLTGLASER JK, 1994, HDB HUMAN STRESS IMM, P321; PAFFENBARGER RS, 1993, MED SCI SPORT EXER, V25, P60, DOI 10.1249/00005768-199301000-00010; Stone A. A., 1993, BEHAV MED, V8, P115; THOITS PA, 1983, AM SOCIOL REV, V48, P174, DOI 10.2307/2095103; Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488; VOGT TM, 1992, J CLIN EPIDEMIOL, V45, P659, DOI 10.1016/0895-4356(92)90138-D; WHITESIDE TL, 1990, J CLIN LAB ANAL, V4, P102, DOI 10.1002/jcla.1860040207	30	903	907	1	99	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1940	1944						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XF087	9200634	Green Submitted			2022-12-28	WOS:A1997XF08700038
J	Chang, HW; Aoki, M; Fruman, D; Auger, KR; Bellacosa, A; Tsichlis, PN; Cantley, LC; Roberts, TM; Vogt, PK				Chang, HW; Aoki, M; Fruman, D; Auger, KR; Bellacosa, A; Tsichlis, PN; Cantley, LC; Roberts, TM; Vogt, PK			Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase	SCIENCE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; NERVE GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; AVIAN-SARCOMA; ACTIVATION; ONCOGENE; VIRUS; PROTOONCOGENE; ASSOCIATION	The avian sarcoma virus 16 (ASV 16) is a retrovirus that induces hemangiosarcomas in chickens. Analysis of the ASV 16 genome revealed that it encodes an oncogene that is derived from the cellular gene for the catalytic subunit of phosphoinositide 3-kinase(PI 3-kinase). The gene is referred to as v-p3k, and like its cellular counterpart c-p3k, it is a potent transforming gene in cultured chicken embryo fibroblasts (CEFs). The products of the viral and cellular p3k genes have PI 3-kinase activity. CEFs transformed with either gene showed elevated levels of phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate and activation of Akt kinase.	Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA; BETH ISRAEL DEACONESS MED CTR, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA; DANA FARBER CANC INST, BOSTON, MA 02115 USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA	Scripps Research Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Fox Chase Cancer Center			Cantley, Lewis C/D-1800-2014; Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016	Cantley, Lewis C/0000-0002-1298-7653; Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490	NCI NIH HHS [CA 42564] Funding Source: Medline; NIGMS NIH HHS [GM 41890, R01 GM041890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki M., UNPUB; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREUND R, 1992, AM J PATHOL, V141, P1409; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; NOBES CD, 1995, J CELL SCI, V108, P225; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; STACK JH, 1994, J BIOL CHEM, V269, P31552; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; TSUCHIE H, 1989, ONCOGENE, V4, P1281; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	36	373	379	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1848	1850		10.1126/science.276.5320.1848	http://dx.doi.org/10.1126/science.276.5320.1848			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188528				2022-12-28	WOS:A1997XF10300045
J	Hartmann, LC; Tschettier, LK; Habermann, TM; Ebbert, LP; Johnson, PS; Mailliard, JA; Levitt, R; Suman, VJ; Witzig, TE; Wieand, HS; Miller, LL; Moertel, CG				Hartmann, LC; Tschettier, LK; Habermann, TM; Ebbert, LP; Johnson, PS; Mailliard, JA; Levitt, R; Suman, VJ; Witzig, TE; Wieand, HS; Miller, LL; Moertel, CG			Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; FEBRILE NEUTROPENIA; CANCER-CHEMOTHERAPY; DRUG-THERAPY; FEVER	Background Randomized trials of colony-stimulating factors in febrile patients with neutropenia after chemotherapy have not consistently shown clinical benefit. Nevertheless, the use of colony-stimulating factors to treat patients with chemotherapy-induced neutropenia is widespread. Methods We performed a randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor (G-CSF) in afebrile outpatients with severe chemotherapy-induced neutropenia. We measured the number of days of neutropenia, rate of hospitalization, number of days in the hospital, number of days the patient received parenteral antibiotics, and number of culture-positive infections. Results We randomly assigned 138 patients to receive G-CSF (n=71) or placebo (n=67). The median time to an absolute neutrophil count higher than 500 per cubic millimeter was significantly shorter for patients who received G-CSF (two days, vs. four days for the patients given placebo). However, there was no effect on the rate of hospitalization, number of days in the hospital, duration of treatment with parenteral antibiotics, or number of culture-positive infections. Conclusions Routine therapeutic application of G-CSF in afebrile patients with severe neutropenia can reduce the duration of neutropenia, but this does not appear to provide practical clinical benefit. (C)1997, Massachusetts Medical Society.	SIOUX COMMUNITY CANC CONSORTIUM, SIOUX FALLS, SD USA; RAPID CITY REG ONCOL GRP, RAPID CITY, SD USA; CREIGHTON UNIV, UNIV NEBRASKA MED CTR, NEBRASKA ONCOL GRP, OMAHA, NE 68178 USA; MERITCARE HOSP, COMMUNITY CLIN ONCOL PROGRAM, FARGO, ND USA; NCI, BETHESDA, MD 20892 USA	Creighton University; University of Nebraska System; University of Nebraska Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hartmann, LC (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.				NCI NIH HHS [CA-25224, CA-37404, CA-37417] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA037417, U10CA025224, U10CA037404] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anaissie EJ, 1996, AM J MED, V100, P17, DOI 10.1016/S0002-9343(96)90006-6; [Anonymous], 1996, J CLIN ONCOL, V14, P1957; [Anonymous], 1994, J CLIN ONCOL, V12, P2471; Bennett CL, 1996, J CLIN ONCOL, V14, P2511, DOI 10.1200/JCO.1996.14.9.2511; BIESMA B, 1990, EUR J CANCER, V26, P932, DOI 10.1016/0277-5379(90)90613-X; COX DR, 1972, J R STAT SOC B, V34, P187; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; GERHARTZ HH, 1993, LEUKEMIA RES, V17, P175, DOI 10.1016/0145-2126(93)90063-Q; GERHARTZ HH, 1993, BLOOD, V82, P2329; GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; HUGHES WT, 1990, J INFECT DIS, V161, P1316; Jones SE, 1996, J CLIN ONCOL, V14, P2976, DOI 10.1200/JCO.1996.14.11.2976; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28; LYMAN GH, 1993, J NATL CANCER I, V85, P488, DOI 10.1093/jnci/85.6.488; MAHER DW, 1994, ANN INTERN MED, V121, P492, DOI 10.7326/0003-4819-121-7-199410010-00004; MAYORDOMO JI, 1995, J NATL CANCER I, V87, P803, DOI 10.1093/jnci/87.11.803; METCALF D, 1989, LANCET, V1, P825; Mitchell P. L. R., 1995, Blood, V86, p500A; OHNO R, 1990, NEW ENGL J MED, V323, P871, DOI 10.1056/NEJM199009273231304; RAVAUD A, 1995, P AN M AM SOC CLIN, V14, P261; RIIKONEN P, 1994, PEDIATR INFECT DIS J, V13, P197, DOI 10.1097/00006454-199403000-00006; Vellenga E, 1996, J CLIN ONCOL, V14, P619, DOI 10.1200/JCO.1996.14.2.619	25	147	152	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	1997	336	25					1776	1780		10.1056/NEJM199706193362502	http://dx.doi.org/10.1056/NEJM199706193362502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE485	9187067				2022-12-28	WOS:A1997XE48500002
J	Lutz, W; Sanderson, W; Scherbov, S				Lutz, W; Sanderson, W; Scherbov, S			Doubling of world population unlikely	NATURE			English	Article								Most national and international agencies producing population projections avoid addressing explicitly the issue of uncertainty. Typically, they provide either a single projection or a set of low, medium and high variants(1,2), and only very rarely do they give these projections a probabilistic interpretation. Probabilistic population projections have been developed for specific industrialized countries, mostly the United States, and are based largely on time-series analysis(3). On a global level, time-series analysis is not applicable because there is a lack of appropriate data, and for conceptual reasons such as the structural discontinuity caused by the demographic transition(4-6). Here we report on a new probabilistic approach that makes use of expert opinion on trends in fertility, mortality and migration, and on the 90 per cent uncertainty range of those trends in different parts of the world. We have used simulation techniques to derive probability distributions of population sizes and age structures for 13 regions of the world up to the year 2100. Among other things, we find that there is a probability of two-thirds that the world's population will not double in the twenty-first century.	SUNY STONY BROOK,DEPT ECON,STONY BROOK,NY 11794; UNIV GRONINGEN,FAC SPATIAL SCI,POPULAT RES CTR,NL-9700 AV GRONINGEN,NETHERLANDS	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Groningen	Lutz, W (corresponding author), INT INST APPL SYST ANAL,SCHLOSSPL 1,A-2361 LAXENBURG,AUSTRIA.		Scherbov, Sergey/F-3158-2019; Sanderson, Warren/R-3398-2019	Scherbov, Sergey/0000-0001-5902-3790; Lutz, Wolfgang/0000-0001-7975-8145; Scherbov, Sergei/0000-0002-0881-1073; Sanderson, Warren/0000-0002-2205-948X				Alho JM, 1997, J ROY STAT SOC A STA, V160, P71, DOI 10.1111/1467-985X.00046; BONGAARTS J, 1996, FUTURE POPULATION WO, P170; Brass W., 1971, BIOL ASPECTS DEMOGRA, P69; CLELAND J, 1996, FUTURE POPULATION WO, P47; Cohen J. E., 1995, MANY PEOPLE CAN EART; GARENNE M, 1996, FUTURE POPULATION WO, P149; Heilig GK, 1996, FUTURE POPULATION WO, P196; KEYFITZ N, 1991, FUTURE DEMOGRAPHIC T, P235; KEYFITZ N, 1977, APPLIED MATH DEMOGRA; LE RD, 1996, RETHINKING POPULATIO; LEE RD, 1992, INT J FORECASTING, V8, P315, DOI 10.1016/0169-2070(92)90050-J; LUTZ W, 1997, SENSITIVITY ANAL EXP; LUTZ W, 1995, WP9557 INT I APPL SY; LUTZ W, 1996, FUTURE POPULATION WO, P14; Lutz W., 1996, FUTURE POPULATION WO; Lutz Wolfgang, 1996, FUTURE POPULATION WO, P253; MANTON KG, 1991, FUTURE DEMOGRAPHIC T, P97; Nordhaus W. D., 1994, MANAGING GLOBAL COMM; Rogers A., 1975, INTRO MULTIREGIONAL; *UN, 1992, LONG RANG WORLD POP; United Nations. Dept. for Economic and Social Information and Policy Analysis. Population Division, 1995, WORLD POP PROSP 1994; Vaupel J. W., 1996, FUTURE POPULATION WO, P278; WESTOFF CF, 1991, FUTURE DEMOGRAPHIC T, P227; WESTOFF CF, 1996, FUTURE POPULATION WO, P73; ZLOTNIK H, 1996, FUTURE POPULATION WO, P299	25	126	137	3	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 19	1997	387	6635					803	805		10.1038/42935	http://dx.doi.org/10.1038/42935			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF144	9194559	Bronze, Green Accepted			2022-12-28	WOS:A1997XF14400049
J	Chertow, GM				Chertow, GM			Nephrology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE-RENAL-FAILURE		HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	Chertow, GM (corresponding author), BRIGHAM & WOMENS HOSP,75 FRANCIS ST,BOSTON,MA 02115, USA.			Chertow, Glenn/0000-0002-7599-0534				*CAN US PER DIAL S, 1996, J AM SOC NEPHROL, V7, P198; Chertow GM, 1996, JAMA-J AM MED ASSOC, V276, P1732, DOI 10.1001/jama.276.21.1732; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; MASSRY SG, 1995, JAMA-J AM MED ASSOC, V273, P1693; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; SCHULMAN G, 1993, KIDNEY INT, V43, pS209; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; vanEssen GG, 1996, LANCET, V347, P94, DOI 10.1016/S0140-6736(96)90213-5	11	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1872	1873						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185809				2022-12-28	WOS:A1997XD54400028
J	Plumb, JD				Plumb, JD			Homelessness: Care, prevention, and public policy	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							UNITED-STATES; RISK	Homeless men, women, and children make up a growing population that is vulnerable to preventable disease, progressive morbidity, and premature death. Homelessness and poverty are inextricably linked, and subgroups of persons who live in poverty have a particularly high risk for becoming homeless. Providing effective primary care for homeless persons is a formidable task because of many internal and external barriers to care. Targeted care strategies and new approaches to primary care are required to lower these barriers. Effective disease prevention in the homeless requires effective programs and policies to prevent homelessness. It is imperative that health professionals, the societies to which they belong, and academic health systems reaffirm their social responsibility, commit to changing public policies that perpetuate homelessness, and assist in the development and provision of primary health care services for persons who are homeless or on the brink of homelessness.			Plumb, JD (corresponding author), THOMAS JEFFERSON UNIV, DEPT FAMILY MED, 1015 WALNUT ST, SUITE 402, PHILADELPHIA, PA 19107 USA.							BRICKNER PW, 1990, SAFETY NET HLTH SOCI; BRICKNER PW, 1992, HOMELESSNESS NATL PE; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; FLEISCHMAN S, 1992, DELIVERING HLTH CARE, P81; FOURNIER AM, 1993, JAMA-J AM MED ASSOC, V270, P2721, DOI 10.1001/jama.270.22.2721; Gelberg L, 1997, AM J PUBLIC HEALTH, V87, P217, DOI 10.2105/AJPH.87.2.217; Haq C L, 1996, Fam Med, V28, P570; HILFIKER D, 1989, JAMA-J AM MED ASSOC, V262, P1375; Hwang SW, 1997, ANN INTERN MED, V126, P625, DOI 10.7326/0003-4819-126-8-199704150-00007; LEVINE RN, 1991, INT C AIDS, V7, P394; LINK BG, 1994, AM J PUBLIC HEALTH, V84, P1907, DOI 10.2105/AJPH.84.12.1907; *NCH, 1997, 1 NCH; PLUMB JD, 1996, MODELS AMBULATORY CA, P17; ROBERTSON MJ, HOMELESSNESS NATL PE, pR11; ROPERS R, 1987, ALCOHOL HEALTH RES W, P38; STARK LR, 1992, HOMELESSNESS PREVENT; STLAWRENCE JS, 1995, AIDS EDUC PREV, V7, P22; SUSSER E, 1994, PSYCHOSOC REHABIL, V47, P33; SWEENEY P, 1995, ARCH PEDIAT ADOL MED, V149, P521, DOI 10.1001/archpedi.1995.02170180051007; SWISLOW L, 1992, INT C AIDS, V8, pD522; VLAHOV D, 1994, AM J PUBLIC HEALTH, V84, P1889, DOI 10.2105/AJPH.84.12.1889; WOLCH J, 1993, HOMELESSNESS AM CITY; 1987, MMWR-MORBID MORTAL W, V36, P297; 1991, MMWR-MORBID MORTAL W, V40, P877; 1997, PHILADELPHIA IN 0329	25	36	38	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1997	126	12					973	975		10.7326/0003-4819-126-12-199706150-00007	http://dx.doi.org/10.7326/0003-4819-126-12-199706150-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XE549	9182475				2022-12-28	WOS:A1997XE54900010
J	Richards, P; Gumpel, M				Richards, P; Gumpel, M			Save our service	BRITISH MEDICAL JOURNAL			English	Article											Richards, P (corresponding author), NORTHWICK PK & ST MARKS NHS TRUST,HARROW HA1 3UJ,MIDDX,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1756	1758		10.1136/bmj.314.7096.1756	http://dx.doi.org/10.1136/bmj.314.7096.1756			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9202510	Green Published			2022-12-28	WOS:A1997XE90900033
J	Negri, ED; Fabbri, S; Bufardeci, E; Baldi, MI; Attardi, DG; Mattoccia, E; TocchiniValentini, GP				Negri, ED; Fabbri, S; Bufardeci, E; Baldi, MI; Attardi, DG; Mattoccia, E; TocchiniValentini, GP			The eucaryal tRNA splicing endonuclease recognizes a tripartite set of RNA elements	CELL			English	Article							INTRON EXCISION REACTION; YEAST TRANSFER RNAPHE; PRE-TRANSFER RNA; XENOPUS-LAEVIS; SUBSTRATE; SITE; POLYMERASE; PRECURSORS; SECONDARY; CLEAVAGE	The tRNA splicing endonuclease cleaves intron-containing tRNA precursors on both sides of the intron, The prevailing belief has been that the enzyme binds only to the mature domain through the invariant bases. We show instead that, for recognition, the endonuclease utilizes distinct sets of structural elements, several of which are within the intron. One subset of recognition elements, localized in the mature domain, is needed for recognition of both cleavage sites, while two other subsets, localized at the exon-intron boundaries, are used for recognition of either one or the other cleavage site. The two cleavage sites are essentially independent: neither is required by the other for cleavage to take place. These results support a two-active-site model for the eucaryal endonuclease.	ENICHEM, INST GUIDO DONEGANI SPA, LAB BIOTECNOL, I-00015 MONTEROTONDO, ROME, ITALY; UNIV CHICAGO, DEPT BIOCHEM & MOL BIOL, CHICAGO, IL 60637 USA	University of Chicago	Negri, ED (corresponding author), CNR, INST CELL BIOL, VIALE MARX 43, I-00137 ROME, ITALY.		Di Nicola Negri, Elisa/G-2251-2014	Di Nicola, Elisa/0000-0003-3659-9708				ABELSON J, 1979, ANNU REV BIOCHEM, V48, P1035, DOI 10.1146/annurev.bi.48.070179.005131; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; BALDI MI, 1986, CELL, V47, P965, DOI 10.1016/0092-8674(86)90811-1; BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BUFARDECI E, 1993, EMBO J, V12, P4697, DOI 10.1002/j.1460-2075.1993.tb06158.x; CARRARA G, 1995, P NATL ACAD SCI USA, V92, P2627, DOI 10.1073/pnas.92.7.2627; GANDINIATTARDI D, 1985, EMBO J, V4, P3289; HASELBECK RC, 1993, BIOCHEMISTRY-US, V32, P8575, DOI 10.1021/bi00084a026; KIERZEK R, 1992, NUCLEIC ACIDS RES, V20, P5079, DOI 10.1093/nar/20.19.5079; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; LEE MC, 1985, J BIOL CHEM, V260, P3108; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; MIAO F, 1993, J BIOL CHEM, V268, P672; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NAZARENKO IA, 1994, EMBO J, V13, P2464, DOI 10.1002/j.1460-2075.1994.tb06531.x; OTSUKA A, 1981, MOL CELL BIOL, V1, P269, DOI 10.1128/MCB.1.3.269; PAN T, 1992, NATURE, V358, P560, DOI 10.1038/358560a0; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SWERDLOW H, 1984, J BIOL CHEM, V259, P5197; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Westaway Shawn K., 1995, P79; WREDE P, 1979, J BIOL CHEM, V254, P9608	24	38	38	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					859	866		10.1016/S0092-8674(00)80271-8	http://dx.doi.org/10.1016/S0092-8674(00)80271-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200604	Bronze			2022-12-28	WOS:A1997XE35700006
J	Ranganathan, R; Lu, KP; Hunter, T; Noel, JP				Ranganathan, R; Lu, KP; Hunter, T; Noel, JP			Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent	CELL			English	Article							CIS-TRANS-ISOMERASE; PROTEIN-PROTEIN RECOGNITION; CYCLOPHILIN HOMOLOG NINAA; ASPERGILLUS-NIDULANS; CELL-CYCLE; BINDING-PROTEIN; CYCLOSPORINE-A; NIMA; MECHANISM; FK506	The human rotamase or peptidyl-prolyl cis-trans isomerase Pin1 is a conserved mitotic regulator essential for the G2/M transition of the eukaryotic cell cycle. We report the 1.35 Angstrom crystal structure of Pin1 complexed with an AlaPro dipeptide and the initial characterization of Pin1's functional properties. The crystallographic structure as well as pH titration studies and mutagenesis of an active site cysteine suggest a catalytic mechanism that includes general acid-base and covalent catalysis during peptide bond isomerization. Pin1 displays a preference for an acidic residue N-terminal to the isomerized proline bond due to interaction of this acidic side chain with a basic cluster. This raises the possibility of phosphorylation-mediated control of Pin1-substrate interactions in cell cycle regulation.	SALK INST BIOL STUDIES,STRUCT BIOL LAB,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,MOL BIOL & VIROL LAB,LA JOLLA,CA 92037; BETH ISRAEL DEACONESS MED CTR,DEPT MED,DIV HEMATOL ONCOL,CANC BIOL PROGRAM,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DIV AGING,BOSTON,MA 02215	Salk Institute; Salk Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Noel, Joseph P/A-9459-2009					ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Creighton T. E., 1993, PROTEINS STRUCTURES; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER S, 1993, BIOCHEMISTRY-US, V32, P13830, DOI 10.1021/bi00213a011; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; Heitman Joseph, 1993, Methods (Orlando), V5, P176, DOI 10.1006/meth.1993.1022; Hemenway CS, 1996, J BIOL CHEM, V271, P18527, DOI 10.1074/jbc.271.31.18527; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; LU KP, 1993, J BIOL CHEM, V268, P8769; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OTWINOSKI Z, 1991, 4 SCI ENG RES COUNC; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PARK ST, 1992, J BIOL CHEM, V267, P3316; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; SCHMID FX, 1995, CURR BIOL, V5, P993, DOI 10.1016/S0960-9822(95)00197-7; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Staub O, 1996, STRUCTURE, V4, P495, DOI 10.1016/S0969-2126(96)00054-8; STEIN RL, 1993, ADV PROTEIN CHEM, V44, P1, DOI 10.1016/S0065-3233(08)60562-8; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x; YOUNG L, 1994, PROTEIN SCI, V3, P717	50	602	626	0	65	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					875	886		10.1016/S0092-8674(00)80273-1	http://dx.doi.org/10.1016/S0092-8674(00)80273-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200606	Bronze			2022-12-28	WOS:A1997XE35700008
J	Gupta, KJ; Clancy, M				Gupta, KJ; Clancy, M			Discontinuation of cervical spine immobilisation in unconscious patients with trauma in intensive care units - Telephone survey of practice in South and West region	BRITISH MEDICAL JOURNAL			English	Article							RADIOLOGIC EVALUATION; COMPUTED-TOMOGRAPHY; BLUNT TRAUMA; FRACTURES; RADIOGRAPHY; INJURY; LIMITATIONS; DIAGNOSIS; VICTIMS	Objective: To study ho cv the cervical spine is assessed before discontinuation of cervical spine immobilisation in unconscious trauma patients in intensive care units. Design: Telephone interview of consultants responsible for adult intensive care units. Setting: All 25 intensive care units in the South and West region that admit victims of major trauma. Main outcome measures: The clinical and radiological basis on which the decision is made to stop cervical spine immobilisation in unconscious patients Results: in 19 units cervical spine immobilisation was stopped in unconscious patients on the basis of radiology alone, and six units combined radiology with clinical examination after the patient had regained consciousness, Sixteen units relied on a normal lateral radiological view of the cervical spine alone, five required a normal lateral and anteroposterior view, and four required a normal lateral, anteroposterior, and open mouth pig view. Conclusions: There are inconsistencies in the clinical and radiological approach to assessing the cervical spine in unconscious patients with trauma before the removal of immobilisation precautions. There is an overreliance on the lateral cervical spine view alone, which has been shown to be insensitive in this setting.	FRENCHAY HOSP, DEPT ANAESTHESIA, BRISTOL BS16 1LE, AVON, ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP, DEPT ACCID & EMERGENCY, BRISTOL BS2 8HW, AVON, ENGLAND	Bristol Royal Infirmary								ACHESON MB, 1987, AM J ROENTGENOL, V148, P1179, DOI 10.2214/ajr.148.6.1179; BACHULIS BL, 1987, AM J SURG, V153, P473, DOI 10.1016/0002-9610(87)90796-3; BOROCK EC, 1991, J TRAUMA, V31, P1001, DOI 10.1097/00005373-199107000-00021; *CMA MED DAT, 1996, DIR EM SPEC CAR UN 1; COHN SM, 1991, J TRAUMA, V31, P570, DOI 10.1097/00005373-199104000-00018; DAVIS JW, 1995, J TRAUMA, V39, P435; DAVIS JW, 1993, J TRAUMA, V34, P342, DOI 10.1097/00005373-199303000-00006; GERRELTS BD, 1991, J TRAUMA, V31, P1622, DOI 10.1097/00005373-199112000-00010; GRADY MS, 1986, NEUROSURGERY, V18, P151; HOFFMAN JR, 1992, ANN EMERG MED, V21, P1454, DOI 10.1016/S0196-0644(05)80059-9; MACDONALD RL, 1990, J TRAUMA, V30, P392, DOI 10.1097/00005373-199030040-00004; MIRVIS SE, 1989, RADIOLOGY, V170, P831, DOI 10.1148/radiology.170.3.2492671; Palmer JD, 1996, BRIT MED J, V313, P296, DOI 10.1136/bmj.313.7052.296a; PLAISIER B, 1994, J TRAUMA, V37, P714, DOI 10.1097/00005373-199411000-00004; REID DC, 1987, J TRAUMA, V27, P980, DOI 10.1097/00005373-198709000-00005; ROBERGE RJ, 1988, J TRAUMA, V28, P784, DOI 10.1097/00005373-198806000-00010; ROSEN PB, 1992, ANN EMERG MED, V21, P1189, DOI 10.1016/S0196-0644(05)81744-5; ROSS SE, 1987, J TRAUMA, V27, P1055, DOI 10.1097/00005373-198709000-00017; SCHLEEHAUF K, 1989, ANN EMERG MED, V18, P815, DOI 10.1016/S0196-0644(89)80202-1; STREITWIESER DR, 1983, ANN EMERG MED, V12, P538, DOI 10.1016/S0196-0644(83)80293-5; The American College of Surgeons, 1993, ADV TRAUM LIF SUPP C; WOODRING JH, 1993, J TRAUMA, V34, P32, DOI 10.1097/00005373-199301000-00006; WOODRING JH, 1992, J TRAUMA, V33, P698, DOI 10.1097/00005373-199211000-00019	23	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 7	1997	314	7095					1652	1655		10.1136/bmj.314.7095.1652	http://dx.doi.org/10.1136/bmj.314.7095.1652			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD874	9180066	Green Published			2022-12-28	WOS:A1997XD87400023
J	Spaulding, CM; Joly, LM; Rosenberg, A; Monchi, M; Weber, SN; Dhainaut, JFA; Carli, P				Spaulding, CM; Joly, LM; Rosenberg, A; Monchi, M; Weber, SN; Dhainaut, JFA; Carli, P			Immediate coronary angiography in survivors of out-of-hospital cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; CARDIOPULMONARY-RESUSCITATION; THROMBOLYTIC THERAPY; DEATH; ANGIOPLASTY; THROMBOSIS; MORPHOLOGY	Background The incidence of acute coronary-artery occlusion among patients with sudden cardiac arrest outside of the hospital is unknown, and the role of reperfusion therapy has not been determined. We therefore performed immediate coronary angiography and angioplasty when indicated in survivors of out-of-hospital cardiac arrest. Methods Between September 1994 and August 1996, coronary angiography was performed in 84 consecutive patients between the ages of 30 and 75 years who had no obvious noncardiac cause of cardiac arrest. Results Sixty of the 84 patients had clinically significant coronary disease on angiography, 40 of whom had coronary-artery occlusion (48 percent). Angioplasty was attempted in 37 patients and was technically successful in 28. Clinical and electrocardiographic findings, such as the occurrence of chest pain and the presence of ST-segment elevation, were poor predictors of acute coronary-artery occlusion. The in-hospital survival rate was 38 percent. Multivariate logistic-regression analysis revealed that successful angioplasty was an independent predictor of survival (odds ratio, 5.2; 95 percent confidence interval, 1.1 to 24.5; P=0.04). Conclusions Acute coronary-artery occlusion is frequent in survivors of out-of-hospital cardiac arrest and is predicted poorly by clinical and electrocardiographic findings. Accurate diagnosis by immediate coronary angiography can be followed in suitable candidates by coronary angioplasty, which seems to improve survival. (C) 1997, Massachusetts Medical Society.	UNIV PARIS 05, COCHIN HOSP, DEPT INTENS CARE MED, F-75014 PARIS, FRANCE; SERV AIDE MED URGENTE 75, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Spaulding, CM (corresponding author), UNIV PARIS 05, COCHIN HOSP, DEPT CARDIOL, 27 RUE FAUBOURG ST JACQUES, F-75014 PARIS, FRANCE.							AMBROSE JA, 1985, J AM COLL CARDIOL, V6, P1233, DOI 10.1016/S0735-1097(85)80207-2; ANDERSON HV, 1993, NEW ENGL J MED, V329, P703; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; COBB LA, 1992, CIRCULATION, V85, P98; CROPP GJ, 1960, CIRCULATION, V22, P25, DOI 10.1161/01.CIR.22.1.25; DAVIES MJ, 1992, CIRCULATION, V85, P19; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DEANTONIO HJ, 1990, PACE, V13, P982, DOI 10.1111/j.1540-8159.1990.tb02144.x; DODGE HT, 1960, AM HEART J, V60, P762, DOI 10.1016/0002-8703(60)90359-8; ELMARAGHI N, 1980, CIRCULATION, V62, P936, DOI 10.1161/01.CIR.62.5.936; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; GORLIN R, 1986, CIRCULATION, V74, P6, DOI 10.1161/01.CIR.74.1.6; GREENE HL, 1990, AM J CARDIOL, V65, pB4; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Grines CL, 1996, NEW ENGL J MED, V335, P1313; GRUBB NR, 1995, LANCET, V346, P417, DOI 10.1016/S0140-6736(95)92784-0; KAHN JK, 1995, AM J CARDIOL, V75, P1069, DOI 10.1016/S0002-9149(99)80727-9; Lange RA, 1996, NEW ENGL J MED, V335, P1311; LO YSA, 1988, AM HEART J, V115, P781, DOI 10.1016/0002-8703(88)90879-4; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; RESNEKOV L, 1965, LANCET, V1, P506; SERRUYS PW, 1986, J AM COLL CARDIOL, V7, P729, DOI 10.1016/S0735-1097(86)80330-8; TENAGLIA AN, 1991, AM J CARDIOL, V68, P1015, DOI 10.1016/0002-9149(91)90488-7; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANCAMPEN LCMC, 1994, AM J CARDIOL, V73, P953, DOI 10.1016/0002-9149(94)90137-6; WILSON RF, 1986, CIRCULATION, V73, P286, DOI 10.1161/01.CIR.73.2.286	26	681	703	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1629	1633		10.1056/NEJM199706053362302	http://dx.doi.org/10.1056/NEJM199706053362302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC086	9171064				2022-12-28	WOS:A1997XC08600002
J	Bussel, JB; Zabusky, MR; Berkowitz, RL; McFarland, JG				Bussel, JB; Zabusky, MR; Berkowitz, RL; McFarland, JG			Fetal alloimmune thrombocytopenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	38th Annual Meeting of the American-Society-of-Hematology	DEC 06-10, 1996	ORLANDO, FL	Amer Soc Hematol, US Dept Vet Affairs Merit Res Funds, NIH			PRENATAL TREATMENT; IMMUNOGLOBULIN; TRANSFUSION; HEMORRHAGE; MANAGEMENT; DIAGNOSIS	Background Alloimmune thrombocytopenia is a serious fetal disorder resulting from platelet-antigen incompatibility between the mother and fetus. The diagnosis is usually made after the discovery of unexpected ted neonatal thrombocytopenia. Approximately 10 to 20 percent of affected fetuses have intracranial hemorrhages, one quarter to one half of which occur in utero. We studied the correlates of thrombocytopenia in affected fetuses. Methods We studied 107 fetuses with alloimmune thrombocytopenia at a mean (+/-SD) gestational age of 25+/-4 weeks, before their entry into one of three treatment protocols. The fetuses were initially evaluated because an older sibling had been given this diagnosis at birth, We compared the initial platelet counts in utero in these 107 fetuses with the platelet count at birth and the history of intracranial hemorrhage in the affected sibling. Results The initial platelet count was less than or equal to 20,000 per cubic millimeter in 53 of the 107 fetuses (50 percent), including 21 of 46 fetuses (46 percent) studied before 24 weeks of gestation. The 97 fetuses with PIA1 incompatibility had more severe thrombocytopenia than the 10 fetuses with other antigen incompatibilities, Among seven fetuses with platelet counts of more than 80,000 per cubic millimeter that were not treated initially, the counts decreased by more than 10,000 per cubic millimeter per week. Although 41 fetuses had initial platelet counts that were lower than those measured at birth in an older affected sibling, only a history of antenatal intracranial hemorrhage in the sibling predicted greater severity of thrombocytopenia in the fetus. Only one treated fetus had an intracranial hemorrhage, and the thrombocytopenia resolved after birth in all cases. Conclusions Fetal alloimmune thrombocytopenia occurs early in gestation, is severe, and is more severe in fetuses with an older affected sibling who had an antenatal intracranial hemorrhage. (C) 1997, Massachusetts Medical Society.	MT SINAI MED CTR,DEPT OBSTET & GYNECOL,NEW YORK,NY 10029; BLOOD CTR SE WISCONSIN INC,MILWAUKEE,WI 53233	Icahn School of Medicine at Mount Sinai; Versiti Blood Center of Wisconsin	Bussel, JB (corresponding author), NEW YORK HOSP,CORNELL MED CTR,DEPT PEDIAT,N740,525 E 68TH ST,NEW YORK,NY 10021, USA.							BERKOWITZ RL, 1986, AM J OBSTET GYNECOL, V155, P574, DOI 10.1016/0002-9378(86)90282-6; BERKOWITZ RL, 1986, AM J OBSTET GYNECOL, V155, P1364; BLANCHETTE VS, 1990, BRIT J HAEMATOL, V74, P209, DOI 10.1111/j.1365-2141.1990.tb02567.x; BOWMAN J, 1992, LANCET, V340, P1034, DOI 10.1016/0140-6736(92)93044-N; BUSSEL J, 1991, THROMB HAEMOSTASIS, V65, P631; Bussel J B, 1996, J Matern Fetal Med, V5, P281, DOI 10.3109/14767059609025435; Bussel JB, 1996, AM J OBSTET GYNECOL, V174, P1414, DOI 10.1016/S0002-9378(96)70582-3; BUSSEL JB, 1988, NEW ENGL J MED, V319, P1374, DOI 10.1056/NEJM198811243192103; DAFFOS F, 1984, LANCET, V2, P632; DAFFOS F, 1988, LANCET, V2, P910; FORESTIER F, 1988, CURR STUD HEMATOL BL, V55, P130; HERMAN JH, 1986, AM J PEDIAT HEMATOL, V8, P312; HOHLFELD P, 1994, BLOOD, V84, P1851, DOI 10.1182/blood.V84.6.1851.bloodjournal8461851; KAPLAN C, 1988, BLOOD, V72, P340; KAPLAN C, 1991, BRIT J HAEMATOL, V78, P425, DOI 10.1111/j.1365-2141.1991.tb04459.x; KAPLAN C, 1991, PLATELET IMMUNOLOGY, V206, P267; KROLL H, 1994, TRANSFUSION MED, V4, P293, DOI 10.1111/j.1365-3148.1994.tb00266.x; KUIJPERS RWAM, 1993, BLOOD, V81, P70; LYNCH L, 1992, OBSTET GYNECOL, V80, P67; MCFARLAND JG, 1991, BLOOD, V78, P2276; MUELLERECKHARDT C, 1989, LANCET, V1, P363; MURPHY MF, 1994, TRANSFUSION MED, V4, P281, DOI 10.1111/j.1365-3148.1994.tb00265.x; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; NICOLINI U, 1988, LANCET, V2, P506; NICOLINI U, 1990, AM J OBSTET GYNECOL, V163, P1144, DOI 10.1016/0002-9378(90)90674-V; PAIDAS MJ, 1995, AM J OBSTET GYNECOL, V172, P475, DOI 10.1016/0002-9378(95)90559-6; PEARSON HA, 1964, BLOOD, V23, P154, DOI 10.1182/blood.V23.2.154.154; SHULMAN NR, 1987, HEMOSTASIS THROMBOSI, P452; ZIMMERMANN R, 1992, LANCET, V340, P606, DOI 10.1016/0140-6736(92)92137-5	29	161	164	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	1997	337	1					22	26		10.1056/NEJM199707033370104	http://dx.doi.org/10.1056/NEJM199707033370104			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH186	9203427	Bronze			2022-12-28	WOS:A1997XH18600004
J	Nadelman, RB; Horowitz, HW; Hsieh, TC; Wu, JM; AgueroRosenfeld, ME; Schwartz, I; Nowakowski, J; Varde, S; Wormser, GP				Nadelman, RB; Horowitz, HW; Hsieh, TC; Wu, JM; AgueroRosenfeld, ME; Schwartz, I; Nowakowski, J; Varde, S; Wormser, GP			Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; SEROLOGIC TESTS; DISEASE; BURGDORFERI; ANTIBODIES; DIAGNOSIS		WESTCHESTER CTY MED CTR,DEPT MED,DIV INFECT DIS,VALHALLA,NY 10595; WESTCHESTER CTY MED CTR,DEPT PATHOL,VALHALLA,NY 10595; NEW YORK MED COLL,DEPT BIOCHEM & MOL BIOL,VALHALLA,NY 10595	Westchester Medical Center; Westchester Medical Center; New York Medical College					NIAMS NIH HHS [R01-AR41508] Funding Source: Medline; PHS HHS [U50/CCU 210180, U50/CCU 210286] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041508] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGUCROROSENFELD ME, 1996, ANN INTERN MED, V125, P904; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; FEDER HM, 1991, NEW ENGL J MED, V325, P1886; FEDER HM, 1992, CLIN INFECT DIS, V15, P788, DOI 10.1093/clind/15.5.788; Goodman JL, 1996, NEW ENGL J MED, V334, P209, DOI 10.1056/NEJM199601253340401; Hofmeister EK, 1996, P 7 INT C LYM BORR S, P222; KAELL AT, 1993, ANN INTERN MED, V119, P1079, DOI 10.7326/0003-4819-119-11-199312010-00004; Krause PJ, 1996, JAMA-J AM MED ASSOC, V275, P1657, DOI 10.1001/jama.275.21.1657; MAGNARELLI LA, 1995, AM J MED, V98, pS10, DOI 10.1016/S0002-9343(99)80039-4; MAGNARELLI LA, 1990, J CLIN MICROBIOL, V28, P1276, DOI 10.1128/JCM.28.6.1276-1279.1990; Mazzella F M, 1996, Conn Med, V60, P515; Nadelman RB, 1996, AM J MED, V100, P502, DOI 10.1016/S0002-9343(95)99915-9; Nadelman RB, 1997, CLIN INFECT DIS, V24, P1027, DOI 10.1093/clinids/24.5.1027-b; PANCHOLI P, 1995, J INFECT DIS, V172, P1007, DOI 10.1093/infdis/172.4.1007; PERSING DH, 1991, J CLIN MICROBIOL, V29, P1281, DOI 10.1128/JCM.29.7.1281-1285.1991; SCHWARTZ I, 1992, J CLIN MICROBIOL, V30, P3082, DOI 10.1128/JCM.30.12.3082-3088.1992; SCHWARTZ I, 1997, NEW ENGL J MED, V336, P49; Telford SR, 1996, P NATL ACAD SCI USA, V93, P6209, DOI 10.1073/pnas.93.12.6209; Wormser GP, 1997, AM J CLIN PATHOL, V107, P142, DOI 10.1093/ajcp/107.2.142; WORMSER GP, 1995, J INFECT DIS, V171, P1379, DOI 10.1093/infdis/171.5.1379; 1995, MMWR MORB MORAL WKLY, V44, P590	21	150	162	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	1997	337	1					27	30		10.1056/NEJM199707033370105	http://dx.doi.org/10.1056/NEJM199707033370105			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH186	9203428				2022-12-28	WOS:A1997XH18600005
J	Nightingale, SL				Nightingale, SL			Drug safety information available on the Internet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					15	15		10.1001/jama.278.1.15	http://dx.doi.org/10.1001/jama.278.1.15			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207323				2022-12-28	WOS:A1997XG38700010
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Xenotransplanters turn xenovirologists	SCIENCE			English	Article																		BENEVISTE RE, 1974, NATURE, V248, P17; COFFIN JM, 1985, RNA TUMOR VIRUSES; MCALLISTER RM, 1972, NATURE-NEW BIOL, V235, P3, DOI 10.1038/newbio235003a0; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282	4	4	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1893	1893						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206845				2022-12-28	WOS:A1997XF10300059
J	Godil, A; McCracken, JD				Godil, A; McCracken, JD			Annular pancreas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Godil, A (corresponding author), LOMA LINDA UNIV,MED CTR,LOMA LINDA,CA 92354, USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 19	1997	336	25					1794	1794		10.1056/NEJM199706193362505	http://dx.doi.org/10.1056/NEJM199706193362505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE485	9187070				2022-12-28	WOS:A1997XE48500005
J	Kemppainen, EA; Hedstrom, JI; Puolakkainen, PA; Sainio, VS; Haapiainen, RK; Perhoniemi, V; Osman, S; Kivilaakso, EO; Stenman, UH				Kemppainen, EA; Hedstrom, JI; Puolakkainen, PA; Sainio, VS; Haapiainen, RK; Perhoniemi, V; Osman, S; Kivilaakso, EO; Stenman, UH			Rapid measurement of urinary trypsinogen-2 as a screening test for acute pancreatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-AMYLASE; SERUM; ENZYMES	Background Acute pancreatitis can be difficult to diagnose. We developed a rapid dipstick screening test for pancreatitis, based on the immunochromatographic measurement of urinary trypsinogen-2. Methods We prospectively compared the urinary trypsinogen-2 dipstick test with a quantitative urinary trypsinogen-2 assay, a urinary dipstick test for amylase, and serum and urinary amylase assays in 500 consecutive patients with acute abdominal pain at two emergency departments. Acute pancreatitis was diagnosed according to standardized criteria. Results The urinary trypsinogen-2 dipstick test was positive in 50 of the 53 patients with acute pancreatitis (sensitivity, 94 percent), including all 7 with severe pancreatitis. Two patients with urinary trypsinogen-2 concentrations below the sensitivity threshold of the test (50 ng per milliliter) and one with a very high concentration had false negative results. The test was also positive in 21 of the 447 patients without pancreatitis (specificity, 95 percent), including 7 with abdominal cancers, 3 with cholangitis, and 2 with chronic pancreatitis. The sensitivity and specificity of the dipstick test were similar to those of the quantitative urinary trypsinogen-2 assay and higher than those of the urinary amylase dipstick test. The serum amylase assay had a sensitivity of 85 percent (with a cutoff value of 300 U per liter for the upper reference limit) and a specificity of 91 percent. The sensitivity and specificity of the urinary amylase assay (cutoff value, 2000 U per liter) were 83 and 88 percent, respectively. Conclusions In patients with acute abdominal pain seen in the emergency department, a negative dipstick test for urinary trypsinogen-2 rules out acute pancreatitis with a high degree of probability. A positive test usually identifies patients in need of further evaluation. (C)1997, Massachusetts Medical Society.	UNIV HELSINKI, CENT HOSP, DEPT CLIN CHEM, FI-00290 HELSINKI, FINLAND; UNIV HELSINKI, CENT HOSP, DEPT SURG 2, FI-00290 HELSINKI, FINLAND; HELSINKI CITY HOSP, HELSINKI, FINLAND	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital								Armitage P., 1987, STAT METHODS MED RES; BALTHAZAR EJ, 1989, RADIOL CLIN N AM, V27, P19; BEGER HG, 1986, GASTROENTEROLOGY, V91, P433, DOI 10.1016/0016-5085(86)90579-2; BRADLEY EL, 1993, ARCH SURG-CHICAGO, V128, P586; BROOKS FP, 1972, NEW ENGL J MED, V286, P300, DOI 10.1056/NEJM197202102860605; BURKITT DS, 1987, BRIT J SURG, V74, P1063, DOI 10.1002/bjs.1800741134; CLAVIEN PA, 1989, ANN SURG, V210, P614, DOI 10.1097/00000658-198911000-00008; CLAVIEN PA, 1989, BRIT J SURG, V76, P1234, DOI 10.1002/bjs.1800761205; CORFIELD AP, 1985, LANCET, V2, P403; GERHARDT W, 1986, SCAND J CLIN LAB INV, V46, P465, DOI 10.3109/00365518609083699; GUNN IR, 1986, LANCET, V1, P1161; Hedstrom J, 1996, BRIT MED J, V313, P333, DOI 10.1136/bmj.313.7053.333; Hedstrom J, 1996, INT J CANCER, V66, P326, DOI 10.1002/(SICI)1097-0215(19960503)66:3<326::AID-IJC10>3.0.CO;2-9; Hedstrom J, 1996, LANCET, V347, P729, DOI 10.1016/S0140-6736(96)90078-1; Hedstrom J, 1996, CLIN CHEM, V42, P685; ITKONEN O, 1990, J LAB CLIN MED, V115, P712; Kemppainen E, 1996, BRIT J SURG, V83, P924, DOI 10.1002/bjs.1800830713; KIMLAND M, 1989, CLIN CHIM ACTA, V184, P31, DOI 10.1016/0009-8981(89)90254-4; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MARSHALL JB, 1993, ARCH INTERN MED, V153, P1185, DOI 10.1001/archinte.153.10.1185; MERO M, 1982, SCAND J GASTROENTERO, V17, P413, DOI 10.3109/00365528209182078; OHLSSON K, 1975, GASTROENTEROLOGY, V69, P668; RINDERKNECHT H, 1973, ENZYME, V14, P116, DOI 10.1159/000459469; STEINBERG W, 1994, NEW ENGL J MED, V330, P1198, DOI 10.1056/NEJM199404283301706; TERADA T, 1991, HEPATOLOGY, V14, P1129, DOI 10.1016/0270-9139(91)90139-M; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; WILSON C, 1988, GUT, V29, P782, DOI 10.1136/gut.29.6.782; WONG ECC, 1993, CLIN CHEM, V39, P234; ZWEIG MH, 1993, CLIN CHEM, V39, P561; ZWEIG MH, 1993, CLIN CHEM, V39, P1589	30	99	107	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	1997	336	25					1788	1793		10.1056/NEJM199706193362504	http://dx.doi.org/10.1056/NEJM199706193362504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE485	9187069				2022-12-28	WOS:A1997XE48500004
J	Dover, JS; Arndt, KA				Dover, JS; Arndt, KA			Dermatology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND; TERBINAFINE; ONYCHOMYCOSIS; TOENAIL		HARVARD UNIV,SCH MED,BOSTON,MA 02138	Harvard University; Harvard Medical School	Dover, JS (corresponding author), BETH ISRAEL DEACONESS MED CTR,BOSTON,MA 02138, USA.							Beutner KR, 1995, ANTIVIR RES, V28, P281, DOI 10.1016/0166-3542(95)00066-6; BRAUTIGAM M, 1995, BRIT MED J, V311, P919, DOI 10.1136/bmj.311.7010.919; DeDoncker P, 1996, ARCH DERMATOL, V132, P34, DOI 10.1001/archderm.132.1.34; Einarson TR, 1996, PHARMACOECONOMICS, V9, P307, DOI 10.2165/00019053-199609040-00004; ELEWSKI BE, IN PRESS ARCH DERMAT; GUPTA AK, 1994, J AM ACAD DERMATOL, V30, P667; Kost RG, 1996, NEW ENGL J MED, V335, P32, DOI 10.1056/NEJM199607043350107; KUOKKANEN K, 1992, J DERMATOL TREAT, V3, P115; SACHS SL, 1996, JAMA-J AM MED ASSOC, V276, P44; SHEAR NH, 1995, ARCH DERMATOL, V131, P937, DOI 10.1001/archderm.131.8.937; THAKRAY AM, 1996, J INFECT DIS, V173, P291; Tosti A, 1996, J AM ACAD DERMATOL, V34, P595, DOI 10.1016/S0190-9622(96)80057-0; TYRING S, 1995, ANN INTERN MED, V123, P89, DOI 10.7326/0003-4819-123-2-199507150-00002; WATSON A, 1995, J AM ACAD DERMATOL, V33, P775, DOI 10.1016/0190-9622(95)91815-9; WELSBY PD, 1994, J INFECTION, V28, P121, DOI 10.1016/S0163-4453(94)95520-4; Whitley RJ, 1996, ANN INTERN MED, V125, P376, DOI 10.7326/0003-4819-125-5-199609010-00004; 1994, MED LETT DRUGS THER, V36, P97	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1848	1850						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185795				2022-12-28	WOS:A1997XD54400014
J	Peterson, WL; Lee, WM				Peterson, WL; Lee, WM			Gastroenterology and hepatology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPATITIS; VIRUS				Peterson, WL (corresponding author), UNIV TEXAS,SW MED SCH,DALLAS,TX 75230, USA.							Alter HJ, 1996, NEW ENGL J MED, V334, P1536, DOI 10.1056/NEJM199606063342310; Atherton JC, 1997, GASTROENTEROLOGY, V112, P92, DOI 10.1016/S0016-5085(97)70223-3; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Hopkins RJ, 1996, GASTROENTEROLOGY, V110, P1244, DOI 10.1053/gast.1996.v110.pm8613015; Kadakia SC, 1996, GASTROINTEST ENDOSC, V44, P112, DOI 10.1016/S0016-5107(96)70126-8; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; Kuipers EJ, 1996, NEW ENGL J MED, V334, P1018, DOI 10.1056/NEJM199604183341603; Lind T, 1996, Helicobacter, V1, P138, DOI 10.1111/j.1523-5378.1996.tb00027.x; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Parsonnet J, 1996, LANCET, V348, P150, DOI 10.1016/S0140-6736(96)01501-2; Poynard T, 1996, HEPATOLOGY, V24, P778; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; US Preventive Services Task Force United States. Office of Disease Prevention Health Promotion, 1996, GUID CLIN PREV SERV, P89; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594	17	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1858	1860						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185801				2022-12-28	WOS:A1997XD54400020
J	Cheung, B				Cheung, B			Increased left-ventricular mass after losartan treatment	LANCET			English	Article											Cheung, B (corresponding author), QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG.		/E-9829-2010	/0000-0001-9106-7363				Caskey FJ, 1997, LANCET, V349, P620, DOI 10.1016/S0140-6736(05)61568-1; CHEUNG BMY, 1997, 5 INT S ACE INH OTH; LIEVRE M, 1995, HYPERTENSION, V25, P92, DOI 10.1161/01.HYP.25.1.92; LINZ W, 1995, PHARMACOL REV, V47, P25; NOZAWA Y, 1994, J PHARMACOL EXP THER, V270, P566	5	30	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1743	1744		10.1016/S0140-6736(05)62955-8	http://dx.doi.org/10.1016/S0140-6736(05)62955-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193389				2022-12-28	WOS:A1997XE06500016
J	Posas, F; Saito, H				Posas, F; Saito, H			Osmotic activation of the HOG MAPK pathway via Ste11p MAPKKK: Scaffold role of Pbs2p MAPKK	SCIENCE			English	Article							PHEROMONE RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; KINASE CASCADE; SIGNAL TRANSDUCTION; PROTEIN-KINASES; YEAST; STE5; PHOSPHORYLATION; COMPONENTS; MITOGEN	Exposure of the yeast Saccharomyces cerevisiae to high extracellular osmolarity induces the Sln1p-Ypd1p-Ssk1p two-component osmosensor to activate a mitogen-activated protein (MAP) kinase cascade composed of the Ssk2p and Ssk22p MAP kinase kinase kinases (MAPKKKs), the Pbs2p MAPKK, and the Hog1p MAPK. A second osmosensor, Sho1p, also activated Pbs2p and Hog1p, but did so through the Ste11p MAPKKK. Although Ste11p also participates in the mating pheromone-responsive MAPK cascade, there was no detectable cross talk between these two pathways. The MAPKK Pbs2p bound to the Sho1p osmosensor, the MAPKKK Ste11p, and the MAPK Hog1p. Thus, Pbs2p may serve as a scaffold protein.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Posas, Francesc/K-1364-2013; Saito, Haruo/AAF-6113-2019	Posas, Francesc/0000-0002-4164-7076; Saito, Haruo/0000-0001-7891-1689	NIGMS NIH HHS [GM53415, GM50909] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050909] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHOI KY, 1994, CELL, V78, P499; CIEJEK E, 1979, CELL, V18, P623, DOI 10.1016/0092-8674(79)90117-X; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MANIVASAKAM P, 1995, NUCLEIC ACIDS RES, V23, P2799, DOI 10.1093/nar/23.14.2799; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; POSAS F, UNPUB; PRINTEN JA, 1994, GENETICS, V138, P609; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	27	452	468	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	1997	276	5319					1702	1705		10.1126/science.276.5319.1702	http://dx.doi.org/10.1126/science.276.5319.1702			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180081				2022-12-28	WOS:A1997XD94700044
J	Sachs, AB; Sarnow, P; Hentze, MW				Sachs, AB; Sarnow, P; Hentze, MW			Starting at the beginning, middle, and end: Translation initiation in eukaryotes	CELL			English	Review							C VIRUS-RNA; INTERNAL RIBOSOME-BINDING; 5' NONTRANSLATED REGION; PROTEIN-SYNTHESIS; MESSENGER-RNA; IN-VITRO; FACTOR EIF-4-GAMMA; PICORNAVIRUS RNA; PHOSPHORYLATION; COMPLEX		STANFORD UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; EUROPEAN MOL BIOL LAB, GENE EXPRESS LAB, D-69117 HEIDELBERG, GERMANY	Stanford University; European Molecular Biology Laboratory (EMBL)	Sachs, AB (corresponding author), UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, 229 STANLEY HALL, BERKELEY, CA 94720 USA.		Hentze, Matthias W/V-3980-2017	Hentze, Matthias W/0000-0002-4023-7876; Sarnow, Peter/0000-0002-2043-2770				ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BORMAN AM, 1995, NUCLEIC ACIDS RES, V23, P3656, DOI 10.1093/nar/23.18.3656; Borman AM, 1997, RNA, V3, P186; Borman AM, 1997, NUCLEIC ACIDS RES, V25, P925, DOI 10.1093/nar/25.5.925; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; Gamarnik AV, 1996, EMBO J, V15, P5988, DOI 10.1002/j.1460-2075.1996.tb00985.x; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GUNNERY S, 1995, MOL CELL BIOL, V15, P3597; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HERSHEY JWB, TRANSLATIONAL CONTRO; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; Iizuka N, 1995, CURR TOP MICROBIOL, V203, P155; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; Jackson RJ, 1995, RNA, V1, P985; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; JOSHI B, 1994, J BIOL CHEM, V269, P2048; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MADER S, 1995, MOL CELL BIOL, V15, P4990; MEEROVITCH K, 1993, SEMIN VIROL, V4, P217, DOI 10.1006/smvy.1993.1018; Merrick WC., 1996, TRANSLATION CONTROL, P31; Meyuhas Oded, 1996, V30, P363; MORLEY SJ, 1993, EUR J BIOCHEM, V218, P39, DOI 10.1111/j.1432-1033.1993.tb18349.x; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; OHLMANN T, 1995, NUCLEIC ACIDS RES, V23, P334; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; PESTOVA TV, 1994, VIROLOGY, V204, P729, DOI 10.1006/viro.1994.1588; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; ZIEGLER E, 1995, VIROLOGY, V213, P549; ZIEGLER E, 1995, J VIROL, V69, P3465, DOI 10.1128/JVI.69.6.3465-3474.1995	61	572	583	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					831	838		10.1016/S0092-8674(00)80268-8	http://dx.doi.org/10.1016/S0092-8674(00)80268-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200601	Bronze			2022-12-28	WOS:A1997XE35700003
J	Lang, J; Hoa, DQ; Gioi, NV; Tho, LT; Vien, NC; Kesmedjian, V; Plotkin, SA				Lang, J; Hoa, DQ; Gioi, NV; Tho, LT; Vien, NC; Kesmedjian, V; Plotkin, SA			Randomised feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants	LANCET			English	Article							IMMUNOGENICITY; IMMUNIZATION; VACCINES; STRAIN	Background Pre-exposure vaccination against rabies generally simplifies treatment and could be especially beneficial to children in countries where the disease is enzootic. We studied the feasibility of administering to infants pre-exposure rabies vaccination with diphtheria, tetanus, whole-cell pertussis, and poliomyelitis vaccine (DTP-IPV). Methods 84 Vietnamese infants were randomly assigned to groups that received three doses of DTP-IPV vaccine at 2, 3, and 4 months of age alone (n=43) or with two doses of purified Vero cell rabies vaccine (PVRV) at 2 and 4 months (n=41). The safety and immunogenicity data of the groups were compared. Findings All infants in both groups developed protective antibody concentrations against diphtheria, tetanus, pertussis, and polio. All infants who received the PVRV vaccine developed protective antibody concentrations against rabies, No serious adverse effects were reported, nor did systemic reactions differ between groups. Interpretation Administration of PVRV with DTP-IPV proved safe, and elicited what are presumed to be protective antibody concentrations to all antigens in all 41 infants. Confirmation of these results could lead to integration of pre-exposure rabies vaccination into Expanded Programme on Immunisation (EPI) sessions in selected countries where rabies is enzootic.	CTR PEDIAT DEV & SANTE, HO CHI MINH CITY, VIETNAM		Lang, J (corresponding author), PASTEUR MERIEUX CONNAUGHT, DEPT MED, F-69007 LYON, FRANCE.							Advisory Committee on Immunization Practices, 1991, MMWR-MORBID MORTAL W, V40, P1; AJJAN N, 1989, VACCINE, V7, P125, DOI 10.1016/0264-410X(89)90050-9; AYLWARD B, 1994, VACCINE, V12, P1155, DOI 10.1016/0264-410X(94)90236-4; CHANTHAVANICH P, 1993, ANN SCI M PAED SOC T; CHAPPUIS G, 1995, BR SMALL ANIMAL VET, V8, P49; CLEMENTS ML, 1994, J INFECT DIS, V170, P510, DOI 10.1093/infdis/170.3.510; COREY L, 1976, ANN INTERN MED, V85, P170, DOI 10.7326/0003-4819-85-2-170; *EXP COMM RAB, 1992, WHO TECHN REP SER, V824, P1; FRIDELL E, 1984, LANCET, V2, P623; Girgsdies OE, 1996, VACCINE, V14, P1421, DOI 10.1016/S0264-410X(96)00081-3; GOUBAU P, 1992, VACCINE, V10, pS114, DOI 10.1016/0264-410X(92)90561-W; MEAN F, 1978, MED HYG, V36, P3818; MESLIN FX, 1991, PREEXPOSURE RABIES V, P1; Montagnon B J, 1989, Dev Biol Stand, V70, P27; STRADY A, 1993, PRESSE MED, V22, P572; SUNTHARASAMAI P, 1986, LANCET, V2, P129; VARNER MW, 1982, AM J OBSTET GYNECOL, V143, P717, DOI 10.1016/0002-9378(82)90121-1; WARRELL MJ, 1985, LANCET, V1, P1059; *WHO, 1993, P S RAB CONTR AS WHO; XIANG ZQ, 1992, VIRUS RES, V24, P297, DOI 10.1016/0168-1702(92)90125-S	20	23	24	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	1997	349	9066					1663	1665		10.1016/S0140-6736(96)10085-4	http://dx.doi.org/10.1016/S0140-6736(96)10085-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186385				2022-12-28	WOS:A1997XD10000011
J	Maldonado, PE; Godecke, I; Gray, CM; Bonhoeffer, T				Maldonado, PE; Godecke, I; Gray, CM; Bonhoeffer, T			Orientation selectivity in pinwheel centers in cat striate cortex	SCIENCE			English	Article							VISUAL-CORTEX; ORGANIZATION; DOMAINS	In primary visual cortex of higher mammals neurons are grouped according to their orientation preference, forming ''pinwheels'' around ''orientation centers.'' Although the general structure of orientation maps is largely resolved, the microscopic arrangement of neuronal response properties in the orientation centers has remained elusive. The tetrode technique, enabling multiple single-unit recordings, in combination with intrinsic signal imaging was used to reveal the fine-grain structure of orientation maps in these locations. The results show that orientation centers represent locations where orientation columns converge containing normal, sharply tuned neurons of different orientation preference lying in close proximity.	UNIV CALIF DAVIS,SECT NEUROBIOL PHYSIOL & BEHAV,DAVIS,CA 95616; MAX PLANCK INST PSYCHIAT,D-82152 MUNICH,GERMANY	University of California System; University of California Davis; Max Planck Society	Maldonado, PE (corresponding author), UNIV CALIF DAVIS,CTR NEUROSCI,DAVIS,CA 95616, USA.		Maldonado, Pedro/AAH-7670-2019; Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634; Maldonado, Pedro/0000-0001-9895-7684				BATSCHELET E, 1991, CIRCULAR STATISTICS; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bonhoeffer Tobias, 1996, P55; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; Ferster D, 1996, NATURE, V380, P249, DOI 10.1038/380249a0; GILBERT CD, 1989, J NEUROSCI, V9, P2432; Gray CM, 1995, J NEUROSCI METH, V63, P43, DOI 10.1016/0165-0270(95)00085-2; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HENRY GH, 1974, J NEUROPHYSIOL, V37, P1394, DOI 10.1152/jn.1974.37.6.1394; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; LEE BB, 1977, EXP BRAIN RES, V27, P301; Maldonado PE, 1996, VISUAL NEUROSCI, V13, P509, DOI 10.1017/S095252380000818X; MALONEK D, 1990, SOC NEUR ABSTR, V130, P4; REID RC, 1995, NATURE, V378, P381; Swindale NV, 1996, NETWORK-COMP NEURAL, V7, P161, DOI 10.1088/0954-898X/7/2/002; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	21	165	168	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 6	1997	276	5318					1551	1555		10.1126/science.276.5318.1551	http://dx.doi.org/10.1126/science.276.5318.1551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171056				2022-12-28	WOS:A1997XC70100039
J	McClearn, GE; Johansson, B; Berg, S; Pedersen, NL; Ahern, F; Petrill, SA; Plomin, R				McClearn, GE; Johansson, B; Berg, S; Pedersen, NL; Ahern, F; Petrill, SA; Plomin, R			Substantial genetic influence on cognitive abilities in twins 80 or more years old	SCIENCE			English	Article							BLOOD-INSTITUTE TWIN; AGING TWINS; LIFE-SPAN; DECLINE; HERITABILITY; PERFORMANCE	General and specific cognitive abilities were studied in intact Swedish same-sex twin pairs 80 or more years old for whom neither twin had major cognitive, sensory, or motor impairment. Resemblance for 110 identical twin pairs significantly exceeded resemblance for 130 fraternal same-sex twin pairs for all abilities. Maximum-likelihood model-fitting estimates of heritability were 62 percent for general cognitive ability, 55 percent for verbal ability, 32 percent for spatial ability, 62 percent for speed of processing, and 52 percent for memory, There was also evidence for the significant influence of idiosyncratic experience as the environmental component that most determines individual differences in cognitive abilities late in life.	INST PSYCHIAT,SOCIAL GENET & DEV PSYCHIAT RES CTR,LONDON SE5 8AF,ENGLAND; KAROLINSKA INST,INST ENVIRONM MED,S-17177 STOCKHOLM,SWEDEN; UNIV COLL HLTH SCI,INST GERONTOL,S-55111 JONKOPING,SWEDEN; PENN STATE UNIV,CTR DEV & HLTH GENET,UNIVERSITY PK,PA 16802	University of London; King's College London; Karolinska Institutet; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Plomin, Robert/B-8911-2008; Petrill, Stephen Anthony/J-3040-2013	Plomin, Robert/0000-0002-0756-3629	NIA NIH HHS [AG08861] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG008861, R37AG008861] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Psychiatric Association, 1987, AM PSYCH ASS DIAGN S; BALTES PB, 1987, DEV PSYCHOL, V23, P611, DOI 10.1037/0012-1649.23.5.611; Berg S, 1980, Acta Psychiatr Scand Suppl, V288, P1; BERGEMAN CS, 1997, AGING DIFFERENTLY GE; BOUCHARD TJ, 1981, SCIENCE, V212, P1055, DOI 10.1126/science.7195071; BRODY N, 1992, INTELLIGENCE; Carroll J. B., 1993, HUMAN COGNITIVE ABIL, DOI DOI 1017/CBO9780511571312; CEDERLOF R, 1978, TWIN RES C, P189; CHIPUER HM, 1990, INTELLIGENCE, V14, P11, DOI 10.1016/0160-2896(90)90011-H; Dureman I., 1959, PSYKOMETRISKA EXPT P; FESKENS EJM, 1994, BRIT MED J, V309, P1202, DOI 10.1136/bmj.309.6963.1202; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hayflick L., 1994, WHY WE AGE; Jonsson CO, 1964, MANUAL TILL CVB SKAL; KAUFMAN AS, 1990, ASSESING ADOLESCENT; LOEHLIN JC, 1989, AM PSYCHOL, V44, P1285, DOI 10.1037/0003-066X.44.10.1285; MARTIN NG, 1978, HEREDITY, V40, P97, DOI 10.1038/hdy.1978.10; MCGUE M, 1984, BEHAV GENET, V14, P325, DOI 10.1007/BF01080045; McGue M, 1993, NATURE NURTURE PSYCH, P59, DOI DOI 10.1037/10131-003; Neale MC, 1992, METHODOLOGY GENETIC; NEALE MC, 1995, STAT MODELING; Pedersen N. L., 1990, SUCCESSFUL AGING PER, P359, DOI [10.1017/CBO9780511665684.014, DOI 10.1017/CBO9780511665684.014]; Pedersen Nancy L., 1996, P59; PEDERSEN NL, 1992, PSYCHOL SCI, V3, P346, DOI 10.1111/j.1467-9280.1992.tb00045.x; PEDERSEN NL, 1997, PROCESSES INDIVIDUAL, P125; PLOMIN R, 1994, BEHAV GENET, V24, P207, DOI 10.1007/BF01067188; PLOMIN R, 1994, SCIENCE, V264, P1733, DOI 10.1126/science.8209254; Plomin R., 1994, SEPARATE SOCIAL WORL, P1; Plomin R., 1986, DEV GENETICS PSYCHOL; Plomin R, 1988, ADV PSYCHOL HUMAN IN, V4, P1; PLOMIN R, 1997, BEHAVIORAL GENETICS; SIMMONS SF, IN PRESS J AGING HLT; SWAN GE, 1990, ARCH NEUROL-CHICAGO, V47, P259, DOI 10.1001/archneur.1990.00530030025010; SWAN GE, 1992, ARCH NEUROL-CHICAGO, V49, P476, DOI 10.1001/archneur.1992.00530290058012; THAPAR A, 1994, BRIT J PSYCHIAT, V164, P747, DOI 10.1192/bjp.164.6.747; Thurstone L.L., 1938, PRIMARY MENTAL ABILI; Wechsler D., 1972, WECHSLERS MEASUREMEN, V5th	37	534	540	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 6	1997	276	5318					1560	1563		10.1126/science.276.5318.1560	http://dx.doi.org/10.1126/science.276.5318.1560			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XC701	9171059				2022-12-28	WOS:A1997XC70100042
J	Betriu, A; Phillips, H; Ellis, S; Topol, E; Califf, R; VanderWerf, F; Ardissino, D; Armstrong, PW; Aylward, P; Bates, E; Beatt, K; Cheseboro, J; Col, J; Emanuelsson, H; Fuster, V; Gibler, WB; Gore, J; Guerci, A; Hochman, J; Holmes, D; Kleiman, D; Morris, D; Neuhaus, K; Ohman, M; Pfisterer, M; Rutsch, W; Simes, J; Simoons, M; Vahanian, A; Weaver, WD; White, H; Granger, C; Hochrein, J; Fraulo, B; Moffie, I; Paraschos, L; Stebbins, A; Woodlief, L; Lee, K; Pieper, K; Wagner, GS; Gates, K; Debowey, D; Poliszczuk, R; Vilsack, H; Luyren, A; Tobback, L; Kava, M; Sutherland, W; Frye, R; Cheitlin, M; DeMets, D; Fisher, L; Hirsh, J; Serruys, P; Walters, L; Hanovich, G; Antolick, A; Kellett, M; Berg, C; Jamal, NM; Whiting, D; Kirshnaswami, V; Heyl, A; Gossman, D; Dorland, M; Berrios, E; Sexson, R; Ibarra, J; Frey, L; Lancaster, L; Lansman, D; Sheridan, F; McRae, R; Hejl, S; Palmeri, S; Casazza, L; Schrading, W; Sonin, N; Talley, D; Talley, J; Ashcraft, S; Niles, N; Edkins, R; Hollywood, L; Symkoviak, G; Pincock, J; Mishkel, D; Lehmann, J; LawMcKenzie, R; Gainey, PC; Baker, D; Maddox, W; Sturm, C; Miller, R; Woods, S; Dageford, D; Hanrahan, J; Gilchrist, I; Zimmerman, H; Williams, M; Stegall, G; Perry, J; Schvaneveldt, W; Riba, A; Draus, C; OToole, JD; Sudina, K; Spriggs, D; Schulz, F; Maddox, WT; Allan, S; Hammer, C; White, C; Smith, J; Harrah, L; Schmidt, P; Ness, C; Kaplan, J; Steffans, G; Gacioch, G; Chiodo, V; Hanger, K; Chapuseaux, C; Fernandez, EG; Aviles, FF; Boland, J; Castadot, M; Legrand, V; Schroeder, E; Vassanelli, C; Cernigliaro, C; Repetto, S; Valsecchi, O; Topp, H; Risenfors, M; Amann, FW; Urban, P; Dolan, S; Nelson, G; Scammell, R; Bett, N; Newitt, C; Labinza, M; Kearns, S				Betriu, A; Phillips, H; Ellis, S; Topol, E; Califf, R; VanderWerf, F; Ardissino, D; Armstrong, PW; Aylward, P; Bates, E; Beatt, K; Cheseboro, J; Col, J; Emanuelsson, H; Fuster, V; Gibler, WB; Gore, J; Guerci, A; Hochman, J; Holmes, D; Kleiman, D; Morris, D; Neuhaus, K; Ohman, M; Pfisterer, M; Rutsch, W; Simes, J; Simoons, M; Vahanian, A; Weaver, WD; White, H; Granger, C; Hochrein, J; Fraulo, B; Moffie, I; Paraschos, L; Stebbins, A; Woodlief, L; Lee, K; Pieper, K; Wagner, GS; Gates, K; Debowey, D; Poliszczuk, R; Vilsack, H; Luyren, A; Tobback, L; Kava, M; Sutherland, W; Frye, R; Cheitlin, M; DeMets, D; Fisher, L; Hirsh, J; Serruys, P; Walters, L; Hanovich, G; Antolick, A; Kellett, M; Berg, C; Jamal, NM; Whiting, D; Kirshnaswami, V; Heyl, A; Gossman, D; Dorland, M; Berrios, E; Sexson, R; Ibarra, J; Frey, L; Lancaster, L; Lansman, D; Sheridan, F; McRae, R; Hejl, S; Palmeri, S; Casazza, L; Schrading, W; Sonin, N; Talley, D; Talley, J; Ashcraft, S; Niles, N; Edkins, R; Hollywood, L; Symkoviak, G; Pincock, J; Mishkel, D; Lehmann, J; LawMcKenzie, R; Gainey, PC; Baker, D; Maddox, W; Sturm, C; Miller, R; Woods, S; Dageford, D; Hanrahan, J; Gilchrist, I; Zimmerman, H; Williams, M; Stegall, G; Perry, J; Schvaneveldt, W; Riba, A; Draus, C; OToole, JD; Sudina, K; Spriggs, D; Schulz, F; Maddox, WT; Allan, S; Hammer, C; White, C; Smith, J; Harrah, L; Schmidt, P; Ness, C; Kaplan, J; Steffans, G; Gacioch, G; Chiodo, V; Hanger, K; Chapuseaux, C; Fernandez, EG; Aviles, FF; Boland, J; Castadot, M; Legrand, V; Schroeder, E; Vassanelli, C; Cernigliaro, C; Repetto, S; Valsecchi, O; Topp, H; Risenfors, M; Amann, FW; Urban, P; Dolan, S; Nelson, G; Scammell, R; Bett, N; Newitt, C; Labinza, M; Kearns, S			A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENOUS STREPTOKINASE; IMMEDIATE ANGIOPLASTY; BALLOON ANGIOPLASTY; ARTERY DISEASE; MORTALITY; THROMBOLYSIS; REPERFUSION; OUTCOMES	Background Among physicians who treat patients with acute myocardial infarction, there is controversy about the magnitude of the clinical benefit of primary (i.e., immediate) coronary angioplasty as compared with thrombolytic therapy. Methods As part of the Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) trial, we randomly assigned 1138 patients from 57 hospitals who presented within 12 hours of acute myocardial infarction (with ST-segment elevation on the electrocardiogram) to primary angioplasty or accelerated thrombolytic therapy with recombinant tissue plasminogen activator (t-PA). We also randomly assigned 1012 patients to heparin or hirudin treatment in a factorial design. The primary study end point was a composite outcome of death, nonfatal reinfarction, and nonfatal disabling stroke at 30 days. Results The incidence of the primary end point in the angioplasty and t-PA groups was 9.6 percent and 13.7 percent, respectively (odds ratio, 0.67; 95 percent confidence interval, 0.47 to 0.97; P = 0.033). Death occurred in 5.7 percent of the patients assigned to angioplasty and 7.0 percent of those assigned to t-PA (P = 0.37), reinfarction in 4.5 percent and 6.5 percent (P = 0.13), and disabling stroke in 0.2 percent and 0.9 percent (P = 0.11). At six months, there was no significant difference in the incidence of the composite outcome (14.1 percent vs. 16.1 percent, P not significant). The primary end point was observed in 10.6 percent of the patients in the angioplasty group assigned to heparin and 8.2 percent of those assigned to hirudin (P = 0.37). Conclusions This trial suggests that angioplasty provides a small-to-moderate, short-term clinical advantage over thrombolytic therapy with t-PA. Primary angioplasty, when it can be accomplished promptly at experienced centers, should be considered an excellent alternative method for myocardial reperfusion. (C) 1997, Massachusetts Medical Society.	CLEVELAND CLIN FDN, ANGIOGRAPH CORE LAB, CLEVELAND, OH 44195 USA; DUKE UNIV, MED CTR, DURHAM, NC USA	Cleveland Clinic Foundation; Duke University			Ardissino, Diego/AAC-4041-2022; Smith, Jane/B-6254-2009; Simes, Robert John/P-1497-2014; Schrading, Walter/AAA-4726-2021; Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1987, LANCET, V2, P871; [Anonymous], 1988, LANCET, V2, P349; ANTMAN EM, 1994, CIRCULATION, V90, P1624, DOI 10.1161/01.CIR.90.4.1624; Antoniucci D., 1997, Journal of the American College of Cardiology, V29, p456A; Braunwald E, 1996, J AM COLL CARDIOL, V27, P1333, DOI 10.1016/0735-1097(96)00007-1; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; DEBOER MJ, 1994, CIRCULATION, V90, P753, DOI 10.1161/01.CIR.90.2.753; DEWOOD MA, 1990, 6 THROMB INT THER AC, P28; Elizaga J., 1993, European Heart Journal, V14, P118; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Grinfeld Liliana, 1996, Journal of the American College of Cardiology, V27, p222A; HOORNTJE JC, 1996, CIRCULATION S1, V94, P570; Jhangiani Anil H., 1996, Journal of the American College of Cardiology, V27, p61A; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEFKOVITS J, 1994, CIRCULATION, V90, P1522, DOI 10.1161/01.CIR.90.3.1522; LINCOFF AM, 1996, CIRCULATION S1, V94, P375; MANCINI GBJ, 1987, CIRCULATION, V75, P452, DOI 10.1161/01.CIR.75.2.452; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; Nakagawa Y, 1996, AM J CARDIOL, V78, P980, DOI 10.1016/S0002-9149(96)00520-6; Neuhaus K.-L., 1996, Journal of the American College of Cardiology, V27, p62A; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Ohman EM, 1997, CIRCULATION, V95, P846; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; Ribichini Flavio, 1996, Journal of the American College of Cardiology, V27, p221A; RITCHIE JL, 1993, CIRCULATION, V88, P2735, DOI 10.1161/01.CIR.88.6.2735; Rodriguez A., 1997, Journal of the American College of Cardiology, V29, p221A; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROSS AM, 1995, CIRCULATION S1, V92, P718; Saito S., 1997, Journal of the American College of Cardiology, V29, p235A; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIMES RJ, 1995, CIRCULATION, V91, P1923, DOI 10.1161/01.CIR.91.7.1923; STONE GW, 1995, J AM COLL CARDIOL, V25, P370, DOI 10.1016/0735-1097(94)00367-Y; STONE GW, 1993, CIRCULATION, V88, P105; The GUSTO Angiographic Investigators, 1994, NEW ENGL J MED, V330, P516; Topol EJ, 1996, NEW ENGL J MED, V335, P775; VEEN G, 1995, J AM COLL CARDIO FEB, pA295; VOGT A, 1993, J AM COLL CARDIOL, V21, P1391, DOI 10.1016/0735-1097(93)90314-Q; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	43	748	766	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1621	1628						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC086	9173270				2022-12-28	WOS:A1997XC08600001
J	Yokomizo, T; Izumi, T; Chang, K; Takuwa, Y; Shimizu, T				Yokomizo, T; Izumi, T; Chang, K; Takuwa, Y; Shimizu, T			A G-protein-coupled receptor for leukotriene B-4 that mediates chemotaxis	NATURE			English	Article							HUMAN NEUTROPHILS; CLONING; BINDING; ANALOGS; CELLS; ACID	Leukotriene B-4 (LTB4)(1) is a potent chemoattractant that is primarily involved in inflammation, immune responses and host defence against infection(2). LTB4 activates inflammatory cells by binding to its cell-surface receptor (BLTR)(3). LTB4 can also bind and activate the intranuclear transcription factor PPAR alpha, resulting in the activation of genes that terminate inflammatory processess(4). Here we report the cloning of the complementary DNA encoding a cell-surface LTB4 receptor that is highly expressed in human leukocytes. Using a subtraction strategy, we isolated two cDNA clones (HL-1 and HL-5) from retinoic acid-differentiated HL-60 cells. These two clones contain identical open reading frames encoding a protein of 352 amino acids and predicted to contain seven membrane-spanning domains, but different 5'-untranslated regions. Membrane fractions of Cos-7 cells transfected with an expression construct containing the open reading frame of HL-5 showed specific LTB4 binding, with a K-d (0.154 nM) comparable to that observed in retinoic acid-differentiated HL-60 cells. In CHO cells stably expressing this receptor, LTB4 induced increases in intracellular calcium, D-myo-inositol-1,4,5-triphosphate (InsP(3)) accumulation, and inhibition of adenlyl cyclase. Furthermore, CHO cells expressing exogenous BLTR showed marked chemotactic responses towards low concentrations of LTB4 in a pertussis-toxin-sensitive manner. Our findings, together with previous reports(4,5), show that LTB4 is a unique lipid mediator that interacts with both cell-surface and nuclear receptors.	UNIV TOKYO,FAC MED,DEPT BIOCHEM & MOL BIOL,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT CARDIOVASC BIOL,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo			Yokomizo, Takehiko/P-5673-2016	Yokomizo, Takehiko/0000-0002-5219-1553				Akbar GKM, 1996, J BIOL CHEM, V271, P18363, DOI 10.1074/jbc.271.31.18363; ALEXANDER SPH, 1997, TRENDS PHARM SCI S, P50; BOMALASKI JS, 1987, PROSTAGLANDINS, V33, P855, DOI 10.1016/0090-6980(87)90114-6; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; DEGIULIO R, 1993, ANN NY ACAD SCI, V685, P614, DOI 10.1111/j.1749-6632.1993.tb35925.x; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; ERBECK K, 1993, J IMMUNOL, V150, P1913; FIORE S, 1993, BLOOD, V81, P3395; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; FIORE S, 1992, J BIOL CHEM, V267, P16168; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Gladue RP, 1996, J EXP MED, V183, P1893, DOI 10.1084/jem.183.4.1893; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; KINKER JE, 1996, GEN PHARMACOL, V27, P33; KISHIKAWA K, 1992, PROSTAGLANDINS, V44, P261, DOI 10.1016/0090-6980(92)90002-B; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NG CF, 1991, J IMMUNOL, V147, P3096; Owman C, 1996, GENOMICS, V37, P187, DOI 10.1006/geno.1996.0541; PALMBLAD J, 1994, J IMMUNOL, V152, P262; POWELL WS, 1993, J BIOL CHEM, V268, P9280; Powell WS, 1996, J IMMUNOL, V156, P336; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; TAYLOR BM, 1991, PROSTAG OTH LIPID M, V42, P211, DOI 10.1016/0090-6980(91)90111-R; YASUDA K, 1992, J BIOL CHEM, V267, P20422; YENUSH L, 1994, J BIOL CHEM, V269, P100; Yokomizo T, 1996, J BIOL CHEM, V271, P2844, DOI 10.1074/jbc.271.5.2844	30	808	856	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					620	624		10.1038/42506	http://dx.doi.org/10.1038/42506			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177352				2022-12-28	WOS:A1997XC52200060
J	Ganot, P; Bortolin, ML; Kiss, T				Ganot, P; Bortolin, ML; Kiss, T			Site-specific pseudouridine formation in preribosomal RNA is guided by small nucleolar RNAs	CELL			English	Article							18S RIBOSOMAL-RNA; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PEPTIDYLTRANSFERASE CENTER; YEAST; U3; NUCLEOTIDE; RESIDUES; SNR30	During the nucleolar maturation of eukaryotic ribosomal RNAs, many selected uridines are converted into pseudouridine by a thus far undefined mechanism. The nucleolus contains a large number of small RNAs (snoRNAs) that share two conserved sequence elements, box H and ACA. In this study, we demonstrate that site-specific pseudouridylation of rRNAs relies on short ribosomal signal sequences that are complementary to sequences in box H/ACA snoRNAs. Genetic depletion and reconstitution studies on yeast snR5 and snR36 snoRNAs demonstrate that box H/ACA snoRNAs function as guide RNAs in rRNA pseudouridylation. These results define a novel function for snoRNAs and further reinforce the idea that base pairing is the most common way to obtain specific substrate-''enzyme'' interactions during rRNA maturation.	UNIV TOULOUSE 3, MOL BIOL LAB, CNRS, F-31062 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier				Kiss, Tamas/0000-0003-0293-3093; Bortolin-Cavaille, Marie-Line/0000-0002-6336-4034				BAKIN A, 1995, NUCLEIC ACIDS RES, V23, P3290, DOI 10.1093/nar/23.16.3290; BAKIN A, 1994, BIOCHEMISTRY-US, V33, P13475, DOI 10.1021/bi00249a036; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; BALAKIN AG, 1993, NUCLEIC ACIDS RES, V21, P5391, DOI 10.1093/nar/21.23.5391; BALLY M, 1988, NUCLEIC ACIDS RES, V16, P5291, DOI 10.1093/nar/16.12.5291; BELTRAME M, 1995, EMBO J, V14, P4350, DOI 10.1002/j.1460-2075.1995.tb00109.x; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; DANDEKAR T, 1993, NUCLEIC ACIDS RES, V21, P5386, DOI 10.1093/nar/21.23.5386; EICHLER DC, 1995, PROG NUCL ACID RES M, V49, P179; ENGBERG J, 1990, NUCLEIC ACIDS RES, V18, P6915, DOI 10.1093/nar/18.23.6915; Ganot P, 1997, GENE DEV, V11, P941, DOI 10.1101/gad.11.7.941; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Goldwasser E, 1966, Prog Nucleic Acid Res Mol Biol, V5, P399, DOI 10.1016/S0079-6603(08)60241-X; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; HADJIOLOV AA, 1985, CELL BIOL MONOGRAPHS; HADJIOLOVA KV, 1994, MOL CELL BIOL, V14, P4044, DOI 10.1128/MCB.14.6.4044; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; Kiss T, 1996, MOL CELL BIOL, V16, P1391; KISS T, 1993, EMBO J, V12, P2913, DOI 10.1002/j.1460-2075.1993.tb05953.x; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; LANE BG, 1995, BIOCHIMIE, V77, P7, DOI 10.1016/0300-9084(96)88098-9; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LIANG WQ, 1995, GENE DEV, V9, P2433, DOI 10.1101/gad.9.19.2433; LUBBEN B, 1995, J BIOL CHEM, V270, P11549, DOI 10.1074/jbc.270.19.11549; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MADEN BEH, 1975, FEBS LETT, V59, P60, DOI 10.1016/0014-5793(75)80341-3; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; NIELSEN H, 1992, FEBS LETT, V307, P337, DOI 10.1016/0014-5793(92)80708-O; Ofengand J, 1997, J MOL BIOL, V266, P246, DOI 10.1006/jmbi.1996.0737; Ofengand J, 1995, BIOCHEM CELL BIOL, V73, P915, DOI 10.1139/o95-099; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; RIMOLDI OJ, 1993, MOL CELL BIOL, V13, P4382, DOI 10.1128/MCB.13.7.4382; RUFF EA, 1993, P NATL ACAD SCI USA, V90, P635, DOI 10.1073/pnas.90.2.635; SAMARSKY DA, 1995, NUCLEIC ACIDS RES, V23, P2548, DOI 10.1093/nar/23.13.2548; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAPONARA AG, 1974, BIOCHIM BIOPHYS ACTA, V349, P61, DOI 10.1016/0005-2787(74)90009-4; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SELDEN RF, 1992, CURRENT PROTOCOLS MO; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIRUMCONNOLLY K, 1993, SCIENCE, V262, P1886, DOI 10.1126/science.8266080; SOLLNERWEBB B, 1996, RIBOSOMAL RNA STRUCT, P469; THOMPSON JR, 1988, NUCLEIC ACIDS RES, V16, P5587, DOI 10.1093/nar/16.12.5587; TOLLERVEY D, 1983, CELL, V35, P753, DOI 10.1016/0092-8674(83)90108-3; TOLLERVEY D, 1985, EMBO J, V4, P3873, DOI 10.1002/j.1460-2075.1985.tb04160.x; TOLLERVEY D, 1987, EMBO J, V6, P469, DOI 10.1002/j.1460-2075.1987.tb04777.x; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TOLLERVEY D, 1997, IN PRESS CURR OPIN C, V9; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025; Tycowski KT, 1996, P NATL ACAD SCI USA, V93, P14480, DOI 10.1073/pnas.93.25.14480; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; TYCOWSKI KT, 1993, GENE DEV, V6, P1120; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; WRZESINSKI J, 1995, BIOCHEMISTRY-US, V34, P8904, DOI 10.1021/bi00027a043; WRZESINSKI J, 1995, RNA, V1, P437	62	482	514	1	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	1997	89	5					799	809		10.1016/S0092-8674(00)80263-9	http://dx.doi.org/10.1016/S0092-8674(00)80263-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182768	Bronze			2022-12-28	WOS:A1997XB92500017
J	Churcher, C; Bowman, S; Badcock, K; Bankler, A; Brown, D; Chillingworth, T; Connor, R; Devlin, K; Gentles, S; Hamlin, N; Harris, D; Horsnell, T; Hunt, S; Jagels, K; Jones, M; Lye, G; Moule, S; Odell, C; Pearson, D; Rajandream, M; Rice, P; Rowley, N; Skelton, J; Smith, V; Walsh, S; Whitehead, S; Barrell, B				Churcher, C; Bowman, S; Badcock, K; Bankler, A; Brown, D; Chillingworth, T; Connor, R; Devlin, K; Gentles, S; Hamlin, N; Harris, D; Horsnell, T; Hunt, S; Jagels, K; Jones, M; Lye, G; Moule, S; Odell, C; Pearson, D; Rajandream, M; Rice, P; Rowley, N; Skelton, J; Smith, V; Walsh, S; Whitehead, S; Barrell, B			The nucleotide sequence of Saccharomyces cerevisiae chromosome IX	NATURE			English	Article							DNA-SEQUENCE; PROJECTS; STADEN; GENES	Large-scale systematic sequencing has generally depended on the availability of an ordered library of large-insert bacterial or viral genomic clones for the organism under study. The generation of these large insert libraries, and the location of each clone on a genome map, is a laborious and time-consuming process. In an effort to overcome these problems, several groups have successfully demonstrated the viability of the whole-genome random 'shotgun' method in large-scale sequencing of both viruses and prokaryotes(1-5). Here we report the sequence of Saccharomyces cerevisiae chromosome IX, determined in part by a whole-chromosome 'shotgun', and describe the particular difficulties encountered in the random 'shotgun' sequencing of an entire eukaryotic chromosome. Analysis of this sequence shows that chromosome IX contains 221 open reading frames (ORFs), of which approximately 30% have been sequenced previously. This chromosome shows features typical of a small Saccharomyces cerevisiae chromosome.	SANGER CTR,CAMBRIDGE CB10 1SA,ENGLAND; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Wellcome Trust Sanger Institute; MRC Laboratory Molecular Biology				Hunt, Sarah/0000-0002-8350-1235	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BUSSEY H, 1995, P NATL ACAD SCI USA, V92, P3809, DOI 10.1073/pnas.92.9.3809; COOPER TG, 1979, GENETICS, V92, P383; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; Davison A J, 1991, DNA Seq, V1, P389, DOI 10.3109/10425179109020794; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; FITZGERALDHAYES M, 1987, YEAST, V3, P187, DOI 10.1002/yea.320030306; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; HALLORAN N, 1992, METHOD MOL BIOL, V10, P297; Hawkins T., 1992, DNA Sequence, V3, P65, DOI 10.3109/10425179209033998; LOUIS EJ, 1995, BIOCHEMICA, V3, P25; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; Rawlinson WD, 1996, J VIROL, V70, P8833, DOI 10.1128/JVI.70.12.8833-8849.1996; RILES L, 1993, GENETICS, V134, P81; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SEUFERT W, 1990, NUCLEIC ACIDS RES, V18, P3653, DOI 10.1093/nar/18.12.3653; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; SMITH V, 1993, METHOD ENZYMOL, V218, P173; Staden R, 1994, Methods Mol Biol, V25, P27; Staden R, 1994, Methods Mol Biol, V25, P37; TELFORD EAR, 1992, VIROLOGY, V189, P304, DOI 10.1016/0042-6822(92)90706-U; Termier M, 1996, YEAST, V12, P369, DOI 10.1002/(SICI)1097-0061(19960330)12:4<369::AID-YEA922>3.0.CO;2-#; TUROSCY V, 1984, GENETICS, V108, P827; VAUDIN M, 1995, NUCLEIC ACIDS RES, V23, P670, DOI 10.1093/nar/23.4.670	25	30	284	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632		S			84	87		10.1038/387s084	http://dx.doi.org/10.1038/387s084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169870				2022-12-28	WOS:A1997XB54600010
J	Shafman, T; Khanna, KK; Kedar, P; Spring, K; Kozlov, S; Yen, T; Hobson, K; Gatei, M; Zhang, N; Watters, D; Egerton, M; Shiloh, Y; Kharbanda, S; Kufe, D; Lavin, MF				Shafman, T; Khanna, KK; Kedar, P; Spring, K; Kozlov, S; Yen, T; Hobson, K; Gatei, M; Zhang, N; Watters, D; Egerton, M; Shiloh, Y; Kharbanda, S; Kufe, D; Lavin, MF			Interaction between ATM protein and c-Abl in response to DNA damage	NATURE			English	Article							ATAXIA-TELANGIECTASIA CELLS; IONIZING-RADIATION; TYROSINE KINASE; RADIOSENSITIVITY; INDUCTION; GENE; P53	The gene mutated in the autosomal recessive disorder ataxia telangiectasia (AT), designated ATM (for 'AT mutated'), is a member of a family of phosphatidylinositol-3-kinase-like enzymes that are involved in cell-cycle control, meiotic recombination, telomere length monitoring and DNA-damage response(1-4). Previous results have demonstrated that AT cells are hypersensitive to ionizing radiation(5-7) and are defective at the G1/S checkpoint after radiation damage(8-10). Because cells lacking the protein tyrosine kinase c-Abl are also defective in radiation-induced G1 arrest(11), we investigated the possibility that ATM might interact with c-Abl in response to radiation damage. Here we show that ATM binds c-Abl constitutively in control cells but not in AT cells. Our results demonstrate that the SH3 domain of c-Abl interacts with a DPAPNPPHFP motif (residues 1,373-1,382) of ATM. The results also reveal that radiation-induction of c-Abl tyrosine kinase activity is diminished in AT cells. These findings indicate that ATM is involved in the activation of c-Abl by DNA damage and this interaction may in part mediate radiation-induced G1 arrest.	QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,ROYAL BRISBANE HOSP,DEPT SURG,BRISBANE,QLD 4029,AUSTRALIA; DANA FARBER CANC INST,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115; DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; FOX CHASE CANC CTR,PHILADELPHIA,PA 19111; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 RAMAT AVIV,ISRAEL	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Fox Chase Cancer Center; Tel Aviv University; Sackler Faculty of Medicine			Kozlov, Sergei/T-9779-2019; Kozlov, Sergei/M-2067-2014; Hobson, Keith/Q-9306-2019; Khanna, Kum Kum/I-1747-2013; Lavin, Martin F/F-5961-2014; Watters, Dianne J/E-6007-2010	Kozlov, Sergei/0000-0001-6183-7339; Lavin, Martin F/0000-0002-5940-4769; Watters, Dianne J/0000-0002-2555-5825; Yen, Tim/0000-0003-2159-0997; Khanna, Kum Kum/0000-0001-8650-5381; Spring, Kevin/0000-0003-0601-924X				BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; CHEN PC, 1975, NATURE, V258, P427; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gilad S, 1996, HUM MOL GENET, V5, P2033, DOI 10.1093/hmg/5.12.2033; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; PATERSON MC, 1979, CANCER RES, V39, P3725; PAWSON T, 1988, ONCOGENE, V3, P491; PECKER L, 1996, GENOMICS, V35, P39; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHAFMAN TD, 1995, CANCER RES, V55, P3242; TAYLOR AM, 1975, NATURE, V274, P484; Telatar M, 1996, AM J HUM GENET, V59, P40; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHANG N, IN PRESS P NATL ACAD	26	400	414	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					520	523		10.1038/387520a0	http://dx.doi.org/10.1038/387520a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168117				2022-12-28	WOS:A1997XB47900053
J	Lynn, J; Daley; Delbanco				Lynn, J; Daley; Delbanco			An 88-year-old woman facing the end of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TERMINALLY ILL; CANCER		GEORGE WASHINGTON UNIV, MED CTR, CTR IMPROVE CARE DYING, WASHINGTON, DC 20037 USA	George Washington University	Lynn, J (corresponding author), CARE OF HARTMAN EE, BETH ISRAEL DEACONESS MED CTR, DIV GEN MED & PRIMARY CARE, E CAMPUS, BOSTON, MA 02215 USA.							ADDINGTONHALL J, 1995, PALLIATIVE MED, V9, P295, DOI 10.1177/026921639500900404; BENSON J, 1996, NEW YORK S HLTH SERV; Berwick DM, 1996, ANN INTERN MED, V125, P839, DOI 10.7326/0003-4819-125-10-199611150-00009; BRAUNWALD E, 1992, HEART DISEASE TXB CA; BREITBART W, 1993, SYMP PAIN R, P49; Byock I, 1997, DYING WELL PROSPECT; CHOCHINOV HM, 1994, AM J PSYCHIAT, V151, P537; DUNN H, 1994, HARD CHOICES LOVING; Gillick MR, 1994, CHOOSING MED CARE OL; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hamel MB, 1996, J AM GERIATR SOC, V44, P1043, DOI 10.1111/j.1532-5415.1996.tb02935.x; JONES S, 1996, WHY NOT BEST CHRONIC; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Kubler-Ross E., 1969, DEATH DYING; KUBLERROSS E, 1981, LIVING DEATH DYING; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Lynn J, 1997, New Horiz, V5, P56; Lynn J, 1997, J AM GERIATR SOC, V45, P489, DOI 10.1111/j.1532-5415.1997.tb05176.x; MILES SH, 1985, JAMA-J AM MED ASSOC, V254, P525, DOI 10.1001/jama.254.4.525; MILES SH, 1987, J AM GERIATR SOC, V35, P74, DOI 10.1111/j.1532-5415.1987.tb01323.x; MORRIS JN, 1986, J CHRON DIS, V39, P47, DOI 10.1016/0021-9681(86)90106-2; *NY STAT TASK FORC, 1987, LIF SUST TREATM MAK; QUILL TE, 1993, NEW ENGL J MED, V328, P965; Shute N, 1997, US News World Rep, V122, P61; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; Teno JM, 1996, J CLIN ETHIC, V7, P205; Teno JM, 1997, J AM GERIATR SOC, V45, P508, DOI 10.1111/j.1532-5415.1997.tb05179.x; *US BUR CENS, 1985, STAT ABSTR US 1995, P86; VERBRUGGE LM, 1994, DISABILITY LATE LIFE; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; Welch HG, 1996, ANN INTERN MED, V124, P577, DOI 10.7326/0003-4819-124-6-199603150-00007; Wells H.G., 1963, TIME MACHINE; *WHO, 1990, WHO TECHN REP SER, V809	34	46	46	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	1997	277	20					1633	1640		10.1001/jama.277.20.1633	http://dx.doi.org/10.1001/jama.277.20.1633			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XA022	9168294				2022-12-28	WOS:A1997XA02200034
J	Bachmann, MF; Kalinke, U; Althage, A; Freer, G; Burkhart, C; Roost, HP; Aguet, M; Hengartner, H; Zinkernagel, RM				Bachmann, MF; Kalinke, U; Althage, A; Freer, G; Burkhart, C; Roost, HP; Aguet, M; Hengartner, H; Zinkernagel, RM			The role of antibody concentration and avidity in antiviral protection	SCIENCE			English	Article							VESICULAR STOMATITIS-VIRUS; MONOCLONAL-ANTIBODIES; MEDIATED CLEARANCE; RABIES VIRUS; T-CELL; INFECTION; AFFINITY; MECHANISMS; RESPONSES; MICE	Neutralizing antibodies are necessary and sufficient for protection against infection with vesicular stomatitis virus(VSV). The in vitro neutralization capacities and in vivo protective capacities of a panel of immunoglobulin G monoclonal antibodies to the glycoprotein of VSV were evaluated. In vitro, neutralizing activity correlated with avidity and with neutralization rate constant, a measure of on-rate. However, in vivo, protection was independent of immunoglobulin subclass, avidity, neutralization rate constant, and in vitro neutralizing activity; above a minimal avidity threshold, protection depended simply on a minimum serum concentration. These two biologically defined thresholds of antibody specificity offer hope for the development of adoptive therapy with neutralizing antibodies.	UNIV ZURICH HOSP,INST EXPT IMMUNOL,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of Zurich; University Zurich Hospital; Swiss Institute Experimental Cancer Research			freer, giulia/H-4609-2012	Kalinke, Ulrich/0000-0003-0503-9564				BACHMANN M, UNPUB; BACHMANN MF, 1994, J IMMUNOL, V152, P4235; BACHMANN MF, 1993, J VIROL, V67, P3917, DOI 10.1128/JVI.67.7.3917-3922.1993; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Bachmann MF, 1995, EUR J IMMUNOL, V25, P3445, DOI 10.1002/eji.1830251236; BRILES DE, 1984, EUR J IMMUNOL, V14, P1027, DOI 10.1002/eji.1830141112; COHN M, 1990, IMMUNOL REV, V115, P7, DOI 10.1111/j.1600-065X.1990.tb00783.x; CYBINSKI DH, 1990, J GEN VIROL, V71, P2065, DOI 10.1099/0022-1317-71-9-2065; DESTGROTH SF, 1981, IMMUNE SYSTEM, P155; DIETZSCHOLD B, 1992, P NATL ACAD SCI USA, V89, P7252, DOI 10.1073/pnas.89.15.7252; EISEN HN, 1964, BIOCHEMISTRY-US, V3, P996, DOI 10.1021/bi00895a027; FLAMAND A, 1993, VIROLOGY, V194, P302, DOI 10.1006/viro.1993.1261; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; FOOTE J, 1995, P NATL ACAD SCI USA, V92, P1254, DOI 10.1073/pnas.92.5.1254; FORGER JM, 1991, J VIROL, V65, P4950, DOI 10.1128/JVI.65.9.4950-4958.1991; GOBET R, 1988, EXP CELL BIOL, V56, P175; Kalinke U, 1996, EUR J IMMUNOL, V26, P2801, DOI 10.1002/eji.1830261202; LEFRANCOIS L, 1984, J VIROL, V51, P208, DOI 10.1128/JVI.51.1.208-214.1984; LEFRANCOIS L, 1982, VIROLOGY, V121, P157, DOI 10.1016/0042-6822(82)90125-8; LEVINE B, 1991, SCIENCE, V254, P856, DOI 10.1126/science.1658936; MILSTEIN C, 1991, IMMUNOL TODAY, V12, P93, DOI 10.1016/0167-5699(91)90164-O; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; RAJEWSKY K, 1989, PROGR IMMUNOLOGY, V7, P397; ROOST HP, 1995, P NATL ACAD SCI USA, V92, P1257, DOI 10.1073/pnas.92.5.1257; ROOST HP, 1996, J IMMUNOL METHODS, V189, P283; STEINHOFF U, 1995, J VIROL, V69, P2153, DOI 10.1128/JVI.69.4.2153-2158.1995; STEWARD MW, 1991, IMMUNOLOGY, V72, P99; TYLER KL, 1993, J VIROL, V67, P3446, DOI 10.1128/JVI.67.6.3446-3453.1993; WAGNER RR, 1987, RHABDOVIRUSES; WRIGHT KE, 1991, J VIROL, V65, P3001, DOI 10.1128/JVI.65.6.3001-3006.1991	30	210	223	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2024	2027		10.1126/science.276.5321.2024	http://dx.doi.org/10.1126/science.276.5321.2024			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197261				2022-12-28	WOS:A1997XG74800059
J	Rydall, AC; Rodin, GM; Olmsted, MP; Devenyi, RG; Daneman, D				Rydall, AC; Rodin, GM; Olmsted, MP; Devenyi, RG; Daneman, D			Disordered eating behavior and microvascular complications in young women with insulin-dependent diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	55th Annual Meeting and Scientific Sessions of the American-Diabetes-Association	JUN 10-13, 1995	ATLANTA, GA	Amer Diabet Assoc			GLYCEMIC CONTROL; ADOLESCENTS; BULIMIA; IDDM; NERVOSA; ADULTS	Background insulin-dependent diabetes mellitus (IDDM) and eating disorders are relatively common among young women in North America. Their coexistence could lead to poor metabolic control and an increased risk of the microvascular complications of IDDM. Methods We studied 91 young women with IDDM at base line and four to five years later to determine the prevalence and persistence of disordered eating behavior (on the basis of self-reported eating and weight-loss practices, including the intentional omission or underdosing of insulin to control weight) and the association of such eating disorders with metabolic control, diabetic retinopathy, and urinary albumin excretion. At base line, the mean age of the young women was 15+/-2 years and the duration of diabetes was 7+/-4 years. Results At base line, 26 of 97 young women (29 percent) had highly or moderately disordered eating behavior, which persisted in 76 (18 percent) and improved in 10 (11 percent). Of the 65 women with normal eating behavior at base line (71 percent), 14 (15 percent) had disordered eating at follow-up. Omission or underdosing of insulin to lose weight was reported by 12 of 88 young women (14 percent) at base line and 30 (34 percent) at follow-up (P=0.003). At base line, the mean (+/-SD) hemoglobin A,, value was higher in the group with highly disordered eating behavior (11.1+/-1.2 percent) than in the groups whose eating behavior was moderately disordered (8.9 +/- 1.7 percent) or nondisordered (8.7+/-1.6 percent, P<0.001). Disordered eating at base line was associated with retinopathy four years later (P=0.004), when 86 percent of the young women with highly disordered eating behavior, 43 percent of those with moderately disordered eating behavior, and 24 percent of those with nondisordered eating behavior had retinopathy. Conclusions Disordered eating behavior is common and persistent in young women with IDDM and is associated with impaired metabolic control and a higher risk of diabetic retinopathy. (C) 1997, Massachusetts Medical Society.	TORONTO HOSP, DEPT PSYCHIAT, TORONTO, ON M5G 2C4, CANADA; HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, TORONTO, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto				Rydall, Anne/0000-0002-4692-9101; Rodin, Gary/0000-0002-6626-6974				[Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210; [Anonymous], 1991, Ophthalmology, V98, P786; BIGGS MM, 1994, DIABETES CARE, V17, P1186, DOI 10.2337/diacare.17.10.1186; Birk R, 1989, Diabetes Educ, V15, P336, DOI 10.1177/014572178901500415; COLAS C, 1991, DIABETOLOGIA, V34, P288, DOI 10.1007/BF00405092; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; DIXON WJ, 1988, BMDP STATISTICAL SOF, V1; DRASH AL, 1987, CLIN INVEST MED, V10, P432; ELLIS G, 1984, CLIN CHEM, V30, P1746; FAIRBURN CG, 1991, BRIT MED J, V303, P17, DOI 10.1136/bmj.303.6793.17; Fairburn CG, 1996, AM J PSYCHIAT, V153, P386; FRIEDMAN S, 1995, ANN MED-PSYCHOL, V153, P282; HUDSON JI, 1983, JAMA-J AM MED ASSOC, V249, P2501, DOI 10.1001/jama.249.18.2501; JOHNSON C, 1985, HDB PSYCHOTHERAPY AN, P19; KROLEWSKI AS, 1986, DIABETES CARE, V9, P443, DOI 10.2337/diacare.9.5.443; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LAWSON ML, 1994, EATING DISORDERS, V2, P261; LITTLEFIELD CH, 1992, DIABETES CARE, V15, P90, DOI 10.2337/diacare.15.1.90; MCKENNA MJ, 1991, ARCH INTERN MED, V151, P1745, DOI 10.1001/archinte.151.9.1745; NORUSIS MJ, 1992, SPSS PC PLUS BASE SY; PEVELER RC, 1992, INT J EAT DISORDER, V11, P45, DOI 10.1002/1098-108X(199201)11:1&lt;45::AID-EAT2260110107&gt;3.0.CO;2-R; POLONSKY WH, 1994, DIABETES CARE, V17, P1178, DOI 10.2337/diacare.17.10.1178; RODIN G, 1991, PSYCHOSOMATICS, V32, P171, DOI 10.1016/S0033-3182(91)72088-4; RODIN GM, 1992, DIABETES CARE, V15, P1402, DOI 10.2337/diacare.15.10.1402; RODIN GM, 1986, INT J PSYCHIAT MED, V16, P49, DOI 10.2190/HULH-CTPR-4V17-383C; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SOCHETT E, 1988, J PEDIATR-US, V112, P744, DOI 10.1016/S0022-3476(88)80694-2; STANCIN T, 1989, DIABETES CARE, V12, P601, DOI 10.2337/diacare.12.9.601; STEEL JM, 1987, BRIT MED J, V294, P859, DOI 10.1136/bmj.294.6576.859; STEEL JM, 1989, BRIT J PSYCHIAT, V155, P515, DOI 10.1192/bjp.155.4.515; SZMUKLER GI, 1983, BRIT J PSYCHIAT, V142, P305, DOI 10.1192/bjp.142.3.305; VILA G, 1993, CAN J PSYCHIAT, V38, P606, DOI 10.1177/070674379303800908; WARD A, 1995, POSTGRAD MED J, V71, P546, DOI 10.1136/pgmj.71.839.546; WING RR, 1986, DIABETES CARE, V9, P162, DOI 10.2337/diacare.9.2.162	34	307	312	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	1997	336	26					1849	1854		10.1056/NEJM199706263362601	http://dx.doi.org/10.1056/NEJM199706263362601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XF756	9197212	Bronze			2022-12-28	WOS:A1997XF75600001
J	Richards, SA; Carey, KL; Macara, IG				Richards, SA; Carey, KL; Macara, IG			Requirement of guanosine triphosphate-bound Ran for signal-mediated nuclear protein export	SCIENCE			English	Article							CHROMOSOME CONDENSATION; BINDING PROTEIN; RCC1; ACTIVATION; MUTANT	A leucine-rich nuclear export signal (NES) allows rapid export of proteins from cell nuclei. Microinjection studies revealed a role for the guanosine triphosphatase (GTPase) Ran in NES-mediated export. Nuclear injection of a Ran mutant (Thr(24)-->Asn) blocked protein export but not import, whereas depletion of the Ran nucleotide exchange factor RCC1 blocked protein import but not export. However, injection of Ran GTPase-activating protein (RanGAP) into RCC1-depleted cell nuclei inhibited export. Coinjection with Ran mutants insensitive to RanGAP prevented this inhibition. Therefore, NES-mediated protein export appears to require a Ran-GTP complex but does not require Ran-dependent GTP hydrolysis.	UNIV VIRGINIA,HLTH SCI CTR,CTR CELL SIGNALING,CHARLOTTESVILLE,VA 22908; UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405	University of Virginia; University of Vermont				Carey, Kimberly/0000-0002-0836-8710	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050526] Funding Source: NIH RePORTER; NIEHS NIH HHS [EST3207122] Funding Source: Medline; NIGMS NIH HHS [GM 50526] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FUKUDA M, 1996, J BIOL CHEM, V271, P21124; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; RICHARDS S, UNPUB; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	19	166	166	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1842	1844		10.1126/science.276.5320.1842	http://dx.doi.org/10.1126/science.276.5320.1842			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188526				2022-12-28	WOS:A1997XF10300043
J	Duncan, J; Martens, S; Ward, R				Duncan, J; Martens, S; Ward, R			Restricted attentional capacity within but not between sensory modalities	NATURE			English	Article							SYSTEM; TASKS	Restrictions to attentional capacity are revealed by the interference that commonly results when two sensory inputs must be identified at the same time(1). To investigate this phenomenon within and between modalities, we presented streams of visual and/or auditory inputs, containing occasional targets to be identified and recalled. For two visual or two auditory streams, identification of one target produced a sustained reduction in the ability to identify a second, the period of interference lasting for several hundred milliseconds. Subjectively, when attention was assigned to one target it was temporarily unavailable for another. In contrast, there was no such time-locked interference between targets in different modalities, The results suggest a modality-specific restriction to concurrent attention and awareness; visual attention io one simple target does not restrict concurrent auditory attention to another.	LEIDEN UNIV,FAC SOCIAL SCI,UNIT EXPT & THEORET PSYCHOL,NL-2300 RB LEIDEN,NETHERLANDS; UNIV WALES,SCH PSYCHOL,BANGOR LL57 2DG,GWYNEDD,WALES	Leiden University; Leiden University - Excl LUMC; Bangor University	Duncan, J (corresponding author), MRC,APPL PSYCHOL UNIT,15 CHAUCER RD,CAMBRIDGE CB2 2EF,ENGLAND.		Martens, Sander/C-5353-2008; Brennan, Kathy/D-6118-2011	Duncan, John S/0000-0002-1373-0681; Martens, Sander/0000-0001-8237-7984; Duncan, John/0000-0002-9695-2764				Bourke PA, 1996, Q J EXP PSYCHOL-A, V49, P525, DOI 10.1080/027249896392487; Broadbent D.E., 1958, PERCEPTION COMMUNICA; BROADBENT DE, 1987, PERCEPT PSYCHOPHYS, V42, P105, DOI 10.3758/BF03210498; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; Driver J, 1996, NATURE, V381, P66, DOI 10.1038/381066a0; DUNCAN J, 1994, NATURE, V369, P313, DOI 10.1038/369313a0; LINDSAY PH, 1968, PERCEPT PSYCHOPHYS, V4, P113, DOI 10.3758/BF03209520; LOGAN GD, 1978, J EXP PSYCHOL GEN, V107, P32, DOI 10.1037/0096-3445.107.1.32; MASSARO DW, 1977, PERCEPT PSYCHOPHYS, V21, P569, DOI 10.3758/BF03198739; PASHLER H, 1994, PSYCHOL BULL, V116, P220, DOI 10.1037/0033-2909.116.2.220; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAYMOND JE, 1992, J EXP PSYCHOL HUMAN, V18, P849, DOI 10.1037/0096-1523.18.3.849; Treisman A. M., 1973, ATTENTION PERFORM, P101	13	319	324	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 19	1997	387	6635					808	810		10.1038/42947	http://dx.doi.org/10.1038/42947			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XF144	9194561	Bronze			2022-12-28	WOS:A1997XF14400051
J	Gu, W; Shi, XL; Roeder, RG				Gu, W; Shi, XL; Roeder, RG			Synergistic activation of transcription by CBP and p53	NATURE			English	Article							NUCLEAR-PROTEIN CBP; FACTOR CREB; COACTIVATOR; BINDING; SUPPRESSION; DOMAIN; MDM-2; CAMP	The tumour suppressor p53 is a transcriptional regulator whose ability to inhibit cell growth is dependent upon its transactivation function(1-3). Here we demonstrate that the transcription factor CBP, which is also implicated in cell proliferation and differentiation(4-14), acts as a p53 coactivator and potentiates its transcriptional activity. The amino-terminal activation domain of p53 interacts with the carboxy-terminal portion of the CBP protein both in vitro and in vivo. In transfected SaoS-2 cells, CBP potentiates activation of the mdm-2 gene by p53 and, reciprocally, p53 potentiates activation of a Gal4-responsive target gene by a Gal4(1-147)-CBP(1678-2441) fusion protein. A double point mutation that destroys the transactivation function of p53 also abolishes its binding to CBP and its synergistic function with CBP The ability of p53 to interact physically and functionally with a coactivator (CBP) that has histone acetyltransferase activity(15,16) and with components (TAFs)(17,18) of the general transcription machinery indicates that it may have different functions in a multistep activation pathway.	ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021	Rockefeller University								ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANISTER AJ, 1996, NATURE, V384, P641; BANISTER AJ, 1995, EMBO J, V14, P4758; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WONG HK, 1994, J VIROL, V68, P4910, DOI 10.1128/JVI.68.8.4910-4920.1994; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	30	516	527	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 19	1997	387	6635					819	823		10.1038/42972	http://dx.doi.org/10.1038/42972			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF144	9194564	Bronze			2022-12-28	WOS:A1997XF14400054
J	Marx, JA				Marx, JA			Emergency medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Marx, JA (corresponding author), CAROLINAS MED CTR,CHARLOTTE,NC 28203, USA.							Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; Birnbaum A, 1996, ACAD EMERG MED, V3, P246, DOI 10.1111/j.1553-2712.1996.tb03428.x; BIROS MH, 1995, JAMA-J AM MED ASSOC, V273, P1283, DOI 10.1001/jama.273.16.1283; Cherpitel CJ, 1996, ANN EMERG MED, V28, P418, DOI 10.1016/S0196-0644(96)70008-2; Derlet RW, 1996, ACAD EMERG MED, V3, P338, DOI 10.1111/j.1553-2712.1996.tb03447.x; Durham B, 1997, ANN EMERG MED, V29, P338, DOI 10.1016/S0196-0644(97)70345-7; Hedges JR, 1996, ACAD EMERG MED, V3, P27, DOI 10.1111/j.1553-2712.1996.tb03299.x; Henry MC, 1996, ANN EMERG MED, V28, P627, DOI 10.1016/S0196-0644(96)70085-9; Kelen GD, 1996, ANN EMERG MED, V27, P687, DOI 10.1016/S0196-0644(96)70184-1; Mikhail MG, 1997, ANN EMERG MED, V29, P88, DOI 10.1016/S0196-0644(97)70314-7; Nader R, 1996, ACAD EMERG MED, V3, P161, DOI 10.1111/j.1553-2712.1996.tb03406.x; RDMAN RJ, 1997, ANN EMERG MED, V29, P109; Rozycki GS, 1996, J TRAUMA, V40, P1, DOI 10.1097/00005373-199601000-00001; Spadafore JC, 1996, ACAD EMERG MED, V3, P326, DOI 10.1111/j.1553-2712.1996.tb03445.x; WEISS HB, 1997, ANN EMERG MED, V29, P348; 1996, FED REG         1002, V61, P51531	16	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1851	1852						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185797				2022-12-28	WOS:A1997XD54400016
J	Takagi, T; Moore, CR; Diehn, F; Buratowski, S				Takagi, T; Moore, CR; Diehn, F; Buratowski, S			An RNA 5'-triphosphatase related to the protein tyrosine phosphatases	CELL			English	Article							CAPPING ENZYME; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GUANYLYLTRANSFERASE; DNA; PURIFICATION; ASSOCIATION; SUBUNITS; LIGASES; GENES	mRNA capping requires the sequential action of three enzymatic activities: RNA triphosphatase, guanylyltransferase, and methyltransferase. Here we characterize a gene (GEL-I) believed to encode the C., elegans capping enzyme. CEL-1 has a C-terminal domain containing motifs found in yeast and vaccinia virus capping enzyme guanylyltransferases. The N-terminal domain of CEL-1 has RNA tri phosphatase activity. Surprisingly, this domain does not resemble the vaccinia virus capping enzyme but does have significant sequence similarity to the protein tyrosine phosphatase (PTP) enzyme family. However, CEL-1 has no detectable PTP activity. The mechanism of the RNA triphosphatase is similar to that of PTPs: the active site contains a conserved nucleophilic cysteine required for activity. These results broaden the superfamily of PTP-like phosphatases to include enzymes with RNA substrates.			Takagi, T (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FRESCO LD, 1994, P NATL ACAD SCI USA, V91, P6624, DOI 10.1073/pnas.91.14.6624; GUO PX, 1990, P NATL ACAD SCI USA, V87, P4023, DOI 10.1073/pnas.87.11.4023; ITOH N, 1987, J BIOL CHEM, V262, P1989; ITOH N, 1984, J BIOL CHEM, V259, P3930; ITOH N, 1984, J BIOL CHEM, V259, P3923; JOVE R, 1984, J BIOL CHEM, V259, P8513; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAO XD, 1995, MOL CELL BIOL, V15, P4167; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; Myette JR, 1996, J BIOL CHEM, V271, P11945, DOI 10.1074/jbc.271.20.11945; NILES EG, 1986, VIROLOGY, V153, P96, DOI 10.1016/0042-6822(86)90011-5; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; YAGI Y, 1983, EMBO J, V2, P611, DOI 10.1002/j.1460-2075.1983.tb01471.x; YamadaOkabe T, 1996, MICROBIOL-UK, V142, P2515, DOI 10.1099/00221287-142-9-2515; Yu L, 1996, J VIROL, V70, P6162, DOI 10.1128/JVI.70.9.6162-6168.1996	26	105	111	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					867	873		10.1016/S0092-8674(00)80272-X	http://dx.doi.org/10.1016/S0092-8674(00)80272-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200605	Bronze			2022-12-28	WOS:A1997XE35700007
J	Wolfe, KH; Shields, DC				Wolfe, KH; Shields, DC			Molecular evidence for an ancient duplication of the entire yeast genome	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; GENE; EVOLUTION; SEQUENCES	Gene duplication is an important source of evolutionary novelty(1,2). Most duplications are of just a single gene, but Ohno(1) proposed that whole-genome duplication (polyploidy) is an important evolutionary mechanism. Many duplicate genes have been found in Saccharomyces cerevisiae, and these often seem to be phenotypically redundant(3-7) Here we show that the arrangement of duplicated genes in the S. cerevisiae genome is consistent with Ohno's hypothesis. We propose a model in which this species is a degenerate tetraploid resulting from a whole-genome duplication that occurred after the divergence of Saccharomyces from Kluyveromyces. Only a small fraction of the genes were subsequently retained in duplicate (most were deleted), and gene order was rearranged by many reciprocal translocations between chromosomes. Protein pairs derived from this duplication event make up 13% of all yeast proteins, and include pairs of transcription factors, protein kinases, myosins, cyclins and pheromones. Tetraploidy may have facilitated the evolution of anaerobic fermentation in Saccharomyces.			Wolfe, KH (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND.		Wolfe, Kenneth H/B-4653-2009	Shields, Denis/0000-0003-4015-2474; Wolfe, Kenneth/0000-0003-4992-4979	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHN S, 1993, P NATL ACAD SCI USA, V90, P7980, DOI 10.1073/pnas.90.17.7980; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BERGKAMPSTEFFENS GK, 1992, YEAST, V8, P903, DOI 10.1002/yea.320081102; DOHRMANN PR, 1992, GENE DEV, V6, P93, DOI 10.1101/gad.6.1.93; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Friis E. M., 1987, ORIGINS ANGIOSPERMS; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HENDRIKS L, 1992, SYST APPL MICROBIOL, V15, P98, DOI 10.1016/S0723-2020(11)80145-1; HEUS JJ, 1993, MOL GEN GENET, V236, P355; HUGHES AL, 1994, P ROY SOC B-BIOL SCI, V256, P119, DOI 10.1098/rspb.1994.0058; HURWITZ N, 1995, P NATL ACAD SCI USA, V92, P11009, DOI 10.1073/pnas.92.24.11009; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; KABACK DB, 1995, YEASTS, V6, P179; Kielland-Brandt M.C., 1995, YEASTS, P223; LALO D, 1993, CR ACAD SCI III-VIE, V316, P367; LARSON GP, 1994, GENE, V150, P35, DOI 10.1016/0378-1119(94)90854-0; MELNICK L, 1993, J MOL BIOL, V233, P372, DOI 10.1006/jmbi.1993.1518; Ohno S., 1970, EVOLUTION GENE DUPLI; OLSON MV, 1991, MOL CELLULAR BIOL YE, V1, P1; ROMAN H, 1953, P NATL ACAD SCI USA, V39, P171, DOI 10.1073/pnas.39.3.171; Ryu SL, 1996, YEAST, V12, P757, DOI 10.1002/(SICI)1097-0061(19960630)12:8<757::AID-YEA970>3.0.CO;2-H; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; SMITH MM, 1987, J MOL EVOL, V24, P252, DOI 10.1007/BF02111238; Spring J, 1997, FEBS LETT, V400, P2, DOI 10.1016/S0014-5793(96)01351-8; STARK MJR, 1989, YEAST, V5, P35, DOI 10.1002/yea.320050106	25	1328	1364	1	116	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					708	713		10.1038/42711	http://dx.doi.org/10.1038/42711			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192896	Bronze			2022-12-28	WOS:A1997XD86900055
J	Ginzberg, E				Ginzberg, E			Managed care and the competitive market in health care - What they can and cannot do	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Ginzberg, E (corresponding author), COLUMBIA UNIV,EISENHOWER CTR CONSERVAT HUMAN RESOURCES,MAIL CODE 7740,2960 BROADWAY,NEW YORK,NY 10027, USA.							*AM HOSP ASS, 1997, EM TRENDS, P1; Arrow Kenneth, 1963, AM ECON REV, V53, P942; COLEMAN D, 1996, MANAGED HEALTHCARE, V6, P30; *DEL TOUCH TOHM IN, 1994, US HOSP FUT HLTH CAR; Drake DF, 1997, JAMA-J AM MED ASSOC, V277, P560, DOI 10.1001/jama.277.7.560; Ginzberg E, 1997, NEW ENGL J MED, V336, P1018, DOI 10.1056/NEJM199704033361411; Ginzberg E, 1996, ACAD MED, V71, P1147, DOI 10.1097/00001888-199611000-00012; HOFFMANN C, 1996, CHRONIC CARE AM 21 C; KRUEGER AB, 1997, 5891 NAT BUR EC RES; MCCUE M, 1997, MANAGED HEALTHCARE, V7, P24; McLaughlin DB, 1996, HEALTH AFFAIR, V15, P180, DOI 10.1377/hlthaff.15.3.180; Smith Adam, 1937, WEALTH NATIONS; WECHSLER J, 1997, MANAGED HEALTHCARE, V7, P16	13	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	1997	277	22					1812	1813		10.1001/jama.277.22.1812	http://dx.doi.org/10.1001/jama.277.22.1812			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC499	9178799				2022-12-28	WOS:A1997XC49900039
J	Molineaux, L				Molineaux, L			Nature's experiment: What implications for malaria prevention?	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM TRANSMISSION; GAMBIAN CHILDREN; MORTALITY; PROGRAM											ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; Binka FN, 1996, TROP MED INT HEALTH, V1, P147; DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0; GREENWOOD BM, 1988, LANCET, V1, P1121; Lengeler C, 1997, PARASITOL TODAY, V13, P123, DOI 10.1016/S0169-4758(97)84870-3; MBOGO CNM, 1995, AM J TROP MED HYG, V52, P201, DOI 10.4269/ajtmh.1995.52.201; MBOGO CNM, 1993, AM J TROP MED HYG, V49, P2345; MOLINEAUX L, 1985, HLTH POLICY SOCIAL P, P13; MOLINEAUX L, IN PRESS AM TROP MED; Nevill CG, 1996, TROP MED INT HEALTH, V1, P139; SNOW RW, 1994, ACTA TROP, V57, P289, DOI 10.1016/0001-706X(94)90074-4; SNOW RW, 1995, PARASITOL TODAY, V11, P188, DOI 10.1016/0169-4758(95)80156-1; TRAPE JF, 1987, T ROY SOC TROP MED H, V81, P34	13	24	24	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1636	1637		10.1016/S0140-6736(97)22023-4	http://dx.doi.org/10.1016/S0140-6736(97)22023-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186376				2022-12-28	WOS:A1997XD10000002
J	Collins, MJ				Collins, MJ			A child's pain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1668	1668		10.1001/jama.277.21.1668	http://dx.doi.org/10.1001/jama.277.21.1668			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169883				2022-12-28	WOS:A1997XB08800010
J	Lambert, TW; Goldacre, MJ; Parkhouse, J				Lambert, TW; Goldacre, MJ; Parkhouse, J			Intentions of newly qualified doctors to practise in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article											Lambert, TW (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,MED CAREERS RES GRP,UNIT HLTH CARE EPIDEMIOL,OXFORD OX3 7LF,ENGLAND.			Lambert, Trevor/0000-0001-9688-3036				Lambert TW, 1996, BRIT MED J, V313, P19, DOI 10.1136/bmj.313.7048.19; PARKHOUSE J, 1991, DOCTORS CAREERS AIMS	2	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 31	1997	314	7094					1591	1592		10.1136/bmj.314.7094.1591	http://dx.doi.org/10.1136/bmj.314.7094.1591			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9186168	Green Published			2022-12-28	WOS:A1997XC50000022
J	Shorr, RI; Ray, WA; Daugherty, JR; Griffin, MR				Shorr, RI; Ray, WA; Daugherty, JR; Griffin, MR			Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANGIOTENSIN-CONVERTING ENZYME; ACUTE MYOCARDIAL-INFARCTION; DIABETIC-PATIENTS; AUTONOMIC NEUROPATHY; BETA-BLOCKERS; PROPRANOLOL; UNAWARENESS; INHIBITORS; METOPROLOL; ATENOLOL	Context.-beta-Blockers and angiotensin-converting enzyme (ACE) inhibitors are effective antihypertensive agents for patients with diabetes mellitus, However, beta-blockers attenuate some components of the autonomic response to hypoglycemia and could increase the risk of hypoglycemia. ACE inhibitors may increase insulin sensitivity and predispose users to hypoglycemia. Objective.-To determine whether use of cardioselective beta-blockers, nonselective beta-blockers, ACE inhibitors, thiazide diuretics, calcium channel blockers, or other antihypertensive drugs alters the risk of developing serious hypoglycemia among older persons prescribed insulin or sulfonylureas, Design.-Retrospective cohort study, Setting.-Tennessee Medicaid Program, Patients.-A total of 13 559 elderly (mean age, 78+/-7 years) Medicaid enrollees, who were prescribed insulin (n=5171, 38%) or sulfonylureas (n=8368, 62%) from 1985 through 1989, These enrollees contributed a total of 33 107 person-years of insulin or sulfonylurea use for follow-up. Measurements.-Hospitalization, emergency department admission, or death associated with hypoglycemic symptoms and a concomitant blood glucose determination of less than 2.8 mmol/L (50 mg/dL), Results.-We identified 598 persons with an episode of serious hypoglycemia during the study period, The rate of serious hypoglycemia was 2.01 per 100 person-years among those who were not prescribed antihypertensives. Crude rates of serious hypoglycemia were highest among users of ACE inhibitors (2.47 per 100 person-years) and lowest among users of cardioselective beta-blockers (1.23 per 100 person-years), However, when we controlled for demographic characteristics and markers of comorbidity, there was no statistically significant increase or decrease in risk of serious hypoglycemia among users of any class of antihypertensive agents compared with nonusers of antihyperiensive drugs. Using nonselective beta-blockers as the reference group, each of these agents was associated with a lower, but not statistically significant, risk of hypoglycemia. Conclusions.-In this population, specific antihypertensive drug therapy had little impact an the risk of hypoglycemia in older diabetic patients. Therapy should be chosen based on other considerations of safety and effectiveness.	UNIV TENNESSEE,MEMPHIS COLL MED,DEPT PREVENT MED,MEMPHIS,TN; VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,DIV PHARMACOEPIDEMIOL,NASHVILLE,TN 37212	University of Tennessee System; University of Tennessee Health Science Center; Vanderbilt University	Shorr, RI (corresponding author), METHODIST HOSP MEMPHIS,DEPT MED EDUC,1265 UNION AVE,MEMPHIS,TN 38104, USA.				NATIONAL INSTITUTE ON AGING [K08AG000559] Funding Source: NIH RePORTER; NIA NIH HHS [K08-AG00559] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*1ST INT STUD INF, 1986, LANCET, V2, P57; ARAUZPACHECO C, 1990, AM J MED, V89, P811, DOI 10.1016/0002-9343(90)90227-5; *AUSTR SWED PIND S, 1983, EUR HEART J, V4, P367; BARNETT AH, 1980, BRIT MED J, V280, P976, DOI 10.1136/bmj.280.6219.976; *BET BLOCK HEART A, 1982, JAMA-J AM MED ASSOC, V247, P1707; DEACON SP, 1977, BRIT MED J, V2, P1255, DOI 10.1136/bmj.2.6097.1255; Fatourechi V, 1996, MAYO CLIN PROC, V71, P53, DOI 10.4065/71.1.53; Harris M I, 1990, Clin Geriatr Med, V6, P703; HEPBURN DA, 1990, DIABETIC MED, V7, P711, DOI 10.1111/j.1464-5491.1990.tb01475.x; HERINGS RMC, 1995, LANCET, V345, P1195, DOI 10.1016/S0140-6736(95)91988-0; HJALMARSON A, 1981, LANCET, V2, P823; *JOINT NAT COMM DE, 1993, ARCH INTERN MED, V153, P154; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; KERR D, 1990, BRIT J CLIN PHARMACO, V29, P685, DOI 10.1111/j.1365-2125.1990.tb03689.x; KJEKSHUS J, 1990, EUR HEART J, V11, P43, DOI 10.1093/oxfordjournals.eurheartj.a059591; *MIAMI TRIAL RES G, 1985, EUR HEART J, V6, P199; *NORW MULT STUD GR, 1981, NEW ENGL J MED, V304, P801; PAYNE CD, 1987, GEN LINEAR INTERACTI; RETT K, 1988, NEW ENGL J MED, V319, P1609; RYDER REJ, 1990, BMJ-BRIT MED J, V301, P783, DOI 10.1136/bmj.301.6755.783; TSE WY, 1994, DIABETIC MED, V11, P137, DOI 10.1111/j.1464-5491.1994.tb02009.x; US Dept of Health and Human Services . International Classification of Diseases, 1988, INT CLASS DIS; WALLIN JD, 1987, ARCH INTERN MED, V147, P654, DOI 10.1001/archinte.147.4.654; *WORK GROUP HYP DI, 1987, ARCH INTERN MED, V147, P830; 1993, DIABETES CARE, V16, P1394	25	79	82	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					40	43		10.1001/jama.278.1.40	http://dx.doi.org/10.1001/jama.278.1.40			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207336				2022-12-28	WOS:A1997XG38700034
J	Tanchot, C; Lemonnier, FA; Perarnau, B; Freitas, AA; Rocha, B				Tanchot, C; Lemonnier, FA; Perarnau, B; Freitas, AA; Rocha, B			Differential requirements for survival and proliferation of CD8 naive or memory T cells	SCIENCE			English	Article							LYMPHOCYTES-T; HOMEOSTATIC REGULATION; POSITIVE SELECTION; MICE; ANTIGEN; EXPRESSION; VIRUS; IDENTIFICATION; SPECIFICITY; MECHANISMS	The requisite molecular interactions for CD8 T cell memory were determined by comparison of monoclonal naive and memory CD8(+) T cells bearing the T cell receptor (TCR) for the HY antigen. Naive T cells required only the right major histocompatibility complex (MHC) class I-restricting molecule to survive; to expand, they also needed antigen. In contrast, for survival, memory cells did not require the restricting MHC allele, but needed only a nonspecific class I; for expansion the correct class I, but not antigen, was required. Thus, maintenance of CD8 T cell memory still required TCR-MHC class I interactions, but memory T cells may have a lower functional activation threshold that facilitates secondary responses.	INST NECKER,INSERM U345,F-75015 PARIS,FRANCE; INST PASTEUR,UNITE IMMUN CELLULAIRE ANTIVIRALE,PARIS,FRANCE; INST PASTEUR,LAB DYNAM LYMPHOCYTAIRES,CNRS,URA 1961,F-75015 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			freitas, antonio/A-2482-2013	freitas, antonio/0000-0001-6392-7178; Tanchot, Corinne/0000-0002-2913-1755				Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; BACHMANN MF, 1995, J IMMUNOL, V155, P3727; BRUNO L, 1995, IMMUNITY, V2, P37, DOI 10.1016/1074-7613(95)90077-2; BUDD RC, 1987, J IMMUNOL, V138, P3120; DELASSUS S, 1994, J IMMUNOL, V152, P2411; DESTGROTH SF, 1966, J EXP MED, V124, P347, DOI 10.1084/jem.124.3.347; DOHERTY PC, 1994, CURR OPIN IMMUNOL, V6, P545, DOI 10.1016/0952-7915(94)90139-2; FREITAS AA, 1993, IMMUNOL TODAY, V14, P25, DOI 10.1016/0167-5699(93)90320-K; Freitas AA, 1996, EUR J IMMUNOL, V26, P2640, DOI 10.1002/eji.1830261115; FREITAS AA, 1975, EUR J IMMUNOL, V5, P831, DOI 10.1002/eji.1830051207; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOSTROM ME, 1979, VIROLOGY, V98, P336, DOI 10.1016/0042-6822(79)90557-9; LYNCH F, 1989, EUR J IMMUNOL, V19, P223, DOI 10.1002/eji.1830190202; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; OWEN JA, 1982, CELL IMMUNOL, V67, P49, DOI 10.1016/0008-8749(82)90198-8; Pascolo S, 1997, J EXP MED, V185, P2043, DOI 10.1084/jem.185.12.2043; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROCHA B, 1995, J EXP MED, V181, P993, DOI 10.1084/jem.181.3.993; ROCHA B, 1989, EUR J IMMUNOL, V19, P1137, DOI 10.1002/eji.1830190626; ROCHA B, UNPUB; SELIN LK, 1994, CURR OPIN IMMUNOL, V6, P553, DOI 10.1016/0952-7915(94)90140-6; Selin LK, 1996, J EXP MED, V183, P2489, DOI 10.1084/jem.183.6.2489; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; TANCHOT C, 1995, EUR J IMMUNOL, V25, P2127, DOI 10.1002/eji.1830250802; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; VANSANTEN HM, 1995, J EXP MED, V181, P787, DOI 10.1084/jem.181.2.787; VONBOEHMER H, 1993, J EXP MED, V177, P891, DOI 10.1084/jem.177.4.891; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333	39	723	732	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2057	2062		10.1126/science.276.5321.2057	http://dx.doi.org/10.1126/science.276.5321.2057			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197272				2022-12-28	WOS:A1997XG74800070
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			A cell growth switch	SCIENCE			English	Article																		Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1891	1891		10.1126/science.276.5320.1891	http://dx.doi.org/10.1126/science.276.5320.1891			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206844				2022-12-28	WOS:A1997XF10300058
J	Gosser, YQ; Nomanbhoy, TK; Aghazadeh, B; Manor, D; Combs, C; Cerione, RA; Rosen, MK				Gosser, YQ; Nomanbhoy, TK; Aghazadeh, B; Manor, D; Combs, C; Cerione, RA; Rosen, MK			C-terminal binding domain of rho GDP-dissociation inhibitor directs N-terminal inhibitory peptide to GTPases	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; REGULATORY PROTEIN; GTP; SPECTROSCOPY; ASSIGNMENTS; AFFINITIES; MEMBRANES; P20	The Rho GDP-dissociation inhibitors (GDIs) negatively regulate Rho-family GTPases(1,2). The inhibitory activity of GDI derives both from an ability to bind the carboxy-terminal isoprene of Rho family members and extract them from membranes(3,4), and from inhibition of GTPase cycling between the GTP- and GDP-bound states(4,5). Here we demonstrate that these binding and inhibitory functions of rhoGDI can be attributed to two structurally distinct regions of the protein, A carboxy-terminal folded domain of relative molecular mass 16,000 (M-r 16K) binds strongly to the Rho-family member Cdc42, yet has little effect on the rate of nucleotide dissociation from the GTPase. The solution structure of this domain shows a beta-sandwich motif with a narrow hydrophobic cleft that binds isoprenes, and an exposed surface that interacts with the protein portion of Cdc42. The amino-terminal region of rhoGDI is unstructured in the absence of target and contributes little to binding, but is necessary to inhibit nucleotide dissociation from Cdc42. These results lead to a model of rhoGDI function in which the carboxy-terminal binding domain targets the amino-terminal inhibitory region to GTPases, resulting in membrane extraction and inhibition of nucleotide cycling.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,DEPT BIOCHEM MOL & CELL BIOL,ITHACA,NY 14853; CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM PHYSIOL & BIOPHYS,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Cornell University								ALCMAN G, 1996, J BIOL CHEM, V271, P30366; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BRUNGER AT, 1993, XPLOR MANUAL; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Danley DE, 1996, J IMMUNOL, V157, P500; EDISON AS, 1994, METHOD ENZYMOL, V239, P3; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GHOMASHCHI F, 1995, BIOCHEMISTRY-US, V34, P11910, DOI 10.1021/bi00037a032; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HOFFMANN RW, 1989, CHEM REV, V89, P1841, DOI 10.1021/cr00098a009; ISOMURA M, 1991, ONCOGENE, V6, P119; KAY LE, 1995, CURR OPIN STRUC BIOL, V5, P674, DOI 10.1016/0959-440X(95)80061-1; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NICHOLS A, 1990, PROTEIN-STRUCT FUNCT, V11, P281; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PLATKO JV, 1995, P NATL ACAD SCI USA, V92, P2974, DOI 10.1073/pnas.92.7.2974; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; SPERA S, 1991, J AM CHEM SOC, V117, P5491; STORCH J, 1993, MOL CELL BIOCHEM, V123, P45, DOI 10.1007/BF01076474; UEDA T, 1990, J BIOL CHEM, V265, P9373; WIBERG KB, 1988, J AM CHEM SOC, V110, P8029, DOI 10.1021/ja00232a012; WU JE, IN PRESS J BIOL CHEM	30	146	152	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 19	1997	387	6635					814	819		10.1038/42961	http://dx.doi.org/10.1038/42961			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF144	9194563	Bronze			2022-12-28	WOS:A1997XF14400053
J	BujBello, A; Adu, J; Pinon, LGP; Horton, A; Thompson, J; Rosenthal, A; Chinchetru, M; Buchman, VL; Davies, AM				BujBello, A; Adu, J; Pinon, LGP; Horton, A; Thompson, J; Rosenthal, A; Chinchetru, M; Buchman, VL; Davies, AM			Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase	NATURE			English	Article							NEUROTROPHIC FACTOR; SURVIVAL FACTOR; NEURONS; GDNF; PROTEIN; TRKB; CD14	Neurturin (NTN)(1) is a recently identified homologue of glial-cellline-derived neurotrophic factor (GDNF)(2). Both factors promote the survival of a variety of neurons(1-5), and GDNF is required for the development of the enteric nervous system and kidney(6-8). GDNF signals through a receptor complex consisting of the receptor tyrosine kinase Ret and a glycosyl-phosphatidylinositol (GPI)-linked receptor termed GDNFR-alpha(9-13). Here we report the cloning of a new GPI-linked receptor termed NTNR-alpha that is homologous with GDNFR-alpha and is widely expressed in the nervous system and other tissues. By using microinjection to introduce expression plasmids into neurons, we show that coexpression of NTNR-alpha with Ret confers a survival response to neurturin but not GDNF, and that coexpression of GDNFR-alpha with Ret confers a survival response to GDNF but not neurturin. Our findings indicate that GDNF and neurturin promote neuronal survival by signalling through similar multicomponent receptors that consist of a common receptor tyrosine kinase and a member of a GPI-linked family of receptors that determines ligand specificity.	UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9AT,FIFE,SCOTLAND; GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080	University of St Andrews; Roche Holding; Genentech			Adu, Jimi/R-8434-2019; Buchman, Vladimir L/A-4814-2010; BUJ-BELLO, Anna/J-7556-2013; Davies, Alun M/A-4334-2010	Buchman, Vladimir L/0000-0002-7631-8352; Davies, Alun M/0000-0001-5841-8176; Chinchetru, Miguel Angel/0000-0002-0559-7403; Adu, Jimi/0000-0002-7838-9699	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Baka ID, 1996, MOL CELL NEUROSCI, V7, P289, DOI 10.1006/mcne.1996.0022; BUJBELLO A, 1994, DEVELOPMENT, V120, P1573; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; DAVIES AM, 1995, EMBO J, V14, P4482, DOI 10.1002/j.1460-2075.1995.tb00127.x; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; GERBER LD, 1992, J BIOL CHEM, V267, P12168; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Ninkina N, 1996, EMBO J, V15, P6385, DOI 10.1002/j.1460-2075.1996.tb01029.x; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657	25	249	262	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					721	724		10.1038/42729	http://dx.doi.org/10.1038/42729			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192899	Bronze			2022-12-28	WOS:A1997XD86900058
J	Ross, LF; Rubin, DT; Siegler, M; Josephson, MA; Thistlethwaite, JR; Woodle, ES				Ross, LF; Rubin, DT; Siegler, M; Josephson, MA; Thistlethwaite, JR; Woodle, ES			Ethics of a paired-kidney-exchange program	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							US TRANSPLANT CENTERS; RENAL-TRANSPLANTATION; LIVING DONORS; ATTITUDES; ALLOGRAFTS; REGISTRY; DONATION				Ross, LF (corresponding author), UNIV CHICAGO, MACLEAN CTR CLIN MED ETH, 5841 S MARYLAND AVE, MC 6098, CHICAGO, IL 60637 USA.		Woodle, E. Steve/N-8059-2013	Woodle, E. Steve/0000-0003-4280-0842				ALEXANDRE GPJ, 1987, TRANSPLANT P, V19, P4538; [Anonymous], 1991, LANCET, V337, P1470; BAY WH, 1987, ANN INTERN MED, V106, P719, DOI 10.7326/0003-4819-106-5-719; BIA MJ, 1995, TRANSPLANTATION, V60, P322, DOI 10.1097/00007890-199508270-00003; BURLEY JA, 1985, TRANSPL P, V17, P123; Cecka J M, 1995, Clin Transpl, P363; Cecka J M, 1995, Clin Transpl, P1; COOK DJ, 1987, TRANSPLANT P, V19, P4549; FELLNER CH, 1971, NEW ENGL J MED, V284, P582, DOI 10.1056/NEJM197103182841105; FELLNER CH, 1970, AM J PSYCHIAT, V126, P1245, DOI 10.1176/ajp.126.9.1245; GOUGE F, 1990, TRANSPLANT P, V22, P2409; HAKIM RM, 1984, KIDNEY INT, V25, P930, DOI 10.1038/ki.1984.112; KOHRMAN AF, 1992, PEDIATRICS, V89, P1116; LEVEY AS, 1986, NEW ENGL J MED, V314, P914, DOI 10.1056/NEJM198604033141409; LIOUNIS B, 1988, MED J AUSTRALIA, V148, P436, DOI 10.5694/j.1326-5377.1988.tb139566.x; NAJARIAN JS, 1992, LANCET, V340, P807, DOI 10.1016/0140-6736(92)92683-7; NELSON PW, 1992, AM J SURG, V164, P541, DOI 10.1016/S0002-9610(05)81197-3; OJO AO, 1994, AM J KIDNEY DIS, V24, P59, DOI 10.1016/S0272-6386(12)80160-0; RAPAPORT FT, 1986, TRANSPLANT P, V18, P5; RUSSELL S, 1993, PATIENT EDUC COUNS, V21, P89, DOI 10.1016/0738-3991(93)90063-3; SADLER HH, 1971, SEMIN PSYCHIAT, V3, P86; SIEGLER M, 1992, CAMBRIDGE Q HLTH CAR, V1, P320; SIMMONS RG, 1971, J AMER MED ASSOC, V215, P909; SIMMONS RG, 1971, SEMIN PSYCHIAT, V3, P102; SINGER PA, 1989, NEW ENGL J MED, V321, P620, DOI 10.1056/NEJM198908313210919; SMITH MD, 1986, AM J KIDNEY DIS, V8, P223, DOI 10.1016/S0272-6386(86)80030-0; SPITAL A, 1994, TRANSPLANTATION, V57, P1722; Spital A, 1996, TRANSPLANTATION, V61, P374, DOI 10.1097/00007890-199602150-00007; SPITAL A, 1989, TRANSPLANTATION, V48, P243, DOI 10.1097/00007890-198908000-00012; SPITAL A, 1988, ARCH INTERN MED, V148, P1077, DOI 10.1001/archinte.148.5.1077; SPITAL A, 1994, TRANSPLANTATION, V58, P268; STARZL TE, 1987, TRANSPLANT P, V19, P4492; Starzl TE., 1992, PUZZLE PEOPLE MEMOIR, V1st ed; TANABE K, 1995, TRANSPLANT P, V27, P1020; TOMA H, 1994, UROL CLIN N AM, V21, P299; *UN NETW ORG SHAR, 1996, 1996 ANN REP US SCI; WILLIAMS SL, 1986, ANN INTERN MED, V105, P1, DOI 10.7326/0003-4819-105-1-1; YOUNGNER SJ, 1993, JAMA-J AM MED ASSOC, V269, P2769, DOI 10.1001/jama.269.21.2769	38	133	135	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	1997	336	24					1752	1755		10.1056/NEJM199706123362412	http://dx.doi.org/10.1056/NEJM199706123362412			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD543	9180096				2022-12-28	WOS:A1997XD54300012
J	Breslin, PAS; Beauchamp, GK				Breslin, PAS; Beauchamp, GK			Salt enhances flavour by suppressing bitterness	NATURE			English	Letter							SODIUM-CHLORIDE; MIXTURES				Breslin, PAS (corresponding author), MONELL CHEM SENSES CTR, 3500 MARKET ST, PHILADELPHIA, PA 19104 USA.			Breslin, Paul/0000-0001-5988-8401				BRAND JG, 1992, IFT BAS SYM, V7, P517; Breslin PAS, 1996, TRENDS FOOD SCI TECH, V7, P390, DOI 10.1016/S0924-2244(96)10039-X; Breslin PAS, 1995, CHEM SENSES, V20, P609, DOI 10.1093/chemse/20.6.609; DEGRAAF C, 1989, CHEM SENSES, V14, P81; Denton D.A., 1982, HUNGER SALT; FORSYTHE RH, 1980, BIOL BEHAVIORAL ASPE, P221; GILLETTE M, 1985, FOOD TECHNOL-CHICAGO, V39, P47; KEMP SE, 1994, J FOOD SCI, V59, P682, DOI 10.1111/j.1365-2621.1994.tb05592.x; LAWLESS HT, 1979, J COMP PHYSIOL PSYCH, V93, P538, DOI 10.1037/h0077582; Michell A R, 1989, Nutr Res Rev, V2, P149, DOI 10.1079/NRR19890012; WOSKOW MH, 1969, FOOD TECHNOL-CHICAGO, V23, P1364	11	158	163	2	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					563	563		10.1038/42388	http://dx.doi.org/10.1038/42388			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177340				2022-12-28	WOS:A1997XC52200035
J	Cheng, AC; vanHoek, AN; Yeager, M; Verkman, AS; Mitra, AK				Cheng, AC; vanHoek, AN; Yeager, M; Verkman, AS; Mitra, AK			Three-dimensional organization of a human water channel	NATURE			English	Article							ELECTRON CRYSTALLOGRAPHY; AQUAPORIN CHIP; PROTEIN; RESOLUTION; MEMBRANE; PROJECTION; MODEL; RECONSTITUTION; CRYOMICROSCOPY; PURIFICATION	Aquaporins (AQP) are members of the major intrinsic protein (MIP) superfamily of integral membrane proteins and facilitate water transport in various eukaryotes and prokaryotes(1,2). The archetypal aquaporin AQP1 is a partly glycosylated water-selective channel(3,4) that is widely expressed in the plasma membranes of several water-permeable epithelial and endothelial cells(2,5). Here we report the three-dimensional structure of deglycosylated, human erythrocyte AQP1,determined at 7 Angstrom resolution in the membrane plane by electron crystallography of frozen-hydrated two-dimensional crystals(6,7). The structure has an inplane, intramolecular 2-fold axis of symmetry located in the hydrophobic core of the bilayer. The AQP1 monomer is composed of six membrane-spanning, tilted alpha-helices. These helices form a barrel that encloses a vestibular region leading to the water-selective channel, which is outlined by densities attributed to the functionally important NPA boxes(8) and their bridges to the surrounding helices. The intramolecular symmetry within the AQP1 molecule represents a new moth for the topology and design of membrane protein channels, and is a simple and elegant solution to the problem of bidirectional transport across the bilayer.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA USA; SCRIPPS CLIN, DIV CARDIOVASC DIS, LA JOLLA, CA 92037 USA	Scripps Research Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Scripps Research Institute			Mitra, Alok/P-7800-2016	Mitra, Alok/0000-0003-0891-5697; Van Hoek, Alfred/0000-0003-2724-6855				AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; DENKER BM, 1988, J BIOL CHEM, V263, P15634; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; JAP BK, 1995, J MOL BIOL, V251, P413, DOI 10.1006/jmbi.1995.0444; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; MITRA AK, 1995, NAT STRUCT BIOL, V2, P726, DOI 10.1038/nsb0995-726; MITRA AK, 1994, BIOCHEMISTRY-US, V33, P12735, DOI 10.1021/bi00209a001; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; Sather William A., 1994, Current Opinion in Neurobiology, V4, P313, DOI 10.1016/0959-4388(94)90091-4; SMITH BL, 1991, J BIOL CHEM, V266, P6407; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; VANHOEK AN, 1995, BIOCHEMISTRY-US, V34, P2212, DOI 10.1021/bi00007a015; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; Verkman AS, 1993, WATER CHANNELS; WALZ T, 1995, NAT STRUCT BIOL, V2, P730, DOI 10.1038/nsb0995-730; Walz T, 1996, J MOL BIOL, V264, P907, DOI 10.1006/jmbi.1996.0686; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	29	236	249	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 5	1997	387	6633					627	630		10.1038/42517	http://dx.doi.org/10.1038/42517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177354				2022-12-28	WOS:A1997XC52200062
J	Sechi, LA; Kronenberg, F; DeCarli, S; Falleti, E; Zingaro, L; Catena, C; Utermann, G; Bartoli, E				Sechi, LA; Kronenberg, F; DeCarli, S; Falleti, E; Zingaro, L; Catena, C; Utermann, G; Bartoli, E			Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	11th Meeting of the American-Society-of-Hypertension	MAY 15-18, 1996	NEW YORK, NY	Amer Soc Hypertens			CORONARY HEART-DISEASE; BLOOD-PRESSURE; DENSITY LIPOPROTEIN; PLASMA-LIPIDS; RISK FACTOR; ATHEROSCLEROSIS; QUANTITATION; PHENOTYPES; LP(A); RECOMMENDATIONS	Objective.-To investigate the association between lipoprotein(a) [Lp(a)] and other plasma lipids and apolipoproteins and target-organ damage (TOD) in patients with arteria[ hypertension. Design.-Cross-sectional study of a case series. Setting.-University medical center. Participants.-Lipoprotein(a) and apolipoproteins were analyzed in 277 untreated patients with mild to moderate essential hypertension and in 102 healthy controls. Apolipoprotein(a) [apo(a)] phenotypes were additionally analyzed in an independent sample set of 106 hypertensive and 105 control subjects. Main Outcome Measures.-Staging of TOD obtained according to World Health Organization guidelines by clinical evaluation, and laboratory tests including measurments of creatinine clearance, proteinuria, ophthalmoscopy, electrocardiography, echocardiography, and ultrasound examination of major arteries; levels of lipids, apolipoproteins, Lp(a), fibrinogen, and apo(a) phenotypes. Results.-Blood pressure, duration of hypertension, and levels of total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, Lp(a), and fibrinogen were significantly related to the presence and severity of TOD in univariate analysis. Stepwise multivariate analysis showed Lp(a) levels (P<.001) to be the best discriminator of the presence of TOD, followed by systolic blood pressure (P<.001), duration of hypertension (P=.01), and low-density lipoprotein cholesterol (P=.04). The Lp(a) levels were related to TOD independent of the level of blood pressure. We confirmed this association between Lp(a) concentrations and severity of TOD in a second independent sample set and observed a significantly higher frequency of low-molecular-weight apo(a) isoforms with increasing severity of TOD (P=.02). Conclusions.-Lipoprotein(a) and apo(a) phenotype are sensitive indicators of the severity of TOD in patients with essential hypertension, and their evaluation might permit identification of hypertensive subjects liable to the development of organ damage. The higher frequency of low-molecular-weight apo(a) isoforms in patients with TOD demonstrates a genetically determined risk for the development of TOD in hypertensive patients.	UNIV UDINE, HYPERTENS UNIT, DEPT INTERNAL MED, I-33100 UDINE, ITALY; UNIV UDINE, DEPT LAB MED, I-33100 UDINE, ITALY; UNIV INNSBRUCK, INST MED BIOL & HUMAN GENET, A-6020 INNSBRUCK, AUSTRIA	University of Udine; University of Udine; University of Innsbruck			Kronenberg, Florian/B-1736-2008; Sechi, Leonardo Antonio/Y-3109-2018	Kronenberg, Florian/0000-0003-2229-1120; Catena, Cristiana/0000-0001-5039-435X				BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DIEKSTALL F, 1987, OPHTHALMOLOGIE, V84, P369; FLESCH M, 1994, CLIN INVESTIGATOR, V72, P944, DOI 10.1007/BF00577733; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GALLE J, 1995, CIRCULATION, V92, P1582, DOI 10.1161/01.CIR.92.6.1582; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; KANNEL WB, 1990, HYPERTENSION PATHOPH, P101; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; KRAFT HG, 1992, HUM GENET, V90, P220; Kraft HG, 1996, ATHEROSCLEROSIS, V125, P53, DOI 10.1016/0021-9150(96)05844-3; KREMPLER F, 1980, J CLIN INVEST, V65, P1483, DOI 10.1172/JCI109813; Kronenberg F, 1996, CRIT REV CL LAB SCI, V33, P495, DOI 10.3109/10408369609080056; Kronenberg F, 1996, AM J KIDNEY DIS, V27, P1, DOI 10.1016/S0272-6386(96)90026-8; KRONENBERG F, 1995, J AM SOC NEPHROL, V6, P110; LEHMANN EL, 1975, NONPARAMETRICS; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAIOLI M, 1993, DIABETOLOGIA, V36, P88, DOI 10.1007/BF00399100; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MOLGAARD J, 1992, ARTERIOSCLER THROMB, V12, P895, DOI 10.1161/01.ATV.12.8.895; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; RADER DJ, 1994, J CLIN INVEST, V93, P2758, DOI 10.1172/JCI117292; RADER DJ, 1994, ANN INTERN MED, V120, P1012, DOI 10.7326/0003-4819-120-12-199406150-00008; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; ROSSI E, 1988, THROMB RES, V52, P453, DOI 10.1016/0049-3848(88)90029-1; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; SANDHOLZER C, 1992, ARTERIOSCLER THROMB, V12, P1214, DOI 10.1161/01.ATV.12.10.1214; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCHEIE HG, 1953, AMA ARCH OPHTHALMOL, V49, P117; SCHREINER PJ, 1993, ARTERIOSCLER THROMB, V13, P826, DOI 10.1161/01.ATV.13.6.826; SECHI LA, 1992, METABOLISM, V41, P1261, DOI 10.1016/0026-0495(92)90019-7; SHINTANI S, 1993, STROKE, V24, P965, DOI 10.1161/01.STR.24.7.965; STEINMETZ A, 1993, CLIN INVESTIGATOR, V71, P145; TSURUMI Y, 1995, J AM COLL CARDIOL, V26, P1242, DOI 10.1016/0735-1097(95)00321-5; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; ZANCHETTI A, 1993, HYPERTENSION, V22, P392; ZENKER G, 1986, STROKE, V17, P942, DOI 10.1161/01.STR.17.5.942	50	58	59	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1689	1695		10.1001/jama.277.21.1689	http://dx.doi.org/10.1001/jama.277.21.1689			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XB088	9169895				2022-12-28	WOS:A1997XB08800029
J	Chang, H; Riese, DJ; Gilbert, W; Stern, DF; McMahan, UJ				Chang, H; Riese, DJ; Gilbert, W; Stern, DF; McMahan, UJ			Ligands for ErbB-family receptors encoded by a neuregulin-like gene	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; CARDIAC DEVELOPMENT; HEREGULIN; ACTIVATION; MEMBER; ARIA; HER4/P180(ERBB4); REQUIREMENT; EXPRESSION; SUBSET	Neuregulins (also called ARIA(1), GGF(2), heregulin(3) or NDF4) are a group of polypeptide factors that arise from alternative RNA splicing of a single gene. Through their interaction with the ErbB family of receptors (ErbB2, ErbB3 and ErbB4), neuregulins help to regulate cell growth and differentiation in many tissue(5-7). Here we report the cloning of a second neuregulin-like gene, neuregulin-2. The encoded product of the neuregulin-2 gene has a motif structure similar to that of neuregulins and an alternative splicing site in the epidermal growth factor(EGF)-like domain gives rise to two isoforms (alpha and beta). Northern blot and in situ hybridization analysis of adult rat tissues indicate that expression of neuregulin-2 is highest in the cerebellum, and the expression pattern is different from that of neuregulins. Recombinant neuregulin-2 beta induces the tyrosine-phosphorylation of ErbB2, ErbB3 and ErbB4 in cell Lines expressing all of these ErbB-family receptors. However, in cell lines with defined combinations of ErbBs, neuregulin-2 beta only activates those with ErbB3 and/or ErbB4, suggesting that signalling by neuregulin-2 is mediated by ErbB3 and/or ErbB4 receptors.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06340; YALE UNIV,DEPT PATHOL,NEW HAVEN,CT 06340; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Yale University; Yale University; Harvard University	Chang, H (corresponding author), STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305, USA.		Riese, David/AAF-3581-2020	Riese, David/0000-0002-8823-5802				BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; Chang H., 1994, Society for Neuroscience Abstracts, V20, P1694; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; DOBASHI Y, 1991, ONCOGENE, V6, P1151; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMKE G, 1993, NATURE, V362, P291, DOI 10.1038/362291a0; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	29	255	298	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					509	512		10.1038/387509a0	http://dx.doi.org/10.1038/387509a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168114				2022-12-28	WOS:A1997XB47900050
J	Lang, BF; Burger, G; OKelly, CJ; Cedergren, R; Golding, GB; Lemieux, C; Sankoff, D; Turmel, M; Gray, MW				Lang, BF; Burger, G; OKelly, CJ; Cedergren, R; Golding, GB; Lemieux, C; Sankoff, D; Turmel, M; Gray, MW			An ancestral mitochondrial DNA resembling a eubacterial genome in miniature	NATURE			English	Article							COMPLETE SEQUENCE; ENDOSYMBIONT HYPOTHESIS; GENE CONTENT; ORGANIZATION; RECLINOMONAS; EUKARYOTES; EVOLUTION	Mitochondria, organelles specialized in energy conservation reactions in eukaryotic cells, have evolved from eubacteria-like endosymbionts(1-3) whose closest known relatives are the rickettsial group of alpha-proteobacteria(4,5). Because characterized mitochondrial genomes vary markedly in structure(3), it has been impossible to infer from them the initial form of the proto-mitochondrial genome. This would require the identification of minimally derived mitochondrial DNAs that better reflect the ancestral state, Here we describe such a primitive mitochondrial genome, in the freshwater protozoon Reclinomonas americana(6). This protist displays ultrastructural characteristics that ally it with the retortamonads(7,8), a protozoan group that lacks mitochondria(8,9). R. americana mtDNA (69,034 base pairs) contains the largest collection of genes (97) so far identified in any mtDNA, including genes for 5S ribosomal RNA, the RNA component of RNase P, and at least 18 proteins not previously known to be encoded in mitochondria, Most surprising are four genes specifying a multisubunit, eubacterial-type RNA polymerase. Features of gene content together with eubacterial characteristics of genome organization and expression not found before in mitochondrial genomes indicate that R. americana mtDNA more closely resembles the ancestral proto-mitochondrial genome than any other mtDNA investigated to date.	DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX,NS B3H 4H7,CANADA; UNIV MONTREAL,DEPT BIOCHIM,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,CTR RECH MATH,MONTREAL,PQ H3C 3J7,CANADA; BIGELOW LAB OCEAN SCI,BOOTHBAY HARBOR,ME 04575; MCMASTER UNIV,DEPT BIOL,HAMILTON,ON L8S 4K1,CANADA; UNIV LAVAL,DEPT BIOCHIM,QUEBEC CITY,PQ G1K 7P4,CANADA; DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX,NS B3H 4H7,CANADA	Dalhousie University; Universite de Montreal; Universite de Montreal; Bigelow Laboratory for Ocean Sciences; McMaster University; Laval University; Dalhousie University			Lemieux, Claude/L-8831-2015; Turmel, Monique/AAC-9752-2020	Lemieux, Claude/0000-0001-9580-8042; Turmel, Monique/0000-0001-7060-035X; Gray, Michael/0000-0001-7125-2625				BOGORAD L, 1991, MOL BIOL PLASTIDS, P93; Brugerolle G., 1990, P259; Burger G, 1996, P NATL ACAD SCI USA, V93, P2328, DOI 10.1073/pnas.93.6.2328; BURGER G, 1995, J MOL BIOL, V245, P522, DOI 10.1006/jmbi.1994.0043; CAVALIERSMITH T, 1987, NATURE, V326, P332, DOI 10.1038/326332a0; Cermakian N, 1996, NUCLEIC ACIDS RES, V24, P648, DOI 10.1093/nar/24.4.648; Chen B, 1996, J BIOL CHEM, V271, P6537, DOI 10.1074/jbc.271.11.6537; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; FLAVIN M, 1993, J EUKARYOT MICROBIOL, V40, P172, DOI 10.1111/j.1550-7408.1993.tb04900.x; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Glick BS, 1996, PROTEIN SCI, V5, P2651, DOI 10.1002/pro.5560051229; GRAY MW, 1982, MICROBIOL REV, V46, P1; GRAY MW, 1993, CURR OPIN GENET DEV, V3, P884, DOI 10.1016/0959-437X(93)90009-E; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; GRAY MW, 1996, EVOLUTION MICROBIAL, P00109; GRAY MW, 1995, MOL BIOL PLANT MITOC, P635; ITO K, 1995, ADV CELL MOL BIOL M, V4, P35; Lang BF, 1996, J MOL BIOL, V261, P607, DOI 10.1006/jmbi.1996.0486; Lee YC, 1996, EUR J BIOCHEM, V235, P297, DOI 10.1111/j.1432-1033.1996.00297.x; Margulis L, 1970, ORIGIN EUKARYOTIC CE; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; OKELLY CJ, 1993, J EUKARYOT MICROBIOL, V40, P627, DOI 10.1111/j.1550-7408.1993.tb06120.x; REITH M, 1995, ANNU REV PLANT PHYS, V46, P549, DOI 10.1146/annurev.arplant.46.1.549; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; Siegel RW, 1996, RNA, V2, P452; WISE CA, 1991, J BIOL CHEM, V266, P19154; WOLFF G, 1994, J MOL BIOL, V237, P75, DOI 10.1006/jmbi.1994.1210; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	30	470	506	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					493	497		10.1038/387493a0	http://dx.doi.org/10.1038/387493a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168110				2022-12-28	WOS:A1997XB47900046
J	James, WPT; Nelson, M; Ralph, A; Leather, S				James, WPT; Nelson, M; Ralph, A; Leather, S			Socioeconomic determinants of health - The contribution of nutrition to inequalities in health	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRANS-FATTY-ACIDS; ANTIOXIDANTS; OBESITY	Social class differences in health are seen at all ages, with lower socioeconomic groups having greater incidence of premature and low birthweight babies, heart disease, stroke, and some cancers in adults. Risk factors including lack of breast feeding, smoking, physical inactivity, obesity, hypertension, and poor diet are clustered in the lower socioeconomic groups. The diet of the lower socioeconomic groups provides cheap energy from foods such as meat products, full cream milk, fats, sugars, preserves, potatoes, and cereals but has little intake of vegetables, fruit, and wholewheat bread. This type of diet is lower in essential nutrients such as calcium, iron, magnesium, folate, and vitamin C than that of the higher socioeconomic groups. New nutritional knowledge on the protective role of antioxidants and other dietary factors suggests that there is scope for enormous health gain if a diet rich in vegetables, fruit, unrefined cereal, fish, and small quantities of quality vegetable oils could be more accessible to poor people.	ROWETT RES INST, BUCKSBURN AB21 9SB, ABERDEEN, SCOTLAND; UNIV LONDON KINGS COLL, DEPT NUTR & DIETET, LONDON W8 7AH, ENGLAND; NATL FOOD ALLIANCE, LONDON EC2A 2BH, ENGLAND	University of Aberdeen; University of London; King's College London								Barker DJP, 1992, FETAL INFANT ORIGINS; BJORNTORP P, 1995, METABOLISM, V44, P21, DOI 10.1016/0026-0495(95)90315-1; *CENTR STAT OFF, 1996, REP 1995 96 FAM EXP; CHANDRA RK, 1993, P NUTR SOC, V52, P77, DOI 10.1079/PNS19930039; CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C; COLHOUN H, 1996, HLTH SURVEY ENGLAND; DOWLER E, 1994, NUTR DIET LONE PAREN; DUTHIE GG, 1993, ANN NY ACAD SCI, V686, P120, DOI 10.1111/j.1749-6632.1993.tb39165.x; FORD G, 1994, SOC SCI MED, V39, P1037, DOI 10.1016/0277-9536(94)90375-1; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; Gregory JR, 1995, NATL DIET NUTR SURVE, V1; James WPT, 1997, NUTR REV, V55, pS31, DOI 10.1111/j.1753-4887.1997.tb06097.x; James WPT, 1996, DIS HEART, V1442-1458; KEYS A, 1965, METABOLIS, V14, P766, DOI 10.1016/0026-0495(65)90003-X; KOLETZKO B, 1994, WORLD REV NUTR DIET, V75, P82; KUSKOWSKAWOLK A, 1993, J EPIDEMIOL COMMUN H, V47, P103, DOI 10.1136/jech.47.2.103; Leather S, 1996, MAKING MODERN MALNUT; MANN GV, 1994, LANCET, V343, P1268, DOI 10.1016/S0140-6736(94)92157-1; MCLAUCHLAN WR, 1995, BIOCHEM SOC T, V23, pS257, DOI 10.1042/bst023257s; Mills A, 1992, FOOD NUTR INTAKES BR; *MIN AGR FISH FOOD, 1981, NAT FOODS SURV 1980; *MIN AGR FISH FOOD, 1996, NAT FOOD SURV 1980; NELSON M, 1993, BUDGET STANDARDS UK; OLSEN SF, 1995, BRIT J NUTR, V73, P397, DOI 10.1079/BJN19950042; PIACHAUD D, 1996, PRICE FOOD MISSING M; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; *ROYAL COLL PHYS F, 1995, GUIDELINES HLTH PROM, V41, P1; Scholl TO, 1996, AM J CLIN NUTR, V63, P520, DOI 10.1093/ajcn/63.4.520; *SCOTT INT GUID NE, 1996, OB SCOTL INT PREV WE; *SCOTT OFF HOM HLT, 1993, SCOTT DIET REP WORK; SHARP L, 1995, J EPIDEMIOL COMMU S2, V49, pS78; Somerville SM, 1996, J PUBLIC HEALTH MED, V18, P98, DOI 10.1093/oxfordjournals.pubmed.a024469	32	436	443	2	94	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	1997	314	7093					1545	1549		10.1136/bmj.314.7093.1545	http://dx.doi.org/10.1136/bmj.314.7093.1545			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9183207	Green Published			2022-12-28	WOS:A1997XB48400036
J	Freedman, DM; Zahm, SH; Dosemeci, M				Freedman, DM; Zahm, SH; Dosemeci, M			Residential and occupational exposure to sunlight and mortality from non-Hodgkin's lymphoma: Composite (threefold) case-control study	BRITISH MEDICAL JOURNAL			English	Article							WESTERN-CANADA-MELANOMA; MALIGNANT-MELANOMA; SUN EXPOSURE; SKIN-CANCER; SOCIOECONOMIC-STATUS; CUTANEOUS MELANOMA; UNITED-STATES; RISK-FACTORS	Objective: To determine whether non-Hodgkin's lymphoma mortality is associated with sunlight exposure. Design: Three case-control studies based on death certificates of non-Hodgkin's lymphoma, melanoma, and skin cancer mortality examining associations with potential sunlight exposure from residence and occupation. Setting: 24 states in the United States. Subjects: All cases were deaths from non-Hodgkin's lymphoma, melanoma, and non-melanotic skin cancer between 1984 and 1991. Two age, sex, and race frequency matched controls per case were selected from non-cancer deaths. Main outcome measures: Odds ratios for non-Hodgkin's lymphoma, melanoma, and skin cancer from residential and occupational sunlight exposure adjusted for age, sex, race, socioeconomic status, and farming occupation. Results: Non-Hodgkin's lymphoma mortality was not positively associated with sunlight exposure based on residence. Both melanoma and skin cancer were positively associated with residential sunlight exposure. Adjusted odds ratios for residing in states with the highest sunlight exposure were 0.83 (95% confidence interval 0.81 to 0.86) for non-Hodgkin's lymphoma, 1.12 (1.06 to 1.19) for melanoma, and 1.30 (1.18 to 1.43) for skin cancer. In addition, non-Hodgkin's lymphoma mortality was not positively associated with occupational sunlight exposure (odds ratio 0.88; 0.81 to 0.96). Skin cancer was slightly positively associated with occupational sunlight exposure (1.14; 0.96 to 1.36). Conclusions: Unlike skin cancer and to some extent melanoma, non-Hodgkin's lymphoma mortality was not positively associated with exposure to sunlight The findings do not therefore support the hypothesis that sunlight exposure contributes to the rising rates of non-Hodgkin's lymphoma.	NCI,DIV CANC EPIDEMIOL & GENET,ROCKVILLE,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Freedman, DM (corresponding author), NCI,DIV CANC PREVENT & CONTROL,EPN-240J,ROCKVILLE,MD 20892, USA.		Zahm, Shelia H/B-5025-2015					ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; ADAMI J, 1995, BMJ-BRIT MED J, V311, P750, DOI 10.1136/bmj.311.7007.750b; Bentham G, 1996, BRIT MED J, V312, P1128; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; *CDC, 1994, MMWR-MORBID MORTAL W, V43, P4; DEVESA SS, 1992, CANCER RES, V52, pS5432; DUBIN N, 1990, INT J EPIDEMIOL, V19, P811, DOI 10.1093/ije/19.4.811; ELWOOD JM, 1990, INT J EPIDEMIOL, V19, P801, DOI 10.1093/ije/19.4.801; ELWOOD JM, 1984, BRIT MED J, V288, P99, DOI 10.1136/bmj.288.6411.99; ELWOOD JM, 1985, INT J CANCER, V35, P427, DOI 10.1002/ijc.2910350403; FIGGS LW, 1995, AM J IND MED, V27, P817, DOI 10.1002/ajim.4700270606; GARLAND CF, 1980, INT J EPIDEMIOL, V9, P227, DOI 10.1093/ije/9.3.227; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GOODMAN KJ, 1995, CANCER CAUSE CONTROL, V6, P451, DOI 10.1007/BF00052186; GREEN LW, 1970, PUBLIC HEALTH REP, V85, P815, DOI 10.2307/4593972; HALL P, 1995, INT J CANCER, V62, P519, DOI 10.1002/ijc.2910620505; Hartge P, 1996, J NATL CANCER I, V88, P298, DOI 10.1093/jnci/88.5.298; HARTGE P, 1992, CANCER RES, V52, pS5566; HARTGE P, 1994, CANCER SURV, V19, P423; KIRKPATRICK CS, 1990, INT J CANCER, V46, P1; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; LEE JAH, 1980, BRIT J CANCER, V41, P757, DOI 10.1038/bjc.1980.138; McMichael AJ, 1996, BRIT J CANCER, V73, P945, DOI 10.1038/bjc.1996.169; MIETTINEN OS, 1981, AM J EPIDEMIOL, V114, P144, DOI 10.1093/oxfordjournals.aje.a113161; Mueller N, 1994, Oncology (Williston Park), V8, P83; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; SCHERR PA, 1992, CANCER RES, V52, pS5503; ZAHM SH, 1992, CANCER RES, V52, pS5485	28	78	79	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1451	1455		10.1136/bmj.314.7092.1451	http://dx.doi.org/10.1136/bmj.314.7092.1451			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167561	Green Published			2022-12-28	WOS:A1997XA20200022
J	HippisleyCox, J; Hardy, C; Pringle, M; Fielding, K; Carlisle, R; Chilvers, C				HippisleyCox, J; Hardy, C; Pringle, M; Fielding, K; Carlisle, R; Chilvers, C			The effect of deprivation on variations in general practitioners' referral rates: A cross sectional study of computerised data on new medical and surgical outpatient referrals in Nottinghamshire	BRITISH MEDICAL JOURNAL			English	Article							UNDERPRIVILEGED AREAS; HEALTH-CARE; UNEMPLOYMENT RATES; SOCIAL DEPRIVATION; JARMAN INDEX; SCORES; INDICATORS; PREVALENCE; MORTALITY; MORBIDITY	Objective: To determine the effect of deprivation on variations in general practitioners' referral rates using the Jarman underprivileged area (UPA(8)) score as a proxy measure. Design: Cross sectional survey of new medical and surgical referrals from general practices to hospitals (determined from hospital activity data). Setting: All of the 183 general practices in Nottinghamshire and all of the 19 hospitals in Trent region. Main outcome measures: The relation between the referral rates per 1000 registered patients and the practice populations's UPA(8) score (calculated on the basis of the electoral ward), with adjustment for the number of partners, percentage of patients aged over 65 years, and fundholding status of each practice. Results: There was a significant independent association between deprivation, as measured by the UPA(8) score, and high total referral rates and high medical referral rates (P < 0.0001). The UPA(8) score along explained 23% of the total variation in total referral rates and 32% of the variation in medical referral rates. On multivariate analysis, where partnership size, fundholding status, and percentage of men and women aged over 65 years were included, the UPA(8) score explained 29% and 35% of the variation in total and medical referral rates respectively. Conclusion: Of the variables studied, the UPA(8) score was the strongest predictor of variations in referral rates. This association is most likely to be through a link with morbidity, although it could reflect differences in patients' perceptions, doctors' behaviour, or the use and provision of services.	QUEENS MED CTR,SCH MED,TRENT INST HLTH SERV RES,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	HippisleyCox, J (corresponding author), QUEENS MED CTR,SCH MED,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.		Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283				ACHESON D, 1990, FACTORS INFLUENCING; ARMSTRONG D, 1988, J ROY COLL GEN PRACT, V38, P494; BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BENSHLOMO Y, 1992, J EPIDEMIOL COMMUN H, V46, P532, DOI 10.1136/jech.46.5.532; BHATTI N, 1995, BRIT MED J, V310, P967, DOI 10.1136/bmj.310.6985.967; CAMPBELL DA, 1991, BMJ-BRIT MED J, V303, P750, DOI 10.1136/bmj.303.6805.750; CARLISLE RD, 1993, BRIT MED J, V306, P1383, DOI 10.1136/bmj.306.6889.1383; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; CHRISTENSEN B, 1989, FAM PRACT, V6, P19, DOI 10.1093/fampra/6.1.19; COTGROVE AJ, 1992, J EPIDEMIOL COMMUN H, V46, P245, DOI 10.1136/jech.46.3.245; CROMBIE DL, 1984, SOCIAL CLASS HLTH ST; CUMMINS RO, 1981, BRIT MED J, V282, P1037, DOI 10.1136/bmj.282.6269.1037; DEMARCO P, 1993, BRIT MED J, V307, P1465, DOI 10.1136/bmj.307.6917.1465; DOWIE R, 1989, BRIT MED J, V298, P1098, DOI 10.1136/bmj.298.6680.1098-c; Eachus J, 1996, BMJ-BRIT MED J, V312, P287; Fleming D, 1991, Health Trends, V23, P100; Forsyth G., 1968, GATEWAY DIVIDING LIN; FYLKESNES K, 1993, SCAND J SOC MED, V21, P40, DOI 10.1177/140349489302100107; Haynes R, 1996, J PUBLIC HEALTH MED, V18, P27, DOI 10.1093/oxfordjournals.pubmed.a024457; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; JESSOP EG, 1992, J EPIDEMIOL COMMUN H, V46, P543, DOI 10.1136/jech.46.5.543; Kammerling RM, 1996, BRIT MED J, V312, P1399; MADELEY RJ, 1990, J PUBLIC HEALTH MED, V12, P22, DOI 10.1093/oxfordjournals.pubmed.a042501; MAJEED FA, 1992, EPIDEMIOL INFECT, V109, P167; MCCORMICK A, 1990, MORBIDITY STAT GENER; MEADOWS P, 1995, DIABETIC MED, V12, P696, DOI 10.1111/j.1464-5491.1995.tb00572.x; Morrell D C, 1971, J R Coll Gen Pract, V21, P77; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; NEWLANDS M, 1992, PUBLIC HEALTH, V106, P163, DOI 10.1016/S0033-3506(05)80394-4; PARKER G, 1985, J PSYCHIAT, P299; PAYNE JN, 1993, J PUBLIC HEALTH MED, V15, P161; PITTS J, 1990, BRIT MED J, V300, P1113, DOI 10.1136/bmj.300.6732.1113; PRINGLE M, 1994, BRIT J GEN PRACT, V44, P53; ROLAND MO, 1990, BRIT MED J, V301, P98, DOI 10.1136/bmj.301.6743.98; ROLAND MO, 1992, REFERRALS MED OUTPAT; SCRIVENER G, 1995, BRIT MED J, V311, P163, DOI 10.1136/bmj.311.6998.163; SHELDON TA, 1994, BRIT MED J, V309, P1059, DOI 10.1136/bmj.309.6961.1059; SLOGGETT A, 1994, BRIT MED J, V309, P1470, DOI 10.1136/bmj.309.6967.1470; SURRENDER R, 1995, BRIT MED J, V311, P1205; TALBOT RJ, 1991, BRIT MED J, V302, P383, DOI 10.1136/bmj.302.6773.383; THORNICROFT G, 1992, BRIT J PSYCHIAT, V161, P612; Townsend P, 1982, THE BLACK REPORT; *US BUR CENS, 1986, CENS POP; WILKIN D, 1987, J ROY COLL GEN PRACT, V37, P350; Wilson RPH, 1996, BRIT MED J, V313, P595; Worrall A, 1997, BRIT MED J, V314, P38, DOI 10.1136/bmj.314.7073.38	47	47	47	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1458	1461		10.1136/bmj.314.7092.1458	http://dx.doi.org/10.1136/bmj.314.7092.1458			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XA202	9167564	Green Published			2022-12-28	WOS:A1997XA20200025
J	Hemmelgarn, B; Suissa, S; Huang, A; Boivin, JF; Pinard, G				Hemmelgarn, B; Suissa, S; Huang, A; Boivin, JF; Pinard, G			Benzodiazepine use and the risk of motor vehicle crash in the elderly	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRIVING PERFORMANCE; HIP FRACTURE; OLDER ADULTS; PSYCHOMOTOR; DIAZEPAM; COHORT; DRUGS; ACCIDENTS; INJURIES; DRIVERS	Context.-Benzodiazepines, used by a sizable number of the elderly population, may affect the ability to drive and thus increase the risk of a motor vehicle crash. Epidemiologic studies of this question have produced inconsistent results that may be due to the different effects of long- and short-half-life benzodiazepines and variations in their duration of use. Objective.-To determine whether the use of benzodiazepines of either long- or short-elimination half-life is associated with the risk of injurious motor vehicle crash in the elderly. Design and Setting.-Nested case-control design within a cohort of 224 734 drivers from the Canadian province of Quebec, aged 67 to 84 years, followed up from 1990 to 1993. Computerized data for the study were obtained from provincial driver's license files, police reports of injurious crashes, and health insurance records. Patients.-We identified all 5579 drivers involved in an injurious crash (cases) and a random sample of 10 controls per case selected from a subcohort of 13 256 subjects. Main Outcome.-Involvement of a cohort member as a driver in a motor vehicle crash in which at least 1 person (not necessarily the driver) sustained bodily injury. Results.-The adjusted rate ratio of crash involvement within the first week of long-half-life benzodiazepine use was 1.45 (95% confidence interval [CI], 1.04-2.03). The rate ratio for continuous use of longer duration up to 1 year was slightly lower but remained significant (rate ratio, 1.26; 95% CI, 1.09-1.45). In contrast, there was no increased risk after the initiation of treatment with short-half-life benzodiazepines (rate ratio, 1.04; 95% CI, 0.81-1.34) or with their continued use (rate ratio, 0.91; 95% CI, 0.82-1.01). Conclusions.-Brief or extended periods of exposure to long-half-life benzodiazepines are associated with an increased risk of motor vehicle crash involvement in the elderly population. There is no such elevated risk for short-half-life benzodiazepines.	ROYAL VICTORIA HOSP, DIV CLIN EPIDEMIOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MCGILL PHARMACOEPIDEMIOL RES UNIT, MONTREAL, PQ, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ, CANADA; MCGILL UNIV, DEPT PSYCHIAT, MONTREAL, PQ, CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University; McGill University			Hemmelgarn, Brenda R./I-6894-2012					ADAMS WL, 1990, J AM GERIATR SOC, V38, P211, DOI 10.1111/j.1532-5415.1990.tb03493.x; ARANKO K, 1983, BRIT J CLIN PHARMACO, V15, P545, DOI 10.1111/j.1365-2125.1983.tb02088.x; BARR RA, 1991, HUM FACTORS, V33, P597, DOI 10.1177/001872089103300510; BROOKHUIS KA, 1990, EUR J CLIN PHARMACOL, V39, P83, DOI 10.1007/BF02657065; *CAN PHARM ASS, 1992, COMP PHARM SPEC, P27; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; EMOND A, 1988, SANTE CA VA RAPPORT; GILLEY DW, 1991, ARCH INTERN MED, V151, P941, DOI 10.1001/archinte.151.5.941; GREENBLATT DJ, 1991, NEW ENGL J MED, V324, P1691, DOI 10.1056/NEJM199106133242403; GREENBLATT DJ, 1989, J CLIN PHARMACOL, V29, P866, DOI 10.1002/j.1552-4604.1989.tb03246.x; HONKANEN R, 1980, BRIT MED J, V281, P1309, DOI 10.1136/bmj.281.6251.1309; HOSMER DW, 1989, APPL LOGISTIC REGRES; JICK H, 1981, AM J PUBLIC HEALTH, V71, P1399, DOI 10.2105/AJPH.71.12.1399; JOHNSON RE, 1994, J CLIN EPIDEMIOL, V47, P1191, DOI 10.1016/0895-4356(94)90106-6; Kleinbaum D.G, 1982, EPIDEMIOLOGIC RES PR, P220; LABERGENADEAU C, 1984, U MONTREAL PUBLICATI, V340; LAGIER G, 1993, DRUG ALCOHOL DEPEN, V33, P19; LEVEILLE SG, 1994, EPIDEMIOLOGY, V5, P591, DOI 10.1097/00001648-199411000-00006; LIDDELL FDK, 1977, J R STAT SOC A STAT, V140, P469, DOI 10.2307/2345280; LINNOILA M, 1983, J CLIN PSYCHOPHARM, V3, P88; LUBIN JH, 1984, BIOMETRICS, V40, P63, DOI 10.2307/2530744; LUCKI I, 1986, PSYCHOPHARMACOLOGY, V88, P426; Neutel C. Ineke, 1995, Annals of Epidemiology, V5, P239; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; RAY WA, 1992, J CLIN PSYCHOPHARM, V12, P386; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; REGESTEIN QR, 1992, CLIN GERIATRIC PSYCH, P235; SALZMAN C, 1992, CLIN GERIATRIC PSYCH, P189; SKEGG DCG, 1979, BRIT MED J, V1, P917, DOI 10.1136/bmj.1.6168.917; SUISSA S, 1994, PHARMACOEPIDEM DR S, P629; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; TAMBLYN RM, 1994, CAN MED ASSOC J, V150, P1801; VANLAAR MW, 1992, J CLIN PSYCHOPHARM, V12, P86; Volkerts ER, 1986, DRUGS DRIVING, P123; VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G; WILLIAMS AF, 1989, AM J PUBLIC HEALTH, V79, P326, DOI 10.2105/AJPH.79.3.326; WOLF ME, 1992, ANNU REV PUBL HEALTH, V13, P509, DOI 10.1146/annurev.pu.13.050192.002453; WOODS JH, 1992, PHARMACOL REV, V44, P151	39	265	274	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					27	31		10.1001/jama.278.1.27	http://dx.doi.org/10.1001/jama.278.1.27			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207334				2022-12-28	WOS:A1997XG38700032
J	Chang, MH; Chen, CJ; Lai, MS; Hsu, HM; Wu, TC; Kong, MS; Liang, DC; Shau, WY; Chen, DS				Chang, MH; Chen, CJ; Lai, MS; Hsu, HM; Wu, TC; Kong, MS; Liang, DC; Shau, WY; Chen, DS			Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIGEN CARRIER MOTHERS; SURFACE-ANTIGEN; MATERNAL TRANSMISSION; VIRUS-INFECTION; CHILDHOOD; PROGRAM; INFANTS; LIVER	Background A nationwide hepatitis B vaccination program was implemented in Taiwan in July 1984. To assess the effect of the program on the development of hepatocellular carcinoma, we studied the incidence of this cancer in children in Taiwan from 1981 to 1994. Methods We collected data on liver cancer in children from Taiwan's National Cancer Registry, which receives reports from each of the country's 142 hospitals with more than 50 beds. Data on childhood liver cancer were also obtained from Taiwan's 17 major medical centers. To prevent the inclusion of cases of hepatoblastoma, the primary analysis was confined to liver cancers in children six years of age or older. Data were also obtained on mortality from liver cancer among children. Results The average annual incidence of hepatocellular carcinoma in children 6 to 14 years of age declined from 0.70 per 100,000 children between 1981 and 1986 to 0.57 between 1986 and 1990, and to 0.36 between 1990 and 1994 (P<0.01). The corresponding rates of mortality from hepatocellular carcinoma also decreased. The incidence of hepatocellular carcinoma in children 6 to 9 years of age declined from 0.52 for those born between 1974 and 1984 to 0.13 for those born between 1984 and 1986 (P<0.001). Conclusions Since the institution of Taiwan's program of universal hepatitis B vaccination, the incidence of hepatocellular carcinoma in children has declined. (C) 1997, Massachusetts Medical Society.	NATL TAIWAN UNIV, COLL MED, HEPATITIS RES CTR, TAIPEI, TAIWAN; NATL TAIWAN UNIV, GRAD INST EPIDEMIOL, COLL PUBL HLTH, TAIPEI, TAIWAN; EXECUT YUAN, DEPT HLTH, TAIPEI, TAIWAN; VET GEN HOSP, DEPT PEDIAT, TAIPEI, TAIWAN; CHANG GUNG CHILDRENS HOSP, DEPT PEDIAT, LINKOU, TAOYUAN, TAIWAN; MACKAY MEM HOSP, DEPT PEDIAT, TAIPEI, TAIWAN	National Taiwan University; National Taiwan University; Chang Gung Memorial Hospital; Mackay Memorial Hospital	Chang, MH (corresponding author), NATL TAIWAN UNIV HOSP, DEPT PEDIAT, 7 CHANG SHAN S RD, TAIPEI, TAIWAN.		Chen, Chien-Jen/C-6976-2008; Chen, Chien-Jen/N-4723-2019	Chang, Mei Hwei/0000-0002-3648-9261; CHEN, DING-SHINN/0000-0001-7791-6154; Lai, Mei-shu/0000-0001-6130-3468				BEASLEY RP, 1981, LANCET, V2, P1129; BRECHOT C, 1981, LANCET, V2, P765; CHANG MH, 1991, HEPATOLOGY, V13, P316, DOI 10.1016/0270-9139(91)92446-F; CHANG MH, 1989, CANCER-AM CANCER SOC, V64, P2377, DOI 10.1002/1097-0142(19891201)64:11<2377::AID-CNCR2820641130>3.0.CO;2-8; CHEN D-S, 1987, Journal of the American Medical Association, V257, P2597, DOI 10.1001/jama.257.19.2597; Chen D-S, 1987, NEOPLASMS LIVER, P71; CHEN DS, 1990, J INFECT DIS, V162, P817, DOI 10.1093/infdis/162.4.817; Chen HL, 1996, JAMA-J AM MED ASSOC, V276, P906, DOI 10.1001/jama.276.11.906; HSU HM, 1988, JAMA-J AM MED ASSOC, V260, P2231, DOI 10.1001/jama.260.15.2231; KUO C-Y, 1991, Acta Paediatrica Sinica, V32, P79; LAROUZE B, 1976, LANCET, V2, P534; NI YH, 1991, CANCER, V68, P1737, DOI 10.1002/1097-0142(19911015)68:8<1737::AID-CNCR2820680815>3.0.CO;2-G; POPPER H, 1982, HEPATOLOGY, V2, pS1; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; SELVIN S, 1995, PRACTICAL BIOSTATIST, P342; Selvin S, 1995, PRACTICAL BIOSTATIST, P455; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; SUNG JL, 1980, SCAND J GASTROENTERO, V15, P321, DOI 10.3109/00365528009181477; WHO, 1977, MAN INT STAT CLASS D, V1; WU TC, 1987, HEPATOLOGY, V7, P46, DOI 10.1002/hep.1840070111	20	1330	1371	4	63	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	1997	336	26					1855	1859		10.1056/NEJM199706263362602	http://dx.doi.org/10.1056/NEJM199706263362602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF756	9197213				2022-12-28	WOS:A1997XF75600002
J	Zhang, YF; Suga, N; Yan, J				Zhang, YF; Suga, N; Yan, J			Corticofugal modulation of frequency processing in bat auditory system	NATURE			English	Article							RECEPTIVE-FIELD PLASTICITY; MEDIAL GENICULATE-BODY; INFERIOR COLLICULUS; MUSTACHED BAT; CORTEX; NEURONS; CAT; REPRESENTATION; PROJECTIONS; STIMULATION	Auditory signals are transmitted from the inner ear through the brainstem to the higher auditory regions of the brain. Neurons throughout the auditory system are tuned to stimulus frequency, and in many auditory regions are arranged in topographical maps with respect to their preferred frequency, These properties are assumed to arise from the interactions of convergent and divergent projections ascending from lower to higher auditory areas(1); such a view, however, ignores the possible role of descending projections from cortical to subcortical regions(2-10). In the bat auditory system, such corticofugal connections modulate neuronal activity to improve the processing of echo-delay information(11,12), a specialized feature. Here we show that corticofugal projections are also involved in the most common type of auditory processing, frequency tuning. When cortical neurons tuned to a specific frequency are inactivated, the auditory responses of subcortical neurons tuned to the same frequency are reduced. Moreover, the responses of other subcortical neurons tuned to different frequencies are increased, and their preferred frequencies are shifted towards that of the inactivated cortical neurons. Thus the corticofugal system mediates a positive feedback which, in combination with widespread lateral inhibition, sharpens and adjusts the tuning of neurons at earlier stages in the auditory processing pathway.	WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA	Washington University (WUSTL)								ANDERSEN P, 1973, BRAIN BEHAV EVOLUT, V6, P170, DOI 10.1159/000123705; ANDERSEN RA, 1980, J COMP NEUROL, V191, P479, DOI 10.1002/cne.901910310; EDELINE JM, 1991, BEHAV NEUROSCI, V105, P154, DOI 10.1037/0735-7044.105.1.154; EDELINE JM, 1992, BEHAV NEUROSCI, V106, P81, DOI 10.1037/0735-7044.106.1.81; EDELINE JM, 1993, BEHAV NEUROSCI, V107, P539, DOI 10.1037/0735-7044.107.4.539; GOLDMAN LJ, 1977, BEHAV ECOL SOCIOBIOL, V2, P411, DOI 10.1007/BF00299509; HERBERT H, 1991, J COMP NEUROL, V304, P103, DOI 10.1002/cne.903040108; HUFFMAN RF, 1990, BRAIN RES REV, V15, P295, DOI 10.1016/0165-0173(90)90005-9; JOHNSON RA, 1974, J ACOUST SOC AM, V55, pS53, DOI 10.1121/1.1919792; MASSOPUST LC, 1962, EXP NEUROL, V6, P465, DOI 10.1016/0014-4886(62)90072-9; MITANI A, 1983, NEUROSCI LETT, V42, P185, DOI 10.1016/0304-3940(83)90404-4; OLSEN JF, 1986, THESIS WASHINGTON U; RYUGO DK, 1976, EXP NEUROL, V51, P377, DOI 10.1016/0014-4886(76)90262-4; SUGA N, 1987, J NEUROPHYSIOL, V58, P643, DOI 10.1152/jn.1987.58.4.643; Suga N, 1997, J NEUROPHYSIOL, V77, P2098, DOI 10.1152/jn.1997.77.4.2098; SUGA N, 1990, NEURAL NETWORKS, V3, P3, DOI 10.1016/0893-6080(90)90043-K; SUGA N, 1982, J NEUROPHYSIOL, V47, P225, DOI 10.1152/jn.1982.47.2.225; SUGA N, 1985, J NEUROPHYSIOL, V53, P1109, DOI 10.1152/jn.1985.53.4.1109; SUGA N, 1983, J NEUROPHYSIOL, V49, P1573, DOI 10.1152/jn.1983.49.6.1573; SUGA N, 1976, SCIENCE, V194, P542, DOI 10.1126/science.973140; SUGA N, 1995, NEUROSCI RES, V21, P287, DOI 10.1016/0168-0102(94)00868-G; SUGA N, 1975, J EXP BIOL, V63, P161; SUGA N, 1995, ACTIVE HEARING, P13; SUN X, 1989, BRAIN RES, V495, P1, DOI 10.1016/0006-8993(89)91212-2; VILLA AEP, 1991, EXP BRAIN RES, V86, P506, DOI 10.1007/BF00230524; Winer J.A., 1992, Springer Handbook of Auditory Research, V1, P222; Yan J, 1996, SCIENCE, V273, P1100, DOI 10.1126/science.273.5278.1100; YANG LC, 1992, J NEUROPHYSIOL, V68, P1760, DOI 10.1152/jn.1992.68.5.1760	28	181	184	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 26	1997	387	6636					900	903		10.1038/43180	http://dx.doi.org/10.1038/43180			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202121	Bronze			2022-12-28	WOS:A1997XG41600051
J	Palmer, RH				Palmer, RH			Quality of care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Palmer, RH (corresponding author), HARVARD UNIV, SCH PUBL HLTH, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.							*AG HLTH CAR ADM S, 1996, 1996 GUID HOSP FLOR; Berman S, 1996, JOINT COMM J QUAL IM, V22, P518, DOI 10.1016/S1070-3241(16)30253-X; Blumenthal D, 1996, NEW ENGL J MED, V335, P1328, DOI 10.1056/NEJM199610243351721; Blumenthal D, 1996, NEW ENGL J MED, V335, P1146, DOI 10.1056/NEJM199610103351511; Blumenthal D, 1996, NEW ENGL J MED, V335, P891, DOI 10.1056/NEJM199609193351213; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Brook RH, 1996, JAMA-J AM MED ASSOC, V276, P476, DOI 10.1001/jama.276.6.476; Chassin MR, 1996, NEW ENGL J MED, V335, P1060, DOI 10.1056/NEJM199610033351413; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; Ellwood PM, 1996, JAMA-J AM MED ASSOC, V276, P1083, DOI 10.1001/jama.276.13.1083; FRIEDMAN MD, 1995, JOINT COMM J QUAL IM, V21, P635, DOI 10.1016/S1070-3241(16)30192-4; Iglehart JK, 1996, NEW ENGL J MED, V335, P995, DOI 10.1056/NEJM199609263351322; Jencks SF, 1996, ANN THORAC SURG, V62, pS12, DOI 10.1016/0003-4975(96)00820-X; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; Palmer RH, 1996, MED CARE, V34, pSS102; Servis KW, 1996, JOINT COMM J QUAL IM, V22, P134, DOI 10.1016/S1070-3241(16)30215-2; *US GEN ACC OFF, 1996, MED MAN CAR SERV DIS; Yelin EH, 1996, JAMA-J AM MED ASSOC, V276, P1048, DOI 10.1001/jama.276.13.1048	18	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1896	1897		10.1001/jama.277.23.1896	http://dx.doi.org/10.1001/jama.277.23.1896			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185823				2022-12-28	WOS:A1997XD54400042
J	Atakan, Z; Davies, T				Atakan, Z; Davies, T			ABC of mental health - Mental health emergencies	BRITISH MEDICAL JOURNAL			English	Review									UNITED MED & DENT SCH,ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Atakan, Z (corresponding author), LAMBETH HEALTHCARE NHS TRUST,LONDON,ENGLAND.							ATAKAN Z, 1995, PSYCHIAT B, V19, P593; Cunnane J., 1994, PSYCHIAT B, V18, P138; PILOWSKY LS, 1992, BRIT J PSYCHIAT, V160, P831, DOI 10.1192/bjp.160.6.831; *ROYAL COLL PSYCH, 1996, CR53 ROYAL COLL PSYC; THOMPSON C, 1994, BRIT J PSYCHIAT, V164, P448, DOI 10.1192/bjp.164.4.448; WESTCOTT R, 1994, PSYCHIAT GEN PRACTIC, P170	6	25	25	2	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1740	1742		10.1136/bmj.314.7096.1740	http://dx.doi.org/10.1136/bmj.314.7096.1740			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XE909	9202506	Green Published			2022-12-28	WOS:A1997XE90900029
J	Stephens, N				Stephens, N			Anti-oxidant therapy for ischaemic heart disease: Where do we stand?	LANCET			English	Editorial Material											Stephens, N (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,DEPT CARDIOL,HARROW HA1 3UJ,MIDDX,ENGLAND.							Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; *HOP STUD INV, 1996, CAN J CARDIOL, V12, P127; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1	6	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1710	1711		10.1016/S0140-6736(97)22024-6	http://dx.doi.org/10.1016/S0140-6736(97)22024-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193375				2022-12-28	WOS:A1997XE06500002
J	Hon, WC; McKay, GA; Thompson, PR; Sweet, RM; Yang, DSC; Wright, GD; Berghuis, AM				Hon, WC; McKay, GA; Thompson, PR; Sweet, RM; Yang, DSC; Wright, GD; Berghuis, AM			Structure of an enzyme required for aminoglycoside antibiotic resistance reveals homology to eukaryotic protein kinases	CELL			English	Article							FREE R-VALUE; BETA-LACTAMASE; KANAMYCIN NUCLEOTIDYLTRANSFERASE; SUBSTRATE-SPECIFICITY; MODIFYING ENZYMES; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; RESOLUTION; BINDING; ANALOG	Bacterial resistance to aminoglycoside antibiotics is almost exclusively accomplished through either phosphorylation, adenylylation, or acetylation of the antibacterial agent. The aminoglycoside kinase, APH(3')IIIa, catalyzes the phosphorylation of a broad spectrum of aminoglycoside antibiotics. The crystal structure of this enzyme complexed with ADP was determined at 2.2 Angstrom resolution. The three-dimensional fold of APH(3')-IIIa reveals a striking similarity to eukaryotic protein kinases despite a virtually complete lack of sequence homology. Nearly half of the APH(3')-IIIa sequence adopts a conformation identical to that seen in these kinases. Substantial differences are found in the location and conformation of residues presumably responsible for second-substrate specificity. These results indicate that APH(3') enzymes and eukaryotic-type protein kinases share a common ancestor.	BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	United States Department of Energy (DOE); Brookhaven National Laboratory	Hon, WC (corresponding author), MCMASTER UNIV,DEPT BIOCHEM,1200 MAIN ST W,HAMILTON,ON L8N 3Z5,CANADA.		Berghuis, Albert M/A-6495-2008; Wright, G/ABB-7666-2021	Berghuis, Albert/0000-0002-2663-025X; Wright, Gerard/0000-0002-9129-7131				BENVENISTE R, 1973, P NATL ACAD SCI USA, V70, P2276, DOI 10.1073/pnas.70.8.2276; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BONOMO RA, 1995, BBA-PROTEIN STRUCT M, V1247, P121, DOI 10.1016/0167-4838(94)00188-M; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CHEN CCH, 1993, J MOL BIOL, V234, P165, DOI 10.1006/jmbi.1993.1571; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; COLE PA, 1995, J BIOL CHEM, V270, P22105, DOI 10.1074/jbc.270.38.22105; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; DOOLITTLE RF, 1994, TRENDS BIOCHEM SCI, V19, P15, DOI 10.1016/0968-0004(94)90167-8; FOURMY D, 1996, SCIENCE, V274, P1371; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HEINZEL P, 1988, ARCH MICROBIOL, V150, P184, DOI 10.1007/BF00425160; HERZBERG O, 1991, BIOCHEMISTRY-US, V30, P9503, DOI 10.1021/bi00103a017; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IMTIAZ U, 1994, BIOCHEMISTRY-US, V33, P5728, DOI 10.1021/bi00185a009; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kennelly PJ, 1996, J BACTERIOL, V178, P4759, DOI 10.1128/jb.178.16.4759-4764.1996; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEATHERBARROW RJ, 1992, GRAFIT 3 0; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; LEMONICK MD, 1994, TIME, V144, P62; LOBKOVSKY E, 1994, BIOCHEMISTRY-US, V33, P6762, DOI 10.1021/bi00188a004; MADHUSUDAN T, 1994, PROTEIN SCI, V3, P176; MARTIN P, 1988, MOL MICROBIOL, V2, P615, DOI 10.1111/j.1365-2958.1988.tb00070.x; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P14115, DOI 10.1021/bi00251a021; MCKAY GA, 1995, J BIOL CHEM, V270, P24686, DOI 10.1074/jbc.270.42.24686; McKay GA, 1996, BIOCHEMISTRY-US, V35, P8680, DOI 10.1021/bi9603884; McPherson A, 1982, PREPARATION ANAL PRO; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; PEDERSEN LC, 1995, BIOCHEMISTRY-US, V34, P13305, DOI 10.1021/bi00041a005; Piepesberg W., 1988, ACTINOMYCETOLOGIA, V2, P83, DOI DOI 10.3209/SAJ.2_83; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; SAKON J, 1993, BIOCHEMISTRY-US, V32, P11977, DOI 10.1021/bi00096a006; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; Thompson PR, 1996, CHEM BIOL, V3, P747, DOI 10.1016/S1074-5521(96)90251-3; Thompson PR, 1996, BIOCHEMISTRY-US, V35, P8686, DOI 10.1021/bi960389w; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WELLS JA, 1987, P NATL ACAD SCI USA, V84, P1219, DOI 10.1073/pnas.84.5.1219; Xu RM, 1996, P NATL ACAD SCI USA, V93, P6308, DOI 10.1073/pnas.93.13.6308; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Zhang CC, 1996, MOL MICROBIOL, V20, P9, DOI 10.1111/j.1365-2958.1996.tb02483.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	59	201	211	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					887	895		10.1016/S0092-8674(00)80274-3	http://dx.doi.org/10.1016/S0092-8674(00)80274-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200607	Bronze			2022-12-28	WOS:A1997XE35700009
J	Masai, H; Arai, K				Masai, H; Arai, K			Frpo: A novel single-stranded DNA promoter for transcription and for primer RNA synthesis of DNA replication	CELL			English	Article							F-SEX FACTOR; COLE1 DNA; NUCLEOTIDE-SEQUENCE; SELECTIVE CLONING; BINDING-PROTEIN; LEADING REGION; ABC-PRIMOSOME; PLASMID DNA; ORIGIN; INITIATION	We describe a novel promoter for E. coli RNA polymerase that functions efficiently only in the form of single-stranded DNA. Derived from the leading region of F plasmid, single-stranded Frpo sequence directs RNA polymerase to initiate transcription at a specific site within Frpo, and this specific transcription is highly stimulated by SSB. Prior denaturation activates transcription from otherwise inactive duplex DNA containing Frpo. Since RNAs synthesized on SSB-coated single-stranded Frpo are efficiently elongated into DNA chains by DNA polymerase III holoenzyme, transcription at Frpo serves also for priming DNA replication. A mode of recognition by RNA polymerase of a unique secondary structure within Frpo is proposed, and possible roles of this novel single-stranded promoter in expression and replication during conjugal transfer of F plasmid are discussed.			Masai, H (corresponding author), UNIV TOKYO, INST MED SCI, DEPT MOL & DEV BIOL, MINATO KU, 4-6-1 SHIROKANEDAI, TOKYO 108, JAPAN.							BAGDASARIAN M, 1992, MOL MICROBIOL, V6, P885, DOI 10.1111/j.1365-2958.1992.tb01539.x; BOUCHE JP, 1978, J BIOL CHEM, V253, P765; CHASE JW, 1983, P NATL ACAD SCI-BIOL, V80, P5480, DOI 10.1073/pnas.80.18.5480; CRAM D, 1984, PLASMID, V11, P221, DOI 10.1016/0147-619X(84)90028-3; DUTTA A, 1993, CURR BIOL, V3, P709, DOI 10.1016/0960-9822(93)90076-Z; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GEIDER K, 1978, P NATL ACAD SCI USA, V75, P645, DOI 10.1073/pnas.75.2.645; GEIDER K, 1974, J BIOL CHEM, V249, P3999; GLUCKSMANN MA, 1992, CELL, V70, P491, DOI 10.1016/0092-8674(92)90173-A; HIGASHITANI N, 1993, J VIROL, V67, P2175, DOI 10.1128/JVI.67.4.2175-2181.1993; Higashitani N, 1996, GENES CELLS, V1, P829, DOI 10.1046/j.1365-2443.1996.d01-279.x; HONDA Y, 1989, GENE, V80, P155; HORIUCHI K, 1976, P NATL ACAD SCI USA, V73, P2341, DOI 10.1073/pnas.73.7.2341; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; ITOH T, 1979, COLD SPRING HARB SYM, V43, P409, DOI 10.1101/SQB.1979.043.01.047; JONES AL, 1992, MOL MICROBIOL, V6, P605, DOI 10.1111/j.1365-2958.1992.tb01507.x; KAGUNI JM, 1982, J BIOL CHEM, V257, P5437; LOH S, 1989, MOL GEN GENET, V219, P177, DOI 10.1007/BF00261174; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MARKIEWICZ P, 1992, GENE DEV, V6, P2010, DOI 10.1101/gad.6.10.2010; MASAI H, 1995, EUR J BIOCHEM, V230, P384; MASAI H, 1989, J BIOL CHEM, V264, P8082; MASAI H, 1990, J BIOL CHEM, V265, P15124; MASAI H, 1990, J BIOL CHEM, V265, P15134; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; MASAI H, 1996, FRONT BIOSCI, V1, P49; MELENDY T, 1993, J BIOL CHEM, V268, P3389; NOMURA N, 1982, GENE, V18, P239, DOI 10.1016/0378-1119(82)90161-5; NOMURA N, 1982, P NATL ACAD SCI-BIOL, V79, P3153, DOI 10.1073/pnas.79.10.3153; NOMURA N, 1991, GENE, V108, P15; ONEILL MC, 1989, J BIOL CHEM, V264, P5522; RAY DS, 1982, GENE, V18, P231, DOI 10.1016/0378-1119(82)90160-3; Roberts CW, 1996, CELL, V86, P495; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; TANAKA K, 1991, PLASMID, V25, P125, DOI 10.1016/0147-619X(91)90024-Q; THOMPSON R, 1984, EMBO J, V3, P1175, DOI 10.1002/j.1460-2075.1984.tb01947.x; VANWEZENBEEK PMGF, 1980, GENE, V11, P129, DOI 10.1016/0378-1119(80)90093-1; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984	39	52	52	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					897	907		10.1016/S0092-8674(00)80275-5	http://dx.doi.org/10.1016/S0092-8674(00)80275-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200608	Bronze			2022-12-28	WOS:A1997XE35700010
J	Adema, GJ; Hartgers, F; Verstraten, R; deVries, E; Marland, G; Menon, S; Foster, J; Xu, YM; Nooyen, P; McClanahan, T; Bacon, KB; Figdor, CG				Adema, GJ; Hartgers, F; Verstraten, R; deVries, E; Marland, G; Menon, S; Foster, J; Xu, YM; Nooyen, P; McClanahan, T; Bacon, KB; Figdor, CG			A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells	NATURE			English	Article							MIP-1-ALPHA; MIP-1-BETA; ALPHA	Dendritic cells form a system of highly efficient antigen-presenting cells. After capturing antigen in the periphery, they migate to lymphoid organs where they present the antigen to T cells(1,2). Their seemingly unique ability to interact with and sensitize naive T cells gives dendritic cells a central role in the initiation of immune responses and allows them to be used in therapeutic strategies against cancer, viral infection and other diseases. How they interact preferentially with naive rather than activated T lymphocytes is still poorly understood. Chemokines direct the transport of white blood cells in immune surveillance(3,4). Here we report the identification and characterization of a C-C chemokine (DC-CK1) that is specifically expressed by human dendritic cells at high levels. Tissue distribution analysis demonstrates that dendritic cells present in germinal centres and T-cell areas of secondary lymphoid organs express this chemokine. We show that DC-CK1, in contrast to RANTES, MIP-1 alpha, and interleukin-8, preferentially attracts naive T cells (CD45RA(+)). The specific expression of DC-CK1 by dendritic cells at the site of initiation of an immune response, combined with its chemotactic activity for naive T cells, suggests that DC-CK1 has an important rule in the induction of immune responses.	UNIV NIJMEGEN ST RADBOUD HOSP,DEPT PATHOL,NL-6525 EX NIJMEGEN,NETHERLANDS; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT BIOL MOL,PALO ALTO,CA 94304	Radboud University Nijmegen; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Adema, GJ (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP,DEPT TUMOR IMMUNOL,PHILIPS VAN LEYDENLAAN 25,NL-6525 EX NIJMEGEN,NETHERLANDS.		Adema, G.J./H-8007-2014; Figdor, Carl G/A-4232-2010	Figdor, Carl G/0000-0002-2366-9212				BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; BAKKER ABH, 1995, CANCER RES, V55, P5330; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; FIGDOR CG, 1982, BLOOD, V60, P46; Grouard G, 1996, NATURE, V384, P364, DOI 10.1038/384364a0; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; MARLAND G, 1997, STEM CELLS, V14, P501; MATTIJSSEN V, 1991, J IMMUNOTHER, V10, P63, DOI 10.1097/00002371-199102000-00009; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Peters JH, 1996, IMMUNOL TODAY, V17, P273, DOI 10.1016/0167-5699(96)80544-5; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; ROSS JS, 1991, J IMMUNOL METHODS, V140, P219, DOI 10.1016/0022-1759(91)90374-O; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Thomson, 1994, CYTOKINE HDB, P418; VANGRONINGEN JJ, 1995, CANCER RES, V15, P6237	20	431	462	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					713	717		10.1038/42716	http://dx.doi.org/10.1038/42716			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192897	Green Submitted			2022-12-28	WOS:A1997XD86900056
J	Graham, IM; Daly, LE; Refsum, HM; Robinson, K; Brattstrom, LE; Ueland, PM; PalmaReis, RJ; Boers, GHJ; Sheahan, RG; Israelsson, B; Uiterwaal, CS; Meleady, R; McMaster, D; Verhoef, P; Witteman, J; Rubba, P; Bellet, H; Wautrecht, JC; deValk, HW; Luis, ACS; ParrotRoulaud, FM; Tan, KS; Higgins, I; Garcon, D; Medrano, MJ; Candito, M; Evans, AE; Andria, G				Graham, IM; Daly, LE; Refsum, HM; Robinson, K; Brattstrom, LE; Ueland, PM; PalmaReis, RJ; Boers, GHJ; Sheahan, RG; Israelsson, B; Uiterwaal, CS; Meleady, R; McMaster, D; Verhoef, P; Witteman, J; Rubba, P; Bellet, H; Wautrecht, JC; deValk, HW; Luis, ACS; ParrotRoulaud, FM; Tan, KS; Higgins, I; Garcon, D; Medrano, MJ; Candito, M; Evans, AE; Andria, G			Plasma homocysteine as a risk factor for vascular disease - The European concerted action project	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERUM TOTAL HOMOCYSTEINE; CORONARY HEART-DISEASE; FOLIC-ACID; MYOCARDIAL-INFARCTION; ARTERIAL-DISEASE; HOMOCYST(E)INE; VITAMIN-B12; ASSOCIATION; METABOLISM; STROKE	Context.-Elevated plasma homocysteine is a known risk factor for atherosclerotic vascular disease, but the strength of the relationship and the interaction of plasma homocysteine with other risk factors are unclear. Objective.-To establish the magnitude of the vascular disease risk associated with an increased plasma homocysteine level and to examine interaction effects between elevated plasma homocysteine level and conventional risk factors. Design.-Case-control study. Setting.-Nineteen centers in 9 European countries. Patients.-A total of 750 cases of atherosclerotic vascular disease (cardiac, cerebral, and peripheral) and 800 controls of both sexes younger than 60 years. Measurements.-Plasma total homocysteine was measured while subjects were fasting and after a standardized methionine-loading test, which involves the administration of 100 mg of methionine per kilogram and stresses the metabolic pathway responsible for the irreversible degradation of homocysteine. Plasma cobalamin, pyridoxal 5'-phosphate, red blood cell folate, serum cholesterol, smoking, and blood pressure were also measured. Results.-The relative risk for vascular disease in the top fifth compared with the bottom four fifths of the control fasting total homocysteine distribution was 2.2 (95% confidence interval, 1.6-2.9). Methionine loading identified an additional 27% of at-risk cases. A dose-response effect was noted between total homocysteine level and risk. The risk was similar to and independent of that of other risk factors, but interaction effects were noted between homocysteine and these risk factors; for both sexes combined, an increased fasting homocysteine level showed a more than multiplicative effect on risk in smokers and in hypertensive subjects. Red blood cell folate, cobalamin, and pyridoxal phosphate, all of which modulate homocysteine metabolism, were inversely related to total homocysteine levels. Compared with nonusers of vitamin supplements, the small number of subjects taking such vitamins appeared to have a substantially lower risk of vascular disease, a proportion of which was attributable to lower plasma homocysteine levels. Conclusions.-An increased plasma total homocysteine level confers an independent risk of vascular disease similar to that of smoking or hyperlipidemia. It powerfully increases the risk associated with smoking and hypertension. It is time to undertake randomized controlled trials of the effect of vitamins that reduce plasma homocysteine levels on vascular disease risk.	ROYAL COLL SURGEONS IRELAND,DEPT EPIDEMIOL & PREVENT MED,DUBLIN 2,IRELAND; UNIV COLL,DEPT PUBL HLTH MED & EPIDEMIOL,DUBLIN,IRELAND; UNIV BERGEN,DEPT BIOL CLIN,DIV PHARMACOL,BERGEN,NORWAY; CLEVELAND CLIN FDN,DEPT CARDIOL,CLEVELAND,OH; CTY HOSP,DEPT MED,KALMAR,SWEDEN; HOSP S FRANCISCO XAVIER,MED SERV,LISBON,PORTUGAL; UNIV NIJMEGEN HOSP,DEPT MED,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV TEXAS,MED BRANCH,DIV CARDIOL,GALVESTON,TX 77550; LUND UNIV,MALMO GEN HOSP,CTR HEART & LUNG DIS,S-21401 MALMO,SWEDEN; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,NL-3000 DR ROTTERDAM,NETHERLANDS; QUEENS UNIV BELFAST,DEPT EPIDEMIOL & PUBL HLTH,BELFAST,ANTRIM,NORTH IRELAND; WAGENINGEN UNIV AGR,DEPT EPIDEMIOL & PUBL HLTH,WAGENINGEN,NETHERLANDS; UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,NAPLES,ITALY; INST BIOL,EXPT MED LAB,MONTPELLIER,FRANCE; FREE UNIV BRUSSELS,SERV PATHOL VASC,BRUSSELS,BELGIUM; UNIV UTRECHT HOSP,DEPT INTERNAL MED,UTRECHT,NETHERLANDS; HOP PELLEGRIN,DEPT CHROMATOG,F-33076 BORDEAUX,FRANCE; TOA PAYOH GEN HOSP,DEPT CARDIOL,SINGAPORE,SINGAPORE; FAC PHARM MARSEILLE,BIOCHIM LAB,MARSEILLE,FRANCE; CTR NACL EPIDEMIOL,INST SALUD CARLOS III,MADRID,SPAIN; HOP LOUIS PASTEUR,BIOCHIM LAB,F-06002 NICE,FRANCE	Royal College of Surgeons - Ireland; University College Dublin; University of Bergen; Cleveland Clinic Foundation; Radboud University Nijmegen; University of Texas System; University of Texas Medical Branch Galveston; Lund University; Erasmus University Rotterdam; Queens University Belfast; Wageningen University & Research; University of Naples Federico II; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Utrecht University; Utrecht University Medical Center; CHU Bordeaux; Instituto de Salud Carlos III; Centro Nacional de Epidemiologia (CNE); CHU Nice	Graham, IM (corresponding author), ADELAIDE HOSP,TRINITY COLL,DEPT CARDIOL,PETER ST,DUBLIN 8,IRELAND.		andria, generoso/V-7172-2019; Melis, Daniela/AAD-3623-2019; Ueland, Per M/C-7340-2013; Refsum, Helga/A-4073-2010	Melis, Daniela/0000-0002-9458-3926; Ueland, Per Magne/0000-0002-1903-0571; Verhoef, Petra/0000-0002-6927-6182				ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; Boers G.H., 1990, HOMOCYSTEINEMIA VASC, P-66; BOSTOM AG, 1995, ATHEROSCLEROSIS, V116, P147, DOI 10.1016/0021-9150(95)05529-6; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM L, 1989, HAEMOSTASIS, V19, P35; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; BRATTSTROM L, 1994, J INTERN MED, V236, P633, DOI 10.1111/j.1365-2796.1994.tb00856.x; COOPER BA, 1987, ANNU REV NUTR, V7, P291, DOI 10.1146/annurev.nu.07.070187.001451; GRAHAM I, 1992, 13927 EUR EN COMM EU; GRAHAM IM, 1991, TRENDS CARDIOVAS MED, V1, P244, DOI 10.1016/1050-1738(91)90029-E; LANDGREN F, 1995, J INTERN MED, V237, P381, DOI 10.1111/j.1365-2796.1995.tb01190.x; LEE J, 1986, INT J EPIDEMIOL, V15, P22, DOI 10.1093/ije/15.1.22; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MAYER E, 1995, J AM COLL CARDIOL, V25, pA390; MCCULLY KS, 1983, ATHER REV, V11, P157; MCCULLY KS, 1975, ATHEROSCLEROSIS, V22, P215, DOI 10.1016/0021-9150(75)90004-0; MUDD SH, 1989, METABOLIC BASIS INHE, V1, P693; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; OLSZEWSKI AJ, 1993, FREE RADICAL BIO MED, V14, P683, DOI 10.1016/0891-5849(93)90151-J; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; PARTHASARATHY S, 1987, BIOCHIM BIOPHYS ACTA, V917, P337, DOI 10.1016/0005-2760(87)90139-1; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; REFSUM H, 1989, CLIN CHEM, V35, P1921; ROSENBLATT DS, 1990, BIOESSAYS, V12, P231; Rothman K, 1986, MODERN EPIDEMIOLOGY; *SAS I INC, 1992, P229 SAS I INC; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Sheahan R., 1994, European Heart Journal, V15, P530; SILBERBERG JS, 1990, J CLIN EPIDEMIOL, V43, P875, DOI 10.1016/0895-4356(90)90071-V; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAYLOR LM, 1991, J VASC SURG, V13, P128, DOI 10.1016/0741-5214(91)90020-U; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; WITTEMAN JCM, 1990, HOMOCYSTEINEMIA VASC, P119	38	1523	1657	2	72	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	1997	277	22					1775	1781		10.1001/jama.277.22.1775	http://dx.doi.org/10.1001/jama.277.22.1775			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC499	9178790	Green Submitted			2022-12-28	WOS:A1997XC49900030
J	Bateman, DN				Bateman, DN			Proton-pump inhibitors: Three of a kind?	LANCET			English	Editorial Material							OMEPRAZOLE				Bateman, DN (corresponding author), UNIV NEWCASTLE UPON TYNE,WOLFSON UNIT CLIN PHARMACOL,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND.			Bateman, David Nicholas/0000-0002-8971-862X				Buckley C, 1996, BRIT J DERMATOL, V135, P660, DOI 10.1111/j.1365-2133.1996.tb03863.x; KRAUS A, 1995, LANCET, V345, P461, DOI 10.1016/S0140-6736(95)90449-2; Kuipers EJ, 1996, NEW ENGL J MED, V334, P1018, DOI 10.1056/NEJM199604183341603; LINDQUIST M, 1992, BRIT MED J, V305, P451, DOI 10.1136/bmj.305.6851.451; Neal KR, 1996, BRIT MED J, V312, P414; PINSON DM, 1995, GASTROENTEROLOGY, V108, P1068, DOI 10.1016/0016-5085(95)90204-X; RICCI RM, 1986, CUTIS, V57, P434; Schapira M, 1996, ACTA GASTRO-ENT BELG, V59, P168; SCHONHOFER PS, 1994, LANCET, V343, P665, DOI 10.1016/S0140-6736(94)92654-9; Shiba S, 1996, DIGEST DIS SCI, V41, P1615, DOI 10.1007/BF02087909; SHIN JM, 1994, ALIMENT PHARM THER, V8, P11; TUCKER GT, 1994, ALIMENT PHARM THERAP, V8, P33; 1995, DRUG THER B, V33, P36; 1991, CURR PROBL       JUN	14	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1637	1638		10.1016/S0140-6736(05)62629-3	http://dx.doi.org/10.1016/S0140-6736(05)62629-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186377				2022-12-28	WOS:A1997XD10000003
J	Turner, J				Turner, J			For WHO or for whom?	LANCET			English	Editorial Material																			0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1639	1640		10.1016/S0140-6736(05)62631-1	http://dx.doi.org/10.1016/S0140-6736(05)62631-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186379				2022-12-28	WOS:A1997XD10000005
J	Cullen, SA; Drysdale, HC; Mayes, RW				Cullen, SA; Drysdale, HC; Mayes, RW			Role of medical factors in 1000 fatal aviation accidents: Case note study	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-AVIATION; INCAPACITATION		RAF,INST HLTH & MED TRAINING,DEPT AVIAT TOXICOL,HALTON HP22 5PG,BUCKS,ENGLAND		Cullen, SA (corresponding author), RAF,INST HLTH & MED TRAINING,DEPT AVIAT PATHOL,HALTON HP22 5PG,BUCKS,ENGLAND.							BOOZE CF, 1989, AVIAT SPACE ENVIR MD, V60, P332; FROOM P, 1988, AVIAT SPACE ENVIR MD, V59, P278; KUHLMAN JJ, 1991, J FORENSIC SCI, V36, P1121; MCCORMICK TJ, 1991, AVIAT SPACE ENVIR MD, V62, P884; MORGAN D, 1989, BMA GUIDE ALCOHOL AC	5	13	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 31	1997	314	7094					1592	1592		10.1136/bmj.314.7094.1592	http://dx.doi.org/10.1136/bmj.314.7094.1592			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9186169	Green Published			2022-12-28	WOS:A1997XC50000023
J	Rothwell, PM; McDowell, Z; Wong, CK; Dorman, PJ				Rothwell, PM; McDowell, Z; Wong, CK; Dorman, PJ			Doctors and patients don't agree: Cross sectional study of patient's and doctors' perceptions and assessments of disability in multiple sclerosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; HEALTH SURVEY QUESTIONNAIRE; OUTCOME MEASURE; SCALE; CARE	Objectives: To compare the judgments of clinicians on which domains of health in the short form questionnaire (SF-36) would be most important to patients with multiple sclerosis with the opinions of patients themselves; to compare assessment of physical disability in multiple sclerosis by a clinician using Kurtzke's expanded disability status scale and a non-clinically qualified assistant using the Office of Population Census and Surveys' (OPCS) disability scale with self assessment of disability and other domains of health related quality of life by patients using the SF-36 and the EuroQol questionnaire; and to compare the scores of patients for each domain of the SF-36 with control data matched for age and sex. Design: Cross sectional study. Setting: Clinical department of neurology, Edinburgh. Subjects: 42 consecutive patients with multiple sclerosis attending a neurology outpatient clinic for review or a neurology ward for rehabilitation. Main outcome measures: Scores on the SF-36; EuroQol; Kurtzke's expanded disability status scale; the OPCS disability scale. Results: Patients and clinicians disagreed on which domains of health status were most important (chi(2) = 21, df = 7, P = 0.003). Patients' assessment of their physical disability using the physical functioning domain of the SF-36 was highly correlated with the clinicians' assessment (r = -0.87, P < 0.001) and the non-clinical assessment (r = -0.90, P < 0.001). However, none of the measures of physical disability correlated with overall health related quality of life measured with EuroQol. Quality of life correlated with vitality, general health, and mental health in the SF-36, each of which patients rated as more important than clinicians and for each of which patients scored lower than the controls. Conclusions: Patients with multiple sclerosis, and possibly those with other chronic diseases, are less concerned than their clinicians about physical disability in their illness. Clinical trials in multiple sclerosis should assess the effect of treatment on the other elements of health status that patients consider important, which are also affected by the disease process, are more closely related to overall health related quality of life, and may well be adversely affected by side effects of treatment.	WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	University of Edinburgh	Rothwell, PM (corresponding author), RADCLIFFE INFIRM, DEPT CLIN NEUROL, OXFORD OX2 6HE, ENGLAND.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	Medical Research Council [G0500987] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AMATO MP, 1988, ARCH NEUROL-CHICAGO, V45, P746, DOI 10.1001/archneur.1988.00520310052017; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; CHALMERS I, 1995, BRIT MED J, V310, P1315, DOI 10.1136/bmj.310.6990.1315; COHEN G, 1995, BRIT MED J, V311, P722, DOI 10.1136/bmj.311.7007.722; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; GERHART KA, 1994, ANN EMERG MED, V23, P807, DOI 10.1016/S0196-0644(94)70318-3; GOODARE H, 1995, BMJ-BRIT MED J, V310, P1277, DOI 10.1136/bmj.310.6990.1277; HUTCHINSON J, 1995, J NEUROL, V242, P650, DOI 10.1007/BF00866915; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Martin J., 1988, OPCS SURVEYS DISABIL, V1; Neilley LK, 1996, NEUROLOGY, V46, P552, DOI 10.1212/WNL.46.2.552; NOSEWORTHY JH, 1994, NEUROLOGY, V44, P16, DOI 10.1212/WNL.44.1.16; OBOYLE CA, 1992, LANCET, V339, P1088, DOI 10.1016/0140-6736(92)90673-Q; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; SCHWARTZ CE, 1995, ARCH NEUROL-CHICAGO, V52, P754, DOI 10.1001/archneur.1995.00540320026010; SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20; VICKREY BG, 1995, QUAL LIFE RES, V4, P187, DOI 10.1007/BF02260859; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	22	423	425	1	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	1997	314	7094					1580	1583		10.1136/bmj.314.7094.1580	http://dx.doi.org/10.1136/bmj.314.7094.1580			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9169401	Green Published			2022-12-28	WOS:A1997XC50000019
J	Ruoslahti, E				Ruoslahti, E			Cell biology - Stretching is good for a cell	SCIENCE			English	Editorial Material							INTEGRINS; APOPTOSIS				Ruoslahti, E (corresponding author), BURNHAM INST,10901 M TORREY PINES RD,LA JOLLA,CA 92037, USA.							Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Lin TH, 1997, J BIOL CHEM, V272, P8849; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; VERDE F, 1995, J CELL BIOL, V131, P1529, DOI 10.1083/jcb.131.6.1529; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6	14	182	189	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1345	1346		10.1126/science.276.5317.1345	http://dx.doi.org/10.1126/science.276.5317.1345			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9190676				2022-12-28	WOS:A1997XB53300030
J	Endo, TA; Masuhara, M; Yokouchi, M; Suzuki, R; Sakamoto, H; Mitsui, K; Matsumoto, A; Tanimura, S; Ohtsubo, M; Misawa, H; Miyazaki, T; Leonor, N; Taniguchi, T; Fujita, T; Kanakura, Y; Komiya, S; Yoshimura, A				Endo, TA; Masuhara, M; Yokouchi, M; Suzuki, R; Sakamoto, H; Mitsui, K; Matsumoto, A; Tanimura, S; Ohtsubo, M; Misawa, H; Miyazaki, T; Leonor, N; Taniguchi, T; Fujita, T; Kanakura, Y; Komiya, S; Yoshimura, A			A new protein containing an SH2 domain that inhibits JAK kinases	NATURE			English	Article							RECEPTORS	The proliferation and differentiation of cells of many Lineages are regulated by secreted proteins known as cytokines. Cytokines exert their biological effect through binding to cell-surface receptors that are associated with one or more members of the JAK family of cytoplasmic tyrosine kinases. Cytokine-induced receptor dimerization leads to the activation of JAKs, rapid tyrosine-phosphorylation of the cytoplasmic domains, and subsequent recruitment of various signalling proteins, including members of the STAT family of transcription factors, to the receptor complex(1-5). Using the yeast two-hybrid system, we have now isolated a new SH2-domain-containing protein, TAB, which is a JAK-binding protein that interacts with the Jak2 tyrosine-kinase JH1 domain(6). JAB is structurally related to CIS, a cytokine-inducible SH2 protein(7,8). Interaction of JAB with Jak1, Jak2 or Jak3 markedly reduces their tyrosine-kinase activity and suppresses the tyrosine-phosphorylation and activation of STATs. TAB and CIS appear to function as negative regulators in the JAK signalling pathway.	KURUME UNIV,INST LIFE SCI,KURUME 839,JAPAN; KURUME UNIV,DEPT ORTHOPED SURG,KURUME 839,JAPAN; UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT TUMOR CELL BIOL,BUNKYO KU,TOKYO 113,JAPAN; OSAKA UNIV,SCH MED,DEPT HEMATOL & ONCOL,SUITA,OSAKA 565,JAPAN	Kurume University; Kurume University; University of Tokyo; Tokyo Metropolitan Institute of Medical Science; Osaka University			Nogueira, Leonor/L-2034-2014; Miyazaki, Tadaaki/D-9368-2012; Yoshimura, Akihiko/K-5515-2013; Endo, Takaho/B-5763-2017; Mitsui, Kaoru/E-1464-2011	Endo, Takaho/0000-0002-2801-2463; Mitsui, Kaoru/0000-0003-0534-9845; ohtsubo, motoaki/0000-0002-2479-3178				Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; HARPER JW, 1993, CELL, V75, P805; HARPUR AG, 1992, ONCOGENE, V7, P1347; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KAWAHARA A, 1995, P NATL ACAD SCI  US, V92, P8721; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schluter G, 1996, MOL REPROD DEV, V43, P1, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;1::AID-MRD1&gt;3.0.CO;2-W; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	19	1186	1255	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					921	924		10.1038/43213	http://dx.doi.org/10.1038/43213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202126	Bronze			2022-12-28	WOS:A1997XG41600056
J	Carpenter, CCJ; Fischl, MA; Hammer, SM; Hirsch, MS; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Saag, MS; Schooley, RT; Thompson, MA; Vella, S; Yeni, PG; Volberding, PA				Carpenter, CCJ; Fischl, MA; Hammer, SM; Hirsch, MS; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Saag, MS; Schooley, RT; Thompson, MA; Vella, S; Yeni, PG; Volberding, PA			Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; LYMPHOID-TISSUE; REPLICATION; LYMPHOCYTES; VACCINATION	Objective.-To provide current recommendations for antiretroviral therapy for h Participants.-The original International AIDS Society-USA 13-member panel representing international expertise in antiretroviral research and care of patients with HIV infection. Evidence.-The following were considered: Newly available clinical and basic science study results, including phase 3 controlled trials; clinical, virological, and immunologic end-point data; interim analyses of studies presented at national and international research conferences; studies of HIV pathophysiology; and expert opinions of panel members. Recommendations were limited to the drugs available in mid 1997. Process.-The full panel met on a regular basis (July 1996, September 1996, November 1996, January 1997, and April 1997) since the publication of its initial recommendations in mid 1996 to review new research reports and interim results. The panel discussed whether and how new information changed its initial recommendations. The recommendations contained herein were determined by group consensus. Conclusions.-New data have provided a stronger rationale for earlier initiation of more aggressive therapy than previously recommended and reinforce the importance of careful selection of initial drug regimen for each patient for optimal long-term clinical benefit and adherence. The plasma viral load is a crucial element of clinical management for assessing prognosis and the effectiveness of therapy, and such testing must be done properly. Treatment failure is most readily indicated by a rising plasma HIV RNA level and should be confirmed prior to a change of treatment. Therapeutic approaches must be updated as new data, particularly on the long-term clinical effect of aggressive antiretroviral treatment, continue to emerge.	UNIV MIAMI, SCH MED, MIAMI, FL USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; INT AIDS SOC USA, SAN FRANCISCO, CA USA; STANFORD UNIV, MED CTR, STANFORD, CA 94305 USA; ST PAULS HOSP, VANCOUVER, BC V6Z 1Y6, CANADA; UNIV CALIF SAN DIEGO, SAN DIEGO, CA 92103 USA; SAN DIEGO VET AFFAIRS MED CTR, SAN DIEGO, CA USA; UNIV ALABAMA, BIRMINGHAM, AL USA; UNIV COLORADO, SCH MED, DENVER, CO USA; AIDS RES CONSORTIUM ATLANTA, ATLANTA, GA USA; INST SUPER SANITA, ROME, ITALY; HOP BICHAT CLAUDE BERNARD, BICHAT MED SCH 10, F-75877 PARIS 18, FRANCE; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	University of Miami; Harvard University; Harvard Medical School; Stanford University; St. Paul's Hospital; University of Saskatchewan; University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Istituto Superiore di Sanita (ISS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Francisco	Carpenter, CCJ (corresponding author), BROWN UNIV, MIRIAM HOSP, SCH MED, 164 SUMMIT AVE, PROVIDENCE, RI 02906 USA.		VELLA, STEFANO/ABI-3368-2020; Vella, Stefano/GZM-0519-2022; Montaner, Julio/K-7621-2012; VELLA, STEFANO/D-4912-2015	VELLA, STEFANO/0000-0003-2347-5984; katzenstein, david/0000-0002-8593-4560				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; BOSWELL SL, 1997, 4 C RETR OPP INF JAN; Brichacek B, 1996, J INFECT DIS, V174, P1191, DOI 10.1093/infdis/174.6.1191; CAMERON B, 1996, 3 C RETR OPP INF JAN; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P468; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P1006; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COHEN C, 1996, 36 INT C ANT AG CHEM; COHEN OJ, 1995, P NATL ACAD SCI USA, V92, P6017, DOI 10.1073/pnas.92.13.6017; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; CONWAY B, 1996, 3 INT C DRUG THER HI; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DeGruttola V, 1997, J INFECT DIS, V175, P237, DOI 10.1093/infdis/175.2.237; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Feinberg M, 1997, LANCET, V349, P1408, DOI 10.1016/S0140-6736(97)22020-9; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; GULICK RM, 1996, 11 INT C AIDS JUL 7; GUPTA P, 1997, 4 C RETR OPP INF JAN; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HAMMER SM, 1997, 8 C CLIN MICR INF DI; HIRSCH M, 1997, 4 C RETR OPP INF JAN; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1997, 4 C RETR OPP INF JAN; KATLAMA C, 1997, 4 C RETR OPP INF JAN; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; LALEZARI J, 1996, 11 INT C AIDS JUL 7; LENNOX J, 1997, 4 C RETR OPP INF JAN; MARKOWITZ M, 1997, 4 C RETR OPP INF JAN; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MELLORS JW, 1996, 11 INT C AIDS JUL 7; MELLORS JW, IN PRESS ANN INTERN; MYERS M, 1996, 11 INT C AIDS JUL 7; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBRIEN WA, 1995, BLOOD, V86, P1082; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; *PAN CLIN PRACT TR, IN PRESS FED REG; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PIALOUX G, 1997, 4 C RETR OPP INF JAN; POLLARD R, 1996, 3 C RETR OPP INF JAN; POWDERLY W, 1997, 4 C RETR OPP INF JAN; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Saravolatz LD, 1996, NEW ENGL J MED, V335, P1099, DOI 10.1056/NEJM199610103351503; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; STAPRANS SI, 1995, J EXP MED, V182, P1727, DOI 10.1084/jem.182.6.1727; STASZEWSKI S, 1997, AIDS, V11, P474; WAINBERG M, 1996, 3 INT C DRUG THER HI; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Welles SL, 1996, J INFECT DIS, V174, P696, DOI 10.1093/infdis/174.4.696; WONG JK, 1997, 4 C RETR OPP INF JAN	61	745	760	0	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1962	1969		10.1001/jama.277.24.1962	http://dx.doi.org/10.1001/jama.277.24.1962			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200638				2022-12-28	WOS:A1997XF08700042
J	Atherton, JJ; Moore, TD; Lele, SS; Thomson, HL; Galbraith, AJ; Belenkie, I; Tyberg, JV; Frenneaux, MP				Atherton, JJ; Moore, TD; Lele, SS; Thomson, HL; Galbraith, AJ; Belenkie, I; Tyberg, JV; Frenneaux, MP			Diastolic ventricular interaction in chronic heart failure	LANCET			English	Article							ACUTE PULMONARY-EMBOLISM; PRESSURE; VOLUME; PERICARDIUM; ADAPTATION; DOGS	Background Diastolic ventricular interaction describes a situation in which the volume of one ventricle is directly influenced by the volume of the other ventricle, Such interaction is normally negligible, but it is accentuated in circumstances associated with pulmonary hypertension and volume overload. When this interaction occurs, acute volume unloading results in a reduction in right ventricular end-diastolic volume, as expected, but left ventricular end-diastolic volume paradoxically increases. Since chronic heart failure is a volume overloaded state associated with pulmonary hypertension, we hypothesised that this interaction may be clinically important in patients with heart failure. Methods A radionuclide technique incorporating cardiac scintigraphy was used to measure the effect of acute volume unloading, achieved by 30 mm Hg lower-body suction, an right and left ventricular end-diastolic volumes in 21 patients with chronic heart failure and 12 healthy individuals (controls). Findings In nine heart-failure patients, there was a paradoxical increase in left ventricular end-diastolicic volume in association with an expected decrease in right ventricular end-diastolic volume during lower-body suction, This response was not seen in the control group. The mean change in left Ventricular end-diastolic volume differed significantly between the heart-failure patients and controls (6 [SD 19] vs -19 [12] mL, p=0.0003). However, the change in right ventricular end-diastolic volume was similar in the two groups (-18 [11] vs -20 [8]%, p=0.70). Patients who increased left ventricular end-diastolic volume during lower-body suction had higher resting pulmonary arterial and pulmonary capillary wedge pressures than the remaining heart-failure patients. Interpretation The response of nine patients in our study suggests diastolic ventricular interaction, which we believe could be common in patients with chronic heart failure. This finding is relevant to their management, since ii emphasises the importance of venodilator therapy, The relation between stroke volume and left Ventricular end-diastolic volume, by the Frank-Starling law of the heart, may explain why some patients with chronic heart failure paradoxically increase stroke volume when pulmonary capillary wedge pressure is lowered with vasodilators.	UNIV WALES COLL MED, DEPT CARDIOL, CARDIFF CF4 4XN, S GLAM, WALES; UNIV QUEENSLAND, HEART FAILURE RES UNIT, BRISBANE, QLD, AUSTRALIA; UNIV CALGARY, DEPT MED, CALGARY, AB T2N 1N4, CANADA; UNIV CALGARY, DEPT MED PHYSIOL, CALGARY, AB T2N 1N4, CANADA	Cardiff University; University of Queensland; University of Calgary; University of Calgary			Atherton, John J/B-9994-2011	Atherton, John J/0000-0003-2271-578X				ABBOUD FM, 1981, DISTURBANCES NEUROGE; APPLEGATE RJ, 1992, AM J PHYSIOL, V262, pH1725, DOI 10.1152/ajpheart.1992.262.6.H1725; Atherton J., 1995, European Heart Journal, V16, P83; ATHERTON JJ, 1995, EUR J CARD PACING EL, V5, P188; BELENKIE I, 1989, CIRCULATION, V80, P178, DOI 10.1161/01.CIR.80.1.178; BELENKIE I, 1988, CIRCULATION, V78, P761, DOI 10.1161/01.CIR.78.3.761; BLANCHARD DG, 1992, CIRCULATION, V85, P1414, DOI 10.1161/01.CIR.85.4.1414; DAUTERMAN K, 1995, ANN INTERN MED, V122, P737, DOI 10.7326/0003-4819-122-10-199505150-00001; DIBONA GF, 1994, AM J PHYSIOL, V266, pR27, DOI 10.1152/ajpregu.1994.266.1.R27; DUPUIS J, 1990, AM HEART J, V120, P625, DOI 10.1016/0002-8703(90)90021-O; FRANK O, 1959, AM HEART J, V58, P282, DOI 10.1016/0002-8703(59)90345-X; FRANK O, 1959, AM HEART J, V58, P467, DOI 10.1016/0002-8703(59)90164-4; GREENBER.TT, 1973, CIRC RES, V33, P424, DOI 10.1161/01.RES.32.4.424; Howell W.H., 1884, PHILOS T ROY SOC LON, V175, P139; JARDIN F, 1984, AM REV RESPIR DIS, V129, P135; JARDIN F, 1987, J AM COLL CARDIOL, V10, P1201, DOI 10.1016/S0735-1097(87)80119-5; LEWINTER MM, 1982, CIRC RES, V50, P501, DOI 10.1161/01.RES.50.4.501; LINKS JM, 1982, CIRCULATION, V65, P82, DOI 10.1161/01.CIR.65.1.82; MARK AL, 1983, J AM COLL CARDIOL, V1, P90, DOI 10.1016/S0735-1097(83)80014-X; MOHANTY PK, 1989, AM HEART J, V118, P78, DOI 10.1016/0002-8703(89)90075-6; NISHIAN K, 1993, CLIN SCI, V84, P271, DOI 10.1042/cs0840271; Patterson SW, 1914, J PHYSIOL-LONDON, V48, P465; Patterson SW, 1914, J PHYSIOL-LONDON, V48, P357; STEVENSON LW, 1986, CIRCULATION, V74, P1303, DOI 10.1161/01.CIR.74.6.1303; TYBERG JV, 1986, CIRCULATION, V73, P428, DOI 10.1161/01.CIR.73.3.428; ZOLLER RP, 1972, J CLIN INVEST, V51, P2967, DOI 10.1172/JCI107121; ZUCKER IH, 1977, J CLIN INVEST, V60, P323, DOI 10.1172/JCI108780	27	158	171	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	1997	349	9067					1720	1724		10.1016/S0140-6736(96)05109-4	http://dx.doi.org/10.1016/S0140-6736(96)05109-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193381				2022-12-28	WOS:A1997XE06500008
J	Low, N; DakerWhite, G; Barlow, D; Pozniak, AL				Low, N; DakerWhite, G; Barlow, D; Pozniak, AL			Gonorrhoea in inner London: Results of a cross sectional study	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	Spring Meeting of the Medical-Society-for-the-Study-of-Venereal-Diseases	MAY 09-11, 1996	EDINBURGH, SCOTLAND	Med Soc Study Venereal Dis			DEPRIVATION; RATES	Objectives: To estimate population based incidence rates of gonorrhoea in an inner London area and examine relations with age, ethnic group, and socioeconomic deprivation. Design: Cross sectional study. Setting: 11 departments of genitourinary medicine in south and central London. Subjects: 1978 first episodes of gonorrhoea diagnosed in 1994 and 1995 in residents of 73 electoral wards in the boroughs of Lambeth, Southwark, and Lewisham who attended any of the departments of genitourinary medicine. Main outcome measures: Yearly age,sex, and ethnic group specific rates of gonorrhoea per 100 000 population aged 15-59 years; rate ratios for the effects of age and ethnic group on gonorrhoea rates in women and men before and after adjustment for confounding factors. Results: Overall incidence rates of gonorrhoea in residents of Lambeth, Southwark, and Lewisham were 138.3 cases-yearly per 100 000 women and 291.9 cases yearly per 100 000 men aged 15-59 years. At all ages gonorrhoea rates were higher in non-white minority ethnic groups. Rate ratios for the effect of age adjusted for ethnic group and underprivilege were 15.2 (95% cofidence interval 11.6 to 19.7) for women and 2.0 (1.7 to 2.5) for men aged 15-19 years compared with those over 30. After deprivation score and age were taken into account, women from black minority groups were 10.5 (8.6 to 12.8) times as likely and men 11.0 (9.7 to 12.6) times as likely as white people to experience gonorrhoea Conclusions: Gonorrhoea rates in Lambeth, Southwark, and Lewisham in 1994-5 were six to seven times higher than for England and Wales one year earlier. The presentation of national trends thus hides the disproportionate contribution of ongoing endemic transmission in the study area. Teenage women and young adult men, particularly those from black minority ethnic groups, are the most heavily affected, even when socioeconomic underprivilege is taken into account. There is urgent need for resources for culturally appropriate research and effective intervention to prevent gonococcal infections and their long term sequelae in this population.	GUYS & ST THOMAS NHS TRUST,DEPT GENITOURINARY MED,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	Low, N (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,ACAD UNIT,DEPT GENITOURINARY MED,CALDECOT CTR,LONDON SE5 9RS,ENGLAND.		Low, Nicola/H-4718-2019	Low, Nicola/0000-0003-4817-8986				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; ARAL SO, 1988, AM J PUBLIC HEALTH, V78, P702, DOI 10.2105/AJPH.78.6.702; BEVERIDGE MM, 1962, BRIT J VENER DIS, V38, P154; Blair I, 1994, Commun Dis Rep CDR Rev, V4, pR25; Calman K, 1996, BRIT J HOSP MED, V56, P125; Cooper R S, 1993, Ann Epidemiol, V3, P137; CURTIS SE, 1990, J EPIDEMIOL COMMUN H, V44, P62, DOI 10.1136/jech.44.1.62; DakerWhite G, 1997, INT J STD AIDS, V8, P32, DOI 10.1258/0956462971918733; Dale A, 1993, 1991 CENSUS USERS GU; *DEP HLTH, 1992, HLTH NAT STRAT HLTH, P92; ELLEN JM, 1995, AM J PUBLIC HEALTH, V85, P1546, DOI 10.2105/AJPH.85.11.1546; *GOV STAT SERV, 1996, SEX TRANSM DIS ENGL, P1; HOLMES KK, 1990, SEXUALLY TRANSMITTED; JOHNSON AM, 1991, HLTH NATION BMJ VIEW, P83; LAIRD SM, 1962, BRIT J VENER DIS, V38, P181; Langlands A, 1996, BRIT J HOSP MED, V56, P171; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; *OFF POP CENS SURV, 1994, 1991 CENS US GUID 58; RICE RJ, 1991, AM J PUBLIC HEALTH, V81, P1252, DOI 10.2105/AJPH.81.10.1252; *ROYAL MAIL, 1995, ROYAL MAIL POST ADDR; SHERRARD J, 1993, LANCET, V341, P245, DOI 10.1016/0140-6736(93)90110-3; TOOMEY KE, 1993, INFECT DIS CLIN N AM, V7, P739; WATT I, 1958, BR J VENER DIS, V34, P9; 1995, COMMUN DIS REP CDR W, V5, P62; [No title captured]; 1996, COMMUN DIS REP CDR W, V6, P304	26	95	96	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1719	1723		10.1136/bmj.314.7096.1719	http://dx.doi.org/10.1136/bmj.314.7096.1719			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9185497	Green Published			2022-12-28	WOS:A1997XE90900020
J	Duncan, MJ; Levison, HF				Duncan, MJ; Levison, HF			A disk of scattered icy objects and the origin of Jupiter-family comets	SCIENCE			English	Article							SHORT-PERIOD COMETS; SOLAR-SYSTEM; NEPTUNE; DELIVERY	Orbital integrations carried out for 4 billion years produced a disk of scattered objects beyond the orbit of Neptune, Objects in this disk can be distinguished from Kuiper belt objects by a greater range of eccentricities and inclinations. This disk was formed in the simulations by encounters with Neptune during the early evolution of the outer solar system. After particles first encountered Neptune, the simulations show that about 1 percent of the particles survive in this disk for the age of the solar system, A disk currently containing as few as similar to 6 x 10(8) objects could supply all of the observed Jupiter-family comets. Two recently discovered objects, 1996 RQ(20) and 1996 TL66, have orbital elements similar to those predicted for objects in this disk, suggesting that they are thus far the only members of this disk to be identified.	SW RES INST, DEPT SPACE SCI, BOULDER, CO 80302 USA		Duncan, MJ (corresponding author), QUEENS UNIV, DEPT PHYS, KINGSTON, ON K7L 3N6, CANADA.		Levison, Harold F/C-6061-2013	Levison, Harold F/0000-0001-5847-8099				AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; Davis DR, 1997, ICARUS, V125, P50, DOI 10.1006/icar.1996.5595; DUNCAN M, 1988, ASTROPHYS J, V328, pL69, DOI 10.1086/185162; Duncan MJ, 1995, ASTRON J, V110, P3073, DOI 10.1086/117748; Edgeworth K.E., 1943, J BR ASTRON ASS, V53, P181; EDGEWORTH KE, 1949, MON NOT R ASTRON SOC, V109, P600, DOI 10.1093/mnras/109.5.600; FERNANDEZ J, 1982, MON NOT R ASTRON SOC, V192, P481; FERNANDEZ JA, 1983, ICARUS, V54, P377, DOI 10.1016/0019-1035(83)90235-X; FERNANDEZ JA, 1984, ICARUS, V58, P109, DOI 10.1016/0019-1035(84)90101-5; HELIN E, 1997, MINOR PLANET ELECT B, V19; HOLMAN MJ, 1993, ASTRON J, V105, P1987, DOI 10.1086/116574; Jewitt D, 1996, ASTRON J, V112, P1225, DOI 10.1086/118093; KOZAI Y, 1962, ASTRON J, V67, P591, DOI 10.1086/108790; Kuiper G.P., 1951, ASTROPHYSICS TOPICAL, P357; LEVISON HF, 1993, ASTROPHYS J, V406, pL35, DOI 10.1086/186780; Levison HF, 1996, ASTR SOC P, V107, P173; LEVISON HF, IN PRESS ICARUS; Luu J, 1997, NATURE, V387, P573, DOI 10.1038/42413; MALHOTRA R, 1995, ASTRON J, V110, P420, DOI 10.1086/117532; QUINN T, 1990, ASTROPHYS J, V355, P667, DOI 10.1086/168800; STERN SA, 1995, ASTRON J, V110, P856, DOI 10.1086/117568; TORBETT MV, 1989, ASTRON J, V98, P1477, DOI 10.1086/115233; TRUJILLO C, 1997, MINOR PLANET ELECT B, V18; WEISSMAN PR, 1990, GEOL SOC AM SPEC PAP, V247, P263; WEISSMAN PR, IN PRESS PLUTO	25	330	332	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1670	1672		10.1126/science.276.5319.1670	http://dx.doi.org/10.1126/science.276.5319.1670			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180070				2022-12-28	WOS:A1997XD94700033
J	Broccolo, A				Broccolo, A			My father's hands	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	1997	277	22					1809	1809						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC499	9178797				2022-12-28	WOS:A1997XC49900037
J	Goldzweig, CL; Mittman, BS; Carter, GM; Donyo, T; Brook, RH; Lee, P; Mangione, CM				Goldzweig, CL; Mittman, BS; Carter, GM; Donyo, T; Brook, RH; Lee, P; Mangione, CM			Variations in cataract extraction rates in Medicare prepaid and fee-for-service settings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-MAINTENANCE ORGANIZATIONS; QUALITY-OF-LIFE; ELDERLY PATIENTS; VISUAL FUNCTION; RISK-FACTORS; SURGERY; VISION; CARE; PHYSICIANS; OUTCOMES	Objective.-To compare rates of cataract extraction in 2 prepaid health settings and in traditional fee-for-service (FFS) settings. Design.-A cross-sectional analysis using 1993 health maintenance organization (HMO) Medicare claims and encounter files, the Health Care Financing Administration (HCFA) 5% Medicare Part B provider/supplier file, and the HCFA October 1992 100% Medicare population file. Setting.-Southern California Medicare FFS settings and the staff-model and independent practice association (IPA) plans of a large California HMO. Patients.-1993 Medicare beneficiaries aged 65 years and older, The study included 43 387 staff-model HMO enrollees, 19 050 IPA enrollees, and 47 150 FFS beneficiaries (a 5% sample of all Southern California FFS beneficiaries). Main Outcome Measure.-Age and risk-factor adjusted rates of cataract extraction per 1000 beneficiary-years. Results.-After controlling for age, sex, and diabetes mellitus status, FFS beneficiaries were twice as likely to undergo cataract extraction as were prepaid beneficiaries (P<.01). Female FFS beneficiaries were nearly twice as likely to undergo the procedure as were male FFS beneficiaries (P<.001); there were no extraction rate differences by sex in the prepaid settings. Conclusion.-Because of the potential implications for vision care in the elderly, the significantly different rates of cataract extraction in FFS and prepaid settings warrant further clinical investigation to determine whether there is overuse in FFS vs underuse in prepaid settings. Such investigations must assess the appropriateness of cataract surgery by evaluating its use relative to clinical need.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; RAND CORP,SANTA MONICA,CA; UNIV SO CALIF,SCH MED,DEPT OPHTHALMOL,LOS ANGELES,CA 90033	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation; University of Southern California	Goldzweig, CL (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR,DIV GEN INTERNAL MED,11301 WILSHIRE BLVD,111G,LOS ANGELES,CA 90073, USA.			Lee, Paul/0000-0002-3338-136X	NIA NIH HHS [K08 AG000605] Funding Source: Medline; OHS HRSA HHS [ST32PE19001] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000605] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); OHS HRSA HHS; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM MED ASS, 1987, CPT PHYS CURR PROC T; [Anonymous], 1988, INT CLASS DIS 9 REV; APPLEGATE WB, 1987, JAMA-J AM MED ASSOC, V257, P1064; BRENNER MH, 1993, ARCH OPHTHALMOL-CHIC, V111, P680, DOI 10.1001/archopht.1993.01090050114040; BROWN RS, 1993, DOES MANAGED CARE WO; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; GLYNN RJ, 1991, ARCH OPHTHALMOL-CHIC, V109, P205, DOI 10.1001/archopht.1991.01080020051041; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; GOMEZ JM, 1994, LOS ANGELES TIM 0227, pD3; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P605, DOI 10.1001/archopht.1993.01090050039024; JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P686, DOI 10.1001/archopht.1993.01090050120041; JAVITT JC, 1995, MED CARE, V33, P90, DOI 10.1097/00005650-199501000-00008; KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546; LESKE MC, 1983, AM J EPIDEMIOL, V118, P152, DOI 10.1093/oxfordjournals.aje.a113625; LOGERFO JP, 1979, MED CARE, V27, P1; LUFT HS, 1978, NEW ENGL J MED, V298, P1336, DOI 10.1056/NEJM197806152982404; MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004; MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1419, DOI 10.1001/archopht.1994.01090230033017; MCCLOSKEY L, 1992, MED CARE, V30, P126, DOI 10.1097/00005650-199202000-00004; PEAR R, 1995, NY TIMES        0910, pN1; STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313; Steinberg E P, 1990, Int J Technol Assess Health Care, V6, P282; STEINBERG EP, 1994, OPHTHALMOLOGY, V101, P1131; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TUSSING AD, 1994, HEALTH SERV RES, V29, P75; UHLMANN RF, 1991, J GEN INTERN MED, V6, P126, DOI 10.1007/BF02598307; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255	28	66	66	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	1997	277	22					1765	1768		10.1001/jama.277.22.1765	http://dx.doi.org/10.1001/jama.277.22.1765			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XC499	9178788	Green Submitted			2022-12-28	WOS:A1997XC49900028
J	Dooley, J; Macfarlane, B; Worwood, M; Walker, A				Dooley, J; Macfarlane, B; Worwood, M; Walker, A			Genetic haemochromatosis	LANCET			English	Editorial Material							HLA-A LOCUS; HEMOCHROMATOSIS GENE; LOCALIZATION; D6S105; MARKERS; DEFINE; LIVER		UNIV LONDON, SCH MED, LONDON NW3 2PF, ENGLAND; UNIV WALES COLL MED, DEPT HAEMATOL, CARDIFF CF4 4XN, S GLAM, WALES	University of London; Cardiff University	Dooley, J (corresponding author), UNIV LONDON ROYAL FREE HOSP, DEPT MED, DIV HEPATOL, LONDON NW3 2PF, ENGLAND.							ADAMS PC, 1991, AM J MED, V90, P445; BAER DM, 1995, AM J MED, V98, P464, DOI 10.1016/S0002-9343(99)80346-5; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; BEZWODA WR, 1979, SCAND J HAEMATOL, V22, P113; BOTHWELL TH, 1995, METABOLIC MOL BASES, P2237; CRAWFORD DHG, 1995, AM J HUM GENET, V57, P362; ELKAHLOUN A, 1993, HUM MOL GENET, V2, P55; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; FLANAGAN PR, 1995, HEPATOLOGY, V22, P828, DOI 10.1002/hep.1840220321; GASPARINI P, 1993, HUM MOL GENET, V2, P571, DOI 10.1093/hmg/2.5.571; GUYADER D, 1992, J HEPATOL, V15, P304, DOI 10.1016/0168-8278(92)90060-3; JAZWINSKA EC, 1993, AM J HUM GENET, V53, P347; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; MCKUSICK VA, ONLINE INHERITANCE M; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Piperno A, 1996, HEPATOLOGY, V24, P43, DOI 10.1002/hep.510240109; Powell LW, 1996, GASTROENTEROLOGY, V110, P1304, DOI 10.1053/gast.1996.v110.agast961304; RAHACHOWDHURY R, 1995, HUM MOL GENET, V4, P1869, DOI 10.1093/hmg/4.10.1869; Raja KB, 1996, GUT, V38, P765, DOI 10.1136/gut.38.5.765; Roberts AG, 1997, LANCET, V349, P321, DOI 10.1016/S0140-6736(96)09436-6; Rothenberg BE, 1996, P NATL ACAD SCI USA, V93, P1529, DOI 10.1073/pnas.93.4.1529; SIMON M, 1988, J HEPATOL, V6, P116, DOI 10.1016/S0168-8278(88)80471-9; SIMON M, 1974, NOUV PRESSE MED, V4, P1432; SIMON M, 1987, AM J HUM GENET, V41, P89; SUMMERS KM, 1990, HEPATOLOGY, V12, P20, DOI 10.1002/hep.1840120105; WHITTAKER P, 1989, J CLIN INVEST, V83, P261, DOI 10.1172/JCI113868; WORWOOD M, 1994, BRIT J HAEMATOL, V86, P863, DOI 10.1111/j.1365-2141.1994.tb04843.x; WORWOOD M, 1994, BAILLIERE CLIN HAEM, V7, P903, DOI 10.1016/S0950-3536(05)80130-1; WORWOOD M, IN PRESS BR J HAEMAT; WORWOOD M, UNPUB SIMPLE GENETIC	31	18	19	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	1997	349	9066					1688	1693		10.1016/S0140-6736(96)09316-6	http://dx.doi.org/10.1016/S0140-6736(96)09316-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186396				2022-12-28	WOS:A1997XD10000044
J	Huppertz, HI; Rutkowski, S; Aleksic, S; Karch, H				Huppertz, HI; Rutkowski, S; Aleksic, S; Karch, H			Acute and chronic diarrhoea and abdominal colic associated with enteroaggregative Escherichia coli in young children living in western Europe	LANCET			English	Article							PERSISTENT DIARRHEA; IDENTIFICATION; ADHERENCE; PATHOGEN; PROBE	Background Enteroaggregative Escherichia coli (EAggEC or EAEC) can spread and cause disease in developing countries, but it is not presently known whether it spreads disease in industrialised countries. Therefore, we did a prospective study to assess the incidence and the clinical manifestations of infections due to EAEC in children in Germany. Methods 798 children with diarrhoea, admitted to hospital within a defined geographical area during a 24-month period, were included in the trial, EAEC were cultured from stool specimens, screened by PCR,and identified by colony hybridisation from DNA sequences found on the virulence plasmid, The findings were confirmed by aggregative adherence to HEp-2 cells. Stool samples from 580 children admitted to hospital without diarrhoea were also studied as controls. Findings EAEC were found in the stools of 16 (2%) of 798 children with diarrhoea, but in none of 580 children without diarrhoea, Only four of the EAEC-infected children had travelled to developing countries. Most EAEC infections were acquired in the summer months. infection with EAEC was associated with acute, watery diarrhoea in 12 children, and with chronic diarrhoea of up to 5 months' duration in four, Five children had abdominal-colic that lasted for 2-4 weeks as their main symptom. The incidence of EAEC infection was 7.7 patients admitted to hospital per 100 000 children in the general population aged younger than 16 years. Interpretation EAEC infection is associated with acute, watery diarrhoea and may be acquired in industrialised countries. Chronic diarrhoea or abdominal colic of unknown aetiology in young children may also be caused by EAEC infection.	UNIV WURZBURG,INST HYG & MICROBIOL,WURZBURG,GERMANY; INST HYG,HAMBURG,GERMANY; NATL REFERENCE CTR ENTEROBACTERIACEAE,HAMBURG,GERMANY	University of Wurzburg	Huppertz, HI (corresponding author), UNIV WURZBURG,CHILDRENS HOSP,KINDERKLIN,D-97080 WURZBURG,GERMANY.							ALBERT MJ, 1993, J CLIN MICROBIOL, V31, P1397, DOI 10.1128/JCM.31.5.1397-1399.1993; BAUDRY B, 1990, J INFECT DIS, V161, P1249, DOI 10.1093/infdis/161.6.1249; BHAN MK, 1989, J INFECT DIS, V159, P1061, DOI 10.1093/infdis/159.6.1061; BHATNAGAR S, 1993, SCAND J INFECT DIS, V25, P579, DOI 10.3109/00365549309008546; BROOK MG, 1994, EPIDEMIOL INFECT, V112, P63, DOI 10.1017/S0950268800057423; Cobeljic M, 1996, EPIDEMIOL INFECT, V117, P11, DOI 10.1017/S0950268800001072; Giammanco A, 1996, J CLIN MICROBIOL, V34, P689, DOI 10.1128/JCM.34.3.689-694.1996; Huppertz HI, 1996, J PEDIATR-US, V128, P341, DOI 10.1016/S0022-3476(96)70278-0; Mews CF, 1993, PEDIAT GASTROINTESTI, P177; NATARO JP, 1987, PEDIATR INFECT DIS J, V6, P829, DOI 10.1097/00006454-198709000-00008; PHILLIPS AD, 1994, J PEDIAT GASTROENTER, V18, P87; SCHMIDT H, 1995, J CLIN MICROBIOL, V33, P701, DOI 10.1128/JCM.33.3.701-705.1995; SCOTLAND SM, 1991, J MED MICROBIOL, V35, P278, DOI 10.1099/00222615-35-5-278; SMITH HR, 1994, J INFECT DIS, V170, P1610, DOI 10.1093/infdis/170.6.1610; WILDE J, 1991, LANCET, V337, P323, DOI 10.1016/0140-6736(91)90945-L	15	72	75	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1660	1662		10.1016/S0140-6736(96)12485-5	http://dx.doi.org/10.1016/S0140-6736(96)12485-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186384				2022-12-28	WOS:A1997XD10000010
J	Rosenbaum, JT				Rosenbaum, JT			Lessons from litigation over silicone breast implants: A call for activism by scientists	SCIENCE			English	Editorial Material							CONNECTIVE-TISSUE DISEASES; RHEUMATOID-ARTHRITIS; COSMETIC SURGERY; AUGMENTATION; CANCER; RISK; SYMPTOMS; WOMEN; SCLERODERMA				Rosenbaum, JT (corresponding author), OREGON HLTH SCI UNIV,CASEY EYE INST,3375 SW TERWILLIGER BLVD,PORTLAND,OR 97201, USA.							*AM MED ASS COUNC, 1993, JAMA-J AM MED ASSOC, V270, P2602; ANGELL M, 1996, SCIENCE TRIAL; BIRDSELL DC, 1993, PLAST RECONSTR SURG, V92, P795, DOI 10.1097/00006534-199392050-00003; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; Brinton LA, 1996, PLAST RECONSTR SURG, V97, P269, DOI 10.1097/00006534-199602000-00001; BRYANT H, 1995, NEW ENGL J MED, V332, P1535, DOI 10.1056/NEJM199506083322302; BURNS CG, 1994, THESIS U MICHIGAN; DEAPEN DM, 1995, J CLIN EPIDEMIOL, V48, P551, DOI 10.1016/0895-4356(94)00212-9; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; ENGLERT HJ, 1994, AUST NZ J MED, V24, P74, DOI 10.1111/j.1445-5994.1994.tb04439.x; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GILTAY EJ, 1994, ANN RHEUM DIS, V53, P194, DOI 10.1136/ard.53.3.194; GOLDMAN JA, 1995, J CLIN EPIDEMIOL, V48, P571, DOI 10.1016/0895-4356(94)00215-C; GOTT D, 1994, SILICONE IMPLANTS CO; Hennekens CH, 1996, JAMA-J AM MED ASSOC, V275, P616, DOI 10.1001/jama.275.8.616; HOCHBERG MC, 1993, ANN INTERN MED, V118, P981, DOI 10.7326/0003-4819-118-12-199306150-00013; Hochberg MC, 1996, ARTHRITIS RHEUM, V39, P1125, DOI 10.1002/art.1780390708; HUBER PW, 1991, GALILEOS REVENGE JUN, P111; Kaiser J, 1997, SCIENCE, V275, P21; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; KUMAGAI Y, 1984, ARTHRITIS RHEUM-US, V27, P1, DOI 10.1002/art.1780270101; Martin L., 1995, Arthritis and Rheumatism, V38, pS264; MCLAUGHLIN JK, 1994, J NATL CANCER I, V86, P1424, DOI 10.1093/jnci/86.18.1424; Rosenbaum J, 1996, ARTHRITIS RHEUM, V39, P1765, DOI 10.1002/art.1780391024; SANCHEZGUERRERO J, 1994, ARTHRITIS RHEUM-US, V37, P158; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; SCHELL RW, 1996, MEALEYS BREAST IMPLA, P471; SCHUSTERMAN MA, 1993, ANN PLAS SURG, V31, P1; Silverman Stuart, 1996, Arthritis and Rheumatism, V39, pS51; SPIERA H, 1988, JAMA-J AM MED ASSOC, V260, P236, DOI 10.1001/jama.260.2.236; STROM BL, 1994, J CLIN EPIDEMIOL, V47, P1211, DOI 10.1016/0895-4356(94)90109-0; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011; WELLS KE, 1994, PLAST RECONSTR SURG, V93, P907, DOI 10.1097/00006534-199404001-00002; *WGBH ED FDN, 1996, FRONTLI; Williams HJ, 1997, ARTHRITIS RHEUM, V40, P437, DOI 10.1002/art.1780400308; Wolfe F., 1995, Arthritis and Rheumatism, V38, pS265	36	19	19	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 6	1997	276	5318					1524	1525		10.1126/science.276.5318.1524	http://dx.doi.org/10.1126/science.276.5318.1524			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9190690				2022-12-28	WOS:A1997XC70100030
J	Sudo, S; Fujikawa, T; Nagakura, T; Ohkubo, T; Sakaguchi, K; Tanaka, M; Nakashima, K; Takahashi, T				Sudo, S; Fujikawa, T; Nagakura, T; Ohkubo, T; Sakaguchi, K; Tanaka, M; Nakashima, K; Takahashi, T			Structures of mollusc shell framework proteins	NATURE			English	Letter									MIE UNIV,FAC BIORESOURCES,DEPT AGR CHEM,TSU,MIE 514,JAPAN	Mie University	Sudo, S (corresponding author), MIE UNIV,FAC MED,DEPT BIOCHEM,TSU,MIE 514,JAPAN.							Belcher AM, 1996, NATURE, V381, P56, DOI 10.1038/381056a0; Falini G, 1996, SCIENCE, V271, P67, DOI 10.1126/science.271.5245.67; Guerette PA, 1996, SCIENCE, V272, P112, DOI 10.1126/science.272.5258.112; MANN S, 1988, NATURE, V332, P119, DOI 10.1038/332119a0; Miyamoto H, 1996, P NATL ACAD SCI USA, V93, P9657, DOI 10.1073/pnas.93.18.9657; NAKAHARA H, 1982, Venus the Japanese Journal of Malacology, V41, P33; SAMATA T, 1988, Venus the Japanese Journal of Malacology, V47, P127; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; WEINER S, 1980, FEBS LETT, V111, P311, DOI 10.1016/0014-5793(80)80817-9; WILBUR KM, 1963, ANN NY ACAD SCI, V109, P82, DOI 10.1111/j.1749-6632.1963.tb13463.x	10	358	397	3	72	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					563	564		10.1038/42391	http://dx.doi.org/10.1038/42391			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177341				2022-12-28	WOS:A1997XC52200036
J	Otto, F; Thornell, AP; Crompton, T; Denzel, A; Gilmour, KC; Rosewell, IR; Stamp, GWH; Beddington, RSP; Mundlos, S; Olsen, BR; Selby, PB; Owen, MJ				Otto, F; Thornell, AP; Crompton, T; Denzel, A; Gilmour, KC; Rosewell, IR; Stamp, GWH; Beddington, RSP; Mundlos, S; Olsen, BR; Selby, PB; Owen, MJ			Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development	CELL			English	Article							EXPRESSION; FAMILY	We have generated Cbfa1-deficient mice. Homozygous mutants die of respiratory failure shortly after birth. Analysis of their skeletons revealed an absence of osteoblasts and bane. Heterozygous mice showed specific skeletal abnormalities that are characteristic of the human heritable skeletal disorder, cleidocranial dysplasia (CCD). These defects are also observed in a mouse Ccd mutant for this disease. The Cbfa1 gene was shown to be deleted in the Ccd mutation. Analysis of embryonic Cbfa1 expression using a lacZ reporter gene revealed strong expression at sites of bone formation prior to the earliest stages of ossification. Thus, the Cbfa1 gene is essential for osteoblast differentiation and bone formation, and the Cbfa1 heterozygous mouse is a paradigm for a human skeletal disorder.	IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOPATHOL,LONDON W12 0HS,ENGLAND; NATL INST MED RES,LONDON NW7 1AA,ENGLAND; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; OAK RIDGE NATL LAB,DIV LIFE SCI,OAK RIDGE,TN 37830	Cancer Research UK; Imperial College London; MRC National Institute for Medical Research; Harvard University; Harvard Medical School; United States Department of Energy (DOE); Oak Ridge National Laboratory			SHINNO, Yasuo/B-2290-2011; Mundlos, Stefan/ABH-9585-2020	Crompton, Tessa/0000-0002-8973-4021	NIAMS NIH HHS [AR36819] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036819, R01AR036819] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; DUCY P, 1995, MOL CELL BIOL, V15, P1858; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Hamvas R, 1996, MAMM GENOME, V6, pS281; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P495; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; MALIK NJ, 1982, J CLIN PATHOL, V35, P1092, DOI 10.1136/jcp.35.10.1092; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Ramesar RS, 1996, J MED GENET, V33, P511, DOI 10.1136/jmg.33.6.511; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SELBY PB, 1978, MUTAT RES, V51, P199, DOI 10.1016/S0027-5107(78)80019-0; SILIENCE DO, 1987, AM J MED GENET, V27, P75; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444	19	2289	2374	6	90	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					765	771		10.1016/S0092-8674(00)80259-7	http://dx.doi.org/10.1016/S0092-8674(00)80259-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182764	Bronze			2022-12-28	WOS:A1997XB92500013
J	Dujon, B; Albermann, K; Aldea, M; Alexandraki, D; Ansorge, W; Arino, J; Benes, V; Bohn, C; BolotinFukuhara, M; Bordonne, R; Boyer, J; Camasses, A; Casamayor, A; Casas, C; Cheret, G; Cziepluch, C; DaignanFornier, B; Dang, DV; deHaan, M; Delius, H; Durand, P; Fairhead, C; Feldmann, H; Gaillon, L; Galisson, F; Gamo, FJ; Gancedo, C; Goffeau, A; Goulding, SE; Grivell, LA; Habbig, B; Hand, NJ; Hani, J; Hattenhorst, U; Hebling, U; Hernando, Y; Herrero, E; Heumann, K; Hiesel, R; Hilger, F; Hofmann, B; Hollenberg, CP; Hughes, B; Jauniaux, JC; Kalogeropoulos, A; Katsoulou, C; Kordes, E; Lafuente, MJ; Landt, O; Louis, EJ; Maarse, AC; Madania, A; Mannhaupt, G; Marck, C; Martin, RP; Mewes, HW; Michaux, G; Paces, V; ParleMcDermott, AG; Pearson, BM; Perrin, A; Pettersson, B; Poch, O; Pohl, TM; Poirey, R; Portetelle, D; Pujol, A; Purnelle, B; Rad, MR; Rechmann, S; Schwager, C; Schweizer, M; Sor, F; Sterky, F; Tarassov, IA; Teodoru, C; Tettelin, H; Thierry, A; Tobiasch, E; Tzermia, M; Uhlen, M; Unseld, M; Valens, M; Vandenbol, M; Vetter, I; Vicek, C; Voet, M; Volckaert, G; Voss, H; Wambutt, R; Wedler, H; Wiemann, S; Winsor, B; Wolfe, KH; Zollner, A; Zumstein, E; Kleine, K				Dujon, B; Albermann, K; Aldea, M; Alexandraki, D; Ansorge, W; Arino, J; Benes, V; Bohn, C; BolotinFukuhara, M; Bordonne, R; Boyer, J; Camasses, A; Casamayor, A; Casas, C; Cheret, G; Cziepluch, C; DaignanFornier, B; Dang, DV; deHaan, M; Delius, H; Durand, P; Fairhead, C; Feldmann, H; Gaillon, L; Galisson, F; Gamo, FJ; Gancedo, C; Goffeau, A; Goulding, SE; Grivell, LA; Habbig, B; Hand, NJ; Hani, J; Hattenhorst, U; Hebling, U; Hernando, Y; Herrero, E; Heumann, K; Hiesel, R; Hilger, F; Hofmann, B; Hollenberg, CP; Hughes, B; Jauniaux, JC; Kalogeropoulos, A; Katsoulou, C; Kordes, E; Lafuente, MJ; Landt, O; Louis, EJ; Maarse, AC; Madania, A; Mannhaupt, G; Marck, C; Martin, RP; Mewes, HW; Michaux, G; Paces, V; ParleMcDermott, AG; Pearson, BM; Perrin, A; Pettersson, B; Poch, O; Pohl, TM; Poirey, R; Portetelle, D; Pujol, A; Purnelle, B; Rad, MR; Rechmann, S; Schwager, C; Schweizer, M; Sor, F; Sterky, F; Tarassov, IA; Teodoru, C; Tettelin, H; Thierry, A; Tobiasch, E; Tzermia, M; Uhlen, M; Unseld, M; Valens, M; Vandenbol, M; Vetter, I; Vicek, C; Voet, M; Volckaert, G; Voss, H; Wambutt, R; Wedler, H; Wiemann, S; Winsor, B; Wolfe, KH; Zollner, A; Zumstein, E; Kleine, K			The nucleotide sequence of Saccharomyces cerevisiae chromosome XV	NATURE			English	Article							OPEN READING FRAMES; COMPLETE DNA-SEQUENCE; LEFT ARM; FRAGMENT; GENE; CONTAINS; SEGMENT	Chromosome XV was one of the last two chromosomes of Saccharomyces cerevisiae to be discovered(1). It is the third-largest yeast chromosome after chromosomes XII and IV, and is very similar in size to chromosome VII. It alone represents 9% of the yeast genome (8% if ribosomal DNA is included). When systematic sequencing of chromosome XV was started, 93 genes or markers were identified, and most of them were mapped(2). However, very little else was known about chromosome XV which, in contrast to shorter chromosomes, had not been the object of comprehensive genetic or molecular analysis. It was therefore decided to start sequencing chromosome XV only in the third phase of the European Yeast Genome Sequencing Programme, after experience was gained on chromosomes III, XI and II (refs 3-5). The sequence of chromosome XV has been determined from a set of partly overlapping cosmid clones derived from a unique yeast strain, and physically mapped at 3.3-kilobase resolution before sequencing. As well as numerous new open reading frames (ORFs) and genes encoding tRNA or small RNA molecules, the sequence of 1,091,283 base pairs confirms the high proportion of orphan genes and reveals a number of ancestral and successive duplications with other yeast chromosomes.	UNIV PARIS 06, INST PASTEUR, UFR 927, F-75724 PARIS 15, FRANCE; MAX PLANCK INST BIOCHEM, MARTINSRIEDER INST PROT SEQUENZEN, D-82152 MARTINSRIED, GERMANY; UNIV LLEIDA, FAC MED, DEPT BASIC MED SCI, E-25006 LLEIDA, SPAIN; FDN RES & TECHNOL HELLAS, IMBB, IRAKLION 71110, CRETE, GREECE; UNIV CRETE, DEPT BIOL, IRAKLION 71110, CRETE, GREECE; EUROPEAN MOL BIOL LAB, BIOCHEM INSTRUMENTAT PROGRAM, D-69117 HEIDELBERG, GERMANY; UNIV AUTONOMA BARCELONA, DEPT BIOQUIM & BIOL MOL, E-08193 BELLATERRA, SPAIN; UNIV PARIS 11, INST GENET & MICROBIOL, F-91405 ORSAY, FRANCE; CNRS, UPR 9005 MMDCD, F-67084 STRASBOURG, FRANCE; INST CURIE, F-91405 ORSAY, FRANCE; DEUTSCH KREBSFORSCHUNGSZENTRUM, TUMORVIROL ABT 0610, D-69009 HEIDELBERG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, INSERM, U375, D-69009 HEIDELBERG, GERMANY; UNIV AMSTERDAM, DEPT MOL CELL BIOL, MOL BIOL SECT, NL-1098 SM AMSTERDAM, NETHERLANDS; DEUTSCH KREBSFORSCHUNGSZENTRUM, ABT ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY; FAC UNIV SCI AGRON, UNITE MICROBIOL, B-5030 GEMBLOUX, BELGIUM; UNIV MUNICH, INST PHYSIOL CHEM PHYS BIOCHEM & ZELLBIOL, D-80336 MUNICH, GERMANY; CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; UNIV DUBLIN TRINITY COLL, DEPT GENET, DUBLIN 2, IRELAND; UNIV DUSSELDORF, INST MIKROBIOL, D-40225 DUSSELDORF, GERMANY; INST FOOD RES, DEPT GENET & MICROBIOL, NORWICH NR4 7UA, NORFOLK, ENGLAND; INST GENBIOL FORSCH, D-14195 BERLIN, GERMANY; GATC GESELL ANAL TECH & CONSULTING MBH, D-78467 CONSTANCE, GERMANY; TIB MOLBIOL, D-10829 BERLIN, GERMANY; JOHN RADCLIFFE HOSP, INST MOL MED, OXFORD OX3 9DU, ENGLAND; CEA SACLAY, DSV, DEPT BIOL CELLULAIRE & MOL, SERV BIOCHIM & GENET MOL, F-91191 GIF SUR YVETTE, FRANCE; ROYAL INST TECHNOL, DEPT BIOCHEM & BIOTECHNOL, S-10044 STOCKHOLM, SWEDEN; KATHOLIEKE UNIV LEUVEN, LAB GENE TECHNOL, B-3001 LOUVAIN, BELGIUM; AGON GMBH, D-12489 BERLIN, GERMANY	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Max Planck Society; Universitat de Lleida; Foundation for Research & Technology - Hellas (FORTH); University of Crete; European Molecular Biology Laboratory (EMBL); Autonomous University of Barcelona; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Amsterdam; Helmholtz Association; German Cancer Research Center (DKFZ); University of Liege; University of Munich; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Universite Catholique Louvain; Trinity College Dublin; Heinrich Heine University Dusseldorf; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; University of Oxford; CEA; UDICE-French Research Universities; Universite Paris Saclay; Royal Institute of Technology; KU Leuven	Dujon, B (corresponding author), INST PASTEUR, UNITE GENET MOL LEVURES, CNRS, URA 1149, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.		Louis, Edward/B-7920-2008; Gancedo, Carlos/E-9831-2016; Aldea, Marti/K-3962-2014; Fairhead, Cecile/D-9011-2014; Hand, Nicholas/Q-4235-2019; Casas, Celia/B-4963-2010; Uhlen, Mathias/B-3262-2016; Michaux, Gregoire/X-6586-2019; Paces, Vaclav/G-3831-2014; Dujon, Bernard A/F-4971-2010; Herrero, Enrique/B-5592-2009; Pujol, Aurora/N-4990-2014; Wolfe, Kenneth H/B-4653-2009; Hernando, Yolanda/D-2520-2014; Wiemann, Stefan/E-4424-2013; Casamayor, Antonio/C-2509-2017; Arino, Joaquin/D-3756-2011; Ansorge, Wilhelm/AAN-8780-2020; Uhlen, Mathias/AAV-8746-2021; Poirey, Rémy/A-4324-2017; Casamayor, Antonio/A-3190-2012; Hand, Nicholas J/O-2508-2016; Mewes, Hans-Werner/A-8204-2019	Louis, Edward/0000-0003-1157-3608; Gancedo, Carlos/0000-0002-6278-3667; Aldea, Marti/0000-0002-8710-5336; Hand, Nicholas/0000-0002-8172-1816; Casas, Celia/0000-0003-4140-5533; Uhlen, Mathias/0000-0002-4858-8056; Michaux, Gregoire/0000-0003-1222-5461; Herrero, Enrique/0000-0002-6763-111X; Pujol, Aurora/0000-0002-9606-0600; Hernando, Yolanda/0000-0001-7378-9434; Wiemann, Stefan/0000-0003-4683-3174; Arino, Joaquin/0000-0002-6774-2987; Casamayor, Antonio/0000-0003-2788-7329; Hand, Nicholas J/0000-0002-8172-1816; Fairhead, Cecile/0000-0002-0456-0377; Poirey, Remy/0000-0001-8171-3317; /0000-0003-3281-8088; Mewes, Hans-Werner/0000-0002-9713-6398; Arino Carmona, Joaquin/0000-0002-0390-4270; Bohn, Chantal/0000-0003-1569-9072; Bolotin-Fukuhara, Monique/0000-0002-5285-5006; Benes, Vladimir/0000-0002-0352-2547				Aldea M, 1996, YEAST, V12, P1053; Bordonne R, 1997, YEAST, V13, P73; Boyer J, 1996, YEAST, V12, P1575, DOI 10.1002/(SICI)1097-0061(199612)12:15<1575::AID-YEA45>3.0.CO;2-E; CASAMAYOR A, 1995, YEAST, V11, P1281, DOI 10.1002/yea.320111308; Casamayor A, 1996, YEAST, V12, P1013, DOI 10.1002/(SICI)1097-0061(199609)12:10B<1013::AID-YEA980>3.3.CO;2-X; CASAS C, 1995, YEAST, V11, P1061, DOI 10.1002/yea.320111107; Cheret G, 1996, YEAST, V12, P1059, DOI 10.1002/(SICI)1097-0061(199609)12:10B<1059::AID-YEA994>3.0.CO;2-7; DUJON B, 1996, TRENDS GENET, V12, P2263; DUJON B, 1994, NATURE, V396, P371; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; Galisson F, 1996, YEAST, V12, P877, DOI 10.1002/(SICI)1097-0061(199607)12:9<877::AID-YEA969>3.0.CO;2-S; Gamo FJ, 1996, YEAST, V12, P709, DOI 10.1002/(SICI)1097-0061(19960615)12:7<709::AID-YEA957>3.0.CO;2-1; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GOFFEAU A, 1993, FEBS LETT, V325, P112, DOI 10.1016/0014-5793(93)81425-Y; HAWTHORNE DC, 1968, GENETICS, V60, P735; Lafuente MJ, 1996, YEAST, V12, P1041; Madania A, 1996, YEAST, V12, P1563; Mannhaupt G, 1996, YEAST, V12, P67, DOI 10.1002/(SICI)1097-0061(199601)12:1<67::AID-YEA884>3.0.CO;2-F; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; Parle-Mcdermott Anne G., 1996, Yeast, V12, P999, DOI 10.1002/(SICI)1097-0061(199609)12:10B<999::AID-YEA976>3.0.CO;2-E; Pearson BM, 1996, YEAST, V12, P1021; Purnelle B, 1996, YEAST, V12, P1475, DOI 10.1002/(SICI)1097-0061(199611)12:14<1475::AID-YEA32>3.0.CO;2-V; Richard GF, 1996, GENE, V174, P165, DOI 10.1016/0378-1119(96)00514-8; Sterky F, 1996, YEAST, V12, P1091; THIERRY A, 1992, NUCLEIC ACIDS RES, V20, P5625, DOI 10.1093/nar/20.21.5625; VANDENBOL M, 1995, YEAST, V11, P1069, DOI 10.1002/yea.320111108; Wiemann S, 1996, YEAST, V12, P281; ZUMSTEIN E, 1994, YEAST, V10, P1383, DOI 10.1002/yea.320101015; ZUMSTEIN E, 1995, YEAST, V11, P975, DOI 10.1002/yea.320111009	30	43	653	0	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632		S			98	102		10.1038/387s098	http://dx.doi.org/10.1038/387s098			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169874				2022-12-28	WOS:A1997XB54600014
J	Wilding, P; Clark, M; Coon, JT; Lewis, S; Rushton, L; Bennett, J; Oborne, J; Cooper, S; Tattersfield, AE				Wilding, P; Clark, M; Coon, JT; Lewis, S; Rushton, L; Bennett, J; Oborne, J; Cooper, S; Tattersfield, AE			Effect of long term treatment with salmeterol on asthma control: A double blind, randomised crossover study	BRITISH MEDICAL JOURNAL			English	Article							TO-MODERATE ASTHMA; ADRENOCEPTOR AGONIST; SALBUTAMOL; ALBUTEROL; XINAFOATE	Objectives: To determine the effect of adding salmeterol 50 mu g twice daily for six months to current treatment in subjects with asthma who control their inhaled corticosteroid dose according to a management plan. Design: A double blind, randomised crossover study. Setting: Nottingham. Subjects: 101 subjects with mild or moderate asthma taking at least 200 mu g twice daily of beclomethasone dipropionate or budesonide. Interventions: Salmeterol 50 mu g twice daily and placebo for six months each, with a one month washout. Subjects adjusted inhaled steroid dose according to guidelines. Main outcome measure: Reduction in inhaled steroid use, exacerbations of asthma, and use of oral steroids. Results: Data were available for 87 subjects. When compared with placebo salmeterol treatment was associated with a 17% reduction in inhaled steroid use (95% confidence interval 12% to 22%) with no significant difference in the number of subjects who had an exacerbation (placebo 25%, salmeterol 16%) or use of oral steroids, For secondary end points salmeterol treatment was associated with higher morning and evening peak expiratory flow and forced expiratory volume in one second; a reduction in symptoms, bronchodilator use, and airway responsiveness to methacholine; and no effect on serum potassium concentration, 24 hour heart rate, or the final forced expiratory volume in one second achieved during a salbutamol dose-response study. Conclusions: Ln subjects who adjusted their inhaled steroid treatment according to guidelines the addition of salmeterol 50 mu g twice daily was associated with a reduction in inhaled steroid use and improved lung function and symptom control.	CITY HOSP NOTTINGHAM,DIV RESP MED,NOTTINGHAM NG5 1PB,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT PUBL HLTH MED,NOTTINGHAM NG7 2UH,ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham			Cooper, Sue/A-7471-2011	Cooper, Sue/0000-0002-1994-6395; Clark, Miranda/0000-0002-6179-046X				Apter AJ, 1996, J ALLERGY CLIN IMMUN, V98, P295, DOI 10.1016/S0091-6749(96)70153-7; BENNETT JA, 1994, THORAX, V49, P771, DOI 10.1136/thx.49.8.771; BRITTON MG, 1992, EUR RESPIR J, V5, P1062; CAMPOSGONGORA H, 1991, AM REV RESPIR DIS, V144, P626; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; DAHL R, 1991, EUR RESPIR J, V4, P1178; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; FITZPATRICK MF, 1990, BRIT MED J, V301, P1365, DOI 10.1136/bmj.301.6765.1365; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006, DOI 10.1164/ajrccm.150.4.7921429; GROVE A, 1995, LANCET, V346, P201, DOI 10.1016/S0140-6736(95)91265-7; *INT ASTHM MAN PRO, 1992, CLIN EXP ALLERGY S1, V22, P1; JONES B, 1989, DESIGN ANAL CROSSOVE; JONES KP, 1994, THORAX, V49, P971, DOI 10.1136/thx.49.10.971; JUNIPER EF, 1995, AM J RESP CRIT CARE, V151, P66, DOI 10.1164/ajrccm.151.1.7812574; LUNDBACK B, 1993, THORAX, V48, P148, DOI 10.1136/thx.48.2.148; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; ROBERTS J A, 1992, American Review of Respiratory Disease, V145, pA418; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SMYTH ET, 1993, BRIT MED J, V306, P543, DOI 10.1136/bmj.306.6877.543; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; ULLMAN A, 1990, AM REV RESPIR DIS, V142, P571, DOI 10.1164/ajrccm/142.3.571; VATHENEN AS, 1988, LANCET, V1, P554; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; 1997, THORAX S1, V52	28	100	110	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1441	1446		10.1136/bmj.314.7092.1441	http://dx.doi.org/10.1136/bmj.314.7092.1441			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167559	Green Published			2022-12-28	WOS:A1997XA20200020
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			How to use Usenet	SCIENCE			English	Article																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1893	&						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206846				2022-12-28	WOS:A1997XF10300060
J	Joseph, JS; Chun, MM; Nakayama, K				Joseph, JS; Chun, MM; Nakayama, K			Attentional requirements in a 'preattentive' feature search task	NATURE			English	Article							VISUAL-SEARCH; VISION; PERCEPTION; ELEMENTS; TEXTONS; MODEL	It is commonly assumed that certain features are so elementary to the visual system that they require no attentional resources to be perceived. Such 'preattentive' features are traditionally identified by visual search performance(1-3), in which the reaction time for detecting a feature difference against a set of distracter items does not increase with the number of distracters. This suggests an unlimited capacity for the perception of such features. We provide evidence to the contrary, demonstrating that detection of differences in a simple feature such as orientation is severely impaired by additionally imposing an attentionally demanding rapid serial visual presentation task involving letter identification. The same visual stimuli exhibit non-increasing reaction time versus set-size functions. These results demonstrate that attention can be critical even for the detection of so-called 'preattentive' features.	YALE UNIV, DEPT PSYCHOL, NEW HAVEN, CT 06520 USA; HARVARD UNIV, DEPT PSYCHOL, CAMBRIDGE, MA 02138 USA	Yale University; Harvard University	Joseph, JS (corresponding author), UNIV NEVADA, DEPT PSYCHOL, RENO, NV 89557 USA.			Chun, Marvin/0000-0003-1070-7993				BRAUN J, 1994, J NEUROSCI, V14, P554; BRAUN J, 1990, PERCEPT PSYCHOPHYS, V48, P45, DOI 10.3758/BF03205010; BRAUN J, 1991, PERCEPTION, V20, P483, DOI 10.1068/p200483; CHUN MM, 1995, J EXP PSYCHOL HUMAN, V21, P109; DUNCAN J, 1994, NATURE, V369, P313, DOI 10.1038/369313a0; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; JULESZ B, 1981, NATURE, V290, P91, DOI 10.1038/290091a0; JULESZ B, 1983, BELL SYST TECH J, V62, P1619, DOI 10.1002/j.1538-7305.1983.tb03502.x; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; MACK A, 1992, COGNITIVE PSYCHOL, V24, P475, DOI 10.1016/0010-0285(92)90016-U; Neisser U., 1967, COGNITIVE PSYCHOL; NORMAN DA, 1975, COGNITIVE PSYCHOL, V7, P44, DOI 10.1016/0010-0285(75)90004-3; RAYMOND JE, 1992, J EXP PSYCHOL HUMAN, V18, P849, DOI 10.1037/0096-1523.18.3.849; ROCK I, 1992, COGNITIVE PSYCHOL, V24, P502, DOI 10.1016/0010-0285(92)90017-V; TREISMAN A, 1990, J EXP PSYCHOL HUMAN, V16, P459, DOI 10.1037/0096-1523.16.3.459; TREISMAN A, 1985, COMPUT VISION GRAPH, V31, P156, DOI 10.1016/S0734-189X(85)80004-9; WOLFE JM, 1994, PSYCHON B REV, V1, P202, DOI 10.3758/BF03200774	17	325	334	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 19	1997	387	6635					805	807		10.1038/42940	http://dx.doi.org/10.1038/42940			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XF144	9194560	Bronze			2022-12-28	WOS:A1997XF14400050
J	Russell, RM				Russell, RM			Nutrition	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Russell, RM (corresponding author), TUFTS UNIV, JEAN MAYER USDA HUMAN NUTR RES CTR AGING, BOSTON, MA 02111 USA.							Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; ATKINSON RL, 1994, AM J CLIN NUTR, V60, P153, DOI 10.1093/ajcn/60.2.153; Blackburn H, 1996, NEW ENGL J MED, V334, P984, DOI 10.1056/NEJM199604113341511; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P669; DIXON ZR, 1994, FREE RADICAL BIO MED, V17, P537, DOI 10.1016/0891-5849(94)90093-0; GOLDSTEIN DJ, 1994, AM J CLIN NUTR, V60, P647, DOI 10.1093/ajcn/60.5.647; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; Rimm EB, 1996, ANN INTERN MED, V125, P384, DOI 10.7326/0003-4819-125-5-199609010-00005; ROLLS BJ, 1992, AM J CLIN NUTR, V56, P84, DOI 10.1093/ajcn/56.1.84; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; SHELOV SP, 1995, PEDIATRICS, V96, P786	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1876	1878						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185812				2022-12-28	WOS:A1997XD54400031
J	Sulmasy, DP; Lynn, J				Sulmasy, DP; Lynn, J			End-of-life care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Sulmasy, DP (corresponding author), GEORGETOWN UNIV, MED CTR, WASHINGTON, DC 20007 USA.							Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; *AMA POLL, 1997, AM MED NEWS     0113, V40, P56; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BACON F, 1905, PHILOS WORKS F BACON, V2, P487; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; ENDE J, 1997, GRADUATE ED INTERNAL; JONES WHS, 1992, HIPPOCRATES, V2, P193; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lee MA, 1996, ANN INTERN MED, V124, P267, DOI 10.7326/0003-4819-124-2-199601150-00014; Lynn J, 1996, NEW ENGL J MED, V335, P201, DOI 10.1056/NEJM199607183350311; Lynn J, 1997, J AM GERIATR SOC, V45, P489, DOI 10.1111/j.1532-5415.1997.tb05176.x; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; *US BUR CENS, 1995, STAT ABSTR US, P86; VITEZ M, 1997, PHILADELPHIA IN 0108, P3; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; 1996, C ED PHYS DYING APR	20	9	9	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1854	1855						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185798				2022-12-28	WOS:A1997XD54400017
J	Linzer, M; Yang, EH; Estes, NAM; Wang, P; Vorperian, VR; Kapoor, WN				Linzer, M; Yang, EH; Estes, NAM; Wang, P; Vorperian, VR; Kapoor, WN			Diagnosing syncope .1. Value of history, physical examination, and electrocardiography	ANNALS OF INTERNAL MEDICINE			English	Article							ORTHOSTATIC HYPOTENSION; TRANSIENT LOSS; CONSCIOUSNESS; DIZZINESS; ATTACK; CARE	Purpose: To review the literature on diagnostic testing in syncope and provide recommendations for a comprehensive, cost-effective approach to establishing its cause. Data Sources: Studies were identified through a MEDLINE search (1980 to present) and a manual review of bibliographies of identified articles. Study Selection: Papers were eligible if they addressed diagnostic testing in syncope or near syncope and reported results for at least 10 patients. Data Extraction: The usefulness of tests was assessed by calculating diagnostic yield: the number of patients with diagnostically positive test results divided by the number of patients tested or, in the case of monitoring studies, the sum of true-positive and true-negative test results divided by the number of patients tested. Data Synthesis: Despite the absence of a diagnostic gold standard and the paucity of data from randomized trials, several points emerge. First, history, physical examination, and electrocardiography are the core of the syncope workup (combined diagnostic yield, 50%). Second, neurologic testing is rarely helpful unless additional neurologic signs or symptoms are present (diagnostic yield of electroencephalography, computed tomography, and Doppler ultrasonography, 2% to 6%). Third, patients in whom heart disease is known or suspected or those with exertional syncope are at higher risk for adverse outcomes and should have cardiac testing, including echocardiography, stress testing, Holter monitoring, or intracardiac electrophysiologic studies, alone or in combination (diagnostic yields, 5% to 35%). Fourth, syncope in the elderly often results from polypharmacy and abnormal physiologic responses to daily events. Fifth, long-term loop electrocardiography (diagnostic yield, 25% to 35%) and tilt testing (diagnostic yield less than or equal to 60%) are most useful in patients with recurrent syncope in whom heart disease is not suspected. Sixth, psychiatric evaluation can detect mental disorders associated with syncope in up to 25% of cases. Seventh, hospitalization may be indicated for patients at high risk for cardiac syncope (those with an abnormal electrocardiogram, organic heart disease, chest pain, history of arrhythmia, age >70 years) or with acute neurologic signs. Conclusions: Many tests for syncope have a low diagnostic yield. A careful history, physical examination, and electrocardiography will provide a diagnosis or determine whether diagnostic testing is necessary in most patients.	UNIV WISCONSIN, SCH MED, MADISON, WI 53705 USA; TUFTS UNIV NEW ENGLAND MED CTR, DIV CARDIOL, BOSTON, MA 02111 USA; UNIV WISCONSIN, SCH MED, DEPT MED, CLIN SCI CTR H6375, MADISON, WI 53792 USA; UNIV PITTSBURGH, PITTSBURGH, PA 15261 USA	University of Wisconsin System; University of Wisconsin Madison; Tufts Medical Center; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Linzer, M (corresponding author), UNIV WISCONSIN, SCH MED, DEPT MED, CLIN SCI CTR J5210, 600 HIGHLAND AVE, MADISON, WI 53792 USA.							ATKINS D, 1991, AM J MED, V91, P179, DOI 10.1016/0002-9343(91)90012-M; BANNISTER SR, 1988, AUTONOMIC FAILURE TX; BENCHETRIT E, 1985, ISRAEL J MED SCI, V21, P950; BRANCH WT, 1986, J GEN INTERN MED, V1, P49, DOI 10.1007/BF02596326; BRIGNOLE M, 1993, J AM COLL CARDIOL, V22, P1123, DOI 10.1016/0735-1097(93)90426-2; Cruikshank D. P., 1991, OBSTETRICS NORMAL PR, P125; DAVIDSON E, 1991, CLIN CARDIOL, V14, P141, DOI 10.1002/clc.4960140210; DAVIS TL, 1990, ARCH INTERN MED, V150, P2027, DOI 10.1001/archinte.150.10.2027; DAY SC, 1982, AM J MED, V73, P15, DOI 10.1016/0002-9343(82)90913-5; EAGLE KA, 1983, YALE J BIOL MED, V56, P1; GENDELMAN HE, 1983, NEW YORK STATE J MED, V83, P1161; GILLIGAN DM, 1992, CIRCULATION, V85, P2140, DOI 10.1161/01.CIR.85.6.2140; GRECH ED, 1991, AM HEART J, V121, P603, DOI 10.1016/0002-8703(91)90737-3; HANLON JT, 1990, ARCH INTERN MED, V150, P2309, DOI 10.1001/archinte.150.11.2309; HOEFNAGELS WAJ, 1991, J NEUROL NEUROSUR PS, V54, P953, DOI 10.1136/jnnp.54.11.953; KAPOOR WN, 1982, JAMA-J AM MED ASSOC, V247, P2687, DOI 10.1001/jama.247.19.2687; KAPOOR WN, 1990, MEDICINE, V69, P160, DOI 10.1097/00005792-199005000-00004; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; KROENKE K, 1992, ANN INTERN MED, V117, P898, DOI 10.7326/0003-4819-117-11-898; LANDON MB, 1991, OBSTETRICS NORMAL PR, P1057; LEITCH JW, 1992, CIRCULATION, V85, P1064, DOI 10.1161/01.CIR.85.3.1064; LINZER M, 1991, J CLIN EPIDEMIOL, V44, P1037, DOI 10.1016/0895-4356(91)90005-T; LINZER M, 1994, AM J MED, V96, P146, DOI 10.1016/0002-9343(94)90135-X; LIPSITZ LA, 1983, J AM GERIATR SOC, V31, P617, DOI 10.1111/j.1532-5415.1983.tb04605.x; LIPSITZ LA, 1989, NEW ENGL J MED, V321, P952; MANOLIS AS, 1990, ANN INTERN MED, V112, P850, DOI 10.7326/0003-4819-112-11-850; MARTIN GJ, 1984, ANN EMERG MED, V13, P499, DOI 10.1016/S0196-0644(84)80511-9; PAVLOVIC SU, 1991, PACE, V14, P2086, DOI 10.1111/j.1540-8159.1991.tb06478.x; POUNGVARIN N, 1990, Journal of the Medical Association of Thailand, V73, P593; SILVERSTEIN MD, 1982, JAMA-J AM MED ASSOC, V248, P1185, DOI 10.1001/jama.248.10.1185; SIMPSON RJ, 1983, JAMA-J AM MED ASSOC, V249, P390, DOI 10.1001/jama.249.3.390; SLOANE PD, 1991, ARCH INTERN MED, V151, P1625, DOI 10.1001/archinte.151.8.1625; URETSKY BF, 1977, AM J CARDIOL, V40, P498, DOI 10.1016/0002-9149(77)90062-5; YONEHARA T, 1994, STROKE, V25, P2407, DOI 10.1161/01.STR.25.12.2407	34	318	333	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1997	126	12					989	996		10.7326/0003-4819-126-12-199706150-00012	http://dx.doi.org/10.7326/0003-4819-126-12-199706150-00012			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE549	9182479				2022-12-28	WOS:A1997XE54900014
J	Bhopal, R				Bhopal, R			Is research into ethnicity and health racist, unsound or important science?	BRITISH MEDICAL JOURNAL			English	Article							BLACK-BOX; MINORITIES; RACE; ASIANS; RISK	Much historical research on race, intelligence, and health was racist, unethical, and ineffective. The concepts of race and ethnicity are difficult to define but continue to be applied to the study of the health of immigrant and ethnic minority groups in the hope of advancing understanding of causes of disease. While a morass of associations has been generated, race and ethnicity in health research have seldom given fundamental new understanding of disease. Most such research is ''black box epidemiology.'' Researchers have not overcome the many conceptual and technical problems of research into ethnicity and health. By emphasising the negative aspects of the health of ethnic minority groups, research may have damaged their social standing and deflected attention from their health priorities, Unless researchers recognise the difficulties with research into ethnicity and health and correct its weaknesses, 20th century research in this subject may suffer the same ignominious fate as that ofrace science in the 19th century.	UNIV NEWCASTLE UPON TYNE,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK								Ahmad W, 1993, RACE HLTH CONT BRITA; AHMAD WIU, 1989, LANCET, V1, P148; *AM COLL EP, 1995, ANN EPIDEMIOL, V5, P505; [Anonymous], 1989, RACIAL ETHNIC DIFFER; BALARAJAN R, 1986, COMMUNITY MED, V8, P131; BALARAJAN R, 1984, BRIT MED J, V289, P1185, DOI 10.1136/bmj.289.6453.1185; BALARAJAN R, 1990, MORTALITY GEOGRAPHY; Banton Michael, 1987, RACIAL THEORIES; Barkan Elazar., 1992, RETREAT SCI RACISM; BARKER RM, 1990, J EPIDEMIOL COMMUNIT, V44, P127; BHOPAL R, IN PRESS ETHN HLTH; Bhopal R S, 1988, Health Educ J, V47, P137, DOI 10.1177/001789698804700411; BHOPAL RS, 1991, J PUBLIC HEALTH MED, V13, P244; BHOPAL RS, 1988, EQUITY; BHOPAL RS, 1996, BR J CANC S29, V74, P522; BHOPAL RS, IN PRESS HLTH NEEDS; BHOPAL RS, 1990, ETHNIC MINORITIES HL, V1, P1; Biddiss M, 1979, IMAGES RACE; Biddiss M., 1970, GOBINEAU SELECTED PO; Bolt Christine, 1971, VICTORIAN ATTITUDES; BRANDT AM, 1978, HASTINGS CENT REP, V8, P21, DOI 10.2307/3561468; CRUIKSHANK JK, 1989, ETHNIC FACTORS HLTH; DONALDSON LJ, 1984, J EPIDEMIOL COMMUN H, V38, P203, DOI 10.1136/jech.38.3.203; DONOVAN JL, 1984, SOC SCI MED, V19, P663, DOI 10.1016/0277-9536(84)90237-5; EBLING FJ, 1974, RACIAL VARIATION MAN; ECOB R, 1991, J EPIDEMIOL COMMUN H, V45, P93, DOI 10.1136/jech.45.2.93; Gould S. J., 1990, HENS TEETH HORSES TO; Gould Stephen Jay, 1984, MISMEASURE MAN; Health Education Authority, 1994, HLTH LIF BLACK MIN E; Hernstein R. J., 1994, BELL CURVE; HOPKINSON ND, 1994, ANN RHEUM DIS, V53, P675, DOI 10.1136/ard.53.10.675; HUTH EJ, 1995, ANN INTERN MED, V122, P619, DOI 10.7326/0003-4819-122-8-199504150-00012; JOHNSON MRD, 1984, J ROY COLL PHYS LOND, V18, P228; KARMI G, 1993, ETHNIC HLTH BIBLIO; Kiple K. F, 2003, ANOTHER DIMENSION BL; Kuper Leo, 1975, RACE SCI SOC; LILLIEBLANTON M, 1993, JAMA-J AM MED ASSOC, V269, P993, DOI 10.1001/jama.269.8.993; Marmot MG, 1984, IMMIGRANT MORTALITY; Matheson L M, 1985, Health Bull (Edinb), V43, P245; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; McKenzie K, 1996, BRIT MED J, V312, P1054; MCMANUS IC, 1995, BRIT MED J, V310, P496, DOI 10.1136/bmj.310.6978.496; MELIA RJW, 1988, BRIT MED J, V296, P1438, DOI 10.1136/bmj.296.6634.1438; Morrison Toni, 1993, BELOVED; MOSS KL, 1996, POVERTY RACE, V5, P1; ODonnell Mike, 1991, RACE ETHNICITY; OSBORNE NG, 1992, JAMA-J AM MED ASSOC, V267, P275, DOI 10.1001/jama.267.2.275; Osborne R.T., 1978, HUMAN VARIATION BIOP; PEARSON M, 1990, ETHNIC FACTORS HLTH, P71; RAMAIYA KL, 1991, BRIT MED J, V303, P271, DOI 10.1136/bmj.303.6797.271; ROTHSCHILD H, 1981, BIOCULTURAL ASPECTS; SAVITZ DA, 1994, EPIDEMIOLOGY, V5, P550; Schoenbach Victor J., 1994, Annals of Epidemiology, V4, P259; SENIOR PA, 1994, BRIT MED J, V309, P327, DOI 10.1136/bmj.309.6950.327; SHELDON TA, 1992, J PUBLIC HEALTH MED, V14, P104; SKRABANEK P, 1994, EPIDEMIOLOGY, V5, P553; SMAJE C, 1995, RACE ETHNICITY HLTH; SMITH JP, 1993, J ADV NURS, V18, P850, DOI 10.1046/j.1365-2648.1993.180508478.x; Stepan N., 1982, IDEA RACE SCI; WILLIAMS JW, 1926, TXB USE STUDENTS PRA; 1992, STATE PUBLIC HLTH 19; 1996, BRIT MED J, V312, P1094	62	207	208	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1751	1756		10.1136/bmj.314.7096.1751	http://dx.doi.org/10.1136/bmj.314.7096.1751			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XE909	9202509	Green Published			2022-12-28	WOS:A1997XE90900032
J	Joyce, GF				Joyce, GF			Evolutionary chemistry: Getting there from here	SCIENCE			English	Editorial Material									Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	Joyce, GF (corresponding author), SCRIPPS RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							CONRAD M, 1979, BIOSYSTEMS, V11, P167, DOI 10.1016/0303-2647(79)90009-1; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P2532, DOI 10.1073/pnas.91.7.2532; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; SMITH JM, 1978, EVOLUTION SEX, P2; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665	5	24	25	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1658	1659		10.1126/science.276.5319.1658	http://dx.doi.org/10.1126/science.276.5319.1658			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9206829				2022-12-28	WOS:A1997XD94700028
J	Lazazzera, BA; Solomon, JM; Grossman, AD				Lazazzera, BA; Solomon, JM; Grossman, AD			An exported peptide functions intracellularly to contribute to cell density signaling in B-subtilis	CELL			English	Article							CONTROL GENE-EXPRESSION; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TRANSPORT-SYSTEM; STREPTOCOCCUS-PNEUMONIAE; TRANSCRIPTION FACTOR; TRANSDUCTION SYSTEM; SPORULATION; COMPETENCE; COMA	Competence development and sporulation in B. subtilis are partly controlled by peptides that accumulate in culture medium as cells grow to high density. We constructed two genes that encode mature forms of two different signaling molecules, the PhrA peptide that stimulates sporulation, and CSF, the competence- and sporulation-stimulating factor. Both pentapeptides are normally produced by secretion and processing of precursor molecules. The mature pentapeptides were functional when expressed inside the cell, indicating that they normally need to be imported to function. Furthermore, at physiological concentrations (10 nM), CSF was transported into the cell by the oligopeptide permease encoded by spoOK (opp). CSF was shown to have at least three different targets corresponding to its three activities: stimulating competence gene expression at low concentrations, and inhibiting competence gene expression and stimulating sporulation at high concentrations.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050895] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50895] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alloing G, 1996, MOL MICROBIOL, V21, P471; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BERGER EA, 1974, J BIOL CHEM, V249, P7747; CANGELOSI GA, 1990, P NATL ACAD SCI USA, V87, P6708, DOI 10.1073/pnas.87.17.6708; CARTER HL, 1991, GENE, V96, P101; COX GB, 1988, J BACTERIOL, V170, P2283, DOI 10.1128/jb.170.5.2283-2286.1988; DONOVAN W, 1987, J MOL BIOL, V196, P1, DOI 10.1016/0022-2836(87)90506-7; FERRARI FA, 1983, J BACTERIOL, V154, P1513, DOI 10.1128/JB.154.3.1513-1515.1983; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; Grossman AD, 1995, ANNU REV GENET, V29, P477, DOI 10.1146/annurev.ge.29.120195.002401; GROSSMAN AD, 1988, GENETICS BIOTECHNOLO, V2, P175; HAGEN DC, 1978, DEV BIOL, V64, P284, DOI 10.1016/0012-1606(78)90079-9; HAHN J, 1994, J BACTERIOL, V176, P5753, DOI 10.1128/JB.176.18.5753-5761.1994; Harwood C.R., 1990, MOL BIOL METHODS BAC; Havarstein LS, 1996, MOL MICROBIOL, V21, P863, DOI 10.1046/j.1365-2958.1996.521416.x; HAVARSTEIN LS, 1995, P NATL ACAD SCI USA, V92, P11140, DOI 10.1073/pnas.92.24.11140; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; Hoch JA, 1995, 2 COMPONENT SIGNAL T; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; JAACKS KJ, 1989, J BACTERIOL, V171, P4121, DOI 10.1128/JB.171.8.4121-4129.1989; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; KOIDE A, 1994, MOL MICROBIOL, V13, P417, DOI 10.1111/j.1365-2958.1994.tb00436.x; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; Leonard BAB, 1996, P NATL ACAD SCI USA, V93, P260, DOI 10.1073/pnas.93.1.260; MAGNUSON R, 1994, CELL, V77, P207, DOI 10.1016/0092-8674(94)90313-1; MANSON MD, 1986, NATURE, V321, P253, DOI 10.1038/321253a0; MATHIOPOULOS C, 1991, MOL MICROBIOL, V5, P1903, DOI 10.1111/j.1365-2958.1991.tb00814.x; Miller J.H., 1972, EXPT MOL GENETICS; MITANI T, 1977, BIOCHEM BIOPH RES CO, V77, P1118, DOI 10.1016/S0006-291X(77)80094-6; MOYE HA, 1979, ANAL LETT, V12, P25; MUELLER JP, 1992, J BACTERIOL, V174, P4361, DOI 10.1128/JB.174.13.4361-4373.1992; MUELLER JP, 1992, J BACTERIOL, V174, P4374, DOI 10.1128/JB.174.13.4374-4383.1992; NAKANO MM, 1989, J BACTERIOL, V171, P5347, DOI 10.1128/jb.171.10.5347-5353.1989; NAKANO MM, 1991, J BACTERIOL, V173, P5487, DOI 10.1128/jb.173.17.5487-5493.1991; NAKANO MM, 1991, J BACTERIOL, V173, P7269, DOI 10.1128/jb.173.22.7269-7274.1991; Nodwell JR, 1996, MOL MICROBIOL, V22, P881, DOI 10.1046/j.1365-2958.1996.01540.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PARMES JR, 1973, J BIOL CHEM, V248, P4429; PEARCE BJ, 1994, MOL MICROBIOL, V12, P881, DOI 10.1111/j.1365-2958.1994.tb01076.x; Perego M, 1996, P NATL ACAD SCI USA, V93, P1549, DOI 10.1073/pnas.93.4.1549; Perego M, 1996, MOL MICROBIOL, V19, P1151, DOI 10.1111/j.1365-2958.1996.tb02460.x; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Pestova EV, 1996, MOL MICROBIOL, V21, P853, DOI 10.1046/j.1365-2958.1996.501417.x; ROGGIANI M, 1993, J BACTERIOL, V175, P3182, DOI 10.1128/JB.175.10.3182-3187.1993; RUDNER DZ, 1991, J BACTERIOL, V173, P1388, DOI 10.1128/jb.173.4.1388-1398.1991; SANDMAN K, 1987, GENETICS, V117, P603; SOLOMON JM, 1995, GENE DEV, V9, P547, DOI 10.1101/gad.9.5.547; Solomon JM, 1996, GENE DEV, V10, P2014, DOI 10.1101/gad.10.16.2014; Solomon JM, 1996, TRENDS GENET, V12, P150, DOI 10.1016/0168-9525(96)10014-7; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WANNER BL, 1993, J CELL BIOCHEM, V51, P47, DOI 10.1002/jcb.240510110; WEINRAUCH Y, 1989, J BACTERIOL, V171, P5362, DOI 10.1128/jb.171.10.5362-5375.1989; WEINRAUCH Y, 1990, GENE DEV, V4, P860, DOI 10.1101/gad.4.5.860; YANSURA DG, 1984, P NATL ACAD SCI-BIOL, V81, P439, DOI 10.1073/pnas.81.2.439	59	192	198	1	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 13	1997	89	6					917	925		10.1016/S0092-8674(00)80277-9	http://dx.doi.org/10.1016/S0092-8674(00)80277-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200610	Green Published, Bronze			2022-12-28	WOS:A1997XE35700012
J	Mackenbach, JP; Kunst, AE; Cavelaars, AEJM; Groenhof, F; Geurts, JJM; Andersen, O; Bonte, JTP; Borgan, JK; Crialesi, R; Desplanques, G; Filakti, H; Harding, S; Grotvedt, L; Helmert, U; Junker, C; Lahelma, E; Lundberg, O; Martikainen, P; Matheson, J; Mielck, A; Minder, CE; Mizrahi, A; Mizrahi, A; Pagnanelli, F; Rasmussen, N; Regidor, E; Spuhler, T; Valkonen, T				Mackenbach, JP; Kunst, AE; Cavelaars, AEJM; Groenhof, F; Geurts, JJM; Andersen, O; Bonte, JTP; Borgan, JK; Crialesi, R; Desplanques, G; Filakti, H; Harding, S; Grotvedt, L; Helmert, U; Junker, C; Lahelma, E; Lundberg, O; Martikainen, P; Matheson, J; Mielck, A; Minder, CE; Mizrahi, A; Mizrahi, A; Pagnanelli, F; Rasmussen, N; Regidor, E; Spuhler, T; Valkonen, T			Socioeconomic inequalities in morbidity and mortality in western Europe	LANCET			English	Article							INTERNATIONAL VARIATION; HEALTH; SWEDEN; FINLAND; BRITAIN; FRANCE; SIZE	Background Previous studies of variation in the magnitude of socioeconomic inequalities in health between countries have methodological drawbacks. We tried to overcome these difficulties in a large study that compared inequalities in morbidity and mortality between different countries in western Europe. Methods Data on four indicators of self-reported morbidity by level of education, occupational class, and/or level of income were obtained for 11 countries, and years ranging from 1985 to 1992. Data on total mortality by level of education and/or occupational class were obtained for nine countries for about 1980 to about 1990. We calculated odds ratios or rate ratios to compare a broad lower with a broad upper socioeconomic group. We also calculated an absolute measure for inequalities in mortality, a risk difference, which takes into account differences between countries in average rates of illhealth. Findings Inequalities in health were found in all countries, Odds ratios for morbidity ranged between about 1.5 and 2.5, and rate ratios for mortality between about 1.3 and 1.7. For men's perceived general health, for instance, inequalities by level of education in Norway were larger than in Switzerland or Spain (odds ratios [95% CI]: 2.57 [2.07-3.18], 1.60 [1.30-1.96], 1.65 [1.44-1.88], respectively). For mortality by occupational class, in men aged 30-44, the rate ratio was highest in Finland (1.76 [1.69-1.83]), although there was no large difference in the size of the inequality in those countries with data. For men aged 45-59, for whom France did have data, this country had the largest inequality (1.71 [1.66-1.77]). In the age-group 45-64, the absolute risk difference ranked Finland second after France (9.8% [9.1-10.4], 11.5% [10.7-12.4]), with Sweden and Norway coming out more favourably than on the basis of rate ratios. In a scatter-plot of average rank scores for morbidity versus mortality, Sweden and Norway had larger relative inequalities in health than most other countries for both measures; France fared badly for mortality but was average for morbidity. Interpretation Our results challenge conventional views on the between-country pattern of inequalities in health in western European countries.	ERASMUS UNIV ROTTERDAM,DEPT HLTH CARE POLICY & MANAGEMENT,HEERLEN,NETHERLANDS; STAT NETHERLANDS,HEERLEN,NETHERLANDS; DANMARKS STAT,COPENHAGEN,DENMARK; STAT NETHERLANDS,VOORBURG,NETHERLANDS; STAT NORWAY,DIV HLTH,OSLO,NORWAY; INST NAZL STAT,ROME,ITALY; INSEE,LYON,FRANCE; OPCS,MED STAT SECT,LONDON,ENGLAND; BREMEN INST PRAVENT FORSCH & SOZIAL MED,BREMEN,GERMANY; UNIV BERN,INST SOZIAL & PRAVENT MED,BERN,SWITZERLAND; UNIV HELSINKI,DEPT PUBL HLTH,HELSINKI,FINLAND; UNIV STOCKHOLM,SWEDISH INST SOCIAL RES,S-10691 STOCKHOLM,SWEDEN; UNIV HELSINKI,DEPT SOCIOL,HELSINKI,FINLAND; GSF MUNICH,INST MED INFORMAT & HLTH SERV RES MEDIS,MUNICH,GERMANY; INST NAZL STAT,ROME,ITALY; DANISH INST CLIN EPIDEMIOL,COPENHAGEN,DENMARK; MINIST HLTH,DEPT EPIDEMIOL,MADRID,SPAIN; BUNDESAMT STAT,BERN,SWITZERLAND	Erasmus University Rotterdam; Statistics Norway; University of Bern; University of Helsinki; Stockholm University; University of Helsinki; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Mackenbach, JP (corresponding author), ERASMUS UNIV ROTTERDAM,DEPT PUBL HLTH,POB 1738,NL-3000 DR ROTTERDAM,NETHERLANDS.		Cavelaars, Adrienne/O-4085-2014; Di Carlo, Antonio/AAB-9776-2022; Lahelma, Eero/ABC-8716-2020	Di Carlo, Antonio/0000-0002-4822-9766; Lahelma, Eero/0000-0002-1064-1333; Kunst, Anton/0000-0002-3313-5273; Martikainen, Pekka/0000-0001-9374-1438				[Anonymous], 1990, RES SOC STRAT MOBIL; BUHMANN B, 1988, REV INCOME WEALTH, V34, P115; Erikson E, 1992, CONSTANT FLUX; Ganzeboom HBG., 1989, RES SOC STRAT MOBIL, V8, P3; Kempthorne O., 1952, DESIGN ANAL EXPT; KUNST AE, 1994, INT J EPIDEMIOL, V23, P742, DOI 10.1093/ije/23.4.742; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; KUNST AE, 1995, J EPIDEMIOL COMMUN H, V49, P117, DOI 10.1136/jech.49.2.117; Kunst AE, 1994, MEASURING SOCIOECONO; KUNST AE, 1996, EU WORK GROUP SOC IN; LAHELMA E, 1994, SOC SCI MED, V38, P517, DOI 10.1016/0277-9536(94)90248-8; LAHELMA E, 1994, EUR J PUBLIC HEALTH, V4, P213; LANG T, 1995, INT J EPIDEMIOL, V24, P331, DOI 10.1093/ije/24.2.331; LECLERC A, 1990, INT J EPIDEMIOL, V19, P1001, DOI 10.1093/ije/19.4.1001; LUNDBERG O, 1986, SOC SCI MED, V23, P511, DOI 10.1016/0277-9536(86)90011-0; Mackenbach JP, 1997, SOC SCI MED, V44, P757, DOI 10.1016/S0277-9536(96)00073-1; MARMOT MG, 1978, BMJ-BRIT MED J, V2, P1109, DOI 10.1136/bmj.2.6145.1109; MINDER CE, 1991, 5TH P M UN WHO CICRE, P278; *OECD, 1990, ED OECD COUNTR 1987; REGIDOR E, 1995, SOC SCI MED, V41, P801, DOI 10.1016/0277-9536(94)00402-F; SMITH GD, 1993, BRIT MED J, V307, P1085, DOI 10.1136/bmj.307.6912.1085; VAGERO D, 1989, LANCET, V2, P35, DOI 10.1016/S0140-6736(89)90266-3; VAGERO D, 1995, ADULT MORTALITY DEV, P223; VALKONEN T, 1993, INT J HLTH SCI, V3, P157; Valkonen T., 1989, HLTH INEQUALITIES EU, P142; VANDOORSLAER E, IN PRESS J HLTH EC; WAGSTAFF A, 1991, SOC SCI MED, V33, P545, DOI 10.1016/0277-9536(91)90212-U; *WHO, 1985, WORLD HLTH STAT ANN; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; WILKINSON RG, 1994, BRIT MED J, V308, P1113, DOI 10.1136/bmj.308.6937.1113	30	803	822	0	63	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1655	1659		10.1016/S0140-6736(96)07226-1	http://dx.doi.org/10.1016/S0140-6736(96)07226-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186383	Green Published			2022-12-28	WOS:A1997XD10000009
J	Webster, NR				Webster, NR			Ventilation in the prone position	LANCET			English	Editorial Material											Webster, NR (corresponding author), UNIV ABERDEEN,ABERDEEN AB25 2ZD,SCOTLAND.							AMIS TC, 1984, RESP PHYSIOL, V56, P145, DOI 10.1016/0034-5687(84)90100-2; BECK KC, 1992, J APPL PHYSIOL, V72, P2292, DOI 10.1152/jappl.1992.72.6.2292; BRYAN AC, 1974, AM REV RESPIR DIS, V110, P143; Chatte G, 1997, AM J RESP CRIT CARE, V155, P473, DOI 10.1164/ajrccm.155.2.9032181; DOUGLAS WW, 1977, AM REV RESPIR DIS, V115, P559; Fridrich P, 1996, ANESTH ANALG, V83, P1206, DOI 10.1097/00000539-199612000-00013; GATTINONI L, 1991, ANESTHESIOLOGY, V74, P15, DOI 10.1097/00000542-199101000-00004; KRAYER S, 1989, ANESTHESIOLOGY, V70, P891, DOI 10.1097/00000542-198906000-00002; LAMM WJE, 1994, AM J RESP CRIT CARE, V150, P184, DOI 10.1164/ajrccm.150.1.8025748; LANGER M, 1988, CHEST, V94, P103, DOI 10.1378/chest.94.1.103; PAPPERT D, 1994, CHEST, V106, P1511, DOI 10.1378/chest.106.5.1511; PIEHL MA, 1976, CRIT CARE MED, V4, P13, DOI 10.1097/00003246-197601000-00003; WEINER CM, 1990, J APPL PHYSIOL, V68, P1386	13	10	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 7	1997	349	9066					1638	1639		10.1016/S0140-6736(05)62630-X	http://dx.doi.org/10.1016/S0140-6736(05)62630-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186378				2022-12-28	WOS:A1997XD10000004
J	Ferveur, JF; Savarit, F; OKane, CJ; Sureau, G; Greenspan, RJ; Jallon, JM				Ferveur, JF; Savarit, F; OKane, CJ; Sureau, G; Greenspan, RJ; Jallon, JM			Genetic feminization of pheromones and its behavioral consequences in Drosophila males	SCIENCE			English	Article							MELANOGASTER; HYDROCARBONS; BIOSYNTHESIS; RECOGNITION; COURTSHIP; ENOCYTES; DIPTERA; LOCUS	Pheromones are intraspecific chemical signals important for mate attraction and discrimination, In the fruit fly Drosophila melanogaster, hydrocarbons on the cuticular surface of the animal are sexually dimorphic in both their occurrence and their effects: Female-specific molecules stimulate male sexual excitation, whereas the predominant male-specific molecule tends to inhibit male excitation, Complete feminization of the pheromone mixture produced by males was induced by targeted expression of the transformer gene in adult oenocytes (subcuticular abdominal cells) or by ubiquitous expression during early imaginal life. The resulting flies generally exhibited male heterosexual orientation but elicited homosexual courtship from other males.	UNIV CAMBRIDGE, DEPT GENET, CAMBRIDGE CB2 3EH, ENGLAND; NYU, DEPT BIOL, NEW YORK, NY 10003 USA; NYU, CTR NEURAL SCI, NEW YORK, NY 10003 USA	University of Cambridge; New York University; New York University	Ferveur, JF (corresponding author), UNIV PARIS 11, CNRS, UNITE RECH ASSOCIEE 1491, BATIMENT 446, F-91405 ORSAY, FRANCE.		O'Kane, Cahir/Q-6681-2019	O'Kane, Cahir/0000-0002-3488-2078	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTONY C, 1985, J CHEM ECOL, V11, P1617, DOI 10.1007/BF01012116; ANTONY C, 1981, CR ACAD SCI III-VIE, V292, P239; ANTONY C, 1982, J INSECT PHYSIOL, V28, P873, DOI 10.1016/0022-1910(82)90101-9; Bell WJ, 1984, CHEM ECOLOGY INSECTS; BRAND AH, 1993, DEVELOPMENT, V118, P401; COBB M, 1990, ANIM BEHAV, V39, P1058, DOI 10.1016/S0003-3472(05)80778-X; Cobb M, 1995, BEHAV PROCESS, V35, P35, DOI 10.1016/0376-6357(95)00052-6; Coyne JA, 1996, GENETICS, V143, P353; COYNE JA, 1994, SCIENCE, V265, P1461, DOI 10.1126/science.8073292; COYNE JA, 1995, P NATL ACAD SCI USA, V92, P9505, DOI 10.1073/pnas.92.21.9505; DIEHL PA, 1975, J INSECT PHYSIOL, V21, P1237, DOI 10.1016/0022-1910(75)90093-1; FERVEUR JF, 1995, SCIENCE, V267, P902, DOI 10.1126/science.7846534; Ferveur JF, 1996, GENET RES, V67, P211, DOI 10.1017/S0016672300033693; Ferveur JF, 1996, P ROY SOC B-BIOL SCI, V263, P967, DOI 10.1098/rspb.1996.0143; Ferveur JF, 1996, GENETICA, V97, P73, DOI 10.1007/BF00132583; GREIG S, 1993, NATURE, V362, P630, DOI 10.1038/362630a0; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; ISMAIL MT, 1983, J INSECT PHYSIOL, V29, P221, DOI 10.1016/0022-1910(83)90088-4; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; Jallon J.-M., 1986, Advances in Invertebrate Reproduction, V4, P445; JALLON JM, 1988, GENET RES, V51, P17, DOI 10.1017/S0016672300023892; JALLON JM, 1984, BEHAV GENET, V14, P441, DOI 10.1007/BF01065444; JALLON JM, 1981, CR ACAD SCI III-VIE, V292, P1147; JALLON JM, 1979, BEHAV GENET, V8, P487; JOHNSON MB, 1985, J MORPHOL, V184, P51, DOI 10.1002/jmor.1051840106; Miller A., 1950, BIOL DROSOPHILA, P420; ODELL KMC, 1995, NEURON, V15, P55, DOI 10.1016/0896-6273(95)90064-0; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; ROMER F, 1991, RECENT ADV COMP ARTH, P542; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; SAVARIT F, UNPUB; SCOTT D, 1988, ANIM BEHAV, V36, P1164, DOI 10.1016/S0003-3472(88)80075-7; VAZ AH, 1989, ARCH INSECT BIOCHEM, V12, P173, DOI 10.1002/arch.940120305; WICKER C, 1995, EUR J ENTOMOL, V92, P197; WIGGLESWORTH V B, 1970, Tissue and Cell, V2, P155, DOI 10.1016/S0040-8166(70)80013-1; YONG TPC, 1986, CR ACAD SCI III-VIE, V303, P197	37	172	172	3	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	1997	276	5318					1555	1558		10.1126/science.276.5318.1555	http://dx.doi.org/10.1126/science.276.5318.1555			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171057				2022-12-28	WOS:A1997XC70100040
J	Pan, Y; Lloyd, C; Zhou, H; Dolich, S; Deeds, J; Gonzalo, JA; Vath, J; Gosselin, M; Ma, JY; Dussault, B; Woolf, E; Alperin, G; Culpepper, J; GutierrezRamos, JC; Gearing, D				Pan, Y; Lloyd, C; Zhou, H; Dolich, S; Deeds, J; Gonzalo, JA; Vath, J; Gosselin, M; Ma, JY; Dussault, B; Woolf, E; Alperin, G; Culpepper, J; GutierrezRamos, JC; Gearing, D			Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation	NATURE			English	Article							MOLECULAR-CLONING; RECEPTOR-BINDING; CC-CHEMOKINES; GROWTH-FACTOR; INTERLEUKIN-8; CLEAVAGE; CELL; TRANSMEMBRANE; LYMPHOTACTIN; LEUKOCYTES	Chemokines are small secreted proteins that stimulate the directional migration of leukocytes and mediate inflammation(1-4). During screening of a murine choroid plexus complementary DNA library, we identified a new chemokine, designated neurotactin. Unlike other chemokines, neurotactin has a unique cysteine pattern, Cys-X-X-X-Cys, and is predicted to be a type 1 membrane protein. Full-length recombinant neurotactin is localized on the surface of transfected 293 cells. Recombinant neurotactin containing the chemokine domain is chemotactic for neutrophils both in vitro and in vivo. Neurotactin messenger RNA is predominantly expressed in normal murine brain and its protein expression in activated brain microglia is upregulated in mice with experimental autoimmune encephalomyelitis, as well as in mice treated with lipopolysaccharide. Distinct from all other chemokine genes, the neurotactin gene is localized to human chromosome 16q. Consequently we propose that neurotactin represents a new delta-chemokine family and that it may play a role in brain inflammation processes.			Pan, Y (corresponding author), MILLENNIUM PHARMACEUT INC,640 MEM DR,CAMBRIDGE,MA 02139, USA.			Lloyd, Clare/0000-0001-8977-6726	Wellcome Trust [087618] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COWEN DS, 1989, J CLIN INVEST, V83, P1651, DOI 10.1172/JCI114064; FALK W, 1980, J IMMUNOL METHODS, V33; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O	31	542	556	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					611	617		10.1038/42491	http://dx.doi.org/10.1038/42491			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177350				2022-12-28	WOS:A1997XC52200058
J	Stack, LB				Stack, LB			Latrodectus mactans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Stack, LB (corresponding author), VANDERBILT UNIV,MED CTR,NASHVILLE,TN 37232, USA.								0	2	20	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1649	1649		10.1056/NEJM199706053362305	http://dx.doi.org/10.1056/NEJM199706053362305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC086	9171067				2022-12-28	WOS:A1997XC08600005
J	Johnston, M; Hillier, L; Riles, L; Albermann, K; Andre, B; Ansorge, W; Benes, V; Bruckner, M; Delius, H; Dubois, E; Dusterhoft, A; Entian, KD; Floeth, M; Goffeau, A; Hebling, U; Heumann, K; HeussNeitzel, D; Hilbert, H; Hilger, F; Kleine, K; Kotter, P; Louis, EJ; Messenguy, F; Mewes, HW; Miosga, T; Mostl, D; MullerAuer, S; Nentwich, U; Obermaier, B; Piravandi, E; Pohl, TM; Portetelle, D; Purnelle, B; Rechmann, S; Rieger, M; Rinke, M; Rose, M; Scharfe, M; Scherens, B; Scholler, P; Schwager, C; Schwarz, S; Underwood, AP; Urrestarazu, LA; Vandenbol, M; Verhasselt, P; Vierendeels, F; Voet, M; Volckaert, G; Voss, H; Wambutt, R; Wedler, E; Wedler, H; Zimmermann, FK; Zollner, A; Hani, J; Hoheisel, JD				Johnston, M; Hillier, L; Riles, L; Albermann, K; Andre, B; Ansorge, W; Benes, V; Bruckner, M; Delius, H; Dubois, E; Dusterhoft, A; Entian, KD; Floeth, M; Goffeau, A; Hebling, U; Heumann, K; HeussNeitzel, D; Hilbert, H; Hilger, F; Kleine, K; Kotter, P; Louis, EJ; Messenguy, F; Mewes, HW; Miosga, T; Mostl, D; MullerAuer, S; Nentwich, U; Obermaier, B; Piravandi, E; Pohl, TM; Portetelle, D; Purnelle, B; Rechmann, S; Rieger, M; Rinke, M; Rose, M; Scharfe, M; Scherens, B; Scholler, P; Schwager, C; Schwarz, S; Underwood, AP; Urrestarazu, LA; Vandenbol, M; Verhasselt, P; Vierendeels, F; Voet, M; Volckaert, G; Voss, H; Wambutt, R; Wedler, E; Wedler, H; Zimmermann, FK; Zollner, A; Hani, J; Hoheisel, JD			The nucleotide sequence of Saccharomyces cerevisiae chromosome XII	NATURE			English	Article							RIBOSOMAL-RNA GENES; COMPLETE DNA-SEQUENCE; SIZE-VARIATION; YEAST; RESOLUTION	The yeast Saccharomyces cerevisiae is the pre-eminent organism for the study of basic functions of eukaryotic cells(1). All of the genes of this simple eukaryotic cell have recently been revealed by an international collaborative effort to determine the complete DNA sequence of its nuclear genome. Here we describe some of the features of chromosome XII.	MAX PLANCK INST BIOCHEM, MARTINSRIEDER INST PROT SEQUENZEN, D-82152 MARTINSRIED, GERMANY; FREE UNIV BRUSSELS, LAB PHYSIOL CELLULAIRE & GENET LEVURES, B-1050 BRUSSELS, BELGIUM; EUROPEAN MOL BIOL LAB, D-69117 HEIDELBERG, GERMANY; GENOTYPE, D-69434 HIRSCHHORN, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY; FREE UNIV BRUSSELS, MICROBIOL LAB, B-1070 BRUSSELS, BELGIUM; QIAGEN GMBH, D-40724 HILDEN, GERMANY; UNIV FRANKFURT, INST MIKROBIOL, D-60439 FRANKFURT, GERMANY; UNIV CATHOLIQUE LOUVAIN, FAC SCI AGRON, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; FAC UNIV SCI AGRON, UNITE MICROBIOL, B-5030 GEMBLOUX, BELGIUM; JOHN RADCLIFFE HOSP, INST MOL MED, DEPT YEAST GENET, OXFORD OX3 9DU, ENGLAND; CERIA COOVI, RES INST, B-1070 BRUSSELS, BELGIUM; INST MIKROBIOL & GENET, D-64287 DARMSTADT, GERMANY; MEDIGENE GMBH, D-82152 MARTINSRIED, GERMANY; GATC GESELL ANAL TECH & CONSULTING MBH, D-78467 CONSTANCE, GERMANY; AGON GMBH, D-12489 BERLIN, GERMANY; FREE UNIV BRUSSELS VIB, DEPT MICROBIOL, B-1070 BRUSSELS, BELGIUM; KATHOLIEKE UNIV LEUVEN, LAB GENE TECHNOL, B-3001 LOUVAIN, BELGIUM; DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY	Max Planck Society; Universite Libre de Bruxelles; Vrije Universiteit Brussel; European Molecular Biology Laboratory (EMBL); Helmholtz Association; German Cancer Research Center (DKFZ); Universite Libre de Bruxelles; Vrije Universiteit Brussel; QIAGEN GmbH; Goethe University Frankfurt; Universite Catholique Louvain; University of Liege; University of Oxford; Technical University of Darmstadt; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; KU Leuven; Helmholtz Association; German Cancer Research Center (DKFZ)	Johnston, M (corresponding author), WASHINGTON UNIV, SCH MED, DEPT GENET, GENOME SEQUENCING CTR, 630 EUCLID AVE, ST LOUIS, MO 63110 USA.		Ansorge, Wilhelm/AAN-8780-2020; Wilson, Richard K./AAF-4139-2019; Louis, Edward/B-7920-2008; Johnston, Mark/K-3543-2019; Johnston, Mark/R-6156-2019; Entian, Karl-Dieter/D-3080-2011; André, Bruno/D-1725-2010; Mewes, Hans-Werner/A-8204-2019	Wilson, Richard K./0000-0002-1992-1358; Louis, Edward/0000-0003-1157-3608; Johnston, Mark/0000-0002-4932-7229; Benes, Vladimir/0000-0002-0352-2547; Underwood, Anthony/0000-0002-8547-4277; Mewes, Hans-Werner/0000-0002-9713-6398	NHGRI NIH HHS [P01 HG000956] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Wellcome Trust(Wellcome TrustEuropean Commission)		CHINDAMPORN A, 1993, J GEN MICROBIOL, V139, P1409, DOI 10.1099/00221287-139-7-1409; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; Galibert F, 1996, EMBO J, V15, P2031, DOI 10.1002/j.1460-2075.1996.tb00557.x; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; JONES EW, 1991, MOL CELLULAR BIOL YE, V1; KIM KW, 1988, J BIOL CHEM, V263, P11948; LOUIS EJ, 1995, GENETICS, V139, P125; LOUIS EJ, 1995, BIOCHEMICA, V3, P25; MCMAHON ME, 1984, NUCLEIC ACIDS RES, V12, P8001, DOI 10.1093/nar/12.21.8001; OLSON MV, 1991, MOL CELLULAR BIOL YE, V1, P1; PASERO P, 1993, MOL GEN GENET, V236, P448, DOI 10.1007/BF00277147; PIPER PW, 1984, NUCLEIC ACIDS RES, V12, P4083, DOI 10.1093/nar/12.10.4083; RILES L, 1993, GENETICS, V134, P81; RODRIGUEZMEDINA JR, 1994, MOL GEN GENET, V243, P532, DOI 10.1007/BF00284201; RUSTCHENKO EP, 1994, YEAST, V10, P1157, DOI 10.1002/yea.320100904; SCHOLLER P, 1995, NUCLEIC ACIDS RES, V23, P3842, DOI 10.1093/nar/23.19.3842; SCHOLLER P, 1995, YEAST, V11, P659, DOI 10.1002/yea.320110706; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; VASSAROTTI A, 1995, J BIOTECHNOL, V41, P131, DOI 10.1016/0168-1656(95)00066-Y; VISWANATHAN M, 1994, GENE, V148, P149, DOI 10.1016/0378-1119(94)90249-6; ZAMB TJ, 1982, CELL, V28, P355, DOI 10.1016/0092-8674(82)90353-1	23	91	696	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632		S			87	90		10.1038/387s087	http://dx.doi.org/10.1038/387s087			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169871				2022-12-28	WOS:A1997XB54600011
J	Misteli, T; Caceres, JF; Spector, DL				Misteli, T; Caceres, JF; Spector, DL			The dynamics of a pre-mRNA splicing factor in living cells	NATURE			English	Article							NASCENT TRANSCRIPTS; PROTEIN; REGULATORS; EXPRESSION; INHIBITION; NUCLEUS	Pre-mRNA splicing is a predominantly co-transcriptional event which involves a large number of essential splicing factors(1,2). Within the mammalian cell nucleus, most splicing factors are concentrated in 20-40 distinct domains called speckles(3). The function of speckles and the organization of cellular transcription and pre-mRNA splicing in vivo are not well understood. We have investigated the dynamic properties of splicing factors in nuclei of living cells. Here we show that speckles are highly dynamic structures that respond specifically to activation of nearby genes. These dynamic events are dependent on RNA polymerase II transcription, and are sensitive to inhibitors of protein kinases and Ser/Thr phosphatases. When single genes are transcriptionally activated in living cells, splicing factors leave speckles in peripheral extensions and accumulate at the new sites of transcription, We conclude that one function of speckles is to supply splicing factors to active genes. Our observations demonstrate that the interphase nucleus is far more dynamic in nature than previously assumed.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Caceres, Javier F/D-5260-2013	Caceres, Javier F/0000-0001-8025-6169	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042694] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM042694] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOOM R, 1986, J VIROL, V58, P851, DOI 10.1128/JVI.58.3.851-859.1986; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; DIRKS RW, 1997, J CELL SCI, V110, P505; Fakan Stanislav, 1994, Trends in Cell Biology, V4, P86, DOI 10.1016/0962-8924(94)90180-5; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HABETS WJ, 1989, J IMMUNOL, V143, P2560; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; Huang S, 1996, J CELL BIOL, V133, P719, DOI 10.1083/jcb.133.4.719; JIMINEZGARCIA LF, 1993, CELL, V73, P47; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; MOENS U, 1990, J GEN VIROL, V71, P1461, DOI 10.1099/0022-1317-71-7-1461; Moore M., 1993, RNA WORLD, P303; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; POMBO A, 1994, EMBO J, V13, P5075, DOI 10.1002/j.1460-2075.1994.tb06837.x; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635	29	507	519	2	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					523	527		10.1038/387523a0	http://dx.doi.org/10.1038/387523a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168118				2022-12-28	WOS:A1997XB47900054
J	Benatar, SR				Benatar, SR			An old health care system gives place to new	LANCET			English	Article											Benatar, SR (corresponding author), UNIV CAPE TOWN, DEPT MED, ZA-7700 RONDEBOSCH, SOUTH AFRICA.		Karim, Salim Safurdeen Abdool/N-5947-2013; Karim, Salim Abdool/P-3117-2019	Karim, Salim Safurdeen Abdool/0000-0002-4986-2133; Karim, Salim Abdool/0000-0002-4986-2133				1991, NEW ENGL J MED, V325, P30	1	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 24	1997	349	9064					1537	1538		10.1016/S0140-6736(97)03264-9	http://dx.doi.org/10.1016/S0140-6736(97)03264-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167473				2022-12-28	WOS:A1997XA90100044
J	DelMar, C; Glasziou, P; Hayem, M				DelMar, C; Glasziou, P; Hayem, M			Are antibiotics indicated as initial treatment for children with acute otitis media? A meta-analysis	BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL; MYRINGOTOMY; PLACEBO	Objective: To determine the effect of antibiotic treatment for acute otitis media in children. Design: Systematic search of the medical literature to identify studies that used antibiotics in randomised controlled trials to treat acute otitis media. Studies were examined blind, and the results of those of satisfactory quality of methodology were pooled. Subjects: Six studies of children aged 7 months to 15 years. Main outcome measures: Pain, deafness, and other symptoms related to acute odds media or antibiotic treatment. Results: 60% of placebo treated children were pain free within 24 hours of presentation, and antibiotics did not influence this. However, at 2-7 days after presentation, by which time only 14% of children in control groups still had pain, early use of antibiotics reduced the risk of pain by 41% (95% confidence interval 14% to 60%). Antibiotics reduced contralateral acute odds media by 43% (9% to 64%). They seemed to have no influence on subsequent attacks of odds media or deafness at one month, although there was a trend for improvement of deafness at three months. Antibiotics were associated with a near doubling of the risk of vomiting, diarrhoea, or rashes (odds ratio 1.97 (1.19 to 3.25)). Conclusions: Early use of antibiotics provides only modest benefit for acute odds media: to prevent one child from experiencing pain by 2-7 days after presentation, 17 children must be treated with antibiotics early.			DelMar, C (corresponding author), UNIV QUEENSLAND,GRAD SCH MED,CTR GEN PRACTICE,BRISBANE,QLD 4006,AUSTRALIA.		Del Mar, Chris B/B-1136-2008; Glasziou, Paul/A-7832-2008	Del Mar, Chris B/0000-0003-3821-8163; Glasziou, Paul/0000-0001-7564-073X				BERMAN S, 1995, PEDIATRICS, V96, P126; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1401, DOI 10.1001/jama.263.10.1401; CLAESSEN JQPJ, 1992, CLIN OTOLARYNGOL, V17, P251, DOI 10.1111/j.1365-2273.1992.tb01838.x; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; HALSTED C, 1968, AM J DIS CHILD, V115, P542, DOI 10.1001/archpedi.1968.02100010544003; HOWIE VM, 1972, CLIN PEDIATR, V11, P205, DOI 10.1177/000992287201100407; KALEIDA PH, 1991, PEDIATRICS, V87, P466; KLEIN J, 1989, INFECT DIS S1, V8, P89; LAXDAL OE, 1970, CAN MED ASSOC J, V192, P263; MYGIND N, 1981, CLIN OTOLARYNGOL, V6, P5, DOI 10.1111/j.1365-2273.1981.tb01781.x; ROSENFELD RM, 1994, J PEDIATR, V124, P335; RUDBERG R, 1954, ACTA OTO LARYNGOL S, V44, P45; RUUSKANEN O, 1991, PEDIATR INFECT DIS J, V10, P425, DOI 10.1097/00006454-199106000-00001; Thalin A, 1985, P INT C AC SECR OT 1, P441; vanBalen FAM, 1996, LANCET, V348, P713, DOI 10.1016/S0140-6736(96)02511-1; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VANBUCHEM FL, 1987, J ROY COLL GEN PRACT, V37, P367; VANBUCHEM FL, 1981, LANCET, V2, P883	20	210	213	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 24	1997	314	7093					1526	1529		10.1136/bmj.314.7093.1526	http://dx.doi.org/10.1136/bmj.314.7093.1526			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9183201	Green Published			2022-12-28	WOS:A1997XB48400027
J	Ulmasov, T; Hagen, G; Guilfoyle, TJ				Ulmasov, T; Hagen, G; Guilfoyle, TJ			ARF1, a transcription factor that binds to auxin response elements	SCIENCE			English	Article							GENE; ENCODES	The plant hormone auxin regulates plant physiology by modulating the interaction of transcription factors with auxin response elements (AuxREs) of the affected genes. A transcription factor, Auxin Response Factor 1 (ARF1), that binds to the sequence TGTCTC in AuxREs was cloned from Arabidopsis by using a yeast one-hybrid system. ARF1 has an amino-terminal DNA-binding domain related to the carboxyl terminus of the maize transactivator Viviparous-1. Sequence requirements for ARF1 binding in vitro are identical to those that confer auxin responsiveness in vivo. The carboxyl terminus of ARF1 contains two motifs found in the Aux/IAA class of proteins and appears to mediate protein-protein interactions.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia								Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; ABEL S, 1994, P NATL ACAD SCI USA, V91, P326, DOI 10.1073/pnas.91.1.326; BALLAS N, 1995, P NATL ACAD SCI USA, V92, P3483, DOI 10.1073/pnas.92.8.3483; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; GUILFOYLE TJ, 1993, AUST J PLANT PHYSIOL, V20, P489, DOI 10.1071/PP9930489; Lehman A, 1996, CELL, V85, P183, DOI 10.1016/S0092-8674(00)81095-8; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; LIU ZB, 1994, PLANT CELL, V6, P645, DOI 10.1105/tpc.6.5.645; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; Moore DD, 1995, GLOB MOB SURV; TRELZENBERG SJ, 1995, CURR BIOL, V5, P190; ULMASOV T, 1995, PLANT CELL, V7, P1611, DOI 10.1105/tpc.7.10.1611; ULMASOV T, UNPUB; YAMAMOTO KR, 1992, TRANSCRIPTIONAL REGU, P1169	15	678	747	7	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1865	1868		10.1126/science.276.5320.1865	http://dx.doi.org/10.1126/science.276.5320.1865			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188533				2022-12-28	WOS:A1997XF10300050
J	Groenewoud, JH; van der Maas, PJ; vanderWal, G; Hengeveld, MW; Tholen, AJ; Schudel, WJ; vanderHeide, A				Groenewoud, JH; van der Maas, PJ; vanderWal, G; Hengeveld, MW; Tholen, AJ; Schudel, WJ; vanderHeide, A			Physician-assisted death in psychiatric practice in the Netherlands	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EUTHANASIA; CONSULTATION; SUICIDE	Background In 1994 the Dutch Supreme Court ruled that in exceptional instances, physician-assist ed suicide might be justifiable for patients with unbearable mental suffering but no physical illness. We studied physician-assisted suicide and euthanasia in psychiatric practice in the Netherlands. Methods In 1996, we sent questionnaires to 673 Dutch psychiatrists - about half of all such special ists in the country - and received 552 responses from the 667 who met the study criteria (response rate, 83 percent). We estimated the annual frequencies of requests for physician-assisted suicide by psychiatrists and actual instances of assistance. Results Of the respondents, 205 (37 percent) had at least once received an explicit, persistent request for physician-assisted suicide and 12 had complied. We estimate there are 320 requests a year in psychiatric practice and 2 to 5 assisted suicides. Excluding those who had ever assisted, 345 of the respondents (64 percent) thought physician-assisted suicide because of a mental disorder could be acceptable, including 241 who said they could conceive of instances in which they themselves would be willing to assist. The most frequent reasons for refusing were the belief that the patient had a treatable mental disorder, opposition to assisted suicide in principle, and doubt that the suffering was unbearable or hopeless. Most, but not all, patients who had been assisted by their psychiatrists in suicide had both a mental disorder and a serious physical illness, often in a terminal phase. Thirty percent of the respondents had been consulted at least once by a physician in another specialty about a patient's request for assisted death. The annual number of such consultations was estimated at 310, about 3 percent of the estimated 9700 requests for euthanasia or physician-assisted suicide in medical practice. Conclusions Explicit requests for physician-assisted suicide are not uncommon in psychiatric practice in the Netherlands, but these requests are rarely granted. Psychiatric consultation for medical patients who request physician-assisted death is relatively rare. (C)1997, Massachusetts Medical Society.	ERASMUS UNIV ROTTERDAM, DEPT PSYCHIAT, NL-3000 DR ROTTERDAM, NETHERLANDS; VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS; LEIDEN UNIV, DEPT PSYCHIAT, LEIDEN, NETHERLANDS; UNIV GRONINGEN, UNIV HOSP GRONINGEN, DEPT PSYCHIAT, GRONINGEN, NETHERLANDS	Erasmus University Rotterdam; Vrije Universiteit Amsterdam; Leiden University; Leiden University - Excl LUMC; University of Groningen	Groenewoud, JH (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.							BAILE WF, 1993, CANCER, V72, P2786, DOI 10.1002/1097-0142(19931101)72:9<2786::AID-CNCR2820720942>3.0.CO;2-2; BLOCK SD, 1995, PSYCHOSOMATICS, V36, P445, DOI 10.1016/S0033-3182(95)71625-5; Bokhove J., 1996, BALANS REKENONDERWIJ; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; *COMM AANV LEV HAN, 1993, DISC NOT HULP BIJ ZE; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; GEVERS S, 1995, BIOETHICS, V9, P309, DOI 10.1111/j.1467-8519.1995.tb00366.x; Griffiths J., 1995, MOD LAW REV, V58, P232, DOI [10.1111/j.1468-2230.1995.tb02006.x, DOI 10.1111/J.1468-2230.1995.TB02006.X]; Humphrey D., 1991, FINAL EXIT PRACTICAL; HUYSE FJ, 1993, HOSP COMMUNITY PSYCH, V44, P733; van der Maas PJ, 1995, JAMA-J AM MED ASSOC, V273, P1411, DOI 10.1001/jama.273.18.1411; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; 1994, NED JURISPRUDENTIE, V656, P3142	14	77	78	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	1997	336	25					1795	1801		10.1056/NEJM199706193362506	http://dx.doi.org/10.1056/NEJM199706193362506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XE485	9187071	Green Published			2022-12-28	WOS:A1997XE48500006
J	Albertsen, PC				Albertsen, PC			Urology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Albertsen, PC (corresponding author), UNIV CONNECTICUT,CTR HLTH,FARMINGTON,CT 06032, USA.							Boyle P, 1996, UROLOGY, V48, P398, DOI 10.1016/S0090-4295(96)00353-6; DelaRosette JJMCH, 1996, J UROLOGY, V156, P97, DOI 10.1016/S0022-5347(01)65952-4; Dugan JA, 1996, JAMA-J AM MED ASSOC, V275, P288, DOI 10.1001/jama.275.4.288; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; Grimm PD, 1996, HEMATOL ONCOL CLIN N, V10, P653, DOI 10.1016/S0889-8588(05)70359-2; GROVE A, 1996, FORTUNE, V133, P54; Helgesen F, 1996, JNCI-J NATL CANCER I, V88, P1216, DOI 10.1093/jnci/88.17.1216; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; Linet OI, 1996, NEW ENGL J MED, V334, P873, DOI 10.1056/NEJM199604043341401; Lowe FC, 1996, UROLOGY, V48, P12, DOI 10.1016/S0090-4295(96)00077-5; LuYao GL, 1996, J NATL CANCER I, V88, P166, DOI 10.1093/jnci/88.3-4.166; Morgan TO, 1996, NEW ENGL J MED, V335, P304, DOI 10.1056/NEJM199608013350502; Smith DS, 1996, JAMA-J AM MED ASSOC, V276, P1309, DOI 10.1001/jama.276.16.1309; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; TROCKMAN BA, 1995, J UROLOGY, V154, P1841, DOI 10.1016/S0022-5347(01)66796-X	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1904	1905						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185828				2022-12-28	WOS:A1997XD54400047
J	Levin, LA				Levin, LA			Ophthalmology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRIAL				Levin, LA (corresponding author), UNIV WISCONSIN,SCH MED,MADISON,WI 53706, USA.							Andersen JS, 1997, ARCH OPHTHALMOL-CHIC, V115, P384, DOI 10.1001/archopht.1997.01100150386012; BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9; BUTLER VP, 1995, ANN INTERN MED, V123, P676, DOI 10.7326/0003-4819-123-9-199511010-00006; Camras CB, 1996, OPHTHALMOLOGY, V103, P138, DOI 10.1016/S0161-6420(96)30749-5; Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147; Gallie BL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1321, DOI 10.1001/archopht.1996.01100140521001; Kingston JE, 1996, ARCH OPHTHALMOL-CHIC, V114, P1339, DOI 10.1001/archopht.1996.01100140539004; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; Marx JL, 1996, ARCH OPHTHALMOL-CHIC, V114, P815, DOI 10.1001/archopht.1996.01100140029003; Murphree AL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1348, DOI 10.1001/archopht.1996.01100140548005; Rahhal FM, 1996, ANN INTERN MED, V125, P98, DOI 10.7326/0003-4819-125-2-199607150-00003; SCHUMAN JS, IN PRESS ARCH OPHTHA; Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Shields CL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1330, DOI 10.1001/archopht.1996.01100140530002; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Tabbara KF, 1996, OPHTHALMOLOGY, V103, P842	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1881	1883						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185815				2022-12-28	WOS:A1997XD54400034
J	Marzuk, PM; Barchas, JD				Marzuk, PM; Barchas, JD			Psychiatry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Marzuk, PM (corresponding author), CORNELL UNIV MED COLL,NEW YORK,NY 10021, USA.							Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; Denollet J, 1996, LANCET, V347, P417, DOI 10.1016/S0140-6736(96)90007-0; Fowler JS, 1996, NATURE, V379, P733, DOI 10.1038/379733a0; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; George MS, 1996, J NEUROPSYCH CLIN N, V8, P172; GEORGE MS, 1996, ARCH GEN PSYCHIAT, V53, P673; GIORS B, 1996, NATURE, V379, P606; LeDoux J. E., 1996, EMOTIONAL BRAIN; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Lieberman JA, 1996, AM J PSYCHIAT, V153, P1388; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602; PascualLeone A, 1996, LANCET, V348, P233, DOI 10.1016/S0140-6736(96)01219-6; Pratt LA, 1996, CIRCULATION, V94, P3123, DOI 10.1161/01.CIR.94.12.3123; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; Schwartz JM, 1996, ARCH GEN PSYCHIAT, V53, P109; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Whitworth AB, 1996, LANCET, V347, P1438, DOI 10.1016/S0140-6736(96)91682-7; Yeh SR, 1996, SCIENCE, V271, P366, DOI 10.1126/science.271.5247.366	20	1	1	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1892	1894						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD544	9185821				2022-12-28	WOS:A1997XD54400040
J	Adler, MW				Adler, MW			Sexual health - A Health of the Nation failure	BRITISH MEDICAL JOURNAL			English	Article											Adler, MW (corresponding author), UCL, SCH MED, DEPT SEXUALLY TRANSMITTED DIS, MORTIMER ST, LONDON WC1E 6AU, ENGLAND.							BABB P, 1993, POPULATION TRENDS, V74, P12; Catchpole MA, 1996, BRIT MED J, V312, P539, DOI 10.1136/bmj.312.7030.539; *COMM DIS SURV CTR, 1996, CDR, V6, P418; *COMM DIS SURV CTR, 1997, CDR, V4, P29; CONNOR N, IN PRESS CDR; COWAN FM, 1994, BRIT MED J, V309, P1325, DOI 10.1136/bmj.309.6965.1325; *DEP HLTH, 1996, UNL AN HIV PREV MON; Haines A, 1997, BRIT MED J, V314, P529, DOI 10.1136/bmj.314.7080.529; Johnson AM, 1996, GENITOURIN MED, V72, P197; Lacey CJN, 1997, BRIT MED J, V314, P1715, DOI 10.1136/bmj.314.7096.1715; Low N, 1997, BRIT MED J, V314, P1719, DOI 10.1136/bmj.314.7096.1719; MILLER E, 1995, BRIT MED J, V311, P545, DOI 10.1136/bmj.311.7004.545; *NHS CTR REV DIS U, 1997, EFFECTIVE HLTH CARE, V3; Secretary of State for Health, 1992, HLTH NAT STRAT HLTH; 1996, CDR, P6	15	40	40	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1743	1747		10.1136/bmj.314.7096.1743	http://dx.doi.org/10.1136/bmj.314.7096.1743			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9202507	Green Published			2022-12-28	WOS:A1997XE90900030
J	Schlemper, RJ; Itabashi, M; Kato, Y; Lewin, KJ; Riddell, RH; Shimoda, T; Sipponen, P; Stolte, M; Watanabe, H; Takahashi, H; Fujita, R				Schlemper, RJ; Itabashi, M; Kato, Y; Lewin, KJ; Riddell, RH; Shimoda, T; Sipponen, P; Stolte, M; Watanabe, H; Takahashi, H; Fujita, R			Differences in diagnostic criteria for gastric carcinoma between Japanese and Western pathologists	LANCET			English	Article							EPITHELIAL-DYSPLASIA; CANCER; INVASION	Background There have been many studies on gastric carcinoma in populations with contrasting cancer risks, We aimed to find out whether the criteria for the histological diagnosis of early gastric carcinoma were comparable in Western countries and Japan. Methods Eight pathologists from Japan, North America, and Europe individually reviewed 35 microscope slides: 17 gastric biopsy samples and 18 endoscopic mucosal resections taken from 17 Japanese patients with lesions ranging from early gastric cancer to adenoma, dysplasia, and reactive atypia. The pathologists were given a list of pathological criteria and a form on which they were asked to indicate the criteria on which they based each diagnosis, Findings For seven slides most Western pathologists diagnosed low-grade adenoma/dysplasia, whereas the Japanese diagnosed definite carcinoma in four slides suspected carcinoma in one, and adenoma in only two. Of 12 slides with high-grade adenoma/dysplasia according to most Western pathologists the Japanese gave the diagnosis of definite carcinoma in 11 and suspected in one. Of six slides showing high-grade adenoma/dysplasia with suspected carcinoma according to most Western pathologists the Japanese diagnosed definite carcinoma in all. There were no major differences in the diagnoses of three slides showing reactive epithelium and seven slides with clearly invasive carcinoma, When the opinion of the majority of the pathologists was taken as the final diagnosis there was agreement between Western and Japanese in 11 of the 35 slides (kappa coefficient 0.15 [95% CI 0.01-0.29]). Presence of invasion was the most important diagnostic criterion for most Western pathologists whereas for the Japanese nuclear features and glandular structures were more important. Interpretation In Japan, gastric carcinoma is diagnosed on nuclear and structural criteria even when invasion is absent according to the Western viewpoint, This diagnostic practice results in almost no discrepancy between the diagnosis of a superficial biopsy sample and that of the final resection specimen. This may also contribute to the relatively high incidence and good prognosis of gastric carcinoma in Japan when compared with Western countries.	IBARAKI CENT HOSP, DIV PATHOL, TOMOBE, JAPAN; JAPANESE FDN CANC RES, INST CANC, DEPT PATHOL, TOKYO 170, JAPAN; UNIV CALIF LOS ANGELES, CTR HLTH SCI, DEPT PATHOL, LOS ANGELES, CA 90024 USA; MCMASTER UNIV, DEPT PATHOL, HAMILTON, ON, CANADA; NATL CANC CTR, CLIN LAB DIV, TOKYO, JAPAN; JORVI HOSP, DEPT PATHOL, SF-02740 ESPOO, FINLAND; KLINIKUM BAYREUTH, INST PATHOL, BAYREUTH, GERMANY; NIIGATA UNIV, SCH MED, DEPT PATHOL 1, NIIGATA, JAPAN	Japanese Foundation for Cancer Research; University of California System; University of California Los Angeles; McMaster University; National Cancer Center - Japan; Klinikum Bayreuth; Niigata University	Schlemper, RJ (corresponding author), SHOWA UNIV, FUJIGAOKA HOSP, DEPT GASTROENTEROL, YOKOHAMA, KANAGAWA 227, JAPAN.		Riddell, Robert H/J-5557-2016					DEDOMBAL FT, 1990, GUT, V31, P115, DOI 10.1136/gut.31.1.115; DIGREGORIO C, 1993, AM J GASTROENTEROL, V88, P1714; FERTITTA AM, 1993, ENDOSCOPY, V25, P265, DOI 10.1055/s-2007-1010311; FORMAN D, 1993, LANCET, V341, P1359; FUJITA S, 1978, PATHOL RES PRACT, V163, P297, DOI 10.1016/S0344-0338(78)80028-4; Hirota T, 1992, PATHOLOGY GASTROINTE, P570; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; ITABASHI M, 1984, JPN J CLIN ONCOL, V14, P253; Japanese Research Society for Gastric Cancer, 1995, JAP CLASS GASTR CARC, P73; Kato Y, 1993, GASTRIC CANCER, P133; KENEKO E, 1977, GUT, V18, P626, DOI 10.1136/gut.18.8.626; Kokkola A, 1996, J CLIN PATHOL, V49, P979, DOI 10.1136/jcp.49.12.979; LANSDOWN M, 1990, GUT, V31, P977, DOI 10.1136/gut.31.9.977; Lewin KJ, 1992, GASTROINTESTINAL PAT; Mizumoto S, 1992, Nihon Geka Gakkai Zasshi, V93, P1071; NISHIZAWA M, 1992, Stomach and Intestine (Tokyo), V27, P16; RUGGE M, 1991, HUM PATHOL, V22, P1002, DOI 10.1016/0046-8177(91)90008-D; RUGGE M, 1994, GASTROENTEROLOGY, V107, P1288, DOI 10.1016/0016-5085(94)90529-0; SAITO K, 1986, ACTA PATHOL JAPON, V36, P1307; SANO T, 1992, BRIT J SURG, V79, P241, DOI 10.1002/bjs.1800790319; SARAGA EP, 1987, AM J SURG PATHOL, V11, P788, DOI 10.1097/00000478-198710000-00006; SCHLEMPER RJ, 1995, GUT, V37, P199, DOI 10.1136/gut.37.2.199; SIPP, 1990, GASTROINTESTINAL PAT, P61; STOLTE M, 1994, ENDOSCOPY, V26, P659, DOI 10.1055/s-2007-1009061; Takahashi T, 1985, Pathol Annu, V20 Pt 1, P419; TORII A, 1995, GASTROINTEST ENDOSC, V42, P475, DOI 10.1016/S0016-5107(95)70053-6; WATANABE H, 1990, INT HISTOLOGICAL CLA, P19; WEINSTEIN WM, 1994, GASTROENTEROLOGY, V107, P1543, DOI 10.1016/0016-5085(94)90561-4; YAMADA Y, 1989, CANCER, V63, P1757	29	277	299	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 14	1997	349	9067					1725	1729		10.1016/S0140-6736(96)12249-2	http://dx.doi.org/10.1016/S0140-6736(96)12249-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193382				2022-12-28	WOS:A1997XE06500009
J	Vaidya, JS; Mittra, I				Vaidya, JS; Mittra, I			Fraction of normal remaining life span: A new method for expressing survival in cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Article									TATA MEM HOSP, DEPT SURG, BOMBAY 400012, MAHARASHTRA, INDIA	Tata Memorial Centre (TMC); Tata Memorial Hospital			Vaidya, Jayant S/F-7717-2010; Vaidya, Jayant S/A-7218-2008	Vaidya, Jayant S/0000-0003-1760-1278; Vaidya, Jayant S/0000-0003-1760-1278; Mittra, Indraneel/0000-0002-5768-3821				BERKSON J, 1950, P STAFF M MAYO CLIN, V25, P270; Berrino F, 1995, IARC SCI PUBL, V132, P1; BRINKLEY D, 1975, LANCET, V2, P95; EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101; HAKAMA M, 1977, J CHRON DIS, V30, P585, DOI 10.1016/0021-9681(77)90057-1; HAKULINEN T, 1982, BIOMETRICS, V38, P933, DOI 10.2307/2529873; HAKULINEN T, 1977, J CHRON DIS, V30, P431, DOI 10.1016/0021-9681(77)90036-4; WALTER G, 1992, ACTUARIAL SURVIVAL C	8	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	1997	314	7095					1682	1684		10.1136/bmj.314.7095.1682	http://dx.doi.org/10.1136/bmj.314.7095.1682			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD874	9193295	Green Published			2022-12-28	WOS:A1997XD87400032
J	Cornell, BA; BraachMaksvytis, VLB; King, LG; Osman, PDJ; Raguse, B; Wieczorek, L; Pace, RJ				Cornell, BA; BraachMaksvytis, VLB; King, LG; Osman, PDJ; Raguse, B; Wieczorek, L; Pace, RJ			A biosensor that uses ion-channel switches	NATURE			English	Article							BIOMIMETIC MEMBRANES; LIPID BILAYERS; ATTACHMENT; GOLD	Biosensors are molecular sensors that combine a biological recognition mechanism with a physical transduction technique. They provide a new class of inexpensive, portable instrument that permit sophisticated analytical measurements to be undertaken rapidly at decentralized locations(1). However, the adoption of biosensors for practical applications other than the measurement of blood glucose is currently limited by the expense, insensitivity and inflexibility of the available transduction methods. Here we describe the development of a biosensing technique in which the conductance of a population of molecular ion channels is switched by the recognition event. The approach mimics biological sensory functions(2,3) and can be used with most types of receptor, including antibodies and nucleotides. The technique is very flexible and even in its simplest form it is sensitive to picomolar concentrations of proteins. The sensor is essentially an impedance element whose dimensions can readily be reduced to become an integral component of a microelectronic circuit. It may be used in a wide range of applications and in complex media, including blood. These uses might include cell typing, the detection of large proteins, viruses, antibodies, DNA, electrolytes, drugs, pesticides and other low-molecular-weight compounds.	AUSTRALIAN NATL UNIV,FAC SCI,DEPT CHEM,CANBERRA,ACT,AUSTRALIA	Australian National University	Cornell, BA (corresponding author), COOPERAT RES CTR MOL ENGN & TECHNOL,126 GREVILLE ST,CHATSWOOD,NSW 2067,AUSTRALIA.		Cornell, Bruce/B-8758-2013; Pace, Ronald J/T-5906-2017	osman, peter/0000-0003-1795-0582; cornell, bruce/0000-0003-4166-3241				AVRON E, 1995, BIOSYSTEMS, V36, P101, DOI 10.1016/0303-2647(95)01531-O; FLORIN EL, 1993, BIOPHYS J, V64, P375, DOI 10.1016/S0006-3495(93)81378-X; FOLKERS JP, 1994, J PHYS CHEM-US, V98, P563, DOI 10.1021/j100053a035; HEYSEL S, 1995, PROTEIN SCI, V4, P2532, DOI 10.1002/pro.5560041210; Hladky SB, 1995, BIOPHYS J, V69, P1758, DOI 10.1016/S0006-3495(95)80046-9; Koeppe RE, 1996, ANNU REV BIOPH BIOM, V25, P231; LANG H, 1994, LANGMUIR, V10, P197, DOI 10.1021/la00013a029; Lu XD, 1996, BIOELECTROCH BIOENER, V39, P285, DOI 10.1016/0302-4598(95)05039-6; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; Nikolelis DP, 1996, ANAL CHEM, V68, P1735, DOI 10.1021/ac950403v; PLANT AL, 1994, BIOPHYS J, V67, P1126, DOI 10.1016/S0006-3495(94)80579-X; Reiken SR, 1996, BIOSENS BIOELECTRON, V11, P91, DOI 10.1016/0956-5663(96)83716-X; Rickert J, 1996, BIOSENS BIOELECTRON, V11, P591, DOI 10.1016/0956-5663(96)83294-5; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; SCHELLER FW, 1996, FRONTIERS BIOSENSORI, V1; Steinem C, 1996, BBA-BIOMEMBRANES, V1279, P169, DOI 10.1016/0005-2736(95)00274-X; STEIZLE M, 1993, J PHYS CHEM-US, V97, P2974; Stetter KO, 1996, FEMS MICROBIOL REV, V18, P149, DOI 10.1111/j.1574-6976.1996.tb00233.x	18	955	1013	6	383	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					580	583		10.1038/42432	http://dx.doi.org/10.1038/42432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177344				2022-12-28	WOS:A1997XC52200049
J	Dyker, AG; Weir, CJ; Lees, KR				Dyker, AG; Weir, CJ; Lees, KR			Influence of cholesterol on survival after stroke: Retrospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CEREBRAL INFARCTION; RISK-FACTORS; MEN; MORTALITY; ARTERIES; RABBITS; AKITA	Objective: To investigate the association between Serum cholesterol concentrat Design: Retrospective study. Setting: Acute stroke unit of inner city general hospital. Subjects: 977 patients with acute stroke. Main outcome measures: Serum total cholesterol concentration, type of stroke investigated by computed tomography or magnetic resonance imaging, three month outcome (good (alive at home) or bad (dead ol in care)), long term mortality Results: After adjustment for known prognostic factors, higher serum cholesterol concentrations were associated with reduced long term mortality after stroke (relative hazard 0.91 (95% confidence interval 0.84 to 0,98) per mmol/l increase in cholesterol) independently of stroke type, vascular territory and extent, age, and hyperglycaemia. Three month outcome was also influenced independently by serum cholesterol (P = 0.024). Conclusions: Our data suggest an association between poor stroke outcome and lower serum cholesterol concentration. Until a prospective controlled study has confirmed the benefits of lowering cholesterol concentration in elderly subjects, the application of cholesterol lowering guidelines cannot be justified as secondary prevention of acute stroke.			Dyker, AG (corresponding author), UNIV GLASGOW, WESTERN INFIRM, DEPT MED & THERAPEUT, ACUTE STROKE UNIT, GLASGOW G11 6NT, LANARK, SCOTLAND.			Weir, Christopher/0000-0002-6494-4903				[Anonymous], 1995, J Clin Epidemiol, V48, P1441; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Butterworth RJ, 1997, CEREBROVASC DIS, V7, P10, DOI 10.1159/000108156; CHUI DH, 1991, BIOMED PHARMACOTHER, V45, P409, DOI 10.1016/0753-3322(91)90005-E; CHUI DH, 1991, BIOMED PHARMACOTHER, V45, P37, DOI 10.1016/0753-3322(91)90152-J; COX DR, 1972, J R STAT SOC B, V34, P187; ERYUREK FG, 1990, RES COMMUN CHEM PATH, V69, P245; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KAGAN A, 1980, STROKE, V11, P14, DOI 10.1161/01.STR.11.1.14; KENDRICK S, 1993, HLTH B EDINB, V51, P1; KONISHI M, 1993, STROKE, V24, P954, DOI 10.1161/01.STR.24.7.954; MORRIS AD, 1993, J NEUROL NEUROSUR PS, V56, P352, DOI 10.1136/jnnp.56.4.352; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIMONSEN U, 1991, CLIN SCI, V80, P119, DOI 10.1042/cs0800119; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; UESHIMA H, 1980, PREV MED, V9, P722, DOI 10.1016/0091-7435(80)90017-1	19	93	97	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	1997	314	7094					1584	1588		10.1136/bmj.314.7094.1584	http://dx.doi.org/10.1136/bmj.314.7094.1584			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9169402	Green Published			2022-12-28	WOS:A1997XC50000020
J	Brunn, GJ; Hudson, CC; Sekulic, A; Williams, JM; Hosoi, H; Houghton, PJ; Lawrence, JC; Abraham, RT				Brunn, GJ; Hudson, CC; Sekulic, A; Williams, JM; Hosoi, H; Houghton, PJ; Lawrence, JC; Abraham, RT			Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; MALIGNANT TRANSFORMATION; MAP KINASE; INITIATION; INSULIN; IDENTIFICATION; ADIPOCYTES; REGULATOR; COMPLEX; BINDS	The immunosuppressant rapamycin interferes with G(1)-phase progression in lymphoid and other cell types by inhibiting the function; of the mammalian target of rapamycin (mTOR), mTOR was determined to be a terminal kinase in a signaling pathway that couples mitogenic stimulation to the phosphorylation of the eukaryotic initiation factor (eIF)-4E-binding protein, PHAS-I. The rapamycin-sensitive protein kinase activity of mTOR was required for phosphorylation of PHAS-I in insulin-stimulated human embryonic kidney cells. mTOR phosphorylated PHAS-I on serine and threonine residues in vitro, and these modifications inhibited the binding of PHAS-I to eIF-4E. These studies define a role for mTOR in translational control and offer further insights into the mechanism whereby rapamycin inhibits G(1)-phase progression in mammalian cells.	MAYO CLIN, DIV ONCOL RES, ROCHESTER, MN 55905 USA; UNIV VIRGINIA, SCH MED, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; ST JUDE CHILDRENS RES HOSP, DEPT MOL PHARMACOL, MEMPHIS, TN 38105 USA	Mayo Clinic; University of Virginia; University of Virginia; St Jude Children's Research Hospital					NIAMS NIH HHS [AR41189] Funding Source: Medline; NIDDK NIH HHS [DK50628, DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BRUNN GJ, UNPUB; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; Fadden P, 1997, J BIOL CHEM, V272, P10240; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Hall MN, 1996, BIOCHEM SOC T, V24, P234, DOI 10.1042/bst0240234; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KAMITZ LM, 1995, MOL CELL BIOL, V15, P3049; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; LAWRENCE J, IN PRESS ADV ENZYME; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Rousseau D, 1996, ONCOGENE, V13, P2415; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SMITH M R, 1990, New Biologist, V2, P648; Sonenberg Nahum, 1993, Gene Expression, V3, P317; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076	35	775	795	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	1997	277	5322					99	101		10.1126/science.277.5322.99	http://dx.doi.org/10.1126/science.277.5322.99			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204908				2022-12-28	WOS:A1997XJ41800048
J	Gleason, PP; Kapoor, WN; Stone, RA; Lave, JR; Obrosky, DS; Schulz, R; Singer, DE; Coley, CM; Marrie, TJ; Fine, MJ				Gleason, PP; Kapoor, WN; Stone, RA; Lave, JR; Obrosky, DS; Schulz, R; Singer, DE; Coley, CM; Marrie, TJ; Fine, MJ			Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-TRACT INFECTIONS; REQUIRING HOSPITALIZATION; ANTIBIOTIC-TREATMENT; INITIAL MANAGEMENT; CLINICAL-PRACTICE; UNITED-STATES; ETIOLOGY; ADULTS; EPIDEMIOLOGY; PERSPECTIVE	Context.-The American Thoracic Society (ATS) published guidelines based on expert opinion and published data-but not clinically derived or validated-for treating adult outpatients with community-acquired pneumonia, Objective.-To compare medical outcomes and antimicrobial costs for patients whose antimicrobial therapy was consistent or inconsistent with ATS guidelines, Design.-Multicenter, prospective cohort study. Setting.-Emergency departments, medical clinics, and practitioner offices affiliated with 3 university hospitals, 1 community teaching hospital, and 1 health maintenance organization, Participants.-A total of 864 immunocompetent, adult outpatients with community-acquired pneumonia, 546 aged 60 years or younger with no comorbidity and 318 older than 60 years or with 1 comorbidity or more. Main Outcome Measures.-Patients' antimicrobial therapy was classified as being consistent or inconsistent with the ATS guidelines, Mortality, subsequent hospitalization, medical complications, symptom resolution, return to work and usual activities, health-related quality of life, and antimicrobial costs were compared among those treated consistently or inconsistently with the guidelines, Results.-Outpatients aged 60 years or younger with no comorbidity who were prescribed therapy consistent with ATS guidelines (ie, erythromycin with some exceptions) had 3-fold lower antimicrobial costs ($5.43 vs $18.51; P<.001) and no significant differences in medical outcomes, Outpatients older than 60 years or with 1 comorbidity or more who were prescribed therapy consistent with ATS guidelines (ie, second-generation cephalosporin, sulfamethoxazble-trimethoprim, or beta-lactam and beta-lactamase inhibitor with or without a macrolide) had 10-fold higher antimicrobial costs ($73.50 vs $7.50; P<.001); despite trends toward higher mortality and subsequent. hospitalization, no significant differences in medical outcomes were observed. Conclusion.-Our findings support the use of erythromycin as recommended by the ATS guidelines for outpatients aged 60 years or younger with no comorbidity, Although the antimicrobial therapy recommended in outpatients older than 60 years or with 1 comorbidity or more is more costly, this observational study provides no evidence of improved medical outcomes in the small subgroup who received ATS guideline-recommended therapy.	UNIV PITTSBURGH, SCH PHARM, DEPT PHARMACEUT SCI, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT MED, DIV GEN INTERNAL MED, PITTSBURGH, PA USA; UNIV PITTSBURGH, DEPT BIOSTAT, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT HLTH SERV ADM, PITTSBURGH, PA USA; UNIV PITTSBURGH, DEPT PSYCHIAT, GRAD SCH PUBL HLTH, PITTSBURGH, PA USA; UNIV PITTSBURGH, UNIV CTR SOCIAL & URBAN RES, PITTSBURGH, PA USA; UNIV PITTSBURGH, CTR RES HLTH CARE, PITTSBURGH, PA USA; MASSACHUSETTS GEN HOSP, GEN INTERNAL MED UNIT, BOSTON, MA 02114 USA; VICTORIA GEN HOSP, DEPT MED, DIV INFECT DIS, HALIFAX, NS B3H 2Y9, CANADA; DALHOUSIE UNIV, FAC MED, HALIFAX, NS, CANADA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Massachusetts General Hospital; Dalhousie University; University of Victoria; Dalhousie University					AHRQ HHS [R01HS06468] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AUBIN J, 1994, MED CARE, V32, P1, DOI 10.1097/00005650-199401000-00001; BARTLETT CLR, 1992, RESP MED, V86, P7; BARTLETT JG, 1995, NEW ENGL J MED, V333, P1618, DOI 10.1056/NEJM199512143332408; BATES JH, 1992, CHEST, V101, P1005, DOI 10.1378/chest.101.4.1005; DIXON RE, 1985, AM J MED, V78, P45, DOI 10.1016/0002-9343(85)90363-8; DULAKE C, 1982, PNEUMONIA PNEUMOCOCC, V27, P87; ERARD P, 1991, 31ST INT C ANT AG CH, P108; EVERETT MT, 1983, PRACTITIONER, V227, P1743; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FASS RJ, 1993, J ANTIMICROB CHEMOTH, V32, P17, DOI 10.1093/jac/32.suppl_A.17; FEIN AM, 1995, AM J RESP CRIT CARE, V152, P1149, DOI 10.1164/ajrccm.152.4.7551362; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; GARIBALDI RA, 1985, AM J MED, V78, P32, DOI 10.1016/0002-9343(85)90361-4; Gilbert K., 1994, Journal of General Internal Medicine, V9, P53; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; Macfarlane J, 1994, Semin Respir Infect, V9, P153; MACFARLANE JT, 1993, LANCET, V341, P511, DOI 10.1016/0140-6736(93)90275-L; Mardh P A, 1976, Infection, V4, P40; MARRIE TJ, 1993, ARCH INTERN MED, V153, P488, DOI 10.1001/archinte.153.4.488; MARRIE TJ, 1989, REV INFECT DIS, V11, P586; Marrie TJ, 1996, AM J MED, V101, P508, DOI 10.1016/S0002-9343(96)00255-0; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCGREW RE, 1985, ENCY MED HIST; *MED EC DAT INC, 1993, 1993 REDB; *MED EC DAT INC, 1996, 1996 REDB; Minogue M. F., 1996, JGIM, V11, P52; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; ORTQVIST A, 1995, J ANTIMICROB CHEMOTH, V35, P205, DOI 10.1093/jac/35.1.205; ORTQVIST A, 1985, SCAND J INFECT DIS, V17, P377; PACHON J, 1990, AM REV RESPIR DIS, V142, P369, DOI 10.1164/ajrccm/142.2.369; RODNICK JE, 1991, WESTERN J MED, V154, P405; Sankilampi U, 1997, EPIDEMIOL INFECT, V118, P7, DOI 10.1017/S0950268896007169; SELKER HP, 1993, AM J CARDIOL, V71, P339, DOI 10.1016/0002-9149(93)90802-J; SHAW AB, 1955, BRIT MED J, V2, P1577, DOI 10.1136/bmj.2.4956.1577; Tenover FC, 1996, AM J MED SCI, V311, P9, DOI 10.1097/00000441-199601000-00003; TORRES A, 1991, AM REV RESPIR DIS, V144, P312, DOI 10.1164/ajrccm/144.2.312; Ware J. E., 1993, SF36 HLTH SURVEY MAN; WARE JE, 1994, SF36 PHYSICAL MENTAL; WOODHEAD MA, 1987, LANCET, V1, P671; 1995, HLTH CARE FINANC SEP, P16	42	154	160	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					32	39		10.1001/jama.278.1.32	http://dx.doi.org/10.1001/jama.278.1.32			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207335				2022-12-28	WOS:A1997XG38700033
J	Applegate, WB; Pahor, M				Applegate, WB; Pahor, M			Geriatric medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXERCISE				Applegate, WB (corresponding author), UNIV TENNESSEE,MEMPHIS,TN 38163, USA.							Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; Knopman D, 1996, NEUROLOGY, V47, P166, DOI 10.1212/WNL.47.1.166; LaCroix AZ, 1996, J AM GERIATR SOC, V44, P113, DOI 10.1111/j.1532-5415.1996.tb02425.x; LORD SR, 1995, J AM GERIATR SOC, V43, P1198, DOI 10.1111/j.1532-5415.1995.tb07394.x; MITTELMAN MS, 1996, AJAMA, V276, P1725; PaganiniHill A, 1996, ARCH INTERN MED, V156, P2213, DOI 10.1001/archinte.156.19.2213; Rozzini R, 1996, J AM GERIATR SOC, V44, P1025, DOI 10.1111/j.1532-5415.1996.tb02932.x; Schnelle JF, 1996, J AM GERIATR SOC, V44, P507, DOI 10.1111/j.1532-5415.1996.tb01434.x; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; WHELTON PK, 1996, CIRCULATION S1, V94, P178; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; Wolfson L, 1996, J AM GERIATR SOC, V44, P498, DOI 10.1111/j.1532-5415.1996.tb01433.x	15	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1863	1864						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD544	9185804				2022-12-28	WOS:A1997XD54400023
J	Johns, ME; Niparko, JK				Johns, ME; Niparko, JK			Otolaryngology head and neck surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Johns, ME (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21218, USA.							Califano J, 1996, CANCER RES, V56, P2488; CLARY R, 1996, HEAD NECK SURG, V122, P1189; COHEN H, 1995, ARCH OTOLARYNGOL, V121, P29; Gates GA, 1996, ARCH OTOLARYNGOL, V122, P161; Gleich LL, 1996, LARYNGOSCOPE, V106, P1378, DOI 10.1097/00005537-199611000-00013; HARALDSSON PO, 1995, ARCH OTOLARYNGOL, V121, P90; Johns ME, 1996, ARCH OTOLARYNGOL, V122, P1039; Johns MM, 1996, CANCER RES, V56, P1151; Koch WM, 1996, JNCI-J NATL CANCER I, V88, P1580, DOI 10.1093/jnci/88.21.1580; Omori K, 1996, LARYNGOSCOPE, V106, P689, DOI 10.1097/00005537-199606000-00006; Orten SS, 1996, ARCH OTOLARYNGOL, V122, P1174; PICCIRILLO J, 1996, ARCH OTOLARYNGOL, V2122, P1045; Piccirillo J F, 1995, Oncology (Williston Park), V9, P831; Pradhan PS, 1996, LARYNGOSCOPE, V106, P1393, DOI 10.1097/00005537-199611000-00016; Shy C, 1996, OTOLARYNG HEAD NECK, V115, P442; Wyatt JR, 1996, LARYNGOSCOPE, V106, P816, DOI 10.1097/00005537-199607000-00006	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1886	1887						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185817				2022-12-28	WOS:A1997XD54400036
J	Ohrt, C; Richie, TL; Widjaja, H; Shanks, D; Fitriadi, J; Fryauff, DJ; Handschin, J; Tang, D; Sandjaja, B; Tjitra, E; Hadiarso, L; Watt, G; Wignall, FS				Ohrt, C; Richie, TL; Widjaja, H; Shanks, D; Fitriadi, J; Fryauff, DJ; Handschin, J; Tang, D; Sandjaja, B; Tjitra, E; Hadiarso, L; Watt, G; Wignall, FS			Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM; EASTERN THAILAND; TRAVELERS; VIVAX; PRIMAQUINE; CHLOROQUINE; PREVENTION; REGIMENS; EFFICACY	Background: Mefloquine and doxycycline are the two drugs recommended for prophylaxis of malaria for visitors to areas where Plasmodium falciparum is resistant to chloroquine. Objective: To compare the efficacy and tolerability of mefloquine with those of doxycycline as prophylaxis for malaria. Design: Randomized, double-blind, placebo-controlled field trial of chemoprophylaxis of malaria. Setting: Northeastern Irian Jaya, Indonesia. Participants: 204 Indonesian soldiers. Intervention: After radical curative treatment, participants were randomly assigned to receive 100 mg of doxycycline per day and mefloquine placebo; 250 mg of mefloquine per week (preceded by a loading dose of 250 mg/d for 3 days) and doxycycline placebo; or placebos for both drugs. Prophylaxis lasted approximately 13 weeks. Measurements: The primary end point for efficacy was the first occurrence of malaria, as documented by a positive malaria smear. Malaria smears were obtained weekly I and when patients had symptoms suggesting malaria. Reported symptoms were recorded daily, and an exit study questionnaire was conducted. Results: In the placebo group, 53 of 69 soldiers developed malaria (9.1 person-years), resulting in an attack rate of 5.8 cases per person-year (95% CI, 4.3 to 7.7 cases per person-year). Plasmodium falciparum accounted for 57% of cases, and P. vivax accounted for 43% of cases. No malaria occurred in the 68 soldiers (16.9 person-years) in the mefloquine group; thus, the protective efficacy of mefloquine was 100% (CI, 96% to 100%). In the doxycycline group, P. falciparum malaria occurred in 1 of 67 soldiers (16.0 person-years), yielding a protective efficacy of 99% (CI, 94% to 100%). Both drugs were very well tolerated. Conclusions: Mefloquine and doxycycline were both highly efficacious and well tolerated as prophylaxis of malaria in Indonesian soldiers.			Ohrt, C (corresponding author), WALTER REED ARMY MED CTR, WALTER REED ARMY INST RES, DEPT CLIN PHARMACOL, DIV EXPT THERAPEUT, WASHINGTON, DC 20307 USA.		; Shanks, George Dennis/F-4056-2014	Richie, Thomas/0000-0002-2946-5456; Shanks, George Dennis/0000-0001-5763-8660				AMENDOLA MA, 1985, JAMA-J AM MED ASSOC, V253, P1009, DOI 10.1001/jama.253.7.1009; ARTHUR JD, 1990, LANCET, V335, P972, DOI 10.1016/0140-6736(90)91035-9; ARTHUR JD, 1990, AM J TROP MED HYG, V43, P608, DOI 10.4269/ajtmh.1990.43.608; BAIRD JK, 1995, J INFECT DIS, V171, P1678, DOI 10.1093/infdis/171.6.1678; BAIRD JK, 1991, AM J TROP MED HYG, V44, P640, DOI 10.4269/ajtmh.1991.44.640; BAIRD JK, 1995, PARASITOL TODAY, V11, P105, DOI 10.1016/0169-4758(95)80167-7; BAIRD JK, 1991, AM J TROP MED HYG, V45, P65, DOI 10.4269/ajtmh.1991.45.65; BEHRENS RH, 1993, BRIT MED BULL, V49, P363, DOI 10.1093/oxfordjournals.bmb.a072615; BEM JL, 1992, J TROP MED HYG, V95, P167; BOUDREAU E, 1993, TROP MED PARASITOL, V44, P257; BOUDREAU E F, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P183; BRADLEY DJ, 1995, BRIT MED J, V310, P709, DOI 10.1136/bmj.310.6981.709; Buma APCCH, 1996, J INFECT DIS, V173, P1506, DOI 10.1093/infdis/173.6.1506; Bunnag D., 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P777; Eamsila Chirapa, 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P672; EDERER F, 1974, AM J EPIDEMIOL, V100, P165, DOI 10.1093/oxfordjournals.aje.a112024; FONTANET AL, 1994, B WORLD HEALTH ORGAN, V72, P73; FRYAUFF DJ, 1995, LANCET, V346, P1190, DOI 10.1016/S0140-6736(95)92898-7; HANDSCHIN J, 1995, LANCET, V346, P1294, DOI 10.1016/S0140-6736(95)91892-2; *HHS, 1995, HHS PUBL, P120; Jaspers CAJJ, 1996, AM J TROP MED HYG, V55, P230, DOI 10.4269/ajtmh.1996.55.230; KAMOLRATANAKUL P, 1989, T ROY SOC TROP MED H, V83, P313, DOI 10.1016/0035-9203(89)90485-9; KEAN BH, 1976, AM J MED, V61, P159, DOI 10.1016/0002-9343(76)90164-9; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; LACKRITZ EM, 1991, JAMA-J AM MED ASSOC, V265, P383, DOI 10.1001/jama.265.3.383; Lee E.T., 1992, STATISTICAL METHODS; LOBEL HO, 1993, LANCET, V341, P848, DOI 10.1016/0140-6736(93)93058-9; NOSTEN F, 1994, J INFECT DIS, V169, P595, DOI 10.1093/infdis/169.3.595; NOSTEN F, 1991, LANCET, V337, P1140, DOI 10.1016/0140-6736(91)92798-7; PANG L, 1988, J INFECT DIS, V158, P1124, DOI 10.1093/infdis/158.5.1124; PANG LW, 1987, LANCET, V1, P1161; PEARLMAN EJ, 1980, AM J TROP MED HYG, V29, P1131, DOI 10.4269/ajtmh.1980.29.1131; SINGH K, 1991, ANN INTERN MED, V114, P994, DOI 10.7326/0003-4819-114-11-994_1; SINGHARAJ P, 1987, R THAI ARMY MED J, V40, P165; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W; SURIYAMONGKOL V, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P515; Wallace MR, 1996, AM J MED, V100, P49, DOI 10.1016/S0002-9343(96)90011-X; WATANASOOK C, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P61; WEINKE T, 1991, AM J TROP MED HYG, V45, P86, DOI 10.4269/ajtmh.1991.45.86; WEISS WR, 1995, J INFECT DIS, V171, P1569, DOI 10.1093/infdis/171.6.1569; *WHO, 1996, IMPR ACC QUAL CAR FA, P67; 1993, MMWR-MORBID MORTAL W, V42, P524; 1995, CANADA COMMUNICABLE, V21, P1; 1995, PHYSICIANS DESK REFE, V46	44	117	118	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1997	126	12					963	972		10.7326/0003-4819-126-12-199706150-00006	http://dx.doi.org/10.7326/0003-4819-126-12-199706150-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE549	9182474				2022-12-28	WOS:A1997XE54900009
J	Fiscella, K; Franks, P				Fiscella, K; Franks, P			Poverty or income inequality as predictor of mortality: Longitudinal cohort study	BRITISH MEDICAL JOURNAL			English	Article							SOCIOECONOMIC-STATUS; UNITED-STATES; FOLLOW-UP; HEALTH; CHALLENGE; DISEASE	Objectives: To determine the effect of inequality in income between communities independent of household income on individual all cause mortality in the United States. Design: Longitudinal cohort study. Subjects: A nationally representative sample of 14 407 people aged 25-74 years in the United States from the first national health and nutrition examination survey. Setting: Subjects were followed from initial interview in 1971-5 until 1987. Complete follow up information was available for 92.2% of the sample. Main outcome measures: Relation between both household income and income inequality in community of residence and individual all cause mortality at follow up was examined with Cox proportional hazards survival analysis. Results: Community income inequality showed a significant association with subsequent community mortality, and with individual mortality after adjustment for age, sex, and mean income in the community of residence. After adjustment for individual household income, however, the association with mortality was lost Conclusions: in this nationally representative American sample, family income, but not community income inequality, independently predicts mortality. Previously reported ecological associations between income inequality and mortality may reflect confounding between individual family income and mortality.			Fiscella, K (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT FAMILY MED,ROCHESTER,NY 14620, USA.							ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; ANDA R, 1993, EPIDEMIOLOGY, V4, P285, DOI 10.1097/00001648-199307000-00003; ANDERSON NB, 1995, PSYCHOSOM MED, V57, P213, DOI 10.1097/00006842-199505000-00003; BAREFOOT JC, 1991, HEALTH PSYCHOL, V10, P18, DOI 10.1037/0278-6133.10.1.18; BenShlomo Y, 1996, BRIT MED J, V312, P1013; BRENNER H, 1992, AM J EPIDEMIOL, V135, P85, DOI 10.1093/oxfordjournals.aje.a116205; COHEN BB, 1987, VITAL HLTH STAT SERI, V1; ELOLA J, 1995, AM J PUBLIC HEALTH, V85, P1397, DOI 10.2105/AJPH.85.10.1397; ENGEL A, 1978, VITAL HLTH STAT SERI; Everson SA, 1996, PSYCHOSOM MED, V58, P113, DOI 10.1097/00006842-199603000-00003; FEIN O, 1995, J GEN INTERN MED, V10, P577, DOI 10.1007/BF02640369; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; Kaplan GA, 1996, BRIT MED J, V312, P999; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; LEGRAND J, 1987, EUR ECON REV, V31, P182, DOI 10.1016/0014-2921(87)90030-4; MADANS JH, 1986, PUBLIC HEALTH REP, V101, P474; MILLER HW, 1977, VITAL HLTH STAT SERI, V1; Miller TQ, 1996, PSYCHOL BULL, V119, P322, DOI 10.1037/0033-2909.119.2.322; MILLER TQ, 1995, PSYCHOSOM MED, V57, P572, DOI 10.1097/00006842-199511000-00010; MORGENSTERN H, 1995, ANNU REV PUBL HEALTH, V16, P61, DOI 10.1146/annurev.pu.16.050195.000425; PLOTNICK RD, 1993, INT J HEALTH SERV, V23, P347, DOI 10.2190/H95U-EX9E-QPM2-XA94; *RES TRIANGL I, 1991, SUDAAN PROF SOFTW SU; ROGERS GB, 1979, POPULATION STUDIES, V33, P343; SELVIN HC, 1958, AM J SOCIOL, V63, P607, DOI 10.1086/222356; Smith GD, 1996, BRIT MED J, V312, P987; SORLIE PD, 1995, AM J PUBLIC HEALTH, V85, P949, DOI 10.2105/AJPH.85.7.949; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; WILKINSON RG, 1995, BRIT MED J, V311, P1285, DOI 10.1136/bmj.311.7015.1285	28	219	221	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1724	1727		10.1136/bmj.314.7096.1724	http://dx.doi.org/10.1136/bmj.314.7096.1724			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XE909	9185498	Green Published			2022-12-28	WOS:A1997XE90900022
J	Sihota, S; Pang, N; Kulasekaram, C; Cheesebrough, B				Sihota, S; Pang, N; Kulasekaram, C; Cheesebrough, B			Endometrial resection versus hysterectomy in management of menorrhagia	LANCET			English	Letter											Sihota, S (corresponding author), UNIV NEWCASTLE,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,SCH HLTH SCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1772	1772		10.1016/S0140-6736(05)62992-3	http://dx.doi.org/10.1016/S0140-6736(05)62992-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193403	Bronze			2022-12-28	WOS:A1997XE06500057
J	Gueiros, FJ; Beverley, SM				Gueiros, FJ; Beverley, SM			Trans-kingdom transposition of the Drosophila element mariner within the protozoan Leishmania	SCIENCE			English	Article							TRANSPOSABLE ELEMENT; HORIZONTAL TRANSMISSION; STABLE TRANSFECTION; GENE REPLACEMENT; DNA; EXPRESSION; MELANOGASTER; REPLICATION; INSECTS; MUTANTS	Transposable elements of the mariner/Tc1 family are postulated to have spread by horizontal transfer and be relatively independent of host-specific factors. This was tested by introducing the Drosophila mauritiana element mariner into the human parasite Leishmania major, a trypanosomatid protozoan belonging to one of the most ancient eukaryotic lineages, Transposition in Leishmania was efficient, occurring in more than 20 percent of random transfectants, and proceeded by the same mechanism as in Drosophila. Insertional inactivation of a specific gene was obtained, and a modified mariner element was used to select for gene fusions, establishing mariner as a powerful genetic tool for Leishmania and other organisms, These experiments demonstrate the evolutionary range of mariner transposition in vivo and underscore the ability of this ubiquitous DNA to parasitize the eukaryotic genome.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Gueiros-Filho, Frederico J./D-2160-2013	Gueiros-Filho, Frederico J./0000-0001-5425-2439; Beverley, Stephen/0000-0001-5319-0811	NIAID NIH HHS [AI2964] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; CAPY P, 1994, TRENDS GENET, V10, P7, DOI 10.1016/0168-9525(94)90012-4; CAPY P, 1994, GENETICA, V93, P161, DOI 10.1007/BF01435248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COATES CJ, 1995, MOL GEN GENET, V249, P246, DOI 10.1007/BF00290372; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DELAFAILLE MAC, 1992, J BIOL CHEM, V267, P23839; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREEDMAN DJ, 1993, MOL BIOCHEM PARASIT, V62, P37, DOI 10.1016/0166-6851(93)90175-W; GARCIAFERNANDEZ J, 1995, MOL BIOL EVOL, V12, P421; GueirosFilho FJ, 1996, MOL CELL BIOL, V16, P5655; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KAPLER GM, 1987, NUCLEIC ACIDS RES, V15, P3369, DOI 10.1093/nar/15.8.3369; Kawasaki ES, 1990, PCR PROTOCOLS GUIDE; KIDWELL MG, 1993, NATURE, V362, P202, DOI 10.1038/362202a0; LACALLE RA, 1989, GENE, V79, P375, DOI 10.1016/0378-1119(89)90220-5; Lampe DJ, 1996, EMBO J, V15, P5470, DOI 10.1002/j.1460-2075.1996.tb00930.x; LEBOWITZ JH, 1991, GENE, V103, P119, DOI 10.1016/0378-1119(91)90402-W; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LIDHOLM DA, 1993, GENETICS, V134, P859; LOHE AR, 1995, MOL BIOL EVOL, V12, P62, DOI 10.1093/oxfordjournals.molbev.a040191; LOUKERIS TG, 1995, P NATL ACAD SCI USA, V92, P9485, DOI 10.1073/pnas.92.21.9485; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; Lozovskaya ER, 1996, GENETICS, V142, P173; MARTINPARRAS L, 1992, J BIOL CHEM, V267, P22496; MARUYAMA K, 1991, J MOL EVOL, V33, P514, DOI 10.1007/BF02102804; MEDHORA M, 1991, GENETICS, V128, P311; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; OBrochta DA, 1996, GENETICS, V142, P907; Plasterk RHA, 1996, CURR TOP MICROBIOL, V204, P125; Reiter LT, 1996, NAT GENET, V12, P288, DOI 10.1038/ng0396-288; ROBERTSON HM, 1995, J INSECT PHYSIOL, V41, P99, DOI 10.1016/0022-1910(94)00082-R; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARTZ F, 1991, P NATL ACAD SCI USA, V88, P10416, DOI 10.1073/pnas.88.23.10416; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; WARREN AM, 1994, PARASITOL TODAY, V10, P56	40	125	137	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1716	1719		10.1126/science.276.5319.1716	http://dx.doi.org/10.1126/science.276.5319.1716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180085				2022-12-28	WOS:A1997XD94700048
J	Subramanian, K; Meyer, T				Subramanian, K; Meyer, T			Calcium-induced restructuring of nuclear envelope and endoplasmic reticulum calcium stores	CELL			English	Article							GREEN-FLUORESCENT PROTEIN; MEIOTIC MATURATION; CA2+ STORES; SEA-URCHIN; RELEASE; REORGANIZATION; FERTILIZATION; CELLS; EGG; GRADIENTS	The spatial organization of endoplasmic reticulum (ER) and nuclear envelope (NE) calcium stores is important for the regulation of localized calcium signals and sustained calcium gradients. Here, we have used a lumenal GFP fusion protein and shown that, in resting cells, large molecules can rapidly diffuse across the cell within the lumenal storage space defined by the ER and NE membranes. Increases in cytosolic calcium concentration reversibly fragmented ER tubules and prevented lumenal diffusion. However, the integrity of the NE was maintained, and a significant fraction of NE lumenal protein accumulated in an NE-associated vesicle. These dynamic properties of ER-NE calcium stores provide insights into the spatiotemporal control of calcium signaling.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University				Meyer, Tobias/0000-0003-4339-3804	NIGMS NIH HHS [GM-51457, GM-48113] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM048113, R01GM048113] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; Button D, 1996, MOL BIOL CELL, V7, P419, DOI 10.1091/mbc.7.3.419; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHANG DC, 1995, J CELL BIOL, V131, P1539, DOI 10.1083/jcb.131.6.1539; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DOWD DR, 1995, ADV SEC MESS PHOSPH, V30, P255; ELLIOTT AC, 1992, PFLUG ARCH EUR J PHY, V422, P245, DOI 10.1007/BF00376209; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; HASHIMOTO S, 1988, J CELL BIOL, V107, P2523, DOI 10.1083/jcb.107.6.2523; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HENSON JH, 1989, J CELL BIOL, V109, P149, DOI 10.1083/jcb.109.1.149; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HIROSE K, 1994, NATURE, V372, P791; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; JAFFE LA, 1994, DEV BIOL, V164, P579, DOI 10.1006/dbio.1994.1225; KOCH GLE, 1988, J CELL SCI, V91, P511; MEHLMANN LM, 1995, DEV BIOL, V170, P607, DOI 10.1006/dbio.1995.1240; MELDOLESI J, 1992, J PHYSIOLOGY-PARIS, V86, P23, DOI 10.1016/S0928-4257(05)80004-X; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MEYER T, 1995, CIBA F SYMP, V188, P252; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; MOHR FC, 1990, AM J PHYSIOL, V258, pC217, DOI 10.1152/ajpcell.1990.258.2.C217; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; Parys JB, 1996, PFLUG ARCH EUR J PHY, V432, P359, DOI 10.1007/s004240050145; PETERSEN OH, 1995, CIBA F SYMP, V188, P85; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SPEKSNIJDER JE, 1993, J CELL BIOL, V120, P1337, DOI 10.1083/jcb.120.6.1337; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Terasaki M, 1996, DEV BIOL, V179, P320, DOI 10.1006/dbio.1996.0263; TERASAKI M, 1991, J CELL BIOL, V114, P929, DOI 10.1083/jcb.114.5.929; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TRUMP BF, 1981, CELL DEATH BIOL PATH, P209; Vertel B M, 1992, Semin Cell Biol, V3, P325, DOI 10.1016/1043-4682(92)90019-R; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	46	190	194	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					963	971		10.1016/S0092-8674(00)80281-0	http://dx.doi.org/10.1016/S0092-8674(00)80281-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200614	Bronze			2022-12-28	WOS:A1997XE35700016
J	Klein, RD; Sherman, D; Ho, WH; Stone, D; Bennett, GL; Moffat, B; Vandlen, R; Simmons, L; Gu, QM; Hongo, JA; Devaux, B; Poulsen, K; Armanini, M; Nozaki, C; Asai, N; Goddard, A; Phillips, H; Henderson, CE; Takahashi, M; Rosenthal, A				Klein, RD; Sherman, D; Ho, WH; Stone, D; Bennett, GL; Moffat, B; Vandlen, R; Simmons, L; Gu, QM; Hongo, JA; Devaux, B; Poulsen, K; Armanini, M; Nozaki, C; Asai, N; Goddard, A; Phillips, H; Henderson, CE; Takahashi, M; Rosenthal, A			A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor	NATURE			English	Article							NEUROTROPHIC FACTOR; TRANSFORMING GENE; SURVIVAL FACTOR; GDNF; ACTIVATION; NEURONS; CELLS; PROTOONCOGENE; NEUROBLASTOMA; EXPRESSION	Glial-cell-line-derived neurotrophic factor (GDNF) and neurturin (NTN) are two structurally related, potent survival factors for sympathetic, sensory and central nervous system neurons(1-6). GDNF mediates its actions through a multicomponent receptor system composed of a ligand-binding glycosyl-phosphatidylinositol (GPI)-linked protein (designated GDNFR-alpha) and the trans-membrane protein tyrosine kinase Ret(7-12). In contrast, the mechanism by which the NTN signal is transmitted is not well understood. Here we describe the identification and tissue distribution of a GPI-linked protein (designated NTNR-alpha) that is structurally related to GDNFR-alpha. We further demonstrate that NTNR-alpha binds NTN (K-d-10 pM) but not GDNF with high affinity; that GDNFR-alpha binds to GDNF but not NTN with high affinity; and that cellular responses to NTN require the presence of NTNR-alpha. Finally, we show that NTN, in the presence of NTNR-alpha, induces tyrosine-phosphorylation of Ret, and that NTN, NTNR-alpha and Ret form a physical complex on the cell surface. These findings identify Ret and NTNR-alpha as signalling and ligand-binding components, respectively, of a receptor for NTN and define a novel family of receptors for neurotrophic and differentiation factors composed of a shared transmembrane protein tyrosine kinase and a ligand-specific GPI-linked protein.	GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOANALYT TECHNOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT BIOCHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOL BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT ANTIBODY TECHNOL,S SAN FRANCISCO,CA 94080; NAGOYA UNIV,SCH MED,DEPT PATHOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; DEV BIOL INST MARSEILLE,INSERM,U382,F-13288 MARSEILLE 09,FRANCE	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Nagoya University; Institut National de la Sante et de la Recherche Medicale (Inserm)			ASAI, Naoya/I-7377-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Henderson, Christopher/0000-0002-9936-3279				Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; BUJBELLO A, 1995, NEURON, V15, P821, DOI 10.1016/0896-6273(95)90173-6; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durbec PL, 1996, DEVELOPMENT, V122, P349; Henderson C.E., 1995, NERVE CELL CULTURE P, P69; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; IKEDA I, 1990, ONCOGENE, V5, P1291; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Lindsay RM, 1996, NEURON, V17, P571, DOI 10.1016/S0896-6273(00)80189-0; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	28	340	357	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					717	721		10.1038/42722	http://dx.doi.org/10.1038/42722			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192898	Bronze			2022-12-28	WOS:A1997XD86900057
J	Teirstein, PS; Massullo, V; Jani, S; Popma, JJ; Mintz, GS; Russo, RJ; Schatz, RA; Guarneri, EM; Steuterman, S; Morris, NB; Leon, MB; Tripuraneni, P				Teirstein, PS; Massullo, V; Jani, S; Popma, JJ; Mintz, GS; Russo, RJ; Schatz, RA; Guarneri, EM; Steuterman, S; Morris, NB; Leon, MB; Tripuraneni, P			Catheter-based radiotherapy to inhibit restenosis after coronary stenting	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTERY BALLOON INJURY; INTRACORONARY IRRADIATION; NEOINTIMA FORMATION; INTRAVASCULAR ULTRASOUND; INTIMAL HYPERPLASIA; ANGIOPLASTY; IMPLANTATION; MODEL; SWINE; DISEASE	Background In animal models of coronary restenosis, intracoronary radiotherapy has been shown to reduce the intimal hyperplasia that is a part of restenosis. We studied the safety and efficacy of catheter-based intracoronary gamma radiation plus stenting to reduce coronary restenosis in patients with previous restenosis. Methods Patients with restenosis underwent coronary stenting, as required, and balloon dilation and were then randomly assigned to receive catheter-based irradiation with iridium-192 or placebo. Clinical follow-up was performed, with quantitative coronary angiographic and intravascular ultrasonographic measurements at six months. Results Fifty-five patients were enrolled; 26 were assigned to the iridium-192 group and 29 to the placebo group. Angiographic studies were performed in 53 patients (96 percent) at a mean (+/-SD) of 6.7+/-2.2 months. The mean minimal luminal diameter at follow-up was larger in the iridium-192 group than in the placebo group (2.43+/-0.78 mm vs. 1.85+/-0.89 mm, P=0.02). Late luminal loss was significantly lower in the iridium-192 group than in the placebo group (0.38+/-1.06 mm vs. 1.03+/-0.97 mm, P=0.03). Angiographically identified restenosis (stenosis of 50 percent or more of the luminal diameter at follow-up) occurred in 17 percent of the patients in the iridium-192 group, as compared with 54 percent of those in the placebo group (P=0.01). There were no apparent complications of the treatment. Conclusions In this preliminary, short-term study of patients with previous coronary restenosis, coronary stenting followed by catheter-based intracoronary radiotherapy substantially reduced the rate of subsequent restenosis. (C) 1997, Massachusetts Medical Society.	SCRIPPS CLIN,DIV RADIAT ONCOL,LA JOLLA,CA 92037; WASHINGTON HOSP CTR,DIV CARDIOL,WASHINGTON,DC 20010	Scripps Research Institute; MedStar Washington Hospital Center	Teirstein, PS (corresponding author), SCRIPPS CLIN,DIV CARDIOVASC DIS,10666 N TORREY PINES RD,SW-206,LA JOLLA,CA 92037, USA.							BOTTCHER HD, 1994, INT J RADIAT ONCOL, V29, P183; CONDADO JA, 1996, CIRCULATION S1, V94, P209; CORN BW, 1990, J CLIN ONCOL, V8, P741, DOI 10.1200/JCO.1990.8.4.741; DUSSAILLANT GR, 1995, J AM COLL CARDIOL, V26, P720, DOI 10.1016/0735-1097(95)00249-4; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; GORDON PC, 1993, J AM COLL CARDIOL, V21, P1166, DOI 10.1016/0735-1097(93)90241-R; HANDLEY DA, 1995, MICRON, V26, P51, DOI 10.1016/0968-4328(94)00047-T; HEBRLEIN C, 1995, CIRCULATION, V92, P1570; Hoffmann R, 1996, CIRCULATION, V94, P1247, DOI 10.1161/01.CIR.94.6.1247; KUNTZ RE, 1992, J AM COLL CARDIOL, V19, P1493, DOI 10.1016/0735-1097(92)90609-Q; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; Laird JR, 1996, CIRCULATION, V93, P529, DOI 10.1161/01.CIR.93.3.529; LIERMANN D, 1994, CARDIOVASC INTER RAD, V17, P12, DOI 10.1007/BF01102065; MAZUR W, 1994, CIRCULATION, V90, P652; Mehran R, 1996, AM J CARDIOL, V78, P618, DOI 10.1016/S0002-9149(96)00381-5; MEIER B, 1984, J AM COLL CARDIOL, V4, P463, DOI 10.1016/S0735-1097(84)80088-1; Mintz GS, 1996, J AM COLL CARDIOL, V27, P1678, DOI 10.1016/0735-1097(96)00083-6; Mintz GS, 1996, CIRCULATION, V94, P35, DOI 10.1161/01.CIR.94.1.35; POPMA JJ, 1991, CIRCULATION, V84, P1426, DOI 10.1161/01.CIR.84.3.1426; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Shefer Arie, 1993, Journal of the American College of Cardiology, V21, p185A; Steidle B., 1994, Strahlentherapie und Onkologie, V170, P151; TEIRSTEIN PS, 1989, J AM COLL CARDIOL, V13, P291, DOI 10.1016/0735-1097(89)90501-9; URBAN P, 1996, CIRCULATION S1, V94, P209; VANDERZWET PMJ, 1994, J AM COLL CARDIOL, V24, P216, DOI 10.1016/0735-1097(94)90566-5; VERIN V, 1995, CIRCULATION, V92, P2284, DOI 10.1161/01.CIR.92.8.2284; WAKSMAN R, 1995, CIRCULATION, V92, P1383, DOI 10.1161/01.CIR.92.6.1383; WAKSMAN R, 1995, CIRCULATION, V92, P3025, DOI 10.1161/01.CIR.92.10.3025; WAKSMAN R, 1995, CIRCULATION, V91, P1533, DOI 10.1161/01.CIR.91.5.1533; WAKSMAN R, 1994, J AM COLL CARDIOL S, V23, pA473; WIEDEMANN J, 1992, CIRCULATION, V86, P188; WIEDERMANN JG, 1995, J AM COLL CARDIOL, V25, P1451, DOI 10.1016/0735-1097(95)00010-2; WIEDERMANN JG, 1994, J AM COLL CARDIOL, V23, P1491, DOI 10.1016/0735-1097(94)90397-2; WIEDERMANN JG, 1994, CIRCULATION, V90, P59; WILLIAMS DO, 1984, AM J CARDIOL, V53, pC32, DOI 10.1016/0002-9149(84)90742-2	35	703	757	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	1997	336	24					1697	1703		10.1056/NEJM199706123362402	http://dx.doi.org/10.1056/NEJM199706123362402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD543	9180087				2022-12-28	WOS:A1997XD54300002
J	Asch, DA; Ubel, PA				Asch, DA; Ubel, PA			Rationing by any other name	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH				Asch, DA (corresponding author), UNIV PENN,SCH MED,PHILADELPHIA,PA 19104, USA.			Asch, David/0000-0002-7970-286X				ASCH DA, 1995, ANN INTERN MED, V122, P846, DOI 10.7326/0003-4819-122-11-199506010-00007; HADORN DC, 1991, JAMA-J AM MED ASSOC, V266, P3328, DOI 10.1001/jama.266.23.3328; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; RELMAN AS, 1990, NEW ENGL J MED, V322, P1809, DOI 10.1056/NEJM199006213222510; Ubel PA, 1997, ANN INTERN MED, V126, P74, DOI 10.7326/0003-4819-126-1-199701010-00010	5	45	45	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1668	1671		10.1056/NEJM199706053362309	http://dx.doi.org/10.1056/NEJM199706053362309			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC086	9171071				2022-12-28	WOS:A1997XC08600009
J	Bodenhofer, K; Hierlemann, A; Seemann, J; Gauglitz, G; Koppenhoefer, B; Gopel, W				Bodenhofer, K; Hierlemann, A; Seemann, J; Gauglitz, G; Koppenhoefer, B; Gopel, W			Chiral discrimination using piezoelectric and optical gas sensors	NATURE			English	Article							ACOUSTIC-WAVE MICROSENSORS; CHROMATOGRAPHY; ENANTIOMERS; SEPARATION; ISOMERS; RESOLUTION	Odour perception in humans can sometimes discriminate different enantiomers of a chiral compound(1-3), such as limonene. Chiral discrimination represents one of the greatest challenges in attempts to devise selective and sensitive gas sensors. The importance of such discrimination for pharmacology is clear, as the physiological effect of enantiomers of drugs and other biologically active molecules may differ significantly(4). Here we describe two different sensor systems that are capable of recognizing different enantiomers and of qualitatively monitoring the enantiomeric composition of amino-acid derivatives and lactates in the gas phase. One sensor detects changes in mass, owing to binding of the compound being analysed (the 'analyte'), by thickness shear-mode resonance(5-7); the other detects changes in the thickness of a surface layer by reflectometric interference spectroscopy(8-10). Both devices use the two enantiomers of a chiral polymeric receptor, and offer rapid on-line detection of chiral species with high selectivity.	UNIV TUBINGEN,INST PHYS & THEORET CHEM,CTR INTERFACE ANAL & SENSORS,D-72076 TUBINGEN,GERMANY; UNIV TUBINGEN,INST ORGAN CHEM,D-72076 TUBINGEN,GERMANY	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen			Hierlemann, Andreas/A-7046-2008	Hierlemann, Andreas/0000-0002-3838-2468				ANHOLT RRH, 1987, TRENDS BIOCHEM SCI, V12, P58, DOI 10.1016/0968-0004(87)90031-4; Bodenhofer K, 1996, ANAL CHEM, V68, P2210, DOI 10.1021/ac9600215; BRECHT A, 1994, FRESEN J ANAL CHEM, V349, P360, DOI 10.1007/BF00326600; FRANK H, 1977, J CHROMATOGR SCI, V15, P174, DOI 10.1093/chromsci/15.5.174; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1991, SCIENCE, V254, P427, DOI 10.1126/science.1925602; FRIEDMAN L, 1971, SCIENCE, V172, P1044, DOI 10.1126/science.172.3987.1044; GAUGLITZ G, 1993, SENSOR ACTUAT B-CHEM, V11, P21, DOI 10.1016/0925-4005(93)85234-2; GRATE JW, 1993, ANAL CHEM, V65, pA940, DOI 10.1021/ac00069a002; GRATE JW, 1993, ANAL CHEM, V65, pA987, DOI 10.1021/ac00070a002; IDE J, 1995, SENSOR ACTUAT A-PHYS, V49, P73, DOI 10.1016/0924-4247(95)01017-U; JAMES TD, 1995, NATURE, V374, P345, DOI 10.1038/374345a0; KONIG WA, 1982, J HIGH RES CHROMATOG, V5, P588, DOI 10.1002/jhrc.1240051102; KOPPENHOEFER B, 1984, CHROMATOGRAPHIA, V19, P123, DOI 10.1007/BF02687727; KOPPENHOEFER B, 1995, CHROMATOGRAPHIA, V40, P718, DOI 10.1007/BF02315143; Kubo Y, 1996, NATURE, V382, P522, DOI 10.1038/382522a0; LEITEREG TJ, 1971, NATURE, V230, P455, DOI 10.1038/230455a0; MEINWALD J, 1991, SCIENCE, V251, P560, DOI 10.1126/science.1846702; NIEUWENHUIZEN MS, 1989, SENSOR MATER, V5, P261; OHLOFF G, 1994, SENT FRAGRANCES FASC; Piehler J, 1996, ANAL CHEM, V68, P139, DOI 10.1021/ac9504878; RAWN JD, 1989, BIOCHEMISTRY; SAUERBREY G, 1959, Z PHYS, V155, P206, DOI 10.1007/BF01337937; SCHURIG V, 1988, J CHROMATOGR, V441, P135, DOI 10.1016/S0021-9673(01)84661-6; TRETTIN U, 1993, THESIS U TUBINGEN	25	132	135	2	85	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					577	580		10.1038/42426	http://dx.doi.org/10.1038/42426			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177343				2022-12-28	WOS:A1997XC52200048
J	Alpers, A; Lo, B				Alpers, A; Lo, B			Does it make clinical sense to equate terminally ill patients who require life-sustaining interventions with those who do not?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; DEATH	Two US courts of appeals have ruled that competent, terminally ill patients have a constitutional right to physician-assisted suicide. The cases are now before the US Supreme Court, which is expected to issue a ruling later this year. This article analyzes the keystone of the courts' ruling: their assertion that competent, terminally ill patients who are being kept alive on life support are equivalent to competent, terminally ill patients who do not require such support. Because the former are permitted to end their lives by refusing treatment, the courts found that the latter also have a right to determine the time and manner of their death, through prescriptions for lethal doses of medication. This article analyzes whether the courts' thinking is premised on a clinically plausible view of the care of terminally ill patients, Based on a discussion of common situations involving terminal illness, we argue that the courts' reasoning is deeply flawed. The article also analyzes how the implications of the courts' reasoning might undermine the care of terminally ill patients.	UNIV CALIF SAN FRANCISCO,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; ALPERS A, 1995, JAMA-J AM MED ASSOC, V273, P156, DOI 10.1001/jama.273.2.156; Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; BRODY H, 1996, BIOLAW, V2, P154; Cantor NL., 1993, CIVILIZATION MIDDLE; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; JECKER N, 1995, J AM GERONTOL, V46, P696; KADISH SH, 1992, CALIF LAW REV, V80, P857, DOI 10.2307/3480699; Kamisar Y, 1996, Duquesne Law Rev, V35, P481; Lee MA, 1996, ANN INTERN MED, V124, P267, DOI 10.7326/0003-4819-124-2-199601150-00014; LO B, 1995, RESOLVING ETHICAL DI, P24; MEISEL A, 1995, LIMITATIONS DECISION, P470; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; 1996, DUQUESNE LAW REV, V35, P1; 1996, JAMA-J AM MED ASSOC, V275, P1232; 1996, BIOLAW           JUL, V2, P119; 1995, JAMA-J AM MED ASSOC, V274, P1591	25	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1705	1708		10.1001/jama.277.21.1705	http://dx.doi.org/10.1001/jama.277.21.1705			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169898				2022-12-28	WOS:A1997XB08800032
J	Blaikie, AJ; Ellis, J; Sanders, R; MacEwen, CJ				Blaikie, AJ; Ellis, J; Sanders, R; MacEwen, CJ			Eye disease associated with handling pet tarantulas: Three case reports	BRITISH MEDICAL JOURNAL			English	Article							OPHTHALMIA-NODOSA				Blaikie, AJ (corresponding author), NINEWELLS HOSP, DEPT OPHTHALMOL, DUNDEE DD1 9SY, SCOTLAND.			Blaikie, Andrew/0000-0001-7913-6872				CADERA W, 1984, CAN J OPHTHALMOL, V19, P40; Cooke J.A.L., 1972, American Museum Novitates, VNo. 2498, P1; HERED RW, 1988, OPHTHALMOLOGY, V95, P166, DOI 10.1016/S0161-6420(88)33191-X; Hung JCC, 1996, ARCH DIS CHILD, V75, P462, DOI 10.1136/adc.75.5.462-b; RUTZEN AR, 1993, AM J OPHTHALMOL, V116, P381, DOI 10.1016/S0002-9394(14)71364-9	5	31	31	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 24	1997	314	7093					1524	1525		10.1136/bmj.314.7093.1524	http://dx.doi.org/10.1136/bmj.314.7093.1524			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9183200	Green Published			2022-12-28	WOS:A1997XB48400026
J	Sudlow, M; Rodgers, H; Kenny, RA; Thomson, R				Sudlow, M; Rodgers, H; Kenny, RA; Thomson, R			Population based study of use of anticoagulants among patients with atrial fibrillation in the community	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,SCH MED,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK	Sudlow, M (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Kenny, Rose Anne/0000-0002-9336-8124				*ATR FIBR INV, 1994, ARCH INTERN MED, V154, P1449; LIP GYH, 1994, BRIT HEART J, V71, P92; OConnell JE, 1996, AGE AGEING, V25, P307, DOI 10.1093/ageing/25.4.307; *STROK PREV ATR FI, 1991, CIRCULATION, V84, P597; SWEENEY KG, 1995, BRIT J GEN PRACT, V45, P153	5	76	76	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 24	1997	314	7093					1529	1530		10.1136/bmj.314.7093.1529	http://dx.doi.org/10.1136/bmj.314.7093.1529			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9183202	Green Published			2022-12-28	WOS:A1997XB48400028
J	Mackenzie, PA; Smith, EA; Wallace, PGM				Mackenzie, PA; Smith, EA; Wallace, PGM			Transfer of adults between intensive care units in the United Kingdom: Postal survey	BRITISH MEDICAL JOURNAL			English	Article							ILL PATIENTS; AUDIT		UNIV GLASGOW,GLASGOW ROYAL INFIRM,GLASGOW G4 0SF,LANARK,SCOTLAND	University of Glasgow	Mackenzie, PA (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DIRECTORATE ANAESTHESIA,GLASGOW G11 6NT,LANARK,SCOTLAND.							*ASS AN GB IR, 1994, REC STAND MON AN REC; BION JF, 1988, BRIT MED J, V296, P170, DOI 10.1136/bmj.296.6616.170; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; OAKLEY PA, 1994, ANAESTHESIA, V49, P565; WRIGHT IH, 1988, BRIT MED J, V296, P543, DOI 10.1136/bmj.296.6621.543	5	39	40	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1455	1456		10.1136/bmj.314.7092.1455	http://dx.doi.org/10.1136/bmj.314.7092.1455			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167562	Green Published			2022-12-28	WOS:A1997XA20200023
J	Tanda, G; Pontieri, FE; DiChiara, G				Tanda, G; Pontieri, FE; DiChiara, G			Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu 1 opioid receptor mechanism	SCIENCE			English	Article							FREELY-MOVING RATS; RHESUS-MONKEYS; DELTA-9-TETRAHYDROCANNABINOL; DELTA(9)-TETRAHYDROCANNABINOL; MICRODIALYSIS; CP-55,940	The effects of the active ingredient of Cannabis, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), and of the highly addictive drug heroin on in vivo dopamine transmission in the nucleus accumbens were compared in Sprague-Dawley rats by brain microdialysis, Delta(9)-THC and heroin increased extracellular dopamine concentrations selectively in the shell of the nucleus accumbens; these effects were mimicked by the synthetic cannabinoid agonist WIN55212-2. SR141716A, an antagonist of central cannabinoid receptors, prevented the effects of Delta(9)-THC but not those of heroin. Naloxone, a generic opioid antagonist, administered systemically, or naloxonazine, an antagonist of mu(1) opioid receptors, infused into the ventral tegmentum, prevented the action of cannabinoids and heroin on dopa mine transmission. Thus, Delta(9)-THC and heroin exert similar effects on mesolimbic dopamine transmission through a common mu(1) opioid receptor mechanism located in the ventral mesencephalic tegmentum.	UNIV CAGLIARI, DEPT TOXICOL, I-09126 CAGLIARI, ITALY; UNIV CAGLIARI, CNR, CTR NEUROPHARMACOL, I-09126 CAGLIARI, ITALY	University of Cagliari; Consiglio Nazionale delle Ricerche (CNR); University of Cagliari			Tanda, Gianluigi/Q-4976-2019; Di Chiara, Gaetano/I-7835-2013; Tanda, Gianluigi/B-3318-2009; PONTIERI, FRANCESCO ERNESTO/K-4232-2018	Tanda, Gianluigi/0000-0001-9526-9878; Tanda, Gianluigi/0000-0001-9526-9878; PONTIERI, FRANCESCO ERNESTO/0000-0002-8693-8432				Bjorklund A., 1984, HDB CHEM NEUROANAT 1, V2, P55; CASTANEDA E, 1991, PHARMACOL BIOCHEM BE, V40, P587, DOI 10.1016/0091-3057(91)90367-B; CHEN JP, 1990, PSYCHOPHARMACOLOGY, V102, P156, DOI 10.1007/BF02245916; CLAYTON RR, 1981, NIDA RES MONOGRAPH, V39; COMPTON DR, 1992, J PHARMACOL EXP THER, V263, P1118; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I; GOLD LH, 1992, J PHARMACOL EXP THER, V262, P479; HAHN EF, 1982, J NEUROSCI, V2, P572; HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y; JOHNSON N, 1984, MOL PHARMACOL, V26, P477; JOHNSON SW, 1992, J NEUROSCI, V12, P483; KANDEL DB, 1984, ARCH GEN PSYCHIAT, V41, P200; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; MANSBACH RS, 1994, BEHAV PHARMACOL, V5, P219, DOI 10.1097/00008877-199404000-00014; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; O'Donnell J A, 1982, Chem Depend, V4, P229; PAXINOS G, 1987, RAT BRAIN STEREOTAXI; Pellegrino L. J., 1979, STEREOTAXIC ATLAS RA; Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P1; WILEY JL, 1995, J PHARMACOL EXP THER, V275, P1; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469	25	839	853	2	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 27	1997	276	5321					2048	2050		10.1126/science.276.5321.2048	http://dx.doi.org/10.1126/science.276.5321.2048			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197269				2022-12-28	WOS:A1997XG74800067
J	Casarett, D; Ross, LF				Casarett, D; Ross, LF			Overriding a patient's refusal of treatment after an iatrogenic complication	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NOT-RESUSCITATE ORDERS; ADVERSE EVENTS; HOSPITALIZED-PATIENTS; PHYSICIANS; ANESTHESIA; SURGERY				Casarett, D (corresponding author), UNIV CHICAGO, CHICAGO, IL 60637 USA.							APPLEGATE WB, 1986, ARCH INTERN MED, V146, P2249, DOI 10.1001/archinte.146.11.2249; BEDELL SE, 1991, JAMA-J AM MED ASSOC, V265, P2815, DOI 10.1001/jama.265.21.2815; BERNAT JL, 1993, SURG NEUROL, V40, P7, DOI 10.1016/0090-3019(93)90161-S; BOSK CL, 1979, FORGIVE REMEMBER; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BUCHANAN AE, 1989, DECIDING OTHERS ETHI, P104; BURGIO GR, 1994, INT CONGR SER, V1071, P1; CHRISTAKIS NA, 1993, LANCET, V342, P642, DOI 10.1016/0140-6736(93)91759-F; CHRISTENSEN JF, 1992, J GEN INTERN MED, V7, P424, DOI 10.1007/BF02599161; COHEN CB, 1991, NEW ENGL J MED, V325, P1879, DOI 10.1056/NEJM199112263252611; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; Engelhardt H. T., 1989, DAXS CASE ESSAYS MED, P79; Feinberg, 1984, HARM OTHERS, VI; Jonsen AR., 1977, PHILOS MED ETHICS IT, P27; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MACKINNON B, 1988, J MED PHILOS, V13, P313, DOI 10.1093/jmp/13.3.313; Nightingale F., 1863, NOTES ON HOSP; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; SCHIMMEL EM, 1964, ANN INTERN MED, V60, P100, DOI 10.7326/0003-4819-60-1-100; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TRUOG RD, 1991, ANESTHESIOLOGY, V74, P606, DOI 10.1097/00000542-199103000-00030; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; 1982, STEDMANS MED DICT	25	38	38	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 26	1997	336	26					1908	1910		10.1056/NEJM199706263362611	http://dx.doi.org/10.1056/NEJM199706263362611			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF756	9197222				2022-12-28	WOS:A1997XF75600011
J	Hawkins, TL; McKernan, KJ; Jacotot, LB; MacKenzie, B; Richardson, PM; Lander, ES				Hawkins, TL; McKernan, KJ; Jacotot, LB; MacKenzie, B; Richardson, PM; Lander, ES			DNA sequencing - A magnetic attraction to high-throughput genomics	SCIENCE			English	Article											Hawkins, TL (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CTR GENOME RES,CAMBRIDGE,MA 02141, USA.				NHGRI NIH HHS [HG00098] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		COLLINS F, 1993, SCIENCE, V262, P43, DOI 10.1126/science.8211127; HAWKINS TL, 1994, NUCLEIC ACIDS RES, V22, P4543, DOI 10.1093/nar/22.21.4543	2	43	55	2	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1887	&		10.1126/science.276.5320.1887	http://dx.doi.org/10.1126/science.276.5320.1887			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206843				2022-12-28	WOS:A1997XF10300057
J	Schwartz, MW; Seeley, RJ				Schwartz, MW; Seeley, RJ			Neuroendocrine responses to starvation and weight loss	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORTICOTROPIN-RELEASING FACTOR; LUTEINIZING-HORMONE SECRETION; NEUROPEPTIDE GENE-EXPRESSION; CENTRAL-NERVOUS-SYSTEM; BODY-WEIGHT; PARAVENTRICULAR NUCLEUS; OBESE GENE; FOOD-DEPRIVATION; ENERGY-BALANCE; MESSENGER-RNA		UNIV WASHINGTON, HARBORVIEW MED CTR, DEPT MED, SEATTLE, WA 98104 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, DEPT PSYCHOL, SEATTLE, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle	Schwartz, MW (corresponding author), VET AFFAIRS PUGET SOUND HLTH CARE SYST, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA.		Schwartz, Michael W/H-9950-2012	Seeley, Randy/0000-0002-3721-5625	NIDDK NIH HHS [DK-12829] Funding Source: Medline; NINDS NIH HHS [NS32273] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032273, R01NS032273] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; BAGDADE JD, 1967, J CLIN INVEST, V46, P1549, DOI 10.1172/JCI105646; Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; Barash IA, 1996, ENDOCRINOLOGY, V137, P3144, DOI 10.1210/en.137.7.3144; BAURA GD, 1993, J CLIN INVEST, V92, P1824, DOI 10.1172/JCI116773; Bergendahl M, 1996, J CLIN ENDOCR METAB, V81, P692, DOI 10.1210/jc.81.2.692; BILLINGTON CJ, 1991, AM J PHYSIOL, V260, pR321, DOI 10.1152/ajpregu.1991.260.2.R321; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; Boyko EJ, 1996, DIABETES, V45, P1010, DOI 10.2337/diabetes.45.8.1010; BRADY LS, 1990, NEUROENDOCRINOLOGY, V52, P441, DOI 10.1159/000125626; BRAY GA, 1990, FRONT NEUROENDOCRIN, V11, P128; BRAY GA, 1992, AM J CLIN NUTR, V55, P265; BRUNZELL JD, 1981, INT J OBESITY, V5, P685; CAHILL GF, 1966, J CLIN INVEST, V45, P1751, DOI 10.1172/JCI105481; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Cheung CC, 1997, ENDOCRINOLOGY, V138, P855, DOI 10.1210/en.138.2.855; CHUA SC, 1991, MOL BRAIN RES, V11, P291, DOI 10.1016/0169-328X(91)90038-Y; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; CLIFTON DK, 1985, BIOL REPROD, V33, P808, DOI 10.1095/biolreprod33.4.808; CLIFTON DK, 1980, ENDOCRINOLOGY, V106, P1099, DOI 10.1210/endo-106-4-1099; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; DALLMAN MF, 1993, TRENDS ENDOCRIN MET, V4, P62, DOI 10.1016/S1043-2760(05)80017-7; Donaldson CJ, 1996, ENDOCRINOLOGY, V137, P2167, DOI 10.1210/en.137.5.2167; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; GARNER DM, 1991, CLIN PSYCHOL REV, V11, P729, DOI 10.1016/0272-7358(91)90128-H; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Grunfeld C, 1996, J CLIN ENDOCR METAB, V81, P4342, DOI 10.1210/jc.81.12.4342; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HARBUZ MS, 1992, ENDOCRINOLOGY, V130, P1394, DOI 10.1210/en.130.3.1394; HARRIS RBS, 1986, J NUTR, V116, P2536, DOI 10.1093/jn/116.12.2536; HELLERSTEIN MK, 1989, J CLIN INVEST, V84, P228, DOI 10.1172/JCI114145; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; KEESEY RE, 1986, ANNU REV PSYCHOL, V37, P109; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; Keys A, 1950, BIOL HUMAN STARVATIO; KRAHN DD, 1988, BRAIN RES, V443, P63, DOI 10.1016/0006-8993(88)91598-3; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEEDOM LJ, 1989, PSYCHONEUROENDOCRINO, V14, P275, DOI 10.1016/0306-4530(89)90030-9; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LIU JP, 1994, J CLIN INVEST, V93, P1439, DOI 10.1172/JCI117121; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; NEEL JV, 1962, AM J HUM GENET, V14, P353; ODONOHUE TL, 1985, PEPTIDES, V6, P755, DOI 10.1016/0196-9781(85)90180-9; PARDRIDGE WM, 1986, ENDOCR REV, V7, P314, DOI 10.1210/edrv-7-3-314; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Pierroz DD, 1996, ENDOCRINOLOGY, V137, P3, DOI 10.1210/en.137.1.3; PIRKE KM, 1989, FERTIL STERIL, V51, P263; PLATASALAMAN CR, 1991, NEUROSCI BIOBEHAV R, V15, P185, DOI 10.1016/S0149-7634(05)80001-6; PONSALLE P, 1992, J NEUROENDOCRINOL, V4, P585, DOI 10.1111/j.1365-2826.1992.tb00207.x; Reed DR, 1996, DIABETES, V45, P691, DOI 10.2337/diabetes.45.5.691; Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424; ROTHWELL NJ, 1990, NEUROSCI BIOBEHAV R, V14, P263, DOI 10.1016/S0149-7634(05)80037-5; SAHU A, 1988, PEPTIDES, V9, P83, DOI 10.1016/0196-9781(88)90013-7; SAHU A, 1995, ENDOCRINOLOGY, V136, P5718, DOI 10.1210/en.136.12.5718; SAKAGUCHI T, 1988, AM J PHYSIOL, V255, pR284, DOI 10.1152/ajpregu.1988.255.2.R284; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SCHWARTZ MW, 1995, AM J PHYSIOL-REG I, V269, pR949, DOI 10.1152/ajpregu.1995.269.5.R949; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; SCHWARTZ MW, 1995, J CLIN ENDOCR METAB, V80, P1571, DOI 10.1210/jc.80.5.1571; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; SCHWARTZ MW, 1992, ENDOCRINOLOGY, V130, P3608, DOI 10.1210/en.130.6.3608; SCHWEIGER U, 1988, FERTIL STERIL, V49, P447; Seeley RJ, 1996, AM J PHYSIOL-REG I, V271, pR819, DOI 10.1152/ajpregu.1996.271.3.R819; SIPOLS AJ, 1995, DIABETES, V44, P147, DOI 10.2337/diabetes.44.2.147; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; Stanley B.G., 1993, BIOL NEUROPEPTIDE RE, P457, DOI [10.1007/978-1-59259-465-8_11, DOI 10.1007/978-1-59259-465-8_11]; STANLEY BG, 1986, PEPTIDES, V7, P1189; STRACK AM, 1995, AM J PHYSIOL-REG I, V268, pR142, DOI 10.1152/ajpregu.1995.268.1.R142; SUEMARU S, 1986, LIFE SCI, V39, P1161, DOI 10.1016/0024-3205(86)90347-4; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VANDERWEELE DA, 1982, APPETITE, V3, P99, DOI 10.1016/S0195-6663(82)80003-2; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; WHITE J D, 1990, Molecular and Cellular Neuroscience, V1, P41; WOODS SC, 1985, AM J CLIN NUTR, V42, P1063, DOI 10.1093/ajcn/42.5.1063; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	88	235	243	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	1997	336	25					1802	1811		10.1056/NEJM199706193362507	http://dx.doi.org/10.1056/NEJM199706193362507			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE485	9187072				2022-12-28	WOS:A1997XE48500007
J	Matloff, JM; Chaux, A				Matloff, JM; Chaux, A			Cardiothoracic surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GRAFTS; RABBIT				Matloff, JM (corresponding author), CEDARS SINAI MED CTR,LOS ANGELES,CA 90048, USA.							AUPART MR, 1996, ANN THORAC SURG, V61, P616; Batista RJV, 1996, J CARDIAC SURG, V11, P96, DOI 10.1111/j.1540-8191.1996.tb00019.x; CHAUX A, 1995, J THORAC CARDIOV SUR, V110, P1381, DOI 10.1016/S0022-5223(95)70061-7; DelRizzo DF, 1996, J THORAC CARDIOV SUR, V112, P1431, DOI 10.1016/S0022-5223(96)70001-6; Elkins RC, 1996, ANN THORAC SURG, V62, P450, DOI 10.1016/0003-4975(96)00278-0; Fann JI, 1996, ANN THORAC SURG, V62, P1301, DOI 10.1016/0003-4975(96)00629-7; Gelb AF, 1996, CHEST, V110, P11, DOI 10.1378/chest.110.1.11; Hlatky MA, 1997, NEW ENGL J MED, V336, P92, DOI 10.1056/NEJM199701093360203; HORSTKOTTE D, 1996, ANN HEMATOL S1, V72, pA83; HORVATH KA, IN PRESS J THORAC CA; Kaplitt MG, 1996, ANN THORAC SURG, V62, P1669, DOI 10.1016/S0003-4975(96)00946-0; KUPFER JM, 1994, HUM GENE THER, V5, P1437, DOI 10.1089/hum.1994.5.12-1437; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Trento A, 1996, J THORAC CARDIOV SUR, V112, P1496, DOI 10.1016/S0022-5223(96)70008-9; Westaby S, 1996, EUR J CARDIO-THORAC, V10, P660	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1843	1845						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185792				2022-12-28	WOS:A1997XD54400011
J	Giugliano, D; Acampora, R; Marfella, R; DeRosa, N; Ziccardi, P; Ragone, R; DeAngelis, L; DOnofrio, F				Giugliano, D; Acampora, R; Marfella, R; DeRosa, N; Ziccardi, P; Ragone, R; DeAngelis, L; DOnofrio, F			Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							OXIDATIVE STRESS; BLOOD-FLOW; GLUCOSE; PATHOGENESIS; BLOCKADE; DISEASE	Background: Diabetic patients are considered less suitable than nondiabetic patients for p-blocker therapy because of the risk for worsened glucose and lipid metabolism and more severe hypoglycemic attacks. Objective: To compare the metabolic and cardiovascular effects of carvedilol with those of atenolol in diabetic patients with hypertension. Design: Randomized, double-blind, 24-week trial. Setting: University hospital clinic. Patients: 45 patients with non-insulin-dependent diabetes mellitus and hypertension. Intervention: After a 4- to 6-week run-in period during which placebo was given in a single-blind manner, patients were randomly assigned to carvedilol or atenolol. Measurements: An oral glucose tolerance test; assessment of insulin sensitivity and hormonal responses to insulin hypoglycemia; and assessment of lipid levels, blood pressure, left ventricular mass, and lipid peroxidation. Results: Changes in systolic and diastolic blood pressure and left ventricular mass index were similar with carvedilol and atenolol (P > 0.2). Fasting plasma glucose and insulin levels decreased with carvedilol and increased with atenolol. Responses to carvedilol were greater than those to atenolol, as follows: increase in total glucose disposal, 9.54 mu mol/kg of body weight per minute (95% CI, 7 to 11.9 mu mol/kg per minute); decrease in plasma glucose response to oral glucose, 61 mmol/L x 180 minutes (CI, -101 to -21 mmol/L x 180 minutes); decrease in insulin response to oral glucose, 6.2 nmol/L x 180 minutes (Cl, -9.8 to -2.6 nmol/L x 180 minutes); decrease in triglyceride level, 0.56 mmol/L(CI, -0.75 to -0.37 mmol/L; P < 0.001); increase in high-density lipoprotein cholesterol level, 0.13 mmol/L (CI, 0.09 to 0.17 mmol/L; P < 0.001); and decrease in lipid peroxidation, 0.25 mu mol/L (CI, -0.34 to -0.16 mu mol/L). Conclusions: By improving glucose and lipid metabolism and reducing lipid peroxidation, carvedilol may offer advantages in patients with diabetes and hypertension.	UNIV NAPLES 2, DEPT GERIATR & METAB DIS, I-80138 NAPLES, ITALY; UNIV NAPLES 2, DEPT BIOCHEM & BIOPHYS, I-80138 NAPLES, ITALY	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli			Marfella, Raffaele/C-6899-2012	Marfella, Raffaele/0000-0003-3960-9270; Giugliano, Dario/0000-0002-9377-873X				ALEXANDER RW, 1995, HYPERTENSION, V25, P155, DOI 10.1161/01.HYP.25.2.155; ALLISON DB, 1995, DIABETES CARE, V18, P245, DOI 10.2337/diacare.18.2.245; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; FEUERSTEIN GZ, 1995, EUR HEART J, V16, P38, DOI 10.1093/eurheartj/16.suppl_F.38; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; GIUGLIANO D, 1993, AM J HYPERTENS, V6, P927, DOI 10.1093/ajh/6.11.927; GIUGLIANO D, 1995, METABOLISM, V44, P363, DOI 10.1016/0026-0495(95)90167-1; HERINGS RMC, 1995, LANCET, V345, P1195, DOI 10.1016/S0140-6736(95)91988-0; Jonas M, 1996, AM J CARDIOL, V77, P1273, DOI 10.1016/S0002-9149(96)00191-9; LAGER I, 1979, LANCET, V1, P458; LIND L, 1993, AM HEART J, V125, P1494, DOI 10.1016/0002-8703(93)90446-G; LITHELL HOL, 1991, DIABETES CARE, V14, P203, DOI 10.2337/diacare.14.3.203; MALMBERG K, 1989, EUR HEART J, V10, P423, DOI 10.1093/oxfordjournals.eurheartj.a059505; MCTAVISH D, 1993, DRUGS, V45, P232, DOI 10.2165/00003495-199345020-00006; PAOLISSO G, 1987, ACTA ENDOCRINOL-COP, V115, P161, DOI 10.1530/acta.0.1150161; POLLARE T, 1989, BRIT MED J, V298, P1152, DOI 10.1136/bmj.298.6681.1152; SMITH RS, 1982, CARDIOVASC RES, V16, P205, DOI 10.1093/cvr/16.4.205; SOWERS JR, 1995, HYPERTENSION, V26, P869, DOI 10.1161/01.HYP.26.6.869; Tomlinson B, 1988, Drugs, V36 Suppl 6, P37; WARAVDEKAR VS, 1959, J BIOL CHEM, V234, P1945	20	220	232	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1997	126	12					955	959		10.7326/0003-4819-126-12-199706150-00004	http://dx.doi.org/10.7326/0003-4819-126-12-199706150-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE549	9182472				2022-12-28	WOS:A1997XE54900007
J	Schmitz, N; Diehl, V				Schmitz, N; Diehl, V			Carmustine and the lungs	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; TOXICITY; BCNU		UNIV COLOGNE,DEPT MED,D-50924 COLOGNE,GERMANY	University of Cologne	Schmitz, N (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL,DEPT INTERNAL MED,GUTENBERGSTR 76-78,D-24098 KIEL,GERMANY.							ARONIN PA, 1980, NEW ENGL J MED, V303, P183, DOI 10.1056/NEJM198007243030403; BEARMAN SI, 1988, J CLIN ONCOL, V6, P1562, DOI 10.1200/JCO.1988.6.10.1562; CLARK JG, 1993, AM REV RESPIR DIS, V147, P1601, DOI 10.1164/ajrccm/147.6_Pt_1.1601; IRIARTE PV, 1966, CANCER, V19, P1187, DOI 10.1002/1097-0142(196609)19:9<1187::AID-CNCR2820190902>3.0.CO;2-T; ODRISCOLL BR, 1990, NEW ENGL J MED, V323, P378, DOI 10.1056/NEJM199008093230604; Rubio C, 1997, BRIT J CANCER, V75, P1044, DOI 10.1038/bjc.1997.178; WHEELER C, 1990, J CLIN ONCOL, V8, P648, DOI 10.1200/JCO.1990.8.4.648	7	14	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1712	1713		10.1016/S0140-6736(05)62951-0	http://dx.doi.org/10.1016/S0140-6736(05)62951-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193378				2022-12-28	WOS:A1997XE06500005
J	Parekh, AB; Fleig, A; Penner, R				Parekh, AB; Fleig, A; Penner, R			The store-operated calcium current I-CRAC: Nonlinear activation by InsP(3) and dissociation from calcium release	CELL			English	Article							HUMAN UMBILICAL VEIN; RBL-2H3 CELLS; INOSITOL TRISPHOSPHATE; ENDOTHELIAL-CELLS; ACINAR-CELLS; CA2+ ENTRY; MAST-CELLS; DEPLETION; RECEPTOR; SIGNALS	Patch-clamp experiments aimed at determining the relationship between intracellular Ca2+ release and activation of store-operated calcium current I-CRAC reveal that both agonist and InsP(3)-mediated activation of I-CRAC are highly nonlinear, occurring over a narrow concentration range. Ca2+ release and Ca2+ influx can be dissociated, as they possess differential sensitivities to InsP(3): low concentrations induce substantial Ca2+ release without any activation of I-CRAC, whereas micromolar concentrations of InsP(3) are required to activate Ca2+ influx. This suggests functionally distinct stores controlling Ca2+ release and influx and enables cells to switch between sources of Ca2+ to fit best their current needs.	MAX PLANCK INST BIOPHYS CHEM, D-37077 GOTTINGEN, GERMANY	Max Planck Society				Penner, Reinhold/0000-0002-5366-1537; Fleig, Andrea/0000-0001-8396-7249				ALI H, 1990, J BIOL CHEM, V265, P745; ALI H, 1994, BIOCHEM J, V304, P431, DOI 10.1042/bj3040431; Berridge Michael J., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P211; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CHIAVAROLI C, 1994, J BIOL CHEM, V269, P25570; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHOI OH, 1993, J IMMUNOL, V151, P5586; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; GIOVANNARDI S, 1992, EXP CELL RES, V202, P398, DOI 10.1016/0014-4827(92)90092-M; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1994, AM J PHYSIOL, V266, pC1736, DOI 10.1152/ajpcell.1994.266.6.C1736; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; NILIUS B, 1993, PFLUG ARCH EUR J PHY, V424, P285, DOI 10.1007/BF00384354; Parekh AB, 1995, J PHYSIOL-LONDON, V489, P377, DOI 10.1113/jphysiol.1995.sp021058; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Schrenzel J, 1995, BIOPHYS J, V69, P2378, DOI 10.1016/S0006-3495(95)80107-4; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	29	199	202	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					973	980		10.1016/S0092-8674(00)80282-2	http://dx.doi.org/10.1016/S0092-8674(00)80282-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200615	Bronze			2022-12-28	WOS:A1997XE35700017
J	Chen, ZM; Hui, JM; Liu, LS; Liu, ZM; Peto, R; Sandercock, P; Wang, WQ; Wang, YX; Wang, ZB; Xie, JX; You, GX; Zhang, FL; Zhang, HQ; Zhao, ZY				Chen, ZM; Hui, JM; Liu, LS; Liu, ZM; Peto, R; Sandercock, P; Wang, WQ; Wang, YX; Wang, ZB; Xie, JX; You, GX; Zhang, FL; Zhang, HQ; Zhao, ZY			CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke	LANCET			English	Article							CEREBROVASCULAR-DISEASE; ISCHEMIC STROKE; CLINICAL-TRIALS; CHINESE	Background Aspirin is effective in the treatment of acute myocardial infarction and in the long-term prevention of serious vascular events in survivors of stroke and myocardial infarction. There is, however, no reliable evidence on the effectiveness of early aspirin use in acute ischaemic stroke. Methods The Chinese Acute Stroke Trial (CAST) was a large randomised, placebo-controlled trial of the effects in hospital of aspirin treatment (160 mg/day) started within 48 h of the onset of suspected acute ischaemic stroke and continued in hospital for up to 4 weeks. The primary endpoints were death from any cause during the 4-week treatment period and death or dependence at discharge, and the analyses were by intention to treat. 21 106 patients with acute ischaemic stroke were enrolled in 413 Chinese hospitals at a mean of 25 h after the onset of symptoms (10 554 aspirin, 10 552 placebo). 87% had a CT scan before randomisation. It was prospectively planned that the results would be analysed in parallel with those of the concurrent International Stroke Trial (IST) of 20 000 patients with acute stroke from other countries. Findings There was a significant 14% (SD 7) proportional reduction in mortality during the scheduled treatment period (343 [3.3%] deaths among aspirin-allocated patients vs 398 [3.9%] deaths among placebo-allocated patients; 2p=0.04). There were significantly fewer recurrent ischaemic strokes in the aspirin-allocated than in the placebo-allocated group (167 [1.6%] vs 215 [2.1%]; 2p=0.01) but slightly more haemorrhagic strokes (115 [1.1%] vs 93 [0.9%]; 2p>0.1). For the combined in-hospital endpoint of death or non-fatal stroke at 4 weeks, there was a 12% (6) proportional risk reduction with aspirin (545 [5.3%] vs 614 [5.9%]; 2p=0.03), an absolute difference of 6.8 (3.2) fewer cases per 1000. At discharge, 3153 (30.5%) aspirin-allocated patients and 3266 (31.6%) placebo-allocated patients were dead or dependent, corresponding to 11.4 (6.4) fewer per 1000 in favour of aspirin (2p=0.08). Interpretation There are two major trials of aspirin in acute ischaemic stroke. Taken together, CAST and the similarly large IST show reliably that aspirin started early in hospital produces a small but definite net benefit, with about 9 (SD 3) fewer deaths or non-fatal strokes per 1000 in the first few weeks (2p=0.001), and with 13 (5) fewer dead or dependent per 1000 after some weeks or months of followup (2p<0.01).			Chen, ZM (corresponding author), RADCLIFFE INFIRM, CLIN TRIAL SERV UNIT, NUFFIELD DEPT CLIN MED, OXFORD OX2 6HE, ENGLAND.		sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P824, DOI 10.1136/jnnp.53.10.824; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; Born GVR, 1997, LANCET, V349, P806, DOI 10.1016/S0140-6736(05)60237-1; CANDELISE L, 1995, LANCET, V346, P1509; CHEN DY, 1987, CHIN MED J, V7, P382; CHEN KJ, 1992, CHINESE MED J-PEKING, V105, P870; Chen Z, 1997, J Stroke Cerebrovasc Dis, V6, P361, DOI 10.1016/S1052-3057(97)80219-4; Chen ZM, 1996, CEREBROVASC DIS, V6, P23; COLLINS R, 1996, OXFORD TXB MED, V1, P21; COUNSELL C, 1997, STROKE MODULE COCHRA; Dennis M, 1997, CEREBROVASC DIS, V7, P19, DOI 10.1159/000108158; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; FELDMANN E, 1990, NEUROLOGY, V40, P1541, DOI 10.1212/wnl.40.10.1540; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; HUANG CY, 1990, STROKE, V21, P230, DOI 10.1161/01.STR.21.2.230; *INT STROK TRIAL C, 1996, CEREBROVASC DIS, V6, P23; KENT J, 1994, POSTGRAD MED J, V70, P185, DOI 10.1136/pgmj.70.821.185; Leon MB, 1996, CIRCULATION, V94, P1206; LI SC, 1985, NEUROLOGY, V35, P1708, DOI 10.1212/WNL.35.12.1708; Lindley RI, 1995, J ROY COLL PHYS LOND, V29, P479; MARSH EE, 1989, NEUROLOGY, V39, P1631, DOI 10.1212/WNL.39.12.1631; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Sandercock P, 1997, LANCET, V349, P1569; WHO, 1995, WORLD HLTH STAT ANN; Williams C, 1992, INTRO NEW TREATMENTS, P49	28	840	881	2	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	1997	349	9066					1641	1649		10.1016/S0140-6736(97)04010-5	http://dx.doi.org/10.1016/S0140-6736(97)04010-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186381				2022-12-28	WOS:A1997XD10000007
J	Bataille, R; Harousseau, JL				Bataille, R; Harousseau, JL			Multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HIGH-DOSE MELPHALAN; BONE-MARROW TRANSPLANTATION; STEM-CELL TRANSPLANTATION; NEWLY-DIAGNOSED PATIENTS; MONOCLONAL GAMMOPATHY; UNDETERMINED SIGNIFICANCE; INTERFERON ALFA-2B; PROGNOSTIC FACTORS; PLATEAU-PHASE; PLASMA-CELLS		UNIV HOSP NANTES,INST BIOL,HEMATOL LAB,NANTES,FRANCE; UNIV HOSP NANTES,DEPT CLIN ONCOL & HEMATOL,NANTES,FRANCE	Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Bataille, R (corresponding author), INST BIOL,HEMATOL LAB,9 QUAI MONCOUSU,F-44035 NANTES 01,FRANCE.							ALEXANIAN R, 1975, CANCER, V36, P1192, DOI 10.1002/1097-0142(197510)36:4<1192::AID-CNCR2820360403>3.0.CO;2-I; ALEXANIAN R, 1994, NEW ENGL J MED, V330, P484; ANDERSON KC, 1993, BLOOD, V82, P2568; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; ATTAL M, 1992, BLOOD, V79, P1130, DOI 10.1182/blood.V79.5.1130.bloodjournal7951130; ATTAL M, 1996, MULTIPLE MYELOMA, P182; BAKKUS MHC, 1992, BLOOD, V80, P2326; BARLOGIE B, 1983, J CLIN INVEST, V72, P853, DOI 10.1172/JCI111056; BARLOGIE B, 1990, BLOOD, V76, P677, DOI 10.1182/blood.V76.4.677.bloodjournal764677; BARLOGIE B, 1988, BLOOD, V72, P2015; BATAILLE R, 1992, HEMATOL ONCOL CLIN N, V6, P285, DOI 10.1016/S0889-8588(18)30345-9; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; Bataille R, 1996, BLOOD, V87, P4762, DOI 10.1182/blood.V87.11.4762.bloodjournal87114762; BELCH AR, 1991, J CLIN ONCOL, V9, P1397, DOI 10.1200/JCO.1991.9.8.1397; Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802; BOCCADORO M, 1984, BRIT J HAEMATOL, V58, P689, DOI 10.1111/j.1365-2141.1984.tb06116.x; BROWMAN GP, 1995, J CLIN ONCOL, V13, P2354, DOI 10.1200/JCO.1995.13.9.2354; CARTER A, 1990, BRIT J HAEMATOL, V74, P424, DOI 10.1111/j.1365-2141.1990.tb06330.x; Casassus P., 1995, Blood, V86, p441A; CAZZOLA M, 1995, BLOOD, V86, P4446, DOI 10.1182/blood.V86.12.4446.bloodjournal86124446; COGNE M, 1992, BLOOD, V79, P2181; COOPER MR, 1993, J CLIN ONCOL, V11, P155, DOI 10.1200/JCO.1993.11.1.155; CORRADINI P, 1993, BLOOD, V81, P2708; CORRADO C, 1989, P AN M AM SOC CLIN, V8, P258; CUNNINGHAM D, 1994, J CLIN ONCOL, V12, P759, DOI 10.1200/JCO.1994.12.4.759; CUNNINGHAM D, 1994, J CLIN ONCOL, V12, P764, DOI 10.1200/JCO.1994.12.4.764; CUNNINGHAM D, 1993, P AN M AM SOC CLIN, V12, P364; DEWALD GW, 1985, BLOOD, V66, P380; DIMOPOULOS MA, 1993, CANCER-AM CANCER SOC, V72, P2589, DOI 10.1002/1097-0142(19931101)72:9<2589::AID-CNCR2820720913>3.0.CO;2-#; DIMOPOULOS MA, 1993, AM J MED, V94, P57, DOI 10.1016/0002-9343(93)90120-E; DRACH J, 1995, BLOOD, V86, P3915, DOI 10.1182/blood.V86.10.3915.bloodjournal86103915; DREWINKO B, 1981, BLOOD, V57, P333; DURIE BGM, 1980, BLOOD, V55, P364; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; DURIE BGM, 1977, RECENT ADV HAEMATOLO, V2, P243; FERMAND JP, 1993, BLOOD, V82, P2005; FRITZ E, 1984, BLOOD, V63, P1072; GAHRTON G, 1995, J CLIN ONCOL, V13, P1312, DOI 10.1200/JCO.1995.13.6.1312; GAILLARD JP, 1993, EUR J IMMUNOL, V23, P820, DOI 10.1002/eji.1830230408; GAZITT Y, 1995, BLOOD, V86, P381, DOI 10.1182/blood.V86.1.381.bloodjournal861381; GOLD JE, 1990, CANCER, V66, P363, DOI 10.1002/1097-0142(19900715)66:2<363::AID-CNCR2820660227>3.0.CO;2-J; GRAHAM RC, 1975, MEDICINE, V54, P225, DOI 10.1097/00005792-197505000-00004; GREIL R, 1991, BLOOD, V78, P180; GREIPP PR, 1985, BLOOD, V65, P305; GREIPP PR, 1983, BLOOD, V62, P166; GROGAN TM, 1993, BLOOD, V81, P490; HARADA H, 1973, SEMIN HEMATOL, V10, P135; HARDIN J, 1994, BLOOD, V84, P3063; Harousseau J. L., 1995, Blood, V86, p184A; HAROUSSEAU JL, 1992, BLOOD, V79, P2827; HAROUSSEAU JL, 1995, BLOOD, V85, P3077, DOI 10.1182/blood.V85.11.3077.bloodjournal85113077; HAROUSSEAU JL, 1994, CYTOKINES HUMAN MULT, P97; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KLEIN B, 1992, HEMATOL ONCOL CLIN N, V6, P273, DOI 10.1016/S0889-8588(18)30344-7; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 1991, BLOOD, V78, P1198; KWAK LW, 1995, LANCET, V345, P1016, DOI 10.1016/S0140-6736(95)90757-2; KYLE RA, 1975, MAYO CLIN PROC, V50, P29; KYLE RA, 1993, MAYO CLIN PROC, V68, P26, DOI 10.1016/S0025-6196(12)60015-9; KYLE RA, 1994, J CLIN ONCOL, V12, P1577, DOI 10.1200/JCO.1994.12.8.1577; KYLE RA, 1989, SEMIN HEMATOL, V26, P176; LAHTINEN M, 1992, LANCET, V340, P1420; LAHTINEN R, 1992, LANCET, V340, P1049, DOI 10.1016/0140-6736(92)93075-X; LATREILLE J, 1980, BLOOD, V55, P403; Lemoli RM, 1996, BLOOD, V87, P1625, DOI 10.1182/blood.V87.4.1625.bloodjournal8741625; Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699; LUDWIG H, 1995, ANN ONCOL, V6, P467, DOI 10.1093/oxfordjournals.annonc.a059217; MACLENNAN ICM, 1995, MYELOMA BIOL MANAGEM, P30; MANDELLI F, 1990, NEW ENGL J MED, V322, P1430, DOI 10.1056/NEJM199005173222005; MASSAIA M, 1995, BLOOD, V85, P3679, DOI 10.1182/blood.V85.12.3679.bloodjournal85123679; MONTUORO A, 1990, BRIT J HAEMATOL, V76, P365, DOI 10.1111/j.1365-2141.1990.tb06369.x; MOULOPOULOS LA, 1995, J CLIN ONCOL, V13, P251, DOI 10.1200/JCO.1995.13.1.251; MOULOPOULOS LA, 1993, J CLIN ONCOL, V11, P1311, DOI 10.1200/JCO.1993.11.7.1311; NERI A, 1993, BLOOD, V81, P128; *NORD MYEL STUD GR, 1996, ANN INTERN MED, V124, P212; Oken M. M., 1995, Blood, V86, p441A; Osterborg A, 1996, BLOOD, V87, P2675, DOI 10.1182/blood.V87.7.2675.bloodjournal8772675; OSTERBORG A, 1993, BLOOD, V81, P1428; PEEST D, 1995, EUR J CANCER, V31A, P146, DOI 10.1016/0959-8049(94)00452-B; PELLATDECEUNYNCK C, 1995, CANCER RES, V55, P3647; RALPH QM, 1993, BLOOD, V82, P202, DOI 10.1182/blood.V82.1.202.bloodjournal821202; REECE DE, 1993, BONE MARROW TRANSPL, V11, P139; RIEDEL DA, 1992, HEMATOL ONCOL CLIN N, V6, P225, DOI 10.1016/S0889-8588(18)30341-1; SALMON SE, 1991, BLOOD, V78, P44; SALMON SE, 1973, SEMIN HEMATOL, V10, P135; SALMON SE, 1974, LANCET, V2, P1230; SALMON SE, 1994, J CLIN ONCOL, V12, P2405, DOI 10.1200/JCO.1994.12.11.2405; SCHILLER G, 1995, BLOOD, V86, P390, DOI 10.1182/blood.V86.1.390.bloodjournal861390; SHIRAN A, 1993, CANCER, V72, P219, DOI 10.1002/1097-0142(19930701)72:1<219::AID-CNCR2820720139>3.0.CO;2-Y; SONNEVELD P, 1992, LANCET, V340, P255, DOI 10.1016/0140-6736(92)92353-H; SUKPANICHNANT S, 1994, HUM PATHOL, V25, P308, DOI 10.1016/0046-8177(94)90204-6; TRICOT G, 1995, BLOOD, V85, P588; TRICOT G, 1995, BLOOD, V86, P4250, DOI 10.1182/blood.V86.11.4250.bloodjournal86114250; Tricot G, 1996, BLOOD, V87, P1196, DOI 10.1182/blood.V87.3.1196.bloodjournal8731196; VESOLE DH, 1994, BLOOD, V84, P950; Vesole DH, 1996, BLOOD, V88, P838; WESTIN J, 1995, BRIT J HAEMATOL, V89, P561, DOI 10.1111/j.1365-2141.1995.tb08364.x; Wisloff F, 1996, BRIT J HAEMATOL, V94, P324, DOI 10.1046/j.1365-2141.1996.d01-1802.x; WITZIG TE, 1993, CANCER, V72, P108, DOI 10.1002/1097-0142(19930701)72:1<108::AID-CNCR2820720121>3.0.CO;2-T; YI Q, 1995, BLOOD, V86, P3043; 1973, BRIT J HAEMATOL, V24, P123	101	416	441	1	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1657	1664		10.1056/NEJM199706053362307	http://dx.doi.org/10.1056/NEJM199706053362307			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC086	9171069				2022-12-28	WOS:A1997XC08600007
J	Ikawa, M; Wada, I; Kominami, K; Watanabe, D; Toshimori, K; Nishimune, Y; Okabe, M				Ikawa, M; Wada, I; Kominami, K; Watanabe, D; Toshimori, K; Nishimune, Y; Okabe, M			The putative chaperone calmegin is required for sperm fertility	NATURE			English	Article							ZONA-PELLUCIDA; MOUSE SPERM; ENDOPLASMIC-RETICULUM; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; BINDING-PROTEIN; CALNEXIN; FERTILIZATION; EGG; MEMBRANE	The proper folding of newly synthesized membrane proteins in the endoplasmic reticulum (ER) is required for the formation of functional mature proteins. Calnexin is a ubiquitous ER chaperone that plays a major role in quality control by retaining incompletely folded or misfolded proteins(1,5). In contrast to other known chaperones such as heat-shock proteins, BiP and calreticulin, calnexin is an integral membrane protein(1,6). Calmegin is a testis-specific ER protein that is homologous to calnexin(7-9). Here we show that calmegin binds to nascent polypeptides during spermatogenesis, and have analysed its physiological function by targeted disruption of its gene. Homozygous-null male mice are nearly sterile even though spermatogenesis is morphologically normal and mating is normal. In vitro, sperm from homozygous-null males do not adhere to the egg extracellular matrix (zona pellucida), and this defect may explain the observed infertility. These results suggest that calmegin functions as a chaperone for one or more sperm surface proteins that mediate the interactions between sperm and egg. The defective zona pellucida-adhesion phenotype of sperm from calmegin-deficient mice is reminiscent of certain cases of unexplained infertility in human males.	OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; SAPPORO MED UNIV,DEPT BIOCHEM,SCH MED,SAPPORO,HOKKAIDO 060,JAPAN; MIYAZAKI MED COLL,DEPT ANAT,MIYAZAKI 88916,JAPAN	Osaka University; Sapporo Medical University; University of Miyazaki			ikawa, masahito/A-5315-2009; Okabe, Masaru/B-6917-2015	ikawa, masahito/0000-0001-9859-6217; Okabe, Masaru/0000-0002-0803-9044; Wada, Ikuo/0000-0001-5668-6994				BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BOOKBINDER LH, 1995, SCIENCE, V269, P86, DOI 10.1126/science.7604284; BURKS DJ, 1995, SCIENCE, V269, P83, DOI 10.1126/science.7541556; CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; GONG XH, 1995, SCIENCE, V269, P1718, DOI 10.1126/science.7569899; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HARDY DM, 1994, J BIOL CHEM, V269, P19000; Herbert Daniel N., 1995, Cell, V81, P425; Hunnicutt GR, 1996, BIOL REPROD, V54, P1343, DOI 10.1095/biolreprod54.6.1343; LIU DY, 1994, HUM REPROD, V9, P489, DOI 10.1093/oxfordjournals.humrep.a138533; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; MACKENNA A, 1993, FERTIL STERIL, V59, P405; OHSAKO S, 1994, J BIOL CHEM, V269, P14140; OKABE M, 1988, J REPROD IMMUNOL, V13, P211, DOI 10.1016/0165-0378(88)90002-2; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RICHARDSON RT, 1994, DEV BIOL, V165, P688, DOI 10.1006/dbio.1994.1285; RUSSELL LD, 1990, HISTOPATHOLOGICAL EV; SALING PM, 1991, BIOL REPROD, V44, P246, DOI 10.1095/biolreprod44.2.246; TANII I, 1994, CELL TISSUE RES, V277, P61, DOI 10.1007/BF00303081; TOSHIMORI K, 1995, MOL REPROD DEV, V42, P72, DOI 10.1002/mrd.1080420110; TOSHIMORI K, 1992, CELL TISSUE RES, V270, P459, DOI 10.1007/BF00645047; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WADA I, 1994, J BIOL CHEM, V269, P7464; WADA I, 1991, J BIOL CHEM, V266, P19599; WATANABE D, 1994, J BIOL CHEM, V269, P7744; WATANABE D, 1992, MOL REPROD DEV, V33, P307, DOI 10.1002/mrd.1080330312; YAMASAKI N, 1995, MOL REPROD DEV, V40, P48, DOI 10.1002/mrd.1080400107; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]	29	221	227	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 5	1997	387	6633					607	611		10.1038/42484	http://dx.doi.org/10.1038/42484			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC522	9177349				2022-12-28	WOS:A1997XC52200057
J	Rauchschwalbe, R; Mann, NC				Rauchschwalbe, R; Mann, NC			Pediatric window-cord strangulations in the United States, 1981-1995	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACCIDENTAL STRANGULATION; CHILDHOOD; CHILDREN; DEATHS; ASCERTAINMENT; EPIDEMIOLOGY; SUFFOCATION; PREVALENCE; HOMICIDE; INFANTS	Objective.-To document the prevalence of pediatric asphyxial death from window-covering cords in the United States and identify associated risk factors. Design.-Retrospective analysis of existing death certificate and incident files compiled by the US Consumer Product Safety Commission. Setting.-United States, 1981 through 1995. Patients.-Children aged 1 month to 8 years suffering unintentional traumatic asphyxiation from a window-covering cord. Results.-A total of 183 fatal window-cord strangulations were reported for the years 1981 through 1995, representing a mortality rate of 0.14 (95% confidence interval [CI], 0.10-0.18) per 100 000 persons (less than or equal to 3 years old) per year in the United States, Ninety-three percent of victims were 3 years of age or younger. Pull cords on venetian-type horizontal window coverings accounted for 86% of documented injuries. Infant victims were more likely to become entangled while put down for a nap and toddlers were more likely to be suspended by the cord after falling or jumping from a height (P=.002), Window coverings remained anchored and did not undrape when substantial weight was suspended in the draw-cord loop. Conclusions.-Window-covering cords represent a substantial strangulation hazard compared with other potentially harmful household products that were modified based on voluntary standards to mitigate the risk of injury. Product design modifications and parental education will be necessary to avert this type of fatal home injury.	OREGON HLTH SCI UNIV,DEPT EMERGENCY MED,PORTLAND,OR 97201; US CONSUMER PROD SAFETY COMMISS,OFF COMPLIANCE,WASHINGTON,DC; OREGON HLTH SCI UNIV,DEPT EMERGENCY MED,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University								*AM NAT STAND I, 1997, AM NAT STAND SAF COR; *ASTM, 1996, 1996 ANN BOOK ASTM S, P509; BERGESON PS, 1977, PEDIATRICS, V59, P1043; Bishop YM., 2007, DISCRETE MULTIVARIAT; BYARD RW, 1994, ARCH DIS CHILD, V71, P497, DOI 10.1136/adc.71.6.497; CLARK MA, 1993, J FORENSIC SCI, V38, P344; FELDMAN KW, 1980, PEDIATRICS, V65, P1079; HOOK EB, 1993, AM J EPIDEMIOL, V137, P1148, DOI 10.1093/oxfordjournals.aje.a116618; HOOK EB, 1992, AM J EPIDEMIOL, V135, P1060, DOI 10.1093/oxfordjournals.aje.a116400; HORD JD, 1993, AM J DIS CHILD, V147, P1038, DOI 10.1001/archpedi.1993.02160340024006; JASON J, 1983, AM J PUBLIC HEALTH, V73, P195, DOI 10.2105/AJPH.73.2.195; KEMPER M, 1945, J PEDIATR-US, V26, P401, DOI 10.1016/S0022-3476(45)80187-7; KRAUS JF, 1985, PUBLIC HEALTH REP, V100, P231; LAPIDUS GD, 1990, AM J PUBLIC HEALTH, V80, P213, DOI 10.2105/AJPH.80.2.213; LITTLE AS, 1994, AM FAM PHYSICIAN, V49, P335; MOORE L, 1993, AM J FOREN MED PATH, V14, P296, DOI 10.1097/00000433-199312000-00005; NELSON T, 1975, HAZARD ANAL INJURIES, P12; NIXON JW, 1995, ARCH DIS CHILD, V72, P6, DOI 10.1136/adc.72.1.6; *OFF DIS PREV HLTH, 1994, PREV REP; PEARN JH, 1979, PEDIATRICS, V64, P68; SATRAN L, 1981, PEDIATRICS, V68, P422; SHEPHERD RT, 1990, MED SCI LAW, V30, P119, DOI 10.1177/002580249003000207; Sturner W Q, 1976, J Forensic Sci, V21, P483; *US BUR CENS, 1992, P251130 US BUR CENS; *US CONS PROD SAF, 1984, NAT EL INJ SURV SYST; *US CONS PROD SAF, 1994, CONS PROD SAF AL CHI; *US CONS PROD SAF, 1979, 1979 ANN REP 1, P29; *US CONS PROD SAF, 1993, CONS PROD SAF AL WIN; *US CONS PROD SAF, 1986, CONS PROD SAF COMM A; US Department of Health and Human Services, 1980, INT CLASS DIS 9 REV; WALLER JA, 1981, PUBLIC HLTH PREVENTI, P1549; WITTES JT, 1972, BIOMETRICS, V28, P592, DOI 10.2307/2556173; YEE WH, 1990, CAN MED ASSOC J, V142, P436	33	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1696	1698		10.1001/jama.277.21.1696	http://dx.doi.org/10.1001/jama.277.21.1696			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XB088	9169896				2022-12-28	WOS:A1997XB08800030
J	Xu, L; Anwyl, R; Rowan, MJ				Xu, L; Anwyl, R; Rowan, MJ			Behavioural stress facilitates the induction of long-term depression in the hippocampus	NATURE			English	Article							POTENTIATED SYNAPTIC RESPONSES; PRIMED BURST POTENTIATION; IN-VIVO; 1-5 HZ; STIMULATION; RAT; DEPOTENTIATION; INHIBITION; ADULT	The induction of activity-dependent persistent increases in synaptic efficacy, such as long-term potentiation (LTP), is inhibited by behavioural stress(1,2). The question arises whether stress also affects the ability to induce persistent decreases in synaptic efficacy, such as long-term depression (LTD)(3-5). We now report that the induction of stable homosynaptic LTD in the CA1 area of the hippocampus of awake adult rats is facilitated, rather than inhibited, by exposure to mild naturalistic stress, The same stress blocked the induction of LTP, The effects of such stress were short lasting: acclimatization to, or removal from, the conditions that facilitated LTD induction led to a rapid loss of the ability to elicit this form of plasticity. The time window in which LTD could be reliably elicited was prolonged by inducing anaesthesia immediately after the stress. These data reveal that even brief exposure to mild stress can produce a striking shift in the susceptibility to synaptic plasticity in the awake animal.	UNIV DUBLIN TRINITY COLL,DEPT PHARMACOL & THERAPEUT,DUBLIN 2,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT PHYSIOL,DUBLIN 2,IRELAND	Trinity College Dublin; Trinity College Dublin			Xu, Lin/T-5531-2017	Xu, Lin/0000-0002-2710-3507; Rowan, Michael Joseph/0000-0002-3867-9536	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALFOUR DJK, 1979, ARCH INT PHARMACOD T, V237, P67; BARRIONUEVO G, 1980, LIFE SCI, V27, P2385, DOI 10.1016/0024-3205(80)90509-3; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; BEAR MF, 1995, NEURON, V15, P1, DOI 10.1016/0896-6273(95)90056-X; DIAMOND DM, 1990, PSYCHOBIOLOGY, V18, P273; DIAMOND DM, 1992, HIPPOCAMPUS, V2, P421, DOI 10.1002/hipo.450020409; Doyle C, 1996, J NEUROSCI, V16, P418; Doyle CA, 1997, NEUROSCIENCE, V77, P75, DOI 10.1016/S0306-4522(96)00427-7; DUDEK SM, 1993, J NEUROSCI, V13, P2910; ERRINGTON ML, 1995, J NEUROPHYSIOL, V74, P1793, DOI 10.1152/jn.1995.74.4.1793; Heynen AJ, 1996, NATURE, V381, P163, DOI 10.1038/381163a0; JOELS M, 1995, NEWS PHYSIOL SCI, V10, P71; KERR DS, 1994, PSYCHOBIOLOGY, V22, P123; Kim JJ, 1996, P NATL ACAD SCI USA, V93, P4750, DOI 10.1073/pnas.93.10.4750; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; MANAHANVAUGHAN D, 1994, BRIT J PHARMACOL, V112, P1083, DOI 10.1111/j.1476-5381.1994.tb13194.x; OCONNOR JJ, 1989, EUR J PHARMACOL, V167, P21, DOI 10.1016/0014-2999(89)90743-7; PAVLIDES C, 1995, NEUROSCIENCE, V68, P379, DOI 10.1016/0306-4522(95)94332-S; SHORS TJ, 1989, SCIENCE, V244, P224, DOI 10.1126/science.2704997; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; THIELS E, 1994, J NEUROPHYSIOL, V72, P3009, DOI 10.1152/jn.1994.72.6.3009	21	411	436	0	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					497	500		10.1038/387497a0	http://dx.doi.org/10.1038/387497a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168111				2022-12-28	WOS:A1997XB47900047
J	Barria, A; Muller, D; Derkach, V; Griffith, LC; Soderling, TR				Barria, A; Muller, D; Derkach, V; Griffith, LC; Soderling, TR			Regulatory phosphorylation of AMPA-type glutamate receptors by CaM-KII during long-term potentiation	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; II MUTANT MICE; HIPPOCAMPAL-NEURONS; SYNAPTIC RESPONSES; ALPHA-SUBUNIT; RAT-BRAIN; LTP; MECHANISM; MODULATION; INHIBITOR	Longterm potentiation (LTP), a cellular model of learning and memory, requires calcium-dependent protein kinases. Induction of LTP increased the phosphorus-32 labeling of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors (AMPA-Rs), which mediate rapid excitatory synaptic transmission. This AMPA-R phosphorylation appeared to be catalyzed by Ca2+- and calmodulin-dependent protein kinase II (CaM-KII): (i) it correlated with the activation and autophosphorylation of CaM-KII, (ii) it was blocked by the CaM-KII inhibitor KN-62, and (iii)its phosphorus-32 peptide map was the same as that of GluR1 coexpressed with activated CaM-KII in HEK-293 cells. This covalent modulation of AMPA-Rs in LTP provides a postsynaptic molecular mechanism for synaptic plasticity.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; CTR MED UNIV GENEVA,DEPT NEUROPHARMACOL,CH-1211 GENEVA 4,SWITZERLAND; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Oregon Health & Science University; University of Geneva; Brandeis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027037] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054408] Funding Source: Medline; NINDS NIH HHS [NS27037] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; Buchs PA, 1996, P NATL ACAD SCI USA, V93, P8040, DOI 10.1073/pnas.93.15.8040; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FONG YL, 1989, J BIOL CHEM, V264, P16759; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HOLLMANN M, 1997, IONOTROPIC GLUTAMATE, P39; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; HVALBY O, 1994, P NATL ACAD SCI USA, V91, P4761, DOI 10.1073/pnas.91.11.4761; ITO I, 1991, NEUROSCI LETT, V121, P119, DOI 10.1016/0304-3940(91)90663-E; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KOLAJ M, 1994, J NEUROPHYSIOL, V72, P2525, DOI 10.1152/jn.1994.72.5.2525; LARKMAN AU, 1995, CURR OPIN NEUROBIOL, V5, P324, DOI 10.1016/0959-4388(95)80045-X; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MALINOW R, 1994, SCIENCE, V266, P1195, DOI 10.1126/science.7973700; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; PATTON BL, 1993, MOL BIOL CELL, V4, P159, DOI 10.1091/mbc.4.2.159; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Roberson ED, 1996, J BIOL CHEM, V271, P30436, DOI 10.1074/jbc.271.48.30436; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; SACTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SODERLING TR, 1995, ADV SEC MESS PHOSPH, V30, P175; SODERLING TR, 1997, IONOTROPIC GLUTAMATE, P121; SUZUKI T, 1992, P NATL ACAD SCI USA, V89, P109, DOI 10.1073/pnas.89.1.109; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; URUSHIHARA H, 1992, J BIOL CHEM, V267, P11697; WANG LY, 1994, J PHYSIOL-LONDON, V475, P431, DOI 10.1113/jphysiol.1994.sp020083; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WYLLIE DJA, 1994, NEURON, V13, P635, DOI 10.1016/0896-6273(94)90031-0; YEAKEL J, 1995, P NATL ACAD SCI USA, V92, P1376	45	836	860	2	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2042	2045		10.1126/science.276.5321.2042	http://dx.doi.org/10.1126/science.276.5321.2042			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197267				2022-12-28	WOS:A1997XG74800065
J	deFonseca, FR; Carrera, MRA; Navarro, M; Koob, GF; Weiss, F				deFonseca, FR; Carrera, MRA; Navarro, M; Koob, GF; Weiss, F			Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal	SCIENCE			English	Article							C-FOS; RAT-BRAIN; PARAVENTRICULAR NUCLEUS; OPIATE WITHDRAWAL; EXPRESSION; STRESS; RECEPTOR; IMMUNOREACTIVITY; MICRODIALYSIS; ANTAGONIST	Corticotropin-releasing factor (CRF) has been implicated in the mediation of the stress-like and negative affective consequences of withdrawal from drugs of abuse, such as alcohol, cocaine, and opiates. This study sought to determine whether brain CRF systems also have a role in cannabinoid dependence. Rats were treated daily for 2 weeks with the potent synthetic cannabinoid HU-210. Withdrawal, induced by the cannabinoid antagonist SR 141716A, was accompanied by a marked elevation in extracellular CRF concentration and a distinct pattern of Fos activation in the central nucleus of the amygdala. Maximal increases in CRF corresponded lo the time when behavioral signs resulting from cannabinoid withdrawal were at a maximum. These data suggest that long-term cannabinoid administration alters CRF function in the limbic system of the brain, in a manner similar to that observed with other drugs of abuse, and also induces neuroadaptive processes that may result in future vulnerability to drug dependence.	Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	deFonseca, FR (corresponding author), UNIV COMPLUTENSE MADRID, INST COMPLUTENSE DROGODEPENDENCIAS, DEPT PSICOBIOL, FAC PSICOL, MADRID 28223, SPAIN.		DE FONSECA, FERNANDO RODRIGUEZ/E-9767-2012		NIDA NIH HHS [DA 08426] Funding Source: Medline; NIDDK NIH HHS [DK26741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA008426] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 1994, SEMIN NEUROSCI; Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; ARNOLD FJL, 1992, NEUROSCIENCE, V51, P377, DOI 10.1016/0306-4522(92)90322-S; BECKMANN AM, 1995, NEUROPHARMACOLOGY, V34, P1183, DOI 10.1016/0028-3908(95)00089-O; BULLITT E, 1990, J COMP NEUROL, V296, P517, DOI 10.1002/cne.902960402; CECCATELLI S, 1989, P NATL ACAD SCI USA, V86, P9569, DOI 10.1073/pnas.86.23.9569; DEFONSECA FR, 1995, NEUROENDOCRINOLOGY, V61, P714, DOI 10.1159/000126899; deFonseca FR, 1996, J PHARMACOL EXP THER, V276, P56; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; FISHMAN MW, 1988, RES COMMUN SUBST ABU, V9, P219; HALIKAS JA, 1985, INT J ADDICT, V20, P701, DOI 10.3109/10826088509044290; HAYWARD MD, 1990, BRAIN RES, V525, P256, DOI 10.1016/0006-8993(90)90872-9; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HOLLISTER LE, 1986, PHARMACOL REV, V38, P1; HONKANIEMI J, 1992, BRAIN RES, V598, P107, DOI 10.1016/0006-8993(92)90173-7; IMAKI T, 1995, NEUROENDOCRINOLOGY, V61, P445, DOI 10.1159/000126867; KAYMAKCALAN S, 1973, B NARCOTICS, V25, P39; KOOB GF, 1985, FED PROC, V44, P259; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; KOOB GF, 1993, SEMIN NEUROSCI, V5, P351; KUBENA RK, 1971, EUR J PHARMACOL, V14, P89, DOI 10.1016/0014-2999(71)90128-2; LARSEN PJ, 1995, J NEUROSCI, V15, P2609; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MCMILLAN DE, 1971, ANN NY ACAD SCI, V191, P83, DOI 10.1111/j.1749-6632.1971.tb13990.x; MENDELSON JH, 1984, AM J PSYCHIAT, V141, P1289; MENZAGHI F, 1994, NEUROSCI LETT, V168, P139, DOI 10.1016/0304-3940(94)90435-9; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Navarro M, 1997, NEUROREPORT, V8, P491, DOI 10.1097/00001756-199701200-00023; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PICH EM, 1995, J NEUROSCI, V15, P5439; PICH EM, 1993, NEUROSCIENCE, V55, P695, DOI 10.1016/0306-4522(93)90435-I; Pope HG, 1996, JAMA-J AM MED ASSOC, V275, P521, DOI 10.1001/jama.275.7.521; RASSNICK S, 1993, BRAIN RES, V605, P25, DOI 10.1016/0006-8993(93)91352-S; RICHTER RM, 1995, NEUROSCI LETT, V187, P169, DOI 10.1016/0304-3940(95)11365-4; RICHTER RP, UNPUB; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Rodriguez de Fonseca F., UNPUB; RYABININ AE, 1995, J NEUROSCI, V15, P721; Santucci Vincent, 1996, Life Sciences, V58, P103; STORNETTA RL, 1993, BRAIN RES, V624, P19, DOI 10.1016/0006-8993(93)90055-R; TAKAHASHI LK, 1989, BEHAV NEUROSCI, V103, P648, DOI 10.1037/0735-7044.103.3.648; TSOU K, 1995, EUR J PHARMACOL, V280, pR13; VALE W, 1983, METHOD ENZYMOL, V103, P565; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VARGAS MA, 1992, ANN NY ACAD SCI, V654, P145, DOI 10.1111/j.1749-6632.1992.tb25963.x; WHANSCHAFFE U, 1993, BRAIN RES, V615, P295; Wiesbeck GA, 1996, ADDICTION, V91, P1469; ZUARDI AW, 1982, PSYCHOPHARMACOLOGY, V76, P245, DOI 10.1007/BF00432554	49	343	351	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2050	2054		10.1126/science.276.5321.2050	http://dx.doi.org/10.1126/science.276.5321.2050			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197270				2022-12-28	WOS:A1997XG74800068
J	West, JB; Elliott, AR; Guy, HJB; Prisk, GK				West, JB; Elliott, AR; Guy, HJB; Prisk, GK			Pulmonary function in space	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUSTAINED MICROGRAVITY; LUNG-VOLUMES; BLOOD-FLOW; BREATH WASHOUTS; SHORT PERIODS; GAS-EXCHANGE; SLS-1; INHOMOGENEITY; VENTILATION; INEQUALITY	The lung is exquisitely sensitive to gravity, and so it is of interest to know how its function is altered in the weightlessness of space. Studies on National Aeronautics and Space Administration (NASA) Spacelabs during the last 4 years have provided the first comprehensive data on the extensive changes in pulmonary function that occur in sustained microgravity. Measurements of pulmonary function were made on astronauts during space shuttle flights lasting 9 and 14 days and were compared with extensive ground-based measurements before and after the flights. Compared with preflight measurements, cardiac output increased by 18% during space flight, and stroke volume increased by 46%. Paradoxically, the increase in stroke volume occurred in the face of reductions in central venous pressure and circulating blood volume. Diffusing capacity increased by 28%, and the increase in the diffusing capacity of the alveolar membrane was unexpectedly large based on findings in normal gravity. The change in the alveolar membrane may reflect the effects of uniform filling of the pulmonary capillary bed. Distributions of blood flow and ventilation throughout the lung were more uniform in space, but some unevenness remained, indicating the importance of nongravitational factors. A surprising finding was that airway closing volume was approximately the same in microgravity and in normal gravity, emphasizing the importance of mechanical properties of the airways in determining whether they close. Residual volume was unexpectedly reduced by 18% in microgravity, possibly because of uniform alveolar expansion. The findings indicate that pulmonary function is greatly altered in microgravity, but none of the changes observed so far will apparently limit long-term space flight. In addition, the data help to clarify how gravity affects pulmonary function in the normal gravity environment on Earth.			West, JB (corresponding author), UNIV CALIF SAN DIEGO,DEPT MED,0623A,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							AGOSTONI E, 1964, HDB PHYSL RESP, P00387; BECK KC, 1986, J APPL PHYSIOL, V61, P530, DOI 10.1152/jappl.1986.61.2.530; Buckey JC, 1996, J APPL PHYSIOL, V81, P19, DOI 10.1152/jappl.1996.81.1.19; BUONO MJ, 1983, J APPL PHYSIOL, V54, P1094, DOI 10.1152/jappl.1983.54.4.1094; CRAWFORD ABH, 1985, J APPL PHYSIOL, V59, P838, DOI 10.1152/jappl.1985.59.3.838; EDYVEAN J, 1991, J APPL PHYSIOL, V71, P1956, DOI 10.1152/jappl.1991.71.5.1956; ELLIOTT AR, 1994, J APPL PHYSIOL, V77, P2005, DOI 10.1152/jappl.1994.77.4.2005; Elliott AR, 1996, J APPL PHYSIOL, V81, P33, DOI 10.1152/jappl.1996.81.1.33; ESTENNE M, 1992, J APPL PHYSIOL, V73, P946, DOI 10.1152/jappl.1992.73.3.946; GLAISTER DH, 1973, RESP PHYSIOL, V17, P365, DOI 10.1016/0034-5687(73)90010-8; GLENNY RW, 1990, J APPL PHYSIOL, V69, P532, DOI 10.1152/jappl.1990.69.2.532; GUY HJB, 1994, J APPL PHYSIOL, V76, P1719, DOI 10.1152/jappl.1994.76.4.1719; GUY HJB, 1991, J APPL PHYSIOL, V70, P2587, DOI 10.1152/jappl.1991.70.6.2587; HAKIM TS, 1987, J APPL PHYSIOL, V63, P1114, DOI 10.1152/jappl.1987.63.3.1114; MICHELS DB, 1978, J APPL PHYSIOL, V45, P987, DOI 10.1152/jappl.1978.45.6.987; MICHELS MD, 1979, J APPL PHYSIOL, V47, P851; MILICEMI.J, 1966, J APPL PHYSIOL, V21, P749, DOI 10.1152/jappl.1966.21.3.749; PAIVA M, 1989, J APPL PHYSIOL, V67, P1542, DOI 10.1152/jappl.1989.67.4.1542; PAIVA M, 1981, RESP PHYSIOL, V44, P325, DOI 10.1016/0034-5687(81)90027-X; PERMUTT SOLBERT, 1967, NAT ACAD SCI NAT RES COUNC PUBL, V1485 B, P38; PRISK GK, 1995, J APPL PHYSIOL, V79, P1290, DOI 10.1152/jappl.1995.79.4.1290; PRISK GK, 1994, J APPL PHYSIOL, V76, P1730, DOI 10.1152/jappl.1994.76.4.1730; PRISK GK, 1995, J APPL PHYSIOL, V78, P597, DOI 10.1152/jappl.1995.78.2.597; PRISK GK, 1993, J APPL PHYSIOL, V75, P15, DOI 10.1152/jappl.1993.75.1.15; UDDEN MM, 1995, J LAB CLIN MED, V125, P442; WAGNER P, 1967, J APPL PHYSIOL, V22, P1115, DOI 10.1152/jappl.1967.22.6.1115; WARRELL DA, 1972, J APPL PHYSIOL, V32, P346, DOI 10.1152/jappl.1972.32.3.346; WEST JB, 1972, J APPL PHYSIOL, V32, P357, DOI 10.1152/jappl.1972.32.3.357; WEST JB, 1960, J APPL PHYSIOL, V15, P405, DOI 10.1152/jappl.1960.15.3.405; WEST JB, 1977, REGIONAL DIFFERENCES	30	28	33	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1957	1961		10.1001/jama.277.24.1957	http://dx.doi.org/10.1001/jama.277.24.1957			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200637				2022-12-28	WOS:A1997XF08700041
J	Goldstein, B; Hammond, M				Goldstein, B; Hammond, M			Physical medicine and rehabilitation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV WASHINGTON,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Goldstein, B (corresponding author), VA PUGET SOUND HLTH CARE SYST,SEATTLE,WA 98195, USA.							Baker JG, 1996, AM J PHYS MED REHAB, V75, P356, DOI 10.1097/00002060-199609000-00011; BATTERHAUM RW, 1996, ARCH PHS MED REHABIL, V77, P219; Bowling A., 1991, MEASURING HLTH REV Q; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Granger C. V., 1996, PHYS MED REHABILITAT, P239; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HAYS RM, 1994, CHRONIC DIS DISABILI, P215; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; *HLTH INS ASS AM, 1992, RES STAT B HLTH INS, V287; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; *MED ETH SER, 1995, AM J PHYS MED REHABI, V74, pS3; MULCAHY C, 1994, NATL UNDERWRITE 0509, P17; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103	15	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1891	1892						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185820				2022-12-28	WOS:A1997XD54400039
J	Gore, JM; Dalen, JE				Gore, JM; Dalen, JE			Cardiovascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV ARIZONA, COLL MED, TUCSON, AZ USA	University of Arizona	Gore, JM (corresponding author), UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01605 USA.							Albers GW, 1996, ARCH INTERN MED, V156, P2311, DOI 10.1001/archinte.156.20.2311; Antman EM, 1996, CIRCULATION, V94, P911, DOI 10.1161/01.CIR.94.5.911; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Blackshear JL, 1996, LANCET, V348, P633; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; Dalen JE, 1996, JAMA-J AM MED ASSOC, V276, P916, DOI 10.1001/jama.276.11.916; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; Grines CL, 1996, NEW ENGL J MED, V335, P1313; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; Lange RA, 1996, NEW ENGL J MED, V335, P1311; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; Topol EJ, 1996, NEW ENGL J MED, V335, P775	13	0	0	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1845	1846						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185793				2022-12-28	WOS:A1997XD54400012
J	Royal, HD; Siegel, BA				Royal, HD; Siegel, BA			Nuclear medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREOPERATIVE EVALUATION; LUNG-CANCER; PERFUSION				Royal, HD (corresponding author), WASHINGTON UNIV,SCH MED,MALLINCKRODT INST RADIOL,ST LOUIS,FRANCE.							Albertini JJ, 1996, JAMA-J AM MED ASSOC, V276, P1818, DOI 10.1001/jama.276.22.1818; BREITZ HB, 1993, SEMIN NUCL MED, V23, P127, DOI 10.1016/S0001-2998(05)80093-5; BURAK WE, 1995, SURGERY, V118, P103, DOI 10.1016/S0039-6060(05)80016-9; Conti PS, 1996, NUCL MED BIOL, V23, P717, DOI 10.1016/0969-8051(96)00074-1; DelVecchio S, 1997, EUR J NUCL MED, V24, P150, DOI 10.1007/BF02439547; GAMBHIR SS, 1996, J NUCL MED, V37, P1228; Jarritt PH, 1996, NUCL MED COMMUN, V17, P758, DOI 10.1097/00006231-199609000-00006; KAHN D, 1994, J UROLOGY, V152, P1490, DOI 10.1016/S0022-5347(17)32453-9; Kaminski MS, 1996, J CLIN ONCOL, V14, P1974, DOI 10.1200/JCO.1996.14.7.1974; LEWIS P, 1994, LANCET, V344, P1265, DOI 10.1016/S0140-6736(94)90753-6; MARSHALL ES, 1995, AM J CARDIOL, V76, P817, DOI 10.1016/S0002-9149(99)80234-3; Moffat FL, 1996, J CLIN ONCOL, V14, P2295, DOI 10.1200/JCO.1996.14.8.2295; OKEEFE JH, 1995, AM J CARDIOL, V75, pD25, DOI 10.1016/S0002-9149(99)80399-3; Weissman IA, 1996, RADIOLOGY, V199, P353, DOI 10.1148/radiology.199.2.8668777; ZARET BL, 1995, CIRCULATION, V91, P313, DOI 10.1161/01.CIR.91.2.313	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1875	1876						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185811				2022-12-28	WOS:A1997XD54400030
J	Todd, MM				Todd, MM			Anesthesiology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Todd, MM (corresponding author), UNIV IOWA, IOWA CITY, IA 52242 USA.							*AM SOC AN, 1995, ANESTHESIOLOGY, V82, P101; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Bode RH, 1996, ANESTHESIOLOGY, V84, P3, DOI 10.1097/00000542-199601000-00002; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; CAPLAN RA, 1993, ANESTHESIOLOGY, V78, P597; Ferrante FM, 1996, ANESTHESIOLOGY, V84, P1243; Go AS, 1996, ANESTHESIOLOGY, V84, P1, DOI 10.1097/00000542-199601000-00001; Gross JB, 1996, ANESTHESIOLOGY, V84, P459; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; McClure JH, 1996, BRIT J ANAESTH, V76, P300, DOI 10.1093/bja/76.2.300; ROIZEN MF, 1993, ANESTHESIOLOGY, V78, P380; Thys DM, 1996, ANESTHESIOLOGY, V84, P986	13	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1842	1843						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185791				2022-12-28	WOS:A1997XD54400010
J	David, AR				David, AR			Disease in Egyptian mummies: The contribution of new technologies	LANCET			English	Article							SCHISTOSOMA				David, AR (corresponding author), MANCHESTER UNIV MUSEUM,OXFORD RD,MANCHESTER M13 9PL,LANCS,ENGLAND.							[Anonymous], 1979, MANCHESTER MUSEUM MU; BARRACO RA, 1978, AM J PHYS ANTHROPOL, V48, P487, DOI 10.1002/ajpa.1330480407; BIRKETT DA, 1986, SCI EGYPTOLOGY, P113; COCKBURN A, 1975, SCIENCE, V187, P1155, DOI 10.1126/science.1090004; Cockburn A, 1980, MUMMIES DIS ANCIENT; Contis G, 1996, PARASITOL TODAY, V12, P253, DOI 10.1016/0169-4758(96)30007-0; Curry A., 1979, Manchester Museum Mummy Project. Multidisciplinary Research on Ancient Egyptian mummified remains., P103; Curry A., 1979, MANCHESTER MUSEUM MU, P113; Daumas F., 1957, B I FRANCAIS ARCHEOL, V56, P35; David A. E., 1986, SCI EGYPTOLOGY; David A. R., 1992, MUMMYS TALE SCI MED; DAVIES WV, 1993, BIOL ANTHR STUDY ANC, P86; Davis David Brion, 1992, PHYTOCHEMICAL RESOUR, P15; DAVIS H, 1993, NEW STATESMAN SOC, V6, P29; DEELDER AM, 1989, AM J TROP MED HYG, V40, P268, DOI 10.4269/ajtmh.1989.40.268; Fawcett RA, 1979, MANCHESTER MUSEUM MU, P25; Flaherty T., 1984, EVIDENCE EMBALMED, P96; HARRIS JE, 1980, XRAY ATLAS ROYAL MUM; HARRISON RG, 1969, NATURE, V224, P326; HORNE PD, 1977, CAN MED ASS J, V117; Krypczyk A., 1986, SCI EGYPTOLOGY, P361; Leek F F, 1969, J Egypt Archaeol, V55, P112, DOI 10.2307/3856007; Leek F. F., 1979, MANCHESTER MUSEUM MU, P65; LEEK FF, 1979, J EGYTPIAN ARCHAEOL, V58, P126; LEWIN PK, 1968, CAN MED ASSOC J, V98, P1011; MILLER RL, 1994, T ROY SOC TROP MED H, V88, P31, DOI 10.1016/0035-9203(94)90484-7; MILLER RL, 1992, BRIT MED J, V304, P555, DOI 10.1136/bmj.304.6826.555; Milne J. G., 1914, J EGYPT ARCHAEOL, V1, P96; Murray Margaret Alice, 1910, TOMB 2 BROTHERS; NEAVE RAH, 1992, PRIEST TEMPLE KARNAK, P162; NIELSEN OV, 1986, SCI EGYPTOLOGY, P25; PAABO S, 1985, NATURE, V314, P644, DOI 10.1038/314644a0; Pettitt C. W., 1984, EVIDENCE EMBALMED, P150; Ruffer M. A., 1921, STUDIES PALAEOPATHOL; SANDISON AT, 1955, STAIN TECHNOL, V30, P277, DOI 10.3109/10520295509114479; TAPP E, 1975, BRIT MED J, V2, P276, DOI 10.1136/bmj.2.5965.276-b; Tapp E., 1986, SCI EGYPTOLOGY, P351; Tapp E., 1986, SCI EGYPTOLOGY, P347	38	40	44	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1760	1763		10.1016/S0140-6736(96)10221-X	http://dx.doi.org/10.1016/S0140-6736(96)10221-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193394				2022-12-28	WOS:A1997XE06500043
J	OBrien, BJ; Heyland, D; Richardson, WS; Levine, M; Drummond, MF				OBrien, BJ; Heyland, D; Richardson, WS; Levine, M; Drummond, MF			Users' guides to the medical literature .13. How to use an article on economic analysis of clinical practice .B. What are the results and will they help me in caring for my patients?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; TISSUE-PLASMINOGEN ACTIVATOR; COST-EFFECTIVENESS; THROMBOLYTIC THERAPY; DECISION-ANALYSIS; MANAGEMENT; GUSTO		ST JOSEPHS HOSP, CTR EVALUAT MED, HAMILTON, ON, CANADA; ROYAL ALEXANDRA HOSP, EDMONTON, AB, CANADA; UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA; UNIV YORK, CTR HLTH ECON, YORK YO1 5DD, N YORKSHIRE, ENGLAND; MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON, CANADA	McGill University; McMaster University; Royal Alexandra Hospital; University of Rochester; University of York - UK; McMaster University								BIRCH S, 1993, J HEALTH ECON, V12, P469, DOI 10.1016/0167-6296(93)90006-Z; DRUMMOND M, 1993, SOC SCI MED, V37, P33, DOI 10.1016/0277-9536(93)90315-U; Drummond M F, 1992, Int J Technol Assess Health Care, V8, P671; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; JOHANNESSON M, 1993, J HEALTH ECON, V12, P459, DOI 10.1016/0167-6296(93)90005-Y; KALISH SC, 1995, J GEN INTERN MED, V10, P321, DOI 10.1007/BF02599951; LEE TH, 1995, NEW ENGL J MED, V332, P1443, DOI 10.1056/NEJM199505253322111; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; MEHREZ A, 1991, MED DECIS MAKING, V11, P140, DOI 10.1177/0272989X9101100212; OBRIEN B, 1995, ARCH INTERN MED, V155, P1958, DOI 10.1001/archinte.155.18.1958; OBRIEN BJ, 1994, MED CARE, V32, P150, DOI 10.1097/00005650-199402000-00006; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1610, DOI 10.1001/jama.273.20.1610; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1292, DOI 10.1001/jama.273.16.1292; RIDKER PM, 1994, ANN INTERN MED, V120, P882, DOI 10.7326/0003-4819-120-10-199405150-00010; RIDKER PM, 1993, ANN INTERN MED, V119, P530, DOI 10.7326/0003-4819-119-6-199309150-00017; RIDKER PM, 1992, AM J CARDIOL, V45, P505; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; VANDEWERF F, 1995, JAMA-J AM MED ASSOC, V273, P1586, DOI 10.1001/jama.273.20.1586	20	153	156	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	1997	277	22					1802	1806						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC499	9178794				2022-12-28	WOS:A1997XC49900034
J	Dihmis, WC; Ridley, P; Dhasmana, JP; Wisheart, JD				Dihmis, WC; Ridley, P; Dhasmana, JP; Wisheart, JD			Drug points - Acute dissection of the aorta with amphetamine misuse	BRITISH MEDICAL JOURNAL			English	Letter							COCAINE				Dihmis, WC (corresponding author), BRISTOL ROYAL INFIRM & GEN HOSP,DEPT CARDIAC SURG,BRISTOL BS2 8HW,AVON,ENGLAND.							BARTH CW, 1986, AM J CARDIOL, V57, P496, DOI 10.1016/0002-9149(86)90787-3; LARSON EW, 1984, AM J CARDIOL, V53, P849, DOI 10.1016/0002-9149(84)90418-1; OM A, 1992, AM HEART J, V123, P532, DOI 10.1016/0002-8703(92)90676-M; WILSON SK, 1982, ARCH PATHOL LAB MED, V106, P175	4	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 7	1997	314	7095					1665	1665		10.1136/bmj.314.7095.1665	http://dx.doi.org/10.1136/bmj.314.7095.1665			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD874	9193291	Green Published			2022-12-28	WOS:A1997XD87400027
J	Hesketh, T; Zhu, WX				Hesketh, T; Zhu, WX			Health in China - The healthcare market	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE SYSTEM	It is now about 15 years since the introduction of the marker into health care in China. This produced fundamental changes in the way that health care is financed and resulted in the disappearance of universal free basic health care. Responsibility for provision of health services has been devolved to the providers have been given considerable financial providers have been given considerable financial independence. A fee for service system has been introduced, and several differ ent payment mechanisms are now in operation. The new financing and pricing structures are responsible for greater inequity of access to services and more inefficient use of resources. These problems are widely acknowledged, and a range of solutions is being developed and tested. Since the introduction of the reforms the measurable health status of the population has not declined, probably as a result of overall improved socioeconomic conditions and a continued emphasis on prevention.	HLTH UNLIMITED, LONDON SE1 9NT, ENGLAND		Hesketh, T (corresponding author), CTR INT CHILD HLTH, LONDON WC1 N1EH, ENGLAND.			Hesketh, Therese/0000-0002-7564-9221				BANTA HD, 1990, HEALTH POLICY, V14, P127; BLOOM G, 1995, 30 I DEV STUD; GROGAN CM, 1995, SOC SCI MED, V41, P1073, DOI 10.1016/0277-9536(94)00419-T; HSIAO WCL, 1995, SOC SCI MED, V41, P1047, DOI 10.1016/0277-9536(94)00421-O; LIU YL, 1995, SOC SCI MED, V41, P1085, DOI 10.1016/0277-9536(95)00428-A; *NAT STAT BUR, 1991, YB CHIN POP STAT; *WORLD BANK, 1993, COUNTR STUD CHIN LON; XUNG Y, 1990, CHIN HLTH EC, V5, P16; ZHENG X, 1995, SOC SCI MED, V41, P1057, DOI 10.1016/0277-9536(94)00431-R; 1996, CHINA DAILY     1202, P3; 1996, CHINA DAILY     1214, P4	11	52	52	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	1997	314	7094					1616	1618		10.1136/bmj.314.7094.1616	http://dx.doi.org/10.1136/bmj.314.7094.1616			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XC500	9186178	Green Published			2022-12-28	WOS:A1997XC50000035
J	Smith, T; Moore, EJH; TunstallPedoe, H				Smith, T; Moore, EJH; TunstallPedoe, H			Review by a local medical research ethics committee of the conduct of approved research projects, by examination of patients' case notes, consent forms, and research records and by interview	BRITISH MEDICAL JOURNAL			English	Article								Objective: To monitor the ocnduct of medical research projects that have already been approved by the local medical research ethics committee. Design: Follow up study of ethically approved studies (randomly selected from all the studies approved in the previous year) by examination of patients' case notes: consent forms, and research records and by interview rr of the researchers at their workplace. Setting: Tayside, Scotland (mixed rural and urban population) Subjects: 30 research projects approved by Tayside local medical research ethics committee, Main outcome measures: Adherence to the agreed protocol, particularly for recruitment (obtaining and recording informed consent) and for specific requirements of the ethics committee, including notification of changes to the protocol and of adverse events, Results: In one project only oral consent had been obtained, and in a quarter of the studies one or more consent forms were incorrectly completed, Inadequate tiling of case notes in five studies and of consent forms in six made them unavailable for scrutiny, Adverse events were reported, but there was a general failure to report the abandoning or non-starting of projects; in two studies the investigators failed to notify a change in the responsible researcher Conclusions: Monitoring of medical research by local medical research ethics committees promotes and preserves ethical standards, protects subjects and researchers, discourages fraud, and has the support of investigators, We recommend that 10% of projects should undergo on-site review, with all others monitored by questionnaire. This would require about six person hours of time and a salary bill of pound 120 per study monitored.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND	University of Dundee	Smith, T (corresponding author), KINGS CROSS HOSP,TAYSIDE COMM MED RES ETH,E DAY HOME,DUNDEE DD3 8EA,SCOTLAND.							ALBERTI KGMM, 1995, BRIT MED J, V311, P639, DOI 10.1136/bmj.311.7006.639; HARRIES UJ, 1994, J ROY COLL PHYS LOND, V28, P150; MEADE TW, 1994, J ROY COLL PHYS LOND, V28, P102; *NHS MAN EX DEP HL, 1991, LOC RES ETH COMM; POWELL DEB, 1995, BRIT J OBSTET GYNAEC, V102, P671, DOI 10.1111/j.1471-0528.1995.tb11414.x; Redshaw ME, 1996, J MED ETHICS, V22, P78, DOI 10.1136/jme.22.2.78; *ROYAL COLL PSYCH, 1990, PSYCHIAT B, V14, P48; *ROYAL COLLPHYS, 1996, GUID PRACT ETH COMM; TUNSTALLPEDOE H, 1995, BRIT MED J, V311, P1570, DOI 10.1136/bmj.311.7019.1570c	9	19	19	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 31	1997	314	7094					1588	1590		10.1136/bmj.314.7094.1588	http://dx.doi.org/10.1136/bmj.314.7094.1588			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9169403	Green Published			2022-12-28	WOS:A1997XC50000021
J	Delbanco, TL; Daley, J; Hartman, EE				Delbanco, TL; Daley, J; Hartman, EE			A 64-year-old man with adult-onset diabetes, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		RUBENSTEIN AH, 1996, JAMA-J AM MED ASSOC, V276, P816	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	1997	277	20					1640	1640		10.1001/jama.277.20.1640	http://dx.doi.org/10.1001/jama.277.20.1640			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA022	9168295				2022-12-28	WOS:A1997XA02200035
J	Autran, B; Carcelain, G; Li, TS; Blanc, C; Mathez, D; Tubiana, R; Katlama, C; Debre, P; Leibowitch, J				Autran, B; Carcelain, G; Li, TS; Blanc, C; Mathez, D; Tubiana, R; Katlama, C; Debre, P; Leibowitch, J			Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROGNOSTIC VALUE; INFECTION; ACTIVATION; LYMPHOCYTES; MEMORY; INHIBITORS; REPERTOIRE; ANTIGENS; DEFECTS	Highly active antiretroviral therapy (HAART) increases CD4(+) cell numbers, but its ability to correct the human immunodeficiency virus (HIV)-induced immune deficiency remains unknown. A three-phase T cell reconstitution was demonstrated after HAART, with: (i) an early rise of memory CD4(+) cells, (ii) a reduction in T cell activation correlated to the decreasing retroviral activity together with an improved CD4(+) T cell reactivity to recall antigens, and (iii) a late rise of ''naive'' CD4(+) lymphocytes while CD8(+) T cells declined, however, without complete normalization of these parameters. Thus, decreasing the HIV load can reverse HIV-driven activation and CD4(+) T cell defects in advanced HIV-infected patients.	HOP RAY POINCARE, SERV IMMUNOL HEMATOL, GARCHES, FRANCE; HOP LA PITIE SALPETRIERE, SERV MALAD INFECT & TROP, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Autran, B (corresponding author), HOP LA PITIE SALPETRIERE, LAB IMMUNOL CELLULAIRE, URA CNRS 625, 47-83 BLVD HOP, PARIS, FRANCE.							AUSSEL C, 1994, CELL IMMUNOL, V155, P436, DOI 10.1006/cimm.1994.1136; AUTRAN B, 1995, J IMMUNOL, V154, P1408; Bofill M, 1996, AIDS, V10, P827, DOI 10.1097/00002030-199607000-00005; BORTHWICK NJ, 1994, AIDS, V8, P431, DOI 10.1097/00002030-199404000-00004; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CLERICI M, 1988, J CLIN INVEST, V82, P1908; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Effros RB, 1996, AIDS, V10, pF17, DOI 10.1097/00002030-199607000-00001; Giorgi J. V., 1996, IMMUNOLOGY HIV INFEC, P181; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; GIORGI JV, 1987, J IMMUNOL, V138, P3725; GULICK R, 1996, 3 NAT C HUM RETR REL; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LEVACHER M, 1992, CLIN EXP IMMUNOL, V90, P376; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MATHEZ D, 1993, ANTIMICROB AGENTS CH, V37, P2206, DOI 10.1128/AAC.37.10.2206; MATHEZ D, IN PRESS ANTIRETROVI; MERKENSCHLAGER M, 1988, EUR J IMMUNOL, V18, P1653, DOI 10.1002/eji.1830181102; MOSLER DE, 1995, NATURE, V375, P193, DOI 10.1038/375193b0; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROEDERER M, 1995, J CLIN INVEST, V95, P2061, DOI 10.1172/JCI117892; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; TANCHOT C, 1995, EUR J IMMUNOL, V25, P2127, DOI 10.1002/eji.1830250802; TEDDER TF, 1985, J IMMUNOL, V134, P2989; Tough DF, 1996, IMMUNOL REV, V150, P129, DOI 10.1111/j.1600-065X.1996.tb00699.x; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543	33	1511	1568	3	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	1997	277	5322					112	116		10.1126/science.277.5322.112	http://dx.doi.org/10.1126/science.277.5322.112			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204894				2022-12-28	WOS:A1997XJ41800052
J	Polymeropoulos, MH; Lavedan, C; Leroy, E; Ide, SE; Dehejia, A; Dutra, A; Pike, B; Root, H; Rubenstein, J; Boyer, R; Stenroos, ES; Chandrasekharappa, S; Athanassiadou, A; Papapetropoulos, T; Johnson, WG; Lazzarini, AM; Duvoisin, RC; DiIorio, G; Golbe, LI; Nussbaum, RL				Polymeropoulos, MH; Lavedan, C; Leroy, E; Ide, SE; Dehejia, A; Dutra, A; Pike, B; Root, H; Rubenstein, J; Boyer, R; Stenroos, ES; Chandrasekharappa, S; Athanassiadou, A; Papapetropoulos, T; Johnson, WG; Lazzarini, AM; Duvoisin, RC; DiIorio, G; Golbe, LI; Nussbaum, RL			Mutation in the alpha-synuclein gene identified in families with Parkinson's disease	SCIENCE			English	Article							ALZHEIMERS-DISEASE; CHROMOSOME-1; NUCLEUS	Parkinson Is disease (PD) is a common neurodegenerative disorder with a lifetime incidence of approximately 2 percent. A pattern of familial aggregation has been documented for the disorder, and it was recently reported that a PD susceptibility gene in a large Italian kindred is located on the long arm of human chromosome 4. A mutation was identified in the alpha-synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, in the Italian kindred and in three unrelated families of Greek origin with autosomal dominant inheritance for the PD phenotype. This finding of a specific molecular alteration associated with PD will facilitate the detailed understanding of the pathophysiology of the disorder.	NIH,LAB GENE TRANSFER,NATL HUMAN GENOME RES INST,BETHESDA,MD 20892; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854; UNIV NAPLES 2,INST NEUROL SCI,FAC MED,NAPLES,ITALY; UNIV PATRAS,SCH MED,GR-26110 PATRAS,GREECE	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Rutgers State University New Brunswick; Rutgers State University Medical Center; Universita della Campania Vanvitelli; University of Patras	Polymeropoulos, MH (corresponding author), NIH,LAB GENET DIS RES,NATL HUMAN GENOME RES INST,BLDG 10,BETHESDA,MD 20892, USA.		soler, martha maricel m gomez/L-6025-2014	soler, martha maricel m gomez/0000-0002-4412-8108; Polymeropoulos, Mihael/0000-0001-5065-5353				*ALZH DIS COLL GRO, 1995, NAT GENET, V11, P219; CHEN XH, 1995, GENOMICS, V26, P425, DOI 10.1016/0888-7543(95)80237-G; DOTY RL, 1992, ANN NEUROL, V32, P97, DOI 10.1002/ana.410320116; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; GOLBE LI, 1990, ANN NEUROL, V27, P276, DOI 10.1002/ana.410270309; GOWERS WR, 1893, MANUAL DIS NERVOUS S, P6366; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; JENSEN PH, 1995, BIOCHEM J, V315, P91; LAVEDAN C, UNPUB; LAZARRINI AM, 1994, NEUROLOGY, V44, P499; LEROY EM, UNPUB; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Parkinson J, 1817, ESSAY SHAKING PALSY; PEARCE RKB, 1995, MOVEMENT DISORD, V10, P283, DOI 10.1002/mds.870100309; PerezTur J, 1995, NEUROREPORT, V7, P297; POLYMEROPOULOS M, UNPUB; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHITASAKI Y, 1995, CYTOGENET CELL GENET, V71, P54; SORBI S, 1995, LANCET, V346, P439, DOI 10.1016/S0140-6736(95)92809-X; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	28	6109	6345	14	854	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2045	2047		10.1126/science.276.5321.2045	http://dx.doi.org/10.1126/science.276.5321.2045			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197268	Green Published			2022-12-28	WOS:A1997XG74800066
J	Kirkpatrick, DT; Petes, TD				Kirkpatrick, DT; Petes, TD			Repair of DNA loops involves DNA-mismatch and nucleotide-excision repair proteins	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; YEAST; MUTANTS	A number of enzymes recognize and repair DNA lesions(1). The DNA-mismatch repair system corrects base-base mismatches and small loops, whereas the nucleotide-excision repair systems removes pyrimidine dimers and other helix-distorting lesions. DNA molecules with mismatches or loops can arise as a consequence of heteroduplex formation during meiotic recombination(2). In the yeast Saccharomyces cerevisiae, repair of mismatches results in gene conversion or restoration, and failure to repair the mismatch results in post-meiotic segregation (PMS) (Fig. 1). The ratio of gene-conversion to PMS events reflects the efficiency of DNA repair(3,4). By examining the PMS patterns in yeast strains heterozygous for a mutant allele with a 26-base-pair insertion, we find that the repair of 26-base loops involves Msh2 (a DNA-mismatch repair protein) and Rad1 (a protein required for nucleotide-excision repair).	UNIV N CAROLINA,DEPT BIOL,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill								ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; ALANI E, 1994, GENETICS, V137, P19; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CARPENTER ATC, 1982, P NATL ACAD SCI-BIOL, V79, P5961, DOI 10.1073/pnas.79.19.5961; DETLOFF P, 1991, MOL CELL BIOL, V11, P737, DOI 10.1128/MCB.11.2.737; DICAPRIO L, 1976, MUTAT RES, V37, P137, DOI 10.1016/0027-5107(76)90061-0; DOWLING EL, 1985, GENETICS, V109, P283; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; FOGEL S, 1981, MOL BIOL YEAST SACCH, P289; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NAG DK, 1989, NATURE, V340, P318, DOI 10.1038/340318a0; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; REENAN RAG, 1992, GENETICS, V132, P975; RESNICK MA, 1983, GENETICS, V104, P603; Saparbaev M, 1996, GENETICS, V142, P727; SEKELSKY JJ, 1995, GENETICS, V141, P619; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; STAPLETON A, 1991, GENETICS, V127, P39; Tran HT, 1996, GENETICS, V143, P1579	24	128	130	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					929	931		10.1038/43225	http://dx.doi.org/10.1038/43225			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202128				2022-12-28	WOS:A1997XG41600058
J	Panin, VM; Papayannopoulos, V; Wilson, R; Irvine, KD				Panin, VM; Papayannopoulos, V; Wilson, R; Irvine, KD			Fringe modulates notch ligand interactions	NATURE			English	Article							DROSOPHILA; GENE; EXPRESSION; PROTEIN; DELTA; BOUNDARY; RECEPTOR; SERRATE; ENCODES; MEMBER	Notch family of transmembrane receptor proteins mediate developmental cell-fate decisions(1), and mutations in mammalian Notch genes have been implicated in leukaemia, breast cancer, stroke and dementia(2-4). During wing development in Drosophila, the Notch receptor is activated along the border between dorsal and ventral cells(5-7), leading to the specification of specialized cells that express Wingless (Wg) and organize wing growth and patterning(6,8,9). Three genes, fringe (fng), Serrate (Ser) and Delta (Dl), are involved in the cellular interactions leading to Notch activation(7,9-15). Ser and Dl encode transmembrane ligands for Notch(16,17), whereas fng encodes a pioneer protein(10). We have investigated the relationship between these genes by a combination of expression and coexpression studies in the Drosophila wing, We found that Ser and Dl maintain each other's expression by a positive feedback loop, fng is expressed specifically by dorsal cells and functions to position and restrict this feedback loop to the developing dorsal-ventral boundary, This is achieved by fng through a cell-autonomous mechanism that inhibits a cell's ability to respond to Serrate protein and potentiates its ability to respond to Delta protein.	RUTGERS STATE UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855; RUTGERS STATE UNIV,DEPT MOL BIOL & BIOCHEM,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Panin, Vlad/G-1583-2016	Panin, Vlad/0000-0001-9126-1481; Papayannopoulos, Venizelos/0000-0002-3741-8190				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BRAND AH, 1993, DEVELOPMENT, V118, P401; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; deCelis JF, 1996, DEVELOPMENT, V122, P359; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, IN PRESS DEVELOPMENT; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Johnston SH, 1997, DEVELOPMENT, V124, P2245; JONSSON E, 1996, DEV GENES EVOL, V206, P91; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOPCZYNSKI CC, 1989, DEVELOPMENT, V107, P623; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SPELCHER SA, 1994, DEVELOPMENT, V120, P535; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; THOMAS U, 1991, DEVELOPMENT, V111, P749; Wu JY, 1996, SCIENCE, V273, P355, DOI 10.1126/science.273.5273.355; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	31	496	501	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 26	1997	387	6636					908	912		10.1038/43191	http://dx.doi.org/10.1038/43191			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG416	9202123				2022-12-28	WOS:A1997XG41600053
J	Gallagher, RB				Gallagher, RB			Nota bene: Immunology - Population biology of lymphocytes	SCIENCE			English	Editorial Material														Gallagher, Richard/0000-0001-5639-2187				McLean AR, 1997, P NATL ACAD SCI USA, V94, P5792, DOI 10.1073/pnas.94.11.5792; WESTMAN BS, 1982, J NUTR, V112, P562	2	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1817	1817		10.1126/science.276.5320.1817	http://dx.doi.org/10.1126/science.276.5320.1817			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206842				2022-12-28	WOS:A1997XF10300034
J	Geppert, M; Goda, Y; Stevens, CF; Sudhof, TC				Geppert, M; Goda, Y; Stevens, CF; Sudhof, TC			The small GTP-binding protein Rab3A regulates a late step in synaptic vesicle fusion	NATURE			English	Article							LONG-TERM POTENTIATION; PAIRED-PULSE FACILITATION; NEUROTRANSMITTER RELEASE; MEMBRANE TRAFFICKING; TRANSMITTER RELEASE; TRANSMISSION; PROBABILITY; INVOLVEMENT; PLASTICITY; EXOCYTOSIS	The Rab family of low-molecular-mass GTP-binding proteins are thought to guide membrane fusion between a transport vesicle and the target membrane, and to determine the specificity of docking(1-3). The docking and fusion of vesicles is, however, a complex multistep reaction, and the precise point at which Rab proteins act in these sequential processes in unknown. In brain, the Rab protein Rab3A is specific to synaptic vesicles, whose exocytosis can be monitored with submillisecond resolution by following synaptic transmission. We have now determined the precise point at which Rab3A acts in the sequence of synaptic vesicle docking and fusion by using electrophysiological analysis of neurotransmitter release in Rab3A-deficient mice. Unexpectedly, the size of the readily releasable pool of vesicles is normal, whereas Ca2+-triggered fusion is altered in the absence of Rab3A in that a more-than-usual number of exocytic events occur within a brief time after arrival of the nerve impulse.	SALK INST BIOL STUDIES,MOL NEUROBIOL LAB,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037; MAX PLANCK INST EXPT MED,D-37075 GOTTINGEN,GERMANY; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Salk Institute; Howard Hughes Medical Institute; Salk Institute; Max Planck Society; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Goda, Yukiko/A-6576-2016; Goda, Yukiko/AAR-5641-2020	Goda, Yukiko/0000-0003-0352-9498; Goda, Yukiko/0000-0003-0352-9498				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; HUANG E, UNPUB J NEUROPHYSIOL; HUBBARD JI, 1963, J PHYSIOL-LONDON, V169, P641, DOI 10.1113/jphysiol.1963.sp007286; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; Katz B., 1969, RELEASE NEURAL TRANS; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MALLART A, 1967, J PHYSIOL-LONDON, V193, P593; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; OLVERMAN HJ, 1988, NEUROSCIENCE, V26, P17, DOI 10.1016/0306-4522(88)90124-8; PERKEL DJ, 1993, J PHYSIOL-LONDON, V471, P481, DOI 10.1113/jphysiol.1993.sp019911; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SCHELLER RH, 1995, NEURON, V14, P893; SCHULZ PE, 1994, J NEUROSCI, V14, P5325; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TRILLER A, 1982, J NEUROPHYSIOL, V48, P708, DOI 10.1152/jn.1982.48.3.708	30	335	345	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 19	1997	387	6635					810	814		10.1038/42954	http://dx.doi.org/10.1038/42954			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF144	9194562	Bronze			2022-12-28	WOS:A1997XF14400052
J	Lill, NL; Grossman, SR; Ginsberg, D; DeCaprio, J; Livingston, DM				Lill, NL; Grossman, SR; Ginsberg, D; DeCaprio, J; Livingston, DM			Binding and modulation of p53 by p300/CBP coactivators	NATURE			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; E1A PROTEINS; GENE; SUPPRESSION; INDUCTION; COMPLEXES; REVEALS; GROWTH; FORMS	The adenovirus E1A and SV40 large-T-antigen oncoproteins bind to members of the p300/CBP transcriptional coactivator family. Binding of p300/CBP is implicated in the transforming mechanisms of EIA and T-antigen oncoproteins. A common region of the T antigen is critical for binding both p300/CBP and the tumour suppressor p53 (ref. 1), suggesting a link between the functions of p53 and p300. Here we report that p300/CBP binds to p53 in the absence of viral oncoproteins, and that p300 and p53 colocalize within the nucleus and coexist in a stable DNA-binding complex. Consistent with its ability to bind to p300, E1A disrupted functions mediated by p53. It reduced p53-mediated activation of the p21 and bax promoters, and suppressed p53-induced cell-cycle arrest and apoptosis. We conclude that members of the p300/CBP family are transcriptional adaptors for p53, modulating its checkpoint function in the G1 phase of the cell cycle and its induction of apoptosis. Disruption of p300/p53-dependent growth control may be part of the mechanism by which E1A induces cell transformation. These results help to explain how p53 mediates growth and checkpoint control, and how members of the p300/CBP family affect progression from G1 to the S phase of the cell cycle.	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School				ginsberg, doron/0000-0002-1257-4920				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAYLEY ST, 1994, INT J ONCOL, V5, P425; CAPOROSSI D, 1990, J GEN VIROL, V71, P801, DOI 10.1099/0022-1317-71-4-801; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; KAHANA JA, 1996, CURRENT PROTOCOLS MO; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; MIYASHITA T, 1995, CELL, V80, P293; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	30	605	619	2	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 19	1997	387	6635					823	827		10.1038/42981	http://dx.doi.org/10.1038/42981			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF144	9194565	Bronze			2022-12-28	WOS:A1997XF14400055
J	Roach, PL; Clifton, IJ; Hensgens, CMH; Shibata, N; Schofield, CJ; Hajdu, J; Baldwin, JE				Roach, PL; Clifton, IJ; Hensgens, CMH; Shibata, N; Schofield, CJ; Hajdu, J; Baldwin, JE			Structure of isopenicillin N synthase complexed with substrate and the mechanism of penicillin formation	NATURE			English	Article							ACTIVE-SITE; CRYSTAL-STRUCTURE; FACTOR REFINEMENT; BIOSYNTHESIS; ENZYMES	The biosynthesis of penicillin and cephalosporin antibiotics in microorganisms requires the formation of the bicyclic nucleus of penicillin(1). Isopenicillin N synthase (IPNS), a non-haem iron-dependent oxidase, catalyses the reaction of a tripeptide, delta-(L-alpha-aminoadipoyl)-L-cysteinyl-D-valine (ACV), and dioxygen to form isopenicillin N and two water molecules(2). Mechanistic studies suggest the reaction is initiated by ligation of the substrate thiolate to the iron centre, and proceeds through an enzyme-bound monocyclic intermediate(3,4) (Fig. 1), Here we report the crystal structure of IPNS complexed to ferrous iron and ACV, determined to 1.3 Angstrom resolution. Based on the structure, we propose a mechanism for penicillin formation that involves ligation of ACV to the iron centre, creating a vacant iron coordination site into which dioxygen can bind. Subsequently, iron-dioxygen and iron-ore species remove the requisite hydrogens from ACV without the direct assistance of protein residues (Fig. 2). The crystal structure of the complex with the dioxygen analogue, NO and ACV bound to the active-site iron supports this hypothesis.	UNIV OXFORD,DYSON PERRINS LAB,OXFORD OX1 3QY,ENGLAND; UNIV OXFORD,OXFORD CTR MOL SCI,OXFORD OX1 3QY,ENGLAND; UNIV UPPSALA,CTR BIOMED,DEPT BIOCHEM,S-75123 UPPSALA,SWEDEN	University of Oxford; University of Oxford; Uppsala University			Roach, Peter/C-6248-2013; Shibata, Norio/A-9628-2008; Roach, Peter/AAW-7071-2021	Shibata, Norio/0000-0002-3742-4064; Schofield, Christopher/0000-0002-0290-6565				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Baldwin J. E., 1992, CHEM BETA LACTAMS, P1; BALDWIN JE, 1984, J CHEM SOC CHEM COMM, P1225, DOI 10.1039/c39840001225; BALDWIN JE, 1988, NAT PROD REP, V5, P129, DOI 10.1039/np9880500129; Baldwin JE, 1996, TETRAHEDRON, V52, P2537, DOI 10.1016/0040-4020(95)01072-6; BALDWIN JE, 1991, P ROY SOC B-BIOL SCI, V245, P43, DOI 10.1098/rspb.1991.0086; BOROVOK L, 1996, BIOCHEMISTRY-US, V35, P1981; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEN VJ, 1989, J BIOL CHEM, V264, P21677; Cooper R D, 1993, Bioorg Med Chem, V1, P1, DOI 10.1016/S0968-0896(00)82098-2; Groves John T., 1995, P3; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; HAN S, 1995, SCIENCE, V270, P976, DOI 10.1126/science.270.5238.976; HANAUSKEABEL HM, 1982, J THEOR BIOL, V94, P421, DOI 10.1016/0022-5193(82)90320-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; LESLIE AGW, 1996, MOSFLM; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PANG CP, 1984, BIOCHEM J, V222, P789, DOI 10.1042/bj2220789; PRESCOTT AG, 1993, J EXP BOT, V44, P849, DOI 10.1093/jxb/44.5.849; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; RANDALL CR, 1993, BIOCHEMISTRY-US, V32, P6664, DOI 10.1021/bi00077a020; Roach PL, 1996, EUR J BIOCHEM, V242, P736, DOI 10.1111/j.1432-1033.1996.0736r.x; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; ROWE CJ, 1995, THESIS OXFORD U; Senda T, 1996, J MOL BIOL, V255, P735, DOI 10.1006/jmbi.1996.0060; SHELDRICK GM, 1993, SHELXL93 PROGRAM CRY; SHU LJ, 1995, BIOCHEMISTRY-US, V34, P6649, DOI 10.1021/bi00020a010	30	374	380	0	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 19	1997	387	6635					827	830		10.1038/42990	http://dx.doi.org/10.1038/42990			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF144	9194566	Bronze			2022-12-28	WOS:A1997XF14400056
J	Bartlett, JG				Bartlett, JG			Infectious diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Bartlett, JG (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21218, USA.							Bloom FE, 1996, SCIENCE, V274, P1987, DOI 10.1126/science.274.5295.1987; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; *CDC, 1996, MMWR-MORBID MORTAL W, V45, P611; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; EMINI EA, 1996, 11 INT C AIDS VANC B; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Foreman KE, 1997, NEW ENGL J MED, V336, P163, DOI 10.1056/NEJM199701163360302; Gorman Christine, 1997, TIME            1230, P56; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Lederberg J, 1996, JAMA-J AM MED ASSOC, V276, P417, DOI 10.1001/jama.276.5.417; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Lorber B, 1996, ANN INTERN MED, V125, P844, DOI 10.7326/0003-4819-125-10-199611150-00010; MARKOWITZ M, 1996, 11 INT C AIDS VANC B; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Potter J, 1997, J INFECT DIS, V175, P1, DOI 10.1093/infdis/175.1.1; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	19	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1865	1866		10.1001/jama.277.23.1865	http://dx.doi.org/10.1001/jama.277.23.1865			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185805				2022-12-28	WOS:A1997XD54400024
J	Larson, EB; Sheffield, JVL				Larson, EB; Sheffield, JVL			General internal medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Larson, EB (corresponding author), UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA.							Blackshear JL, 1996, LANCET, V348, P633; BORHANINO, 1996, JAMA-J AM MED ASSOC, V276, P785; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Espeland MA, 1996, J AM GERIATR SOC, V44, P1183, DOI 10.1111/j.1532-5415.1996.tb01367.x; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; Fetters MD, 1996, JAMA-J AM MED ASSOC, V275, P940, DOI 10.1001/jama.275.12.940; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; King AC, 1997, JAMA-J AM MED ASSOC, V277, P32, DOI 10.1001/jama.277.1.32; MONTGOMERY EB, 1995, AM J MED, V122, P64; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; Pearce KF, 1996, NEW ENGL J MED, V335, P1559, DOI 10.1056/NEJM199611213352103; PEDERSEN TR, 1994, LANCET, V344, P1383; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115	19	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1860	1861						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185802				2022-12-28	WOS:A1997XD54400021
J	Mata, J; Nurse, P				Mata, J; Nurse, P			tea1 and the microtubular cytoskeleton are important for generating global spatial order within the fission yeast cell	CELL			English	Article							SCHIZOSACCHAROMYCES-POMBE; GENETIC-ANALYSIS; S-POMBE; PROTEIN; ENCODES; GROWTH; MORPHOGENESIS; ORGANIZATION; CYTOKINESIS; SCRUIN	Fission yeast cells identify and maintain growing regions exactly opposed at the ends of a cylindrical cell. tea1 mutants disrupt this organization, producing bent and T-shaped cells. We have cloned teal and shown that teal is located at the cell poles. Microtubules are continuously required to transfer teal to the cell ends, and teal is located at the ends of microtubules growing toward the cell poles. We suggest that teal acts as an end marker, directing the growth machinery to the cell poles. tea1 is down-regulated in cells treated with pheromone that grow toward a mating partner and no longer maintain their ends exactly opposed. teal may also influence microtubular organization, affecting the maintenance of a single central axis.			Mata, J (corresponding author), IMPERIAL CANC RES FUND, CELL CYCLE LAB, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.			Mata, Juan/0000-0002-5514-3653				ALFA CE, 1983, METHOD CELL BIOL, V37, P201; BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; BALASUBRAMANIAN MK, 1994, J CELL BIOL, V125, P1289, DOI 10.1083/jcb.125.6.1289; BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; Chang F, 1996, J CELL SCI, V109, P131; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; FUKUI Y, 1986, EMBO J, V5, P1991, DOI 10.1002/j.1460-2075.1986.tb04454.x; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; HAGAN IM, 1988, J CELL SCI, V89, P343; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; IMAI Y, 1992, MOL CELL BIOL, V12, P1827, DOI 10.1128/MCB.12.4.1827; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LEHMANN R, 1995, CELL, V83, P353, DOI 10.1016/0092-8674(95)90111-6; LEUPOLD U, 1987, CURR GENET, V12, P543, DOI 10.1007/BF00419564; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAEDA T, 1990, P NATL ACAD SCI USA, V87, P7814, DOI 10.1073/pnas.87.20.7814; MARKS J, 1986, J CELL SCI, P229; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MITCHISON JM, 1985, J CELL SCI, V75, P357; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Morgan BA, 1996, P NATL ACAD SCI USA, V93, P2801, DOI 10.1073/pnas.93.7.2801; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Roemer T, 1996, TRENDS CELL BIOL, V6, P434, DOI 10.1016/S0962-8924(96)10039-8; SCHMIDT H, 1993, CURR GENET, V24, P271, DOI 10.1007/BF00351803; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; SNELL V, 1993, J CELL SCI DEV S, P289; Stern B, 1997, EMBO J, V16, P534, DOI 10.1093/emboj/16.3.534; TODA T, 1984, CELL, V37, P233, DOI 10.1016/0092-8674(84)90319-2; UMESONO K, 1983, J MOL BIOL, V168, P271, DOI 10.1016/S0022-2836(83)80018-7; VARKEY JP, 1995, GENE DEV, V9, P1074, DOI 10.1101/gad.9.9.1074; VERDE F, 1995, J CELL BIOL, V131, P1529, DOI 10.1083/jcb.131.6.1529; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WOODS A, 1989, J CELL SCI, V93, P491; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Yaffe MP, 1996, P NATL ACAD SCI USA, V93, P11664, DOI 10.1073/pnas.93.21.11664	40	297	304	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 13	1997	89	6					939	949		10.1016/S0092-8674(00)80279-2	http://dx.doi.org/10.1016/S0092-8674(00)80279-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200612	Bronze			2022-12-28	WOS:A1997XE35700014
J	Schmidt, G; Sehr, P; Wilm, M; Selzer, J; Mann, M; Aktories, K				Schmidt, G; Sehr, P; Wilm, M; Selzer, J; Mann, M; Aktories, K			Gln 63 of Rho is deamidated by Escherichia coli cytotoxic necrotizing factor-1	NATURE			English	Article							BINDING PROTEIN-RHO; ACTIN STRESS FIBERS; DIFFICILE TOXIN-B; CLOSTRIDIUM-DIFFICILE; GTPASE; MICROINJECTION; INDUCTION; CELLS; RAC	The actin cytoskeleton is regulated by GTP-hydrolysing proteins, the Rho GTPases(1,2), which act as molecular switches in diverse signal-transduction processes(3). Various bacterial toxins can inactivate Rho GTPases by ADP-ribosylation(1) or glucosylation(4). Previous research has identified Rho proteins as putative targets for Escherichia coli cytotoxic necrotizing factors 1 and 2 (CNF1 and 2)(5,6). These toxins induce actin assembly and multinucleation in culture cells. Here we show that treatment of RhoA with CNF1 inhibits the intrinsic GTPase activity of RhoA and completely blocks GTPase activity stimulated by the Rho-GTPase-activating protein (rhoGAP). Analysis by mass spectrometry and amino-acid sequencing of proteolytic peptides derived from CNF1-treated RhoA indicate that CNF1 induces deamidation of a glutamine residue at position 63 (Gln63) to give constitutively active Rho protein.	UNIV FREIBURG,INST PHARMAKOL & TOXIKOL,D-79104 FREIBURG,GERMANY; EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY	University of Freiburg; European Molecular Biology Laboratory (EMBL)			Aktories, Klaus/CAJ-5682-2022; Mann, Matthias/A-3454-2013	Aktories, Klaus/0000-0002-5397-0436; Mann, Matthias/0000-0003-1292-4799; Sehr, Peter/0000-0002-4348-5066; Wilm, Matthias/0000-0002-5461-6834				AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; CAPRIOLI A, 1983, INFECT IMMUN, V39, P1300, DOI 10.1128/IAI.39.3.1300-1306.1983; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DERYCKE J, 1990, J CLIN MICROBIOL, V28, P694, DOI 10.1128/JCM.28.4.694-699.1990; DIEKMANN D, 1995, METHOD ENZYMOL, V256, P207; FALBO V, 1993, INFECT IMMUN, V61, P4909, DOI 10.1128/IAI.61.11.4909-4914.1993; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; FIORENTINI C, 1995, INFECT IMMUN, V63, P3936, DOI 10.1128/IAI.63.10.3936-3944.1995; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HORIGUCHI Y, 1995, J CELL SCI, V108, P3243; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; MACHESKY IM, 1996, TRENDS CELL BIOL, V6, P304; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Renshaw MW, 1996, J BIOL CHEM, V271, P21691, DOI 10.1074/jbc.271.36.21691; RIDLEY AJ, 1995, METHOD ENZYMOL, V256, P313; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	22	438	445	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					725	729		10.1038/42735	http://dx.doi.org/10.1038/42735			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192900	Bronze			2022-12-28	WOS:A1997XD86900059
J	Frydenberg, M; Stricker, PD; Kaye, KW				Frydenberg, M; Stricker, PD; Kaye, KW			Prostate cancer diagnosis and management	LANCET			English	Article							DIGITAL RECTAL EXAMINATION; QUALITY-OF-LIFE; RADICAL RETROPUBIC PROSTATECTOMY; POSITIVE SURGICAL MARGINS; THERAPY ONCOLOGY GROUP; RADIATION-THERAPY; PELVIC LYMPHADENECTOMY; ANDROGEN DEPRIVATION; ECONOMIC-IMPLICATIONS; CONFORMAL RADIATION		UNIV WESTERN AUSTRALIA, QUEEN ELIZABETH II MED CTR, UROL RES CTR, NEDLANDS, WA 6009, AUSTRALIA; ST VINCENTS HOSP, SYDNEY, NSW 2010, AUSTRALIA; ROYAL MELBOURNE HOSP, MELBOURNE, VIC, AUSTRALIA	University of Western Australia; St Vincents Hospital Sydney; Royal Melbourne Hospital								ADOLFSSON J, 1993, J UROLOGY, V149, P326, DOI 10.1016/S0022-5347(17)36071-8; [Anonymous], 1995, Lancet, V346, P265; ARCANGELI G, 1991, INT J RADIAT ONCOL, V20, P439, DOI 10.1016/0360-3016(91)90055-9; AUS G, 1995, J UROLOGY, V154, P466, DOI 10.1016/S0022-5347(01)67075-7; AUS G, 1994, SCAND J UROL NEPHROL, P1; Bagshaw M A, 1988, NCI Monogr, P47; BAGSHAW MA, 1994, J UROLOGY, V152, P1781, DOI 10.1016/S0022-5347(17)32385-6; BECK JR, 1994, J UROLOGY, V152, P1894, DOI 10.1016/S0022-5347(17)32409-6; BENOIT RM, 1994, UROLOGY, V44, P795, DOI 10.1016/S0090-4295(94)80160-6; BISHOFF JT, 1995, UROLOGY, V45, P270, DOI 10.1016/0090-4295(95)80017-4; BOS SD, 1994, PROSTATE, P23; BRAWER MK, 1993, CANCER-AM CANCER SOC, V71, P899, DOI 10.1002/1097-0142(19930201)71:3+<899::AID-CNCR2820711406>3.0.CO;2-6; CARTER BS, 1993, J UROLOGY, V150, P797, DOI 10.1016/S0022-5347(17)35617-3; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; CHENG WS, 1993, UROLOGY, V42, P283, DOI 10.1016/0090-4295(93)90617-J; CHODAK G, 1995, UROLOGY, V46, P849, DOI 10.1016/S0090-4295(99)80356-2; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; Cohen JK, 1996, UROLOGY, V47, P395, DOI 10.1016/S0090-4295(99)80459-2; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; COX RL, 1995, J UROLOGY, V154, P1991, DOI 10.1016/S0022-5347(01)66670-9; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; Crook J, 1996, UROLOGY, V47, P387, DOI 10.1016/S0090-4295(99)80458-0; DENIS LJ, 1993, UROLOGY, V42, P119, DOI 10.1016/0090-4295(93)90634-M; DUPONT A, 1993, J UROLOGY, V150, P908, DOI 10.1016/S0022-5347(17)35646-X; FLANIGAN RC, 1994, J UROLOGY, V152, P1506, DOI 10.1016/S0022-5347(17)32457-6; FOSSA SD, 1994, BRIT J UROL, V74, P345, DOI 10.1111/j.1464-410X.1994.tb16625.x; FRYDENBERG M, 1995, CANC FORUM, V19, P15; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GOHAGAN JK, 1994, J UROLOGY, V152, P1905, DOI 10.1016/S0022-5347(17)32412-6; GRONBERG H, 1994, J UROLOGY, V152, P1484, DOI 10.1016/S0022-5347(17)32452-7; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; HANCOCK SL, 1995, J UROLOGY, V154, P1412, DOI 10.1016/S0022-5347(01)66879-4; HANKS GE, 1994, J UROLOGY, V152, P1775, DOI 10.1016/S0022-5347(17)32384-4; HODGE KK, 1989, J UROLOGY, V142, P71, DOI 10.1016/S0022-5347(17)38664-0; HRICAK H, 1987, RADIOLOGY, V162, P331, DOI 10.1148/radiology.162.2.3797645; JOHANSSON JE, 1994, J UROLOGY, V152, P1753, DOI 10.1016/S0022-5347(17)32378-9; KAISARY AV, 1995, EUR UROL, V28, P215; KAYE KW, 1995, J UROLOGY, V153, P1020, DOI 10.1016/S0022-5347(01)67626-2; KAYE KW, 1995, MED J AUSTRALIA, V162, P540, DOI 10.5694/j.1326-5377.1995.tb138517.x; KIRK D, 1995, CANCER SURV, V23, P183; Labrie F, 1996, UROLOGY, V47, P212, DOI 10.1016/S0090-4295(99)80419-1; LANGE PH, 1989, J UROLOGY, V141, P873; LANKFORD SP, 1995, INT J RADIAT ONCOL, V33, P907, DOI 10.1016/0360-3016(95)02005-0; LEIBEL SA, 1994, J UROLOGY, V152, P1792, DOI 10.1016/S0022-5347(17)32387-X; LERNER SE, 1995, J UROLOGY, V154, P1447, DOI 10.1016/S0022-5347(01)66888-5; LEVRAN Z, 1995, BRIT J UROL, V75, P778, DOI 10.1111/j.1464-410X.1995.tb07390.x; LITTRUP PJ, 1994, CANCER-AM CANCER SOC, V74, P2016, DOI 10.1002/1097-0142(19941001)74:7+<2016::AID-CNCR2820741705>3.0.CO;2-J; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; MAHLER C, 1995, SEMIN SURG ONCOL, V11, P77, DOI 10.1002/ssu.2980110112; MCCARTHY JF, 1994, J UROLOGY, V151, P1575, DOI 10.1016/S0022-5347(17)35305-3; McLeod D. G., 1996, CONT UROL, V8, P19; METTLIN C, 1993, CANCER, V72, P1701, DOI 10.1002/1097-0142(19930901)72:5<1701::AID-CNCR2820720534>3.0.CO;2-E; MYERS RP, 1992, J UROLOGY, V147, P910, DOI 10.1016/S0022-5347(17)37420-7; NARAYAN P, 1994, UROLOGY, V44, P519, DOI 10.1016/S0090-4295(94)80050-2; NOBLE RL, 1977, CANCER RES, V37, P1929; OESTERLING JE, 1995, UROLOGY, V46, P26, DOI 10.1016/S0090-4295(99)80247-7; OESTERLING JE, 1993, UROL CLIN N AM, V20, P705; OESTERLING JE, 1993, J UROLOGY, V149, P779, DOI 10.1016/S0022-5347(17)36206-7; OESTERLING JE, 1996, CONT UROL, V8, P76; OHORI M, 1995, J UROLOGY, V154, P1818, DOI 10.1016/S0022-5347(01)66792-2; OHORI M, 1994, CANCER-AM CANCER SOC, V74, P104, DOI 10.1002/1097-0142(19940701)74:1<104::AID-CNCR2820740119>3.0.CO;2-5; PARTIN AW, 1993, J UROLOGY, V150, P110, DOI 10.1016/S0022-5347(17)35410-1; PARTIN AW, 1994, J UROLOGY, V152, P1358, DOI 10.1016/S0022-5347(17)32422-9; Perez C A, 1988, NCI Monogr, P85; PIENTA KJ, 1993, ANN INTERN MED, V118, P793, DOI 10.7326/0003-4819-118-10-199305150-00007; PILEPICH MV, 1995, UROLOGY, V45, P616, DOI 10.1016/S0090-4295(99)80053-3; ROSEN MA, 1995, UROLOGY, V46, P757, DOI 10.1016/S0090-4295(99)80339-2; SCHELLHAMMER PF, 1993, J UROLOGY, V150, P1851, DOI 10.1016/S0022-5347(17)35913-X; SCHMID HP, 1993, CANCER-AM CANCER SOC, V71, P2031, DOI 10.1002/1097-0142(19930315)71:6<2031::AID-CNCR2820710618>3.0.CO;2-Q; SCHRODER FH, 1992, PROSTATE, P129; SHIPLEY WU, 1994, J UROLOGY, V152, P1799, DOI 10.1016/S0022-5347(17)32388-1; SOLOWAY MS, 1995, J UROLOGY, V154, P424, DOI 10.1016/S0022-5347(01)67067-8; STAMEY TA, 1994, SCAND J UROL NEPHROL, P73; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; STEINER MS, 1993, UROLOGY, V41, P201, DOI 10.1016/0090-4295(93)90557-Q; VALLANCIEN G, 1994, J UROLOGY, V152, P1152, DOI 10.1016/S0022-5347(17)32526-0; VANDENOUDEN D, 1994, J UROLOGY, V151, P646, DOI 10.1016/S0022-5347(17)35037-1; VANPOPPEL H, 1995, J UROLOGY, V154, P429, DOI 10.1016/S0022-5347(01)67068-X; VOGELZANG NJ, 1995, UROLOGY, V46, P220, DOI 10.1016/S0090-4295(99)80197-6; WALSH PC, 1994, J UROLOGY, V152, P1831, DOI 10.1016/S0022-5347(17)32396-0; WALSH PC, 1994, UROLOGY, V44, P463, DOI 10.1016/S0090-4295(94)80039-1; WOOLF SH, 1995, NEW ENGL J MED, V333, P1401, DOI 10.1056/NEJM199511233332107; ZAGARS GK, 1988, INT J RADIAT ONCOL, V14, P1085, DOI 10.1016/0360-3016(88)90383-5; ZINCKE H, 1994, J UROLOGY, V152, P1850, DOI 10.1016/S0022-5347(17)32399-6	85	71	73	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	1997	349	9066					1681	1687		10.1016/S0140-6736(96)07393-X	http://dx.doi.org/10.1016/S0140-6736(96)07393-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD100	9186395				2022-12-28	WOS:A1997XD10000043
J	Fraser, HSF; Kohane, IS; Long, WJ				Fraser, HSF; Kohane, IS; Long, WJ			Using the technology of the world wide web to manage clinical information	BRITISH MEDICAL JOURNAL			English	Article									CHILDRENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; MIT,COMP SCI LAB,CAMBRIDGE,MA 02139	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Fraser, HSF (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,DIV CLIN DECIS MAKING,NEMC-302,750 WASHINGTON ST,BOSTON,MA 02111, USA.		Fraser, Hamish HS/E-3773-2013; Kohane, Isaac Kohane/K-3716-2012	Kohane, Isaac Kohane/0000-0003-2192-5160				AFRAN C, 1996, MD COMPUTING, V13, P46; CAMPIONE M, 1997, JAVA TUTORIAL OBJECT; CIMINO JJ, 1995, J AM MED INFORM ASSN, V2, P273, DOI 10.1136/jamia.1995.96073829; Elhanan G, 1996, Proc AMIA Annu Fall Symp, P348; *HLTH LEV 7, 1990, HLTH LEV 7 APPL PROT; JAGANNATHAN V, 1996, P S COMP APPL MED CA, P12; Kennedy RL, 1996, EUR HEART J, V17, P1181; Kohane IS, 1996, J AM MED INFORM ASSN, V3, P191, DOI 10.1136/jamia.1996.96310633; LEE N, 1996, ABC MED COMPUTING, P37; Long W J, 1996, Proc AMIA Annu Fall Symp, P762; LONG WJ, 1994, J AM MED INFORM ASSN, V1, P127, DOI 10.1136/jamia.1994.95236144; MCDONALD CJ, 1990, MED INFORMATICS COMP; Neame R, 1997, BRIT MED J, V314, P573, DOI 10.1136/bmj.314.7080.573; Nenov V, 1996, J AM MED INFORM ASSN, V3, P318, DOI 10.1136/jamia.1996.97035023; Resnick P, 1996, COMMUN ACM, V39, P87, DOI 10.1145/236156.236175; Smith R, 1996, BRIT MED J, V313, P1062; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; *US NAT RES ASS, 1997, REC PROT EL HLTH INF; van Wingerde F J, 1996, Proc AMIA Annu Fall Symp, P643; Wang K, 1996, Proc AMIA Annu Fall Symp, P729; 1997, LANCET, V349, P369	21	20	21	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 31	1997	314	7094					1600	1603		10.1136/bmj.314.7094.1600	http://dx.doi.org/10.1136/bmj.314.7094.1600			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XC500	9186174	Green Published			2022-12-28	WOS:A1997XC50000028
J	Wu, H; Kwong, PD; Hendrickson, WA				Wu, H; Kwong, PD; Hendrickson, WA			Dimeric association and segmental variability in the structure of human CD4	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS GP120; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; BINDING; INFECTION; FRAGMENT; HIV; OLIGOMERIZATION; RECEPTORS; DOMAINS	CD4 is a co-receptor in the cellular immune response, It increases the avidity of association between a T cell and an antigen-presenting cell by interacting with non-polymorphic portions of the complex between class II major histocompatibility complex (MHC) and T-cell receptor (TCR) molecules, and it contributes directly to signal transduction through its cytoplasmic association with the lymphocyte kinase Lck (ref. 1). CD4 also serves as the high-affinity receptor for cellular attachment and entry of the human immunodeficiency virus (HIV)(2). The extracellular portion of CD4 comprises four immunoglobulin-like domains (D1-D4), This part of human CD4 (residues 1-369) has been characterized as a recombinant soluble protein (sCD4)(3,4), and crystal structures have been described for the human D1D2 fragment(5,6) and for the rat D3D4 fragment(7). We have now determined the structures of intact sCD4 in three crystal lattices. These structures have a hinge-like variability at the D1D2 to D3D4 junction that might be important in immune recognition and HIV fusion, and a common dimeric association through D4 domains. Dynamic light scattering measurements and chemical crosslinking of sCD4 corroborate dimerization at high protein concentration. We suggest that such dimers may have relevance as mediators of signal transduction in T cells.	COLUMBIA UNIV, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute								BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; Harding S E, 1994, Methods Mol Biol, V22, P97; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; Huang B, 1997, J IMMUNOL, V158, P216; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KONIG R, 1995, J EXP MED, V182, P779, DOI 10.1084/jem.182.3.779; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; KWONG PD, 1994, J APPL CRYSTALLOGR, V27, P504, DOI 10.1107/S0021889893012592; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LIFSON JD, 1989, IMMUNOL REV, V109, P93, DOI 10.1111/j.1600-065X.1989.tb00021.x; MOEBIUS U, 1992, P NATL ACAD SCI USA, V89, P12008, DOI 10.1073/pnas.89.24.12008; MOEBIUS U, 1993, P NATL ACAD SCI USA, V90, P8259, DOI 10.1073/pnas.90.17.8259; Moir S, 1996, J VIROL, V70, P8019, DOI 10.1128/JVI.70.11.8019-8028.1996; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; SAKIHAMA T, 1995, P NATL ACAD SCI USA, V92, P6444, DOI 10.1073/pnas.92.14.6444; Tong L, 1996, ACTA CRYSTALLOGR A, V52, P782, DOI 10.1107/S010876739600548X; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	29	234	247	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632					527	530		10.1038/387527a0	http://dx.doi.org/10.1038/387527a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168119				2022-12-28	WOS:A1997XB47900055
J	Pozzilli, P				Pozzilli, P			BCG vaccine in insulin-dependent diabetes mellitus	LANCET			English	Article							RECENT-ONSET IDDM; NICOTINAMIDE				Pozzilli, P (corresponding author), UNIV ROMA LA SAPIENZA,INST MED CLIN 2,I-00161 ROME,ITALY.		Pozzilli, Paolo/A-5235-2010	Pozzilli, Paolo/0000-0001-5090-636X				Pozzilli P, 1996, DIABETES CARE, V19, P1357, DOI 10.2337/diacare.19.12.1357; POZZILLI P, 1995, DIABETOLOGIA, V38, P848, DOI 10.1007/s001250050362; POZZILLI P, 1994, DIABETES CARE, V17, P897, DOI 10.2337/diacare.17.8.897; SHEHADEH N, 1994, LANCET, V343, P706, DOI 10.1016/S0140-6736(94)91583-0; WILLIAMS G, 1994, LANCET, V343, P684, DOI 10.1016/S0140-6736(94)91574-1	5	24	29	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1520	1521		10.1016/S0140-6736(05)62100-9	http://dx.doi.org/10.1016/S0140-6736(05)62100-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167468				2022-12-28	WOS:A1997XA90100018
J	Cumming, RG; Mitchell, P; Leeder, SR				Cumming, RG; Mitchell, P; Leeder, SR			Use of inhaled corticosteroids and the risk of cataracts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BEAVER DAM EYE; STEROID-THERAPY; LENS OPACITIES; ASTHMA; BECLOMETHASONE; ASSOCIATION; PREVALENCE; CHILDREN; AEROSOL	Background The use of systemic corticosteroids is a risk factor for the development of posterior subcapsular cataracts, but the association between inhaled corticosteroids and cataracts is uncertain. Methods We conducted a population-based, cross-sectional study of vision and common eye diseases in an urban area of the Blue Mountains, near Sydney, Australia. We recruited 3654 people 49 to 97 years of age; the participation rare was 82 percent. We collected information by questionnaire on potential risk factors for cataracts, including the current or prior use of inhaled corticosteroids (beclomethasone or budesonide). Photographs of the subjects' lenses were graded, without information on the subjects, to determine the presence and severity of cortical, nuclear, and posterior subcapsular cataracts. Results Three hundred seventy subjects reported using inhaled corticosteroids, 164 currently and 206 previously. Among these subjects, after adjustment for age and sex, there was a higher prevalence of nuclear cataracts (relative prevalence, 1.5; 95 percent confidence interval, 1.2 to 1.9) and posterior subcapsular cataracts (relative prevalence, 1.9; 95 percent confidence interval, 1.3 to 2.8) than among the subjects with no inhaled-corticosteroid use, but the prevalence of cortical cataracts was nor significantly higher (relative prevalence, 1.1; 95 percent confidence interval, 0.9 to 1.3). Higher cumulative lifetime doses of beclomethasone were associated with higher risks of posterior subcapsular cataracts (P for trend <0.001); the highest prevalence (27 percent) was found in subjects whose lifetime dose was over 2000 mg (relative prevalence, 5.5). Adjusting for the use of systemic corticosteroids and other potential confounders had little effect on the magnitude of the associations. The associations with posterior subcapsular cataracts, but not those with nuclear cataracts, were less marked when the analyses were restricted to subjects who had never used systemic corticosteroids. Conclusions The use of inhaled corticosteroids is associated with the development of posterior subcapsular and nuclear cataracts. (C) 1997, Massachusetts Medical Society.	UNIV SYDNEY, DEPT OPHTHALMOL, SYDNEY, NSW 2006, AUSTRALIA; WESTMEAD HOSP, SYDNEY, NSW, AUSTRALIA	University of Sydney; University of Sydney	Cumming, RG (corresponding author), UNIV SYDNEY, DEPT PUBL HLTH & COMMUNITY MED, BLDG A27, SYDNEY, NSW 2006, AUSTRALIA.		Cumming, Robert G/R-1548-2016	Cumming, Robert G/0000-0002-0261-6103				ABUEKTEISH F, 1995, THORAX, V50, P674, DOI 10.1136/thx.50.6.674; ADAMSONS I, 1991, ARCH OPHTHALMOL-CHIC, V109, P993, DOI 10.1001/archopht.1991.01080070105046; ALLEN MB, 1989, BRIT MED J, V299, P432, DOI 10.1136/bmj.299.6696.432; ARMSTRONG BG, 1989, AM J EPIDEMIOL, V129, P191, DOI 10.1093/oxfordjournals.aje.a115109; Attebo K, 1996, OPHTHALMOLOGY, V103, P357; BLACK RL, 1960, JAMA-J AM MED ASSOC, V174, P166, DOI 10.1001/jama.1960.63030020005014; Hodge WG, 1995, EPIDEMIOL REV, V17, P336, DOI 10.1093/oxfordjournals.epirev.a036197; IP M, 1994, CHEST, V105, P1722, DOI 10.1378/chest.105.6.1722; KARIM AKA, 1989, EXP EYE RES, V48, P215, DOI 10.1016/S0014-4835(89)80071-5; KEWLEY GD, 1980, AUST PAEDIATR J, V16, P117; KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428; KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546; Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; PANCHAPAKESAN J, IN PRESS OPHTHALMIC; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P17; SIMONS FER, 1993, LANCET, V342, P776, DOI 10.1016/0140-6736(93)91541-S; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TOOGOOD JH, 1993, J ALLERGY CLIN IMMUN, V91, P571, DOI 10.1016/0091-6749(93)90263-F; TOOGOOD JH, 1993, BRONCHIAL ASTHMA MEC, P818; URBAN RC, 1986, SURV OPHTHALMOL, V31, P102, DOI 10.1016/0039-6257(86)90077-9	21	374	382	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	1997	337	1					8	14		10.1056/NEJM199707033370102	http://dx.doi.org/10.1056/NEJM199707033370102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH186	9203425				2022-12-28	WOS:A1997XH18600002
J	Quinn, TC				Quinn, TC			Acute primary HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 INFECTION; CLINICAL MANIFESTATIONS; IMMUNE-RESPONSE; T-CELLS; PLASMA; SEROCONVERSION; VIREMIA; LYMPHOCYTES; ZIDOVUDINE				Quinn, TC (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,ROSS 1159,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.							BALSLEV E, 1990, J CLIN PATHOL, V43, P201, DOI 10.1136/jcp.43.3.201; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CALABRESE LH, 1987, ANN INTERN MED, V107, P849, DOI 10.7326/0003-4819-107-6-849; CARNE CA, 1985, LANCET, V2, P1206; Cates W, 1995, NEW ENGL J MED, V333, P1783; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLARK SJ, 1994, J INFECT DIS, V170, P194, DOI 10.1093/infdis/170.1.194; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COOPER DA, 1985, LANCET, V1, P537; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; Fauci AS, 1996, ANN INTERN MED, V124, P654, DOI 10.7326/0003-4819-124-7-199604010-00006; FOX R, 1987, AIDS, V1, P35; GOUDSMIT J, 1986, LANCET, V2, P177; Graziosi C, 1996, P NATL ACAD SCI USA, V93, P4386, DOI 10.1073/pnas.93.9.4386; HAGBERG L, 1986, SCAND J INFECT DIS, V18, P591, DOI 10.3109/00365548609021668; Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006; HENRARD DR, 1994, TRANSFUSION, V34, P376, DOI 10.1046/j.1537-2995.1994.34594249046.x; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; HOLODNIY M, 1996, 11 INT C AIDS JUL 8; JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LEBOIT PE, 1992, DERMATOL CLIN, V10, P59, DOI 10.1016/S0733-8635(18)30354-1; MACKEWICZ CE, 1994, LANCET, V344, P1671, DOI 10.1016/S0140-6736(94)90459-6; MARKOWITZ M, 1996, 11 INT C AIDS JUL 8; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; NIELSEN C, 1993, AIDS, V7, P1035, DOI 10.1097/00002030-199308000-00002; NIU MT, 1993, J INFECT DIS, V168, P1490, DOI 10.1093/infdis/168.6.1490; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PERLSON AS, 1996, 11 INT C AIDS JUL 8; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SINICCO A, 1993, AIDS, V7, P1167, DOI 10.1097/00002030-199309000-00003; STRAMER SL, 1989, JAMA-J AM MED ASSOC, V262, P64, DOI 10.1001/jama.262.1.64; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; Tindall B, 1988, Infect Dis Clin North Am, V2, P329; TINDALL B, 1989, AIDS, V3, P747, DOI 10.1097/00002030-198911000-00010; *US PUBL HLTH SERV, 1996, MMWR-MORBID MORTAL W, V45, P1; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZAUNDERS J, 1995, AIDS, V9, P561, DOI 10.1097/00002030-199506000-00005; 1990, MMWR-MORBID MORTAL W, V49, P117; 1990, MMWR-MORBID MORTAL W, V49, P110	51	81	85	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					58	62		10.1001/jama.278.1.58	http://dx.doi.org/10.1001/jama.278.1.58			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207340				2022-12-28	WOS:A1997XG38700038
J	Perkins, TT; Smith, DE; Chu, S				Perkins, TT; Smith, DE; Chu, S			Single polymer dynamics in an elongational flow	SCIENCE			English	Article							STRONG EXTENSIONAL FLOW; INDUCED SCISSION; DRAG REDUCTION; DNA; MACROMOLECULES; BIREFRINGENCE; ELASTICITY; VISCOSITY; MOLECULE	The stretching of individual polymers in a spatially homogeneous velocity gradient was observed through use of fluorescently labeled DNA molecules, The probability distribution of molecular extension was determined as a function of lime and strain rate. Although some molecules reached steady state, the average extension did not, even after a similar to 300-fold distortion of the underlying fluid element. At the highest strain rates, distinct conformational shapes with differing dynamics were observed, There was considerable variation in the onset of stretching, and chains with a dumbbell shape stretched more rapidly than folded ones. As the strain rate was increased, chains did not deform with the fluid element. The steady-state extension can be described by a model consisting of two beads connected by a spring representing the entropic elasticity of a worm-like chain, but the average dynamics cannot.	STANFORD UNIV,DEPT PHYS,STANFORD,CA 94305	Stanford University			Smith, Douglas E/A-3131-2017	Smith, Douglas E/0000-0002-8206-3632; Perkins, Thomas/0000-0003-4826-9490	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033289] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33289] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1987, DYNAMICS POLYM LIQUI; ATKINS EDT, 1992, BIOPOLYMERS, V32, P911, DOI 10.1002/bip.360320803; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; CALLIS PR, 1969, BIOPOLYMERS, V8, P379, DOI 10.1002/bip.1969.360080308; Carrington SP, 1996, J NON-NEWTON FLUID, V67, P269, DOI 10.1016/S0377-0257(96)01455-3; CATHEY CA, 1990, J NON-NEWTON FLUID, V34, P63, DOI 10.1016/0377-0257(90)80012-O; DAOUDI S, 1978, MACROMOLECULES, V11, P751, DOI 10.1021/ma60064a027; De Gennes P.-G., 1979, SCALING CONCEPTS POL; DUNLAP PN, 1987, J NON-NEWTON FLUID, V23, P5, DOI 10.1016/0377-0257(87)80009-5; FULLER GG, 1980, RHEOL ACTA, V19, P580, DOI 10.1007/BF01517512; HINCH EJ, 1994, J NON-NEWTON FLUID, V54, P209, DOI 10.1016/0377-0257(94)80023-5; HINCH EJ, 1977, PHYS FLUIDS, V20, P522; HU C, 1976, APPL PHYS LETT, V29, P582, DOI 10.1063/1.89195; JAMES DF, 1995, J RHEOL, V39, P713, DOI 10.1122/1.550653; JAMES DF, 1980, J FLUID MECH, V97, P655, DOI 10.1017/S0022112080002741; KELLER A, 1985, COLLOID POLYM SCI, V263, P181, DOI 10.1007/BF01415506; Keunings R, 1997, J NON-NEWTON FLUID, V68, P85, DOI 10.1016/S0377-0257(96)01497-8; KING DH, 1983, J CHEM PHYS, V78, P4749, DOI 10.1063/1.445274; KLOTZ LC, 1972, J MOL BIOL, V72, P779, DOI 10.1016/0022-2836(72)90191-X; Larson R. G., 1988, CONSTITUTIVE EQUATIO; LARSON RG, 1989, MACROMOLECULES, V22, P3004, DOI 10.1021/ma00197a022; Larson RG, 1997, PHYS REV E, V55, P1794, DOI 10.1103/PhysRevE.55.1794; LARSON RG, 1990, RHEOL ACTA, V29, P371, DOI 10.1007/BF01376787; LUMLEY JL, 1977, PHYS FLUIDS, V20, pS64, DOI 10.1063/1.861760; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; MENASVETA MJ, 1991, MACROMOLECULES, V24, P3427, DOI 10.1021/ma00011a060; NGUYEN TQ, 1995, MACROMOLECULES, V28, P4851, DOI 10.1021/ma00118a010; ODELL JA, 1988, J CHEM PHYS, V88, P4022, DOI 10.1063/1.453855; ODELL JA, 1992, COLLOID POLYM SCI, V270, P307, DOI 10.1007/BF00655846; ODELL JA, 1994, BIOPOLYMERS, V34, P1483, DOI 10.1002/bip.360341106; Orr NV, 1996, J NON-NEWTON FLUID, V67, P77, DOI 10.1016/S0377-0257(96)01487-5; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; PERKINS TT, 1995, SCIENCE, V268, P83, DOI 10.1126/science.7701345; Rallison JM, 1997, J NON-NEWTON FLUID, V68, P61, DOI 10.1016/S0377-0257(96)01492-9; REESE HR, 1990, J CHEM PHYS, V92, P2650, DOI 10.1063/1.457960; ROUSE PE, 1953, J CHEM PHYS, V21, P1272, DOI 10.1063/1.1699180; RYSKIN G, 1987, J FLUID MECH, V178, P423, DOI 10.1017/S0022112087001290; RYSKIN G, 1987, PHYS REV LETT, V59, P2059, DOI 10.1103/PhysRevLett.59.2059; SCHMITZ KS, 1975, BIOPOLYMERS, V14, P521, DOI 10.1002/bip.1975.360140308; Smith DE, 1996, MACROMOLECULES, V29, P1372, DOI 10.1021/ma951455p; SMITH KA, 1975, C INT CNRS PARIS, V233, P341; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; Spiegelberg SH, 1996, J NON-NEWTON FLUID, V67, P49, DOI 10.1016/S0377-0257(96)01475-9; THOMPSON DS, 1967, J CHEM PHYS, V47, P5008, DOI 10.1063/1.1701752; TIRTAATMADJA V, 1993, J RHEOL, V37, P1081, DOI 10.1122/1.550372; VOLKMUTH WD, 1992, NATURE, V358, P600, DOI 10.1038/358600a0; VOLOGODSKII A, 1994, MACROMOLECULES, V27, P5623, DOI 10.1021/ma00098a016; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462	51	747	761	0	191	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2016	2021		10.1126/science.276.5321.2016	http://dx.doi.org/10.1126/science.276.5321.2016			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197259				2022-12-28	WOS:A1997XG74800057
J	Tearney, GJ; Brezinski, ME; Bouma, BE; Boppart, SA; Pitris, C; Southern, JF; Fujimoto, JG				Tearney, GJ; Brezinski, ME; Bouma, BE; Boppart, SA; Pitris, C; Southern, JF; Fujimoto, JG			In vivo endoscopic optical biopsy with optical coherence tomography	SCIENCE			English	Article								Current medical imaging technologies allow visualization of tissue anatomy in the human body at resolutions ranging from 100 micrometers to 1 millimeter. These technologies are generally not sensitive enough to detect early-stage tissue abnormalities associated with diseases such as cancer and atherosclerosis, which require micrometer-scale resolution. Here, optical coherence tomography was adapted to allow high-speed visualization of tissue in a living animal with a catheter-endoscope 1 millimeter in diameter. This method, referred to as ''optical biopsy,'' was used to obtain cross-sectional images of the rabbit gastrointestinal and respiratory tracts at 10-micrometer resolution.	MIT,DEPT ELECT ENGN & COMP SCI,CAMBRIDGE,MA 02139; MIT,ELECT RES LAB,CAMBRIDGE,MA 02139; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CARDIAC UNIT,KNIGHT CATHETERIZAT LAB,BOSTON,MA 02114; SINAI SAMARITAN HOSP,DEPT PATHOL,MILWAUKEE,WI 53233	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Massachusetts General Hospital			Boppart, Stephen A/C-7338-2009	Pitris, Costas/0000-0002-5559-1050; Boppart, Stephen/0000-0002-9386-5630	NATIONAL EYE INSTITUTE [R01EY011289] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055686] Funding Source: NIH RePORTER; NEI NIH HHS [NIH-9-RO1-EY11289] Funding Source: Medline; NHLBI NIH HHS [NIH-1-R29-HL55686-01A1] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bouma BE, 1996, OPT LETT, V21, P1839, DOI 10.1364/OL.21.001839; Brezinski ME, 1996, CIRCULATION, V93, P1206, DOI 10.1161/01.CIR.93.6.1206; BREZINSKI ME, IN PRESS J SURG RES; FERCHER AF, 1993, AM J OPHTHALMOL, V116, P113, DOI 10.1016/S0002-9394(14)71762-3; FUJIMOTO JG, 1995, NAT MED, V1, P970, DOI 10.1038/nm0995-970; FULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217; Gelikonov V. M., 1995, JETP LETT, V61, P149; HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025; HERITAGE JP, 1985, OPT LETT, V10, P609, DOI 10.1364/OL.10.000609; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; KWONG KF, 1993, OPT LETT, V18, P558, DOI 10.1364/OL.18.000558; PHILLIPS RW, 1991, GASTROENTEROL CLIN N, V20, P791; SCHMITT JM, 1994, PHYS MED BIOL, V39, P1705, DOI 10.1088/0031-9155/39/10/013; SCHMITT JM, 1995, DERMATOLOGY, V191, P93, DOI 10.1159/000246523; SEAS A, 1992, OPT LETT, V17, P937, DOI 10.1364/OL.17.000937; SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864; Tearney GJ, 1996, OPT LETT, V21, P1408, DOI 10.1364/OL.21.001408; Tearney GJ, 1996, OPT LETT, V21, P543, DOI 10.1364/OL.21.000543; TEARNEY GJ, 1997, J UROLOGY, V157, P1913; TEARNEY GJ, IN PRESS AM J GASTRO	20	1103	1325	8	170	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2037	2039		10.1126/science.276.5321.2037	http://dx.doi.org/10.1126/science.276.5321.2037			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197265				2022-12-28	WOS:A1997XG74800063
J	Daley, J; Delbanco, TL; Hartman, EE				Daley, J; Delbanco, TL; Hartman, EE			A 17-year-old mother seeking contraception, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Grimes DA, 1996, JAMA-J AM MED ASSOC, V276, P1163, DOI 10.1001/jama.276.14.1163	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 25	1997	277	24					1976	1976						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF087	9200640				2022-12-28	WOS:A1997XF08700044
J	Pleskoff, O; Treboute, C; Brelot, A; Heveker, N; Seman, M; Alizon, M				Pleskoff, O; Treboute, C; Brelot, A; Heveker, N; Seman, M; Alizon, M			Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BRAIN-DERIVED CELLS; CMV INFECTION; ENVELOPE GLYCOPROTEIN; T-CELLS; TYPE-1; AIDS; REPLICATION; HEMOPHILIACS; LYMPHOCYTES	The human cytomegalovirus encodes a beta-chemokine receptor (US28) that is distantly related to the human chemokine receptors CCR5 and CXCR4, which also serve as cofactors for the entry into cells of human immunodeficiency virus-type 1 (HIV-1). Like CCR5, US28 allowed infection of CD4-positive human cell lines by primary isolates of HIV-1 and HIV-2, as well as fusion of these cell lines with cells expressing the viral envelope proteins. In addition, US28 mediated infection by cell line-adapted HIV-1 for which CXCR4 was an entry cofactor.	INST COCHIN GENET MOL,INSERM,U332,F-75014 PARIS,FRANCE; UNIV PARIS 07,LAB IMMUNODIFFERENCIAT,F-75005 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite			Brelot, Anne/P-4129-2017; Heveker, Nikolaus/G-5306-2012	Brelot, Anne/0000-0002-8095-4909				AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bates P, 1996, CELL, V86, P1, DOI 10.1016/S0092-8674(00)80070-7; BECHERER PR, 1990, AM J HEMATOL, V34, P204, DOI 10.1002/ajh.2830340310; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BRAUN RW, 1986, J VIROL, V60, P29, DOI 10.1128/JVI.60.1.29-36.1986; Broder CC, 1996, PATHOBIOLOGY, V64, P171, DOI 10.1159/000164032; BRUNVEZINET F, 1987, LANCET, V1, P128; CANN AJ, 1992, J VIROL, V66, P305, DOI 10.1128/JVI.66.1.305-309.1992; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FINKLE C, 1991, J ACQ IMMUN DEF SYND, V4, P735; GAO JL, 1994, J BIOL CHEM, V269, P28539; HARRINGTON RD, 1993, J VIROL, V67, P5939, DOI 10.1128/JVI.67.10.5939-5947.1993; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; HIRKA G, 1991, J VIROL, V65, P2732, DOI 10.1128/JVI.65.5.2732-2735.1991; HO WZ, 1991, J ACQ IMMUN DEF SYND, V4, P1098; HO WZ, 1990, J GEN VIROL, V71, P97, DOI 10.1099/0022-1317-71-1-97; IBANEZ CE, 1991, J VIROL, V65, P6581, DOI 10.1128/JVI.65.12.6581-6588.1991; JACKSON JB, 1988, TRANSFUSION, V28, P187, DOI 10.1046/j.1537-2995.1988.28288179029.x; JAULT FM, 1994, J VIROL, V68, P959, DOI 10.1128/JVI.68.2.959-973.1994; KOVAL V, 1991, J VIROL, V65, P6969, DOI 10.1128/JVI.65.12.6969-6978.1991; LATHEY JL, 1994, VIROLOGY, V199, P98, DOI 10.1006/viro.1994.1101; LEACH CT, 1993, J ACQ IMMUN DEF SYND, V6, P407; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; NELSON JA, 1988, VIROLOGY, V165, P286, DOI 10.1016/0042-6822(88)90685-X; NELSON JA, 1990, AIDS, V4, P1, DOI 10.1097/00002030-199001000-00001; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nicholas J, 1996, J VIROL, V70, P5975, DOI 10.1128/JVI.70.9.5975-5989.1996; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; Pleskoff O, 1997, J VIROL, V71, P3259, DOI 10.1128/JVI.71.4.3259-3262.1997; PLESKOFF O, UNPUB; RABKIN CS, 1993, J INFECT DIS, V168, P1260, DOI 10.1093/infdis/168.5.1260; RANDO RF, 1990, VIROLOGY, V176, P87, DOI 10.1016/0042-6822(90)90233-H; Rawlinson WD, 1996, J VIROL, V70, P8833, DOI 10.1128/JVI.70.12.8833-8849.1996; RICE GPA, 1984, P NATL ACAD SCI-BIOL, V81, P6134, DOI 10.1073/pnas.81.19.6134; SABIN CA, 1995, EPIDEMIOL INFECT, V114, P361, DOI 10.1017/S095026880005799X; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SCHRIER RD, 1985, SCIENCE, V230, P1048, DOI 10.1126/science.2997930; SCHWARTZ O, 1994, VIROLOGY, V198, P360, DOI 10.1006/viro.1994.1042; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; SKOLNIK PR, 1989, AM J OPHTHALMOL, V107, P361, DOI 10.1016/0002-9394(89)90659-4; SKOLNIK PR, 1988, J INFECT DIS, V157, P508, DOI 10.1093/infdis/157.3.508; SPIRE B, 1989, GENE, V81, P275, DOI 10.1016/0378-1119(89)90188-1; TOTH FD, 1995, J VIROL, V69, P2223; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WEBSTER A, 1989, LANCET, V2, P63; WEBSTER A, 1992, CLIN EXP IMMUNOL, V88, P6; WELCH AR, 1991, J VIROL, V65, P3915, DOI 10.1128/JVI.65.7.3915-3918.1991; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; WILEY CA, 1988, AM J PATHOL, V133, P73; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0	68	271	274	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1874	1878		10.1126/science.276.5320.1874	http://dx.doi.org/10.1126/science.276.5320.1874			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188536				2022-12-28	WOS:A1997XF10300053
J	Lindberg, DAB; Humphreys, BL				Lindberg, DAB; Humphreys, BL			Medical informatics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Lindberg, DAB (corresponding author), NATL LIB MED,BETHESDA,MD 20894, USA.							CIMINO JJ, 1995, J AM MED INFORM ASSN, V2, P273, DOI 10.1136/jamia.1995.96073829; Humphreys BL, 1996, J AM MED INFORM ASSN, V3, P281, DOI 10.1136/jamia.1996.96413136; Institute of Medicine, 1996, TEL GUID ASS TEL HLT; Lindberg CCS, 1997, J AM MED INFORM ASSN, V4, P14, DOI 10.1136/jamia.1997.0040014; Lindberg DAB, 1996, JAMA-J AM MED ASSOC, V275, P1821, DOI 10.1001/jama.275.23.1821; Macilwain C, 1996, NATURE, V383, P653, DOI 10.1038/383653a0; *NAT RES COUNC, IN PRESS REC PROT EL; RISHER CA, 1994, LIBR J, V119, P34; Rodgers RPC, 1996, J AM MED INFORM ASSN, V3, P303, DOI 10.1136/jamia.1996.97035021; RUTKOWSKI AM, INTERNET HOSTS 1989; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Scolamiero SJ, 1997, M D COMPUT, V14, P12; Trimbach J, 1995, Healthc Inform, V12, P14; TRIMBACH J, 1995, HLTH CARE INF, V12, P14; TRIMBACH J, 1995, HLTH CARE INF, V12, P12	15	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1870	1872						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD544	9185808				2022-12-28	WOS:A1997XD54400027
J	DeCock, KM; Low, N				DeCock, KM; Low, N			HIV and AIDS, other sexually transmitted diseases, and tuberculosis in ethnic minorities in United Kingdom: Is surveillance serving its purpose?	BRITISH MEDICAL JOURNAL			English	Article							STATES; INFECTION	Experience of disease differs across ethnic groups, and ethnicity is a relevant personal characteristic for descriptive epidemiology, Information about ethnicity and country of birth is omitted from the routine notification of many diseases, HIV infection and AIDS, other sexually transmitted diseases, and tuberculosis have different incidence rates in different ethnic groups in the United Kingdom. Omission of ethnic data from surveillance activities allows such differences in incidence to go undetected and unaddressed. Surveillance data that included ethnic details could guide interventions to reduce inequalities in health between different subpopulations.	UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT GENITOURINARY MED,LONDON,ENGLAND	University of London; King's College London	DeCock, KM (corresponding author), LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.		Low, Nicola/H-4718-2019	Low, Nicola/0000-0003-4817-8986				ADES AE, 1993, BRIT MED J, V306, P1296, DOI 10.1136/bmj.306.6888.1296; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; Catchpole M A, 1992, Commun Dis Rep CDR Rev, V2, pR1; *CDC, 1989, MMWR-MORBID MORTAL W, V38, P236; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P121; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DelAmo J, 1996, AIDS, V10, P1563, DOI 10.1097/00002030-199611000-00016; *DEP HLTH, 1996, UNL AN HIV PREV MON; *DEP HLTH, 1992, HLTH NAT; DOHERTY MJ, 1995, TUBERCLE LUNG DIS, V76, P196, DOI 10.1016/S0962-8479(05)80004-8; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; HAHN RA, 1992, JAMA-J AM MED ASSOC, V267, P268, DOI 10.1001/jama.267.2.268; Herrera J. L., 1993, Morbidity and Mortality Weekly Report, V42, P1; HOLMES KK, 1990, SEXUALLY TRANSMITTED; Johnson AM, 1994, SEXUAL ATTITUDES LIF; LACEY CJN, 1995, 11 M INT SOC STD RES; LAGA M, 1994, AIDS S1, V8, pS119; LANGMUIR AD, 1963, NEW ENGL J MED, V268, P182, DOI 10.1056/NEJM196301242680405; LOW N, 1996, GENITORURIN MED, V72, P305; MacDonagh SE, 1996, BRIT MED J, V313, P532; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; Mortimer J Y, 1995, Commun Dis Rep CDR Rev, V5, pR183; NAVARRO V, 1990, LANCET, V336, P1238, DOI 10.1016/0140-6736(90)92846-A; Noone A, 1991, CDR (Lond Engl Rev), V1, pR39; *OFF POP CENS SURV, 1993, 1991 CENS; *OFF POP CENS SURV, 1993, 1991 CENS US GUID 58; Ormerod P, 1996, BRIT J HOSP MED, V56, P209; *PHLS AIDS CTR, 1991, CDR REV, V1, pR51; *PUBL HLTH AB SERV, 1995, CDR WKLY, V5, P62; *PUBL HLTH LAB SER, 1996, COMMUN DIS REP CDR R, V6, P251; Rieder HL, 1996, EUR RESPIR J, V9, P1097, DOI 10.1183/09031936.96.09051097; SENIOR PA, 1994, BRIT MED J, V309, P327, DOI 10.1136/bmj.309.6950.327; THACKER SB, 1994, AM J EPIDEMIOL, V140, P383, DOI 10.1093/oxfordjournals.aje.a117261; WATSON JM, 1993, BRIT MED J, V306, P221, DOI 10.1136/bmj.306.6872.221	34	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1747	1751		10.1136/bmj.314.7096.1747	http://dx.doi.org/10.1136/bmj.314.7096.1747			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9202508	Green Published			2022-12-28	WOS:A1997XE90900031
J	Rapola, JM; Virtamo, J; Ripatti, S; Huttunen, JK; Albanes, D; Taylor, PR; Heinonen, OP				Rapola, JM; Virtamo, J; Ripatti, S; Huttunen, JK; Albanes, D; Taylor, PR; Heinonen, OP			Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction	LANCET			English	Article							VITAMIN-E CONSUMPTION; HEART-DISEASE; ATHEROSCLEROTIC PLAQUE; RISK; MORTALITY; ANGINA; LASER	Background Epidemiological data suggest that the intake of antioxidants such as alpha-tocopherol (vitamin E) and beta-carotene has an inverse correlation with the incidence of coronary heart disease. The results from clinical of antioxidant supplementation in people with coronary heart disease are inconclusive. Methods We studied the frequency of major coronary events in 1862 men enrolled in the Alpha-tocopherol Beta-carotene Cancer Prevention Study (smokers aged between 50 and 69 years) who had a previous myocardial infarction. In this randomised, double-blind, placebo-controlled study, men had received dietary supplements of alpha-tocopherol (50 mg/day), beta-carotene (20 mg/day), both, or placebo. The median follow-up was 5.3 years. The endpoint of this substudy was the first major coronary event after randomisation. Analyses were by intention to treat. Findings 424 major coronary events (non-fatal myocardial infarction and fatal coronary heart disease) occurred during follow-up. There were no significant differences in the number of major coronary events between any supplementation group and the placebo group (alpha-tocopherol 94/466; beta-carotene 113/461; alpha-tocopherol and beta-carotene 123/497; placebo 94/438 [log-rank test, p=0.25]). There were significantly more deaths from fatal coronary heart disease in the beta-carotene (74/461, multivariate-adjusted relative risk 1.75 [95% CI 1.16-2.64], p=0.007) and combined alpha-tocopherol and beta-carotene groups (67/497, relative risk 1.58 [1.05-2.40], p=0.03) than in the placebo group (39/438), but there was no significant increase in the alpha-tocopherol supplementation group (54/466, relative risk 1.33 [0.86-2.05], p=0.20). Interpretation The proportion of major coronary events in men with a previous myocardial infarction who smoke was not decreased with either alpha-tocopherol or beta-carotene supplements. In fact, the risk of fatal coronary heart disease increased in the groups that received either beta-carotene or the combination of alpha-tocopherol and beta-carotene; there was a non-significant trend of increased deaths in the alpha-tocopherol group. We do not recommend the use of alpha-tocopherol or beta-carotene supplements in this group of patients.	NCI,BETHESDA,MD 20892; UNIV HELSINKI,DEPT PUBL HLTH,HELSINKI,FINLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Helsinki	Rapola, JM (corresponding author), NATL PUBL HLTH INST,MANNERHEIMINTIE 166,FIN-00300 HELSINKI,FINLAND.		Ripatti, Samuli/H-9446-2014; Albanes, Demetrius/B-9749-2015	Ripatti, Samuli/0000-0002-0504-1202; 	NCI NIH HHS [N01-CN-45165] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN045165] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*ALPH TOC BET CART, 1994, NEW ENGL J MED, V330, pS1029; AMBROSIO G, 1995, J MOL CELL CARDIOL, V27, P1035, DOI 10.1016/0022-2828(95)90072-1; *ATBC CANC PREV ST, 1994, ANN EPIDEMIOL, V4, P1; DIEBERROTHENEDER M, 1991, J LIPID RES, V32, P1325; GAZIANO JM, 1990, CIRCULATION, V82, P201; Gaziano JM, 1996, CIRCULATION S1, V94, P508; Greenberg ER, 1996, JAMA-J AM MED ASSOC, V275, P699, DOI 10.1001/jama.275.9.699; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; KANNEL WB, 1979, AM J CARDIOL, V44, P58; KLONER RA, 1995, CIRCULATION, V91, P37, DOI 10.1161/01.CIR.91.1.37; KLONER RA, 1994, J AM COLL CARDIOL, V24, P1133, DOI 10.1016/0735-1097(94)90880-X; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; MILNE DB, 1986, CLIN CHEM, V32, P874; MITCHELL DC, 1993, LASER SURG MED, V13, P149, DOI 10.1002/lsm.1900130202; Morris SD, 1996, LANCET, V347, P1690; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Pandey DK, 1995, AM J EPIDEMIOL, V142, P1269, DOI 10.1093/oxfordjournals.aje.a117594; PRINCE MR, 1988, CIRCULATION, V78, P338, DOI 10.1161/01.CIR.78.2.338; PRINCEN HMG, 1992, ARTERIOSCLER THROMB, V12, P554, DOI 10.1161/01.ATV.12.5.554; Rapola JM, 1997, EUR J EPIDEMIOL, V13, P133, DOI 10.1023/A:1007380408729; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SCHLANT RC, 1982, CIRCULATION, V66, P401, DOI 10.1161/01.CIR.66.2.401; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Sun JZ, 1996, J CLIN INVEST, V97, P562, DOI 10.1172/JCI118449; TERVAHAUTA M, 1995, J AM COLL CARDIOL, V26, P1623, DOI 10.1016/0735-1097(95)00395-9; YELLON DM, 1993, LANCET, V342, P276, DOI 10.1016/0140-6736(93)91819-8	29	461	472	0	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 14	1997	349	9067					1715	1720		10.1016/S0140-6736(97)01234-8	http://dx.doi.org/10.1016/S0140-6736(97)01234-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE065	9193380	Green Submitted			2022-12-28	WOS:A1997XE06500007
J	Wilkinson, RG				Wilkinson, RG			Income inequality summarises the health burden of individual relative deprivation - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							MORTALITY				Wilkinson, RG (corresponding author), UNIV SUSSEX,TRAFFORD CTR MED RES,BRIGHTON BN1 9RY,E SUSSEX,ENGLAND.							BenShlomo Y, 1996, BRIT MED J, V312, P1013; Kaplan GA, 1996, BRIT MED J, V312, P999; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; MACKENBACH JP, 1994, J EPIDEMIOL COMMUN H, V48, P140, DOI 10.1136/jech.48.2.140; MCCORD C, 1990, NEW ENGL J MED, V322, P173, DOI 10.1056/NEJM199001183220306; Mcisaac SJ, 1997, EUR J PUBLIC HEALTH, V7, P45, DOI 10.1093/eurpub/7.1.45; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; SAPOLSKY RM, 1993, RECENT PROG HORM RES, V48, P437; SHIVELY CA, 1994, ARTERIOSCLER THROMB, V14, P721, DOI 10.1161/01.ATV.14.5.721; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; WILKINSON BG, 1996, UNHEALTHY SOC AFFLIC; WILKINSON BG, 1997, BRIT MED J, V314, P591; WILKINSON RG, IN PRESS AM J PUBLIC	13	48	48	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1727	1728		10.1136/bmj.314.7096.1727	http://dx.doi.org/10.1136/bmj.314.7096.1727			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9202502	Green Published			2022-12-28	WOS:A1997XE90900023
J	Kawata, T; Shevchenko, A; Fukuzawa, M; Jermyn, KA; Totty, NF; Zhukovskaya, NV; Sterling, AE; Mann, M; Williams, JG				Kawata, T; Shevchenko, A; Fukuzawa, M; Jermyn, KA; Totty, NF; Zhukovskaya, NV; Sterling, AE; Mann, M; Williams, JG			SH2 signaling in a lower eukaryote: A STAT protein that regulates stalk cell differentiation in Dictyostelium	CELL			English	Article							GENE-EXPRESSION; PRESTALK CELLS; DISCOIDEUM; KINASE; PRESPORE; CAMP; SPORE; MATURATION; MORPHOGEN; DNA	The TTGA-binding factor is a transcriptional regulator activated by DIF, the chlorinated hexaphenone that induces prestalk cell differentiation in Dictyostelium. The same activity also functions as a repressor, controlling stalk cell differentiation. We show that the TTGA-binding factor is a STAT protein. Like the metazoan STATs, it functions via the reciprocal interaction of a phosphotyrosine residue on one molecule with an SH2 domain on a dimerizing partner. Furthermore, it will bind specifically to a mammalian interferon-stimulated response element. In Saccharomyces cerevisiae, where the entire genomic sequence is known, SH2 domains have not been identified. It would seem, therefore, that SH2 signaling pathways arose very early in the evolution of multicellular organisms, perhaps to facilitate intercellular communication.	UCL, DEPT BIOL, LONDON WC1E 6BT, ENGLAND; EUROPEAN MOL BIOL LAB, PROT & PEPTIDE GRP, D-69117 HEIDELBERG, GERMANY; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	University of London; University College London; European Molecular Biology Laboratory (EMBL); Ludwig Institute for Cancer Research	Kawata, T (corresponding author), UCL, MRC, MOL CELL BIOL LAB, GOWER ST, LONDON WC1E 6BT, ENGLAND.		Mann, Matthias/A-3454-2013; Fukuzawa, Masashi/G-1726-2014	Mann, Matthias/0000-0003-1292-4799; Kawata, Takefumi/0000-0002-3685-4492	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adler K, 1996, FEBS LETT, V395, P286, DOI 10.1016/0014-5793(96)01053-8; Briscoe J, 1996, PHILOS T ROY SOC B, V351, P167, DOI 10.1098/rstb.1996.0013; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; Clarke M, 1995, EXPERIENTIA, V51, P1124, DOI 10.1007/BF01944730; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EARLY A, 1995, CELL, V83, P91, DOI 10.1016/0092-8674(95)90237-6; FUKUZAWA M, 1997, IN PRESS DEVELOPMENT, V124; Gamper M, 1996, MOL CELL BIOL, V16, P2431; HARWOOD AJ, 1993, DEVELOPMENT, V118, P1041; HARWOOD AJ, 1992, CELL, V69, P615, DOI 10.1016/0092-8674(92)90225-2; HOPPER NA, 1993, EMBO J, V12, P2459, DOI 10.1002/j.1460-2075.1993.tb05900.x; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; HOWARD PK, 1994, MOL CELL BIOL, V14, P5154, DOI 10.1128/MCB.14.8.5154; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; INOUYE K, 1993, DEVELOPMENT, V118, P523; INSALL R, 1990, EMBO J, V9, P3323, DOI 10.1002/j.1460-2075.1990.tb07532.x; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; JERMYN KA, 1987, DEVELOPMENT, V100, P745; Kawata T, 1996, EMBO J, V15, P3085, DOI 10.1002/j.1460-2075.1996.tb00671.x; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KAY RR, 1989, DEVELOPMENT, V105, P753; KIMMEL AR, 1985, MOL CELL BIOL, V5, P2123, DOI 10.1128/MCB.5.8.2123; KUBOHARA Y, 1993, EXP CELL RES, V207, P107, DOI 10.1006/excr.1993.1168; MAEDA M, 1988, DEV GROWTH DIFFER, V30, P573; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN SKO, 1993, DEVELOPMENT, V119, P135; MANN SKO, 1994, P NATL ACAD SCI USA, V91, P10561, DOI 10.1073/pnas.91.22.10561; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; Nuckolls GH, 1996, DEVELOPMENT, V122, P3295; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RICHARDSON DL, 1994, DEVELOPMENT, V120, P2891; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8	47	187	189	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 13	1997	89	6					909	916		10.1016/S0092-8674(00)80276-7	http://dx.doi.org/10.1016/S0092-8674(00)80276-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XE357	9200609	Bronze			2022-12-28	WOS:A1997XE35700011
J	Skuse, DH; James, RS; Bishop, DVM; Coppin, B; Dalton, P; AamodtLeeper, G; BacareseHamilton, M; Creswell, C; McGurk, R; Jacobs, PA				Skuse, DH; James, RS; Bishop, DVM; Coppin, B; Dalton, P; AamodtLeeper, G; BacareseHamilton, M; Creswell, C; McGurk, R; Jacobs, PA			Evidence from Turner's syndrome of an imprinted X-linked locus affecting cognitive function	NATURE			English	Article							BEHAVIOR PROBLEMS; INACTIVATION; DIAGNOSIS; MOUSE	Turner's syndrome is a sporadic disorder of human females in which all or part of one X chromosome is deleted(1). Intelligence is usually normal(2) but social adjustment problems are common(3). Here we report a study of 80 females with Turner's syndrome and a single X chromosome, in 55 of which the X was maternally derived (45,X-m) and in 25 it was of paternal origin (45,X-p). Members of the 45,XP group were significantly better adjusted, with superior verbal and higher-order executive function skills, which mediate social interactions(4). Our observations suggest that there is a genetic locus for social cognition, which is imprinted(5) and is not expressed from the maternally derived X chromosome. Neuropsychological and molecular investigations of eight females with partial deletions of the short arm of the X chromosome(6) indicate that the putative imprinted locus escapes inactivation(7), and probably lies on Xq or close to the centromere on Xp. If expressed only from the X chromosome of paternal origin, the existence of this locus could explain why 46,XY males (whose single X chromosome is maternal) are more vulnerable to developmental disorders of language and social cognition, such as autism, than are 46,XX females(8).	SALISBURY DIST HOSP,WESSEX REG GENET LAB,SALISBURY SP2 8BJ,WILTS,ENGLAND; MRC,APPL PSYCHOL UNIT,CAMBRIDGE CB2 2EF,ENGLAND; PRINCESS ANNE HOSP,WESSEX REG GENET SERV,SOUTHAMPTON SO16 5YA,HANTS,ENGLAND	Salisbury District Hospital; University of Cambridge	Skuse, DH (corresponding author), INST CHILD HLTH,BEHAV SCI UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.		Creswell, Cathy/L-9306-2013	Creswell, Cathy/0000-0003-1889-0956; Bishop, Dorothy/0000-0002-2448-4033	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Achenbach T. M., 1991, MANUAL SELF REPORT 1; Achenbach T.M., 1991, MANUAL TEACHERS REPO; ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; Bailey A, 1996, J CHILD PSYCHOL PSYC, V37, P89, DOI 10.1111/j.1469-7610.1996.tb01381.x; Ballabio Andrea, 1992, Human Molecular Genetics, V1, P221, DOI 10.1093/hmg/1.4.221; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; Bjorklund DF, 1996, PSYCHOL BULL, V120, P163, DOI 10.1037/0033-2909.120.2.163; BORYS SV, 1982, J EXP CHILD PSYCHOL, V33, P87, DOI 10.1016/0022-0965(82)90008-X; DAMASIO AR, 1995, P NY ACAD SCI, V769, P241; DISTECHE CM, 1995, TRENDS GENET, V11, P17, DOI 10.1016/S0168-9525(00)88981-7; EAGLY AH, 1995, AM PSYCHOL, V50, P145, DOI 10.1037/0003-066X.50.3.145; HASSOLD T, 1992, HUM GENET, V89, P647; JACOBS PA, 1990, ANN HUM GENET, V54, P209, DOI 10.1111/j.1469-1809.1990.tb00379.x; LEDBETTER DH, 1995, HUM MOL GENET, V4, P1757, DOI 10.1093/hmg/4.suppl_1.1757; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MANLY T, TEST EVERYDAY ATTENT; MCCAULEY E, 1987, CHILD DEV, V58, P464, DOI 10.2307/1130523; MCCAULEY E, 1986, J AM ACAD CHILD PSY, V25, P105, DOI 10.1016/S0002-7138(09)60606-3; PENNINGTON BF, 1985, CORTEX, V21, P391, DOI 10.1016/S0010-9452(85)80004-6; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; RABBITT PMA, IN PRESS METHODOLOGI; SAENGER P, 1993, J CLIN ENDOCR METAB, V77, P297, DOI 10.1210/jcem.77.2.8345029; SKUSE D, 1994, GROWTH STATURE ADAPT, P151; TEMPLE CM, 1995, CORTEX, V31, P109, DOI 10.1016/S0010-9452(13)80109-8; Wechsler D., 1986, WECHSLER ADULT INTEL; Wechsler D., 1992, WECHSLER INTELLIGENC; Wolff DJ, 1996, AM J HUM GENET, V58, P154; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; ZUCCOTTI M, 1995, NAT GENET, V9, P316, DOI 10.1038/ng0395-316	29	500	507	0	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 12	1997	387	6634					705	708		10.1038/42706	http://dx.doi.org/10.1038/42706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XD869	9192895	Bronze, Green Submitted			2022-12-28	WOS:A1997XD86900054
J	Mechanic, D				Mechanic, D			Managed care as a target of distrust	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NATIONAL-HEALTH-SERVICE				Mechanic, D (corresponding author), RUTGERS STATE UNIV, INST HLTH HLTH CARE POLICY & AGING RES, 30 COLL AVE, NEW BRUNSWICK, NJ 08903 USA.							Bodenheimer T, 1996, NEW ENGL J MED, V335, P1601, DOI 10.1056/NEJM199611213352112; Chassin MR, 1996, NEW ENGL J MED, V335, P1060, DOI 10.1056/NEJM199610033351413; Davis K, 1997, HEALTH SERV RES, V31, P641; FOOT M, 1973, ANEURIN BEVAN BIOGRA, V2, P195; KLEIN R, 1995, MILBANK Q, V73, P299, DOI 10.2307/3350370; Lawson N, 1993, VIEW NO 11 MEMOIRS T, P612; LUFT HS, 1987, HLTH MAINTENANCE ORG; MECHANIC D, 1995, BRIT MED J, V310, P1655, DOI 10.1136/bmj.310.6995.1655; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; MECHANIC D, 1995, MILBANK Q, V73, P19, DOI 10.2307/3350312; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Newhouse JP, 1993, FREE ALL LESSONS RAN; PURDY R, 1995, MANAGING CARE PUBLIC, P30; ROSENTHAL E, 1996, NY TIMES        0115, P1; SALTER B, 1993, POLICY POLIT, V21, P171, DOI 10.1332/030557393782331074; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027	16	39	39	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	1997	277	22					1810	1811						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XC499	9178798				2022-12-28	WOS:A1997XC49900038
J	Weatherall, DJ				Weatherall, DJ			Fortnightly review - The thalassaemias	BRITISH MEDICAL JOURNAL			English	Review							IRON-CHELATION-THERAPY; THALASSEMIA MAJOR; BETA-THALASSEMIA; DEFEROXAMINE				Weatherall, DJ (corresponding author), JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9DU,ENGLAND.							BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056/NEJM199409013310902; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002/ajh.2830420116; CAO A, 1993, BAILLIERE CLIN HAEM, V6, P263, DOI 10.1016/S0950-3536(05)80072-1; HIGGS DR, 1993, BAILLIERE CLIN HAEM, V6, P117, DOI 10.1016/S0950-3536(05)80068-X; HIGGS DR, 1993, HAEMOPGLOBINOPATHIES, V6; HOFFBRAND AV, 1996, HAEMATOLOGY 1996, P241; HUISMAN THJ, 1996, HAEMATOLOGY 1996, P233; LUCARELLI G, 1993, NEW ENGL J MED, V329, P840, DOI 10.1056/NEJM199309163291204; MODELL BMP, IN PRESS BMJ; Olivieri NF, 1997, BLOOD, V89, P739, DOI 10.1182/blood.V89.3.739; Olivieri NF, 1996, SEMIN HEMATOL, V33, P24; OLIVIERI NF, 1992, AM J PEDIAT HEMATOL, V14, P48; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; OLIVIERI NF, 1995, NEW ENGL J MED, V332, P918, DOI 10.1056/NEJM199504063321404; Porter J B, 1989, Baillieres Clin Haematol, V2, P459, DOI 10.1016/S0950-3536(89)80027-7; THEIN SL, 1993, BAILLIERE CLIN HAEM, V6, P151, DOI 10.1016/S0950-3536(05)80069-1; THEIN SL, 1996, HAEMATOLOGY 1996, P236; WASI P, 1996, HAEMATOLOGY 1996, P226; Weatherall D.J., 1981, THALASSAEMIA SYNDROM, V3rd ed.; WEATHERALL DJ, 1994, MOL BASIS BLOOD DIS, V2, P157; Weatherall DJ, 1996, NAT MED, V3, P47; WEATHERALL DJ, 1996, MOL MED TODAY, V1, P15; WEATHERALL DJ, IN PRESS ANTENATAL N; WEATHERALL DJ, 1996, HAEMATOLOGY 1996 ED, P11; WILLIAMS TI, IN PRESS NATURE; 1983, B WORLD HEALTH ORGAN, V61, P63	26	75	84	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 7	1997	314	7095					1675	1678		10.1136/bmj.314.7095.1675	http://dx.doi.org/10.1136/bmj.314.7095.1675			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD874	9193293	Green Published			2022-12-28	WOS:A1997XD87400030
J	Ikeda, S; Nasrallah, JB; Dixit, R; Preiss, S; Nasrallah, ME				Ikeda, S; Nasrallah, JB; Dixit, R; Preiss, S; Nasrallah, ME			An aquaporin-like gene required for the Brassica self-incompatibility response	SCIENCE			English	Article							RECEPTOR KINASE GENE; ARABIDOPSIS-THALIANA; WATER CHANNELS; PLASMA-MEMBRANE; POLLEN; PROTEIN; LOCUS; EXPRESSION; CLONING; CELLS	Self-incompatibility in Brassica refers to the rejection of self-related pollen and is mediated by a receptor protein kinase localized to the plasma membrane of the stigma epidermis in the flower. The recessive mutation mod eliminates self-incompatibility in the stigma. In mod mutants, self-compatibility was shown to be associated with the absence of transcripts encoded by an aquaporin-related gene. This observation suggests that a water channel is required for the self-incompatibility response of Brassica, which is consistent with the concept that regulation of water transfer from the stigma to pollen is a checkpoint in the early events of pollination in the crucifer family.	CORNELL UNIV, DIV BIOL SCI, ITHACA, NY 14853 USA	Cornell University								AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; Bower MS, 1996, PLANT CELL, V8, P1641, DOI 10.1105/tpc.8.9.1641; CHRISPEELS MJ, 1994, PLANT PHYSIOL, V105, P9, DOI 10.1104/pp.105.1.9; DANIELS MJ, 1994, PLANT PHYSIOL, V106, P1325, DOI 10.1104/pp.106.4.1325; de Nettancourt D., 1977, INCOMPATIBILITY ANGI; DICKINSON H, 1995, SEX PLANT REPROD, V8, P1, DOI 10.1007/BF00228756; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; HESLOPHARRISON J, 1979, AM J BOT, V66, P737, DOI 10.2307/2442418; HESLOPHARRISON J, 1975, ANNU REV PLANT PHYS, V26, P403, DOI 10.1146/annurev.pp.26.060175.002155; HOFTE H, 1992, PLANT PHYSIOL, V99, P561, DOI 10.1104/pp.99.2.561; HULSKAMP M, 1995, PLANT J, V8, P703, DOI 10.1046/j.1365-313X.1995.08050703.x; JOHNSON KD, 1990, PLANT CELL, V2, P525, DOI 10.1105/tpc.2.6.525; KAMMERLOHER W, 1994, PLANT J, V6, P187, DOI 10.1046/j.1365-313X.1994.6020187.x; KANDASAMY MK, 1989, DEV BIOL, V134, P462, DOI 10.1016/0012-1606(89)90119-X; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; KHO YO, 1968, EUPHYTICA, V17, P298; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MAUREL C, 1995, EMBO J, V14, P3028, DOI 10.1002/j.1460-2075.1995.tb07305.x; NASRALLAH JB, 1994, PLANT J, V5, P373, DOI 10.1111/j.1365-313X.1994.00373.x; NASRALLAH JB, 1994, SCIENCE, V266, P1505, DOI 10.1126/science.266.5190.1505; NASRALLAH ME, 1992, PLANT J, V2, P497, DOI 10.1111/j.1365-313X.1992.00497.x; NASRALLAH ME, UNPUB; NASRALLAH ME, 1989, PLANT REPRODUCTION F, V1, P146; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; Robinson DC, 1996, PLANT PHYSIOL, V111, P645, DOI 10.1104/pp.111.2.645; Stein JC, 1996, PLANT CELL, V8, P429, DOI 10.1105/tpc.8.3.429; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; YAMAGUCHISHINOZAKI K, 1992, PLANT CELL PHYSIOL, V33, P217, DOI 10.1093/oxfordjournals.pcp.a078243; [No title captured]	31	95	110	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 6	1997	276	5318					1564	1566		10.1126/science.276.5318.1564	http://dx.doi.org/10.1126/science.276.5318.1564			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171060				2022-12-28	WOS:A1997XC70100043
J	Elder, GH; Hift, RJ; Meissner, PN				Elder, GH; Hift, RJ; Meissner, PN			The acute porphyrias	LANCET			English	Article							ACUTE INTERMITTENT PORPHYRIA; ACUTE HEPATIC PORPHYRIA; PORPHOBILINOGEN DEAMINASE GENE; VARIEGATE PORPHYRIA; HEME ARGINATE; ATTACKS; FINLAND; ANESTHESIA; MUTATIONS; PATIENT		UNIV CAPE TOWN, DEPT MED, MRC UCT LIVER RES CTR, ZA-7925 CAPE TOWN, SOUTH AFRICA	South African Medical Research Council; University of Cape Town	Elder, GH (corresponding author), UNIV WALES COLL MED, DEPT BIOCHEM MED, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES.		Moore, Michael R/C-4163-2012	Moore, Michael R/0000-0002-7012-9534				ANDERSON KE, 1990, ARCH INTERN MED, V150, P1469, DOI 10.1001/archinte.150.7.1469; ANDERSON KE, 1995, HEPATOLOGY TXB LIVER, P417; Arnold WN, 1992, V VANGOGH CHEM CRISE; BENGTSSON NO, 1986, BRIT J CANCER, V54, P115, DOI 10.1038/bjc.1986.159; BONKOVSKY HL, 1993, GASTROENTEROLOGY, V105, P590, DOI 10.1016/0016-5085(93)90739-Y; Bont A, 1996, SCHWEIZ MED WSCHR, V126, P6; BRODIE MJ, 1977, CLIN SCI MOL MED, V53, P365, DOI 10.1042/cs0530365; BROWNLIE PD, 1994, PROTEIN SCI, V3, P1644, DOI 10.1002/pro.5560031004; BUTTERY JE, 1995, CLIN CHEM, V41, P1670; CHEN CH, 1994, J CLIN INVEST, V94, P1927, DOI 10.1172/JCI117543; CHURCH SE, 1992, NEPHROL DIAL TRANSPL, V7, P986; Dean G., 1971, PORPHYRIAS STORY INH, V2nd, P1; DEYBACH JC, 1995, J BIOENERG BIOMEMBR, V27, P197, DOI 10.1007/BF02110034; Disler P B, 1985, Clin Dermatol, V3, P112, DOI 10.1016/0738-081X(85)90037-9; DOVER SB, 1993, GASTROENTEROLOGY, V105, P500, DOI 10.1016/0016-5085(93)90726-S; DOVER SB, 1994, GUT, V35, P1112, DOI 10.1136/gut.35.8.1112; EALES L, 1980, INT J BIOCHEM, V12, P837; ELDER GH, 1990, ANN CLIN BIOCHEM, V27, P395, DOI 10.1177/000456329002700501; ELDER GH, 1993, J CLIN PATHOL, V46, P977, DOI 10.1136/jcp.46.11.977; GOLDBERG A, 1959, Q J MED, V28, P183; GRANDCHAMP B, 1995, J BIOENERG BIOMEMBR, V27, P215, DOI 10.1007/BF02110036; HARRISON GG, 1993, ANAESTHESIA, V48, P417, DOI 10.1111/j.1365-2044.1993.tb07018.x; HERRICK AL, 1989, LANCET, V1, P1295; HIFT RJ, 1993, POSTGRAD MED J, V69, P781, DOI 10.1136/pgmj.69.816.781; Jenkins T, 1996, NAT GENET, V13, P7, DOI 10.1038/ng0596-7; KAPPAS A, 1989, METABOLIC BASIS INHE, P1305; KAUPPINEN R, 1992, MEDICINE, V71, P1; KAUPPINEN R, 1995, HUM MOL GENET, V4, P215, DOI 10.1093/hmg/4.2.215; Lindberg RLP, 1996, NAT GENET, V12, P195, DOI 10.1038/ng0296-195; LIP GYH, 1991, BRIT MED J, V302, P507, DOI 10.1136/bmj.302.6775.507; LITMAN DA, 1983, SCIENCE, V222, P1031, DOI 10.1126/science.6648517; LLEWELLYN DH, 1992, HUM GENET, V89, P97, DOI 10.1007/BF00207051; Macalpine Ida, 1969, GEORGE 3 MAD BUSINES, P3; MCCOLL KEL, 1985, LANCET, V2, P796; Meissner PN, 1996, NAT GENET, V13, P95, DOI 10.1038/ng0596-95; MEISSNER PN, 1995, DIAGNOSIS MANAGEMENT, P225; Moore M. R., 1987, DISORDERS PORPHYRIN; MUSTAJOKI P, 1992, J INTERN MED, V231, P389, DOI 10.1111/j.1365-2796.1992.tb00949.x; MUSTAJOKI P, 1976, ACTA MED SCAND, V200, P171; Mustajoki Pertti, 1993, Archives of Internal Medicine, V153, P2004, DOI 10.1001/archinte.153.17.2004; PATIENCE DA, 1994, ACTA PSYCHIAT SCAND, V89, P262, DOI 10.1111/j.1600-0447.1994.tb01511.x; POHFITZPATRICK MB, 1980, ARCH DERMATOL, V116, P543, DOI 10.1001/archderm.116.5.543; Puy H, 1996, J CLIN INVEST, V97, P104, DOI 10.1172/JCI118376; PUY H, IN PRESS AM J HUM GE; ROBERT TL, 1994, NUTRITION, V10, P551; Sassa S, 1996, BLOOD REV, V10, P53, DOI 10.1016/S0268-960X(96)90020-X; STEIN JA, 1970, MEDICINE, V49, P1, DOI 10.1097/00005792-197001000-00001; TISHLER PV, 1985, AM J PSYCHIAT, V142, P1430; WALDENSTROM J, 1957, AM J MED, V22, P758, DOI 10.1016/0002-9343(57)90126-2; Warren MJ, 1996, TRENDS BIOCHEM SCI, V21, P229; WHATLEY SD, 1995, LANCET, V346, P1007, DOI 10.1016/S0140-6736(95)91692-X; WOOD S, 1995, MOL MED TODAY, V1, P232, DOI 10.1016/S1357-4310(95)91513-3; XU W, 1995, PEDIATR RES, V37, pA155	53	113	119	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 31	1997	349	9065					1613	1617		10.1016/S0140-6736(96)09070-8	http://dx.doi.org/10.1016/S0140-6736(96)09070-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174571				2022-12-28	WOS:A1997XB67300043
J	Perez, V; Gilaberte, I; Faries, D; Alvarez, E; Artigas, F				Perez, V; Gilaberte, I; Faries, D; Alvarez, E; Artigas, F			Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment	LANCET			English	Article							SEROTONIN REUPTAKE INHIBITORS; MAJOR DEPRESSION; DRUGS; BRAIN; MICRODIALYSIS; IMPROVEMENT; RECEPTORS; BINDING; ONSET; LONG	Background Major depression affects more than 5% of the population and is a serious health and economic problem. Antidepressants have a slow onset of action and are effective in less than two-thirds of patients. The biochemical effects of selective serotonin reuptake inhibitors may be limited by the negative feedback from serotonin autoreceptors. Pindolol is an antagonist of both serotonin autoreceptors and beta-adrenoceptors, We studied the effect of the addition of pindolol to fluoxetine antidepressant treatment. Methods Of 132 eligible patients with major depression, 111 were randomly assigned to treatment with fluoxetine (20 mg daily) and either placebo or pindolol (7.5 mg daily). Patients were assessed twice a week for the first 3 weeks of active treatment and then once a week until the end of the study (42 days). Hamilton and Montgomery-Asberg depression-rating scales were used to assess depression severity. Findings The proportion of patients who responded to treatment with fluoxetine and pindolol was greater than that with fluoxetine and placebo (41/55 [75%] vs 33/56 [59%], [90% CI 1.1-30.1], p=0.04). The proportion of patients who achieved a sustained response was also greater in the fluoxetine and pindolol group than in the fluoxetine and placebo group (38/55 [69%] vs 27/56 [48%] [5.9-35.9], p=0.03). The number of days to reach a sustained response was lower in the fluoxetine and pindolol group than in the fluoxetine and placebo group (median 19 vs 29 days, p=0.01), however, there was no difference in the time-to onset of clinical improvement when stringent conditions were used (15 vs 18 days, p=0.20). Interpretation The addition of pindolol to fluoxetine antidepressant treatment increases the effectiveness of fluoxetine therapy. Further work is needed to resolve whether the time to clinical improvement benefits from this combination and whether the increase in efficacy occurs with other antidepressants.	CONSEJO SUPER INVEST CIENT,DEPT NEUROCHEM,BARCELONA,SPAIN; HOSP SANTA CRUZ & SAN PABLO,SERV PSIQUIATRIA,BARCELONA,SPAIN; LILLY SPAIN,MADRID,SPAIN; LILLY USA,INDIANAPOLIS,IN	Consejo Superior de Investigaciones Cientificas (CSIC); Lilly USA LLC			Artigas, Francesc/G-8500-2013	Artigas, Francesc/0000-0002-5880-5720; Perez, Victor/0000-0002-5825-2337; Alvarez Martinez, Enric/0000-0002-5180-5541				ADELL A, 1991, N-S ARCH PHARMACOL, V343, P237; [Anonymous], 1993, MARTINDALE EXTRA PHA; ARTIGAS F, 1994, ARCH GEN PSYCHIAT, V51, P248; ARTIGAS F, 1993, TRENDS PHARMACOL SCI, V14, P262, DOI 10.1016/0165-6147(93)90125-4; AVORN J, 1986, JAMA-J AM MED ASSOC, V255, P357, DOI 10.1001/jama.255.3.357; Bailly D, 1996, CNS DRUGS, V5, P115, DOI 10.2165/00023210-199605020-00004; Bel N, 1996, J NEUROCHEM, V67, P669; BLIER P, 1995, J CLIN PSYCHOPHARM, V15, P217, DOI 10.1097/00004714-199506000-00011; BROWNER WS, 1988, DESIGNING CLIN RES, P128; CUSACK B, 1994, PSYCHOPHARMACOLOGY, V114, P559, DOI 10.1007/BF02244985; DELGADO PL, 1990, ARCH GEN PSYCHIAT, V47, P411; Dreshfield LJ, 1996, NEUROCHEM RES, V21, P557, DOI 10.1007/BF02527753; HYTTEL J, 1994, INT CLIN PSYCHOPHARM, V9, P19, DOI 10.1097/00004850-199403001-00004; Judd LL, 1995, INT CLIN PSYCHOPHARM, V10, P5, DOI 10.1097/00004850-199512004-00002; KOCH CG, 1991, J BIOPHARM STAT, V1, P161; LASKA EM, 1995, PSYCHOPHARMACOL BULL, V31, P29; Lee E.T., 1992, STATISTICAL METHODS; MONTGOMERY SA, 1995, PSYCHOPHARMACOL BULL, V31, P41; NORMAN TR, 1994, CNS DRUGS, V2, P120, DOI 10.2165/00023210-199402020-00005; OVERALL JE, 1995, PSYCHOPHARMACOL BULL, V31, P45; PALVIMAKI EP, 1994, PSYCHOPHARMACOLOGY, V115, P543, DOI 10.1007/BF02245579; PEACE KE, 1989, J CLIN EPIDEMIOL, V42, P472; PEROUTKA SJ, 1980, SCIENCE, V210, P88, DOI 10.1126/science.6251550; Romero L, 1996, NEUROPSYCHOPHARMACOL, V15, P349, DOI 10.1016/0893-133X(95)00240-E; ROTHSCHILD R, 1992, PSYCHOTHER PSYCHOSOM, V58, P170, DOI 10.1159/000288625; RUDORFER MV, 1989, DRUGS, V37, P713, DOI 10.2165/00003495-198937050-00006; Stassen H H, 1993, Eur Neuropsychopharmacol, V3, P127, DOI 10.1016/0924-977X(93)90264-M; TOLLEFSON GD, 1994, INT CLIN PSYCHOPHARM, V9, P245, DOI 10.1097/00004850-199400940-00003; TOLLEFSON GD, 1994, J CLIN PSYCHIAT, V55, P50	29	283	295	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 31	1997	349	9065					1594	1597		10.1016/S0140-6736(96)08007-5	http://dx.doi.org/10.1016/S0140-6736(96)08007-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174562				2022-12-28	WOS:A1997XB67300011
J	Petersen, JS; Kyvik, KO; Bingley, PJ; Gale, EAM; Green, A; Dyrberg, T; BeckNielsen, H				Petersen, JS; Kyvik, KO; Bingley, PJ; Gale, EAM; Green, A; Dyrberg, T; BeckNielsen, H			Population based study of prevalence of islet cell autoantibodies in monozygotic and dizygotic Danish twin pairs with insulin dependent diabetes mellitus	BRITISH MEDICAL JOURNAL			English	Article							GLUTAMIC-ACID DECARBOXYLASE; FIRST-DEGREE RELATIVES; COWS MILK; IDDM; ANTIBODIES; RISK; CONCORDANCE; INFECTION; EXPOSURE; RATES	Objective: To study the comparative importance of environment and genes in the development of islet cell autoimmunity associated with insulin dependent diabetes mellitus. Design: Population based study of diabetic twins. Setting: Danish population. Subjects: 18 monozygotic and 36 dizygotic twin pairs with one or both partners having insulin dependent diabetes. Main outcome measures: Presence of islet cell antibodies, insulin autoantibodies, and autoantibodies to glutamic acid decarboxylase (GAD65) in serum samples from twin pairs 10 years (range 0-30 years) and 9.5 years (2-30 years) after onset of disease. Results: In those with diabetes the prevalence of islet cell antibodies, insulin autoantibodies, and autoantibodies to glutamic acid decarboxylase in the 26 monozygotic twins was 38%, 85%, and 92%, respectively, and in the dizygotic twins was 57%, 70%, and 57%, respectively. Ln those without diabetes the proportions were 20%, 50%, and 40% in the 10 monozygotic twins and 26%, 49%, and 40% in the 35 dizygotic twins. Conclusion: There is no difference between the prevalence of islet cell autoantibodies in dizygotic and monozygotic twins without diabetes, suggesting that islet cell autoimmunity is environmentally rather than genetically determined. Furthermore, the prevalence of islet cell antibodies was higher in the non-diabetic twins than in other first degree relatives of patients with insulin dependent diabetes. This implies that the prenatal or early postnatal period during which twins are exposed to the same environment, in contrast with that experienced by first degree relatives, is of aetiological importance.	HAGEDORN RES INST,DK-2820 GENTOFTE,DENMARK; NOVO NORDISK AS,DK-2880 BAGSVAERD,DENMARK; ODENSE UNIV,GENET EPIDEMIOL RES UNIT,INST COMMUNITY HLTH,DK-5000 ODENSE,DENMARK; ODENSE UNIV HOSP,DEPT ENDOCRINOL,CLIN RES INST,DK-5000 ODENSE,DENMARK; ST BARTHOLOMEWS HOSP,LONDON EC1A 7AB,ENGLAND	Novo Nordisk; Hagedorn Research Institute; Novo Nordisk; University of Southern Denmark; University of Southern Denmark; Odense University Hospital; University of London; Queen Mary University London			Kyvik, Kirsten Ohm/K-5680-2016	Kyvik, Kirsten Ohm/0000-0003-2981-0245				BINGLEY PJ, 1994, DIABETES, V43, P1304, DOI 10.2337/diabetes.43.11.1304; BOTTAZZO GF, 1986, DIABETOLOGIA, V29, P125, DOI 10.1007/BF00456124; DAHLQUIST GG, 1995, DIABETES, V44, P408, DOI 10.2337/diabetes.44.4.408; Gamble D R, 1980, Epidemiol Rev, V2, P49; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; GRUBIN CE, 1994, DIABETOLOGIA, V37, P344, DOI 10.1007/BF00408469; HAGOPIAN WA, 1993, J CLIN INVEST, V91, P368, DOI 10.1172/JCI116195; HAGOPIAN WA, 1995, J CLIN INVEST, V95, P1501; Hauge M, 1981, PROSPECTIVE LONGITUD, P217; KAPRIO J, 1992, DIABETOLOGIA, V35, P1060, DOI 10.1007/BF02221682; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; KARLSEN AE, 1992, DIABETES, V41, P1355, DOI 10.2337/diabetes.41.10.1355; KARLSEN AE, 1991, P NATL ACAD SCI USA, V88, P8337, DOI 10.1073/pnas.88.19.8337; KOSTRABA JN, 1993, DIABETES, V42, P288, DOI 10.2337/diabetes.42.2.288; KRISCHER JP, 1993, J CLIN ENDOCR METAB, V77, P743, DOI 10.1210/jc.77.3.743; KULMALA P, 1995, AUTOIMMUNITY, V21, P26; KUMAR D, 1993, DIABETES, V42, P1352; KYVIK KO, 1995, INT J EPIDEMIOL, V24, P589, DOI 10.1093/ije/24.3.589; KYVIK KO, 1995, BRIT MED J, V311, P913; LESLIE RDG, 1994, DIABETES, V43, P843, DOI 10.2337/diabetes.43.7.843; LORENZEN T, 1994, DIABETOLOGIA, V37, P321, DOI 10.1007/BF00398061; MENSER MA, 1978, LANCET, V1, P57; PETERSEN JS, 1994, DIABETES, V43, P459, DOI 10.2337/diabetes.43.3.459; RILEY WJ, 1990, NEW ENGL J MED, V323, P1167, DOI 10.1056/NEJM199010253231704; ROLL U, 1994, DIABETES, V43, P154, DOI 10.2337/diabetes.43.1.154; SOOTHILL JF, 1993, PAEDIAT IMMUNOLOGY; VERGE CF, 1995, DIABETES, V44, P1176, DOI 10.2337/diabetes.44.10.1176; WAGENKNECHT LE, 1991, AM J EPIDEMIOL, V133, P1024, DOI 10.1093/oxfordjournals.aje.a115811; WARD KP, 1979, LANCET, V1, P479	29	34	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 31	1997	314	7094					1575	1579		10.1136/bmj.314.7094.1575	http://dx.doi.org/10.1136/bmj.314.7094.1575			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC500	9169400	Green Published			2022-12-28	WOS:A1997XC50000017
J	Mundlos, S; Otto, F; Mundlos, C; Mulliken, JB; Aylsworth, AS; Albright, S; Lindhout, D; Cole, WG; Henn, W; Knoll, JHM; Owen, MJ; Mertelsmann, R; Zabel, BU; Olsen, BR				Mundlos, S; Otto, F; Mundlos, C; Mulliken, JB; Aylsworth, AS; Albright, S; Lindhout, D; Cole, WG; Henn, W; Knoll, JHM; Owen, MJ; Mertelsmann, R; Zabel, BU; Olsen, BR			Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia	CELL			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; ACUTE MYELOID-LEUKEMIA; AML1 GENE; DROSOPHILA; FAMILY; PROTEIN; CHROMOSOME-6; MICE; PCR	Cleidocranial dysplasia (CCD) is an autosomal-dominant condition characterized by hypoplasia/aplasia of clavicles, patent fontanelles, supernumerary teeth, short stature, and other changes in skeletal patterning and growth. In some families, the phenotype segregates with deletions resulting in heterozygous loss of CBFA1, a member of the runt family of transcription factors. In other families, insertion, deletion, and missense mutations lead to translational stop codons in the DNA binding domain or in the C-terminal transactivating region. In-frame expansion of a polyalanine stretch segregates in an affected family with brachydactyly and minor clinical findings of CCD. We conclude that CBFA1 mutations cause CCD and that heterozygous loss of function is sufficient to produce the disorder.	HARVARD UNIV,SCH MED,CHILDRENS HOSP,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHILDRENS HOSP,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BETH ISRAEL DEACONESS MED CTR,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHILDRENS HOSP,DIV PLAST SURG,BOSTON,MA 02115; HARVARD UNIV,SCH DENT MED,HARVARD FORSYTH DEPT ORAL BIOL,BOSTON,MA 02115; KLINIKUM ALBERT LUDWIGS UNIV,HAMATOL ONKOL ABT,D-79108 FREIBURG,GERMANY; UNIV N CAROLINA,DEPT GENET,DIV GENET & METAB,CHAPEL HILL,NC 27599; ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,MGC,NL-3000 DR ROTTERDAM,NETHERLANDS; HOSP SICK CHILDREN,DIV ORTHOPAED,TORONTO,ON M5G 1X8,CANADA; UNIV SAARLAND,INST HUMANGENET,HOMBURG,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard School of Dental Medicine; University of Freiburg; University of North Carolina; University of North Carolina Chapel Hill; Erasmus University Rotterdam; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Saarland University; Cancer Research UK	Mundlos, S (corresponding author), KLINIKUM JOHANNES GUTENBERG UNIV,KINDERKLIN,D-55101 MAINZ,GERMANY.		Henn, Wolfram/AAU-1608-2020; Mundlos, Stefan/ABH-9585-2020; Lindhout, Dick/AAH-5765-2019	Knoll, Joan/0000-0001-6691-1710; Lindhout, Dick/0000-0001-9580-624X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD018658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036819, R01AR036819] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35820, AR 36819] Funding Source: Medline; NICHD NIH HHS [HD 18658] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BALDINI A, 1992, GENOMICS, V14, P181, DOI 10.1016/S0888-7543(05)80303-9; BIRREN B, 1993, PULSED FIELD GEL ELE, P49; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Jones K. L., 1997, SMITHS RECOGNIZABLE; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KNOLL JHM, 1994, CURRENT PROTOCOLS HU; KWIATKOWSKI TJ, 1991, GENOMICS, V10, P921, DOI 10.1016/0888-7543(91)90180-M; LEDLEY FD, 1988, AM J HUM GENET, V42, P839; LEHRACH H., 1990, GENOME ANAL, P39; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Mortlock DP, 1996, NAT GENET, V13, P284, DOI 10.1038/ng0796-284; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; MUNDLOS S, 1995, HUM MOL GENET, V4, P71, DOI 10.1093/hmg/4.1.71; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; NIENHAUS H, 1993, AM J MED GENET, V46, P630, DOI 10.1002/ajmg.1320460605; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; SELBY PB, 1978, MUTAT RES, V51, P199, DOI 10.1016/S0027-5107(78)80019-0; SILLENCE DO, 1987, AM J MED GENET, V27, P75, DOI 10.1002/ajmg.1320270109; Tagle Danilo A., 1992, Human Molecular Genetics, V1, P121, DOI 10.1093/hmg/1.2.121; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444	30	1201	1267	0	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					773	779		10.1016/S0092-8674(00)80260-3	http://dx.doi.org/10.1016/S0092-8674(00)80260-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182765	Green Published, Bronze			2022-12-28	WOS:A1997XB92500014
J	Nomoto, K; Iwamoto, K; Kishimoto, N				Nomoto, K; Iwamoto, K; Kishimoto, N			Type Ia supernovae: Their origin and possible applications in cosmology	SCIENCE			English	Article							WHITE-DWARF MODELS; EXPLOSIVE NUCLEOSYNTHESIS; DETONATION MODELS; EVOLUTION; SN-1991T; SEQUENCE; CONSTANT; LMC	Spectroscopic and photometric evidence indicates that Type la supernovae (SNe Ia) are the thermonuclear explosions of accreting white dwarfs. However, the progenitor binary systems and hydrodynamical models for SNe Ia are still controversial, The relatively uniform light curves and spectral evolution of SNe Ia have led to their use as a standard candle for determining cosmological parameters, such as the Hubble constant, the density parameter, and the cosmological constant, Recent progress includes the calibration of the absolute maximum brightness of SNe Ia with the Hubble Space Telescope, the reduction of the dispersion in the Hubble diagram through the use of the relation between the light curve shape and the maximum brightness of SNe Ia, and the discovery of many SNe Ia with high red shifts.			Nomoto, K (corresponding author), UNIV TOKYO, DEPT ASTRON, BUNKYO KU, 7-3-1 HONGO, TOKYO 113, JAPAN.							Arnett W. D., 1996, NUCLEOSYNTHESIS SUPE; ARNETT WD, 1985, NATURE, V314, P337, DOI 10.1038/314337a0; ARNETT WD, 1994, APJ, V427, P314; BRANCH D, 1992, ANNU REV ASTRON ASTR, V30, P359; Branch D, 1997, NATO ADV SCI I C-MAT, V486, P715; Branch D., 1991, Comments on Astrophysics. Comments on Modern Physics: Part C, V15, P221; BRANCH D, 1995, PASP, V107, P717; Canal R, 1996, ASTROPHYS J, V456, pL101, DOI 10.1086/309869; FILIPPENKO AV, IN PRESS ANN REV AST; FISHER A, 1995, ASTROPHYS J, V447, pL73; Hachisu I, 1996, ASTROPHYS J, V470, pL97, DOI 10.1086/310303; HAMUY M, 1995, ASTRON J, V109, P1, DOI 10.1086/117251; HASHIMOTO M, 1989, ASTRON ASTROPHYS, V210, pL5; HASHIMOTO MA, 1986, ASTROPHYS J, V307, P687, DOI 10.1086/164453; Hoflich P, 1996, ASTROPHYS J, V472, pL81, DOI 10.1086/310363; Hoflich P, 1996, ASTROPHYS J, V457, P500, DOI 10.1086/176748; IBEN I, 1984, ASTROPHYS J SUPPL S, V54, P335, DOI 10.1086/190932; JEFFERY DJ, 1992, ASTROPHYS J, V397, P304, DOI 10.1086/171787; KHOKHLOV AM, 1991, ASTRON ASTROPHYS, V245, P114; KHOKHLOV AM, 1991, ASTRON ASTROPHYS, V245, pL25; LIVNE E, 1990, ASTROPHYS J, V354, pL53, DOI 10.1086/185721; MAZZALI PA, 1995, ASTRON ASTROPHYS, V297, P509; Meikle WPS, 1996, MON NOT R ASTRON SOC, V281, P263, DOI 10.1093/mnras/281.1.263; Niemeyer JC, 1997, ASTROPHYS J, V475, P740, DOI 10.1086/303544; NIGENT P, IN PRESS ASTROPHYS J; NOMOTO K, 1991, ASTROPHYS J, V367, pL19, DOI 10.1086/185922; NOMOTO K, 1982, ASTROPHYS J, V253, P798, DOI 10.1086/159682; NOMOTO K, 1984, ASTROPHYS J, V286, P644, DOI 10.1086/162639; Nomoto K, 1997, NATO ADV SCI I C-MAT, V486, P349; NOMOTO K, 1994, SUPERNOVAE, P199; NOMOTO KI, 1982, ASTROPHYS J, V257, P780, DOI 10.1086/160031; NUGENT P, 1995, ASTROPHYS J, V455, pL147, DOI 10.1086/309846; PERLMUTTER S, 1997, 6596 IAU; PERLMUTTER S, IN PRESS ASTROPHYS J; RAPPAPORT S, 1994, ASTROPHYS J, V426, P692, DOI 10.1086/174106; Renzini A, 1996, IAU COLLOQ, V145, P77, DOI 10.1017/S0252921100007934; RIESS AG, 1995, ASTROPHYS J, V438, pL17, DOI 10.1086/187704; Riess AG, 1996, ASTROPHYS J, V473, P88, DOI 10.1086/178129; RUIZLAPUENTE P, 1993, NATURE, V365, P728, DOI 10.1038/365728a0; RUIZLAPUENTE P, 1995, ASTROPHYS J, V447, pL69, DOI 10.1086/309564; RuizLapuente P, 1996, ASTROPHYS J, V465, pL83, DOI 10.1086/310155; RUIZLAPUENTE P, 1997, THERMONUCLEAR SUPERN; SAHA A, IN PRESS ASTROPHYS J; Sandage A, 1996, ASTROPHYS J, V460, pL15, DOI 10.1086/309973; Schaefer BE, 1996, ASTROPHYS J, V460, pL19, DOI 10.1086/309963; SCHMIDT BP, 1997, 6602 IAU; SHIGEYAMA T, 1992, ASTROPHYS J, V386, pL13, DOI 10.1086/186281; Thielemann FK, 1996, ASTROPHYS J, V460, P408, DOI 10.1086/176980; THIELEMANN FK, 1986, ASTRON ASTROPHYS, V158, P17; TSUJIMOTO T, 1995, MON NOT R ASTRON SOC, V277, P945, DOI 10.1093/mnras/277.3.945; TURATTO M, 1997, MON NOT R ASTRON SOC, V283, P1; VANDENHEUVEL EPJ, 1992, ASTRON ASTROPHYS, V262, P97; WEBBINK RF, 1984, ASTROPHYS J, V277, P355, DOI 10.1086/161701; WHEELER JC, 1990, REP PROG PHYS, V53, P1467, DOI 10.1088/0034-4885/53/12/001; WOOSLEY SE, 1995, ASTROPHYS J SUPPL S, V101, P181, DOI 10.1086/192237; WOOSLEY SE, 1994, ASTROPHYS J, V423, P371, DOI 10.1086/173813; WOOSLEY SE, 1990, SUPERNOVAE, P182; WOOSLEY SE, 1994, SUPERNOVAE, P63; YAMAOKA H, 1992, ASTROPHYS J, V393, pL55, DOI 10.1086/186450; Yoshii Y, 1996, ASTROPHYS J, V462, P266, DOI 10.1086/177147	64	152	159	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 30	1997	276	5317					1378	1382		10.1126/science.276.5317.1378	http://dx.doi.org/10.1126/science.276.5317.1378			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB533	9190677	Green Submitted			2022-12-28	WOS:A1997XB53300039
J	Cook, SP; Vulchanova, L; Hargreaves, KM; Elde, R; McCleskey, EW				Cook, SP; Vulchanova, L; Hargreaves, KM; Elde, R; McCleskey, EW			Distinct ATP receptors on pain-sensing and stretch-sensing neurons	NATURE			English	Article							SENSORY NEURONS; EXTRACELLULAR ATP; NERVE ACTIVITY; CHANNELS; RAT; CAT	The initial pain from tissue damage may result from the release of cytoplasmic components that act upon nociceptors, the sensors for pain. ATP was proposed to fill this role(1,2) because it elicits pain when applied intradermally(3) and may be the active compound in cytoplasmic fractions that cause pain(4). Moreover, ATP opens ligand-gated ion channels (P2X receptors) in sensory neurons(5,6,7) and only sensory neurons express messenger RNA for the P2X3 receptor(8,9). To test whether ATP contributes to nociception, we developed a tissue culture system that allows comparison of nociceptive (tooth-pulp afferent) and non-nociceptive (muscle-stretch receptor) rat sensory neurons. Low concentrations of ATP evoked action potentials and large inward currents in both types of neuron. Nociceptors had currents that were similar to those of heterologously expressed channels containing P2X3 subunits, and had P2X3 immunoreactivity in their sensory endings and cell bodies. Stretch receptors had currents that differed from those of P2X3 channels, and had no P2X3 immunoreactivity. These results support the theory that P2X3 receptors mediate a form of nociception, but also suggest non-nociceptive roles for ATP in sensory neurons.	UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	Cook, SP (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST L474,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.		Hargreaves, Kenneth M/F-5308-2010	Vulchanova, Lucy/0000-0002-6577-4467				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; AHLQUIST ML, 1985, ADV PAIN RES THER, V9, P351; AHLQUIST ML, 1984, PAIN, V19, P353, DOI 10.1016/0304-3959(84)90081-2; ANDERSON DJ, 1967, ARCH ORAL BIOL, V12, P417, DOI 10.1016/0003-9969(67)90227-0; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; BEAN BP, 1990, J NEUROSCI, V10, P1; BLEEHEN T, 1976, J PHYSIOL-LONDON, V262, P131, DOI 10.1113/jphysiol.1976.sp011589; BLEEHEN T, 1977, PAIN, V3, P367, DOI 10.1016/0304-3959(77)90066-5; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Burnstock G, 1996, LANCET, V347, P1604, DOI 10.1016/S0140-6736(96)91082-X; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; CODY FWJ, 1972, J PHYSIOL-LONDON, V226, P249, DOI 10.1113/jphysiol.1972.sp009983; Collo G, 1996, J NEUROSCI, V16, P2495; CORBIN KB, 1940, J NEUROPHYSIOL, V3, P425; EDWALL L, 1977, PAIN, V3, P121, DOI 10.1016/0304-3959(77)90075-6; HOLTON P, 1959, J PHYSIOL-LONDON, V145, P494, DOI 10.1113/jphysiol.1959.sp006157; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; JYVASJARVI E, 1987, J PHYSIOL-LONDON, V391, P193, DOI 10.1113/jphysiol.1987.sp016733; KENNEDY C, 1995, NATURE, V377, P285; KHAHK BS, 1997, J PHYSL, V498, P709; KRISHTAL OA, 1988, NEUROSCIENCE, V27, P995, DOI 10.1016/0306-4522(88)90203-5; Lawson SN., 1992, SENSORY NEURONS DIVE, P27; LESTER RAJ, 1993, J NEUROSCI, V13, P1088; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Nakamura F, 1996, P NATL ACAD SCI USA, V93, P10465, DOI 10.1073/pnas.93.19.10465; NARHI M, 1994, ARCH ORAL BIOL, V39, pA23; PHILLIS JW, 1978, GEN PHARMACOL, V9, P239, DOI 10.1016/0306-3623(78)90043-5; TADDESE A, 1995, SCIENCE, V270, P1366, DOI 10.1126/science.270.5240.1366; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; WILLIS WD, 1978, SENSORY MECHANISMS S, P1	31	392	400	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632					505	508		10.1038/387505a0	http://dx.doi.org/10.1038/387505a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB479	9168113				2022-12-28	WOS:A1997XB47900049
J	Mewes, HW; Albermann, K; Bahr, M; Frishman, D; Gleissner, A; Hani, J; Heumann, K; Kleine, K; Maierl, A; Oliver, SG; Pfeiffer, F; Zollner, A				Mewes, HW; Albermann, K; Bahr, M; Frishman, D; Gleissner, A; Hani, J; Heumann, K; Kleine, K; Maierl, A; Oliver, SG; Pfeiffer, F; Zollner, A			Overview of the yeast genome	NATURE			English	Editorial Material							CHROMOSOME-III	The collaboration of more than 600 scientists from over 100 laboratories to sequence the Saccharomyces cerevisiae genome was the largest decentralised experiment in modern molecular biology and resulted in a unique data resource representing the first complete set of genes from a eukaryotic organism, 12 million bases were sequenced in a truly international effort involving European, US, Canadian and Japanese laboratories. While the yeast genome represents only a small fraction of the information in today's pubic sequence databases, the complete, ordered and non-redundant sequence provides an invaluable resource for the detailed analysis of cellular gene function and genome architecture. In terms of throughput, completeness and information content, yeast has always been the lead eukaryotic organism in genomics; it is still the largest genome to be completely sequenced.	UNIV MANCHESTER,INST SCI & TECHNOL,MANCHESTER M60 1QD,LANCS,ENGLAND	University of Manchester	Mewes, HW (corresponding author), MAX PLANCK INST BIOCHEM,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Frishman, Dmitrij/AAT-7815-2020; Mewes, Hans-Werner/A-8204-2019	Mewes, Hans-Werner/0000-0002-9713-6398; Pfeiffer, Friedhelm/0000-0003-4691-3246				Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BORK P, 1992, PROTEIN SCI, V1, P1677, DOI 10.1002/pro.5560011216; CASARI G, 1995, NATURE, V376, P647, DOI 10.1038/376647a0; DAYHOFF MO, 1976, FED PROC, V35, P2132; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HEUMANN K, 1996, P 4 INT C INT SYST M, P98; KOONIN EV, 1994, EMBO J, V13, P493, DOI 10.1002/j.1460-2075.1994.tb06287.x; Oliver S, 1996, TRENDS GENET, V12, P241, DOI 10.1016/0168-9525(96)30053-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993	10	436	454	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 29	1997	387	6632		S			7	8		10.1038/387s007	http://dx.doi.org/10.1038/387s007			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169865	Bronze			2022-12-28	WOS:A1997XB54600002
J	Brooke, H; Gibson, A; Tappin, D; Brown, H				Brooke, H; Gibson, A; Tappin, D; Brown, H			Case-control study of sudden infant death syndrome in Scotland, 1992-5	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMOKING; SIDS	Objective: To investigate the relation between routine infant care practices and the sudden infant death syndrome in Scotland. Methods: National study of 201 infants dying of the sudden infant death syndrome (cases) and 276 controls by means of home interviews comparing methods of infant care and socioeconomic factors. Results: Sleeping prone (odds ratio 6.96 (95% confidence interval 1.51 to 31.97)) and drug treatment in the previous week (odds ratio 2.33 (1.10 to 4.94)) were more common in the cases than controls on multivariate analysis. Smoking was confirmed as a significant risk factor (odds ratio for mother and father both smoking 5.19 (2.26 to 11.91)). The risk increased with the number of parents smoking (P < 0.0001), with the number of cigarettes smoked by mother or father (P = 0.0001), and with bed sharing (P < 0.005). A new finding was an increased risk of dying of the syndrome for infants who slept at night on a mattress previously used by another infant or adult (odds ratio 2.51 (1.39 to 4.52)). However, this increased risk was not established for mattresses totally covered by polyvinyl chloride. Conclusions: Sleeping prone and parental smoking are confirmed as modifiable risk factors for the sudden infant death syndrome. Sleeping on an old mattress may be important but needs confirmation before recommendations can be made.	UNIV EDINBURGH, SCH MED, MED STAT UNIT, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; UNIV GLASGOW, GLASGOW G12 8QQ, LANARK, SCOTLAND	University of Edinburgh; University of Glasgow	Brooke, H (corresponding author), ROYAL HOSP SICK CHILDREN, SCOTTISH COT DEATH TRUST, GLASGOW G3 8SJ, LANARK, SCOTLAND.							ARNEIL GC, 1985, LANCET, V1, P740; Carstairs V., 1991, DEPRIVATION HLTH SCO; CLULOW E, 1978, TEXTILES, V1, P2; COWAN SF, 1996, 4 SIDS INT C WASH DC; COWNA S, 1996, HLTH ED, V1, P20; ENGELBERTS AC, 1991, J PAEDIATR CHILD H, V27, P329, DOI 10.1111/j.1440-1754.1991.tb00413.x; FAROOQI S, 1993, PAEDIATR PERINAT EP, V57, P245; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; GANTLEY M, 1993, BRIT MED J, V306, P16, DOI 10.1136/bmj.306.6869.16; GIBSON AAM, 1992, J CLIN PATHOL, V45, P7; GIBSON AAM, 1994, 3 SIDS INT C STAV NO; KLONOFFCOHEN H, 1995, BMJ-BRIT MED J, V311, P1269, DOI 10.1136/bmj.311.7015.1269; MALLOY MH, 1992, AM J PUBLIC HEALTH, V82, P1380, DOI 10.2105/AJPH.82.10.1380; MITCHELL EA, 1993, PEDIATRICS, V91, P893; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS3, DOI 10.1111/j.1440-1754.1992.tb02729.x; MITCHELL EA, 1988, AUST NZ J MED, V18, P861, DOI 10.1111/j.1445-5994.1988.tb01646.x; RICHARDSON BA, 1990, LANCET, V335, P670, DOI 10.1016/0140-6736(90)90463-F; SCHECHTMAN VL, 1992, PEDIATRICS, V89, P865; SCRAGG R, 1993, BMJ-BRIT MED J, V307, P1312, DOI 10.1136/bmj.307.6915.1312; Scragg RKR, 1996, LANCET, V347, P7, DOI 10.1016/S0140-6736(96)91554-8; [No title captured]	21	148	152	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 24	1997	314	7093					1516	1520		10.1136/bmj.314.7093.1516	http://dx.doi.org/10.1136/bmj.314.7093.1516			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9169398	Green Published			2022-12-28	WOS:A1997XB48400023
J	Ballew, KA				Ballew, KA			Recent advances - Cardiopulmonary resuscitation	BRITISH MEDICAL JOURNAL			English	Review							HOSPITAL CARDIAC-ARREST; ACTIVE COMPRESSION-DECOMPRESSION; HIGH-DOSE EPINEPHRINE; AUTOMATIC EXTERNAL DEFIBRILLATOR; AMERICAN-HEART-ASSOCIATION; BYSTANDER CPR; CLINICAL-TRIAL; BLOOD-FLOW; SURVIVAL; EXPERIENCE				Ballew, KA (corresponding author), UNIV VIRGINIA,SCH MED,DIV GEN INTERNAL MED,2955 IVY RD,SUITE 205,CHARLOTTESVILLE,VA 22908, USA.							AUBLE TE, 1995, ANN EMERG MED, V25, P642, DOI 10.1016/S0196-0644(95)70178-8; BALLEW KA, 1994, ARCH INTERN MED, V154, P2426, DOI 10.1001/archinte.154.21.2426; Ballew KA, 1995, RESUSCITATION, V30, P203, DOI 10.1016/0300-9572(95)00894-2; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BERG RA, 1995, ANN EMERG MED, V26, P342, DOI 10.1016/S0196-0644(95)70084-6; BERRYMAN CR, 1984, ANN EMERG MED, V13, P226, DOI 10.1016/S0196-0644(84)80467-9; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; Callaham M, 1996, ANN EMERG MED, V27, P638, DOI 10.1016/S0196-0644(96)70169-5; CALLAHAM M, 1992, JAMA-J AM MED ASSOC, V268, P2667, DOI 10.1001/jama.268.19.2667; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; COHEN TJ, 1992, JAMA-J AM MED ASSOC, V267, P2916, DOI 10.1001/jama.267.21.2916; COHEN TJ, 1993, NEW ENGL J MED, V329, P1918, DOI 10.1056/NEJM199312233292603; CRONE PD, 1995, NEW ZEAL MED J, V108, P297; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; DITCHEY RV, 1982, CIRCULATION, V66, P297, DOI 10.1161/01.CIR.66.2.297; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; HALPERIN HR, 1993, NEW ENGL J MED, V329, P762, DOI 10.1056/NEJM199309093291104; HERLITZ J, 1994, BRIT HEART J, V72, P408; KERBER RE, 1991, CIRCULATION, V83, P2233; Kuisma M, 1996, HEART, V76, P18, DOI 10.1136/hrt.76.1.18; Lindner KH, 1996, ANN INTERN MED, V124, P1061, DOI 10.7326/0003-4819-124-12-199606150-00006; LINDNER KH, 1993, CIRCULATION, V88, P1254, DOI 10.1161/01.CIR.88.3.1254; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; LURIE KG, 1994, JAMA-J AM MED ASSOC, V271, P1405, DOI 10.1001/jama.271.18.1405; Martens P, 1996, RESUSCITATION, V31, P25, DOI 10.1016/0300-9572(95)00909-4; MILLER B, 1995, RESUSCITATION, V30, P3, DOI 10.1016/0300-9572(95)00868-T; MURPHY DM, 1987, J EMERG MED SERV, V12, P67; *NAT CTR HLTH STAT, 1993, ADV REP FIN MORT S S, V47; SACK JB, 1992, JAMA-J AM MED ASSOC, V267, P379; SMITH DL, 1995, J AM COLL SURGEONS, V180, P402; SPAITE DW, 1990, ANN EMERG MED, V19, P1264, DOI 10.1016/S0196-0644(05)82285-1; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P1417, DOI 10.1001/jama.275.18.1417; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; VANHOEYWEGHEN RJ, 1993, RESUSCITATION, V26, P47, DOI 10.1016/0300-9572(93)90162-J; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEISFELDT ML, 1995, CIRCULATION, V92, P2740, DOI 10.1161/01.CIR.92.9.2740; WIK L, 1994, RESUSCITATION, V28, P195, DOI 10.1016/0300-9572(94)90064-7	42	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 17	1997	314	7092					1462	1465		10.1136/bmj.314.7092.1462	http://dx.doi.org/10.1136/bmj.314.7092.1462			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA202	9167565	Green Published			2022-12-28	WOS:A1997XA20200027
J	Etkin, LD				Etkin, LD			Developmental biology - A new face for the endoplasmic reticulum: RNA localization	SCIENCE			English	Editorial Material							MATERNAL MESSENGER-RNA; XENOPUS-OOCYTES; VEGETAL CORTEX; BINDING PROTEIN; VG1; MICROTUBULES; TRANSLOCATION; ASSOCIATION; ATTACHMENT				Etkin, LD (corresponding author), UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOL GENET, HOUSTON, TX 77030 USA.							ALLAN V, 1994, J CELL SCI, V107, P1885; Deshler JO, 1997, SCIENCE, V276, P1128, DOI 10.1126/science.276.5315.1128; ELISHA Z, 1995, EMBO J, V14, P5109, DOI 10.1002/j.1460-2075.1995.tb00193.x; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; Jeffery W R, 1988, Dev Biol (N Y 1985), V5, P3; KLOC M, 1995, DEVELOPMENT, V121, P287; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; KLOC M, UNPUB; KU M, 1993, DEVELOPMENT, V119, P1161; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LIPSHITZ HD, 1995, LOCALIZED RNAS, P1; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; Mowry KL, 1996, P NATL ACAD SCI USA, V93, P14608, DOI 10.1073/pnas.93.25.14608; SCHWARTZ SP, 1992, P NATL ACAD SCI USA, V89, P11895, DOI 10.1073/pnas.89.24.11895; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; WATERMANSTORER CM, 1995, J CELL BIOL, V130, P1161, DOI 10.1083/jcb.130.5.1161; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; Zhou Y, 1996, DEVELOPMENT, V122, P2947	22	12	12	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 16	1997	276	5315					1092	1093		10.1126/science.276.5315.1092	http://dx.doi.org/10.1126/science.276.5315.1092			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9173541				2022-12-28	WOS:A1997WZ22500036
J	Kay, SA				Kay, SA			UPDATE: Circadian rhythms - As time PASses: The first mammalian clock gene	SCIENCE			English	Editorial Material											Kay, SA (corresponding author), SCRIPPS RES INST, NSF CTR BIOL TIMING, DEPT CELL BIOL, LA JOLLA, CA 92037 USA.		Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878				Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Kay SA, 1997, SCIENCE, V276, P753, DOI 10.1126/science.276.5313.753; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KING DP, IN PRESS GENETIC; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325	7	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 16	1997	276	5315					1093	1093		10.1126/science.276.5315.1093	http://dx.doi.org/10.1126/science.276.5315.1093			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	WZ225	9173542				2022-12-28	WOS:A1997WZ22500037
J	Braun, BR; Johnson, AD				Braun, BR; Johnson, AD			Control of filament formation in Candida albicans by the transcriptional repressor TUP1	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; GROWTH; TRANSFORMATION; MORPHOGENESIS; ALPHA-2	The pathogenic yeast Candida albicans regulates its cellular morphology in response to environmental conditions. Ellipsoidal, single cells (blastospores) predominate in rich media, whereas filaments composed of elongated cells that are attached end-to-end form in response to starvation, serum, and other conditions. The TUP1 gene, which encodes a general transcriptional repressor in Saccharomyces cerevisiae, was isolated from C. albicans and disrupted. The resulting tup1 mutant strain of C. albicans grew exclusively as filaments under all conditions tested. TUP1 was epistatic to the transcriptional activator CPH1, previously found to promote filamentous growth. The results suggest a model where TUP1 represses genes responsible for initiating filamentous growth and this repression is lifted under inducing environmental conditions.			Braun, BR (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, 513 PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037049] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37049] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DUDLEY MN, 1990, PHARMACOTHERAPY, V10, P133; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; FIDEL PL, UNPUB; FONZI WA, 1993, GENETICS, V134, P717; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GIMENO GJ, 1992, CELL, V68, P14077; GOW NAR, 1984, SABOURAUDIA, V22, P137; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KRON SJ, 1995, CURR OPIN CELL BIOL, V7, P845, DOI 10.1016/0955-0674(95)80069-7; LEBERER E, 1996, P NATL ACAD SCI US, V93; LEMONTT JF, 1980, GENETICS, V94, P899; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; McGinnis M.R., 1980, LAB HDB MED MYCOLOGY; MERSONDAVIES LA, 1989, J GEN MICROBIOL, V135, P3143; Odds F. C., 1994, ASM News (Washington), V60, P313; ODDS FC, 1985, CRC CR REV MICROBIOL, V12, P45, DOI 10.3109/10408418509104425; Odds FC., 1988, CANDIDA CANDIDOSIS; OHAMA T, 1993, NUCLEIC ACIDS RES, V21, P4039, DOI 10.1093/nar/21.17.4039; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rubin R. H., 1993, European Journal of Clinical Microbiology and Infectious Diseases, V12, pS42; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WAHI M, 1995, GENETICS, V140, P79; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WRIGHT RM, 1993, CURR GENET, V23, P388, DOI 10.1007/BF00312623	30	444	454	4	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	1997	277	5322					105	109		10.1126/science.277.5322.105	http://dx.doi.org/10.1126/science.277.5322.105			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204892				2022-12-28	WOS:A1997XJ41800050
J	Xia, D; Yu, CA; Kim, H; Xian, JZ; Kachurin, AM; Zhang, L; Yu, L; Deisenhofer, J				Xia, D; Yu, CA; Kim, H; Xian, JZ; Kachurin, AM; Zhang, L; Yu, L; Deisenhofer, J			Crystal structure of the cytochrome bc(1) complex from bovine heart mitochondria	SCIENCE			English	Article							AMINO-ACID SEQUENCE; C REDUCTASE COMPLEX; UBIQUINONE-BINDING-PROTEIN; ELECTRON-TRANSPORT CHAIN; RAT-LIVER MITOCHONDRIA; PROTONMOTIVE Q-CYCLE; IRON SULFUR PROTEIN; BEEF-HEART; BC1 COMPLEX; RHODOBACTER-SPHAEROIDES	On the basis of x-ray diffraction data to a resolution of 2.9 angstroms, atomic models of most protein components of the bovine cytochrome bc(1) complex were built, including core 1, core 2, cytochrome b, subunit 6 subunit 7, a carboxyl-terminal fragment of cytochrome c(1), and an amino-terminal fragment of the iron-sulfur protein. The positions of the four iron centers within the be, complex and the binding sites of the two specific respiratory inhibitors antimycin A and myxothiazol were identified. The membrane-spanning region of each bc(1) complex monomer consists of 13 transmembrane helices, eight of which belong to cytochrome b. Closely interacting monomers are arranged as symmetric dimers and form cavities through which the inhibitor binding pockets can be accessed. The proteins core 1 and core 2 are structurally similar to each other and consist of two domains of roughly equal size and identical folding topology.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; OKLAHOMA STATE UNIV, DEPT BIOCHEM & MOL BIOL, STILLWATER, OK 74078 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Oklahoma State University System; Oklahoma State University - Stillwater					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiba T, 1996, NAT STRUCT BIOL, V3, P553, DOI 10.1038/nsb0696-553; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BERRY EA, 1992, J MOL BIOL, V224, P1161, DOI 10.1016/0022-2836(92)90476-Z; BERRY EA, 1995, ACTA CRYSTALLOGR D, V51, P235, DOI 10.1107/S0907444994010486; BORCHART U, 1986, FEBS LETT, V200, P81, DOI 10.1016/0014-5793(86)80515-4; BORCHART U, 1985, FEBS LETT, V191, P125, DOI 10.1016/0014-5793(85)81007-3; BRAND MD, 1976, J BIOL CHEM, V251, P5670; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; COCCO T, 1991, EUR J BIOCHEM, V195, P731, DOI 10.1111/j.1432-1033.1991.tb15760.x; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; CROFTS A, 1987, CYTOCHROME SYSTEMS M, P617; *DAR LAB, 1979, CCP4 SERC UK COLL CO; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DENG K, UNPUB; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; ERECINSKA M, 1972, P NATL ACAD SCI USA, V69, P50, DOI 10.1073/pnas.69.1.50; GENCIC S, 1991, EUR J BIOCHEM, V199, P123, DOI 10.1111/j.1432-1033.1991.tb16099.x; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; Glaser E, 1996, BBA-BIOENERGETICS, V1275, P33, DOI 10.1016/0005-2728(96)00046-1; GLASER E, 1994, FEBS LETT, V346, P83, DOI 10.1016/0014-5793(94)00312-2; GLASER EG, 1984, BIOCHIM BIOPHYS ACTA, V766, P322, DOI 10.1016/0005-2728(84)90248-2; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; GREEN DW, 1954, PROC R SOC LON SER-A, V225, P287, DOI 10.1098/rspa.1954.0203; HATEFI Y, 1962, J BIOL CHEM, V237, P1681; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWAMOTO M, 1994, J MOL BIOL, V244, P238, DOI 10.1006/jmbi.1994.1722; KUBOTA T, 1991, J MOL BIOL, V221, P379, DOI 10.1016/0022-2836(91)80059-4; LEE JW, 1995, J MOL BIOL, V252, P15, DOI 10.1006/jmbi.1994.0470; LEONARD K, 1981, J MOL BIOL, V149, P259, DOI 10.1016/0022-2836(81)90301-6; MIKI T, 1994, J BIOL CHEM, V269, P1827; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MITCHELL R, 1986, BIOCHIM BIOPHYS ACTA, V849, P229, DOI 10.1016/0005-2728(86)90029-0; MUSATOV A, 1994, BIOCHEMISTRY-US, V33, P13005, DOI 10.1021/bi00248a009; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V236, P619; OHNISHI T, 1989, J BIOL CHEM, V264, P735; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROBERTSON DE, 1988, BIOCHIM BIOPHYS ACTA, V935, P273, DOI 10.1016/0005-2728(88)90223-X; SALERNO JC, 1990, BIOCHEMISTRY-US, V29, P6987, DOI 10.1021/bi00482a006; SCHAGGER H, 1987, FEBS LETT, V219, P161, DOI 10.1016/0014-5793(87)81210-3; SCHAGGER H, 1985, FEBS LETT, V190, P89, DOI 10.1016/0014-5793(85)80434-8; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; Tolkatchev D, 1996, J BIOL CHEM, V271, P12356, DOI 10.1074/jbc.271.21.12356; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSAI AL, 1983, J BIOL CHEM, V258, P2122; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; VONJAGOW G, 1986, J BIOENERG BIOMEMBR, V18, P157, DOI 10.1007/BF00743462; WAKABAYASHI S, 1985, J BIOL CHEM, V260, P337; WAKABAYASHI S, 1982, J BIOCHEM, V91, P2077, DOI 10.1093/oxfordjournals.jbchem.a133901; WEST IC, 1986, BIOCHIM BIOPHYS ACTA, V849, P236, DOI 10.1016/0005-2728(86)90030-7; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; WIKSTROM MK, 1972, BIOCHIM BIOPHYS ACTA, V283, P403, DOI 10.1016/0005-2728(72)90258-7; YU CA, 1994, J MOL BIOL, V243, P802, DOI 10.1016/0022-2836(94)90051-5; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU CA, 1978, BIOCHEM BIOPH RES CO, V82, P1070, DOI 10.1016/0006-291X(78)90296-6; YU L, 1995, J BIOL CHEM, V270, P25634, DOI 10.1074/jbc.270.43.25634; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017	69	869	902	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 4	1997	277	5322					60	66		10.1126/science.277.5322.60	http://dx.doi.org/10.1126/science.277.5322.60			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XJ418	9204897				2022-12-28	WOS:A1997XJ41800037
J	Linet, MS; Hatch, EE; Kleinerman, RA; Robison, LL; Kaune, WT; Friedman, DR; Severson, RK; Haines, CM; Hartsock, CT; Niwa, S; Wacholder, S; Tarone, RE				Linet, MS; Hatch, EE; Kleinerman, RA; Robison, LL; Kaune, WT; Friedman, DR; Severson, RK; Haines, CM; Hartsock, CT; Niwa, S; Wacholder, S; Tarone, RE			Residential exposure to magnetic fields and acute lymphoblastic leukemia in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ELECTRICAL WIRING CONFIGURATIONS; CHILDHOOD-CANCER; SELECTION BIAS; POWER-LINES; WIRE CODES; RISK	Background Previous studies found associations between childhood leukemia and surrogate indicators of exposure to magnetic fields (the power-line classification scheme known as ''wire coding''), but not between childhood leukemia and measurements of 60-Hz residential magnetic fields. Methods We enrolled 638 children with acute lymphoblastic leukemia (ALL) who were under 15 years of age and were registered with the Children's Cancer Group and 620 controls in a study of residential exposure to magnetic fields generated by nearby power lines. In the subjects' current and former homes, data collectors blinded to the subjects' health status measured magnetic fields for 24 hours in each child's bedroom and for 30 seconds in three or four other rooms and outside the front door. A computer algorithm assigned wire-code categories, based on the distance and configuration of nearby power lines, to the subjects' main residences (for 416 case patients and 416 controls) and to those where the family had lived during the mother's pregnancy with the subject (for 230 case patients and 230 controls). Results The risk of childhood ALL was not linked to summary time-weighted average residential magnetic-field levels, categorized according to a priori criteria. The odds ratio for ALL was 1.24 (95 percent confidence interval, 0.86 to 1.79) at exposures of 0.200 mu T or greater as compared with less than 0.065 mu T. The risk of ALL was not increased among children whose main residences were in the highest wire-code category (odds ratio as compared with the lowest category, 0.88; 95 percent confidence interval, 0.48 to 1.63). Furthermore, the risk was not significantly associated with either residential magnetic-field levels or the wire codes of the homes mothers resided in when pregnant with the subjects. Conclusions Our results provide little evidence that living in homes characterized by high measured time-weighted average magnetic-field levels or by the highest wire-code category increases the risk of ALL in children. (C) 1997, Massachusetts Medical Society.	CHILDRENS CANC GRP,ARCADIA,CA; UNIV MINNESOTA,SCH MED,DIV PEDIAT EPIDEMIOL & CLIN RES,MINNEAPOLIS,MN 55455; EM FACTORS,RICHLAND,WA; WESTAT CORP,ROCKVILLE,MD; INFORMAT MANAGEMENT SERV INC,ROCKVILLE,MD	University of Minnesota System; University of Minnesota Twin Cities; Westat; Information Management Services, Inc.	Linet, MS (corresponding author), NCI,DIV CANC EPIDEMIOL & GENET,EXECUT PLAZA N,SUITE 408,BETHESDA,MD 20892, USA.		Robison, Leslie/N-8122-2018	Hatch, Elizabeth/0000-0001-7901-3928; Kleinerman, Ruth/0000-0001-7415-2478	NCI NIH HHS [R01 CA48051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES F, 1989, BIOELECTROMAGNETICS, V10, P13, DOI 10.1002/bem.2250100103; Breslow NE., 1980, IARC SCI PUBL, V32, P122; *COMM POSS EFF EL, 1996, POSS HLTH EFF EXP RE, P113; DOVAN T, 1993, BIOELECTROMAGNETICS, V14, P145, DOI 10.1002/bem.2250140207; FEYCHTING M, 1993, AM J EPIDEMIOL, V138, P467, DOI 10.1093/oxfordjournals.aje.a116881; Friedman DR, 1996, EPIDEMIOLOGY, V7, P151, DOI 10.1097/00001648-199603000-00008; FULTON JP, 1980, AM J EPIDEMIOL, V111, P292, DOI 10.1093/oxfordjournals.aje.a112899; GURNEY JG, 1995, EPIDEMIOLOGY, V6, P31, DOI 10.1097/00001648-199501000-00007; *HIGH VOLT TRANSM, 1993, SURV RES MAGN FIELD, V1; JONES TL, 1993, J CLIN EPIDEMIOL, V46, P545, DOI 10.1016/0895-4356(93)90127-M; KAUNE WT, 1994, BIOELECTROMAGNETICS, V15, P33, DOI 10.1002/bem.2250150108; KAUNE WT, 1987, BIOELECTROMAGNETICS, V8, P315, DOI 10.1002/bem.2250080402; KAUNE WT, 1994, BIOELECTROMAGNETICS, V15, P275, DOI 10.1002/bem.2250150402; KLEINERMAN RA, IN PRESS EPIDEMIOLOG; LONDON S, 1993, AM J EPIDEMIOL, V137, P381; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; *NAT RAD PROT BOAR, 1992, DOC NRPB, V3, P54; *OAK RIDG ASS U PA, 1992, PUBL OAK RID ASS U P, pR1; OLSEN JH, 1993, BRIT MED J, V307, P891, DOI 10.1136/bmj.307.6909.891; POOLE C, 1991, CANCER CAUSE CONTROL, V2, P267, DOI 10.1007/BF00052144; Robison L L, 1987, Prog Clin Biol Res, V246, P19; ROBISON LL, 1984, AM J EPIDEMIOL, V120, P164, DOI 10.1093/oxfordjournals.aje.a113866; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SAVITZ DA, 1989, EPIDEMIOL REV, V11, P59, DOI 10.1093/oxfordjournals.epirev.a036045; Tenforde T. S., 1996, P185; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; Tynes T, 1997, AM J EPIDEMIOL, V145, P219, DOI 10.1093/oxfordjournals.aje.a009094; VERKASALO PK, 1993, BRIT MED J, V307, P895, DOI 10.1136/bmj.307.6909.895; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WERTHEIMER N, 1982, INT J EPIDEMIOL, V11, P345, DOI 10.1093/ije/11.4.345	31	309	319	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	1997	337	1					1	7		10.1056/NEJM199707033370101	http://dx.doi.org/10.1056/NEJM199707033370101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH186	9203424	Bronze			2022-12-28	WOS:A1997XH18600001
J	Ligterink, W; Kroj, T; zurNieden, U; Hirt, H; Scheel, D				Ligterink, W; Kroj, T; zurNieden, U; Hirt, H; Scheel, D			Receptor-mediated activation of a MAP kinase in pathogen defense of plants	SCIENCE			English	Article							FUNGAL ELICITOR; EXTRACELLULAR GLYCOPROTEIN; PHYTOPHTHORA-MEGASPERMA; NUCLEAR-LOCALIZATION; PARSLEY CELLS; PHOSPHORYLATION; PROTOPLASTS; TRANSIENT; PATHWAYS	Parsley cells recognize the fungal plant pathogen Phytophthora sojae through a plasma membrane receptor. A pathogen-derived oligopeptide elicitor binds to this receptor and thereby stimulates a multicomponent defense response through sequential activation of ion channels and an oxidative burst. An elicitor-responsive mitogen-activated protein (MAP) kinase was identified that acts downstream of the ion channels but independently or upstream of the oxidative burst. Upon receptor-mediated activation, the MAP kinase is translocated to the nucleus where it might interact with transcription factors that induce expression of defense genes.	UNIV VIENNA,INST MICROBIOL & GENET,VIENNA BIOCTR,A-1030 VIENNA,AUSTRIA; INST PLANT BIOCHEM,D-06120 HALLE,GERMANY	University of Vienna; Vienna Biocenter (VBC); Leibniz Institut fur Pflanzenbiochemie			Ligterink, Wilco/C-8103-2009; Hirt, Heribert/A-2061-2013	Ligterink, Wilco/0000-0002-0228-169X; 				Bogre L, 1996, NATURE, V383, P489, DOI 10.1038/383489a0; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DANGL JL, 1987, EMBO J, V6, P2551, DOI 10.1002/j.1460-2075.1987.tb02543.x; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirt H, 1997, TRENDS PLANT SCI, V2, P11, DOI 10.1016/S1360-1385(96)10048-0; Jabs T, 1997, P NATL ACAD SCI USA, V94, P4800, DOI 10.1073/pnas.94.9.4800; Jonak C, 1996, P NATL ACAD SCI USA, V93, P11274, DOI 10.1073/pnas.93.20.11274; Kombrink E, 1995, ADV BOT RES, V21, P1; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIGTERINK W, UNPUB; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mehdy MC, 1996, PHYSIOL PLANTARUM, V98, P365, DOI 10.1034/j.1399-3054.1996.980219.x; Mizoguchi T, 1997, TRENDS BIOTECHNOL, V15, P15, DOI 10.1016/S0167-7799(96)10074-3; Mizoguchi T, 1996, P NATL ACAD SCI USA, V93, P765, DOI 10.1073/pnas.93.2.765; MIZOGUCHI T, 1994, PLANT J, V5, P111, DOI 10.1046/j.1365-313X.1994.5010111.x; NURNBERGER T, 1994, CELL, V78, P449, DOI 10.1016/0092-8674(94)90423-5; PARKER JE, 1991, MOL PLANT MICROBE IN, V4, P19, DOI 10.1094/MPMI-4-019; Rushton PJ, 1996, EMBO J, V15, P5690, DOI 10.1002/j.1460-2075.1996.tb00953.x; SACKS W, 1995, MOL GEN GENET, V246, P45, DOI 10.1007/BF00290132; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SCHEEL D, 1986, RECOGNITION MICROBE, P325; SCHMELZER E, 1989, PLANT CELL, V1, P993, DOI 10.1105/tpc.1.10.993; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; SOMSSICH IE, 1989, PLANT MOL BIOL, V12, P227, DOI 10.1007/BF00020507; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; VANLAMMEREN AAM, 1985, PLANTA, V165, P1, DOI 10.1007/BF00392205; ZIMMERMANN S, 1997, P NATL ACAD SCI USA, V94, P275	30	299	326	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2054	2057		10.1126/science.276.5321.2054	http://dx.doi.org/10.1126/science.276.5321.2054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9197271				2022-12-28	WOS:A1997XG74800069
J	Beamer, LJ; Carroll, SF; Eisenberg, D				Beamer, LJ; Carroll, SF; Eisenberg, D			Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution	SCIENCE			English	Article							ESTER TRANSFER PROTEIN; PERMEABILITY-INCREASING PROTEIN; LIPOPOLYSACCHARIDE-BINDING-PROTEIN; MESSENGER-RNA; TISSUE DISTRIBUTION; MOLECULAR-CLONING; AMINO-ACIDS; FRAGMENT; SEQUENCE; CDNA	Bactericidal/permeability-increasing protein (BPI), a potent antimicrobial protein of 456 residues, binds to and neutralizes lipopolysaccharides from the outer membrane of Gram-negative bacteria. At a resolution of 2.4 angstroms, the crystal structure of human BPI shows a boomerang-shaped molecule formed by two similar domains. Two apolar pockets on the concave surface of the boomerang each bind a molecule of phosphatidylcholine, primarily by interacting with their acyl chains; this suggests that the pockets may also bind the acyl chains of lipopolysaccharide. As a model for the related plasma lipid transfer proteins, BPI illuminates a mechanism of lipid transfer for this protein family.	UNIV CALIF LOS ANGELES,INST MOL BIOL,LAB STRUCT BIOL & MOL MED,LOS ANGELES,CA 90095; XOMA CORP,BERKELEY,CA 94710	University of California System; University of California Los Angeles					NIGMS NIH HHS [GM31299] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031299] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahamson SL, 1997, J BIOL CHEM, V272, P2149; AGELLON LB, 1990, BIOCHEMISTRY-US, V29, P1372, DOI 10.1021/bi00458a004; ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; Alexandrov NN, 1996, PROTEINS, V25, P354, DOI 10.1002/(SICI)1097-0134(199607)25:3<354::AID-PROT7>3.3.CO;2-W; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Capodici C, 1996, J IMMUNOL, V156, P4789; COHEN GH, 1986, J MOL BIOL, V190, P593; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; CONNOLLY ML, 1985, J AM CHEM SOC, V107, P1118, DOI 10.1021/ja00291a006; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAY JR, 1994, J BIOL CHEM, V269, P9388; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; ELSBACH P, 1995, INFECT AGENT DIS, V4, P102; Fischer D, 1995, PROTEIN ENG, V8, P981, DOI 10.1093/protein/8.10.981; GAZZANOSANTORO H, 1995, INFECT IMMUN, V63, P2201, DOI 10.1128/IAI.63.6.2201-2205.1995; GRAY PW, 1989, J BIOL CHEM, V264, P9505; HEUMANN D, 1994, SCI AM SCI MED, V1, P28; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; HOLM L, 1996, NUCLEIC ACIDS RES, V25, P341; Horwitz AH, 1996, PROTEIN EXPRES PURIF, V8, P28, DOI 10.1006/prep.1996.0071; JIANG XC, 1991, J BIOL CHEM, V266, P4631; JIANG XC, 1995, BIOCHEMISTRY-US, V34, P7258, DOI 10.1021/bi00021a042; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; LEONG SR, 1990, NUCLEIC ACIDS RES, V18, P3052, DOI 10.1093/nar/18.10.3052; LITTLE RG, 1994, J BIOL CHEM, V269, P1865; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAGASHIMA M, 1988, J LIPID RES, V29, P1643; OHLENDORF DH, 1983, J MOL BIOL, V169, P757, DOI 10.1016/S0022-2836(83)80169-7; OOI CE, 1987, J BIOL CHEM, V262, P14891; OOI CE, 1991, J EXP MED, V174, P649, DOI 10.1084/jem.174.3.649; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PAPE ME, 1991, ARTERIOSCLER THROMB, V11, P1759, DOI 10.1161/01.ATV.11.6.1759; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; REEKE GN, 1975, J BIOL CHEM, V250, P1525; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SU GL, 1994, J IMMUNOL, V153, P743; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TAYLOR AH, 1995, J BIOL CHEM, V270, P17934, DOI 10.1074/jbc.270.30.17934; VONDERMOHLEN MAM, 1995, J INFECT DIS, V172, P144, DOI 10.1093/infdis/172.1.144; WANG S, 1992, J BIOL CHEM, V267, P17487	49	307	340	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1861	1864		10.1126/science.276.5320.1861	http://dx.doi.org/10.1126/science.276.5320.1861			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188532				2022-12-28	WOS:A1997XF10300049
J	Umemori, H; Inoue, T; Kume, S; Sekiyama, N; Nagao, M; Itoh, H; Nakanishi, S; Mikoshiba, K; Yamamoto, T				Umemori, H; Inoue, T; Kume, S; Sekiyama, N; Nagao, M; Itoh, H; Nakanishi, S; Mikoshiba, K; Yamamoto, T			Activation of the G protein Gq/11 through tyrosine phosphorylation of the alpha subunit	SCIENCE			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; SIGNAL-TRANSDUCTION; KINASES; CELLS; INHIBITORS; EXPRESSION; MGLUR1; SYSTEM; FYN	Various receptors coupled to the heterotrimeric guanine nucleotide-binding protein Gq/11 stimulate formation of inositol-1,4,5-trisphosphate (IP3). Activation of these receptors also induces protein tyrosine phosphorylation. Formation of IP3 in response to stimulated receptors that couple to Gq/11 was blocked by protein tyrosine kinase inhibitors. These inhibitors appeared to act before activation of Gq/11. Moreover, stimulation of receptors coupled to Gq/11 induced phosphorylation on a tyrosine residue (Tyr(356)) Of the G alpha(q/11) subunit, and this tyrosine phosphorylation event was essential for Gq/11 activation. Tyrosine phosphorylation of G alpha(q/11) induced changes in its interaction with receptors. Therefore, tyrosine phosphorylation of G alpha(q/11) appears to regulate the activation of Gq/11 protein.	UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,TOKYO 108,JAPAN; KYOTO UNIV,FAC MED,DEPT SCI BIOL,KYOTO 606,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT SCI BIOL,YOKOHAMA,KANAGAWA 226,JAPAN	University of Tokyo; Kyoto University; Tokyo Institute of Technology	Umemori, H (corresponding author), UNIV TOKYO,INST MED SCI,DEPT ONCOL,TOKYO 108,JAPAN.		Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015; Kume, Shoen/M-4356-2016	Inoue, Takafumi/0000-0002-2728-0060; Kume, Shoen/0000-0002-4292-205X; Umemori, Hisashi/0000-0001-7198-2062				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLUML K, 1994, J BIOL CHEM, V269, P18870; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; ILLIC D, 1995, NATURE, V377, P539; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; NAKAMURA F, 1995, J BIOL CHEM, V270, P6246, DOI 10.1074/jbc.270.11.6246; NAKAMURA K, 1994, J PHYSIOL-LONDON, V474, P35, DOI 10.1113/jphysiol.1994.sp020000; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; UMEMORI H, UNPUB; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	34	117	117	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1878	1881		10.1126/science.276.5320.1878	http://dx.doi.org/10.1126/science.276.5320.1878			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9188537				2022-12-28	WOS:A1997XF10300054
J	Wilson, DS				Wilson, DS			Evolution - Human groups as units of selection	SCIENCE			English	Editorial Material											Wilson, DS (corresponding author), SUNY BINGHAMTON,DEPT BIOL SCI,BINGHAMTON,NY 13902, USA.							Boehm C, 1997, AM NAT, V150, pS100, DOI 10.1086/286052; WILSON DS, 1997, AM NAT S, V150	2	26	26	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 20	1997	276	5320					1816	1817		10.1126/science.276.5320.1816	http://dx.doi.org/10.1126/science.276.5320.1816			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XF103	9206841				2022-12-28	WOS:A1997XF10300033
J	Gostin, LO				Gostin, LO			Law and medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									JOHNS HOPKINS UNIV,PROGRAM LAW & PUBL HLTH,BALTIMORE,MD 21218	Johns Hopkins University	Gostin, LO (corresponding author), GEORGETOWN UNIV,PROGRAM LAW & PUBL HLTH,WASHINGTON,DC 20057, USA.							*GEN ACC OFF, 1996, GAOHEHS96207 GEN ACC; Gostin LO, 1997, JAMA-J AM MED ASSOC, V277, P410; 1996, FED REG         1231, V61, P69034	3	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1866	1867		10.1001/jama.277.23.1866	http://dx.doi.org/10.1001/jama.277.23.1866			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185806				2022-12-28	WOS:A1997XD54400025
J	Tanji, JL				Tanji, JL			Sports medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALL-CAUSE MORTALITY; PHYSICAL-FITNESS; MEN; EXERCISE; HEALTHY; PREGNANCY				Tanji, JL (corresponding author), UNIV CALIF DAVIS, MED CTR, SACRAMENTO, CA 95817 USA.							*AM COLL OBST GYNE, 1994, AM COLL OBST GYN TEC, V189; American College of Sports Medicine, 1993, MED SCI SPORTS EXERC, V25, pi, DOI DOI 10.1249/00005768-199310000-00024; [Anonymous], 1990, Med Sci Sports Exerc, V22, P265; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P576; CLAPP JF, 1984, MED SCI SPORT EXER, V16, P556; CLAPP JF, 1990, AM J OBSTET GYNECOL, V163, P1805, DOI 10.1016/0002-9378(90)90754-U; DEBUSK RF, 1990, AM J CARDIOL, V65, P1010, DOI 10.1016/0002-9149(90)91005-Q; HAGBERG JM, 1988, J APPL PHYSIOL, V65, P900, DOI 10.1152/jappl.1988.65.2.900; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; REAVEN GM, 1991, AM J MED, V90, pS7, DOI 10.1016/0002-9343(91)90028-V; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; STERNFELD B, 1995, MED SCI SPORT EXER, V27, P634	16	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1901	1902						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185826				2022-12-28	WOS:A1997XD54400045
J	Brody, SA				Brody, SA			What's wrong with this picture?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Brody, SA (corresponding author), GASTROENTEROL & GERIATR, 1450 COOLIDGE AVE, BALDWIN, NY 11510 USA.								0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1997	126	12					997	998		10.7326/0003-4819-126-12-199706150-00013	http://dx.doi.org/10.7326/0003-4819-126-12-199706150-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE549	9182480				2022-12-28	WOS:A1997XE54900015
J	Vila, C; Savolainen, P; Maldonado, JE; Amorim, IR; Rice, JE; Honeycutt, RL; Crandall, KA; Lundeberg, J; Wayne, RK				Vila, C; Savolainen, P; Maldonado, JE; Amorim, IR; Rice, JE; Honeycutt, RL; Crandall, KA; Lundeberg, J; Wayne, RK			Multiple and ancient origins of the domestic dog	SCIENCE			English	Article							MITOCHONDRIAL-DNA; EVOLUTION; HAPLOTYPES; CARNIVORES; SEQUENCE; REGION; WOLF	Mitochondrial DNA control region sequences were analyzed from 162 wolves at 27 localities worldwide and from 140 domestic dogs representing 67 breeds. Sequences from both dogs and wolves showed considerable diversity and supported the hypothesis that wolves were the ancestors of dogs. Most dog sequences belonged to a divergent monophyletic clade sharing no sequences with wolves. The sequence divergence within this clade suggested that dogs originated more than 100,000 years before the present. Associations of dog haplotypes with other wolf lineages indicated episodes of admixture between wolves and dogs. Repeated genetic exchange between dog and wolf populations may have been an important source of variation for artificial selection.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90095; ROYAL INST TECHNOL,DEPT BIOCHEM,S-10044 STOCKHOLM,SWEDEN; TEXAS A&M UNIV,FAC GENET,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT WILDLIFE & FISHERIES SCI,COLLEGE STN,TX 77843; BRIGHAM YOUNG UNIV,DEPT ZOOL,PROVO,UT 84602; BRIGHAM YOUNG UNIV,ML BEAN MUSEUM,PROVO,UT 84602	University of California System; University of California Los Angeles; Royal Institute of Technology; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Brigham Young University; Brigham Young University			Rosário, Isabel M Amorim do/P-5140-2015; Maldonado, Jesus/AIE-8664-2022; Klein, Richard G/B-5910-2009; Vila, Carles/H-4893-2013; Crandall, Keith A./H-2789-2019; Amorim do Rosario, Isabel/AAW-2610-2020	Rosário, Isabel M Amorim do/0000-0001-6847-3320; Maldonado, Jesus/0000-0002-4282-1072; Vila, Carles/0000-0002-4206-5246; Crandall, Keith A./0000-0002-0836-3389; Amorim do Rosario, Isabel/0000-0001-6847-3320				BRISBIN IL, 1976, AM KENNEL GAZ    JAN, P23; Clutton-Brock J., 1987, NATURAL HIST DOMESTI; Clutton-Brock Juliet, 1995, P7; Coppinger Raymond, 1995, P21; DAVILA FO, 1995, MAR MAMM SCI, V11, P46; DESALLE R, 1993, METHOD ENZYMOL, V224, P176, DOI 10.1016/0076-6879(93)24015-M; Epstein H., 1971, ORIGIN DOMESTIC ANIM; EXCOFFIER L, 1992, GENETICS, V131, P479; GarciaMoreno J, 1996, CONSERV BIOL, V10, P376, DOI 10.1046/j.1523-1739.1996.10020376.x; GOTTELLI D, 1994, MOL ECOL, V3, P301, DOI 10.1111/j.1365-294X.1994.tb00070.x; Gray AP, 1954, MAMMALIAN HYBRIDS CH; Hedrick PW, 1997, ZOO BIOL, V16, P47, DOI 10.1002/(SICI)1098-2361(1997)16:1<47::AID-ZOO7>3.0.CO;2-B; HOELZEL AR, 1994, J MOL EVOL, V39, P191; MOREY DF, 1994, AM SCI, V82, P336; Nobis G., 1979, UMSCHAU, V19, P610; NOWAK RM, 1979, MONOGRAPH MUSEUM NAT, V6; Olsen S.J., 1985, ORIGINS DOMESTIC DOG; OLSEN SJ, 1977, SCIENCE, V197, P533, DOI 10.1126/science.197.4303.533; Parsons TJ, 1997, NAT GENET, V15, P363, DOI 10.1038/ng0497-363; SACCONE C, 1987, J MOL EVOL, V26, P205, DOI 10.1007/BF02099853; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SWOFFORD DL, 1990, PAUP PHYLOGENETIC AN; TAJIMA F, 1993, GENETICS, V135, P599; TEMPLETON AR, 1992, GENETICS, V132, P619; TEMPLETON AR, 1983, EVOLUTION, V37, P221, DOI 10.1111/j.1558-5646.1983.tb05533.x; THURSTON ME, 1996, LOST HIST CANINE RAC; VILA C, UNPUB; WAYNE RK, 1991, MOL BIOL EVOL, V8, P297; WAYNE RK, 1993, TRENDS GENET, V9, P218, DOI 10.1016/0168-9525(93)90122-X; ZEUNER FE, 1963, HIST DOMESTICATED AN	30	654	691	0	319	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1687	1689		10.1126/science.276.5319.1687	http://dx.doi.org/10.1126/science.276.5319.1687			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180076				2022-12-28	WOS:A1997XD94700039
J	Dajani, AS; Taubert, KA; Wilson, W; Bolger, AF; Bayer, A; Ferrieri, P; Gewitz, MH; Shulman, ST; Nouri, S; Newburger, JW; Hutto, C; Pallasch, TJ; Gage, TW; Levison, ME; Peter, G; Zuccaro, G				Dajani, AS; Taubert, KA; Wilson, W; Bolger, AF; Bayer, A; Ferrieri, P; Gewitz, MH; Shulman, ST; Nouri, S; Newburger, JW; Hutto, C; Pallasch, TJ; Gage, TW; Levison, ME; Peter, G; Zuccaro, G			Prevention of bacterial endocarditis - Recommendations by the American Heart Association	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MITRAL-VALVE PROLAPSE; UPPER GASTROINTESTINAL ENDOSCOPY; BENIGN ESOPHAGEAL STRICTURE; ORAL IRRIGATION DEVICE; INFECTIVE ENDOCARDITIS; HURST BOUGIENAGE; BACTEREMIA; PROPHYLAXIS; RISK; SIGMOIDOSCOPY	Objective.-To update recommendations issued by the American Heart Association last published in 1990 for the prevention of bacterial endocarditis in individuals at risk for this disease. Participants.-An ad hoc writing group appointed by the American Heart Association for their expertise in endocarditis and treatment with liaison members representing the American Dental Association, the Infectious Diseases Society of America, the American Academy of Pediatrics, and the American Society for Gastrointestinal Endoscopy. Evidence.-The recommendations in this article reflect analyses of relevant literature regarding procedure-related endocarditis, in vitro susceptibility data of pathogens causing endocarditis, results of prophylactic studies in animal models of endocarditis, and retrospective analyses of human endocarditis cases in terms of antibiotic prophylaxis usage patterns and apparent prophylaxis failures. MEDLINE database searches from 1936 through 1996 were done using the root words endocarditis, bacteremia, and antibiotic prophylaxis. Recommendations in this document fall into evidence level III of the US Preventive Services Task Force categories of evidence. Consensus Process.-The recommendations were formulated by the writing group after specific therapeutic regimens were discussed. The consensus statement was subsequently reviewed by outside experts not affiliated with the writing group and by the Science Advisory and Coordinating Committee of the American Heart Association. These guidelines are meant to aid practitioners but are not intended as the standard of care or as a substitute for clinical judgment. Conclusions.-Major changes in the updated recommendations include the following: (1) emphasis that most cases of endocarditis are not attributable to an invasive procedure; (2) cardiac conditions are stratified into high-, moderate-, and negligible-risk categories based on potential outcome if endocarditis develops; (3) procedures that may cause bacteremia and for which prophylaxis is recommended are more clearly specified; (4) an algorithm was developed to more clearly define when prophylaxis is recommended for patients with mitral valve prolapse; (5) for oral or dental procedures the initial amoxicillin dose is reduced to 2 g, a follow-up antibiotic dose is no longer recommended, erythromycin is no longer recommended for penicillin-allergic individuals, but clindamycin and other alternatives are offered; and (6) for gastrointestinal or genitourinary procedures, the prophylactic regimens have been simplified. These changes were instituted to more clearly define when prophylaxis is or is not recommended, improve practitioner and patient compliance, reduce cost and potential gastrointestinal adverse effects, and approach more uniform worldwide recommendations.	AMER HEART ASSOC,OFF SCI & MED,DALLAS,TX 75231; AMER DENT ASSOC,CHICAGO,IL; INFECT DIS SOC AMER,ALEXANDRIA,EGYPT; AMER ACAD PEDIAT,ELK GROVE VILLAGE,IL; AMER SOC GASTROINTESTINAL ENDOSCOPY,MANCHESTER,MA	American Academy of Pediatrics								AWADALLAH SM, 1991, AM J CARDIOL, V68, P90, DOI 10.1016/0002-9149(91)90717-Y; BASKIN G, 1989, AM J GASTROENTEROL, V84, P311; BAYER AS, 1990, CHEST, V97, P1203, DOI 10.1378/chest.97.5.1203; BENDER IB, 1984, J AM DENT ASSOC, V109, P415, DOI 10.14219/jada.archive.1984.0432; BERGER SA, 1974, ANN INTERN MED, V80, P510, DOI 10.7326/0003-4819-80-4-510; BERNEY P, 1990, J INFECT DIS, V161, P281; BOTOMAN VA, 1986, GASTROINTEST ENDOSC, V32, P342, DOI 10.1016/S0016-5107(86)71880-4; BOUDOULAS H, 1995, MOSS ADAMS HEART DIS, P1068; BRYNE W, 1982, J PEDIAT GASTROENTER, V1, P551; Carabello B A, 1993, Curr Probl Cardiol, V18, P423; Cheitlin MD, 1997, CIRCULATION, V95, P1686; Child John S., 1996, Cardiology Clinics, V14, P327, DOI 10.1016/S0733-8651(05)70287-3; COHEN LB, 1983, GASTROINTEST ENDOSC, V29, P198, DOI 10.1016/S0016-5107(83)72584-8; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; DAJANI AS, 1994, CLIN INFECT DIS, V18, P157, DOI 10.1093/clinids/18.2.157; DANCHIN N, 1989, LANCET, V1, P743; DEVEREUX RB, 1989, ANN INTERN MED, V111, P305, DOI 10.7326/0003-4819-111-4-305; DEVEREUX RB, 1994, AM J CARDIOL, V74, P1024, DOI 10.1016/0002-9149(94)90853-2; DEVEREUX RB, 1986, AM J MED, V81, P751, DOI 10.1016/0002-9343(86)90339-6; DURACK DT, 1995, NEW ENGL J MED, V332, P38, DOI 10.1056/NEJM199501053320107; DURACK DT, 1983, JAMA-J AM MED ASSOC, V250, P2318, DOI 10.1001/jama.250.17.2318; FELIX JE, 1971, J PERIODONTOL, V42, P785, DOI 10.1902/jop.1971.42.12.785; FLUCKIGER U, 1994, J INFECT DIS, V169, P397; GERSONY WM, 1993, CIRCULATION, V87, P121; GUNTHEROTH WG, 1984, AM J CARDIOL, V54, P797, DOI 10.1016/S0002-9149(84)80211-8; HO H, 1991, GASTROENTEROLOGY, V101, P1642, DOI 10.1016/0016-5085(91)90403-8; HUNTER KM, 1989, BRIT DENT J, V167, P275, DOI 10.1038/sj.bdj.4806998; KAYE D, 1986, ANN INTERN MED, V104, P419, DOI 10.7326/0003-4819-104-3-419; LEVINER E, 1987, ORAL SURG ORAL MED O, V64, P417, DOI 10.1016/0030-4220(87)90145-9; LOGAN RF, 1988, BRIT MED J, V296, P1107, DOI 10.1136/bmj.296.6629.1107; LOW DE, 1987, CAN J SURG, V30, P421; LOW DE, 1987, DIGEST DIS SCI, V32, P1239, DOI 10.1007/BF01296372; MACMAHON SW, 1987, AM HEART J, V113, P1291, DOI 10.1016/0002-8703(87)90957-4; MARKS AR, 1989, NEW ENGL J MED, V320, P1031, DOI 10.1056/NEJM198904203201602; MCKINSEY DS, 1987, AM J MED, V82, P681, DOI 10.1016/0002-9343(87)90001-5; MORALES AR, 1992, HUM PATHOL, V23, P129, DOI 10.1016/0046-8177(92)90233-S; NISHIMURA RA, 1985, NEW ENGL J MED, V313, P1305, DOI 10.1056/NEJM198511213132101; NIV Y, 1985, GASTROINTEST ENDOSC, V31, P265, DOI 10.1016/S0016-5107(85)72179-7; NORFLEET RG, 1991, J CLIN GASTROENTEROL, V13, P448, DOI 10.1097/00004836-199108000-00017; Pallasch TJ, 1996, PERIODONTOL 2000, V10, P107, DOI 10.1111/j.1600-0757.1996.tb00071.x; PRABHU SD, 1997, ATLAS HEART DIS VALV, V11; PRITCHARD TM, 1991, AM J MED, V90, P516; RAINES DR, 1977, AUST N Z J MED, V7, P22; RIGILANO J, 1984, ARCH INTERN MED, V144, P850, DOI 10.1001/archinte.144.4.850; RODRIGUEZ W, 1984, WESTERN J MED, V140, P951; ROMANS AR, 1971, J PERIODONTOL, V42, P757, DOI 10.1902/jop.1971.42.12.757; ROUSE MS, IN PRESS ANTIMICROB; SAIMAN L, 1993, J PEDIATR-US, V122, P847, DOI 10.1016/S0022-3476(09)90006-3; SANDE M A, 1990, P1117; SHULL HJ, 1975, ANN INTERN MED, V83, P212, DOI 10.7326/0003-4819-83-2-212; SIMMONS NA, 1986, LANCET, V1, P1267; STARKEBAUM M, 1977, YALE J BIOL MED, V50, P49; STECKELBERG JM, 1993, INFECT DIS CLIN N AM, V7, P9; STEPHENSON PM, 1977, AUST NZ J MED, V7, P32, DOI 10.1111/j.1445-5994.1977.tb03353.x; STODDARD MF, 1995, J AM COLL CARDIOL, V25, P693, DOI 10.1016/0735-1097(94)00408-I; STROM BL, 1996, J INVEST MED, V44, P229; SUGRUE D, 1980, BRIT HEART J, V44, P499, DOI 10.1136/hrt.44.5.499; SULLIVAN NM, 1973, J INFECT DIS, V127, P49, DOI 10.1093/infdis/127.1.49; TSENG CC, 1992, GASTROINTEST ENDOSC, V38, P336, DOI 10.1016/S0016-5107(92)70427-1; WATANAKUNAKORN C, 1988, AM HEART J, V116, P1115, DOI 10.1016/0002-8703(88)90173-1; WEISSMAN NJ, 1994, AM J CARDIOL, V73, P1080, DOI 10.1016/0002-9149(94)90287-9; WELSH JD, 1983, J CLIN GASTROENTEROL, V5, P109, DOI 10.1097/00004836-198304000-00003; WOOLEY CF, 1991, PROG CARDIOVASC DIS, V33, P397, DOI 10.1016/0033-0620(91)90005-7; YIN TP, 1983, ENDOSCOPY, V15, P27, DOI 10.1055/s-2007-1018601; Yin TP, 1983, ENDOSCOPY, V31, P265; ZUPPIROLI A, 1995, AM J CARDIOL, V75, P1028, DOI 10.1016/S0002-9149(99)80718-8	66	705	732	1	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	1997	277	22					1794	1801		10.1001/jama.277.22.1794	http://dx.doi.org/10.1001/jama.277.22.1794			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XC499	9178793				2022-12-28	WOS:A1997XC49900033
J	delaFuente, JM; RamirezRodriguez, V; CabreraPonce, JL; HerreraEstrella, L				delaFuente, JM; RamirezRodriguez, V; CabreraPonce, JL; HerreraEstrella, L			Aluminum tolerance in transgenic plants by alteration of citrate synthesis	SCIENCE			English	Article							TRITICUM-AESTIVUM L; SORGHUM GENOTYPES; ROOT APICES; TOXICITY; ACID; GROWTH	Aluminum when in soluble form, as found in acidic soils that comprise about 40 percent of the world's arable land, is toxic to many crops. Organic acid excretion has been correlated with aluminum tolerance in higher plants. Overproduction of citrate was shown to result in aluminum tolerance in transgenic tobacco (Nicotiana tabacum) and papaya (Carica papaya) plants.	CINVESTAV IPN,DEPT INGN GENET,UNIDAD IRAPUATO,IRAPUATO 36500,GUANAJUATO,MEXICO	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional			Estrella, Luis R Herrera/G-7351-2011; PONCE, JOSE LUIS CABRERA/H-3051-2012; Herrera-Estrella, Luis/AAL-2472-2020; Herrera-Estrella, Luis/ABC-7431-2020	Estrella, Luis R Herrera/0000-0001-7936-3856; Herrera-Estrella, Luis/0000-0001-7936-3856; CABRERA PONCE, JOSE LUIS/0000-0002-6142-1963				BALIGAR VC, 1989, PLANT SOIL, V116, P257, DOI 10.1007/BF02214555; BALIGAR VC, 1993, PLANT SOIL, V150, P271, DOI 10.1007/BF00013024; BARTLETT RJ, 1972, PLANT SOIL, V37, P419, DOI 10.1007/BF02139985; CABRERAPONCE JL, 1995, PLANT CELL REP, V15, P1, DOI 10.1007/BF01690242; DELAFUENTE JM, UNPUB; DELHAIZE E, 1993, PLANT PHYSIOL, V103, P695, DOI 10.1104/pp.103.3.695; DELHAIZE E, 1995, PLANT PHYSIOL, V107, P315, DOI 10.1104/pp.107.2.315; DELHAIZE E, 1993, PLANT PHYSIOL, V103, P685, DOI 10.1104/pp.103.3.685; DONALD LJ, 1989, J BACTERIOL, V171, P5542, DOI 10.1128/jb.171.10.5542-5550.1989; FOY CD, 1978, ANNU REV PLANT PHYS, V29, P511, DOI 10.1146/annurev.pp.29.060178.002455; Herrera-Estrella L., 1988, PLANT MOL BIOL PRACT, P131; HUE NV, 1986, SOIL SCI SOC AM J, V50, P28, DOI 10.2136/sssaj1986.03615995005000010006x; KOCHIAN VL, 1995, PLANT MOL BIOL, V46, P237; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MIYASAKA SC, 1991, PLANT PHYSIOL, V96, P737, DOI 10.1104/pp.96.3.737; OWNBY J D, 1989, Journal of Plant Physiology, V135, P588; PARROT WA, 1990, CROP SCI, V30, P387, DOI 10.2135/cropsci1990.0011183X003000020030x; PELLET DM, 1995, PLANTA, V196, P788, DOI 10.1007/BF01106775; PICHA DH, 1985, J AGR FOOD CHEM, V33, P743, DOI 10.1021/jf00064a045; POLLE E, 1978, CROP SCI, V30, P389; RYAN PR, 1993, J EXP BOT, V44, P437, DOI 10.1093/jxb/44.2.437; RYAN PR, 1995, PLANTA, V196, P103, DOI 10.1007/BF00193223; TAIZ L, 1995, PLANT PHYSIOL, V108, P29	23	345	372	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 6	1997	276	5318					1566	1568		10.1126/science.276.5318.1566	http://dx.doi.org/10.1126/science.276.5318.1566			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XC701	9171061				2022-12-28	WOS:A1997XC70100044
J	Craig, TKJ; Boardman, AP				Craig, TKJ; Boardman, AP			ABC of mental health - Common mental health problems in primary care	BRITISH MEDICAL JOURNAL			English	Article									LAMBETH HEALTHCARE NHS TRUST,LONDON,ENGLAND; UNIV KEELE,KEELE ST5 5BG,STAFFS,ENGLAND	Keele University	Craig, TKJ (corresponding author), UNITED MED & DENT SCH,ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND.		Craig, Tom K J/A-9083-2011					[Anonymous], 1995, WORLD MENTAL HLTH PR; Goldberg DP., 1992, COMMON MENTAL DISORD; MELTZER H, 1995, PREVALENCE PSYCHIAT, V1; Pullen I, 1994, PSYCHIAT GEN PRACTIC; USTUN TB, 1995, MENTAL ILLNESS GEN H; 1996, PRESCRIBERS J, V36, P181	6	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 31	1997	314	7094					1609	1612		10.1136/bmj.314.7094.1609	http://dx.doi.org/10.1136/bmj.314.7094.1609			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XC500	9186176	Green Published			2022-12-28	WOS:A1997XC50000032
J	Robertson, NP; ORiordan, JI; Chataway, J; Kingsley, DPE; Miller, DH; Clayton, D; Compston, DAS				Robertson, NP; ORiordan, JI; Chataway, J; Kingsley, DPE; Miller, DH; Clayton, D; Compston, DAS			Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis	LANCET			English	Article							EAST-ANGLIA; MRI; CONSANGUINITY; DISTRICT; CRITERIA; TWINS	Background There has been no previous systematic study of conjugal multiple sclerosis. This study of conjugal pairs with complex traits investigated disease transmissibility and the genetic contribution to frequency and clinical course. Methods We studied 45 conjugal pairs concordant for multiple sclerosis from 58 pairs recorded in a national register of familial disease. 86 offspring of the 45 pairs were individually assessed for clinical evidence of neurological disease; those over age 16 underwent cranial resonance imaging. Clinical features were in 33 pairs in whom neither member had symptoms before they met. Findings Of the 86 offspring, five (6%) bad clinically definite multiple sclerosis. A further five children had either characteristic imaging abnormalities or clinical symptoms consistent with demyelination, but did not meet the criteria for clinically definite disease. There was no evidence of clinical concordance, clustering at year of onset, or distortion of the expected pattern of age of onset in the second affected spouse from 33 pairs. The crude recurrence in children of conjugal pairs (1 in 17) is significantly higher than previously reported population-based risks for offspring of single affected parents (1 in 200). Interpretation Taken with the low prevalence of multiple sclerosis in the spouses of affected individuals, and the lack of concordance for age at onset in these families, the disparity in crude recurrence between children of conjugal pairs and those of single affected parents shows that the recurrence risk in children is determined by genetic factors inherited from both parents.	INST NEUROL,MR RES UNIT,LONDON WC1N 3BG,ENGLAND; MRC,CAMBRIDGE CTR BRAIN REPAIR,CAMBRIDGE,ENGLAND; INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND	University of London; University College London; University of Cambridge; MRC Biostatistics Unit; University of Cambridge	Robertson, NP (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,NEUROL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND.			O'Riordan, Jonathan/0000-0001-6774-2488				Agresti A, 1992, Stat Methods Med Res, V1, P201, DOI 10.1177/096228029200100205; Allison RS, 1954, ULSTER MED J      S2, V23, P5; BINZER M, 1994, J NEUROL NEUROSUR PS, V57, P497, DOI 10.1136/jnnp.57.4.497; *CAMBR COUNT COUNC, 1992, POP FOR 1989 2001; CENDROWSKI WS, 1966, J NEUROL SCI, V3, P349, DOI 10.1016/0022-510X(66)90012-8; CONFAVREUX C, 1992, J NEUROL NEUROSUR PS, V55, P671, DOI 10.1136/jnnp.55.8.671; Constantinescu C S, 1995, Mult Scler, V1, P170; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; EDAN G, 1991, REV NEUROL, V147, P595; FAZEKAS F, 1989, EUR NEUROL, V29, P164, DOI 10.1159/000116401; FINELLI PF, 1991, NEUROLOGY, V441, P1320; FREDRIKSON S, 1992, NEUROLOGY, V42, P577, DOI 10.1212/WNL.42.3.577; GILBERT GJ, 1971, NEUROLOGY, V21, P1169, DOI 10.1212/WNL.21.11.1169; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LYNCH SG, 1990, NEUROLOGY, V40, P900, DOI 10.1212/WNL.40.6.900; McAlpine D., 1955, MULT SCLER J; MUMFORD CJ, 1992, J NEUROL NEUROSUR PS, V55, P877, DOI 10.1136/jnnp.55.10.877; MUMFORD CJ, 1994, NEUROLOGY, V44, P5; OFFENBACHER H, 1993, NEUROLOGY, V43, P905, DOI 10.1212/WNL.43.5.905; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; ROBERTS DF, 1991, GENET EPIDEMIOL, V8, P147, DOI 10.1002/gepi.1370080302; ROBERTSON N, 1995, J NEUROL NEUROSUR PS, V59, P71, DOI 10.1136/jnnp.59.1.71; Robertson NP, 1996, BRAIN, V119, P449, DOI 10.1093/brain/119.2.449; ROBERTSON NP, 1996, J EPIDEMIOL COMMUNIT, V50, P1; Sadovnick AD, 1996, LANCET, V347, P1728, DOI 10.1016/S0140-6736(96)90807-7; SADOVNICK AD, 1982, LANCET, V1, P1068; SCHAPIRA K, 1963, BRAIN, V86, P315, DOI 10.1093/brain/86.2.315; SWINGLER RJ, 1988, J NEUROL NEUROSUR PS, V51, P1520, DOI 10.1136/jnnp.51.12.1520; THORPE JW, 1994, J NEUROL NEUROSUR PS, V57, P491, DOI 10.1136/jnnp.57.4.491; TIENARI PJ, 1992, J NEUROL NEUROSUR PS, V55, P883, DOI 10.1136/jnnp.55.10.883	31	79	80	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 31	1997	349	9065					1587	1590		10.1016/S0140-6736(96)07317-5	http://dx.doi.org/10.1016/S0140-6736(96)07317-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB673	9174560				2022-12-28	WOS:A1997XB67300009
J	Kouhara, H; Hadari, YR; SpivakKroizman, T; Schilling, J; BarSagi, D; Lax, I; Schlessinger, J				Kouhara, H; Hadari, YR; SpivakKroizman, T; Schilling, J; BarSagi, D; Lax, I; Schlessinger, J			A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway	CELL			English	Article							GROWTH-FACTOR RECEPTOR; INSULIN-RECEPTOR; TYROSINE KINASES; POINT MUTATION; SH3 DOMAINS; PC12 CELLS; DIFFERENTIATION; GRB2; TRANSDUCTION; MITOGENESIS	Activation of the Ras/MAPK signaling cascade is essential for growth factor-induced cell proliferation and differentiation. In this report, we describe the purification, cloning, and characterization of a novel protein, designated FRS2, that is tyrosine phosphorylated and binds to Grb2/Sos in response to FGF or NGF stimulation. We find that FRS2 is myristylated and that this modification is essential for membrane localization, tyrosine phosphorylation, Grb2/Sos recruitment, and MAPK activation. FRS2 functions as a lipid-anchored docking protein that targets signaling molecules to the plasma membrane in response to FGF stimulation to link receptor activation with the MAPK and other signaling pathways essential for cell growth and differentiation. Finally, we demonstrate that FRS2 is closely related and probably indentical to SNT, the long-sought target of FGF and NGF receptors.	SUGEN INC,REDWOOD CITY,CA 94063; SUNY STONY BROOK,DEPT MICROBIOL & MOL GENET,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kouhara, H (corresponding author), NYU,MED CTR,DEPT PHARMACOL,500 1ST AVE,NEW YORK,NY 10016, USA.			Bar-Sagi, Dafna/0000-0003-2597-8948				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; ONEILL TJ, 1994, MOL CELL BIOL, V14, P8433; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002	29	707	722	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 30	1997	89	5					693	702		10.1016/S0092-8674(00)80252-4	http://dx.doi.org/10.1016/S0092-8674(00)80252-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182757	hybrid			2022-12-28	WOS:A1997XB92500006
J	Malmberg, K				Malmberg, K			Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus	BRITISH MEDICAL JOURNAL			English	Article							GLYCEMIC CONTROL; GLUCOSE INFUSION; RISK-FACTORS; PROGNOSIS; MORTALITY; DISEASE; TRIAL; NIDDM	Objectives: To test the hypothesis that intensive metabolic treatment with insulin-glucose infusion followed by multidose insulin treatment in patients with diabetes mellitus and acute myocardial infarction improves the prognosis. Design: Patients with diabetes mellitus and acute myocardial infarction were randomly allocated standard treatment plus insulin-glucose infusion for at least 24 hours followed by multidose insulin treatment or standard treatment (controls). Subjects: 620 patients were recruited of whom 306 received intensive insulin treatment and 314 served as controls. Main outcome measure: Long term all cause mortality. Results: The mean (range) follow up was 3.4 (1.6-5.6) years. There were 102 (33%) deaths in the treatment group compared with 138 (44%) deaths in the control group (relative risk (95% confidence interval) 0.72 (0.55 to 0.92); P = 0.011). The effect was most pronounced among the predefined group that included 272 patients without previous insulin treatment and at a low cardiovascular risk (0.49 (0.30 to 0.80); P = 0.004). Conclusion: Insulin-glucose infusion followed by intensive subcutaneous insulin in diabetic patients with acute myocardial infarction improves long term survival, and the effect seen at one year continues for at least 3.5 years, with an absolute reduction in mortality of 11%. This means that one life was saved for nine treated patients. The effect was most apparent in patients who had not previously received insulin treatment and who were at a low cardiovascular risk.			Malmberg, K (corresponding author), KAROLINSKA HOSP,DEPT CARDIOL,S-17176 STOCKHOLM,SWEDEN.							ABBUD ZA, 1995, AM HEART J, V130, P51, DOI 10.1016/0002-8703(95)90235-X; ANDERSSON DKG, 1995, DIABETES CARE, V18, P1534, DOI 10.2337/diacare.18.12.1534; COX DR, 1972, J R STAT SOC B, V34, P187; DAVI G, 1990, NEW ENGL J MED, V322, P1769, DOI 10.1056/NEJM199006213222503; Diabet Control Complications Trial DCCT Res Grp, 1995, AM J CARDIOL, V75, P894; GALL MA, 1995, DIABETES, V44, P1303, DOI 10.2337/diabetes.44.11.1303; GRANGER CB, 1993, J AM COLL CARDIOL, V21, P920, DOI 10.1016/0735-1097(93)90348-5; HERLITZ J, 1988, ACTA MED SCAND, V24, P31; JACOBY RM, 1992, J AM COLL CARDIOL, V20, P736, DOI 10.1016/0735-1097(92)90033-J; JAFFE AS, 1984, AM HEART J, V108, P31, DOI 10.1016/0002-8703(84)90541-6; JAIN SK, 1993, DIABETIC MED, V10, P27, DOI 10.1111/j.1464-5491.1993.tb01992.x; KARLSON BW, 1993, DIABETIC MED, V10, P449, DOI 10.1111/j.1464-5491.1993.tb00097.x; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LINDSTROM T, 1993, THESIS LINKOPING U; Malmberg K, 1996, EUR HEART J, V17, P1337; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; MALMBERG K, 1988, EUR HEART J, V9, P256; MALMBERG KA, 1994, DIABETES CARE, V17, P1007, DOI 10.2337/diacare.17.9.1007; ORLANDER PR, 1994, DIABETES, V43, P897, DOI 10.2337/diabetes.43.7.897; ROGERS WJ, 1979, AM J CARDIOL, V43, P801, DOI 10.1016/0002-9149(79)90081-X; RYTTER L, 1984, ACTA ENDOCR-COP    S, V262, P83; SAVAGE MP, 1988, AM J CARDIOL, V62, P665, DOI 10.1016/0002-9149(88)91199-X; SINGER DE, 1989, DIABETES, V38, P350, DOI 10.2337/diabetes.38.3.350; SMITH JW, 1984, AM J CARDIOL, V54, P718, DOI 10.1016/S0002-9149(84)80196-4; STONE PH, 1989, J AM COLL CARDIOL, V14, P49, DOI 10.1016/0735-1097(89)90053-3; ULVENSTAM G, 1985, DIABETES, V34, P787, DOI 10.2337/diabetes.34.8.787; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063	27	903	968	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 24	1997	314	7093					1512	1515		10.1136/bmj.314.7093.1512	http://dx.doi.org/10.1136/bmj.314.7093.1512			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB484	9169397	Green Published			2022-12-28	WOS:A1997XB48400022
J	Hawley, RS				Hawley, RS			Update: Cell biology - Sticky endings: Separating telomeres	SCIENCE			English	Editorial Material											Hawley, RS (corresponding author), UNIV CALIF DAVIS,DEPT GENET,SECT MOL & CELLULAR BIOL,DAVIS,CA 95616, USA.			Hawley, R. Scott/0000-0002-6478-0494				Cenci G, 1997, GENE DEV, V11, P863, DOI 10.1101/gad.11.7.863; Conrad MN, 1997, SCIENCE, V276, P1252, DOI 10.1126/science.276.5316.1252; DERNBURG AF, 1996, TELOMERES, P295; Hawley RS, 1997, SCIENCE, V275, P1441; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478	5	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 23	1997	276	5316					1215	1215		10.1126/science.276.5316.1215	http://dx.doi.org/10.1126/science.276.5316.1215			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XA497	9182332				2022-12-28	WOS:A1997XA49700031
J	Brunner, E				Brunner, E			Socioeconomic determinants of health - Stress and the biology of inequality	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRITISH CIVIL-SERVANTS; ISCHEMIC-HEART-DISEASE; CHRONIC SOCIAL STRESS; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; EMPLOYMENT GRADE; WHITEHALL-II; WILD BABOONS; SELF-ESTEEM; ASSOCIATION	It is well established that health depends an socioeconomic circumstances, but the biology of this relation is not well described. Psychosocial factors operating throughout the life course, beginning in early life, Influence a variety of biological variables. Research with non-human primates shows the effects of dominance hierarchy on biology, and similar metabolic differentials are evident in a hierarchy of white collar civil servants. The neuroendocrine ''fight or flight'' response produces physiological and metabolic alterations which parallel those observed with lower socioeconomic status. The biological effects of the psychosocial environment could explain health inequalities between relatively affluent groups.			Brunner, E (corresponding author), UCL, INT CTR HLTH & SOC, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND.		Brunner, Eric/H-2114-2011	Brunner, Eric/0000-0002-0595-4474				ALGRA A, 1993, CIRCULATION, V88, P180, DOI 10.1161/01.CIR.88.1.180; ANDA R, 1993, EPIDEMIOLOGY, V4, P285, DOI 10.1097/00001648-199307000-00003; BARTLEY M, 1994, J EPIDEMIOL COMMUN H, V48, P333, DOI 10.1136/jech.48.4.333; BJORNTORP P, 1991, J INTERN MED, V230, P195; Bosma H, 1997, BRIT MED J, V314, P558, DOI 10.1136/bmj.314.7080.558; BROWN GW, 1986, PSYCHOL MED, V16, P813, DOI 10.1017/S0033291700011831; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; BRUNNER EJ, 1993, ATHEROSCLEROSIS, V102, P195, DOI 10.1016/0021-9150(93)90162-N; BRUNNER EJ, 1997, DIET NUTRITION CHRON; CARROLL D, 1996, J HEALTH PSYCHOL, V1, P1; CHECKLEY S, 1992, BRIT J PSYCHIAT, V160, P7, DOI 10.1192/S0007125000296633; COHEN S, 1992, PSYCHOL SCI, V3, P301, DOI 10.1111/j.1467-9280.1992.tb00677.x; COLHOUN W, 1997, HLTH SURVEY ENGLAND; DELITALA G, 1991, NEUROENDOCRINOLOGY, V53, P41, DOI 10.1159/000125695; EAKER ED, 1992, AM J EPIDEMIOL, V135, P854, DOI 10.1093/oxfordjournals.aje.a116381; FONAGY P, 1996, SOCIAL ORG HLTH, P125; GALLIE D, 1994, SOCIAL CHANGE EXPERI, P299; GROSSMAN AB, 1991, STRESS NEUROBIOLOGY, P151; HEMINGWAY H, 1997, EVIDENCE BASED CARDI; KARASEK R, 1981, AM J PUBLIC HEALTH, V71, P694, DOI 10.2105/AJPH.71.7.694; MARMOT MG, 1986, POSTGRAD MED J, V62, P683, DOI 10.1136/pgmj.62.729.683; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1984, LANCET, V1, P1003; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; McCarty R, 1996, PSYCHOSOM MED, V58, P590, DOI 10.1097/00006842-199611000-00007; MCEWEN BS, 1997, ANN NY ACAD SCI, V57, P275; North FM, 1996, AM J PUBLIC HEALTH, V86, P332, DOI 10.2105/AJPH.86.3.332; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; POCOCK SJ, 1987, LANCET, V2, P197; Power C, 1997, BRIT MED BULL, V53, P210; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; SAPOLSKY RM, 1993, RECENT PROG HORM RES, V48, P437; SAPOLSKY RM, 1986, ENDOCR REV, V7, P284, DOI 10.1210/edrv-7-3-284; SAPOLSKY RM, 1987, ENDOCRINOLOGY, V121, P1605, DOI 10.1210/endo-121-5-1605; SAPOLSKY RM, 1991, SCIENCES, V31, P8, DOI 10.1002/j.2326-1951.1991.tb02328.x; SCHNALL PL, 1994, ANNU REV PUBL HEALTH, V15, P381, DOI 10.1146/annurev.pu.15.050194.002121; SEEMAN TE, 1995, J PSYCHOSOM RES, V39, P69, DOI 10.1016/0022-3999(94)00076-H; Selye H, 1956, J BONE JOINT SURG; SHIVELY CA, 1994, ARTERIOSCLER THROMB, V14, P721, DOI 10.1161/01.ATV.14.5.721; Smith GD, 1997, BMJ-BRIT MED J, V314, P547, DOI 10.1136/bmj.314.7080.547; Suomi SJ, 1997, BRIT MED BULL, V53, P170; Townsend P, 1990, INEQUALITIES HLTH BL; ULLAH P, 1990, J OCCUP PSYCHOL, V63, P317, DOI 10.1111/j.2044-8325.1990.tb00533.x; WIDDOWSON EM, 1951, LANCET, V260, P1318; WOODROFFE C, 1993, CHILDREN TEENAGERS H	45	282	286	1	57	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 17	1997	314	7092					1472	1476		10.1136/bmj.314.7092.1472	http://dx.doi.org/10.1136/bmj.314.7092.1472			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XA202	9167568	Green Published			2022-12-28	WOS:A1997XA20200030
J	Gutmann, DH; Aylsworth, A; Carey, JC; Korf, B; Marks, J; Pyeritz, RE; Rubenstein, A; Viskochil, D				Gutmann, DH; Aylsworth, A; Carey, JC; Korf, B; Marks, J; Pyeritz, RE; Rubenstein, A; Viskochil, D			The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							AU-LAIT SPOTS; BILATERAL ACOUSTIC NEUROMAS; SEGMENTAL NEUROFIBROMATOSIS; TYPE-1 NEUROFIBROMATOSIS; STEREOTAXIC RADIOSURGERY; MRI ABNORMALITIES; NOONAN SYNDROME; GENE; CHILDREN; MUTATIONS	Objective.-Neurofibromatosis 1 and neurofibromatosis 2 are autosomal dominant genetic disorders in which affected individuals develop both benign and malignant tumors at an increased frequency, Since the original National Institutes of Health Consensus Development Conference in 1987, there has been significant progress toward a more complete understanding of the molecular bases for neurofibromatosis 1 and neurofibromatosis 2. Our objective was to determine the diagnostic criteria for neurofibromatosis 1 and neurofibromatosis 2, recommendations for the care of patients and their families at diagnosis and during routine follow-up, and the role of DNA diagnostic testing in the evaluation of these disorders, Data Sources.-Published reports from 1966 through 1996 obtained by MEDLINE search and studies presented at national and international meetings. Study Selection.-All studies were reviewed and analyzed by consensus from multiple authors. Data Extraction.-Peer-reviewed published data were critically evaluated by independent extraction by multiple authors. Data Synthesis.-The main results of the review were qualitative and were reviewed by neurofibromatosis clinical directors worldwide through an Internet Web site. Conclusions.-On the basis of the information presented in this review, we propose a comprehensive approach to the diagnosis and treatment of individuals with neurofibromatosis 1 and neurofibromatosis 2.	UNIV N CAROLINA, CHAPEL HILL, NC USA; UNIV UTAH, SALT LAKE CITY, UT USA; BOSTON CHILDRENS HOSP, BOSTON, MA USA; SARAH LAWRENCE COLL, BRONXVILLE, NY 10708 USA; ALLEGHENY UNIV HLTH SCI, PITTSBURGH, PA USA; MT SINAI SCH MED, NEW YORK, NY USA	University of North Carolina; University of North Carolina Chapel Hill; Utah System of Higher Education; University of Utah; Harvard University; Boston Children's Hospital; Sarah Lawrence College; Icahn School of Medicine at Mount Sinai	Gutmann, DH (corresponding author), WASHINGTON UNIV, SCH MED, ST LOUIS CHILDRENS HOSP, DEPT NEUROL, NEUROFIBROMATOSIS PROGRAM, ST LOUIS, MO 63110 USA.		Pyeritz, Reed/A-1364-2010	Gutmann, David/0000-0002-3127-5045				ABELIOVICH D, 1995, J MED GENET, V32, P985, DOI 10.1136/jmg.32.12.985; AHLBOM BE, 1995, CLIN GENET, V48, P85; ALLANSON JE, 1991, J MED GENET, V28, P752, DOI 10.1136/jmg.28.11.752; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; ARNSMEIER SL, 1994, ARCH DERMATOL, V130, P1425, DOI 10.1001/archderm.130.11.1425; BADER JL, 1986, ANN NY ACAD SCI, V486, P57, DOI 10.1111/j.1749-6632.1986.tb48062.x; BASER M, 1996, 1996 FASEB SUMM RES; BOURN D, 1994, HUM MOL GENET, V3, P813, DOI 10.1093/hmg/3.5.813; BRIGGS RJS, 1994, ARCH OTOLARYNGOL, V120, P1307; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Chapman CA, 1996, AM J MED GENET, V67, P127, DOI 10.1002/(SICI)1096-8628(19960409)67:2<127::AID-AJMG1>3.0.CO;2-P; CHARROW J, 1993, AM J MED GENET, V45, P606, DOI 10.1002/ajmg.1320450518; Clementi M, 1996, HEADACHE, V36, P10, DOI 10.1046/j.1526-4610.1996.3601010.x; Colman SD, 1996, AM J HUM GENET, V58, P484; CROWE FW, 1964, ANN INTERN MED, V61, P1142, DOI 10.7326/0003-4819-61-6-1142; DIPAOLO DP, 1995, RADIOLOGY, V195, P721, DOI 10.1148/radiology.195.3.7754001; DUFFNER PK, 1989, NEUROLOGY, V39, P373, DOI 10.1212/WNL.39.3.373; EVANS DGR, 1995, J MED GENET, V32, P470, DOI 10.1136/jmg.32.6.470; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; EVANS DGR, 1992, Q J MED, V84, P603; Gutmann DH, 1996, ARCH DERMATOL, V132, P1390, DOI 10.1001/archderm.132.11.1390; HEIM RA, 1994, NAT GENET, V8, P218, DOI 10.1038/ng1194-218; HOFFMAN RA, 1992, AM J OTOL, V13, P525; HOFMAN KJ, 1994, J PEDIATR-US, V124, pS1, DOI 10.1016/S0022-3476(05)83163-4; Huson SHR, 1994, NEUROFIBROMATOSES PA; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; KANTER WR, 1980, NEUROLOGY, V30, P851, DOI 10.1212/WNL.30.8.851; KAYES LM, 1992, J MED GENET, V29, P686, DOI 10.1136/jmg.29.10.686; KORF BR, 1992, PEDIATRICS, V90, P924; LINSKEY ME, 1992, NEUROSURGERY, V31, P829, DOI 10.1227/00006123-199211000-00002; Listernick R, 1997, ANN NEUROL, V41, P143, DOI 10.1002/ana.410410204; LISTERNICK R, 1995, J PEDIATR-US, V127, P718, DOI 10.1016/S0022-3476(95)70159-1; LUNSFORD LD, 1992, OTOLARYNG CLIN N AM, V25, P471; MacCollin M, 1996, NEUROLOGY, V46, P1072, DOI 10.1212/WNL.46.4.1072; Matsui I, 1993, CANCER, V72, P746; Mautner VF, 1996, NEUROSURGERY, V38, P880, DOI 10.1097/00006123-199605000-00004; MEREL P, 1995, GENE CHROMOSOME CANC, V12, P117, DOI 10.1002/gcc.2870120206; MIYAMOTO RT, 1990, OTOLARYNG HEAD NECK, V103, P619, DOI 10.1177/019459989010300416; Moore BD, 1996, NEUROLOGY, V46, P1660, DOI 10.1212/WNL.46.6.1660; MOSS C, 1994, BRIT J DERMATOL, V130, P106, DOI 10.1111/j.1365-2133.1994.tb06893.x; MULVIHILL JJ, 1990, ANN INTERN MED, V113, P39, DOI 10.7326/0003-4819-113-1-39; NADOL JB, 1992, LARYNGOSCOPE, V102, P1153, DOI 10.1288/00005537-199210000-00010; NORTH K, 1993, J CHILD NEUROL, V8, P395, DOI 10.1177/088307389300800421; NORTH K, 1994, NEUROLOGY, V44, P878, DOI 10.1212/WNL.44.5.878; OBRINGER AC, 1989, AM J DIS CHILD, V143, P717, DOI 10.1001/archpedi.1989.02150180099028; OJEMANN RG, 1993, CLIN NEUROSURG, V40, P489; PACKER RJ, 1993, J CLIN ONCOL, V11, P850, DOI 10.1200/JCO.1993.11.5.850; PARRY DM, 1994, AM J MED GENET, V52, P450, DOI 10.1002/ajmg.1320520411; Parry DM, 1996, AM J HUM GENET, V59, P529; PULST SM, 1993, NEUROLOGY, V43, P2096, DOI 10.1212/WNL.43.10.2096; RAGGE NK, 1995, AM J OPHTHALMOL, V120, P634, DOI 10.1016/S0002-9394(14)72210-X; Riccardi V. M., 1992, NEUROFIBROMATOSIS PH; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Ruttledge MH, 1996, AM J HUM GENET, V59, P331; Scoles DR, 1996, NEUROLOGY, V47, P544, DOI 10.1212/WNL.47.2.544; SHARLAND M, 1992, ARCH DIS CHILD, V67, P178, DOI 10.1136/adc.67.2.178; SLOAN JB, 1990, J AM ACAD DERMATOL, V22, P461, DOI 10.1016/0190-9622(90)70065-P; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WATSON GH, 1967, ARCH DIS CHILD, V42, P303, DOI 10.1136/adc.42.223.303; WOODRUFF JM, 1983, AM J SURG PATHOL, V7, P691, DOI 10.1097/00000478-198310000-00009; WU BL, 1995, AM J MED GENET, V59, P528, DOI 10.1002/ajmg.1320590427; ZIGMOND N, 1995, J CHILD NEUROL, V10, pS86, DOI 10.1177/08830738950100S117; ZVULUNOV A, 1995, ARCH DERMATOL, V131, P904, DOI 10.1001/archderm.131.8.904	66	916	962	3	75	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					51	57		10.1001/jama.278.1.51	http://dx.doi.org/10.1001/jama.278.1.51			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG387	9207339				2022-12-28	WOS:A1997XG38700037
J	McManus, BM; Gascoyne, RD				McManus, BM; Gascoyne, RD			Pathology and laboratory medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											McManus, BM (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER,BC V5Z 1M9,CANADA.							*COLL AM PATH C 29, 1996, ARCH PATHOL LAB MED, V120, P693; Farkas DH, 1996, ARCH PATHOL LAB MED, V120, P591; Goldschmidt D, 1996, LAB INVEST, V75, P295; Hancock WW, 1996, AM J PATHOL, V148, P681; Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Jones BA, 1996, ARCH PATHOL LAB MED, V120, P523; LiVolsi VA, 1996, AM J CLIN PATHOL, V105, P260; MacLeod MC, 1996, MOL CARCINOGEN, V15, P241, DOI 10.1002/(SICI)1098-2744(199604)15:4<241::AID-MC1>3.0.CO;2-J; Nolte KB, 1996, HUM PATHOL, V27, P1253, DOI 10.1016/S0046-8177(96)90332-9; Oury TD, 1996, LAB INVEST, V75, P617; Steeg PS, 1996, AM J PATHOL, V149, P733; Tykocinski ML, 1996, AM J PATHOL, V148, P1; Vidal R, 1996, AM J PATHOL, V148, P361; Weinberg DS, 1996, HUM PATHOL, V27, P111, DOI 10.1016/S0046-8177(96)90363-9	15	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1887	1889		10.1001/jama.277.23.1887	http://dx.doi.org/10.1001/jama.277.23.1887			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185818				2022-12-28	WOS:A1997XD54400037
J	Gruer, L; Wilson, P; Scott, R; Elliott, L; Macleod, J; Harden, K; Forrester, E; Hinshelwood, S; McNulty, H; Silk, P				Gruer, L; Wilson, P; Scott, R; Elliott, L; Macleod, J; Harden, K; Forrester, E; Hinshelwood, S; McNulty, H; Silk, P			General practitioner centred scheme for treatment of opiate dependent drug injectors in Glasgow	BMJ-BRITISH MEDICAL JOURNAL			English	Article							METHADONE-MAINTENANCE; USERS		UNIV GLASGOW, DEPT GEN PRACTICE, WOODSIDE HLTH CTR, GLASGOW G20 7LR, LANARK, SCOTLAND; RUCHILL HOSP, PROBLEM SERV, GLASGOW G20 9NB, LANARK, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP, SCH NURSING & MIDWIFERY, DUNDEE DD1 9SY, SCOTLAND; LOCAL MED COMM, GLASGOW G4 9JT, LANARK, SCOTLAND; GLASGOW ROYAL INFIRM, PRESCRIBING ADVISERS DEPT, GLASGOW G4 0SF, LANARK, SCOTLAND; GREATER GLASGOW HLTH BOARD, GLASGOW G1 1ET, LANARK, SCOTLAND; GLASGOW CITY COUNCIL, DEPT SOCIAL WORK, COMMUNITY CARE SERV, GLASGOW G2 4PF, LANARK, SCOTLAND	University of Glasgow; University of Dundee; University of Glasgow	Gruer, L (corresponding author), RUCHILL HOSP, HIV & ADDICT RESOURCE CTR, GLASGOW G20 9NB, LANARK, SCOTLAND.		Wilson, Philip/V-6519-2019	Wilson, Philip/0000-0002-4123-8248; Gruer, Laurence/0000-0002-1089-2896				ABED RT, 1990, BRIT J ADDICT, V85, P131; *ADV COUNC MIS DRU, 1993, AIDS DRUG MIS UPD RE; Ball J.C., 2012, EFFECTIVENESS METHAD; Bell J, 1996, ADDICT RES, V3, P315, DOI 10.3109/16066359609005245; BURY J, 1995, INT J DRUG POLICY, V6, P267; Cairns A, 1996, BMJ-BRIT MED J, V313, P264, DOI 10.1136/bmj.313.7052.264; CLANZ A, 1986, BRIT MED J, V293, P543; COHEN J, 1992, BRIT MED J, V304, P1158, DOI 10.1136/bmj.304.6835.1158; DARKE S, 1992, BR J ADDICT, V87, P593; FARRELL M, 1994, BMJ-BRIT MED J, V309, P997, DOI 10.1136/bmj.309.6960.997; FRISCHER M, 1993, AM J EPIDEMIOL, V138, P170, DOI 10.1093/oxfordjournals.aje.a116843; FRISCHER M, 1993, J EPIDEMIOL COMMUN H, V47, P59, DOI 10.1136/jech.47.1.59; GREENWOOD J, 1992, BRIT J ADDICT, V87, P567; GREENWOOD J, 1990, BRIT MED J, V300, P587, DOI 10.1136/bmj.300.6724.587; GREENWOOD J, 1996, PSYCHIAT B, V20, P8; Gruer L, 1997, BRIT MED J, V314, P1691, DOI 10.1136/bmj.314.7095.1691; GRUER L, 1993, DRUG MISUSE HLTH GLA; *I STUD DRUG DEP, 1997, DRUG US BRIT 1996; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; *MIN DRUGS TASK FO, 1994, SCOTL M CHALL; PLATT JJ, 1995, HEROIN ADDICTION THE, V3; *SCOTT CTR INF ENV, 1995, HIV AIDS SURV SCOTL; SCOTT RA, 1994, BRIT MED J, V308, P1438, DOI 10.1136/bmj.308.6941.1438; SCOTT RTA, 1995, BMJ-BRIT MED J, V310, P464, DOI 10.1136/bmj.310.6977.464c; Strang J, 1996, BMJ-BRIT MED J, V313, P270, DOI 10.1136/bmj.313.7052.270; *TASK FORC REV SER, 1996, REP; WILSON P, 1994, BRIT MED J, V309, P641, DOI 10.1136/bmj.309.6955.641	27	61	62	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	1997	314	7096					1730	1735		10.1136/bmj.314.7096.1730	http://dx.doi.org/10.1136/bmj.314.7096.1730			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9202504	Green Published			2022-12-28	WOS:A1997XE90900026
J	Stenger, S; Mazzaccaro, RJ; Uyemura, K; Cho, S; Barnes, PF; Rosat, JP; Sette, A; Brenner, MB; Porcelli, SA; Bloom, BR; Modlin, RL				Stenger, S; Mazzaccaro, RJ; Uyemura, K; Cho, S; Barnes, PF; Rosat, JP; Sette, A; Brenner, MB; Porcelli, SA; Bloom, BR; Modlin, RL			Differential effects of cytolytic T cell subsets on intracellular infection	SCIENCE			English	Article							LYMPHOCYTES-T; FAS LIGAND; PERFORIN; CYTOTOXICITY; MECHANISM; RECOGNITION; PATHWAYS; PEPTIDE; LYSIS; MICE	In analyzing mechanisms of protection against intracellular infections, a series of human CD1-restricted T cell lines of two distinct phenotypes were derived. Both CD4(-)-CD8(-) (double-negative)T cells and CD8(+) T cells efficiently lysed macrophages infected with Mycobacterium tuberculosis. The cytotoxicity of CD4(-)CD8(-) T cells was mediated by Fas-FasL interaction and had no effect on the viability of the mycobacteria. The CD8(+) T cells lysed infected macrophages by a Fas-independent, granule-dependent mechanism that resulted in killing of bacteria. These data indicate that two phenotypically distinct subsets of human cytolytic T lymphocytes use different mechanisms to kill infected cells and contribute in different ways to host defense against intracellular infection.	UNIV CALIF LOS ANGELES, SCH MED, DIV DERMATOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90095 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, HOWARD HUGHES MED INST, BRONX, NY 10461 USA; UNIV SO CALIF, SCH MED, DEPT MED, LOS ANGELES, CA 90033 USA; BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA; CYTEL CORP, DEPT IMMUNOL, SAN DIEGO, CA 92121 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; University of Southern California; Harvard University; Brigham & Women's Hospital			Sette, Alessandro/AFO-8916-2022; Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X				ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Benihoud K, 1997, EUR J IMMUNOL, V27, P415, DOI 10.1002/eji.1830270211; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; Braun MY, 1996, J EXP MED, V183, P657, DOI 10.1084/jem.183.2.657; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN PL, 1981, METHOD ENZYMOL, V80, P408; Cooper AM, 1997, INFECT IMMUN, V65, P1317, DOI 10.1128/IAI.65.4.1317-1320.1997; DELIBERO G, 1988, EUR J IMMUNOL, V18, P59, DOI 10.1002/eji.1830180110; FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAUFMANN SHE, 1988, IMMUNOL TODAY, V9, P168, DOI 10.1016/0167-5699(88)91292-3; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; Laochumroonvorapong P, 1997, INFECT IMMUN, V65, P127, DOI 10.1128/IAI.65.1.127-132.1997; Lee RK, 1996, J IMMUNOL, V157, P1919; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MAZZACCARO RJ, UNPUB; MCMICHAEL AJ, 1988, P NATL ACAD SCI USA, V85, P9194, DOI 10.1073/pnas.85.23.9194; MISKOVSKY EP, 1994, J IMMUNOL, V153, P2787; Miyakawa Y, 1996, INFECT IMMUN, V64, P926, DOI 10.1128/IAI.64.3.926-932.1996; NEIGHBOUR PA, 1982, J IMMUNOL, V128, P1236; NEIGHBOUR PA, 1982, EUR J IMMUNOL, V12, P588, DOI 10.1002/eji.1830120711; Pena SV, 1997, J IMMUNOL, V158, P2680; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; QUAN PC, 1982, J IMMUNOL, V128, P1786; ROSAT JP, UNPUB; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; Turner J, 1996, IMMUNOLOGY, V87, P339, DOI 10.1046/j.1365-2567.1996.512590.x; WALSH CM, 1994, P NATL ACAD SCI USA, V91, P10854, DOI 10.1073/pnas.91.23.10854; YAGITA H, 1995, IMMUNOL REV, V146, P223, DOI 10.1111/j.1600-065X.1995.tb00691.x	34	423	431	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 13	1997	276	5319					1684	1687		10.1126/science.276.5319.1684	http://dx.doi.org/10.1126/science.276.5319.1684			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180075	Green Submitted			2022-12-28	WOS:A1997XD94700038
J	Wedemayer, GJ; Patten, PA; Wang, LH; Schultz, PG; Stevens, RC				Wedemayer, GJ; Patten, PA; Wang, LH; Schultz, PG; Stevens, RC			Structural insights into the evolution of an antibody combining site	SCIENCE			English	Article							ESCHERICHIA-COLI; CATALYTIC ANTIBODIES; ANTIGEN INTERACTIONS; DIVERSITY; BINDING; RECOGNITION; GENERATION; EXPRESSION; FRAGMENTS; SEGMENTS	The crystal structures of a germline antibody Fab fragment and its complex with hapten have been solved at 2.1 Angstrom resolution. These structures are compared with the corresponding crystal structures of the affinity-matured antibody, 48G7, which has a 30,000 times higher affinity for hapten as a result of nine replacement somatic mutations. Significant changes in the configuration of the combining site occur upon binding of hapten to the germline antibody, whereas hapten binds to the mature antibody by a lock-and-key fit mechanism. The reorganization of the combining site that was nucleated by hapten binding is further optimized by somatic mutations that occur up to 15 Angstrom from bound hapten. These results suggest that the binding potential of the primary antibody repertoire may be significantly expanded by the ability of germline antibodies to adopt more than one combining-site configuration, with both antigen binding and somatic mutation stabilizing the configuration with optimal hapten complementarity.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550; HOWARD HUGHES MED INST,SEATTLE,WA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; Howard Hughes Medical Institute			Stevens, Raymond/K-7272-2015	Stevens, Raymond/0000-0002-4522-8725	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039089] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI39089] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALFTHAN K, 1993, GENE, V128, P203, DOI 10.1016/0378-1119(93)90564-J; Breinl F., 1930, Z PHYSL CHEM, V192, P45; BRUNGER AT, 1996, XPLOR 3 8; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BURNET FM, 1959, CLONAL SELECTION THE, P53; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DAVIES DR, 1993, ACCOUNTS CHEM RES, V26, P421, DOI 10.1021/ar00032a005; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; DUENAS M, 1995, GENE, V158, P61, DOI 10.1016/0378-1119(95)00077-J; Fischer E., 1894, BER DTSCH CHEM GES, V27, P2985, DOI DOI 10.1002/CBER.18940270364; FOOTE J, 1994, P NATL ACAD SCI USA, V91, P10370, DOI 10.1073/pnas.91.22.10370; FOUGEREAU M, 1988, IMMUNOL REV, V105, P69, DOI 10.1111/j.1600-065X.1988.tb00766.x; FRENCH DL, 1989, SCIENCE, V244, P1152, DOI 10.1126/science.2658060; GHOSH S, 1986, IMMUNOL TODAY, V7, P217, DOI 10.1016/0167-5699(86)90108-8; HARTMAN AB, 1989, MOL IMMUNOL, V26, P359, DOI 10.1016/0161-5890(89)90125-9; HAUROWTIZ F, 1967, COLD SPRING HARB SYM, P559; HsiehWilson LC, 1996, P NATL ACAD SCI USA, V93, P5363, DOI 10.1073/pnas.93.11.5363; HSIEHWILSON LC, 1996, ACCOUNTS CHEM RES, V29, P391; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; JACOBS JW, 1989, THESIS U CALIFORNIA; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1993, O COMPUTER GRAPHICS; KABAT EA, 1991, J IMMUNOL, V147, P1709; KOSHLAND DE, 1994, ANGEW CHEM INT EDIT, V33, P2375; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MARIUZZA RA, 1993, CURR OPIN IMMUNOL, V5, P50, DOI 10.1016/0952-7915(93)90080-C; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, UNPUB; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; Pauling L, 1940, J AM CHEM SOC, V62, P2643, DOI 10.1021/ja01867a018; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROMESBERG FE, UNPUB; SCHULTZ PG, 1993, ACCOUNTS CHEM RES, V26, P391, DOI 10.1021/ar00032a001; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; Stevens RC, 1996, ISR J CHEM, V36, P121; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3749, DOI 10.1021/bi00229a023; TALMAGE DW, 1959, SCIENCE, V129, P1649; Tomlinson IM, 1996, J MOL BIOL, V256, P813, DOI 10.1006/jmbi.1996.0127; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; ULRICH H, UNPUB; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; Wedemayer GJ, 1997, J MOL BIOL, V268, P390, DOI 10.1006/jmbi.1997.0974; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; YASUI H, 1994, FEBS LETT, V353, P143, DOI 10.1016/0014-5793(94)01027-7	56	468	504	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 13	1997	276	5319					1665	1669		10.1126/science.276.5319.1665	http://dx.doi.org/10.1126/science.276.5319.1665			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD947	9180069				2022-12-28	WOS:A1997XD94700032
J	Magid, DJ; Koepsell, TD; Every, NR; Martin, JS; Siscovick, DS; Wagner, EH; Weaver, WD				Magid, DJ; Koepsell, TD; Every, NR; Martin, JS; Siscovick, DS; Wagner, EH; Weaver, WD			Absence of association between insurance copayments and delays in seeking emergency care among patients with myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIAL; MEDIA CAMPAIGN; THROMBOLYTIC THERAPY; HEALTH-INSURANCE; PUBLIC-EDUCATION; CHEST PAIN; TIMES; DEFIBRILLATION; SYMPTOMS	Background The requirement of copayments for emergency care is thought to control costs by reducing ''inappropriate'' visits to the emergency department. However, requiring copayments may lead to adverse outcomes if patients delay seeking care for emergency conditions. To determine whether such requirements are associated with delays in seeking care, we examined the length of time from the onset of symptoms to arrival at the hospital among patients with myocardial infarction who did or did not have required insurance copayments. Methods All patients were enrolled in a single health maintenance organization (HMO) and presented with myocardial infarction at 1 of 19 hospitals in King County, Washington, from 1989 through 1994. There were 602 patients whose health insurance required a copayment for emergency department care (range, $25 to $100) and 729 patients with no copayment requirement. Data on the time to presentation were obtained from a review of ambulance and hospital records. Results The median length of time from the onset of symptoms to arrival at the hospital, as adjusted for age, sex, and race, was 135 minutes for the copayment group and 137 minutes for the group with no copayment (95 percent confidence interval for the difference, -19 to +16 minutes). There was no significant association between the presence or absence of a copayment requirement and the time to arrival at the hospital after adjustment for calendar year, income, educational level, cardiac history, or clinical symptoms. Since some patients may be unaware of their copayment requirement, we performed a subgroup analysis of data on patients who had a previous visit to the emergency department with the same copayment status - that is, of patients who were likely to know about their copayment. This analysis also showed no significant association between the requirement for a copayment and delays in seeking treatment. Conclusions For privately insured patients in this HMO, the requirement of modest, fixed copayments for emergency services did not lead to delays in seeking treatment for myocardial infarction. (C) 1997, Massachusetts Medical Society.	UNIV COLORADO, HLTH SCI CTR, DEPT PREVENT MED & BIOMETR, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DIV EMERGENCY MED, DENVER, CO USA; UNIV WASHINGTON, ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT CARDIOL, SEATTLE, WA 98195 USA; VET AFFAIRS MED CTR, NW HLTH SERV RES & DEV FIELD PROGRAM, SEATTLE, WA 98108 USA; GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, SEATTLE, WA 98101 USA; HENRY FORD HLTH SYST, DIV CARDIOVASC MED, DETROIT, MI USA; HENRY FORD HLTH SYST, INST HEART & VASC, DETROIT, MI USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Group Health Cooperative; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital	Magid, DJ (corresponding author), COLORADO PERMANENTE MED GRP, CLIN RES UNIT, 10350 E DAKOTA AVE, DENVER, CO 80231 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038454] Funding Source: NIH RePORTER; AHRQ HHS [HS0836] Funding Source: Medline; NHLBI NIH HHS [R01-HL38454] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, Lancet, V1, P545; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BLOHM M, 1991, HEART LUNG, V20, P661; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; CHERKIN DC, 1992, SOC SCI MED, V34, P33, DOI 10.1016/0277-9536(92)90064-W; CHERKIN DC, 1989, MED CARE, V27, P1036, DOI 10.1097/00005650-198911000-00005; HERLITZ J, 1991, CARDIOLOGY, V79, P127, DOI 10.1159/000174870; HERLITZ J, 1989, AM J CARDIOL, V64, P90, DOI 10.1016/0002-9149(89)90659-0; HO MT, 1989, ANN EMERG MED, V18, P727, DOI 10.1016/S0196-0644(89)80004-6; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; LOHR KN, 1986, MED CARE, V24, pUS1; MANNING WG, 1987, AM ECON REV, V77, P251; MITIC WR, 1984, CAN J PUBLIC HEALTH, V75, P414; MOSES HW, 1991, AM J CARDIOL, V68, P249, DOI 10.1016/0002-9149(91)90753-8; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; OGRADY KF, 1985, NEW ENGL J MED, V313, P484, DOI 10.1056/NEJM198508223130806; RASELL ME, 1995, NEW ENGL J MED, V332, P1164, DOI 10.1056/NEJM199504273321711; Selby JV, 1996, NEW ENGL J MED, V334, P635, DOI 10.1056/NEJM199603073341006; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SHEEHAN FH, 1987, J AM COLL CARDIOL, V9, P937, DOI 10.1016/S0735-1097(87)80252-8; SISCOVICK DS, 1993, ANN EMERG MED, V22, P92, DOI 10.1016/S0196-0644(05)80258-6; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WILCOX RG, 1988, LANCET, V2, P525	28	45	46	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	1997	336	24					1722	1729		10.1056/NEJM199706123362406	http://dx.doi.org/10.1056/NEJM199706123362406			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XD543	9180090				2022-12-28	WOS:A1997XD54300006
J	Side, L; Taylor, B; Cayouette, M; Conner, E; Thomspon, P; Luce, M; Shannon, K				Side, L; Taylor, B; Cayouette, M; Conner, E; Thomspon, P; Luce, M; Shannon, K			Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TUMOR-SUPPRESSOR GENE; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; MOLECULAR ANALYSIS; MUTATIONS; PROTEINS; RAS; DISEASE; IDENTIFICATION; RETINOBLASTOMA; NEUROBLASTOMA	Background The risk of malignant myeloid disorders in young children with neurofibromatosis type 1 is 200 to 500 times the normal risk. The gene for neurofibromatosis type 1 (NF1) encodes neurofibromin, a protein that negatively regulates signals transduced by Ras proteins. Genetic and biochemical data support the hypothesis that NF1 functions as a tumor-suppressor gene in immature myeloid cells, but inactivation of both NF1 alleles has not been demonstrated in leukemic cells from patients with neurofibromatosis type 1. Methods Using an in vitro transcription and translation system, we screened bone marrow samples from 18 children with neurofibromatosis type 1 and myeloid disorders for NF1 mutations that cause a truncated protein. Mutations were confirmed by direct sequencing of genomic DNA from the patients, and from their affected parents, in cases of familial neurofibromatosis type 1. Results Specimens from 9 of the 18 children contained abnormal peptide fragments, and truncating mutations of the NF1 gene were found in specimens from 8 of these children. The normal NF1 allele was absent in bone marrow samples from five of the eight children. We detected the same mutation in DNA from the affected parent of each child with familial neurofibromatosis type 1. Conclusions Both alleles of the NF1 gene are inactivated in leukemic cells in some patients with neurofibromatosis type 1. NF1 appears to function as a tumor-suppressor gene in immature myeloid. (C) 1997, Massachusetts Medical Society.	UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; ROCHE BIOMED LABS,RES TRIANGLE PK,NC	University of California System; University of California San Francisco			Side, Lucy/A-6990-2011		NATIONAL CANCER INSTITUTE [R01CA072614] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER; NCI NIH HHS [CA72614] Funding Source: Medline; NCRR NIH HHS [RR01271-13S1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Binnie CG, 1997, MUTAT RES-GEN TOX EN, V388, P21, DOI 10.1016/S1383-5718(96)00104-0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOS JL, 1990, CANCER RES, V50, P1352; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANNAN CI, 1994, GENE DEV, V8, P2792; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; CASTROMALASPINA H, 1984, CANCER, V54, P675, DOI 10.1002/1097-0142(1984)54:4<675::AID-CNCR2820540415>3.0.CO;2-Q; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; COLMAN SD, 1995, NAT GENET, V11, P90, DOI 10.1038/ng0995-90; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; EASTON DF, 1993, AM J HUM GENET, V53, P305; Emanuel PD, 1996, MOL MED TODAY, V2, P468, DOI 10.1016/1357-4310(96)10044-7; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; GADNER H, 1992, HEMATOL ONCOL CLIN N, V6, P655, DOI 10.1016/S0889-8588(18)30334-4; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HEIM RA, 1994, NAT GENET, V8, P218, DOI 10.1038/ng1194-218; HEIM RA, 1995, HUM MOL GENET, V4, P975, DOI 10.1093/hmg/4.6.975; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JENSEN S, 1995, CANCER, V76, P674, DOI 10.1002/1097-0142(19950815)76:4<674::AID-CNCR2820760421>3.0.CO;2-4; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; KALRA R, 1994, BLOOD, V84, P3435; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LI Y, 1995, GENOMICS, V25, P9, DOI 10.1016/0888-7543(95)80104-T; Maris JM, 1997, CANCER-AM CANCER SOC, V79, P1438, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1438::AID-CNCR22>3.3.CO;2-A; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; Miles DK, 1996, BLOOD, V88, P4314; PASSMORE SJ, 1995, BLOOD, V85, P1742, DOI 10.1182/blood.V85.7.1742.bloodjournal8571742; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Purandare SM, 1995, GENOMICS, V30, P476, DOI 10.1006/geno.1995.1268; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Sawada S, 1996, NAT GENET, V14, P110, DOI 10.1038/ng0996-110; SHANNON KM, 1992, BLOOD, V79, P1311; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; SKUSE GR, 1989, GENE CHROMOSOME CANC, V1, P36, DOI 10.1002/gcc.2870010107; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; UPADHYAYA M, 1994, HUM MUTAT, V4, P83, DOI 10.1002/humu.1380040202; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411	53	212	213	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 12	1997	336	24					1713	1720		10.1056/NEJM199706123362404	http://dx.doi.org/10.1056/NEJM199706123362404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD543	9180088				2022-12-28	WOS:A1997XD54300004
J	Torchia, J; Rose, DW; Inostroza, J; Kamei, Y; Westin, S; Glass, CK; Rosenfeld, MG				Torchia, J; Rose, DW; Inostroza, J; Kamei, Y; Westin, S; Glass, CK; Rosenfeld, MG			The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function	NATURE			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC ACID; ESTROGEN-RECEPTOR; CRYSTAL-STRUCTURE; DOMAIN; COACTIVATOR; PROTEINS; AF-2	The functionally conserved proteins CBP and p300 act in conjunction with other factors to activate transcription of DNA. A new factor, p/CIP, has been discovered that is present in the cell as a complex with CEP and is required for transcriptional activity of nuclear receptors and other CBP/p300-dependent transcription factors. The highly related nuclear-receptor co-activator protein NCoA-1 is also specifically required for ligand-dependent activation of genes by nuclear receptors, p/CIP, NCoA-1 and CBP all contain related leucine-rich charged helical interaction motifs that ape required for receptor-specific mechanisms of gene activation, and allow the selective inhibition of distinct signal-transduction pathways.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, WHITTIER DIABET PROGRAM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CELLULAR & MOL MED SCH, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592				ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AUSUBEL EM, 1994, CURRENT PROTOCOLS MO; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bisotto S, 1996, J BIOL CHEM, V271, P17746, DOI 10.1074/jbc.271.30.17746; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; KAMEI Y, 1996, CELL, V85, P1; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; ONATE SA, 1995, SCIENCE, V270, P1354; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; TONE Y, 1994, J BIOL CHEM, V269, P31157; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	46	1092	1132	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 12	1997	387	6634					677	684		10.1038/42652	http://dx.doi.org/10.1038/42652			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XD869	9192892	Bronze			2022-12-28	WOS:A1997XD86900045
J	Batavia, AI				Batavia, AI			Disability and physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE				Batavia, AI (corresponding author), MCDERMOTT WILL & EMERY,MIAMI,FL 33131, USA.							Angell M, 1996, NEW ENGL J MED, V335, P1676, DOI 10.1056/NEJM199611283352209; BATAVIA AI, 1991, J HEALTH POLIT POLIC, V16, P523, DOI 10.1215/03616878-16-3-523; BATAVIA AI, 1993, HEALTH AFFAIR, V12, P40, DOI 10.1377/hlthaff.12.1.40; BATAVIA AI, 1990, M HLTH CARE NEEDS PH; BOWE F, 1980, REHABILITATING AM; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; CORBET B, 1997, NEW MOBILITY     APR, P48; DEJONG G, 1979, ARCH PHYS MED REHAB, V60, P435; Gallagher H.G., 1995, TRUST BETRAYED PATIE; NAGLER M, 1993, PERSPECTIVES DISABIL; *NAT COUNC HAND, 1986, THRESH IND; PFLUEGER SS, 1977, INDEPENDENT LIVING; TINDALL B, 1993, J ACQ IMMUN DEF SYND, V6, P1069; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VNADERMAAS PJ, 1996, NEW ENGL J MED, V335, P1699; WEST J, 1991, AM DISABILITES ACT P	16	19	20	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 5	1997	336	23					1671	1673		10.1056/NEJM199706053362310	http://dx.doi.org/10.1056/NEJM199706053362310			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XC086	9171072				2022-12-28	WOS:A1997XC08600010
J	Badgett, RG; Lucey, CR; Mulrow, CD				Badgett, RG; Lucey, CR; Mulrow, CD			Can the clinical examination diagnose left-sided heart failure in adults?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							VENTRICULAR EJECTION FRACTION; ACUTE MYOCARDIAL-INFARCTION; PULMONARY-ARTERY CATHETERIZATION; CRITICALLY ILL PATIENTS; CHEST-X-RAY; RADIONUCLIDE VENTRICULOGRAPHY; DIASTOLIC DYSFUNCTION; SYSTOLIC FUNCTION; ECHOCARDIOGRAPHIC INSIGHTS; VALSALVA MANEUVER	We systematically reviewed the literature to ascertain how well clinicians determine the probability and type of left-sided heart failure in their patients, Left-sided heart failure is characterized by decreased left ventricular ejection fraction or increased filling pressure. The type of heart failure determines optimal treatment, Systolic dysfunction exists when ejection fraction is reduced, Diastolic dysfunction is presumed to be present when filling pressure is increased with a normal ejection fraction and without another explanatory diagnosis, Many findings are associated with heart failure, and wide variation exists in clinicians' ability to detect these findings. The best findings for detecting increased filling pressure are jugular venous distention and radiographic redistribution, The best findings for detecting systolic dysfunction are abnormal apical impulse, radiographic cardiomegaly, and q waves or left bundle branch block on an electrocardiogram. Diastolic dysfunction is especially difficult to diagnose, but is associated with an elevated blood pressure during heart failure.	AUDIE L MURPHY MEM VET ADM MED CTR, DEPT MED, SAN ANTONIO, TX 78284 USA; WASHINGTON HOSP CTR, WASHINGTON, DC 20010 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; MedStar Washington Hospital Center	Badgett, RG (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MED, DIV GEN MED, 4200 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.			Badgett, Robert/0000-0003-2888-3303				AGUIRRE FV, 1989, AM J CARDIOL, V63, P1098, DOI 10.1016/0002-9149(89)90085-4; ARONOW WS, 1989, AM J CARDIOL, V63, P1526; Badgett RG, 1996, J GEN INTERN MED, V11, P625, DOI 10.1007/BF02599031; BADGETT RG, 1993, AM J MED, V94, P188, DOI 10.1016/0002-9343(93)90182-O; BATES B, 1995, GUIDE PHYSICAL EXAMI, P286; BETHELL HJN, 1973, BRIT HEART J, V35, P902; BIER AJ, 1988, ANGIOLOGY, V39, P211, DOI 10.1177/000331978803900302; BONOW RO, 1992, ANN INTERN MED, V117, P502, DOI 10.7326/0003-4819-117-6-502; BRAUNWALD E, 1963, AM J MED, V34, P147, DOI 10.1016/0002-9343(63)90049-4; BRAUNWALD E, 1992, HEART DISEASE TXB CA, P393; BURKO H, 1971, AMER J ROENTGENOL RA, V111, P687, DOI 10.2214/ajr.111.4.687; BUTMAN SM, 1993, J AM COLL CARDIOL, V22, P968, DOI 10.1016/0735-1097(93)90405-P; CARLSON KJ, 1985, J CHRON DIS, V38, P733, DOI 10.1016/0021-9681(85)90115-8; CEASE KB, 1986, AM J MED, V81, P429, DOI 10.1016/0002-9343(86)90294-9; CELORIA G, 1990, ARCH SURG-CHICAGO, V125, P1036; CHAKKO S, 1991, AM J MED, V90, P353, DOI 10.1016/0002-9343(91)90576-J; CHIKOS PM, 1977, AM J ROENTGENOL, V128, P367, DOI 10.2214/ajr.128.3.367; Cocchi A, 1991, Aging (Milano), V3, P257; COHN JN, 1990, CIRCULATION, V81, P48; Comeau WJ, 1942, AM J ROENTGENOL RADI, V47, P665; CONN RD, 1971, ANN INTERN MED, V75, P185, DOI 10.7326/0003-4819-75-2-185; CONNORS AF, 1990, CHEST, V98, P1200, DOI 10.1378/chest.98.5.1200; CONNORS AF, 1983, NEW ENGL J MED, V308, P263, DOI 10.1056/NEJM198302033080508; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P630, DOI 10.1001/jama.275.8.630; Danzer CS, 1919, AM J MED SCI, V157, P513, DOI 10.1097/00000441-191904000-00007; DOUGHERTY AH, 1984, AM J CARDIOL, V54, P778, DOI 10.1016/S0002-9149(84)80207-6; EAGLE KA, 1988, ARCH INTERN MED, V148, P882, DOI 10.1001/archinte.148.4.882; ECHEVERRIA HH, 1983, AM J MED, V75, P750, DOI 10.1016/0002-9343(83)90403-5; EICHNA LW, 1960, CIRCULATION, V22, P864, DOI 10.1161/01.CIR.22.5.864; EILEN SD, 1983, ANN INTERN MED, V99, P628, DOI 10.7326/0003-4819-99-5-628; EISENBERG PR, 1984, CRIT CARE MED, V12, P549, DOI 10.1097/00003246-198407000-00001; FEDULLO AJ, 1986, NEW YORK STATE J MED, V86, P4; FEILD B J, 1974, Circulation, V50, P331; FEIN AM, 1984, AM REV RESPIR DIS, V129, P1006; FORRESTER JS, 1977, AM J CARDIOL, V39, P137, DOI 10.1016/S0002-9149(77)80182-3; FORRESTER JS, 1976, NEW ENGL J MED, V295, P1356, DOI 10.1056/NEJM197612092952406; Gaasch William H., 1994, JAMA (Journal of the American Medical Association), V271, P1276, DOI 10.1001/jama.271.16.1276; GADSBOLL N, 1989, AM J CARDIOL, V63, P1301, DOI 10.1016/0002-9149(89)91039-4; GADSBOLL N, 1989, EUR HEART J, V10, P1017, DOI 10.1093/oxfordjournals.eurheartj.a059414; GHALI JK, 1991, AM J CARDIOL, V67, P1002, DOI 10.1016/0002-9149(91)90174-J; Gillespie ND, 1997, BMJ-BRIT MED J, V314, P936, DOI 10.1136/bmj.314.7085.936; GLOVER L, 1973, CIRCULATION, V47, P1289, DOI 10.1161/01.CIR.47.6.1289; GUYATT GH, 1986, DRUGS, V32, P538, DOI 10.2165/00003495-198632060-00004; HARLAN R, 1977, ANN INTERN MED, V86, P132; HARVEY WP, 1989, CLIN AUSCULTATION CA; HECKERLING PS, 1993, JAMA-J AM MED ASSOC, V270, P1943, DOI 10.1001/jama.270.16.1943; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; HUTCHEON D, 1980, J CLIN PHARMACOL, V20, P59, DOI 10.1002/j.1552-4604.1980.tb01667.x; Jain A P, 1993, J Assoc Physicians India, V41, P17; KONSTAM M, 1994, HEART FAILURE EVALUA, P2; KONSTAM M, 1994, HEART FAILURE EVALUA, P67; KONSTAM M, 1994, HEART FAILURE EVALUA, P49; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MANGIONE S, 1993, ANN INTERN MED, V119, P47, DOI 10.7326/0003-4819-119-1-199307010-00009; MANGSCHAU A, 1986, ACTA MED SCAND, V220, P101; MATTLEMAN SJ, 1983, J AM COLL CARDIOL, V1, P417, DOI 10.1016/S0735-1097(83)80068-0; MCDERMOTT MM, 1995, AM J MED, V99, P629, DOI 10.1016/S0002-9343(99)80250-2; MCNAMARA RF, 1988, AM J CARDIOL, V62, P192, DOI 10.1016/0002-9149(88)90210-X; MILNE ENC, 1985, AM J ROENTGENOL, V144, P879, DOI 10.2214/ajr.144.5.879; MINIATI M, 1988, INVEST RADIOL, V23, P433, DOI 10.1097/00004424-198806000-00005; MULROW CD, 1993, J GEN INTERN MED, V8, P383, DOI 10.1007/BF02600079; MUSTCHIN CP, 1982, LANCET, V2, P907; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; NORGAARD H, 1990, EUR J RADIOL, V11, P203, DOI 10.1016/0720-048X(90)90057-I; OSTOJIC MC, 1989, AM HEART J, V117, P590, DOI 10.1016/0002-8703(89)90733-3; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; PERLOFF JK, 1984, PHYSICAL EXAMINATION; Raudenbush S. W., 1994, HDB RES SYNTHESIS, P301, DOI DOI 10.1111/ACPS.12078; REEVES RA, 1995, JAMA-J AM MED ASSOC, V273, P1211, DOI 10.1001/jama.1995.03520390071036; RIHAL CS, 1995, AM J CARDIOL, V75, P220, DOI 10.1016/0002-9149(95)80023-L; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P120; SANFORD CF, 1982, AM J CARDIOL, V49, P637, DOI 10.1016/0002-9149(82)91940-3; SCHMITT BP, 1986, J GEN INTERN MED, V1, P386, DOI 10.1007/BF02596424; SILVER MT, 1994, ANN INTERN MED, V121, P750, DOI 10.7326/0003-4819-121-10-199411150-00004; SIMEL DL, 1987, MED DECIS MAKING, V7, P107, DOI 10.1177/0272989X8700700208; SIMON M, 1961, CIRCULATION, V24, P185, DOI 10.1161/01.CIR.24.2.185; STCLAIR EW, 1992, ANN INTERN MED, V117, P751, DOI 10.7326/0003-4819-117-9-751; STEINER RM, 1992, HEART DIS, P213; STEINGRUB JS, 1991, CHEST, V99, P1451, DOI 10.1378/chest.99.6.1451; STEVENSON LW, 1989, JAMA-J AM MED ASSOC, V261, P884, DOI 10.1001/jama.261.6.884; TAKARADA A, 1992, JPN CIRC J, V56, P527, DOI 10.1253/jcj.56.527; Tavel M.E., 1973, HEART SOUNDS MURMURS; Tilkian AG, 1984, UNDERSTANDING HEART; TUCHSCHMIDT J, 1987, CRIT CARE MED, V15, P840, DOI 10.1097/00003246-198709000-00008; WESTMAN EC, 1995, J GEN INTERN MED, V10, P455, DOI 10.1007/BF02599919; WILLIS PW, 1990, HEART ARTERIES VEINS, P165; WONG WF, 1989, AM J CARDIOL, V63, P1526, DOI 10.1016/0002-9149(89)90022-2; ZEMA MJ, 1980, BRIT HEART J, V44, P560; ZEMA MJ, 1984, CHEST, V85, P59, DOI 10.1378/chest.85.1.59	89	160	163	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 4	1997	277	21					1712	1719		10.1001/jama.277.21.1712	http://dx.doi.org/10.1001/jama.277.21.1712			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XB088	9169900				2022-12-28	WOS:A1997XB08800034
J	Taylor, SS; McKeon, F				Taylor, SS; McKeon, F			Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage	CELL			English	Article							CELL-CYCLE CHECKPOINTS; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; PROTEIN-KINASE; BUDDING YEAST; ANAPHASE; MITOSIS; PHOSPHOEPITOPE; PROGRESSION; EXPRESSION	The mitotic checkpoint ensures proper chromosome segregation by delaying anaphase until chromosomes are aligned on the spindle. Following prolonged spindle damage, however, cells eventually exit mitosis and undergo apoptosis. We show here that a murine homolog of the yeast mitotic checkpoint gene BUB1 localizes to the kinetochore during mitosis. By expressing a dominant-negative mutant, we show that mBub1 is not only required for the checkpoint response to spindle damage, but acts in the timing of a normal mitosis. In addition, when mBub1 function is compromised, cells escape apoptosis and continue cell cycle progression, despite leaving mitosis with a disrupted spindle. These data demonstrate a role for kinetochore-associated mBub1 in regulating exit from mitosis, and suggest functional links between the mitotic checkpoint and subsequent apoptotic events in G1.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School			Taylor, Stephen/GZL-6499-2022; Pillay, Nischalan/F-9536-2012	Taylor, Stephen/0000-0003-4621-9326	NIGMS NIH HHS [GM52027] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; DAVIS FM, 1983, P NATL ACAD SCI USA, V80, P2962; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GORBSKY GJ, 1995, TRENDS CELL BIOL, V5, P143, DOI 10.1016/S0962-8924(00)88968-0; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; IMIGER S, 1995, CELL, V81, P269; KERR SM, 1994, MAMM GENOME, V5, P557, DOI 10.1007/BF00354930; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Pangilinan F, 1996, MOL BIOL CELL, V7, P1195, DOI 10.1091/mbc.7.8.1195; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; WANG YC, 1995, MOL CELL BIOL, V15, P6838; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	48	483	500	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	1997	89	5					727	735		10.1016/S0092-8674(00)80255-X	http://dx.doi.org/10.1016/S0092-8674(00)80255-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182760	Bronze			2022-12-28	WOS:A1997XB92500009
J	Philippsen, P; Kleine, K; Pohlmann, R; Dusterhoft, A; Hamberg, K; Hegemann, JH; Obermaier, B; Urrestarazu, LA; Aert, R; Albermann, K; Altmann, R; Andre, B; Baladron, V; Ballesta, JPG; Becam, AM; Beinhauer, J; Boskovic, J; Buitrago, MJ; Bussereau, F; Coster, F; Crouzet, M; DAngelo, M; DalPero, F; DeAntoni, A; DelRey, F; Doignon, F; Domdey, H; Dubois, E; Fiedler, T; Fleig, U; Floeth, M; Fritz, C; Gaillardin, C; GarciaCantalejo, JM; Glansdorff, NN; Goffeau, A; Gueldener, U; Herbert, C; Heumann, K; HeussNeitzel, D; Hilbert, H; Hinni, K; Houssaini, II; Jacquet, M; Jimenez, A; Jonniaux, JL; Karpfinger, L; Lanfranchi, G; Lepingle, A; Levesque, H; Lyck, R; Maftahi, M; Mallet, L; Maurer, KCT; Messenguy, F; Mewes, HW; Mostl, D; Nasr, F; Nicaud, JM; Niedenthal, RK; Pandolfo, D; Pierard, A; Piravandi, E; Planta, RJ; Pohl, TM; Purnelle, B; Rebischung, C; Remacha, M; Revuelta, JL; Rinke, M; Saiz, JE; Sartorello, F; Scherens, B; SenGupta, M; SolerMira, A; Urbanus, JHM; Valle, G; VanDyck, L; Verhasselt, P; Vierendeels, F; Vissers, S; Voet, M; Volckaert, G; Wach, A; Wambutt, R; Wedler, H; Zollner, A; Hani, J				Philippsen, P; Kleine, K; Pohlmann, R; Dusterhoft, A; Hamberg, K; Hegemann, JH; Obermaier, B; Urrestarazu, LA; Aert, R; Albermann, K; Altmann, R; Andre, B; Baladron, V; Ballesta, JPG; Becam, AM; Beinhauer, J; Boskovic, J; Buitrago, MJ; Bussereau, F; Coster, F; Crouzet, M; DAngelo, M; DalPero, F; DeAntoni, A; DelRey, F; Doignon, F; Domdey, H; Dubois, E; Fiedler, T; Fleig, U; Floeth, M; Fritz, C; Gaillardin, C; GarciaCantalejo, JM; Glansdorff, NN; Goffeau, A; Gueldener, U; Herbert, C; Heumann, K; HeussNeitzel, D; Hilbert, H; Hinni, K; Houssaini, II; Jacquet, M; Jimenez, A; Jonniaux, JL; Karpfinger, L; Lanfranchi, G; Lepingle, A; Levesque, H; Lyck, R; Maftahi, M; Mallet, L; Maurer, KCT; Messenguy, F; Mewes, HW; Mostl, D; Nasr, F; Nicaud, JM; Niedenthal, RK; Pandolfo, D; Pierard, A; Piravandi, E; Planta, RJ; Pohl, TM; Purnelle, B; Rebischung, C; Remacha, M; Revuelta, JL; Rinke, M; Saiz, JE; Sartorello, F; Scherens, B; SenGupta, M; SolerMira, A; Urbanus, JHM; Valle, G; VanDyck, L; Verhasselt, P; Vierendeels, F; Vissers, S; Voet, M; Volckaert, G; Wach, A; Wambutt, R; Wedler, H; Zollner, A; Hani, J			The nucleotide sequence of Saccharomyces cerevisiae chromosome XIV and its evolutionary implications	NATURE			English	Article							OPEN READING FRAMES; KB DNA SEGMENT; LEFT ARM; PHYSICAL MAPS; YEAST; GENE; PROTEIN; FRAGMENT; HOMOLOG; CENTROMERE	In 1992 we started assembling an ordered library of cosmid clones from chromosome XIV of the yeast Saccharomyces cerevisiae. At that time, only 49 genes were known to be located on this chromosome(1) and we estimated that 80% to 90% of its genes were yet to be discovered. In 1993, a team of 20 European laboratories began the systematic sequence analysis of chromosome XIV. The completed and intensively checked final sequence of 784,328 base pairs was released in April, 1996 (ref. 2), Substantial parts had been published before(3-22) or had previously been made available on request. The sequence contained 419 known or presumptive protein-coding genes, including two pseudogenes and three retrotransposons, 14 tRNA genes, and three small nuclear RNA genes. For 116 (30%) protein-coding sequences, one or more structural homologues were identified elsewhere in the yeast genome. Half of them belong to duplicated groups of 6-14 loosely linked genes, in most cases with conserved gene order and orientation (relaxed interchromosomal synteny). We have considered the possible evolutionary origins of this unexpected feature of yeast genome organization.	UNIV GIESSEN, INST MIKRO & MOL BIOL, D-35392 GIESSEN, GERMANY; MAX PLANCK INST BIOCHEM, MARTINSRIEDER INST PROT SEQUENZEN, D-82152 MARTINSRIED, GERMANY; QIAGEN GMBH, D-40724 HILDEN, GERMANY; LMU MUNCHEN, GENZENTRUM, MOL BIOL LAB, D-811377 MUNICH, GERMANY; MEDIGENE GMBH, D-82152 MARTINSRIED, GERMANY; FREE UNIV BRUSSELS, B-1050 BRUSSELS, BELGIUM; KATHOLIEKE UNIV LEUVEN, LAB GENE TECHNOL, B-3001 LOUVAIN, BELGIUM; UNIV SALAMANCA, DEPT GENET & MICROBIOL, E-37007 SALAMANCA, SPAIN; CSIC, CTR BIOL MOL, E-28049 MADRID, SPAIN; UNIV AUTONOMA MADRID, E-28049 MADRID, SPAIN; UNIV PARIS 06, CTR GENET MOL, CNRS LAB, F-91198 GIF SUR YVETTE, FRANCE; UNIV PARIS 11, INST GENET & MICROBIOL, LAB INFORMAT GENET & DEV, F-91405 ORSAY, FRANCE; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; UNIV BORDEAUX 2, LBMS, CNR, UPR 9026, F-33076 BORDEAUX, FRANCE; UNIV PADUA, DEPT BIOL, CRIBI BIOTECHNOL CTR, I-35121 PADUA, ITALY; CERIA COOVI, B-1070 BRUSSELS, BELGIUM; INST NATL AGRON PARIS GRIGNON, LAB GENET MOL & CELLULAIRE, CTR BIOTECHNOL AGROIND, F-78850 THIVERVAL GRIGNON, FRANCE; VRIJE UNIV AMSTERDAM, BIOCENTRUM AMSTERDAM, IMBW, DEPT BIOCHEM & MOL BIOL, NL-1081 HV AMSTERDAM, NETHERLANDS; GATC GESELL ANAL TECH & CONSULTING MBH, D-78467 CONSTANCE, GERMANY; AGON GMBH, D-12489 BERLIN, GERMANY	Justus Liebig University Giessen; Max Planck Society; QIAGEN GmbH; University of Munich; Universite Libre de Bruxelles; Vrije Universiteit Brussel; KU Leuven; University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Universite Catholique Louvain; UDICE-French Research Universities; Universite de Bordeaux; University of Padua; AgroParisTech; University of Amsterdam; Vrije Universiteit Amsterdam	Philippsen, P (corresponding author), UNIV BASEL, BIOZENTRUM, INST APPL MICROBIOL, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND.		Nicaud, jean marc/G-4204-2016; NICAUD, Jean-marc/ABA-9076-2021; boskovic, jasminka/L-5117-2018; Revuelta, Jose L/C-2324-2012; del Rey, Francisco/L-7132-2014; DOIGNON, François/AAX-8788-2020; Güldener, Ulrich/G-5227-2012; André, Bruno/D-1725-2010; Remacha, Miguel/G-1250-2016; Baladron, Victoriano/L-1758-2014; Revuelta, Jose Luis/ABG-1502-2020; Mewes, Hans-Werner/A-8204-2019	Nicaud, jean marc/0000-0002-6679-972X; boskovic, jasminka/0000-0001-6135-0686; Revuelta, Jose L/0000-0001-7838-5308; del Rey, Francisco/0000-0002-6517-7400; DOIGNON, François/0000-0002-9007-2408; Güldener, Ulrich/0000-0001-5052-8610; Baladron, Victoriano/0000-0003-4574-8760; Revuelta, Jose Luis/0000-0001-7838-5308; Garcia-Cantalejo, Jesus/0000-0001-6465-1273; VALLE, GIORGIO/0000-0003-4377-5685; Mewes, Hans-Werner/0000-0002-9713-6398; De Antoni, Anna/0000-0003-4908-1684; Buitrago, Maria Jose/0000-0003-1878-6067; Lyck, Ruth/0000-0002-6479-4837				BERGEZ P, 1995, YEAST, V11, P967, DOI 10.1002/yea.320111008; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; COSTER F, 1995, YEAST, V11, P85, DOI 10.1002/yea.320110111; Friedman KL, 1996, GENE DEV, V10, P1595, DOI 10.1101/gad.10.13.1595; Garcia-Cantalejo Jesus Manuel, 1996, Yeast, V12, P599, DOI 10.1002/(SICI)1097-0061(199605)12:6<599::AID-YEA938>3.0.CO;2-9; Garrels JI, 1996, NUCLEIC ACIDS RES, V24, P46, DOI 10.1093/nar/24.1.46; HAMBERG K, 1993, THESIS U GIESSEN; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; JONNIAUX JL, 1994, YEAST, V10, P1639, DOI 10.1002/yea.320101213; KALOGEROPOULOS A, 1995, YEAST, V11, P555, DOI 10.1002/yea.320110605; KICK CT, 1995, YEAST, V11, P1303; LALO D, 1993, CR ACAD SCI III-VIE, V316, P367; Levesque H, 1996, YEAST, V12, P289, DOI 10.1002/(SICI)1097-0061(19960315)12:3<289::AID-YEA909>3.0.CO;2-M; LOGGHE M, 1994, YEAST, V10, P1093, DOI 10.1002/yea.320100811; LOUIS EJ, 1995, GENETICS, V139, P125; Louis EJ, 1995, YEAST, V11, P1553, DOI 10.1002/yea.320111604; MAFTAHI M, 1995, YEAST, V11, P1077, DOI 10.1002/yea.320111109; MAFTAHI M, 1995, YEAST, V11, P567, DOI 10.1002/yea.320110606; MALLET L, 1995, YEAST, V11, P1195, DOI 10.1002/yea.320111210; MAURER KCT, 1995, YEAST, V11, P1303, DOI 10.1002/yea.320111311; MELNICK L, 1993, J MOL BIOL, V233, P372, DOI 10.1006/jmbi.1993.1518; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; NASR E, 1996, YEAST, V12, P169; Nasr F, 1996, YEAST, V12, P493, DOI 10.1002/(SICI)1097-0061(199604)12:5<493::AID-YEA929>3.0.CO;2-W; Pandolfo D, 1996, YEAST, V12, P1071; Pohlmann R, 1996, YEAST, V12, P391; POHLMANN R, 1995, YEAST, V11, P634; RILES L, 1993, GENETICS, V134, P81; RODRIGUEZMEDINA JR, 1994, MOL GEN GENET, V243, P532, DOI 10.1007/BF00284201; Saiz JE, 1996, YEAST, V12, P403, DOI 10.1002/(SICI)1097-0061(19960330)12:4<403::AID-YEA923>3.3.CO;2-8; SenGupta M, 1996, YEAST, V12, P505, DOI 10.1002/(SICI)1097-0061(199604)12:5<505::AID-YEA932>3.0.CO;2-F; SolerMira A, 1996, YEAST, V12, P485, DOI 10.1002/(SICI)1097-0061(199604)12:5<485::AID-YEA928>3.0.CO;2-U; STEENSMA HY, 1989, CURR GENET, V16, P131; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; STUCKA R, 1994, MOL GENETICS YEAST P, P49; THIERRY A, 1995, YEAST, V11, P121, DOI 10.1002/yea.320110204; TUGENDREICH S, 1994, HUM MOL GENET, V3, P1509, DOI 10.1093/hmg/3.suppl_1.1509; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; VANDYCK L, 1995, YEAST, V11, P987, DOI 10.1002/yea.320111010; VERHASSELT P, 1994, YEAST, V10, P1355, DOI 10.1002/yea.320101013; VERHASSELT P, 1994, YEAST, V10, P945, DOI 10.1002/yea.320100709; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; WOLFE KH, 1994, YEAST, V10, P41	43	54	501	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 29	1997	387	6632		S			93	98		10.1038/387s093	http://dx.doi.org/10.1038/387s093			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XB546	9169873				2022-12-28	WOS:A1997XB54600013
J	Whelton, PK; He, J; Cutler, JA; Brancati, FL; Appel, LJ; Follmann, D; Klag, MJ				Whelton, PK; He, J; Cutler, JA; Brancati, FL; Appel, LJ; Follmann, D; Klag, MJ			Effects of oral potassium on blood pressure - Meta-analysis of randomized controlled clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MILD ESSENTIAL-HYPERTENSION; PLACEBO-CONTROLLED TRIAL; MODERATE SODIUM RESTRICTION; DIETARY-SODIUM; DOUBLE-BLIND; NORMOTENSIVE WOMEN; SUPPLEMENTATION; MEN; CHLORIDE; RENIN	Objective.-To assess the effects of supplementation with oral potassium on blood pressure in humans. Design.-Meta-analysis of randomized controlled trials. Data Sources.-English-language articles published before July 1995. Study Selection.-Thirty-three randomized controlled trials (2609 participants) in which potassium supplementation was the only difference between the intervention and control conditions. Data Extraction.-Using a standardized protocol, 2 of us independently abstracted information on sample size, duration, study design, potassium dose, participant characteristics, and treatment results. Results.-By means of a random-effects model, findings from individual trials were pooled, after results for each trial were weighted by the inverse of its variance. An extreme effect of potassium in lowering blood pressure was noted in 1 trial. After exclusion of this trial, potassium supplementation was associated with a significant reduction in mean (95% confidence interval) systolic and diastolic blood pressure of -3.11 mm Hg (-1.91 to -4.31 mm Hg) and -1.97 mm Hg (-0.52 to -3.42 mm Hg), respectively. Effects of treatment appeared to be enhanced in studies in which participants were concurrently exposed to a high intake of sodium. Conclusions.-Our results support the premise that low potassium intake may play an important role in the genesis of high blood pressure. Increased potassium intake should be considered as a recommendation for prevention and treatment of hypertension, especially in those who are unable to reduce their intake of sodium.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, WELCH CTR PREVENT EPIDEMIOL & CLIN RES, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, BETHESDA, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Appel, Larry/GLT-2608-2022		NCRR NIH HHS [RR0035, 5 MO1 RR00722] Funding Source: Medline; NHLBI NIH HHS [5 KO8 HL02642] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002642] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Addison WLT, 1928, CAN MED ASSOC J, V18, P281; [Anonymous], 1990, Arch Intern Med, V150, P153, DOI 10.1001/archinte.150.1.153; ARZILLI F, 1986, J HYPERTENS, V4, pS347; BARDEN A, 1991, AM J HYPERTENS, V4, P206, DOI 10.1093/ajh/4.3.206; BARDEN AE, 1986, J HYPERTENS, V4, P339, DOI 10.1097/00004872-198606000-00013; Beilin L J, 1987, J Hypertens Suppl, V5, pS447; BOMPIANI GD, 1988, INT J CLIN PHARM TH, V26, P129; Brancati FL, 1996, ARCH INTERN MED, V156, P61, DOI 10.1001/archinte.156.1.61; BRUCE NG, 1993, J HUM HYPERTENS, V7, P229; BRUNNER HR, 1970, J CLIN INVEST, V49, P2128, DOI 10.1172/JCI106430; Budrikis G, 1985, Aust Fam Physician, V14, P1340; BULPITT CJ, 1985, ANN CLIN RES, V17, P126; BURSTYN P, 1980, BMJ-BRIT MED J, V281, P537, DOI 10.1136/bmj.281.6239.537; CAPPUCCIO FP, 1991, J HYPERTENS, V9, P465, DOI 10.1097/00004872-199105000-00011; CHALMERS J, 1986, J HYPERTENS, V4, pS629; CUSHMAN WC, 1988, CIRCULATION S2, V78, P370; DAI WS, 1984, J CHRON DIS, V37, P75, DOI 10.1016/0021-9681(84)90128-0; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; ELLIOTT P, 1988, BRIT MED J, V297, P319; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; FORRESTER TE, 1988, W INDIAN MED J, V37, P92; FOTHERBY MD, 1992, J HYPERTENS, V10, P1403, DOI 10.1097/00004872-199211000-00013; FUJITA T, 1984, HYPERTENSION, V6, P184, DOI 10.1161/01.HYP.6.2_Pt_1.184; GILLUM RF, 1982, AM HEART J, V103, P449, DOI 10.1016/0002-8703(82)90295-2; GREENBERG G, 1987, J CLIN PHARMACOL, V27, P271, DOI 10.1002/j.1552-4604.1987.tb03012.x; GRIMM RH, 1988, J HYPERTENS, V6, pS591, DOI 10.1097/00004872-198812040-00185; GRIMM RH, 1990, NEW ENGL J MED, V322, P569, DOI 10.1056/NEJM199003013220901; GROBBEE DE, 1987, J HYPERTENS, V5, P115, DOI 10.1097/00004872-198702000-00016; GROBBEE DE, 1994, TXB HYPERTENSION, P539; GROS G, 1971, AM J CLIN NUTR, V24, P605; HE J, 1991, AM J EPIDEMIOL, V134, P1085, DOI 10.1093/oxfordjournals.aje.a116012; HOLLY JMP, 1981, LANCET, V2, P1384; IIMURA O, 1981, CLIN SCI, V61, pS77, DOI 10.1042/cs061077s; JEFFERY RW, 1984, AM J PUBLIC HEALTH, V74, P492, DOI 10.2105/AJPH.74.5.492; JONES DR, 1995, STAT MED, V14, P137, DOI 10.1002/sim.4780140206; KAPLAN NM, 1985, NEW ENGL J MED, V312, P746, DOI 10.1056/NEJM198503213121203; KAPLAN NM, 1990, NEW ENGL J MED, V322, P623, DOI 10.1056/NEJM199003013220909; KHAW KT, 1982, LANCET, V2, P1127; KHAW KT, 1982, INT J EPIDEMIOL, V11, P372, DOI 10.1093/ije/11.4.372; KLAG MJ, 1990, HYPERTENSION, V16, P700, DOI 10.1161/01.HYP.16.6.700; KRISHNA GG, 1989, NEW ENGL J MED, V320, P1177, DOI 10.1056/NEJM198905043201804; LANGFORD HG, 1983, ANN INTERN MED, V98, P770, DOI 10.7326/0003-4819-98-5-770; LEVER AF, 1981, BRIT MED J, V283, P463, DOI 10.1136/bmj.283.6289.463; MACGREGOR GA, 1982, LANCET, V2, P567; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MATLOU SM, 1986, J HYPERTENS, V4, P61, DOI 10.1097/00004872-198602000-00010; McQuarrie I, 1936, J NUTR, V11, P77, DOI 10.1093/jn/11.1.77; MICKELSEN O, 1977, AM J CLIN NUTR, V30, P2033, DOI 10.1093/ajcn/30.12.2033; MILLER JZ, 1987, HYPERTENSION, V10, P437, DOI 10.1161/01.HYP.10.4.437; MILLER JZ, 1986, CLIN EXP THEORY PRAC, V4, P823; MORGAN TO, 1982, CLIN SCI, V63, pS407, DOI 10.1042/cs063407s; MULLEN JT, 1990, J HUM HYPERTENS, V4, P589; *NAT RES COUNC, COMB INF STAT ISS OP; OBEL AO, 1989, J CARDIOVASC PHARM, V14, P294, DOI 10.1097/00005344-198908000-00016; OBEL AO, 1991, J CARDIOVASC PHARM, V17, P504, DOI 10.1097/00005344-199103000-00021; OS I, 1986, ACTA MED SCAND, V220, P195; OVERLACK A, 1991, KLIN WOCHENSCHR, V69, P79; OVERLACK A, 1983, J HYPERTENSION S2, V1, P165; PARFREY PS, 1981, LANCET, V1, P59; PARFREY PS, 1981, LANCET, V1, P113; PATKI PS, 1990, BRIT MED J, V301, P521, DOI 10.1136/bmj.301.6751.521; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; POULTER NR, 1986, E AFR MED J, V63, P798; Priddle WW, 1931, CAN MED ASSOC J, V25, P5; PRIOR IAM, 1974, INT J EPIDEMIOL, V3, P225, DOI 10.1093/ije/3.3.225; REED D, 1985, HYPERTENSION, V7, P405, DOI 10.1161/01.HYP.7.3_Pt_1.405; Rice JA, 1988, MATH STAT DATA ANAL; RICHARDS AM, 1984, LANCET, V1, P757, DOI 10.1016/S0140-6736(84)91276-5; SALVETTI A, 1988, AM J HYPERTENS, V1, pS201, DOI 10.1093/ajh/1.3.201S; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SEVER PS, 1980, LANCET, V2, P60; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SIANI A, 1991, ANN INTERN MED, V115, P753, DOI 10.7326/0003-4819-115-10-753; SIANI A, 1987, BMJ-BRIT MED J, V294, P1453, DOI 10.1136/bmj.294.6585.1453; SIMPSON FO, 1985, PREV MED, V14, P436, DOI 10.1016/0091-7435(85)90005-2; SINAIKO AR, 1993, HYPERTENSION, V21, P989, DOI 10.1161/01.HYP.21.6.989; SINGH RB, 1993, J HUM HYPERTENS, V7, P33; SKRABAL F, 1981, LANCET, V2, P895; Smith S J, 1983, J Hypertens Suppl, V1, P27; SMITH SJ, 1985, BMJ-BRIT MED J, V290, P110, DOI 10.1136/bmj.290.6462.110; SMITH SR, 1992, J AM SOC NEPHROL, V2, P1302; SMITH WCS, 1988, BRIT MED J, V297, P329, DOI 10.1136/bmj.297.6644.329; STAMLER R, 1991, HYPERTENSION, V17, pI16, DOI 10.1161/01.HYP.17.1_Suppl.I16; SVETKEY LP, 1987, HYPERTENSION, V9, P444, DOI 10.1161/01.HYP.9.5.444; TABUCHI Y, 1985, J CLIN HYPERTENS, V2, P145; TANNEN RL, 1983, ANN INTERN MED, V98, P773, DOI 10.7326/0003-4819-98-5-773; TREASURE J, 1983, HYPERTENSION, V5, P864, DOI 10.1161/01.HYP.5.6.864; VALDES G, 1991, J HUM HYPERTENS, V5, P91; WALKER WG, 1979, HYPERTENSION, V1, P287, DOI 10.1161/01.HYP.1.3.287; WEISSBERG PL, 1985, J HYPERTENS, V3, P475; Whelton Paul K., 1995, Annals of Epidemiology, V5, P85, DOI 10.1016/1047-2797(94)00053-V; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; WHELTON PK, 1994, LANCET, V344, P101, DOI 10.1016/S0140-6736(94)91285-8; WHELTON PK, 1992, J HYPERTENS, V10, pS77; WHELTON PK, 1987, CLIN NUTR, V6, P76; WHELTON PK, 1993, HYPERTENSION PRIMER, P170; ZOCCALI C, 1985, J HYPERTENS, V3, P67, DOI 10.1097/00004872-198502000-00011	97	703	730	0	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	1997	277	20					1624	1632		10.1001/jama.277.20.1624	http://dx.doi.org/10.1001/jama.277.20.1624			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA022	9168293				2022-12-28	WOS:A1997XA02200033
J	Kuttner, R				Kuttner, R			The Kassebaum-Kennedy bill - The limits of incrementalism	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Kuttner, R (corresponding author), AMER PROSPECT,6 UNIV RD,CAMBRIDGE,MA 02138, USA.							*BUR NAT AFF, 1997, MANAGED CARE RE 0526, P7; *GEN ACC OFF, 1996, PRIV HLTH INS MILL R; *GOV ACC OFF, 1996, PRIV HLTH INS MILL R, P59; OLEARY K, 1996, TRENTON TIMES   0524; 1995, COMPREHENSIVE HLTH I; 1997, FED REGISTER, V62, P16893	6	13	13	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	1997	337	1					64	67		10.1056/NEJM199707033370123	http://dx.doi.org/10.1056/NEJM199707033370123			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH186	9203434				2022-12-28	WOS:A1997XH18600032
J	Leplege, A; Hunt, S				Leplege, A; Hunt, S			The problem of quality of life in medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE; HEALTH; MORTALITY	The use of the term ''quality of life'' to encompass the values and perceptions of patients has created doubt, confusion, and misunderstanding among practitioners, researchers, policymakers, and patients. The principal reason for this state of affairs is that a clear conceptual basis for quality-of-life measures is lacking. In this article, the current rationale for quality-of-life measurement in the health field is examined, and the drawbacks of the various models being used are outlined. Our suggestion is that quality of life as an outcome could be explored more clearly (ie, defined) if quality of life were replaced with a more easily handled notion such as that of ''subjective health status.'' However, the idea that the patient's perspective is as valid as that of the clinician when it comes to evaluating outcomes has a great deal of legitimacy and should certainly not be abandoned.	UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh	Leplege, A (corresponding author), HOP BICETRE,INSERM,UNITE 292,82 RUE GEN LECLERC,F-94276 LE KREMLIN BICETR,FRANCE.							ANDERSON R, 1995, QUALITY LFIE PHARMAC; [Anonymous], 1982, JUDGMENT UNCERTAINTY; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BURY M, 1991, SOCIOL HEALTH ILL, V13, P451, DOI 10.1111/j.1467-9566.1991.tb00522.x; CARRHILL RA, 1991, BRIT MED J, V303, P699, DOI 10.1136/bmj.303.6804.699; DRUMMOND M, 1993, SOC SCI MED, V37, P33, DOI 10.1016/0277-9536(93)90315-U; DRUMMOND N, 1997, THESIS U ABERDEEN; ELINSON J, 1976, SOCIOMEDICAL HLTH IN; FINLAYSON T, 1977, CORONARY HEART DIS P; HALL R, 1976, BMJ-BRIT MED J, V1, P814, DOI 10.1136/bmj.1.6013.814; HODGE J, 1990, QUALITY LIFE PERSPEC; HUNT SM, 1986, HEALTH POLICY, V6, P149, DOI 10.1016/0168-8510(86)90004-7; HUNT SM, 1987, HEALTH POLICY, V8, P227, DOI 10.1016/0168-8510(87)90064-9; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; HUNT SM, 1995, EPILEPSY; HUNT SM, 1995, QUALITY LIFE HLTH, P1; Jachuck S J, 1982, J R Coll Gen Pract, V32, P103; Leplege A., 1995, INT ASSESSMENT HLTH, P93; Leplege A, 1996, ENSEIGNEMENT PHILOS, V46, P23; Lerner M, 1973, Health Serv Res, V8, P6; LOUGH ME, 1985, HEART TRANSPLANT, V4, P446; MAHONEY F I, 1965, Md State Med J, V14, P61; MOSSEY JM, 1982, AM J PUBLIC HEALTH, V72, P800, DOI 10.2105/AJPH.72.8.800; PEARLMAN RA, 1982, ANN INTERN MED, V97, P420, DOI 10.7326/0003-4819-97-3-420; SARTRE JP, 1946, EXISTENTIALISME HUMA; SAVAGE LJ, 1972, F STATISTICS; SCAMBLER G, 1990, SOC SCI MED, V30, P1187, DOI 10.1016/0277-9536(90)90258-T; SMITH GT, 1990, AM HEART J, V119, P725, DOI 10.1016/S0002-8703(05)80052-3; SUGARBAKER PH, 1982, SURGERY, V91, P17; TESTA MA, 1993, NEW ENGL J MED, V328, P907, DOI 10.1056/NEJM199304013281302; THOMAS MR, 1980, J PSYCHOSOM RES, V24, P297, DOI 10.1016/0022-3999(80)90020-3; WALSH RM, 1990, ARCH SURG-CHICAGO, V125, P1564; Warwick D.P., 1973, COMP RES METHODS; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; *WHO, 1994, QUAL LIF ASS HLTH CA	35	434	449	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	1997	278	1					47	50		10.1001/jama.278.1.47	http://dx.doi.org/10.1001/jama.278.1.47			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XG387	9207338				2022-12-28	WOS:A1997XG38700036
J	Santoli, JM; DeAngelis, CD				Santoli, JM; DeAngelis, CD			Pediatrics and adolescent medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; IMMUNIZATION; VACCINE				Santoli, JM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21218 USA.							*AM AC PED, 1996, PEDC AAP MEM AL; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P574; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P868; GERSHON AA, 1995, PEDIATR INFECT DIS J, V14, P742, DOI 10.1097/00006454-199509000-00003; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; HALL CB, 1995, PEDIATRICS, V95, P791; HALL CB, 1995, PEDIATRICS, V95, P135; HALL CB, 1992, PEDIATRICS, V89, P795; HALL CB, 1994, PEDIATRICS, V93, P131; Halsey NA, 1996, PEDIATRICS, V97, P282; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; MCBEAN AM, 1987, PEDIATR INFECT DIS J, V6, P881, DOI 10.1097/00006454-198710000-00001; Woodruff BA, 1996, PEDIATRICS, V97, P798	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	1997	277	23					1889	1890						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD544	9185819				2022-12-28	WOS:A1997XD54400038
J	Kamal, IS; Forsyth, DR; Jones, JR				Kamal, IS; Forsyth, DR; Jones, JR			Does it matter who requests necropsies? Prospective study of effect of clinical audit on rate of requests	BRITISH MEDICAL JOURNAL			English	Article							AUTOPSY				Kamal, IS (corresponding author), ADDENBROOKES NHS TRUST HOSP,DEPT MED ELDERLY,CAMBRIDGE CB2 2QQ,ENGLAND.							BROWN HG, 1984, ARCH PATHOL LAB MED, V108, P446; *JOINT WORK PART R, 1991, AUT AUD; MCGOOGAN E, 1978, SCOT MED J, V23, P19, DOI 10.1177/003693307802300106; MCPHEE SJ, 1986, AM J MED, V80, P665, DOI 10.1016/0002-9343(86)90822-3; Pathmanathan R, 1985, Med J Malaysia, V40, P267	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 14	1997	314	7096					1729	1729		10.1136/bmj.314.7096.1729	http://dx.doi.org/10.1136/bmj.314.7096.1729			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XE909	9202503	Green Published			2022-12-28	WOS:A1997XE90900025
J	Sessler, DI				Sessler, DI			Mild perioperative hypothermia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SHIVERING THRESHOLDS; EPIDURAL-ANESTHESIA; INTRAOPERATIVE HYPOTHERMIA; ISOFLURANE ANESTHESIA; TEMPERATURE-CHANGES; SLIGHTLY INCREASES; SWEATING THRESHOLD; GENERAL-ANESTHESIA; SPINAL-ANESTHESIA; ELDERLY PATIENTS		UNIV VIENNA, DEPT ANESTHESIA & GEN INTENS CARE, OUTCOMES RES LAB, VIENNA, AUSTRIA	University of Vienna	Sessler, DI (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIA, SAN FRANCISCO, CA 94143 USA.		Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077	NIGMS NIH HHS [GM49670] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNADATA R, 1995, ANESTHESIOLOGY, V83, P1205, DOI 10.1097/00000542-199512000-00011; BREDAHL C, 1991, ACTA ANAESTH SCAND, V35, P548, DOI 10.1111/j.1399-6576.1991.tb03346.x; BRUCK K, 1976, PFLUG ARCH EUR J PHY, V363, P125, DOI 10.1007/BF01062280; BUONO MJ, 1988, J APPL PHYSIOL, V65, P811, DOI 10.1152/jappl.1988.65.2.811; CAPOGNA G, 1993, BRIT J ANAESTH, V71, P294, DOI 10.1093/bja/71.2.294; CARLI F, 1989, BRIT J ANAESTH, V63, P276, DOI 10.1093/bja/63.3.276; CORK RC, 1983, ANESTH ANALG, V62, P211; DAWKINS MJR, 1965, NATURE, V206, P201, DOI 10.1038/206201b0; DERIAZ H, 1992, ANN FR ANESTH, V11, P145, DOI 10.1016/S0750-7658(05)80005-X; DETRY JMR, 1972, J APPL PHYSIOL, V32, P506, DOI 10.1152/jappl.1972.32.4.506; Eilers H, 1996, ANESTHESIOLOGY, V85, P600, DOI 10.1097/00000542-199609000-00020; EMERICK TH, 1994, ANESTHESIOLOGY, V81, P289, DOI 10.1097/00000542-199408000-00005; FLAVAHAN NA, 1991, NEWS PHYSIOL SCI, V6, P251; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; FRANK SM, 1995, ANESTHESIOLOGY, V82, P83, DOI 10.1097/00000542-199501000-00012; GLOSTEN B, 1992, ANESTHESIOLOGY, V77, P10, DOI 10.1097/00000542-199207000-00003; Guffin A, 1987, J Cardiothorac Anesth, V1, P24, DOI 10.1016/S0888-6296(87)92593-2; GUFFIN A, 1987, J CARDIOTHORAC ANEST, V1, pA501; Hales J.R.S., 1985, CARD SHUNTS A BENZ S, P433; HEIER T, 1991, ANESTHESIOLOGY, V74, P815, DOI 10.1097/00000542-199105000-00003; HYNSON JM, 1993, ANESTHESIOLOGY, V79, P695; Iaizzo PA, 1996, ANESTH ANALG, V82, P803, DOI 10.1097/00000539-199604000-00022; JESSEN C, 1984, AM J PHYSIOL, V247, pR456, DOI 10.1152/ajpregu.1984.247.3.R456; JUST B, 1992, ANESTHESIOLOGY, V76, P60, DOI 10.1097/00000542-199201000-00009; KURZ A, 1995, ANESTHESIOLOGY, V83, P1212, DOI 10.1097/00000542-199512000-00012; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; KURZ A, 1995, J CLIN ANESTH, V7, P359, DOI 10.1016/0952-8180(95)00028-G; KURZ A, 1995, ANESTHESIOLOGY, V83, P293, DOI 10.1097/00000542-199508000-00009; KURZ A, 1993, ANESTH ANALG, V77, P721; KURZ A, 1993, ANESTH ANALG, V77, P89; KURZ A, 1995, ANESTHESIOLOGY, V83, P491, DOI 10.1097/00000542-199509000-00007; KURZ M, 1993, ANESTHESIOLOGY, V79, P1193, DOI 10.1097/00000542-199312000-00009; LENHARDT R, 1995, ANESTHESIOLOGY, V83, pA1114; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; Leslie K, 1996, ANESTHESIOLOGY, V84, P1327, DOI 10.1097/00000542-199606000-00008; LOPEZ M, 1994, ANESTHESIOLOGY, V80, P780, DOI 10.1097/00000542-199404000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARKS LE, 1974, NATURE, V247, P473, DOI 10.1038/247473a0; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P662, DOI 10.1097/00000542-199503000-00008; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P1169, DOI 10.1097/00000542-199505000-00012; MATSUKAWA T, 1995, ANESTHESIOLOGY, V83, P961, DOI 10.1097/00000542-199511000-00008; MICHELSON AD, 1994, THROMB HAEMOSTASIS, V71, P633; Plattner O, 1997, ANESTHESIOLOGY, V86, P772, DOI 10.1097/00000542-199704000-00006; REED RL, 1992, J TRAUMA, V33, P465, DOI 10.1097/00005373-199209000-00022; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; ROE CF, 1971, AM J SURG, V122, P13, DOI 10.1016/0002-9610(71)90338-2; SATINOFF E, 1978, SCIENCE, V201, P16, DOI 10.1126/science.351802; SCHELLER MS, 1992, J THORAC CARDIOV SUR, V104, P1396; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; SESSLER DI, 1990, ANESTHESIOLOGY, V72, P816, DOI 10.1097/00000542-199005000-00008; SESSLER DI, 1993, ANESTH ANALG, V77, P73; Sessler DI., 1994, ANESTHESIOL CLIN, V12, P425; SHARKEY A, 1987, ANESTHESIOLOGY, V66, P249, DOI 10.1097/00000542-198702000-00029; SHIMOSATO S, 1969, ANESTHESIOLOGY, V30, P619, DOI 10.1097/00000542-196906000-00009; SIMON E, 1974, REV PHYSIOL BIOCH P, V71, P1, DOI 10.1007/BFb0027660; TAKAHASHI H, 1994, CLIN EXP PHARMACOL P, V21, P539, DOI 10.1111/j.1440-1681.1994.tb02553.x; VASSILIEFF N, 1995, ANESTHESIOLOGY, V83, P1162, DOI 10.1097/00000542-199512000-00005; VILLAR J, 1993, RESUSCITATION, V26, P183, DOI 10.1016/0300-9572(93)90178-S; WASHINGTON DE, 1993, J APPL PHYSIOL, V74, P82, DOI 10.1152/jappl.1993.74.1.82; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; Xiong JY, 1996, ANESTHESIOLOGY, V85, P240, DOI 10.1097/00000542-199608000-00003	61	398	472	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 12	1997	336	24					1730	1737		10.1056/NEJM199706123362407	http://dx.doi.org/10.1056/NEJM199706123362407			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XD543	9180091				2022-12-28	WOS:A1997XD54300007
J	Soderstrom, CA; Smith, GS; Dischinger, PC; McDuff, DR; Hebel, JR; Gorelick, DA; Kerns, TJ; Ho, SM; Read, KM				Soderstrom, CA; Smith, GS; Dischinger, PC; McDuff, DR; Hebel, JR; Gorelick, DA; Kerns, TJ; Ho, SM; Read, KM			Psychoactive substance use disorders among seriously injured trauma center patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	40th Annual Meeting of the Association-for-the-Advancement-of-Automotive-Medicine	OCT 07-09, 1996	VANCOUVER, CANADA	Assoc Adv Automot Med			HARMFUL ALCOHOL-CONSUMPTION; UNITED-STATES; COLLABORATIVE PROJECT; CAGE QUESTIONNAIRE; SCREENING-TEST; FOLLOW-UP; ABUSE; DEPENDENCE; PREVALENCE; DISEASE	Objective.-To assess the prevalence of psychoactive substance use disorders (PSUDs) among a large, unselected group of seriously injured trauma center patients, using a standardized diagnostic interview and criteria. Design.-Prevalence study. Setting.-A level I regional trauma center. Patients. Trauma center patients fulfilling the following criteria were eligible subjects: aged 18 years or older, admission from injury scene, length of stay of 2 days or longer, and intact cognition. Outcome Measures. The PSUDs were diagnosed using the Structured Clinical Interview (SCID) for the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition (DSM-III-R) and were categorized as abuse or dependence and past or current (within past 6 months). The SCID results were analyzed with respect to demographic factors, injury type, and blood alcohol concentration and urine toxicology results, using chi(2) and logistic regression techniques. Results.-Of the 1220 patients approached for study, 1118 (91.6%) consented. More than half (54.2%) had a diagnosis of a PSUD in their lifetime. Approximately 90% of alcohol and other drug use diagnoses were for dependence and more than 62% were current. Overall, 24.1% of patients were currently alcohol dependent (men, 27.7%; women, 14.7%; P<.001), and 17.7% were currently dependent on other drugs (men, 20.2%; women, 11.2%; P<.001). Current alcohol dependence rates were not associated with race; rates of dependence on other drugs were higher among nonwhites and victims classified with intentional injuries. While 54.3% of blood alcohol-positive patients were currently alcohol dependent and 38.7% of patients with positive urine screening test results for drugs other than alcohol and nicotine were currently drug dependent, 11.7% of blood alcohol-negative and 3.9% of drug-negative patients, respectively, had current diagnoses of dependence on psychoactive substances. Conclusions. A high percentage of seriously injured trauma center patients are at risk of having current PSUDs. Patients with positive toxicology screening test results and/or positive screening questionnaire responses should be referred for formal evaluation and treatment.	JOHNS HOPKINS UNIV, CTR INJURY RES & POLICY, BALTIMORE, MD USA; UNIV MARYLAND, SCH MED, NATL STUDY CTR TRAUMA & EMERGENCY MED SYST, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT PSYCHIAT, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT EPIDEMIOL, BALTIMORE, MD 21201 USA; NIDA, DIV INTRAMURAL RES, BALTIMORE, MD USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Soderstrom, CA (corresponding author), UNIV MARYLAND, MED SYST, CTR SHOCK TRAUMA, 22 S GREENE ST, BALTIMORE, MD 21201 USA.		Gorelick, David/ABF-4941-2021	Smith, Gordon/0000-0002-2911-3071	NIAAA NIH HHS [R01 AA09050] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009050] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDA RF, 1988, JAMA-J AM MED ASSOC, V260, P2529, DOI 10.1001/jama.260.17.2529; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHERPITEL CJ, 1995, ANN EMERG MED, V26, P158, DOI 10.1016/S0196-0644(95)70146-X; CLARK DE, 1985, ANN EMERG MED, V14, P274, DOI 10.1016/S0196-0644(85)80456-X; Collins JJ, 1993, ALCOHOL HEALTH RES W, V17, P93; COTTROL C, 1993, HOSP COMMUNITY PSYCH, V44, P715; Dunham C M, 1989, Md Med J, V38, P227; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FLOERCHINGER SL, 1992, AM COLL SURG COMM TR; FULLER MG, 1995, J STUD ALCOHOL, V56, P267, DOI 10.15288/jsa.1995.56.267; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; GRANT BF, 1994, ALCOHOL HEALTH RES W, V18, P243; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KITCHENS JM, 1994, JAMA-J AM MED ASSOC, V272, P1782, DOI 10.1001/jama.272.22.1782; LINDENBAUM GA, 1989, J TRAUMA, V29, P1654, DOI 10.1097/00005373-198912000-00012; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; LUNDBERG GD, 1984, JAMA-J AM MED ASSOC, V252, P1911, DOI 10.1001/jama.252.14.1911; MACKENZIE EJ, 1989, J TRAUMA, V29, P757, DOI 10.1097/00005373-198906000-00011; Maio RF, 1997, ACAD EMERG MED, V4, P256, DOI 10.1111/j.1553-2712.1997.tb03545.x; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; *NAT I ALC AB ALC, 1991, ALCOHOL ALERT, V285, P1; *NAT I ALC AB ALC, 1991, ALCOHOL ALERT, V294, P1; NILSSEN O, 1994, J TRAUMA, V36, P784, DOI 10.1097/00005373-199406000-00006; PARRAN TV, 1995, J TRAUMA, V38, P278, DOI 10.1097/00005373-199502000-00026; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; POOLE GV, 1993, SURGERY, V113, P608; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; RIVARA FP, 1989, J TRAUMA, V29, P462, DOI 10.1097/00005373-198904000-00008; RUTLEDGE R, 1992, J TRAUMA, V33, P737, DOI 10.1097/00005373-199211000-00024; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SAUNDERS JB, 1993, ADDICTION, V88, P349, DOI 10.1111/j.1360-0443.1993.tb00822.x; *SECR HLTH HUM SER, 1994, NIH PUBL; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; SODERSTROM CA, 1994, J TRAUMA, V36, P68, DOI 10.1097/00005373-199401000-00010; Soderstrom CA, 1997, J TRAUMA, V42, P67, DOI 10.1097/00005373-199701000-00012; SODERSTROM CA, 1992, JAMA-J AM MED ASSOC, V267, P2756, DOI 10.1001/jama.267.20.2756; Spitzer R. L., STRUCTURED CLIN INTE; *US DEP HHS, 1992, MOD TRAUM SYST CAR P; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WALLER PF, 1995, P ASS ADV AUTOMOTIVE, V39, P89; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; Zuska J J, 1981, Bull Am Coll Surg, V66, P5	50	180	182	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	1997	277	22					1769	1774		10.1001/jama.277.22.1769	http://dx.doi.org/10.1001/jama.277.22.1769			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XC499	9178789				2022-12-28	WOS:A1997XC49900029
J	Rout, MP; Blobel, G; Aitchison, JD				Rout, MP; Blobel, G; Aitchison, JD			A distinct nuclear import pathway used by ribosomal proteins	CELL			English	Article							PORE COMPLEX PROTEINS; SACCHAROMYCES-CEREVISIAE; LOCALIZATION SIGNALS; YEAST SACCHAROMYCES; TRANSPORT SUBSTRATE; CYTOSOLIC FACTORS; MEDIATED BINDING; CELL-CYCLE; IDENTIFICATION; ENVELOPE	Protein transport into the nucleus is governed by the interaction of soluble transport factors with their import substrates and nuclear pore complexes. Here, we identify a major distinct nuclear import pathway, mediated by a previously uncharacterized yeast beta karyopherin Kap123p. The predominant substrates for this pathway are ribosomal proteins, which must be imported into the nucleus prior to assembly into pre-ribosomes. Kap123p binds directly to its transport substrates, repeat motif-containing nucleoporins, and Ran-GTP. We show that the related protein Pse1p is also a karyopherin and can functionally substitute for Kap123p; both are capable of specifically directing a ribosomal nuclear localization signal reporter to the nucleus in vivo.			Rout, MP (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA.		Rout, Michael/Y-7090-2018	Rout, Michael/0000-0003-2010-706X				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Aitchison JD, 1995, J CELL BIOL, V131, P1659, DOI 10.1083/jcb.131.6.1659; AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BOEHLKE KW, 1975, J BACTERIOL, V121, P429, DOI 10.1128/JB.121.2.429-433.1975; BONIFACI N, 1997, IN PRESS P NATL ACAD; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHOW TYK, 1992, J CELL SCI, V101, P709; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Enenkel C, 1996, P NATL ACAD SCI USA, V93, P12986, DOI 10.1073/pnas.93.23.12986; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; GARCIABUSTOS JF, 1991, J BIOL CHEM, V266, P22303; Gharahdaghi F, 1996, ANAL BIOCHEM, V233, P94, DOI 10.1006/abio.1996.0012; GHARAHDAGHI F, 1992, TECHNIQUES PROTEIN C, P249; Goldfarb D, 1991, Trends Cell Biol, V1, P20, DOI 10.1016/0962-8924(91)90065-H; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MUTVEI A, 1992, EUR J CELL BIOL, V59, P280; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; ROUT MP, 1994, CELL BIOL LAB HDB, P605; SCHAAP PJ, 1991, J MOL BIOL, V221, P225; SCHMIDT C, 1995, MOL BIOL CELL, V6, P1875, DOI 10.1091/mbc.6.12.1875; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; STRAMBIODECASTILLIA C, 1995, J CELL BIOL, V131, P19, DOI 10.1083/jcb.131.1.19; UNDERWOOD MR, 1990, EMBO J, V9, P91, DOI 10.1002/j.1460-2075.1990.tb08084.x; WARNER JR, 1985, MOL CELL BIOL, V5, P1512, DOI 10.1128/MCB.5.6.1512; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WOZNIAK RW, 1994, J CELL BIOL, V125, P31, DOI 10.1083/jcb.125.1.31; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; ZINKER S, 1976, J BIOL CHEM, V251, P1799	66	301	306	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 30	1997	89	5					715	725		10.1016/S0092-8674(00)80254-8	http://dx.doi.org/10.1016/S0092-8674(00)80254-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XB925	9182759	Bronze			2022-12-28	WOS:A1997XB92500008
J	Cook, LS; Daling, JR; Voigt, LF; deHart, P; Malone, KE; Stanford, JL; Weiss, NS; Brinton, LA; Gammon, MD; Brogan, D				Cook, LS; Daling, JR; Voigt, LF; deHart, P; Malone, KE; Stanford, JL; Weiss, NS; Brinton, LA; Gammon, MD; Brogan, D			Characteristics of women with and without breast augmentation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONNECTIVE-TISSUE DISEASES; RHEUMATOID-ARTHRITIS; ORAL-CONTRACEPTIVES; UNITED-STATES; IMPLANTS; CANCER; RISK; SYMPTOMS	Objective.-To compare selected characteristics of women with and without augmentation mammaplasty to identify differences between these 2 groups of women. Design and Study Participants.-White women identified as controls in previously conducted population-based, case-control studies formed the study population for the present cross-sectional analysis (N=3570). Main Outcome Measure.-Interview information on selected characteristics was compared between women who had received augmentation mammaplasty (n=80) and other women (n=3490) using the prevalence odds ratio (pOR) as the measure of association. Results.-Women with breast implants were more likely to drink a greater average number of alcoholic drinks per week (for greater than or equal to 7 drinks vs 0 drinks: pOR=2.9, 95% confidence interval [CI]=1.5-5.5), be younger at first pregnancy (for age <20 years vs age 20-29 years: pOR=1.6, 95% CI=1.0-2.7), be younger at first birth (for age <20 years vs age 20-29 years: pOR=1.9, 95% CI=1.1-3.3), have a history of terminated pregnancies (for greater than or equal to 1 termination vs 0 terminations: pOR=2.0, 95% CI=1.2-3.4), have ever used oral contraceptives (pOR=2.2, 95% CI=1.0-4.7), have ever used hair dyes (pOR=4.5, 95% CI=1.3-15.4), and have had a greater lifetime number of sexual partners (for greater than or equal to 14 partners vs less than or equal to 4 partners: pOR=8.9, 95% CI=3.1-25.5) than other women. A history of smoking, lactation, high blood pressure, or thyroid disorders, as well as the number of pregnancies, full-term births, or miscarriages, differed little between women with and without implants, Women with breast augmentation were much less likely to be heavy than other women (for greater than or equal to 74 kg vs (56 kg: pOR=0.1, 95% CI=0.03-0.3). Conclusion.-The differences we found between women with and without breast implants suggest that consideration and evaluation of confounding factors in future studies will help to clarify some of the long-term health consequences of having breast implants.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV UTAH,HUNTSMAN CANC INST,DEPT ONCOL SCI,SALT LAKE CITY,UT; NCI,ENVIRONM EPIDEMIOL BRANCH,BETHESDA,MD 20892; COLUMBIA UNIV,DIV EPIDEMIOL,NEW YORK,NY; EMORY UNIV,DEPT BIOSTAT,ATLANTA,GA 30322	University of Washington; University of Washington Seattle; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Columbia University; Emory University	Cook, LS (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,1110 FAIRVIEW AVE N,POB 19024,SEATTLE,WA 98109, USA.		Brinton, Louise A/G-7486-2015	Brinton, Louise A/0000-0003-3853-8562	NCI NIH HHS [R35-CA-39779, R01-CA-41416, KO7-CA-01364] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039779, R01CA041416, K07CA001364] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELL M, 1992, NEW ENGL J MED, V326, P1695, DOI 10.1056/NEJM199206183262510; Breslow N, 1980, STATISTICAL METHODS, V32; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; Brinton LA, 1996, PLAST RECONSTR SURG, V97, P269, DOI 10.1097/00006534-199602000-00001; BRINTON LA, 1995, J NATL CANCER I, V87, P827, DOI 10.1093/jnci/87.11.827; BROGAN D, 1996, SEM PRES STAT DEP AP; BRYANT H, 1995, NEW ENGL J MED, V332, P1535, DOI 10.1056/NEJM199506083322302; COOK RR, 1995, J CLIN EPIDEMIOL, V48, P519, DOI 10.1016/0895-4356(94)00208-8; Daling JR, 1996, AM J EPIDEMIOL, V144, P373, DOI 10.1093/oxfordjournals.aje.a008938; DEAPEN DM, 1992, PLAST RECONSTR SURG, V89, P660, DOI 10.1097/00006534-199204000-00010; FRENITITULAER LWJ, 1989, AM J EPIDEMIOL, V130, P404, DOI 10.1093/oxfordjournals.aje.a115348; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GILTAY EJ, 1994, ANN RHEUM DIS, V53, P194, DOI 10.1136/ard.53.3.194; Green PK, 1996, CANCER CAUSE CONTROL, V7, P575, DOI 10.1007/BF00051699; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; HAZES JM, 1991, ANN RHEUM DIS, P72; HAZES JMW, 1990, ARTHRITIS RHEUM-US, V33, P173, DOI 10.1002/art.1780330204; Hennekens CH, 1996, JAMA-J AM MED ASSOC, V275, P616, DOI 10.1001/jama.275.8.616; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; Koepsell T, 1989, Br J Rheumatol, V28 Suppl 1, P42; MCLAUGHLIN JK, 1994, J NATL CANCER I, V86, P1424, DOI 10.1093/jnci/86.18.1424; PETRI M, 1992, ARTHRITIS RHEUM, V35, P625, DOI 10.1002/art.1780350605; PladevallVila M, 1996, AM J EPIDEMIOL, V144, P1, DOI 10.1093/oxfordjournals.aje.a008846; SanchezGuerrero J, 1996, ARTHRITIS RHEUM, V39, P657, DOI 10.1002/art.1780390418; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; Silverman BG, 1996, ANN INTERN MED, V124, P744, DOI 10.7326/0003-4819-124-8-199604150-00008; SPECTOR TD, 1990, ARTHRITIS RHEUM-US, V33, P782, DOI 10.1002/art.1780330604; SPIERA H, 1988, JAMA-J AM MED ASSOC, V260, P236, DOI 10.1001/jama.260.2.236; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; VANDENBROUCKE JP, 1982, LANCET, V2, P839; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; VOIGT LF, 1994, EPIDEMIOLOGY, V5, P525; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WHITE E, 1994, JNCI-J NATL CANCER I, V86, P505, DOI 10.1093/jnci/86.7.505	34	81	82	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	1997	277	20					1612	1617		10.1001/jama.277.20.1612	http://dx.doi.org/10.1001/jama.277.20.1612			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA022	9168291				2022-12-28	WOS:A1997XA02200031
J	Kirsch, R				Kirsch, R			The future for health care	LANCET			English	Article									UNIV CAPE TOWN,MRC,LIVER RES CTR,ZA-7700 RONDEBOSCH,SOUTH AFRICA	University of Cape Town	Kirsch, R (corresponding author), UNIV CAPE TOWN,DEPT MED,ZA-7700 RONDEBOSCH,SOUTH AFRICA.		Karim, Salim Safurdeen Abdool/N-5947-2013; Karim, Salim Abdool/P-3117-2019	Karim, Salim Safurdeen Abdool/0000-0002-4986-2133; Karim, Salim Abdool/0000-0002-4986-2133					0	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 24	1997	349	9064					1544	1545		10.1016/S0140-6736(97)03264-9	http://dx.doi.org/10.1016/S0140-6736(97)03264-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XA901	9167473				2022-12-28	WOS:A1997XA90100052
